
Drugs & Chemicals

1: Tumor Suppressor Protein p53 (1029)

activ apoptosi arf cell express function inactiv induc
mdm2 mutat **p53** p73 pathwai protein regul
respons suppress suppressor tumor wild-typ

3: RNA, Transfer (110)

codon contain differ eukaryot gene initi
mrna protein region ribosom rna
sequenc site speci suggest synthesi
termin **translat** trna utr

5: Saccharomyces cerevisiae Proteins (733)

albican bud candida cerevisia complex encod

eukaryot fission function growth interact involv

mutant pomb protein requir saccharomyc

strain suggest **yeast**

7: Plant Proteins (414)

access arabidopsi cultivar flower hybrid leaf leav

line maiz **plant** pollen rice root seed
seedl speci thaliana tomato transgen wheat

2: Heterogeneous-Nuclear Ribonucleo- proteins (14)

altern assai **associ** bind
complex detect exon famili genom
interact intron isoform nuclear **protein**
sensit site specif splice suggest variant

4: DNA Primers (1987)

amplifi analysi chain clone detect dna express
fragment **gene** genotyp mutat pcr
polymorph popul primer reaction region restrict
sequenc speci

6: Apoptosis Regulatory Proteins (291)

activ **apoptosi** apoptosis-induc
apoptot bcl-2 caspas caspase-8 **cell**
death fasl induc induct ligand methyl necrosi
pathwai program sensit surviv trail

8: Membrane Proteins (1608)

apoptosi cell conserv domain **express**
function **gene** human identifi inhibitor
mammalian membran mice moys mutant
mutat **protein** signal
suggest transport

9: Tumor Suppressor Proteins (815)

activ arrest cell cycl cyclin damag delet dna

express function gene methyl mutat p53

promot protein repair suppressor system

tumor

11: Proteins (1227)

algorithm apoptosi avail cell data databas domain encod
express function gene inform method mice mutat

network predict protein set structur

13: Caspase 1 (15)

apoptosi associ cell control

death express famili gene
increas induc level member mice mous
mutant phenotyp rat respons role select

15: Cytochromes c (184)

activ apoptosi apoptot bax

bcl-2 caspas caspase-3 cell cytochrom death
induc induct inhibitor mechan mitochondri
mitochondria mtdna pathwai protein releas

10: 1-Phosphatidylinositol 3-Kinase (441)

3-kinas activ akt cell egf egfr

epiderm factor gefitinib

growth inhibit inhibitor kinas

pathwai phosphoryl pi3k receptor
signal surviv tyrosin

12: Enzyme Precursors (42)

activ analysi cell differ evid express
function increas kinas mechan phosphoryl protein
provid role signal site specif structur suggest
tyrosin

14: Caspases (794)

activ apoptosi apoptot bax

bcl-2 caspas caspase-3 cell death induc induct
inhibit inhibitor mechan pathwai proapoptot protein
releas surviv trail

16: Intracellular Signaling Peptides and Proteins (602)

activ apoptosi cell death

diseas express function gene induc

interact kinas mechan mutat pathwai

patient phosphoryl protein regul role
signal

17: Frizzled Receptors (22)

activ beta-catenin cell differ famili form format
identifi involv local mechan **pathwai** protein
regul requir role sequenc **signal**
transduct wnt

19: Macromolecular Substances (157)

activ assembl bind **complex**
compon dna essenti form format function human
interact model process protein recruit requir site
structur subunit

21: Drosophila Proteins (613)

adult aphid conserv control differ
drosophila fli fly function
host insect larva larval mammalian melanogast
mosquito pheromon speci suggest wing

23: DNA-Binding Proteins (3805)

activ bind cell damag **dna** domain
express factor function **gene**
mice mutat promot protein regul regulatori
repair signal site **transcript**

18: Receptors, G-Protein-Coupled (175)

action activ agonist alpha antagonist beta cell express
gamma gene glucocorticoid ligand mediat pathwai
receptor role signal stimul studi
subunit

20: Eye Proteins (215)

cell conclusions cone degener develop
examin express gene implant macular
methods mutat optic photoreceptor pigment
protein **retin** retina studi
visual

22: Protein Kinase C (266)

activ c-jun cell erk increas induc inhibit
inhibitor jnk **kinas** mapk
mitogen-activ p38 pathwai
phosphoryl pkc protein regul
signal stimul

24: Nerve Tissue Proteins (954)

associ bind cell depress **diseas**
disord express function **gene** genet
identifi interact mechan mice motor mutat
neuron progress protein studi

25: Transcription Factors (3309)

activ bind cell develop differenti element express

factor function **gene** mutat pathwai

promot regul regulatori repress role signal site

transcript

27: DNA (2387)

allel analysi associ bind damag **dna** fragment
gene genet genom genotyp mutat per
polymorph popul promot region repair replic
sequenc

29: Nitrates (54)

concentr demonstr differ **effect** group
increas level model nitric oxid
produc **product** rate reduc sampl
studi suggest **synthas**
synthesi water

31: Lead (43)

caus dose effect expos
exposur function genet group health
increas irradi **lead** level method model
radiat respons sampl studi water

26: Repressor Proteins (859)

activ cell chromatin control domain express

factor function **gene** histon mutat pathwai

promot protein regul regulatori repress role

signal **transcript**

28: Tumor Markers, Biological (1491)

analysi cancer carcinoma clinic express

factor gene lesion **marker**

outcom **patient** poor predict prognosi

prognost specimen stage stain

surviv tumor

30: Organometallic Compounds (54)

acid **activ** associ caus cell chang

combin complex **compound**

deriv **effect** group high

increas model process select structur

studi **treatment**

32: Kinesin (65)

cell centrosom **chromosom**

develop divis express famili

function **gene** meiotic

microtubul mitosi

mitot protein requir

respons segreg sequenc specif

spindl

33: Neutral Red (6)

assai caus cell concentr dai
detect determin dna effect evid
exposur light method microm min rat
sensit specif support test

35: Tubulin Modulators (5)

agent bind cancer data drug
effect estim exposur identifi
inhibit larg method NEW reduc screen
size small structur target therapi

37: HLA Antigens (146)

allele antigen associ class complex donor
drb1 genet histocompat hla human leukocyt major
mhc molecul natur patient present transplant
type

39: Spectrin (22)

cell control decreas defici earli function
human identifi increas
larg level local new number
observ protein rel sampl studi suggest

34: Paclitaxel (309)

advanc agent anticanc cancer
chemotherapi cisplatin combin cytotox
drug effect median paclitaxel
patient phase regimen respons sensit
surviv toxic treatment

36: Tubulin (142)

activ cell centrosom checkpoint
chromosom cytokinesi divis
express increas local meiosi meiotic
microtubul mitosi
mitot protein requir segreg
spindl studi

38: Histocompatibility Antigens Class I (233)

allele antigen barrier class complex drb1
gap histocompat hla human iron junction leukocyt
major mhc molecul natur present specif type

40: Factor IX (28)

adenoviru adult analysi deliveri develop differ
effici express factor gene group
growth human mechan molecular studi
therapi transfer vector year

41: Hepatitis delta Antigens (3)

affect analysi blot conserv detect dna
express form format gene gener
mammalian mutant protein region
respons reveal sequenc vector
western

43: Glycine (128)

acid activ analysi control diseas enzym function
gene increas model mutant mutat
patient polymorph posit residu site structur
studi substitut

45: Sulfatases (11)

activ detect develop
enzym function gene genom
high isol level low mutat product protein
site specif strain structur substrat tissu

47: Histones (546)

acetyl activ associ chromatin
coactiv deacetylas dna gene hdac
histon mechan modif nucleosom
p300 recruit regul remodel repress silenc
transcript

42: Calcium (528)

activ atp bone ca2+ calcium cam cell
channel current function gate
human intracellular ion potassium potenti
receptor releas sodium subunit

44: Oxygen (281)

activ antioxid damag differ endotheli
energi enzym free function increas level
measur oxid oxygen rate reactiv
respons speci stress studi

46: Cysteine (166)

chang cleavag cystein form function group human
increas indic mutant mutat posit proteas protein
residu role serin site stabil structur

48: Histone Deacetylases (285)

acetyl activ associ cbp chromatin
coactiv deacetylas gene hdac histon
mechan modif nucleosom p300 recruit regul
remodel repress silenc transcript

49: Sirtuins (40)

acetyl activ **chromatin** coactiv
combin deacetylase function hdac
histon mechan modif mutant
nucleosom recruit regul remodel repress role
studi transcript

51: Silent Information Regulator Proteins, *Saccharomyces cerevisiae* (23)

acetyl activ **chromatin** complex
control deacetylase enhanc gene high
histon level low modif mutat
popul recruit regul suggest transcript yeast

53: NAD (47)

activ biochem biosynthesi catalyt catalyz cell
control dehydrogenase effect **enzym**
enzymat human metabol pathwai protein reaction
reductas respons substrat treatment

55: Mutagens (252)

assai assess carcinogen chemic damag dna dose
effect expos **exposur** frequenc
genotox increas indic induc mutagen potenti studi
toxic worker

50: Lysine (199)

acetyl activ **chromatin** cleavag degrad differ
domain effect function gene **histon** increas
mutat proteas protein residu **site**
specif structur transcript

52: Phosphoglycerate Dehydrogenase (1)

acetyl activ assembl biosynthesi catalyt
chromatin complex compon
conform crystal deacetylase **enzym** form
histon modif recruit **structur**
substrat subunit transcript

54: O-Acetyl-ADP-Ribose (2)

activ alter **chang** chromatin
complex conserv decreas **enzym** function
gene **histon** increas mutant peptid recombin
splice substrat variant wild-typ yeast

56: RNA, Viral (502)

antivir capsid genom hbv hcv hepat hiv hiv-1 host
human immunodefici **infect** infecti partiel replic
rna viral virion **viru** virus

57: Fluorouracil (367)

advanc agent cancer **chemotherapi**
cisplatin combin cycl dai drug grade median
month **patient** phase rate
regimen respons surviv toxic treatment

59: Arabidopsis Proteins (300)

arabidopsi chloroplast floral flower fruit germin leaf
leav **plant** plastid pollen root seed
seedl shoot speci thaliana tobacco tomato transgen

61: RNA, Messenger (3704)

analysi cell down-regul **express**
expression **gene** identifi level mice microarra **mrna**
profil protein regul rt-pcr transcript translat up-regul
upregul variant

63: RNA, Plant (113)

arabidopsi **express** flower gene hybrid leaf leav
plant pollen rice rna root seed seedl
speci thaliana tobacco tomato transgen wheat

58: Factor VIII (63)

associ bleed coagul **factor** fibrinogen
folat folic homocystein leiden model mthfr
plasma platelet reductas risk studi thrombin
thrombosi venou vitamin

60: Protein-Serine-Threonine Kinases (1159)

activ akt cell damag diseas dna
egfr factor gene growth inhibit inhibitor
kinas mutat pathwai
phosphoryl protein receptor repair
signal

62: DNA, Plant (361)

access arabidopsi barlei crop cultivar differ
diploid hybrid leaf leav line maiz parent
plant popul rice root seed speci
wheat

64: Peptide Nucleic Acids (24)

analysi arrai detect dna fish fluoresc **gene**
genom human **hybrid** label method
oligonucleotid patient perform **probe** signal
situ specif techniqu

65: Molecular Probes (33)

analysi arrai assai bind **detect** fish
fluoresc gene **hybrid** label
method new oligonucleotid probe sampl
select sensit **Situ** specif techniqu

67: Sesame Oil (1)

bodi breed differ **distribut** effect
fluid increas indic **local** nitric oxid
pattern plant primari rice suggest synthas
synthesi weight wheat

69: Antibodies, Viral (189)

antibodi antigen detect differ gene hbv
hcv hepat human immun **infect** monoclon
replic respons specif test vaccin viral
viru virus

71: Viral Envelope Proteins (191)

antivir capsid differ gene genom hbv hcv hepat herp
hiv hiv-1 host human immunodefici **infect**
infecti replic viral **viru** virus

66: Plant Oils (41)

acid activ amino associ control
decreas determin **effect** genet
increas level nitric oxid patient
reduc studi subject suggest synthas
synthesi

68: Soybean Oil (2)

acid **activ** assai detect differ
distribut evid form format larg local
produc **product** provid sensit
size small suggest support synthas

70: Apolipoproteins C (23)

apoe apolipoprotein associ
cholesterol concentr develop diseas
function genotyp group human
increas ldl level **lipid**
lipoprotein patient plasma
polymorph studi

72: Proto-Oncogene Proteins c-ets (50)

activ analysi bind cell chang chromosom
element **express** famili gene
human identifi interact **promot**
protein respons site tissu transcript treatment

73: Recombinant Fusion Proteins (957)

activ bind cell chimer complet construct
contain demonstr domain express function
fusion gene interact mutant partial
protein replac result vector

75: Nuclear Proteins (1730)

activ cancer cell cytoplasm damag dna
domain express factor function **gene**
interact mutat nuclear p53 promot
protein regul repair transcript

77: Myeloid-Lymphoid Leukemia Protein (52)

activ **acut** aml associ blast cell chromosom
chronic cml develop gene imatinib leukaemia
leukem **leukemia** lymphoblast
mds myelodysplast myeloid patient

79: Proto-Oncogene Proteins (1417)

activ akt apoptosi cancer cell egfr express
factor gene growth kinas **mutat**
p53 pathwai phosphoryl protein receptor
regul signal transcript

74: Neoplasm Proteins (1100)

analysi apoptosi cancer cell colon colorect differenti
express expression gene methyl
microarra mutat patient profil protein resist surviv
tissu tumor

76: Oncogene Proteins, Fusion (163)

activ **acut** aml case cell chromosom
chronic complet express fusion gene
human imatinib **leukemia** mds
myeloid partial patient sarcoma tumor

78: Proto-Oncogene Proteins c-bcl-2 (733)

activ anti-apoptot **apoptosi**
apoptot bax bcl-2 caspas caspase-3 cell death
induc induct inhibit inhibitor mechan pathwai
proapoptot protein releas surviv

80: Proto-Oncogene Proteins c-bcl-6 (21)

b-cell case cell cll earli express function
group hybrid identifi larg lymphocyt
lymphoma non-hodgkin
normal patient respons screen time Tissu

81: Core Binding Factor Alpha 2 Subunit (68)

activ **acut** aml associ blast cell chronic
develop express factor gene leukaemia
leukemia lymphoblast mds
myeloid patient regul role **transcript**

83: Histamine H1 Antagonists (11)

affect analysi care case clinic detect differ
gene **group** health human
manag medic metabol **patient** popul
sampl structur studi treatment

85: Nitrosamines (33)

activ concentr critic demonstr depend deplet
essenti establish express function human increas
indic maintain mainten necessari
requir role studi suffici

87: Poly(ADP-ribose) Polymerases (150)

activ apoptosi assai **cell** cytotox decreas
dose-depend effect growth human increas induc
induct inhibit line manner poli prolifer treatment vitro

82: ras GTPase-Activating Proteins (26)

activ cell chang complex
develop express gene
interact kinas level local mechan migrat
number protein regul
requir signal time treatment

84: Adrenal Cortex Hormones (75)

asthma case **clinic** cystic dai diagnosi diseas
effect fibrosi level **patient** popul
present report SEVER studi symptom therapi
treatment year

86: Peptide Fragments (462)

bind c-termin cell contain demonstr deriv
domain function immun motif novel
patient **peptid** protein receptor
region respons specif studi synthet

88: Anesthetics, Intravenous (25)

complic **concentr** control dai effect
group microg microm min oper
patient perform postop procedur
rat resect studi subject surgeri surgic

89: Norepinephrine (40)

cell chang compar control dai decreas
effect enhanc express gene
increas level mechan mice model
rat reduc **respons** stimul studi

91: Potassium Channels (55)

activ associ atp ca2+ calcium cam
channel conduct current
function gene intracellular ion mutat potassium
potenti releas sequenc sodium studi

93: Transcription Factors, General (2)

activ character dna enzym express
factor gene induc induct modifi multipl
phenotyp protein residu respond
respons singl site suggest transcript

95: Cell Cycle Proteins (1303)

activ arrest **cell cycl** cyclin
damag dna gene kinas mitot p21 p27 p53
phase progress prolifer protein regul repair role

90: Propofol (20)

complic **concentr** dai develop
effect group higher increas low microg microm
min oper **patient** plasma procedur
respect studi surgeri surgic

92: Ligands (557)

activ affin agonist alpha antagonist beta **bind**
bound cell complex gamma interact ligand mediat
protein **receptor** site specif
structur target

94: Cyclin-Dependent Kinase Inhibitor
p18 (8)

carcinoma cell complex cycl event
express form format gene
interact involv model p53 **process** region
regul sequenc **specif** tumor tumour

96: Protein Kinases (415)

activ cell express gene induc inhibit
kinas mitot mutat pathwai
phosphatas phosphoryl protein regul
requir respons role **signal** stat3 tyrosin

97: Antibodies, Neoplasm (95)

analysisi **antibodi** antigen associ
cell clinic express immun lymphoma mab
monoclon neutral patient posit respons specif
studi therapi tumor vaccin

99: Muscle Proteins (162)

analysisi cell dystrophi exercis express famili fiber
function gene human interact **muscl**
muscular mutat patient protein role skelet
smooth studi

101: Intermediate Filament Proteins (92)

activ analysisi associ carcinoma **cell**
chang differ differenti express gene human
model mutat **patient** phenotyp progenitor
protein skin stem studi

103: ATP-Binding Cassette Transporters (207)

abc acquir class confer drug gene genet human major
mdr mdrl mechan multidrug mutat p-gp
resist revers sensit suscept transport

98: Actinin (28)

actin analysisi associ bind **cell** data express
famili function gene human
interact member migrat muscl mutat
process protein regul role

100: Vimentin (72)

activ analysisi case **cell** develop differenti
express form format gene **human**
includ kit patient protein sarcoma stromal
studi tissu tumor

102: Oligopeptides (146)

apoptosi cell demonstr deriv effect gene group
human identifi novel patient **peptid**
protein receptor specif studi synthet target
treatment vector

104: DNA, Helminth (26)

analysisi cluster develop **differ**
dna fragment gene host **infect**
model new pathogen pattern pcr popul
provid restrict sequenc speci studi

105: *Caenorhabditis elegans* Proteins
(183)

area caenorhabd climat dispers divers

ecolog **elegan** fish forest function gene

habitat marin natur nematod rang region sea

season **speci**

107: N-Acetylgalactosaminyltransferases
(15)

anim associ blood cell character decreas
detect express featur gene genet **increas**

model mutat **phenotyp**
popul region sequenc site studi

109: Narcotics (18)

alcohol assai care consumpt dai depend
detect effect ethanol health method model

oral **patient** prefer respons
sampl sensit studi substanc

111: Receptors, Interleukin (52)

analysi associ **cell** chain cytokin differ
effect **express** gene gener group human

level **patient** reaction receptor risk
role studi treatment

106: Mitogen-Activated Protein Kinase
8 (20)

activ cell develop erk event featur gene

inhibit **kinas** level mapk
pathwai patient **phosphoryl**
process protein regul sampl serum signal

108: Methadone (8)

alcohol analysi case children data depend
develop effect identifi new oral

patient product provid ratio report
requir risk studi treatment

110: Peptides (678)

bind cell demonstr deriv displai domain form identifi

lectin molecul novel **peptid** protein
recogn recognit specif structur studi synthet target

112: Peptidyl-Dipeptidase A (100)

ace allel **arteri** associ blood
cardiovascular coronari gene genotyp

hypertens infarct ischem ischemia
myocardi polymorph **pressur** stroke
vascular vein vessel

113: Heptanoic Acids (14)

apoe apolipoprotein cholesterol
dai effect function gene growth increas
ldl level lipid lipoprotein model
patient plasma respons studi
subject trial

115: Pyrroles (69)

activ base bind cell compound
detect effect famili function
growth inhibit inhibitor lipid
patient select studi target treatment
vitro vivo

117: Tetrahydroisoquinolines (14)

activ assai clinic detect
diagnosi earli effect express
gene normal phase sarcoma
sensit stage studi test
tissu treatment trial tumor

119: Smad3 Protein (59)

bmp cartilag chondrocyt collagen effect
express factor factor-beta fibroblast
growth induc mechan regul
signal smad smad4 sox9 tgf-beta
tgf-beta1 transform

114: Hydroxymethylglutaryl-CoA Reductase Inhibitors (78)

apoe apolipoprotein associ atherosclerosi
chd cholesterol diseas effect hdl
increas ldl level lipid
lipoprotein metabol new plasma studi
total triglycerid

116: Fibrin Fibrinogen Degradation Products (10)

blood clinic compar control diagnosi
diagnost differ group higher imag
increas level patient rate studi
test time tissu treatment valu

118: Angiotensin-Converting Enzyme Inhibitors (54)

ace arteri blood cardiovascular
clinic coronari effect hypertens
incid infarct ischem ischemia myocardi
patient pressur product stroke
vascular women year

120: Transforming Growth Factor beta (538)

bmp cartilag chondrocyt collagen effect
express factor factor-beta fibroblast
growth induc regul respons role
signal smad sox9 tgf-beta
tgf-beta1 transform

121: Trans-Activators (1586)

activ beta-catenin cell develop express factor
gene involv kinas mice mutat pathwai
promot regul repress **signal** target
transcript transduct wnt

123: DNA, Neoplasm (505)

alter analysi cancer carcinoma case cell
chromosom delet detect dna express gene
genom identifi loss methyl **mutat**
patient region tumor

125: Acyl-CoA Dehydrogenase, Long-Chain (9)

acid activ amino analysi combin
decreas defect defici effect increas mice
mutant patient protein respons role sampl
sever test time

127: Fatty Acids (124)

acid amino atra composit contain differ
effect fas fatti free gene increas isol nucleic residu retino
retinoid strain studi substitut

122: Cytidine Deaminase (58)

activ cell develop **dna** duplex express fork
function helicas human mutat patient pol polymeras
process replic single-strand strand synthesi templat

124: Lipids (193)

activ apoe apolipoprotein associ
cholesterol differ effect group
increas ldl level **lipid**
lipoprotein metabol patient plasma
studi total treatment triglycerid

126: Recombinant Proteins (1227)

activ **bind** cell construct contain domain
effici enzym express form gene homolog
interact plasmid **protein**
recombin site stabil structur
vector

128: Sp1 Transcription Factor (107)

activ assai bind box contain element express factor
gene human **promot** region regul
regulatori report shift site sp1 transcript upstream

129: Ephrin-A2 (4)

activ bind cell compar
control differenti element
express frequenc gene initi mice number
plai prolifer promot regul role site
transcript

131: Adenosine (56)

activ adduct analog analogu cell chemic
compound control deriv
develop effect group human patient protein
region role sequenc structur tumour

133: Antigens, CD40 (75)

activ cd4 cd4+ cd8 cd8+ cell control cytotox
express gene human il-2 immun increas lymphocyt
mechan receptor studi t-cell ter

135: TNF Receptor-Associated Factor
2 (12)

activ cell chemokin effect
express factor function il-8
induc necrosi nf-kappab
nuclear phenotyp protein rat receptor
suggest target tnf tnf-alpha

130: RNA, Archaeal (13)

analysi bacteria compar differ eukaryot form format
gene genom group identifi new
number reveal rna rrna select sequenc speci studi

132: NF-kappa B (580)

activ alpha chemokin constitut cxcr4
cytokin express factor il-8 induc
inflammatori necrosi
nf-kappab nuclear p65
receptor role tnf tnf-alpha tumor

134: Receptors, Tumor Necrosis Factor,
Type I (38)

activ associ chemokin develop express factor
group il-8 increas induc necrosi
nf-kappab nuclear number
patient popul receptor role tnf
tnf-alpha

136: Receptors, Tumor Necrosis Factor,
Type II (25)

activ analysi associ chemokin
compar control differ express
factor frequenc gene genotyp human
increas necrosi nf-kappab
patient polymorph studi treatment

137: JNK Mitogen-Activated Protein Kinases (171)

activ c-jun cell erk function induc
inhibit inhibitor jnk **kinas** mapk
mitogen-activ p38 pathwai
phosphoryl pkc protein regul
respons signal

139: Tetradecanoylphorbol Acetate (121)

activ associ cell control differenti effect
express function gene human inhibit kinas mapk mice
pathwai phosphoryl promot protein regul signal

141: Organic Chemicals (63)

activ cell **chain** combin
compar control detect differ
effect increas **method**
model number organ per
polymeras quantit **reaction**
sampl studi

143: Venoms (9)

cell combin compar diabet effect enhanc high
higher **human** increas level low
mechan molecular new pancreat **patient**
product provid rate

138: Forkhead Transcription Factors (119)

activ associ cell control develop effect express
factor famili function gene increas mechan
mutat promot regul repress sequenc studi

transcript

140: I-kappa B Proteins (78)

activ alpha chemokin constitut cxcr4
express factor il-8 induc necrosi
nf-kappab normal nuclear
p65 receptor respons tissu tnf tnf-alpha tumor

142: Insulin (381)

adipocyt adiponectin associ **diabet** fast
glucos impair increas **insulin** level mellitu
metabol nod obes peroxisom ppargamma resist studi
subject toler

144: Phosphoproteins (516)

activ analysi associ bind cell complex domain
epitheli express function gene interact kinas
mutat pathwai **protein** regul role
signal transcript

145: Protein Precursors (145)

activ analysi associ cell develop
differ express gene human
mice mous mutant **mutat**
peptid protein receptor region
sequenc site studi

147: Glucagon (32)

cell determin diabet effect express gene genom
group increas islet level local mice pancrea
pancreat patient secret
sequenc studi suggest

149: Glucagon-Like Peptide 1 (6)

analysi cell combin compar
decreas differenti effect high higher
increas level low method mice
organ pancreat process **rate**
receptor reveal

151: Bone Morphogenetic Proteins (158)

bmp bone cartilag cell chondrocyt collagen
develop differenti express
factor gene **growth** human
induc regul signal tgf-beta
tgf-beta1 tissu transform

146: Smad Proteins (55)

activ bmp cartilag chondrocyt collagen
effect express factor fibroblast
growth induc regul respons
signal smad sox9 tgf-beta
tgf-beta1 tissu transform

148: Protein Isoforms (557)

activ **altern** bind differ encod exon express form
gene identifi intron isoform lack novel protein
site **splice** suggest transcript

variant

150: Smad1 Protein (11)

activ analysi blot cell combin
demonstr differenti enhanc express factor
growth new popul protein recombin signal
tgf-beta tgf-beta1 transform western

152: Smad8 Protein (5)

assai bind collect compar **control** detect
evid express frequenc growth level mutant
pathwai report **sampl** sensit signal
studi support test

153: Smad5 Protein (9)

analysi **cell** differenti earli enhanc
express factor famili gene
growth identifi **interact** mechan
mutant **respons** screen signal state
tgf-beta transform

155: Carrier Proteins (1129)

activ apoptosi bind cancer cell colorect complex
domain encod **express** famili function **gene** identifi
interact mutat patient **protein**
regul role

157: Copper (120)

activ air **concentr** contamin control
copper differ **diseas** environment group
liver measur metal pah pollut sediment
soil sourc structur **water**

159: Interferon Regulatory Factor-1 (20)

activ associ cell class combin
cytokin effect **express** famili gene high
human level mice normal
respons role select studi tissu

154: DNA, Complementary (1247)

analysi cdna cell character **clone** encod est
express **gene** homolog identifi isol librari
microarraai novel profil protein region **sequenc** tag

156: Culture Media (322)

activ cell cerevisia condit **cultur**
fibroblast **gene** growth human increas infect isol
media medium pathogen product saccharomyc
strain vitro yeast

158: Interferon Type II (447)

antigen **cell** cytokin dendrit ifn
ifn-gamma il-10 il-6 **immun**
induc inflammatori interferon interleukin
lymphocyt macrophag product
respons stimul t-cell vaccin

160: Multienzyme Complexes (94)

activ approach catalyt complex data
differ **enzym** function gene
identifi increas kinas model phenotyp protein
rate role screen studi substrat

161: Proteasome Endopeptidase Complex (291)

activ cellular **degrad** finger function
indic ligas mechan pathwai prion process
proteasom **protein** prp regul
stabil suggest target ubiquitin zinc

163: p38 Mitogen-Activated Protein Kinases (188)

activ c-jun erk erk1 induc inhibit inhibitor
jnk **kinas** mapk mitogen-activ p38
pathwai **phosphoryl** pkc protein
regul serin signal stimul

165: Prostaglandin D2 (14)

activ analysi associ cell data
diabet differenti glucos **human**
inhibit insulin larg mechan model respons
reveal role size small time

167: Thiazolidinediones (63)

adiponectin associ cell develop **diabet**
effect fast glucos increas **insulin** mellitu
metabol obes peroxisom ppargamma reduc studi
subject tissu toler

162: Platelet-Derived Growth Factor (89)

activ c-kit cell differ differenti effect enhanc express
factor gene group **growth** igf-i
increas kit level sarcoma stromal studi tumor

164: PTEN Phosphohydrolase (121)

addit biolog contribut demonstr determin develop

egfr erythematosu growth includ involv lupu major

observ provid pten relev sle studi

system

166: Phosphoric Monoester Hydrolases (181)

activ addit biolog cell demonstr develop function
human includ involv kinas lupu phosphoryl provid

pten signal sle studi **system** tyrosin

168: Proto-Oncogene Proteins c-akt (451)

3-kinas activ akt cell egf **egfr**
epiderm factor gefitinib **growth**
inhibit inhibitor kinas pathwai phosphoryl
pi3k **receptor** signal surviv tyrosin

169: PPAR gamma (130)

adiponectin associ **diabet** differ fast
gene glucos group increas **insulin** level mellitu
metabol obes peroxisom ppargamma resist studi
subject toler

171: Isotretinoin (12)

acid activ amino cell chain combin
effect estim express increas male patient per
point polymeras reaction respons target time
trial

173: Retinoid X Receptors (32)

acid activ agonist alpha antagonist beta cell express
gamma gene ligand mediat number rat
receptor respons role studi target
therapi

175: Ikaros Transcription Factor (9)

activ associ cell chromatin develop express
form format **gene** gener genom
genotyp histon model mutat promot regul
respons transcript tumor

170: Receptors, Retinoic Acid (99)

acid agonist alpha amino antagonist beta
cell develop express fatti gene increas ligand methyl
patient promot **receptor** respons retino
role

172: Tretinoin (198)

acid activ amino atra cell composi
differenti effect express fas fatti increas leukemia nucleic
prolifer residu retino retinoid role substitut

174: CCAAT-Enhancer-Binding Proteins (92)

activ apoptosi bind cell effect element
express factor **gene** human increas patient
promot protein region regul
respons role site transcript

176: Thiazoles (142)

activ apoptosi assai **cell** cytotox effect
express form format human induc inhibit line
mechan prolifer protein structur studi suggest
treatment

177: Cyclin-Dependent Kinase Inhibitor p21 (289)

activ arrest **cell** cycl cyclin
cyclin-depend express induc inhibitor kinas p21 p27
p53 phase progress prolifer protein regul
retinoblastoma suppressor

179: Tetrazolium Salts (89)

activ apoptosi assai **cell** cytotox effect
express group growth human increas induc inhibit
line prolifer protein resist studi treatment vitro

181: Coloring Agents (116)

activ blue **cell** color composit differ
effect express high increas intens laser level
light method observ patient rat red
studi

183: Cytokines (658)

activ **cell** cpg **cytokin**
express gene ifn ifn-gamma il-10 il-4 il-6
immun induc inflammatori interferon
interleukin macrophag product
respons stimul

178: Cyclin D1 (207)

activ arrest **cell** cycl cyclin
cyclin-depend gene growth inhibitor kinas level p21
p27 patient phase progress prolifer regul
retinoblastoma tumor

180: RNA, Small Interfering (885)

antisens effect express function gene inhibit
interf interfer knockdown oligonucleotid
rna rnai sens short silenc sirna small
specif suppress target

182: Luciferases (384)

activ assai bind **cell** element enhanc
express factor fluoresc gene
promot protein region regul
report respons site **transcript** transfect
vector

184: Anti-Inflammatory Agents, Non-Steroidal (147)

activ agent chemoprevent clinic COX-2
cyclooxygenase-2 diseas drug effect increas inhibit
inhibitor mechan patient prevent
reduc select studi suggest treatment

185: Sulindac (16)

agent associ cancer cell chemoprevent combin
cox-2 effect high induc inhibit
inhibitor low mice number
prevent reduc respons suggest treatment

187: Viral Vaccines (95)

antigen challeng ctl dendrit develop elicit epitop
gene **immun** immunogen
immunotherapi induc infect protect replic
respons studi **vaccin** viral viru

189: Vaccines, Synthetic (68)

antigen challeng ctl cytotox dendrit elicit epitop
gene gener **immun** immunogen
immunolog immunotherapi induc innat protect
protein respons t-cell **vaccin**

191: Enzyme Inhibitors (925)

activ apoptosi block cell cox-2 effect induc
inhibit inhibitor inhibitori kinas
mechan pathwai phosphoryl prevent protein
suggest suppress target treatment

186: Membrane Glycoproteins (1104)

activ apoptosi apoptot **cell** cytokin
death depress disord express gene immun induc
mechan membran mice mutat patient protein role trail

188: Vaccines, Inactivated (6)

acid antigen assai cell dai detect dose
express **function** gener
genet **immun** individu level organ
regul respons sensit specif vaccin

190: Vaccines, DNA (137)

adjuv antigen antitumor challeng ctl cytotox
dendrit elicit epitop **immun**
immunogen immunolog immunotherapi induc innat
lymphocyt protect respons t-cell
vaccin

192: Valproic Acid (46)

acid ASSOCI case cell children chromatin
disord effect epilepsi gene histon
patient report seizur
stress studi suggest suicid time
treatment

193: RNA (686)

express function
analysi cdna cell differenti dna
gene identifi level melanoma mice
microarra mrna polymeras profil protein rna
sequenc transcript

195: Bromodeoxyuridine (115)

cellular cycl develop
cell
differenti effect express function gene
induc mice number pcna prolif **prolifer** regul studi
suggest termin tissu

197: S-Phase Kinase-Associated Proteins (29)

arrest **cell cycl** cyclin
cyclin-depend degrad increas individu inhibitor
kinas p21 p27 phase progress prolif protein
regul respons retinoblastoma role

199: Sirolimus (94)

cell donor effect human inhibit
activ
kinas pathwai patient phosphatas
phosphoryl protein receptor regul **signal**
src stat3 target transplant tyrosin

194: Azacitidine (108)

aberr cpg demethyl dna epigenet gene
hypermethyl inactiv island mechan
methyl methyltransferas mgmt p16
promot rassf1a region silenc statu suppressor

196: Antimetabolites, Antineoplastic (257)

activ advanc agent cancer chemotherapi
combin dai drug gene median methyl
patient rate regimen respons
studi surviv therapi toxic treatment

198: Cyclin-Dependent Kinase Inhibitor p27 (183)

arrest cdk cdk2 **cell** cell-cycl cip1
cycl cyclin cyclin-depend inhibitor
kinas p21 p27 phase prb progress prolif protein
regul retinoblastoma

200: Antineoplastic Agents (2119)

advanc agent cancer cell chemotherapi
clinic cytotox drug effect efficac improv
patient target therapeut
therapi toxic treat
treatment trial tumor

201: Antibiotics, Antineoplastic (191)

agent anticanc cancer cell chemotherapeut
chemotherapi cisplatin combin cytotox
drug effect human paclitaxel patient
resist respons sensit surviv toxic treatment

203: MAP Kinase Kinase 1 (42)

activ cell erk growth human induc inhibit
inhibitor jnk kinas mapk
mitogen-activ p38 pathwai
phosphoryl protein regul role
signal treatment

205: Extracellular Signal-Regulated
MAP Kinases (227)

activ c-jun cell erk erk1 induc inhibit
inhibitor jnk kinas mapk
mitogen-activ p38 pathwai
phosphoryl pkc protein regul
respons signal

207: MAP Kinase Kinase 4 (41)

activ analysi associ cell erk high induc
inhibit inhibitor kinas level low
mapk p38 pathwai phosphoryl
protein regul respons signal

202: Staurosporine (68)

activ apoptosi apoptot bax bcl-2
caspas cell cycl death famili human
increas induc inhibitor kinas mutat protein
repeat respons role

204: CDC2 Protein Kinase (70)

activ arrest cell cycl cyclin
cyclin-depend earli gene growth human inhibitor
kinas p21 p27 phase progress prolifer protein
regul retinoblastoma

206: Proto-Oncogene Proteins c-raf
(42)

activ cell control erk gene group
increas inhibit interact jnk kinas
mapk p38 pathwai phosphoryl
protein regul role signal structur

208: Mitogen-Activated Protein Kinase
Kinases (99)

activ c-jun cell erk erk1 induc inhibit
inhibitor jnk kinas mapk
mitogen-activ p38 pathwai
phosphoryl pkc protein regul
respons signal

209: bcl-X Protein (143)

activ **apoptosi** apoptot bax
bcl-2 caspas caspase-3 cell death increas induc
induct inhibit inhibitor mechan pathwai proapoptot
protein releas surviv

211: Crk-Associated Substrate Protein (4)

activ **cell** earli
famili analysi antibodi interact mechan member mice
moleculer patient plai report **role**
stage studi suggest target tumour

213: Adaptor Proteins, Signal Transducing (351)

activ apoptosi associ **cell** death
domain express function gene
interact kinas mutant mutat
pathwai phosphoryl **protein**
regul role **signal** tyrosin

215: Cyclic AMP-Dependent Protein Kinases (114)

activ analysi c-jun cell erk express gene
inhibit inhibitor jnk **kinas** mapk
mitogen-activ p38 pathwai
phosphoryl protein regul
signal stimul

210: Retinoblastoma-Like Protein p130 (25)

activ arrest **cell** correl cycl
cyclin famili gene interact kinas larg method
p21 p27 **patient** phase process
protein role size

212: Tyrosine (215)

activ **kinas** cell domain effect group inhibit
mechan mutant pathwai
phosphatas phosphoryl protein
receptor role **signal** stat3 structur
studi tyrosin

214: Genetic Markers (872)

allel analysi associ chromosom gene genet
genotyp identifi linkag loci locu map
marker moleculer polymorph
popul qtl region studi trait

216: Natriuretic Peptide, Brain (18)

analysi assai **cardiac**
cardiomyocyt cardiomyopathi detect develop
failur gene **heart** high left level
model peptid respons risk sensit time
ventricular

217: Troponin T (16)

cardiac compar decreas differ express form
function heart **increas** level muscul
patient protein requir role studi
time valu variabl ventricular

219: Biological Markers (897)

biomark cell clinic correl detect elev higher identifi
level marker
increas
measur molecular **patient** plasma potenti predict
serum studi test

221: Vascular Endothelial Growth Factor Receptor-3 (14)

angiogenesi **endotheli**
factor gene growth hypoxia mice
model mutat normal rate respons role
subject target **tissu** treatment
vascular vegf vessel

223: Immunoglobulin Fragments (39)

antibodi antigen autoantibodi
detect develop differ epitop gene human igg
immunoglobulin mab monoclon neutral protein
recogn sera specif studi target

218: Atrial Natriuretic Factor (17)

analysi anim cardiac cluster compar
control express failur gene genom **heart**
high left level model **peptid** rat
rel studi ventricular

220: Connexins (115)

barrier commun connexin contact coupl
cx43 demonstr form **gap** hear
hemochromatosis hfe indic intercellular
iron junction loss
studi suggest tight

222: Vascular Endothelial Growth Factor Receptor-2 (116)

angiogen **angiogenesi** antiangiogen associ
cell densiti develop endostatin
endotheli factor growth
hif-1alpha hypox hypoxia hypoxia-induc
microvessel **vascular vegf** vessel vhl

224: Antibodies, Bispecific (17)

activ **antibodi** antigen
approach bind **cell** concentr control develop
express human mab model monoclon number
role specif studi target tumor

225: Vascular Endothelial Growth Factor A (580)

angiogen angiogenesi antiangiogen densiti
endostatin endotheli factor
growth hif-1 hif-1alpha huvec hypox hypoxia
hypoxia-induc induc microvessel vascular
vegf vessel vhl

227: Green Fluorescent Proteins (936)

cell construct effici egfp enhanc express
fluoresc gene gfp green mutant protein report
stabil stabli transfect transfer transgen transient
vector

229: Tumor Necrosis Factor-alpha (754)

activ apoptosi apoptot cell
chemokin cytokin death express factor
il-8 induc necrosi nf-kappab nuclear
patient receptor respons tnf tnf-alpha trail

231: Receptor, Epidermal Growth Factor (570)

3-kinas activ akt cell egf egfr
epiderm factor gefitinib
growth inhibit inhibitor kinas
pathwai phosphoryl pi3k receptor
signal surviv tyrosin

226: Angiogenesis Inhibitors (266)

agent angiogen angiogenesi cell clinic
endotheli factor growth
hif-1alpha hypox hypoxia hypoxia-induc improv
therapeut therapi treatment trial
vascular vegf vessel

228: Pyrazines (74)

addit cell combin convent data demonstr effect highli
includ multipl myeloma novel
patient potenti provid result simultan singl studi
suggest

230: Boronic Acids (59)

addit cell combin convent data demonstr effect highli
includ multipl myeloma novel
potenti provid result simultan singl studi suggest
treatment

232: Receptor, erbB-2 (377)

amplif assess breast cancer case correl determin evalu
fals her-2 her2 ihc investig neg neu overexpress
posit respect statu trastuzumab

233: Neuregulin-1 (32)

activ affect akt analysi associ
cell egf egfr epiderm factor
gene genet growth inhibitor kinas
pathwai pi3k rate receptor signal

235: Glycoproteins (406)

antibodi bone cell express famili
function gene group human increas level mutat
pathwai patient protein residu signal site
studi tumor

237: S100 Proteins (74)

analysi associ carcinoma case cell
correl express gene level
lymph metastasi metastat node
patient primari protein
studi surviv tissu tumor

239: Na(+)-K(+)-Exchanging ATPase (32)

activ analysi atp ca2+ calcium
channel combin control current
effect famili gene increas ion member
mice mutant respons sodium studi

234: Antibodies, Monoclonal (1007)

antibodi antigen autoantibodi
cell chemotherapi clinic human igg lymphoma mab
monoclon neg neutral patient posit sera specif
therapeut therapi treatment

236: Deoxyadenosines (15)

base compound dai differ effect
express function gene level mean
measur observ pair patient presenc
protein structur studi time
valu

238: Nerve Growth Factors (109)

brain cell chang control develop express factor
gene growth human level mechan
neuron patient protein role
serum studi suggest synapt

240: Antiviral Agents (238)

activ earli hbv hcv hepat hiv hiv-1 host human
immunodefici infect patient question
remain replic therapi treatment viral
viru virus

241: Etoposide (221)

advanc agent apoptosi cancer cell
chemotherapi cisplatin combin
cytotox drug effect paclitaxel
patient regimen respons sensit
surviv therapi toxic treatment

243: Dipeptidyl Peptidases (5)

activ approach cell clone diseas
express gene larg mechan mutat number
protein requir size small specif treatment
tumor vitro vivo

245: Antigens, Neoplasm (480)

analysi antibodi antigen carcinoma cell ctl
epitop express gene immun
immunotherapi induc patient posit protect
respons surviv tissu tumor
vaccin

247: Transforming Growth Factor al-
pha (51)

activ akt cell develop differ egf
egfr epiderm factor
growth inhibit inhibitor kinas
local mice pathwai patient pi3k
receptor signal

242: Alanine (136)

activ bind cleavag codon domain effect function
gene genotyp mutant mutat patient polymorph
posit proteas protein residu serin site
substitut

244: Serine (238)

activ allel control gene genotyp
group kinas model mutant
mutat pathwai phosphoryl
polymorph protein residu respons role signal
site studi

246: Serine Endopeptidases (199)

activ associ cell cleavag contain cystein express
form gene glycosyl human indic level posit proteas
protein residu role serin site

248: Heparitin Sulfate (24)

activ adhes attach cell collagen
evid express extracellular function human
integrin interact matrix method migrat
molecul role sulfat support surfac

249: Fibroblast Growth Factors (141)

associ cell cultur dai develop
dose effect embryo embryon express factor
fibroblast gene growth medium neural
pattern signal vitro zebrafish

251: Receptor, Platelet-Derived
Growth Factor alpha (32)

c-kit case cell differenti factor gastrointestin

giant gist growth hsp90 imatinib includ

kit malign sarcoma soft

stromal studi tissu tumor

253: Triterpenes (27)

acid activ adduct analog analogu
apoptosi cell chemic combin
compound deriv differ effect
exposur express induc inhibit sampl
select tumor

255: Receptors, Tumor Necrosis Factor
(234)

activ apoptosi apoptot bone cell
control death express factor increas induc level
ligand mechan necrosi nf-kappab patient receptor
sensit trail

250: Sulfotransferases (28)

activ adhes cell chang differ effect
enzym express function gene
human metabol mutat
normal phenotyp protein structur
studi suggest tissu

252: Hydrogen Peroxide (188)

activ antioxid damag enzym free glutathion
increas induc level oxid oxygen
peroxid protect radic reactiv reduc ros speci
STRESS superoxid

254: bcl-2-Associated X Protein (273)

activ anti-apoptot apoptosi
apoptot bax bcl-2 caspas caspase-3 cell death
induc induct inhibit inhibitor mechan pathwai
proapoptot protein releas surviv

256: Amino Acid Chloromethyl Ke-
tones (35)

activ apoptosi apoptot bax
bcl-2 caspas caspase-3 cell chang combin
death effect human induc induct model pathwai
protein respons tumor

257: Antineoplastic Agents, Hormonal
(201)

breast cancer cell clinic combin
effect estrogen express function increas mcf-7 patient
prostat receptor respons surviv tamoxifen therapi
treatment women

259: Taxoids (259)

advanc cancer **chemotherapi**
cisplatin combin cycl dai docetaxel drug
gemcitabin grade median month
patient phase regimen respons
surviv toxic treatment

261: Vinblastine (102)

advanc agent cell **chemotherapi**
cisplatin combin cycl dai drug grade median
month **patient** phase regimen
resist respons surviv toxic treatment

263: Mitomycin (80)

agent anticanc cancer cell chemotherapeut
chemotherapi cisplatin cytotox develop dna
drug effect group paclitaxel patient
respons sensit studi toxic treatment

258: Estramustine (22)

advanc androgen **cancer** chemotherapi
clinic combin effect increas patient progress
prostat psa respons studi surviv therapi toxic treat
treatment trial

260: Antineoplastic Agents, Phytogetic
(356)

agent anticanc cancer **cell**
chemotherapi cisplatin combin cytotox
drug effect human inhibit paclitaxel
patient respons sensit surviv toxic treat
treatment

262: Camptothecin (222)

activ advanc agent cancer
chemotherapi cisplatin combin
cytotox dai **drug** median paclitaxel
patient phase rate regimen
respons surviv toxic treatment

264: Telomerase (315)

activ cap cell cellular end htert **human**
length maintain mainten mechan replic revers
senesc shorten suggest **telomer**
telomeras transcriptas trap

265: Catechin (49)

certain complement compon defin demonstr determin
gener highli identifi includ known major natur
particular provid **specif** tea type uniqu
util

267: Dobutamine (7)

cardiac compar dai decreas detect earli
form format **function** genom heart
increas isol model
patient polymorph posit rate
specif valu

269: Glyceraldehyde-3-Phosphate Dehydrogenases (19)

associ chang differ effect **express** famili
gene **human** level method mrna
normal protein recombin regul role sampl
studi tissu valu

271: Culture Media, Serum-Free (96)

activ **cell** condit **cultur** differ
differenti **express** fibroblast function gene group
human increas induc inhibit level media medium
role vitro

266: Cardiotonic Agents (17)

cardiac chang earli
function heart
human left **mechan** model
molecular **patient** rate
respons role stage **studi** time
treatment ventricular year

268: Antidepressive Agents (54)

adhd anxieti **associ** behavior bipolar depress
disord estim major mental method
patient person psychiatr **respons** serotonin sleep
studi symptom treatment

270: CCAAT-Enhancer-Binding Protein-delta (12)

acid activ analysi assai **cell** control
differenti effect **express** factor **gene**
growth **human** increas induc
level patient **promot** **respons**
transcript

272: Suspensions (6)

assess **cell** clinic concentr cultur data
dynam effect mean measur method
model paramet **patient**
popul predict ratio respect score valu

273: Receptor, Notch1 (51)

character **conserv** control delta
evolutionarily function highli homolog
homologu human ident identifi mammal
mammalian mous notch ortholog
similar suggest vertebr

275: Cation Transport Proteins (129)

activ associ barrier channel
diseas express function gap
gene genet haplotyp increas iron
junction **membran** patient
polymorph protein studi transport

277: DNA-Directed DNA Polymerase (161)

analysi chain detect **dna** duplex fragment gene
genom helicas mutat pcr pol polymeras reaction replic
sequenc single-strand strand studi synthesi

279: Glucose (249)

activ associ cell cerevisia **diabet**
effect enzym fast function gene glucos growth
increas **insulin** mellitu metabol peroxisom
saccharomyc studi yeast

274: Receptors, Cell Surface (638)

activ alpha beta cell **conserv** cytokin express
function gene human identifi mammalian
mous mutat pathwai protein
receptor respons role signal

276: DNA, Mitochondrial (602)

analys cytochrom divers **dna** genet indic involv
membran **mitochondri**
mitochondria mtdna oxidas phylogenet popul
relationship sequenc **speci** suggest tree variat

278: Amino Acids (207)

acid amino analysi codon composit differ
fatti genom nucleic patient protein rate residu retino
retinoid select site structur studi substitut

280: Immunoglobulin Light Chains (36)

analysi **antibodi** antigen
cell detect differ form format gene
gener human level lymphoma normal
patient region select sequenc
tissu treatment

281: Immunoglobulin G (244)

antibodi antigen
activ autoantibodi cell epitop human igg immun
immunoglobulin mab monoclon neutral patient
recogn respons sera specif studi vaccin

283: Calcium-Binding Proteins (162)

activ analysi cell conserv domain express
function gene highli homolog human
identifi mammalian mous plai
protein role structur studi
suggest

285: Analgesics (28)

activ arthriti combin dai differ diseas
effect function genet genom health model pain
patient rat receptor role studi subject
treatment

287: Protein Subunits (315)

activ assembl biochem **complex**
compon compos contain essenti form format function
interact mediat process protein receptor recruit requir
structur subunit

282: Immunoglobulin Heavy Chains (136)

antibodi b-cell case cell cil develop differ
hodgkin human immunoglobulin larg lymphocyt
lymphoma malign nhl
non-hodgkin region rituximab sequenc studi

284: Oligonucleotides (269)

activ analysi bind detect differ **dna**
express gene gener genom hybrid promot region
replic rna sequenc site specif structur target

286: Carbon Isotopes (60)

approxim carbon determin electron
energi exchang experi fluoresc
free measur mol product proton reaction
solut spectra spectral spectroscopi
transfer yield

288: Succinate Dehydrogenase (31)

activ analysi case cell chang clinic combin
control dna gene hormon
mitochondri mitochondria
mtdna mutat **patient** rate
studi subject thyroid

289: Electron Transport Complex I (29)

activ analysi compar complex control
cytochrom dna express function gene indic involv
mitochondri
mitochondria mtdna mutat protein rate suggest
valu

291: Alkaline Phosphatase (106)

alkalin bmd **bone** calcium cell densiti
differ express fractur gene hip miner osteoblast
osteoporosi patient protein skelet spine studi
vitamin

293: Erythropoietin (85)

abnorm anaemia anemia caus cell defect
defici disord epo erythrocyt erythroid
erythropoietin g6pd hemoglobin increas model
normal patient sever studi

295: Apolipoproteins E (217)

apoe apolipoprotein associ atherosclerosi
chd **cholesterol** diseas genotyp
hdl increas ldl level **lipid**
lipoprotein metabol plasma polymorph
studi total triglycerid

290: Mitochondrial Proteins (174)

activ apoptosi associ cell cytochrom dna effect
function gene indic involv membran
mitochondri
mitochondria mtdna oxidas potenti protein resist
suggest

292: Amyloid (69)

abeta **accumul** amyloid caus
degrad deposit diseas famili form gene increas
lead lysosom mutat precursor protein reduc
report storag suggest

294: Actins (398)

actin activ **cell** cytoskelet
cytoskeleton express fak filament format
function gtpase **migrat** motil myosin polar
protein regul requir rho role

296: MADS Domain Proteins (36)

arabidopsi chang control develop differ flower
function gene group increas leaf leav patient
plant pollen protein root seed thaliana
transgen

297: Homeodomain Proteins (633)

activ associ cell **develop** differenti earli
embryo embryon **express** factor
gene mous mutat neural pattern
promot regul role **transcript**
zebrafish

299: STAT3 Transcription Factor (154)

activ cell constitut demonstr express
inhibit **kinas** mtor pathwai
phosphatas phosphoryl protein rapamycin
receptor regul role **signal** src stat3
tyrosin

301: Ciliary Neurotrophic Factor (8)

anim area cell **combin** decreas develop
differenti earli **effect** enhanc
increas local mice
model organ **protein** receptor
reduc stage studi

303: Mitogen-Activated Protein Kinases (224)

activ c-jun cell erk induc inhibit
inhibitor jnk **kinas** mapk
mitogen-activ p38 pathwai
phosphoryl protein receptor regul
role signal stimul

298: Growth Substances (135)

cell clinic develop differenti effect **factor** function
growth height hormon igf-i insulin-lik
model patient regul role studi target therapi treatment

300: Basic Helix-Loop-Helix Transcription Factors (179)

activ cell **conserv** develop differ differenti
express factor function **gene** mous promot
protein regul repress respons stem studi suggest
transcript

302: Otx Transcription Factors (15)

analysi area **develop** embryo embryon
express famili gene genom
growth identifi interact method neural
pattern **region** respons
sequenc specif studi

304: Peptide Hydrolases (100)

accumul **activ** analysi **cell** chang
complex degrad differ express **gene**
increas invas matrix model process
protein residu role **site**
suggest

305: Acyl Coenzyme A (15)

acid activ amino base data develop
effect ENZYm express fatti genom group human
increas isol model protein role structur substrat

307: Monosaccharide Transport Proteins (58)

associ cell **diabet** differ express
function gene glucos growth human insulin
metabol mutat normal patient protein respons
studi tissu yeast

309: Silicon Dioxide (34)

chang composit deliveri determin differ
effici extract high intens laser **light**
measur method observ organ particl
prepar studi surfac time

311: Calcium Hydroxide (1)

compar complex control data differ error estim
group induc induct kinet lesion light
method power respond **respons** signific state
statist

306: Glucose Transporter Type 1 (24)

ASSOCI cell control diabet differ distribut
endotheli **express** factor gene
group human increas level
local region respons studi vascular vegf

308: Zirconium (9)

assess blue color composit differ evalu extract
intens laser **light** measur method
model observ red score shed studi
treatment valu

310: Resin Cements (15)

blue captur color composit cure dark differ dye
effect group human intens laser **light**
observ red shed studi time unit

312: Composite Resins (43)

blue captur color colour composit cure dark differ
dye influenc intens irradi laser **light**
observ red shed studi time unit

313: rho GTP-Binding Proteins (96)

actin activ **cell** cytoskelet
cytoskeleton filament format gtpase mechan
migrat motil myosin polar protein regul
respons rho role signal suggest

315: Cisplatin (489)

advanc **agent** anticanc cancer
chemotherapi cisplatin combin cytotox
drug effect median paclitaxel
patient phase regimen respons sensit
surviv toxic treatment

317: RNA, Ribosomal, 28S (18)

analysi bacteria divers dna element eukaryot
evolut **gene** genet genom insert method
phylogenet rdna region role rrna select
sequenc speci

319: Methylenetetrahydrofolate Reduc-
tase (NADPH2) (124)

associ bleed coagul **factor** fibrinogen
folat folic homocystein leiden mthfr plasma
platelet prothrombin reductas risk studi
thrombin thrombosi venou vitamin

314: Oligonucleotides, Antisense (244)

antisens cell effect express function gene
inhibit interf **interfer** knockdown
oligonucleotid **rna** rnai short silenc
sirna small specif suppress target

316: RNA, Ribosomal, 16S (218)

16s analysi bacteri bacteria base commun
divers eukaryot **gene** isol microbi organ
phylogenet rdna ribosom **rrna**
sequenc similar **speci** strain

318: DNA, Ribosomal Spacer (92)

analys analysi base clade close data diverg genu
group isol molecular morpholog phylogenet
phylogeni relat relationship sequenc
speci strain tree

320: Niacinamide (13)

activ caus cell control **develop**
differ effect **enzym** function
gene increas mechan model mutat
patient **structur** studi substrat treatment
year

321: Carbon Dioxide (93)

carbon compar control determin
develop effect electron **energi**
free imag increas **measur** process
rate respons solut spectroscopi
studi tissu transfer

323: Cyclophosphamide (252)

advanc chemotherapi combin dai grade
lymphoma median month **patient**
phase rate receiv regimen **respons** surviv
therapi **toxic** transplant treat treatment

325: Receptors, Progesterone (144)

associ **breast cancer** cell
correl estrogen function gene group increas mcf-7
ovarian **patient** receptor respons signific studi surviv
tamoxifen **women**

327: DNA, Bacterial (597)

analysi bacteri bacteria coli divers dna
escherichia fragment gene gener infect **isol**
pcr restrict rrna sequenc speci **strain**
toxin type

322: Ki-67 Antigen (242)

assess **correl** evalu grade higher index
invers ki-67 lesion neg observ paramet posit relat
relationship **signific** stain statist studi surviv

324: Doxorubicin (373)

agent anticanc cancer cell chemotherapi
cisplatin combin cytotox doxorubicin
drug effect lymphoma paclitaxel
patient resist respons sensit surviv toxic
treatment

326: Receptors, Estrogen (269)

associ **breast cancer** cell
differ endometri estrogen express gene group mcf-7
number ovarian **patient** receptor respons studi surviv
tamoxifen **women**

328: Deoxyribonucleases, Type II Site-Specific (90)

allel amplif amplifi analysi associ detect
differ **dna** fragment gene
genom **genotyp** isol length method pcr
polymorph primer restrict
sequenc

329: Bacterial Outer Membrane Proteins (77)

analysi antibiot bacteri bacteria coli differ
express gene host infect **isol** membran
pathogen protein sequenc specif
strain structur studi type

331: DNA Helicases (204)

dna duplex effici famili fork gene
damag helicase mechan mutat number pol polymeras recomb
repair replic single-strand strand studi synthesi

333: Metalloproteins (24)

activ alter analysi bind cell
chang data determin effect
enzym express increas
number process protein region sequenc
structur studi substrat

335: Carbon Monoxide (21)

cell control decreas **effect** energi
experi form **increas** inhibit initi
measur model product rate reduc risk
state structur **studi** time

330: Xeroderma Pigmentosum Group D Protein (21)

adjust **ASSOCI** break case compar confid
control **damag dna** factor group
increas interv odd polymorph ratio **repair**
risk smoke studi

332: Molybdenum (11)

acid **activ** anim bind differ earli energi
experiment form format **group** high
low **model** respons structur studi therapi
treatment year

334: Aldehyde Oxidoreductases (19)

acid activ associ cell compar earli
enzym express function gene
high higher human increas level new
number **rate** substrat treatment

336: Microfilament Proteins (189)

actin **activ** adhes **cell** chang
cytoskeleton express filament gene gtpase
migrat model motil polar protein
regul rho role studi suggest

337: Protozoan Proteins (149)

compar differ evalu exact falciparum gene genom

hypothesi malaria mutant parasit perform plasmodium

protein rna sequenc signific statist studi **test**

339: Interferon Type I, Recombinant (14)

activ cell clinic develop effect

express famili form

format gene group infect member number

patient role studi therapi

treatment viru

341: Protein Kinase Inhibitors (272)

activ akt cell egfr epiderm
factor growth inhibit inhibitor

kinas pathwai phosphoryl

protein receptor signal **target**

therapeut therapi treatment tyrosin

343: Pyrimidines (310)

activ **acut** aml cell chronic effect

human imatinib kinas **leukemia**

mds myeloid patient respons sarcoma

stromal studi target treatment tumor

338: DNA, Protozoan (97)

analysi assai clone detect differ dna fragment gene

genom infect **isol** per region sampl sensit sequenc

speci strain studi **test**

340: Proto-Oncogene Proteins c-kit (176)

c-kit case cell differenti gastrointestin gene

giant gist hsp90 imatinib includ **kit** malign

sarcoma soft stromal sts

studi tissu **tumor**

342: Piperazines (272)

activ **acut** aml cell chronic imatinib kit

leukaemia **leukemia**

lymphoblast malign mds myeloid patient

sarcoma stromal studi therapi treatment

tumor

344: Biological Response Modifiers (24)

analysi assess cell clinic combin diseas effect

enhanc evalu function improv measur

patient respons score studi system

therapi treat **treatment**

345: RNA, Helminth (12)

activ differ elegan express function **gene**
genom human life method new pattern protein
report rna sequenc speci specif studi time

347: Avian Proteins (23)

activ analysi cell chicken cluster control
develop differ express **gene** identifi
individu japanes protein rate
role sequenc studi suggest time

349: Quinolones (43)

activ affect **cell** cox-2 dai differ dose
effect increas infect inhibit
inhibitor mechan rate reduc
resist studi suggest target treatment

351: Alkyl and Aryl Transferases (71)

activ agent cell chemoprevent COX-2 drug effect
enzym gene inhibit **inhibitor**
model potenti prevent reduc select studi suggest
target treatment

346: Microphthalmia-Associated Transcription Factor (26)

cell data differ differenti elong express genom
mechan melanocyt **melanoma** mirna model
polymeras prolifer protein **rna** rnase role
specif transcript

348: Proto-Oncogene Proteins p21(ras) (39)

activ analysi associ **cell** control
decreas effect enhanc express human
increas inhibit interact level
overexpress p53 patient suggest transform
treatment

350: Pyridines (142)

activ cell chemotherapi
compound **effect** function group
increas inhibit **inhibitor**
kinas patient
phosphoryl protein receptor requir
respons studi therapi treatment

352: Farnesyltransferase (45)

agent chemoprevent COX-2 cyclooxygenase-2 drug
effect increas inhibit **inhibitor**
patient potent potenti prevent prostaglandin reduc
select suggest suppress target treatment

353: Piperidines (89)

activ cell clinic concentr cycl
dai develop dose effect
group human increas inhibit
inhibitor model patient
receptor studi treatment
trial

355: Arsenicals (49)

activ acut cell concentr effect glioblastoma
glioma includ increas indic leukemia malign
model primari protein sampl
secondari studi suggest treatment

357: Glial Fibrillary Acidic Protein (89)

adult astrocyt brain case cell control differ express
glial glutam hippocamp mice model
neuron patient primari report
studi suggest synapt

359: Antigens, CD34 (251)

acut adult cell differenti embryon express
group hematopoiet high hsc human leukemia lineag
patient potenti precursor progenitor stem
transplant tumor

354: Immunosuppressive Agents (260)

acut allogene allograft autolog condit disease donor
effect follow graft immunosuppress patient receiv
recipi reject stem surviv therapi
transplant treatment

356: STAT6 Transcription Factor (27)

activ cell chang cytokin famili
function gene group ifn-gamma il-10 il-6
immun increas induc interact macrophag
mice product respons role

358: Endostatins (57)

activ angiogen angiogenesi antiangiogen
endostatin endotheli factor
gene growth hif-1alpha human hypox
hypoxia hypoxia-induc treatment tumor
vascular vegf vessel vivo

360: Folic Acid (118)

associ bleed coagul factor fibrinogen
folat folic homocystein leiden mthfr plasma
platelet prothrombin reductas risk studi
thrombin thrombosi venou vitamin

361: Thymidylate Synthase (68)

analysi associ chemotherapi combin effect
express group high increas level nitric
oxid **patient** prognost reduc
studi suggest **Surviv** synthas
synthesi

363: Homocysteine (103)

associ bleed coagul **factor** fibrinogen
folat homocystein leiden level mthfr patient
plasma platelet reductas risk studi thrombin
thrombosi venou vitamin

365: Calcium Channels (103)

activ atp ca2+ calcium cam
channel current develop famili
function gene intracellular ion member patient
potassium potenti releas sodium subunit

367: Asparaginase (22)

acut cell children clinic differ **express**
femal group leukemia male month
myeloid **new patient**
provid respons sampl studi treatment year

362: 3' Untranslated Regions (172)

associ contain gene genom genotyp haplotyp
human initi **3' UTR** nucleotid polymorph
protein **region** ribosom rna
sequenc site translat trna
utr

364: Ion Channels (135)

activ atp ca2+ calcium cam cell
channel current function gene
intracellular ion mitochondri model potenti
protein regul releas respons sodium

366: TRPC Cation Channels (15)

activ atp base ca2+ calcium cam cell
channel current famili featur
function high intracellular ion level low pair
product sodium

368: Prednisone (115)

adult b-cell case chemotherapi clinic dai dose
group **lymphoma** month multipl
patient respons studi surviv
therapi time treat **treatment** year

369: Glucocorticoids (173)

administr case clinic combin dai
dose effect follow gene group increas
patient rat receptor report
studi therapi treat treatment week

371: Spermine (14)

activ adapt assai cell detect effect gene high
increas level marker natur protein respons
select sensit serum specif treatment
valu

373: Nucleoside-Diphosphate Kinase (24)

cell chang correl develop effect
express function gene
group identifi metastasi
phenotyp posit protein reduc
respons role suggest tumor tumour

375: Antigens, CD44 (84)

activ adhes cell express
extracellular increas inhibitor invas
matrix metalloproteinas migrat mmp
mmp-2 mmp-9 normal patient plasminogen
role surviv tissu

370: Carcinoembryonic Antigen (96)

analysi biomark clinic detect diagnost group identifi
immun level marker molecular
patient potenti predict respons select specif studi
tumor vaccin

372: CA-19-9 Antigen (23)

biomark compar detect differ group higher identifi
increas level marker molecular
patient plasma potenti predict rate serum
studi time valu

374: Oncogene Proteins, Viral (109)

associ cancer cell cervic cin
cytolog detect hpv human infect
intraepitheli lesion neoplasia papillomaviru
posit protein signific squamou studi type

376: Naltrexone (8)

alcohol correl depend effect ethanol follow
high level low normal oral rat
receptor region sequenc signific studi tissu
treat treatment

377: Polyamines (46)

activ adapt advantag competit constraint direct
environ evolut evolutionari evolv fit gener increas
maintain natur plastic pressur **select**
strong trait

379: Methylnitroinosoguanidine (18)

activ carcinogen cell chemic damag differ dna
effect expos **exposur** gene
genotox human increas mutagen mutant
number repair time toxic

381: Carcinogens (250)

activ anim carcinogen chemic control dai effect
expos **exposur** genotox increas induc
inject mice mous mutagen **rat** toxic tumor
week

383: Ferric Compounds (28)

acid **activ** analysi base concentr
differ effect function **high**
human increas level low
model number oxid product
rate **respons** studi

378: Ornithine Decarboxylase (21)

activ adapt associ cell constitut develop
enzymat femal function gene inact increas male mice
number rat regul select studi tpa

380: 9,10-Dimethyl-1,2-benzanthracene (32)

activ administr anim cell compar control dai decreas
effect group increas induc inject mice model
rat treat treatment tumor week

382: Antimanic Agents (14)

adhd anxieti associ behavior bipolar case
depress **disord** find function
patient person psychiatr report serotonin sleep
studi symptom therapi treatment

384: DNA, Viral (623)

cervic detect dna gene genom hbv hcv hepat hiv
hiv-1 host hpv human **infect** replic
sequenc vector viral **viru** virus

385: Anti-Bacterial Agents (378)

aeruginosa antibiot antimicrobi aureu bacteri
bacteria biofilm gene host **infect**
isol parasit pathogen patient recomb resist
salmonella staphylococcu **Strain** virul

387: Neuroprotective Agents (85)

anim brain compar control dai develop diseas
effect gene model **neuron**
patient rat reduc role studi therapi tissu treat
treatment

389: Anticonvulsants (99)

associ attempt condit data eeg epilepsi follow
gener idiopath includ involv patient report respons
seizur **stress** stress-induc studi
suggest suicid

391: Androgens (105)

activ androgen **cancer** differ femal
hormon increas level lncap male pc-3 pca progress
prostat psa reproduct role sex studi women

386: Lithium Carbonate (7)

activ adult assai depress detect
disord function gener high increas
level low mechan **patient**
respons risk sensit **studi** time year

388: Antipsychotic Agents (125)

affect associ control disord effect evid
examin find implic influenc involv met possibl relat
report **schizophrenia** signific studi suggest
unaffected

390: Enzymes (98)

activ analysi biosynthesi catalyt data
dehydrogenas develop differ **enzym**
express function gene genet identifi mechan
metabol method popul reaction substrat

392: Hemoglobins (117)

abnorm **activ** anemia **blood** caus count defect
defici erythrocyt erythroid hemoglobin
level lymphocyt normal number patient peripher
respons sever studi

393: Blood Substitutes (7)

analysis compar **concentr**
dai earli effect factor form format gener
group higher increas level measur
method new number rate risk

395: Testosterone Congeners (3)

abil **analysis** blot cancer confirm
correl demonstr detect express normal
northern **number** organ
proporti prostat protein receptor reveal
tissu western

397: Ribonucleoproteins, Small Nuclear (41)

assembl associ **complex** compon
differ essenti form function gene individu interact
patient requir rna sampl splice structur studi
subunit variant

399: Gonadotropins (20)

assist chang cycl follicl fsh
hormon human ivf ovari ovarian
pregnanc reproduct respons **steroid**
stimul studi testosteron treatment
women year

394: Metribolone (3)

abil acid analysis blot cancer demonstr detect
effect event **express** hybrid involv
process properti prostat transcript treat
treatment vivo western

396: Xenopus Proteins (151)

activ **develop** development dna
earli **embryo** embryon **express** gene
interact mous neural oocyt organ pattern
regul requir role vertebr zebrafish

398: Cadherins (315)

basal cadherin **cell** develop differenti
e-cadherin **epitheli** epithelia
epithelium **express** gene gland loss mammari
normal role salivari snail studi tissu

400: Chemokines, CXC (111)

activ alpha chemokin constitut cxcr4
express **factor** il-8 induc inflammatori
necrosi **nf-kappab** nuclear
p65 receptor role suggest tnf tnf-alpha tumor

401: Receptors, CXCR4 (77)

activ alpha chemokin cxcr4 express
factor gene human il-8 induc necrosi
nf-kappab nuclear patient
receptor role sequenc tnf tnf-alpha tumor

403: Archaeal Proteins (60)

16s analysi bacteri bacteria base cluster

commun divers dna eukaryot gene microbi

organ rdna ribosom rrna sequenc similar

speci structur

405: Culture Media, Conditioned (106)

activ cell condit cultur differenti
effect express factor fibroblast growth human
increas inhibit level media medium protein studi
tumor vitro

407: Estrogen Antagonists (41)

activ breast cancer cell
compar control decreas develop effect increas
model normal plai role studi subject tissu
treatment tumor women

402: HIV Envelope Protein gp120 (36)

aids antiretrovir children env gag herp hiv
hiv-1 hsv-1 human

immunodefici increas infect

replic respons select simplex structur viral

viru

404: Endodeoxyribonucleases (59)

activ break cell complex damag develop differ
dna gene group identifi number polymeras
process repair replic sequenc site strand studi

406: alpha-Macroglobulins (9)

activ cell clinic decreas femal gene

high increas level low male

new normal phenotyp select size

studi target therapi tissu

408: Selective Estrogen Receptor Modulators (29)

activ analysi associ breast
cancer clinic develop effect increas
model ovarian plai resist respons role select studi
treatment trial women

409: Estradiol (224)

breast **cancer** cell cycl
endometri estrogen follicl hormon increas level
ovari **ovarian** periton pregnanc progesteron
reproduct steroid studi uterin women

411: Triazoles (94)

breast **cancer** cell clinic
combin effect express improv mcf-7 model new reduc
studi tamoxifen therapi time treat **treatment** trial
women

413: Deoxyribonuclease I (64)

activ assai bind cell chang **dna** element
express factor form **gene** genom identifi
promot region regul replic select
site transcript

415: Capsid Proteins (170)

adenoviru deliveri effici express **gene** hbv hcv
hepat **infect** **isol** region replic sequenc
strain therapi transfer vector viral
viru virus

410: Nitriles (125)

activ associ **breast**
cancer cell control effect express
increas inhibit kinas new pathwai patient
phosphoryl protein signal tamoxifen **treatment**
women

412: Nucleoproteins (21)

activ associ **dna** effect form gene
genom infect mechan molecular **protein**
rate recombin region repeat replic
sequenc **structur** viral
viru

414: Escherichia coli Proteins (317)

bacillu bacteri bacteria bacteriophag **coli**
dna encod **escherichia** gene operon phage
plasmid produc protein pseudomona sigma **strain**
structur subtili toxin

416: Oligonucleotide Probes (98)

analysi arrai design detect fish fluoresc gene
group human **hybrid** label method
microarra oligonucleotid perform **probe** signal
situ specif techniqu

417: Nucleotides (92)

activ analysi base bind control differ
dna gene genom group human model
new nucleotid provid region replic
sequenc structur studi

418: Radon (30)

air area concentr contamin
copper data differ dose estim increas
irradi measur metal method model
popul radiat soil studi
water

419: DNA Transposable Elements (338)

contain copi delet dna element end
gene gener genom host insert
integr locat mobil retrotransposon sequenc
site transpos transposit transposon

420: Twist Transcription Factor (19)

analysi associ cell correl
develop differ express
famili interact mechan mice
normal pattern process region
regul sequenc studi tissu tumor

421: Insect Proteins (122)

adult anophel aphid baculoviru control differ
drosophila fi fly host insect
larva larval melanogast mosquito pheromon
protein speci suggest wing

422: Antigens, Differentiation (130)

activ allele associ cell cytokin express
frequenc function gene genotyp haplotyp
human immun increas patient polymorph
responsn snp studi suscept

423: C-Peptide (13)

case clinic dai decreas diabet
diagnosi diagnost gene glucos group
human increas insulin level patient
resist test time treatment year

424: Amylases (11)

activ analysi detect determin differ distribut
group high level local mean pancreat
patient respect respons reveal
sampl time treatment valu

425: Blood Glucose (228)

adipocyt adiponectin associ **diabet** fast
glucos group increas **insulin** mellitu metabol
nod obes patient peroxisom ppargamma resist studi
subject toler

427: Antigens, CD (657)

activ allel antibodi associ **cell** differ express
gene genotyp human immun lymphocyt lymphoma
mice patient polymorph respons stem studi t-cell

429: Adjuvants, Immunologic (155)

antigen cell control ctl cytokin dendrit differ
effect **immun** immunotherapi
increas induc patient product protect
respons studi treatment trial
vaccin

431: Soil Pollutants, Radioactive (41)

air area concentr **contamin** copper
environment hydrocarbon measur metal pah
pollut radiat rate remov sediment soil sourc
total valu **water**

426: Autoantibodies (192)

antibodi antigen autoantibodi
case direct diseas elisa epitop igg immunoglobulin mab
monoclon neutral patient reactiv recogn sera serum
specif studi

428: Cell Extracts (53)

activ analysi associ **cell** complex damag
detect **dna** extract function high
human level normal protein region repair
sequenc studi tissu

430: Strontium Radioisotopes (21)

air area **chang** concentr
contamin control copper differ
express human measur metal method
patient soil studi subject tumour valu
water

432: Receptors, LH (12)

chang develop effect event express famili
gene hormon **human**
increas level model process product
protein receptor sampl serum studi women

433: GTP-Binding Protein alpha Subunits, Gi-Go (14)

activ adult alpha associ beta bind caus cell
differ function gene group increas mechan
model molecular protein

receptor signal year

435: Cyclic AMP (170)

activ agonist alpha antagonist beta cell effect gene
increas inhibit kinas ligand mutant pathwai

phosphoryl protein receptor
regul signal stimul

437: Hydroxyl Radical (27)

activ antioxid bind damag
develop dna effect form format
interact mechan method oxid
oxygen reactiv region respons site stress
structur

439: Deoxyribonucleases (34)

activ apoptosi bind cell develop dna
function gene human mechan method molecular
number patient plai protein replic role structur
target

434: GTP-Binding Protein alpha Subunits (18)

activ alpha beta cell develop express
femal function gene human identifi increas
male mutant phenotyp rate
receptor signal test wild-typ

436: Chorionic Gonadotropin (45)

assist compar control cycl differ follicl

group higher hormon human

level ovari ovarian pregnanc rate

reproduct steroid stimul studi

women

438: Viral Proteins (501)

construct contain dna effici gene genom hbv hcv
hepat host infect plasmid protein
recombin replic rna sequenc viral
viru virus

440: DNA-Directed RNA Polymerases (107)

activ coli control develop differ dna function
gene gener isol melanoma model
polymeras protein rna sequenc
strain studi transcript type

441: Germanium (4)

abil case demonstr electron enhanc extract
layer light microscop **microscopi**
morpholog normal observ potenti
properti requir structur **studi** surfac
tissu

443: Erbium (1)

blue captur color colour composit cure dark differ
dye effect intens irradi laser **light**
observ red shed studi time unit

445: Lactic Acid (64)

acid activ amino cell compar
concentr control differ effect enzym
function **group** increas muscul patient
produc product reduc studi surfac

447: Focal Adhesion Kinase 1 (54)

actin activ adhes associ **cell**
cytoskeleton express filament format gene
gtpase increas level mechan **migrat** motil
polar protein regul rho

442: Aluminum Oxide (9)

alter **chang** clinic compar concentr differ
dose effect gener **group** improv
irradi light mean measur radiat studi subject
trial valu

444: Focal Adhesion Protein-Tyrosine Kinases (55)

actin activ adhes **cell** chang control
cytoskeleton effect filament gtpase increas
kinas **migrat** motil polar protein regul rho
role signal

446: Granulocyte Colony Stimulating Factor, Recombinant (13)

blood bone case Cell clinic concentr dai dose
factor follow level marrow method month
patient risk subject therapi
treatment year

448: Fibroblast Growth Factor 2 (137)

angiogenesi cell condit **cultur**
endotheli express factor fibroblast growth
human hypoxia increas incub induc media medium
vascular vegf vessel vitro

449: Angiogenesis Inducing Agents (31)

angiogen angiogenesi cell
endotheli factor famili
growth hif-1alpha high hypoxia level low
normal prolifer subject therapi tissu
vascular vegf vessel

451: Insulin-Like Growth Factor Binding Protein 1 (11)

analysi anim caus cell children concentr correl effect
factor genom growth increas
model number rate resist respons sequenc studi
treatment

453: Growth Hormone (80)

associ control dai differ effect express factor group
grow growth height hormon igf-i
increas insulin-lik patient rat receptor statur stimul

455: Deoxycytidine (256)

advanc chemotherapi combin cycl
dai docetaxel gemcitabin grade median
metastat month patient phase
rate receiv regimen respons surviv toxic
treatment

450: Hepatocyte Growth Factor (95)

action activ block cell decreas effect express
factor growth hgf increas induc
inhibit inhibitor inhibitori mechan
mediat prevent suggest suppress

452: Receptor, IGF Type 1 (51)

autocrin effect express factor final grow
growth height hormon igf igf-1 igf-i
igf-ii igf-ir igfbp-3 insulin-lik receptor role statur stimul

454: Carboplatin (136)

advanc chemotherapi combin cycl
dai docetaxel gemcitabin grade median
metastat month patient phase
rate receiv regimen respons surviv toxic
treatment

456: Spin Labels (19)

condit degre determin effect energi famili
function high increas new number oxid
oxygen protein rat sampl select solut stress

structur

457: HSP70 Heat-Shock Proteins (129)

cold **condit** **degre** differ heat
high hsp hsp70 increas indic investig low observ
physiolog preserv protein shock stress
temperatur thermal

459: Benzoquinones (43)

activ analysi associ **cell** chang
combin control differ effect famili form
function increas mechan model regul resist
studi tumor valu

461: alpha-Synuclein (63)

alpha-synuclein alzheimer associ autoimmun caus
diseas disord gene
common dementia
includ neurodegen onset parkin parkinson pathogenesi
patholog progress studi tau

463: Soil Pollutants (48)

air concentr contamin copper

environment hydrocarbon increas measur

metal organ pah pollut popul remov sampl

sediment soil sourc total **water**

458: Lactams, Macrocyclic (29)

activ cell combin control dai
degre differ effect increas kit mutant
normal pattern process protein sarcoma
stromal **tissu** treatment tumor

460: Quinones (34)

activ analysi associ compound
control effect enzym express form format
identifi increas interact measur **protein**
reduc role screen state suggest

462: Synucleins (77)

alpha-synuclein alzheimer autoimmun caus common
diseas disord fabri gene includ
dementia
neurodegen onset parkin parkinson pathogenesi patholog
progress symbol tau

464: Soil (66)

air associ **concentr** contamin

copper differ eleganc environment level

measur metal model pah pollut rate

sediment soil sourc speci **water**

465: Fungicides, Industrial (26)

activ aspergillu compar concentr
control differ effect fungal
fungi fungu increas isol
pathogen produc product
rat speci studi test treatment

467: Azurin (2)

bind complex demonstr domain find form
imag indic p53 period point previou protein
report stabil state studi suggest **time**
water

469: Fibroblast Growth Factor 3 (3)

activ addit approach complex
develop endogen
enhanc increas individu injuri
modul mutant presenc promot reduc regul
studi suggest transcript trial

471: Synaptotagmins (12)

bind cell decreas demonstr function high
increas level membran mutant
normal presenc protein report role
studi suggest **tissu** tumour vivo

466: Bacterial Proteins (858)

bacillu bacteri bacteria bind **COLI** encod
escherichia **gene** gener host infect
isol operon pathogen phage protein
sequenc **strain** structur toxin

468: Receptors, Glucocorticoid (61)

activ agonist alpha antagonist associ beta combin
effect express function gamma gene genet glucocorticoid
increas ligand mediat **receptor**
respons subunit

470: Transcription Factor RelA (57)

activ alpha associ chemokin constitut
cxcr4 demonstr express **factor** il-8 induc
necrosi **nf-kappab** nuclear
p65 receptor suggest tnf tnf-alpha tumor

472: Receptors, Fibroblast Growth Factor (117)

activ cell condit **cultur** express factor
fibroblast function growth human increas incub
media medium mutat passag patient primari role
vitro

473: Receptor Protein-Tyrosine Kinases (285)

activ acut cell cultur develop
fibroblast function gene kinas leukemia
medium **mutat** pathwai patient
phosphoryl protein receptor **signal** thyroid
tyrosin

475: Fibroblast Growth Factor 10 (12)

cell cultur **develop** embryo embryon
express factor gene
growth hybrid **increas** interact model
mutat neural pattern **protein** rat
regul requir

477: Antimalarials (63)

carri compar comparison differ evalu exact falciparum
fisher hypothesi malaria parasit perform plasmodium
posit resist signific standard statist studi **test**

479: Ethanolamines (14)

adult analysi assai chang correl
detect enzym function
group high **increas** mechan
metabol method rat
receptor respons sensit specif
year

474: Receptor, Fibroblast Growth Factor, Type 2 (29)

associ cell correl **cultur**
fibroblast function gene growth human
medium **mutat** normal process region respons
role sequenc target tissu vitro

476: Triazines (27)

associ cell control dai differ
effect group human
increas individu method model
patient plant respons
select studi time treatment
tumour

478: Fluorenes (14)

activ cell chang **concentr**
detect determin develop dna effect
extract fraction gene **increas**
modif **modifi** protein respons
sampl studi time

480: Interleukin-10 (182)

cell cpg **cytokin** ifn ifn-gamma
il-10 il-4 il-6 immun induc inflammatori
interferon interleukin lps macrophag odn
patient product **respons** stimul

481: Cancer Vaccines (337)

adjuv **antigen** antitumor challeng ctl cytotox
dendrit elicit epitop **immun**
immunogen immunolog immunotherapi induc innat
lymphocyt protect **respons** t-cell
vaccin

483: Genistein (35)

associ **cancer** cell compar develop
differ effect endometri enhanc estrogen
human increas inhibit **ovarian**
patient phenotyp rat studi suggest treatment

485: Dexamethasone (142)

activ addit cell **combin** compar
demonstr dexamethason effect enhanc evalu increas
multipl patient plu respons result simultan singl studi
synergist

487: Glutathione Transferase (405)

control determin domain enzym function
glutathion gst gstm1 gstp1 increas **interact**
involv **modif modifi** null protein
s-transferas signific studi suggest

482: Glycogen (42)

accumul amyloid caus cell
control deposit develop differ diseas enzym
form gene lysosom mutat patient precursor
report size storag suggest

484: DNA, Cruciform (15)

activ base differ **dna** evid famili form
format function gene plasmid polymeras popul protein
rate recombin replic role **structur** support

486: Epidermal Growth Factor (208)

activ akt cell egf **egfr** epiderm
express **factor** gefitinib
growth inhibit inhibitor kinas
pathwai phosphoryl pi3k **receptor**
signal surviv tyrosin

488: Guanosine Triphosphate (54)

actin **activ** associ bind **cell**
control develop form format gene increas
migrat mutant new phenotyp
protein regul requir **structur** studi

489: RNA, Double-Stranded (105)

antisens express **function** gene inhibit
interf interfer knockdown oligonucleotid
region **rna** rna sequenc short silenc
sirna small specif suppress target

491: Galectin 1 (15)

analysi **cell** control differ differenti
express famili function gene **group**
human identifi line **peptid** plai popul
process protein role tumour

493: 5' Untranslated Regions (177)

code conserv contain gene identifi initi locat motif
mrna nucleotid promot protein
region ribosom rna
sequenc site transcript translat
trna

495: Ubiquitin-Protein Ligases (269)

cellular **degrad** **diseas**
finger function genet ligas mutat pathwai prion
proteasom **protein** prp regul role
stabil suggest target ubiquitin zinc

490: Antigens, CD95 (205)

activ **apoptosi** apoptosis-induc apoptot
caspas caspase-8 **cell** death express fasl
group induc induct ligand necrosi pathwai program
sensit surviv trail

492: Viral Nonstructural Proteins (83)

antivir capsid genom hbv hcv hepat host **infect**
infecti influenza packag particl protein replic rna
sequenc viral virion **viru** virus

494: Autoantigens (120)

analysi **antibodi** antigen
cell data differ function gene group
human monoclon number patient protein
repeat respons role specif studi suggest

496: Zinc (99)

activ cell chang concentr **degrad**
develop differ group increas level measur
model proteasom **protein** rat
regul soil studi ubiquitin water

497: Hepatitis B Surface Antigens (56)

associ capsid effect hbv hcv hepat host human
infect infecti normal number patient replic
respons tissu treatment viral **VIRU**
virus

499: Antigens, CD20 (60)

b-cell case chronic cll diffus follicular hodgkin
immunoglobulin larg leukemia lymphocyt lymphoid
lymphoma malign nhl
non-hodgkin patient rituximab t-cell treatment

501: Methotrexate (124)

arthriti associ cell chemotherapi dai diseas
median methods month pain **patient**
rate receiv resist respons surviv toxic treat
treatment year

503: Von Hippel-Lindau Tumor Suppressor Protein (49)

angiogen angiogenesi cell develop
endotheli factor famili
function growth hif-1alpha hypox hypoxia
increas mutat patient studi tumor
vascular vegf vessel

498: Hepatitis B Core Antigens (22)

activ assess associ differ gene **group**
hbv hcv identifi infect measur mutat open
patient rate replic score viral **VIRU**
virus

500: Azathioprine (20)

associ chronic clinic detect develop diseas
effect gene gener **GROUP** inflammatori intestin
metabol **patient** risk sampl studi
system target treatment

502: Quinazolines (218)

activ akt cell egf **egfr** epiderm
factor growth inhibit inhibitor
kinas pathwai patient pi3k **receptor**
signal surviv therapi treatment tyrosin

504: Adenosine Triphosphate (266)

activ atp bind ca2+ calcium cell
channel complex current differ
dna effect **enzym** function
ion mitochondri protein role structur
substrat

505: Receptors, Cytoplasmic and Nuclear (225)

activ agonist alpha antagonist beta cell cytoplasm
express gene ligand local mediat nuclear nucleu
protein **receptor** regul respons role
studi

507: Tissue Inhibitor of Metalloproteinases (27)

activ cell develop express extracellular
human increas inhibitor **invas**
matrix metalloproteinas migrat mmp
mmp-2 mmp-9 plai plasminogen role sampl
tissu

509: Anti-Infective Agents (66)

activ antibiot bacteri bacteria caus clinic
compound develop gene host **infect** isol
parasit pathogen **patient** resist
strain studi treatment virul

511: Lipopolysaccharides (208)

activ cell **cytokin** gene group
ifn ifn-gamma il-10 il-6 immun induc
inflammatori interferon interleukin isol
macrophag mice product respons strain

506: Proteome (217)

analysi analyz capillari data differ
electrophoresi express gel gene
genom identif identifi
mass profil protein proteom separ
sequenc spectrometri spot

508: Adenosine Deaminase (38)

activ adduct analog analogu

compound deriv develop differ

effect **gene** increas level malign mutat

patient pattern region sequenc studi

tumour

510: Invertebrate Hormones (2)

analysi compound core encod flow frame
identifi indic initi open origin produc
product read receptor
recombin report second state studi

512: Molecular Chaperones (187)

cell chaperon character cross-link **dimer** diseas
express fold **form** function gene indic
molecular nativ **protein** solubl
stabil stabl structur suggest

513: Isoleucine (43)

acid allel associ bind codon control differ
famili frequenc gene genotyp mutant
mutat polymorph posit
protein site structur studi substitut

515: Mitogen-Activated Protein Kinase
1 (157)

activ c-jun cell erk express induc inhibit
inhibitor jnk **kinas** mapk
mitogen-activ p38 pathwai
phosphoryl pkc protein regul
respons signal

517: Viral Regulatory Proteins (4)

acid amino assess **bind** domain dynam
evalu flow genom measur **model** neg
plai posit **protein** respons
role score site structur

519: Receptor, Macrophage Colony-
Stimulating Factor (15)

activ bone **cell** chang control differ
differenti **express** factor growth identifi
increas macrophag marrow model normal role
sampl screen tissu

514: Leucine (91)

acid activ associ chang code codon domain
famili function gene identifi **mutat**
nucleotid patient posit protein sequenc studi
substitut suggest

516: Gene Products, gag (61)

aids antiretrovir control env express gag herp
hiv hiv-1 hsv hsv-1 human
immunodefici **infect** interact
replic revers simplex viral **viru**

518: Immunoglobulins (123)

analysi antibodi antigen **cell** chang
class control differ effect express
gene high human increas mice
number patient protein specif studi

520: Mitogen-Activated Protein Kinase
3 (167)

activ c-jun cell erk erk1 induc inhibit
inhibitor jnk **kinas** mapk
mitogen-activ p38 pathwai
phosphoryl pkc protein regul
signal stimul

521: MAP Kinase Kinase 2 (15)

activ analysi cell differ earli
effect induc inhibit kinas
mapk pathwai pattern phosphoryl
protein reduc respons role
sequenc signal stage

523: Fibrinogen (58)

activ analysi associ bleed factor
famili folat function gene high level mthfr
patient platelet protein risk specif studi
thrombosi venou

525: Cell Adhesion Molecules (219)

adhes analysi antibodi associ cell
collagen epitheli express extracellular gene
identifi integrin interact matrix migrat molecul
patient role studi surfac

527: Cell Adhesion Molecules, Neu-
ronal (24)

analysi cell control develop
differ dna epigenet express gene
genet group mechan methyl
model neuron promot reveal role studi
suggest

522: Fatty Acid Synthetase Complex
(22)

acid activ amino cell control express fatti
genom human mechan molecular neg nucleic posit
retino retinoid role studi substitut tissu

524: C-Reactive Protein (93)

albumin circul compar concentr correl crp determin elev
higher increas level lower marker measur
patient plasma risk serum signific total

526: Extracellular Matrix Proteins
(167)

activ adhes analysi associ cell
collagen express extracellular gene
genet integrin matrix methyl molecul
mutat patient protein studi surfac
tissu

528: COUP Transcription Factors (4)

cell conserv develop earli genom
human identifi interact late
mammalian phase progress protein region screen
sequenc stage structur target test

529: Receptors, Steroid (73)

activ agonist alpha antagonist beta bind control differ
express famili gene human level ligand mediat metabol

receptor regul role studi

531: COUP Transcription Factor II (3)

analysi associ blot conserv
develop express
famili identifi initi interact loss mammalian
marker member origin protein region
sequenc signal western

533: Deoxyribonuclease BamHI (7)

analys analysi associ base
bind blot correl detect dna express gener
normal phenotyp posit
protein reveal site test tissu western

535: Cesium Radioisotopes (41)

activ air area Concentr contamin
copper differ dose environment irradi
measur metal model pollut radiat size
soil sourc studi water

530: COUP Transcription Factor I (2)

acid adapt amino cell conserv develop
differenti earli express induc
induct late mammalian phase prolifer receptor
respons select signal stage

532: Lactates (15)

associ concentr differ effect enzym
extract high imag level mean
measur patient product
protein regul respect studi subject
valu volum

534: Epstein-Barr Virus Nuclear Anti-
gens (31)

associ character characterist consist contribut correl
displai distinct ebv epstein-barr exhibit identifi includ
indic lack latent observ phenotyp
similar suggest

536: Thioguanine (10)

activ base cell compar content
control determin differ effect
flow function group mice mutat
observ pair protein respons signific
treatment

537: Air Pollutants (87)

air chemic concentr contamin copper

environment exposur hydrocarbon measur

metal organ pah pollut remov sediment soil

sourc studi total water

539: Benzo(a)pyrene (57)

activ air cell concentr contamin

copper effect environment exposur

express human measur metabol metal

pollut respons SOIL sourc studi

water

541: Complement Inactivator Proteins (16)

bind complement defin demonstr determin develop differ gener highli human known major natur protein

provid regul specif test unigu util

543: Heat-Shock Proteins (201)

cold condit degre differ gene

heat high hsp hsp70 increas indic low observ physiolog preserv protein shock stress temperatur thermal

538: Hypoxanthine Phosphoribosyl-transferase (43)

activ analysi cell chang control defici effect enzym expos exposur gene genom

increas model mutant mutat sequenc studi test toxic

540: Gene Products, rev (16)

activ cell chang genom high

hiv hiv-1 immunodefici

increas infect local

nuclear respons select

sequenc structur target

tissu viral Viru

542: alpha-Crystallins (3)

bind cancer complex concentr condit

degre domain gener high infect

length level long low protein repeat

requir short structur test

544: Porphyrins (29)

chang compar control decreas differ effect gene increas light mutat observ patient phenotyp region retin sequenc studi treat

treatment visual

545: Photosensitizing Agents (49)

blue captur cell color composit cure differ dye
effect intens irradi laser **light** observ
red retin shed studi time treatment

547: HMGB Proteins (20)

cell differenti evolut express gene
genom **group** human increas interact level
mutat plai posit progenitor protein requir role
stem transcript

549: GABA Plasma Membrane Transport Proteins (3)

analys **analysi** base cleavag clone contain
indic initi mutant origin pair plai residu
reveal **role** second **site** specif state
suggest

551: Sodium, Dietary (8)

area assess **concentr** correl
decreas determin effect higher increas lower
measur microg microm min plasma respect
signific studi subject time

546: Transcription Factor CHOP (28)

activ apoptosi
cell combin control decreas effect
express gene group **increas**
induc level patient promot **protein**
requir respons role time

548: Membrane Transport Proteins (306)

activ allele associ bipolar depress
disord famili gene genotyp
membran mutat patient person
polymorph protein psychiatr **resist**
studi symptom transport

550: Thymidine Kinase (87)

cell chang effect enzym express **gene**
group hiv hiv-1 human immunodefici increas
infect model studi therapi transfer vector
viral viru

552: Iodine (21)

adenoma adren **area** cell children
compar **develop** differ express health
higher hormon number pituitari rate risk
studi subject **thyroid** valu

553: HLA-B27 Antigen (16)

allel antigen chines **class** compar
control data develop differ
frequenc gene **group** major mhc molecul
patient respons signific studi subtyp

555: Cholinesterases (9)

activ compar concentr dai differ
dose effect evolut expos **exposur** inhibit mean
pattern respect respons studi subject time
toxic valu

557: Butyrylcholinesterase (16)

associ carcinogen chemic control effect enzym
expos **exposur** frequenc
function genotox human interact mutagen
mutat new **patient** rate studi
toxic

559: Furosemide (4)

caus center conclusions dai decreas design
dose hospit **increas** level main
medic month normal objective **patient**
record studi tissu year

554: Succinylcholine (4)

analysi blood case chain diseas exposur factor
follow genet muscul **patient**
period point region regul risk sequenc skelet
time variabl

556: Neuromuscular Depolarizing Agents (4)

blood chain clinic dai diagnosi exposur factor
muscl **patient** pcr period point
polymeras reaction revers risk skelet splice
time variant

558: Diuretics (19)

activ associ compar concentr control dai
effect enhanc gene genet group higher increas
level number **patient** rate
respons studi valu

560: Chitosan (26)

activ cation conjug deliveri dna
effici formul group liposom nanoparticl
particl polym prepar properti releas
respons solut subject **surfac**
treatment

561: Minerals (20)

activ analysi avail chain
correl data databas
develop differ effect evid
health mice model pcr
protein provid rate
reaction studi

563: Antigens, CD59 (9)

assess cell combin complement demonstr determin
flow highli human increas major mechan mutant
natur protein radiat regul respons
specif util

565: Antigens, CD55 (20)

analysi complement defin demonstr determin develop
effect express function highli human major method
natur normal protein sampl specif tissu
util

567: Complement System Proteins (37)

cell complement defin demonstr determin express
famili femal function gene gener highli identifi increas
major male natur provid specif util

562: Antigens, CD46 (10)

chang complement control demonstr determin
differ function gene genom human identifi
major mechan mice number patient regul
respons specif vector

564: Complement Factor H (21)

associ bind complement control demonstr
determin develop factor gene genom highli human
major polymorph protein provid risk sequenc
specif util

566: Receptors, Complement (12)

bind compar complement control demonstr
determin differ function human identifi interact
mechan molecular patient phenotyp protein rate
regul respons specif

568: Complement C1 Inactivator Proteins (7)

clinic combin defect defici diagnosi
diagnost effect function interact
patient popul protein regul
risk sever specif studi therapi treat
treatment

569: Serpins (76)

express ^{analisi carcinoma cell control}
famili gene identifi
increas inhibitor member normal patient
protein role site structur studi tissu
tumor

571: Interleukin-1 (184)

cytokin ^{allele associ} gene
genet genotyp ifn ifn-gamma il-10 il-6
immun induc inflammatori interferon
interleukin macrophag patient
polymorph product respons

573: Receptors, Antigen, B-Cell (72)

cell ^{activ associ b-cell} develop differ
express high kinas lymphocyt
lymphoma ^{mechan mice phosphoryl}
protein role sequenc signal studi tyrosin

575: B-Cell-Specific Activator Protein (20)

cell ^{activ analysi} data develop differ
differenti earli express level lymphoma
mice mous prolifer role stage studi time
transcript tumour

570: Receptors, Interleukin-1 (41)

cytokin ^{allele cell control} develop
express function gene genotyp
ifn-gamma il-10 il-6 immun induc macrophag
patient ^{polymorph}
respons ^{tissu treatment}

572: Immunoglobulin Variable Region (116)

antibodi ^{antigen b-cell cell}
control develop evolut gene human
immunoglobulin lymphocyt lymphoma mab
monoclon neutral patient recombin region
sequenc specif

574: Immunoglobulin J-Chains (3)

function ^{adult base clone combin effect} gene gener involv isol
mechan ^{molecul}
presenc region report sequenc studi
underli understand year

576: Serotonin Plasma Membrane Transport Proteins (78)

depress ^{adhd anxieti associ behavior bipolar}
disord ^{find gene hyperact ill major}
mental person psychiatr serotonin sleep studi
symptom transport

577: Antigens, CD3 (86)

activ blood cd4 cd4+ cd8 cd8+ **cell** control
cytotox effector express il-2 immun lymphocyt natur
patient respons studi t-cell ter

579: ZAP-70 Protein-Tyrosine Kinase (24)

approach associ b-cell **cell** chang data
express function gene group human
lymphocyt **lymphoma**
method model patient predict sampl
select signal

581: Microtubule-Associated Proteins (305)

cell contribut **examin** extent
find indic investig involv later lesser mark
mitot observ possibl protein sclerosi
signific studi suggest survivin

583: gamma-Aminobutyric Acid (45)

acid activ amino analysi brain detect develop
effect express function human mutant mutat
neuron receptor region sequenc
studi suggest synapt

578: Receptors, Antigen, T-Cell (163)

activ antigen cd4 cd4+ cd8 cd8+ **cell** class
express human il-2 immun lymphocyt molecul natur
popul receptor respons t-cell ter

580: Polycyclic Hydrocarbons, Aromatic (41)

activ air chemic concentr contamin
copper environment exposur hydrocarbon
level measur metal pah pollut remov
sediment Soil sourc total **water**

582: Carbocyanines (23)

approach cell control detect differ
fish fluoresc gene group high
hybrid increas
method number plai
probe role situ studi
techniqu

584: 6-Mercaptopurine (18)

ASSOCI children compar control dai effect
factor function group month
patient rate ratio risk signific
studi surviv treat treatment year

585: Methyltransferases (64)

activ associ differ dna enzym epigenet
express function **gene** human inactiv
increas isol mechan metabol
methyl patient promot strain
studi

587: Aminopeptidases (14)

activ associ compar control enzym
famili gene increas inhibit level mechan model
number organ peptid phenotyp respons select
tumour vivo

589: Ubiquitin (295)

cellular **degrad** finger function indic
ligas mechan pathwai prion process proteasom
protein prp regul stabil substrat
suggest target ubiquitin zinc

591: Sodium (77)

activ atp ca2+ calcium **channel**
concentr current decreas
effect function **increas** ion level microg
microm min patient protein sodium structur

586: Histocompatibility Antigens Class II (125)

allele antigen cell **class** complex drb1
histocompat hla hla-drb1 human immun kir leukocyt
major mhc molecul natur present specif type

588: Epitopes (207)

antibodi antigen class
complex ctl differ epitop **immun**
immunotherapi induc mab monoclon neutral
peptid protect protein **respons** specif structur
vaccin

590: Sodium Bicarbonate (4)

anim chang concentr **differ** experiment
human increas level **model**
number patient pattern period point
respons studi subject **time**
valu variant

592: Ribosomal Proteins (117)

cell contain differ express **gene** genom
initi mrna **protein** region resist
ribosom rna sequenc site structur studi
suggest **translat** trna

593: Antigens (120)

activ analysi antibodi antigen **cell**
differ express function gene group immun
lymphocyt patient protein respons specif
structur studi t-cell vaccin

595: HLA-D Antigens (20)

allel analysi antigen associ cell **class**
codon complex develop express histocompat hla
human major mhc model molecul present
produc product

597: Radioactive Waste (14)

activ air **area** base concentr
contamin control copper correl differ
environment metal organ pollut soil sourc
studi time water year

599: Antigens, Surface (100)

activ analysi associ cancer **cell** differ
express function gene human increas
normal number patient protein role specif
studi tissu tumor

594: Antigens, Differentiation, B-Lymphocyte (40)

activ analysi antibodi antigen **cell**
class detect effect **express** flow
group **human** identifi increas
level mice molecul studi target treatment

596: Dimethyl Sulfoxide (32)

activ **cell** compar content determin
develop differenti **express** flow gene higher
human level model observ prolifer rate studi
target tissu

598: Uranium (24)

air approach **area** assess associ

concentr contamin copper

environment human increas measur

metal **number** popul score soil
studi time water

600: Cytotoxins (17)

activ assai associ blood **cell**
control detect **express** gene group high
human increas interact level low product
studi subject treatment

601: Receptors, Immunologic (214)

allel antigen associ cell **class** complex
control cytokin express gene histocompat hla
human immun major mhc molecul present
receptor respons

603: Toll-Like Receptors (154)

activ cpg **cytokin** genet ifn
ifn-gamma il-10 il-4 il-6 immun induc
inflammatori interferon interleukin lps
macrophag odn product **respons**
stimul

605: Plasminogen Activator Inhibitor 1 (69)

activ cathepsin **cell** express extracellular
increas inhibitor **invas** matrix
metalloproteinas migrat mmp mmp-2 mmp-9
pai-1 plasminogen role tissu upa upar

607: Integrases (125)

carri cassett **construct** contain cre effici element
gene gener homolog insert mice mous **plasmid**
recombin select transfer
transform transgen vector

602: Interferon Type I (26)

cell **cytokin** enhanc group human ifn
ifn-gamma il-10 il-6 immun increas induc
macrophag mechan molecular product provid
requir **respons** role

604: Inflammation Mediators (70)

associ cell combin **cytokin** differ
diseas **effect** enhanc function
increas induc measur **patient**
product **respons** role score
stimul studi tissu

606: beta-Galactosidase (216)

activ adenovir adenoviru cell deliveri effici
express **gene** inject mice promot
recombin target therapi transduc transduct
transfer transgen **vector** vivo

608: GTP-Binding Protein alpha Subunits, Gs (23)

activ analysi associ cell develop
express gene identifi individu interact
mutat **patient**
protein rate receptor respons reveal
role studi time

609: Ethanol (135)

abus activ alcohol consumpt depend
drink drug effect ethanol examin indic opioid
oral prefer saliva signific studi substanc
suggest withdraw

611: CD40 Ligand (49)

activ cd4 cds **cell** control differ express
famili function group high immun increas
lymphocyt patient receptor respons t-cell tcr
treatment

613: ras Proteins (167)

activ c-myc **cell** control express
famili human induc inhibit kinas oncogen
overexpress pathwai phosphoryl
protein regul role signal target
transform

615: Stem Cell Factor (52)

activ analysi **cell** combin develop differ
differenti effect embryon express group hematopoiect
lineag model patient progenitor prolifer protein
stem studi

610: Rh-Hr Blood-Group System (42)

analysi analyz blood china chines
determin **differ** heterogen
includ investig observ peripher popul predomin
respect sampl signific studi
subtyp weak

612: Angiopoietin-1 (27)

angiogenesi cell effect
endotheli express factor
function growth hif-1alpha high hypoxia
level patient plai requir role studi
vascular vegf vessel

614: Receptor, TIE-2 (40)

activ angiogen angiogenesi cell
endotheli express factor
growth hif-1alpha hypox hypoxia
hypoxia-induc mice normal tissu treatment
tumor vascular vegf vessel

616: Macrophage Colony-Stimulating Factor (22)

bone **cell** demonstr differenti express
factor function granulocyt group level macrophag
marrow matur mice monocyt mucl neutrophil
protein stromal studi

617: fms-Like Tyrosine Kinase 3 (62)

acut aml blast cell chronic cml develop
gene gener imatinib leukaemia leukem
leukemia lymphoblast mds
myelodysplast myeloid patient rate syndrom

619: Colony-Stimulating Factors (10)

analysi care cell chemotherapi control data
effect factor famili function
group growth health interact patient studi
surviv therapi treatment year

621: Interleukins (66)

activ cell combin cytokin effect
express famili gene human il-6 immun increas
induc level patient popul product respons
role studi

623: HIV Protease Inhibitors (47)

aids antiretrovir associ differ function gag
herp hiv hiv-1 hsv-1 human
immunodefici infect patient
replic resist simplex structur viral

viru

618: Chemokines (79)

activ cell chemokin express
factor famili function gene human il-8
induc necrosi nf-kappab
nuclear receptor respons role tnf
tnf-alpha tumor

620: Interferons (78)

activ analysi cell cytokin data estim
function ifn-gamma il-10 il-6 immun
induc infect macrophag patient
respons studi treatment viral
viru

622: Semaphorins (19)

activ cell data delet develop dna effect
function gene interact loss
methyl migrat mutant patient plai promot
regul role suggest

624: 3-Isopropylmalate Dehydrogenase (5)

activ assai clone control detect diverg duplic
enzym evolut evolutionari gene isol
method origin region sensit
sequenc speci strain substrat

625: Alcohol Oxidoreductases (48)

acid **activ** amino associ cell
enzym gene gener human
identifi increas mutat number **patient** process
protein sequenc specif studi substrat

627: NADP (33)

acid **activ** biosynthesi catalyt catalyz cell
dehydrogenas **enzym** enzymat high
increas level mechan **metabol** product rat reaction
reductas respons substrat

629: Isocitrate Lyase (2)

analys **analysi** approach character defect
enzym express **gener** genom indic
mutant mutat **phenotyp**
region reveal sequenc strategi suggest target
wild-typ

631: P-Glycoprotein (138)

abc acquir bcrp confer dox **drug** drug-resist efflux
major mdr **mdr1** multidrug overcom p-glycoprotein p-gp
resist revers sensit suscept transport

626: Acetates (28)

analysi base cell dai decreas effect extract
gene increas level method
patient phenotyp popul process
produc product studi test trial

628: Isocitrate Dehydrogenase (9)

activ biosynthesi catalyt catalyz cell combin
dehydrogenas differenti earli **enzym**
function gene identifi level **metabol** mutant
protein reaction sequenc substrat

630: Multidrug Resistance-Associated Proteins (64)

abc acquir anim confer **drug** experiment human mdr
mdr1 **model** multidrug mutat p-glycoprotein p-gp
resist revers sensit studi suscept transport

632: Vault Ribonucleoprotein Particles (13)

acquir associ bind confer **drug** famili function human
level mdr1 multidrug number plai protein
resist role sampl sensit suscept transport

633: Phospholipase C (54)

activ associ cell channel develop
famili gene human increas kinas mutant mutat
pathwai phosphoryl protein receptor regul role
signal tyrosin

635: Phospholipase C gamma (29)

activ analysi ASSOCI bind cell
famili group human inhibit kinas
model mutant pathwai phosphoryl
protein receptor requir role signal
tyrosin

637: STAT1 Transcription Factor (72)

activ cell cytokin function
gene il-6 immun induc interact kinas
pathwai phosphoryl protein receptor regul
respons role signal target
tyrosin

639: Retinoblastoma Protein (176)

activ arrest **cell cycl** cyclin
cyclin-depend develop express human inhibitor kinas
p21 p27 phase progress prolifer protein regul
retinoblastoma role

634: Protein-Tyrosine-Phosphatase (148)

activ associ cell develop express
gene group **kinas** mice pathwai
phosphatas phosphoryl protein receptor
regul respons **signal** stat3 studi
tyrosin

636: Suppressor of Cytokine Signaling Proteins (44)

activ cell differ gene group growth
increas **kinas** mice pathwai
phosphatas phosphoryl protein receptor
regul role **signal** src stat3
tyrosin

638: Receptors, Cytokine (47)

activ associ **cell** combin control differ
differenti effect express gene level mechan new
normal patient stem studi tissu vitro vivo

640: Pyridinium Compounds (14)

caus **cell** differ function
measur method model presenc
process product protein rat rate regul
respons score studi suggest
target treatment

641: Quaternary Ammonium Compounds (35)

activ cell deliveri differenti

effect effici gene high interact level low

model new particl point protein select

studi surfac time

643: Polysaccharides (86)

activ analysi cell cleavag form genom human
indic organ pathogen posit produc product

proteas protein rat residu serin site
studi

645: RNA, Antisense (82)

antisens cell develop express gene inhibit
interf interfer knockdown oligonucleotid

rna rna sequenc short silenc sirna
small specif suppress target

647: RNA, Catalytic (79)

activ cell elong express gene group melanocyt
melanoma mirna polymeras ribozym

rna rnase sequenc small structur target
transcript variant vitro

642: Virulence Factors (58)

activ aeruginosa antibiot antimicrobi aureu
bacteri bacteria biofilm genom host

infect mechan molecular mutant
parasit pathogen role salmonella strain virul

644: Fungal Proteins (345)

aspergillu bud candida cerevisia function

fungal fungi fungu growth involv isol

pathogen produc product protein requir

saccharomyc speci strain yeast

646: Receptor, Platelet-Derived Growth Factor beta (35)

c-kit case cell develop factor gastrointestin

giant gist growth human includ

kit malign model normal sarcoma soft

stromal tissu tumor

648: Collagen (238)

activ adhes bone cell collagen differ
effect express extracellular gene human increas
integrin invas matrix migrat molecul role
surfacc tissu

649: Rhodopsin (44)

analisi base cone degener famili gene level
macular method model optic photoreceptor
pigment **retin** retina select speci
structur vision **visual**

651: Flupenthixol (1)

cancer cohort data drug function identifi incid
interact involv men mortal
phenotyp popul preval protein rate resist
suggest women year

653: Chloride Channels (37)

associ atp ca2+ calcium
channel current develop famili
gene genet intracellular ion method mutat
new patient process provid sodium studi

655: Cytoskeletal Proteins (520)

actin activ beta-catenin cell compon downstream
epitheli express gene involv mediat migrat mutat
pathwai protein regul role
signal transduct wnt

650: Gene Products, env (49)

aids antiretrovir env express gag herp **hiv**
hiv-1 hsv-1 human
immunodefici **infect** patient
protein replic role sampl simplex viral
viru

652: Receptors, Nicotinic (43)

ala analysi arg chang **code**
codon gene nicotin nucleotid
posit pro receptor result sequenc singl stop
substitut suggest synonym usag

654: DNA, Antisense (47)

activ cell combin decreas effect
express function gene genom human
increas inhibit level mechan mice product
protein rna target vivo

656: Anti-HIV Agents (170)

aids antiretrovir env envelop gag herp **hiv**
hiv-1 hsv hsv-1 human
immunodefici **infect** opn replic
revers simplex viral **viru** virus

657: Oxazines (26)

activ cell chang dai differ effect gene
group hiv-1 increas infect light
method patient resist rice studi
test viru wheat

659: Viral Core Proteins (32)

activ analysi cell chang core encod hbv hcv hepat
host human infect open protein replic
respons sampl viral viru virus

661: Cyanoacrylates (4)

activ adapt care compar drug famili
gene higher inform level life member
method mice particip person qualiti rate
resist select

663: Benzothiazoles (13)

acid activ analysi cell control develop
diseas effect famili hybrid induc inhibit
mechan normal p53 radiat respons
role target tissu

658: Reverse Transcriptase Inhibitors (105)

aids antiretrovir env gag herp hiv hiv-1
hsv-1 human immunodefici infect
method patient replic resist simplex therapi
viral viru virus

660: Triglycerides (142)

apoe apolipoprotein associ atherosclerosi
chd cholesterol diseas effect hdl
increas ldl level lipid
lipoprotein metabol plasma statin studi
total triglycerid

662: Toluene (18)

activ analysi approach area
associ cell chang control differ effect
exposur high level method p53
recombin specif studi target treatment

664: Ribosomal Protein S6 Kinases, 70-kDa (29)

activ associ cell effect function
human increas inhibit kinas pathwai
phosphatas phosphoryl protein receptor regul
role signal stat3 test tyrosin

665: Transcription Factor AP-1 (135)

activ cell erk express function induc
inhibit inhibitor kinas mapk p38
pathwai phosphoryl promot protein
regul respons role signal transcript

667: Tissue Plasminogen Activator (35)

activ cell compar control effect express
follow function group high interact invas level matrix
patient repeat studi time tissu treatment

669: HMGA2 Protein (9)

bind cell chromosom clinic express

famili gene genom group

human loop marker member plai rate

report role studi suggest

tumor

671: DNA Topoisomerases, Type II, Eukaryotic (46)

agent case cell cisplatin correl cytotox dna drug
express gene her-2 her2 neg neu posit
resist respons statu surviv treatment

666: Nitric Oxide (235)

decreas demonstr effect enos incorpor
increas induc investig level nitric oil oxid
product reduc role studi suggest synthas
synthesi thymidin

668: Cilazapril (1)

cardiac cell effect expos exposur express follow
function heart human impair
improv line physiolog structur therapi transfect treat
treatment untreat

670: DNA-Activated Protein Kinase (44)

activ atm base break cell checkpoint comet control
damag develop dna double-strand dsb
excis induc lesion pathwai repair respons strand

672: Hyaluronic Acid (49)

acid adhes amino cell collagen
effect express extracellular gene human
integrin matrix model molecul patient
phenotyp product role surfac tumor

673: Oxidoreductases (118)

activ analysi associ cell differ effect **enzym**
express **gene** gener increas mutant
mutat oxid protein region sequenc speci studi
substrat

675: Histone Acetyltransferases (113)

acetyl activ associ **chromatin**
coactiv complex deacetylas function gene hdac
histon modif nucleosom recruit
regul remodel repress silenc structur transcript

677: Ephrin-A5 (2)

abil **activ** analys **analysi** bind
cell demonstr genet indic initi level origin
popul potenti properti reveal second serum
target vivo

679: Indium Radioisotopes (13)

antibodi bind cell **dai** dose
earli **high** imag level low model
posit protein role studi subject
target tumor vitro vivo

674: Matrix Metalloproteinases (92)

activ cathepsin **cell** express extracellular
increas inhibitor **invas** matrix
metalloproteinas metastasi migrat mmp
mmp-2 mmp-9 pai-1 plasminogen role tissu upa

676: Acetyltransferases (142)

acetyl activ associ **chromatin**
deacetylas famili gene hdac **histon**
increas modif nucleosom protein recruit regul
remodel repress role select transcript

678: Receptors, Fc (22)

antibodi cell develop effect express featur
gene **human** includ increas level
normal process remain **respons** specif
studi system tissu tumor

680: Immunoconjugates (31)

antibodi antigen cell combin
effect gene genet group human mab monoclon
neutral patient specif therapi transplant
treatment tumor vitro vivo

681: Ribonuclease III (48)

antisens express function gene inhibit interf
interfer knockdown melanoma oligonucleotid
polymeras **rna** rnai short silenc sirna small
specif suppress target

683: Antioxidants (333)

activ antioxid damag free glutathion group
increas induc level **oxid** oxygen
peroxid protect radic reactiv reduc ros speci
stress superoxid

685: Glutathione Peroxidase (46)

activ antioxid damag decreas free glutathion
increas induc level **oxid** oxygen
patient peroxid protect radic reactiv ros speci
stress superoxid

687: Magnesium (91)

activ bind ca2+ calcium channel complex
conform current differ dna enzym form function
group ion level patient region sequenc

structur

682: Intercalating Agents (18)

acid activ bind cell chang combin compound
dna effect high method number polymeras
protein replic report structur studi tissu treatment

684: Peroxidases (44)

activ analysi antioxid associ cell chang
damag enzym express increas level
oxid oxygen protein reactiv sampl
select speci stress studi

686: Aspartic Acid (89)

acid **activ** brain cell control differ
enzym function gene level mutant
mutat patient residu **site**
structur studi subject substrat suggest

688: Transcription Factor AP-2 (35)

associ bind bone cell combin differ enhanc
express factor famili format function
gene increas mechan **promot**
region regul site transcript

689: Core Binding Factors (7)

analysi associ bind bone cell express form
format gene high interact level low model
mutat phenotyp rel size studi valu

691: Antigens, CD29 (44)

activ **adhes** associ attach **cell**
collagen ecm express extracellular fibronectin
function integrin matrix migrat molecul
role spread studi sulfat surfac

693: Proteochondroitin Sulfates (19)

activ adhes analysi associ **cell**
effect **express** famili form format gene
growth integrin interact molecul plai
process requir **role** suggest

695: Acetyl-CoA Carboxylase (10)

acid amino area cell correl diabet
effect express form format high increas level
model new protein regul role studi target

690: Core Binding Factor alpha Sub-
units (5)

base bind bone control essenti evid
function gene interact
model mutant pair plai promot protein regul
requir role support transcript

692: Contraceptives, Oral (20)

associ cancer combin control correl decreas
earli effect factor genet hormon incid
increas level number
patient risk studi
women year

694: Lectins, C-Type (77)

activ allel antigen **cell** chang
class complex differ **express**
gene group hla major mhc mice model
molecul protein receptor role

696: Malonyl Coenzyme A (7)

acid activ amino detect effect express
form inhibit mice model plai presenc resist
respons role select sensit studi suggest time

697: Antigens, CD80 (60)

activ antigen **cell** combin develop
differ effect express high immun increas
induc lymphocyt mice new patient respons
t-cell treatment vaccin

699: Receptors, Virus (99)

adenovir adenoviru cell deliveri effici express
gene human infect replic therapi
transduc transduct transfer transgen
vector viral viru virus vivo

701: Receptors, Notch (123)

character **conserv** delta
evolutionarili function highli homolog
homologu human ident identifi mammal
mammalian mous notch ortholog
protein similar suggest vertebr

703: Perindopril (5)

anim clinic combin compar control differ earli effect
group inhibit level model new rat
signific studi therapi treatment trial tumor

698: Receptors, Chemokine (107)

activ alpha cell chemokin cxcr4
demonstr express **factor** il-8 induc
necrosi **nf-kappab** nuclear
receptor regul role suggest tnf tnf-alpha
tumor

700: Antigens, CD28 (41)

activ cd4 cd4+ cd8 cd8+ **cell** cytotox develop
differ effector express group il-2 immun lymphocyt
pattern receptor studi t-cell ter

702: HMGN1 Protein (2)

cell chromosom **effect** enhanc increas level
mice mutant peptid prevent protect
protein radiat rat reduc reduct
serum **tumor** vitro vivo

704: Vitamin K 2 (1)

carcinoma character **characterist**
classic COMMON distinct endotheli
featur growth human lesion liver
mice similar stain typic unqu vascular vitro
vivo

705: Antifibrinolytic Agents (4)

activ associ children clinic data develop earli

effect group includ inhibit model month

patient rang reduc risk signific stage

studi

707: Toll-Like Receptor 5 (7)

acid clinic compar control
cytokin dai distribut dose identifi immun
infect local mechan model respons screen
signal strain subject week

709: alpha 1-Antitrypsin (38)

cell defect defici develop differ
express function gene
human increas level mechan normal
patient phenotyp protein residu
site studi time

711: Nitric Oxide Donors (28)

cell effect express

function group high human

increas induc inhibit level mechan

nitric oxid rat reduc studi suggest

synthas synthesi

706: Vaccines, Subunit (27)

analysi antigen challeng ctl dendrit elicit epitop

human immun immunogen

immunotherapi induc innat peptid product

protect protein respons tumor vaccin

708: Amidohydrolases (34)

acid activ analysi data develop effect enzym
express function gene genom increas
level method mutat patient protein sequenc
target treatment

710: Cathepsin B (21)

activ cell control effect express
extraçellular function inhibitor
invas level matrix
metalloproteinas migrat mmp mmp-2 mmp-9
plasminogen rate tissu treatment

712: Leukocyte Elastase (15)

analysi associ bone cell control diseas factor
famili function human increas
number patient process product ratio
respons risk structur studi

713: Platelet Aggregation Inhibitors (46)

activ arteri clinic dai differ effect express

factor function group inhibit inhibitor

patient risk select structur studi

therapi treat treatment

715: Drug Carriers (59)

cation conjug deliveri develop dna

effici formul function liposom

nanoparticl particl patient polym

prepar properti rate releas scaffold solut

surfac

717: Fragile X Mental Retardation Protein (61)

addit chimera chimera complet consist
construct contain demonstr form fragil fuse

fusion indic lack observ partial
replac report result suggest

719: Morphine (25)

alcohol analysi consumpt depend
drink drug effect ethanol examin function

indic new oral prefer product rat signific
studi substanc suggest

714: Orosomucoid (5)

adult analysi base cluster complex concentr express

extract function higher level method
posit process protein rate residu site structur year

716: RNA-Binding Proteins (354)

altern bind complet contain domain

exon fusion gene initi interact

isoform mrna partial protein

rna splice suggest transcript

translat variant

718: Agglutinins (10)

cell compar control develop
differ effect express
gene gener group human plai reduc
region role sampl sequenc specif studi
tissu

720: Receptors, Opioid (11)

alcohol associ chang depend

effect function individu
model oral plai process receptor reduc

respons role signific studi suggest
time treatment

721: Melatonin (47)

cho circadian clock cycl cyclic
feedback gener hamster
increas level loop oscil oxid
period phase rat rhythm suggest
synchron time

723: Proto-Oncogene Proteins c-myc (164)

c-myc cell cellular deregul express growth
human implic induc k-ra malign myc oncogen
overexpress prolifer
promot role suggest transform
tumorigenesi

725: src-Family Kinases (92)

activ cell constitut demonstr human
inhibit kinas mtor pathwai
phosphatas phosphoryl protein rapamycin
receptor regul requir signal src stat3
tyrosin

727: Halogens (10)

analysi blue captur chang color composit correl
cure differ dye famili intens laser light
observ posit red shed studi test

722: Chlorophyll (58)

arabidopsi control energi flower function increas
leaf leav light measur plant pollen
respons root seed sequenc speci thaliana transgen
treatment

724: F-Box Proteins (26)

cell control degrad develop
distribut function gene increas ligas local
model pathwai plai proteasom
protein regul role suggest
ubiquitin zinc

726: Proto-Oncogene Proteins c-mdm2 (110)

activ apoptosi arf cell express function inactiv induc
level mdm2 p53 p73 pathwai protein regul role
suppress suppressor tumor wild-typ

728: Bisphenol A-Glycidyl Methacrylate (6)

blue captur color composit cure dark differ dye
effect intens irradi laser light observ
red shed studi time treatment unit

729: Xenon (4)

blue captur color composit differ dye
follow form format intens laser light
method observ pattern red shed studi
time type

731: Glass (22)

chang control detect develop
differ fish fluoresc group
hybrid intens laser light
method model probe sampl
select situ studi surfac

733: Apolipoproteins B (53)

apoe apolipoprotein associ atherosclerosi
chd cholesterol diseas effect hdl
increas ldl level lipid lipoprotein
metabol plasma statin studi total triglycerid

735: Cyclic AMP Response Element-Binding Protein (110)

activ cell diseas disord erk function
gene increas kinas mapk motor
number pathwai phosphoryl
promot protein regul role signal transcript

730: Methacrylates (25)

blue captur color composit differ dye effect
gene human identifi intens laser light
observ red respons shed studi surfac time

732: Polymethyl Methacrylate (21)

associ decreas differ dose effect
enhanc group imag implant increas
irradi level light measur method model
pattern radiat radiotherapi studi

734: Antibodies (238)

activ antibodi antigen
autoantibodi cell detect epitop express function
human igg increas mab monoclon neutral patient
protein sera specif studi

736: Antigens, CD45 (66)

activ analysi cell compar content
cytometri determin develop differ evalu flow
human increas load observ patient percentag
select signific studi

737: Polylysine (22)

activ deliveri effici express
function gene group human improv
model particl polym popul structur
studi surfac therapi transfer
treatment vector

739: Forskolin (39)

activ cell control effect express
famili function high human increas
inhibit kinas level low phosphoryl
promot protein receptor
respons role

741: HLA-DQ Antigens (73)

allele antigen associ class complex drb1
genet histocompat hla human leukocyt major
mhc molecul natur patient polymorph present
specif type

743: Tamoxifen (197)

activ adjuv aromatas breast
cancer cell chang control develop ductal
estrogen hormon increas mcf-7 mice receptor studi
tamoxifen treatment WOMEN

738: Myogenic Regulatory Factors (40)

activ bind cell control differenti dystrophi
exercis express function high method
muscl muscular protein regul skelet
smooth studi test transcript

740: Rad52 DNA Repair and Recombination Protein (13)

bind damag develop dna form format
gene interact model mutat new presenc protein
recombin repair replic sequenc suggest telomer
time

742: Thiophenes (32)

activ analysi cell
chemotherapi combin control
effect express group
identifi increas inhibit
patient product respons risk
screen studi toxic treatment

744: Pyrrolidines (18)

activ base cell chang control dai decreas
dose effect enhanc gene increas inhibit level rat
resist select studi suggest treatment

745: Mitoxantrone (70)

advanc cancer chemotherapi combin confer drug
median month patient phase rate regimen

resist respons sensit surviv suscept
therapi toxic treatment

747: Daunorubicin (28)

acut analysi associ drug effect gene group
high leukemia mean month new patient

resist respons studi surviv therapi
treatment valu

749: Cyclin-Dependent Kinase Inhibitor p16 (156)

associ cell cervic cpg cycl dna epigenet express
gene human hypermethyl inactiv island

methyl methyltransferas p16
p53 promot statu suppressor

751: Dopamine and cAMP-Regulated Phosphoprotein 32 (10)

area cell express **famili**
function increas larg local member model
neuron plai **protein** recombin rel role size
small test tumour

746: Estrogen Receptor beta (56)

alpha associ beta **CANCER** cell combin differ
endometri epitheli estrogen express gene

increas **ovarian** periton

receptor signific studi suggest
uterin

748: Acid Anhydride Hydrolases (20)

activ correl cpg differ dna epigenet express
gene hypermethyl inactiv island loss

methyl methyltransferas p16
patient promot rate region statu

750: Tumor Suppressor Protein p14ARF (50)

activ cell delet dna express function gene human
inactiv induc loss mdm2 mechan methyl mutat

p53 protein regul suppressor tumor

752: Midazolam (17)

behavior chang children compar correl dai
differ enzym function **group**

increas level **metabol** metabolit

patient rate signific studi time year

753: Hypnotics and Sedatives (29)

alcohol care compar concentr control dai
develop differ dose effect function
group inform oral particip
patient person studi surgeri treatment

755: Tissue Inhibitor of
Metalloproteinase-2 (28)

activ cathepsin cell chang express
extracellular group increas inhibitor
invas matrix metalloproteinas
migrat mmp mmp-2 mmp-9 pai-1 plasminogen
tissu upa

757: Dinucleoside Phosphates (16)

cluster cpg dna epigenet famili gene human
hypermethyl inactiv increas level
methyl model new promot
protein respons sampl site structur

759: Receptors, Transforming Growth
Factor beta (71)

bmp cartilag chondrocyt collagen develop
effect express factor fibroblast
growth induc new regul signal
smad sox9 **tgf-beta** **tgf-beta.1** Tissu
transform

754: Estrogen Receptor alpha (131)

alpha associ breast **cancer** compar
control endometri epitheli eralpha estrogen
group human increas **ovarian** periton
receptor signific studi suggest uterin

756: Metalloendopeptidases (153)

activ cathepsin cell express extracellular
human inhibitor **invas** matrix
metalloproteinas migrat mmp mmp-2 mmp-9
pai-1 plasminogen role Tissu upa upar

758: Connexin 43 (61)

barrier c282y cell commun connexin
contact coupl cx43 demonstr form gap
hemochromatosi hfe indic intercellular
iron junction studi
suggest tight

760: Receptors, Interleukin-8B (8)

activ cancer case caus compar control
express factor high
human level low nf-kappab
organ potenti receptor regul subject target
tumor

761: ras-GRF1 (7)

analysi blot caus cell cluster
control differenti effect
embryo enhanc express gene
includ level profil protein rang reduc
western wide

763: Silk (6)

care children clone differ dna form
fragment gene genet health
high initi level low origin phenotyp protein
region sequenc speci

765: Immunotoxins (38)

antibodi antigen cell detect
human mab model monoclon new patient
provid select specif studi target therapeut
therapi treatment vitro vivo

767: Proto-Oncogene Proteins B-raf
(83)

activ adenoma adren analysi braf detect express gene
hormon identifi kinas mutat papillari
phosphoryl pituitari ptc ret rna thyroid tumor

762: Guanine Nucleotide Exchange
Factors (75)

actin activ analysi cell cytoskeleton
differ express famili filament function
gene mechan mice migrat polar process
protein regul rho role

764: TCF Transcription Factors (33)

activ beta-catenin cell develop differ enhanc
express factor function gene human
pathwai patient plai regul role
signal target transcript wnt

766: Prodrugs (53)

activ agent cell chemotherapi
clinic combin dai develop drug
effect gene model patient studi
target therapeut therapi
treatment tumor vector

768: Monophenol Monooxygenase (55)

activ analysi biolog chang demonstr differ
diseas gene high identifi includ melanocyt
melanoma mutat polymeras respons
rna specif studi system

769: Melanins (55)

activ associ basal bodi cell cutan differ effect
epiderm express function increas keratinocyt

lesion mice mutant protein role **skin**
weight

771: Integrins (113)

activ **adhes** attach beta1 **cell**
collagen ecm express extracellular fibronectin
integrin interact laminin matrix migrat
molecul role spread sulfat surfac

773: Parathyroid Hormone-Related Protein (25)

analysi associ bone **cell** decreas
differenti express gene increas level
measur mechan molecular patient

peptid protein rat reveal specif
studi

775: Interleukin-6 (271)

activ cell **cytokin** effect ifn
ifn-gamma il-10 il-4 il-6 immun induc
inflammatori interferon interleukin level
macrophag mice product **respons** stimul

770: Integrin alpha5beta1 (12)

activ **adhes** associ attach bind
cell collagen demonstr differ express
extracellular fibronectin **function**
integrin interact matrix migrat molecul
sulfat surfac

772: Integrin alpha2beta1 (14)

adhes **cell** chang compar control
decreas express factor form format
gene genotyp human **increas**
polymorph rate receptor **risk** tissu
treatment

774: Glycogen Synthase Kinase 3 (76)

activ beta-catenin **casca**d cell combin compon control
downstream intracellular involv mediat
pathwai protein regul role **signal**
studi target transduct wnt

776: Interleukin-8 (115)

activ **alpha** chemokin constitut
cxcr4 express **factor** il-8 induc necrosi
nf-kappab nuclear patient
receptor role suggest tissu tnf tnf-alpha tumor

777: Globins (117)

abnorm anemia associ caus chain defect
defici differ erythroid erythropoietin
evolut function gene hemoglobin interact normal
number sequenc sever structur

779: Receptor, erbB-3 (33)

activ akt cell effect egf **egfr** epiderm
express factor famili growth inhibit
inhibitor kinas neg pathwai **posit**
receptor signal surviv

781: Radiation-Sensitizing Agents (87)

activ beam damag **dose** effect expos exposur
fraction gamma ion ioniz **irradi** partiel
radiat radiation-induc radiosensit
radiotherapi rai surviv x-rai

783: Integrin alphaVbeta3 (33)

adhes attach **cell** collagen
express extracellular fibronectin group human
integrin interact matrix migrat molecul
patient role studi sulfat surfac tumor

778: raf Kinases (30)

activ analysi associ cell develop
effect express function **gene** increas interact
kinas pathwai phosphoryl protein
regul requir role signal treatment

780: HSP90 Heat-Shock Proteins (61)

associ cell **condit** degre
express function
human increas interact kit
level mutant **protein** respons
sarcoma stromal studi target
tissu **tumor**

782: Integrin alphaV (13)

adenoviru adhes cell chang combin complex
deliveri effici express **gene** integrin
molecul popul protein therapi transduct
transfer transgen tumor **vector**

784: Drug Combinations (191)

activ analysi cell **combin**
compar dai **effect** express group increas
invas matrix patient popul rate respons studi
test time treatment

785: Laminin (135)

activ adhes attach **cell** collagen
effect express extracellular function increas
integrin invas matrix migrat molecul muscul
role studi sulfat surfac

787: Proteoglycans (162)

activ adhes **cell** collagen differ differenti
express extracellular growth human inhibit
integrin invas matrix migrat molecul patient
role studi surfac

789: Hydroxamic Acids (112)

acetyl activ cell **chromatin**
coactiv deacetylas effect gene hdac
histon modif nucleosom p300
protein recruit regul remodel repress silenc
transcript

791: X-Linked Inhibitor of Apoptosis
Protein (42)

activ **apoptosi** apoptot bax
bcl-2 caspas caspase-3 cell combin death effect
function increas induc induct inhibitor pathwai protein
releas surviv

786: Vitronectin (18)

adhes associ **cell** collagen express
extracellular high human integrin level low
matrix migrat molecul new protein receptor regul
studi surfac

788: Fibronectins (106)

adhes attach beta1 **cell**
collagen ecm express extracellular fibronectin
function **integrin** interact laminin matrix
migrat molecul role spread sulfat surfac

790: Cyclin B (79)

activ arrest cdk cdk2 **cell** cell-cycl cip1
cycl cyclin cyclin-depend inhibitor kinas
p21 p27 phase progress prolifer protein regul
retinoblastoma

792: DNA Topoisomerases, Type I (65)

activ agent anticanc cancer cell chemotherapi
cisplatin combin cytotox **dna** drug effect
enhanc paclitaxel patient protein replic sensit studi
treatment

793: Butyrates (30)

acetyl **activ** analysi associ **cell**
chang **chromatin** combin control
differ differenti effect express
histon human new prolifer protein
regul transcript

795: HLA-A Antigens (67)

allel antigen **class** complex differ drb1
histocompat hla human immun leukocyt major
mhc molecul natur present respons specif type
vaccin

797: CA-125 Antigen (24)

associ **CANCER** clinic elev endometri estim
estrogen identifi **level** marker measur
ovarian **patient** plasma
respons sampl screen serum studi valu

799: Intramolecular Oxidoreductases (27)

activ antigen **cell** control correl
develop differ differenti enhanc
express function **gene** human
immun increas induc patient rate
respons vaccin

794: L-Selectin (11)

activ adhes **cell** clinic compar
concentr **control** correl
diagnosi earli extracellular famili higher
increas integrin **level** molecul serum
signific time

796: HLA-B Antigens (62)

allel antigen associ **class** complex drb1
histocompat hla human kir leukocyt major mhc
molecul natur patient present respons specif type

798: Epitopes, T-Lymphocyte (112)

antigen cd8+ **cell** challeng ctl cytotox dendrit
elicit epitop **immun** immunogen
immunolog immunotherapi induc innat lymphocyt
protect respons t-cell **vaccin**

800: CA-15-3 Antigen (68)

analysi bone carcinoma **cell** express
factor group human immun increas level
macrophag marrow patient repeat respons
reveal studi **tumor** vaccin

801: Receptors, Interleukin-2 (99)

activ cd4 cd4+ cd8 cd8+ **cell** cytotox effector
express group il-2 immun level lymphocyt natur
patient respons studi t-cell ter

803: Insulin-Like Growth Factor I (212)

autocrin effect **factor** final grow
growth height hormon igf igf-1 igf-i
igf-ii igf-ir igfbp-3 increas insulin-lik receptor role statur
stimul

805: Dopamine Uptake Inhibitors (10)

alcohol behavior bind caus chang dai
decreas depend detect dose **effect** increas
lead mice model oral reduc **respons**
studi treatment

807: Bupropion (7)

ASSOCI bodi case confid control genotyp
interv level **metabol** muscl odd
polymorph ratio report **respons**
risk smoke **studi** subject
treatment

802: Protease Inhibitors (102)

activ cell develop effect human includ
increas inhibitor invas matrix
multipl protein role singl site
studi suggest target therapi treatment

804: Follistatin (7)

effect express function gene genet induc induct plai
rat receptor reduc respond **respons**
role specif **studi** test transfer valu vector

806: Ticlopidine (9)

administr conclusions control **dai** design
dose **effect** healthi hospit mean methods
patient reduc **studi** subject
treat **treatment** valu week year

808: Oxidoreductases, N-Demethylating (25)

activ associ cyp1a1 cyp2d6 cyp3a4 cytochrom
determin differ drug enzym function group
human interact **metabol**
metabolit microsom p450 respect select

809: Aryl Hydrocarbon Hydroxylases (137)

activ clearanc cyp cyp1a1 cyp1a2 cyp2c9 cyp2d6
cyp3a4 cyp3a5 cytochrom determin differ drug
enzym human **metabol**
metabolit microsom p450 respect

811: Anticarcinogenic Agents (119)

activ cancer **cell** cox-2 decreas effect
human increas induc inhibit **inhibitor**
model prevent rat reduc risk select studi target
treatment

813: Anti-Retroviral Agents (25)

aids gag herp hiv **hiv-1** hsv-1
human immunodefici increas
infect number patient resist
respons simplex therapi time treatment

viral **viru**

815: Rifampin (39)

data demonstr function gene **gener** human
includ indic infect **isol** mutat mycobacterium report
resist sequenc specif **strain** studi treatment
tuberculosi

810: Antimetabolites (38)

activ **cell** compar control decreas
develop differ effect genom **group**
increas level mice mutant
patient reduc respons role tissu treatment

812: Deoxyglucose (16)

cell content **control**
develop dose **effect** enhanc
famili flow increas irradi mice model
patient **radiat** reduc respons role
studi treatment

814: Lorazepam (2)

activ assess associ behavior control dai dose
effect factor genotyp **inhibit** measur
polymorph **risk** sampl score
studi subject suppress system

816: Glucuronosyltransferase (69)

activ analysi associ cyp1a1 cyp2c9 cyp2d6 cyp3a4
cytochrom determin differ drug enzym human
liver **metabol** metabolit
microsom p450 respect studi

817: Serotonin Agonists (10)

analysis behavior change compar
control differ disorder
function higher
increases patient product
product random rate
receptor response study
treatment trial

819: Gastrointestinal Agents (20)

active analysis case clinic comparison diagnosis disease
effect function group increase
patient rat rate study therapy tissue
treat treatment

821: Annexin A2 (11)

association cancer cell control differ
differently distributed family form format
gene interact local mass mutation
normal pattern protein site tissue

823: ADAM Proteins (58)

active analysis association cell control
detect differ express factor
family gene genetic human identification
invasion matrix patient protein
response role

818: Indoles (183)

active adduct association cell
compound derivation development
effect expression gene increase inhibition kinase
mice patient product protein response role
treatment

820: RNA, Neoplasm (209)

analysis cell chain detect differentiation
express gene human identification level
line microarray mRNA normal patient PCR profile
reaction tissue tumor

822: RNA, Complementary (20)

analysis cell change development differentiation express
gene human identification microarray
model mutant normal profile sequence size specific
study time tissue

824: Testosterone (89)

assist cancer cycle development female
follicle group hormone level male
model ovarian patient pregnancy
reproduction response steroid study
treatment women

825: Dehydroepiandrosterone (16)

cancer children cycl effect
famili follicl hormon human
increas level mechan pregnanc
rel reproduct risk serum steroid
studi test Women

827: Hemin (7)

cell clinic decreas diagnosi
diagnost differenti earli genet identifi
imag increas oxid patient process
protein risk screen specif
studi treatment

829: Chemokines, CC (62)

activ associ cell chemokin control
express factor gene il-8 increas induc
necrosi nf-kappab nuclear
number receptor respons time tnf
tnf-alpha

831: Antigens, Nuclear (53)

analysi break cell chang combin control
damag decreas dna effect express
function human increas level mutant nuclear
patient repair studi

826: beta Carotene (30)

cell concentr decreas determin
develop differ effect group higher increas low lower
measur microg microm min plasma rang respect
studi

828: Viral Matrix Proteins (65)

associ character contribut displai distinct ebv
epstein-barr exhibit human identifi includ indic infect
lack latent phenotyp similar
suggest viral viru

830: DNA Repair Enzymes (81)

atm break cancer cell colon colorect damag
develop dna double-strand dsb excis function
induc lesion number pathwai repair respons strand

832: Chromosomal Proteins, Non-Histone (200)

cell chromatin
chromosom complex divis
dna function gene histon
mechan methyl microtubul mitot
mutat protein requir role spindl
syndrom transcript

833: DNA Polymerase I (34)

activ assai base detect **dna** express gene
genom helicase level pair per polymerase produc product
protein replic respons sensit strand

835: DNA Restriction Enzymes (53)

amplif amplifi analysi design detect digest
dna fragment genom group
identif length method **pcr** polymorph
primer product recombin restrict sequenc

837: Telomeric Repeat Binding Protein
2 (23)

activ cap cell cellular end htert human
length mainten mechan model patient revers
senesc shorten suggest **telomer**
telomeras transcriptas trap

839: Antimicrobial Cationic Peptides
(43)

bacteri barrier cell contact famili gap gene
genet high host indic **infect** iron
junction pathogen patient
peptid respons studi suggest

834: Rec A Recombinases (42)

activ bacillu bacteri bacteria **coli** differ
dna encod escherichia form format
gene model operon phage presenc product replic
strain toxin

836: E2F4 Transcription Factor (16)

activ arrest bind **cell** complex
cycl cyclin express
function gene model p21 p27 phase plai
progress prolifer protein rate role

838: Pertussis Toxin (11)

activ cell distribut effect
enhanc express gene high inhibit level
local low new protein respons specif
subject suggest test treatment

840: HLA-B8 Antigen (7)

allel analysi antigen **class** compar
complex control differ genet group healthi
hla major mhc molecul **patient**
posit sequenc studi **subject**

841: Antigens, CD8 (48)

activ analysi cd4 cd4+ cd8 cd8+ **cell** cytotox
develop express function il-2 immun lymphocyt model
natur t-cell target tcr tumor

843: Plasmin (11)

activ analysi associ cell chang
effect express extracellular interact
invas involv level **matrix**
mechan metalloproteinas mmp mmp-2
moleculer **process** tumor

845: Nucleotidyltransferases (23)

acid activ cell control differ **dna**
function gene identifi increas mice
pattern plant protein recombin replic resist
respons speci time

847: Dermatologic Agents (33)

basal chain clinic cutan data develop differ
epiderm epidermi includ keratinocyt lesion
patient per reaction **skin** studi treat
treatment uvb

842: Plasminogen (16)

activ cell effect enhanc express
form format genet human increas inhibit **invas**
isol matrix metalloproteinas mmp role suggest
tissu tumor

844: DNA Ligases (33)

activ analysi associ break chain control **damag** differ
dna genom method per polymeras reaction
repair replic requir role sequenc strand

846: Anti-Infective Agents, Local (16)

assess **cell** dai differ effect evalu
group increas level light
measur method patient protein respons
score signific studi test treatment

848: Cytochrome P-450 CYP2D6 (64)

activ clearanc cyp cyp1a1 cyp2c9 cyp2d6 cyp3a4
cyp3a5 cytochrom determin differ drug enzym
human **metabol** metabolit
microsom p450 patient respect

849: Tramadol (5)

compar control dai differ effect **group**
higher identifi increas mean measur respect screen
sequenc signific stress studi subject test valu

851: RNA, Ribosomal (147)

analys analysi bacteria base clade close diverg
divers gene genom genu group phylogenet
rdna relat relationship rrna sequenc
speci tree

853: Organic Anion Transport Polypeptide C (11)

allel **associ** develop
drug factor gene genotyp liver
membran metabol number
patient polymorph popul
rate resist **risk** studi subject
transport

855: Cytochrome P-450 Enzyme System (251)

activ clearanc cyp cyp1a1 cyp2c9 cyp2d6 cyp3a4
cyp3a5 cytochrom determin differ drug enzym
human **metabol** metabolit
microsom p450 patient respect

850: Analgesics, Opioid (33)

alcohol consumpt depend differ
drink drug effect ethanol examin group high
oral patient prefer rat signific
studi substanc suggest

852: Aminoglycosides (51)

activ analysi antibodi cell clinic control data
develop effect express gene increas infect
loss **patient** product protein
resist studi therapi

854: Hypoglycemic Agents (113)

adiponectin associ **diabet** effect fast
glucos group human increas insulin level
mellitu metabol obes patient peroxisom
ppargamma studi subject toler

856: Carbamates (21)

activ cell compound deriv
develop differ effect function
group human increas method
mutant **patient** protein reduc resist
structur studi subject

857: Manure (7)

analysi anim cluster compar effect higher
lower model normal organ phenotyp produc
product rate recombin
reveal sampl sourc tissu water

859: Receptor, Fibroblast Growth Factor, Type 1 (34)

associ cell chang condit **cultur**
develop differ express fibroblast gene human
increas incub mechan media **medium** molecular
normal tissu vitro

861: Flavoproteins (45)

activ analysi **apoptosi**
cell cho circadian clock feedback
hamster indic induc **loop** model
period protein reveal studi suggest
synchron time

863: Ecdysterone (13)

activ cell combin compar **control**
dai decreas dna drosophila effect express
function **increas** level reduc
report respons studi suggest time

858: Peroxides (13)

activ cell chang compar **control**
dai decreas differ effect **group**
human increas **level**
light observ oxid rate role stress
system

860: Myosin Heavy Chains (58)

activ associ cardiac cell chain chang differ
express famili function gene heart
muscl mutat protein rate
reaction respons skelet smooth

862: Neuregulins (4)

analysi blot cancer cell dai decreas differenti egfr
express growth **human** increas level
pathwai plai prolifer recombin **role** signal western

864: Mitogen-Activated Protein Kinase 9 (10)

activ cell event **express** form
format gene increas involv kinas level new
phosphoryl process regul requir specif
studi subject treatment

865: Anthracenes (22)

activ apoptosi bind cell control
correl dna event high induc inhibit kinas
pathwai phosphoryl process product protein
respons select stimul

867: Coumarins (22)

activ analysi assai cell
compound deriv detect differ earli
human metabol method mutat patient
respons role sampl select sensit studi

869: beta Catenin (302)

activ beta-catenin cascadi cell compon downstream
epitheli express gland intracellular involv mammari
mechan mediat **pathwai** regul
signal target transduct wnt

871: Gadolinium DTPA (16)

assess chang comput detect develop evalu
function **imag** magnet measur
method mri perform reson scan techniqu
tomographi tumor ultrasound volum

866: Proto-Oncogene Proteins c-jun (82)

activ cell effect erk express gene induc
inhibit inhibitor jnk **kinas** mapk
mitogen-activ p38 pathwai
phosphoryl protein regul respons
signal

868: Chelating Agents (38)

activ cell concentr
control dai effect
famili group high increas
level low model organ patient
protein select **studi**
therapi treatment

870: Granulocyte Colony-Stimulating Factor (94)

bone **cell** chemotherapi combin
differenti factor gene group human **macrophag**
marrow matur monocyt neutrophil number
patient respons surviv toxic treatment

872: Serum Albumin (49)

cell concentr correl determin effect elev famili function
group high higher human increas **level** lower
measur model patient plasma serum

873: Vacuolar Proton-Translocating ATPases (9)

analys **analysisi** assembl
complex compon genom
human increas mutat new normal perform
process protein reveal role specif studi subunit
tissu

875: GTP-Binding Proteins (94)

activ alpha associ cell express function genet
interact mechan mutant mutat pathwai patient
protein receptor role signal
studi suggest tissu

877: Benzodiazepines (42)

affect associ control disord effect
enhanc examin find involv major met new
patient possibl report schizophrenia signific
studi suggest treatment

879: Gluten (21)

activ chang children **chronic** control
differ **diseas** function group
increas inflammatori **intestin**
number patient plant region rice
sequenc **treatment** wheat

874: Benzenesulfonates (18)

activ associ base **Cell** chang control
effect express gene **group** model
patient produc product
respons studi target therapi
time **treatment**

876: Heterotrimeric GTP-Binding Proteins (19)

activ allele alpha associ beta bind complex
effect gene genotyp **human**
increas interact patient polymorph
protein **receptor** respons studi
variabl

878: Arylamine N-Acetyltransferase (50)

associ control determin enzym glutathion gst
gstm1 gstp1 gstt1 increas influenc involv
modif **modifi** null observ
s-transferas signific studi suggest

880: Transglutaminases (42)

activ **cell** chronic detect
differenti **diseas** express
famili form format
function increas intestin normal
patient prolifer
protein skin stabil tissu

881: Acids (25)

acid activ amino bind concentr decreas
develop effect fatti function group high increas
level low new reduc resist risk test

883: Myelin Proteins (37)

analisi associ axon chang cord demyelin heal
injury mechan myelin nerv
neuropathi oligodendrocyt patient peripher
regener sensori spinal trauma wound

885: Uteroglobin (15)

affect assai associ blood **breast**
cancer cell compar control
detect effect gene high level lung
polymorph protein sensit studi subject

887: Phosphatidylcholines (36)

acid activ apoe cell chang
cholesterol develop differ **effect**
group high level lipid lipoprotein
membran plasma protein reduc
time transport

882: Oligosaccharides (55)

analisi cell cleavag contain control cystein differ
express glycosyl high human indic level patient posit
proteas residu serin **site** subject

884: Proteolipids (10)

activ bind caus cell clone combin
develop effect form format gene genom
identifi larg method mutat
number protein sequenc tissu

886: Receptor, EphA2 (6)

analisi case cell effect famili larg
level model **protein** reduc report size
small studi treat **treatment**
tumor tumour valu variabl

888: Stearoyl-CoA Desaturase (12)

acid amino compar control evid express
fatti gene high level method normal provid rate retino
role studi subject support tissu

889: STAT5 Transcription Factor (71)

activ cell constitut express inhibit
kinas mice mtor pathwai phosphatas
phosphoryl protein rapamycin receptor regul
role signal src stat3 tyrosin

891: Milk Proteins (98)

activ anim bovin breed cell develop
express gene kinas milk phosphatas
phosphoryl pig protein regul respons role
signal stat3 tyrosin

893: Intercellular Signaling Peptides and Proteins (414)

activ beta-catenin cell compon diabet downstream
express function gene growth insulin involv level mediat
pathwai regul role signal
transduct wnt

895: Agar (23)

analysi associ cell control express
form format function gene
group human increas oncogen
overexpress protein resist studi
suggest test transform

890: Wnt1 Protein (23)

activ beta-catenin cell compon downstream gene
increas involv mechan mediat pathwai plai
rat regul role signal time transduct
tumor wnt

892: Wnt Proteins (246)

activ beta-catenin canon cascad compon develop
downstream intracellular involv kei lead mechan mediat
pathwai regul role signal
target transduct wnt

894: Cytarabine (89)

acut aml cell chemotherapi chronic combin
dai differ effect leukaemia leukemia
lymphoblast mds month myeloid
patient rate studi surviv year

896: Dental Implants (25)

cleft clinic compar control dental
differ effect facial function group
higher lip lower palat patient
rate sampl studi time treatment

897: Transaminases (24)

acid activ analysi approach ASSOCI clinic
effect famili form gene **group** human
level liver **patient** serum
sever studi target treatment

899: Thymidine (65)

activ **cell** compar compound control
differ differenti dna effect express gene group
increas induc number patient prolifer rate
respons studi

901: Tuftsin (1)

activ allogene blood donor effect
exposur graft light median month patient peripher
prevent protect recipi reduc reduct stem transplant
year

903: Immunoglobulin E (96)

airwai allerg allergen associ
asthma cell cftr cystic
differ diseas eosinophil **fibrosi** ige
obstruct patient pulmonari
respiratori sever studi ventil

898: Hydrocarbons, Halogenated (4)

correl cours decreas determin dna event femal
gene increas inhibit involv male mechan
molecular mutat number period point
process **time**

900: Topotecan (40)

advanc cell chemotherapi combin dai
differ dose drug human median month
patient phase regimen resist
respons surviv toxic treatment tumor

902: Cystic Fibrosis Transmembrane
Conductance Regulator (168)

airwai allerg allergen **asthma**
cftr channel chronic conduct copd **cystic**
diseas eosinophil **fibrosi** ige obstruct
pulmonari **respiratori** sever studi
ventil

904: Isoenzymes (436)

activ cell control differ divers enzym express
gene genet increas metabol modif modifi
patient **popul** studi substrat suggest
variant variat

905: Interleukin-2 (175)

activ cd4 cd4+ cd8 cd8+ **cell** cytotox effector
express function gene group il-2 immun lymphocyt
patient receptor respons t-cell tcr

907: Environmental Pollutants (82)

air associ chemic concentr contamin copper
data develop effect environment expos
exposur increas metal product
soil sourc studi toxic **water**

909: Hydrocarbons (25)

activ **analysi** chang concentr
data develop differ effect
environment **estim** factor femal
field **genet** influenc male
method sampl **studi**
water

911: Hydrogen Cyanide (4)

concentr condit degre earli effect experi
field **function** genet movement
organ patient popul produc
product reduc sampl
space stage tumour

906: Metals, Heavy (48)

activ air cadmium **concentr**
contamin content copper environment
hydrocarbon measur metal organ pah pollut
remov sediment **soil** sourc total

water

908: Acetaminophen (18)

activ **associ** case compar control
design effect follow function **hospit**
increas liver objective patient process
product ratio risk **studi** year

910: Hydrogen Sulfide (6)

cell condit degre **group**
high human identifi
interact level life **low** new phenotyp
produc **product** qualiti rat regul
screen temperatur

912: Water Pollutants, Chemical (115)

air chemic **concentr** contamin
copper effect environment exposur
hydrocarbon indic measur metal pah pollut
remov sediment **soil** sourc toxic

water

913: Actin-Related Protein 2-3 Complex (2)

actin anim cell demonstr find
function identif identifi migrat
model neg new novel **posit** previou
provid recombin report screen studi

915: Actin-Related Protein 2 (15)

actin **cell** complex cytoskeleton
evid famili filament **function** gtpase
local **migrat** mutant phenotyp polar
protein provid regul rho suggest support

917: Acid Rain (2)

acid alter amino chang concentr correl data
dynam effect experiment extract incid
model paramet popul predict preval
reduc signific simul

919: Fructose (17)

combin dai differ **effect** function high
human increas number **patient**
plant produc product random resist structur
studi time treatment trial

914: Wiskott-Aldrich Syndrome Protein Family (8)

actin **activ** cell cytoskeleton enhanc
filament genet gtpase interact migrat polar
produc **product** protein regul report rho studi
suggest variabl

916: Trehalose (10)

analysi cell compar condit control
decreas degre enzym higher
increas level produc product
rate requir resist temperatur time
treatment yeast

918: Glucosephosphate Dehydrogenase (36)

acid activ analysi anemia control defect
defici detect differ effect enzym
express gene **group** method normal
number sampl sensit studi

920: Aluminum (27)

activ cell compar develop differ **dose** effect
genom group imag **irradi** measur method
model **radiat** radiotherapi rate role
studi subject

921: Trehalase (5)

acid activ addit amino combin
compound decreas **effect** enhanc
increas initi isol posit potenti reduc
regul select strain target yeast

923: Hormones, Ectopic (16)

bodi children correl **diabet** glucos
increas **insulin** level metabol normal obes
plai protein report role specif studi tissu
tumour weight

925: Resistin (14)

bodi children correl decreas detect
diabet gene glucos increas
insulin level mellitu metabol new normal
obes sensit serum tissu year

927: Atrazine (6)

abil chromosom combin concentr effect
enhanc exposur **femal** gene increas
male mate number product properti
rat select sex sexual studi

922: Leptin (87)

bmi **bodi** consumpt diet dietari energi
fat fed feed food increas index intak leptin mass
measur nutrit obes supplement **weight**

924: Adiponectin (47)

adipocyt adiponectin associ **diabet** fast
gene glucos increas **insulin** level mellitu
metabol nod obes peroxisom ppargamma resist studi
subject toler

926: Herbicides (64)

arabidopsi concentr control effect exposur flower
leaf leav organ **plant** pollen product
rate rice root seed studi thaliana transgen water

928: Cadmium (59)

activ air **concentr** contamin copper

environment express individu level measur

metal organ pah pollut respons sampl

sediment Soil sourc **water**

929: Apoptosis Inducing Factor (20)

activ **apoptosi** apoptot bax
bcl-2 caspas caspase-3 **cell** death develop dna
induc inhibitor normal pathwai process protein role
studi tissu

931: Tumor Necrosis Factors (22)

activ apoptosi **cell** control death
develop effect express factor famili
function induc mice nf-kappab number
patient plai risk **role** treatment

933: Saposins (10)

accumul associ case control develop
differ diseas express **famili**
human interact number process
region report role sequenc structur
suggest tissu

935: Monoamine Oxidase Inhibitors (10)

compar control demonstr develop
disord find **human** mutat previou
rate report role select site specif
structur **studi** subject
suggest valu

930: Inhibitor of Apoptosis Proteins (40)

activ **apoptosi** apoptot bax
bcl-2 caspas **cell** death develop express
famili gene group identifi induc model mutant
patient screen test

932: Sphingomyelin Phosphodiesterase (18)

accumul **activ** amyloid
caus cell complex deposit diseas function
lysosom mice precursor process rate requir
respons site specif storag suggest

934: Harmine (5)

analys **analysi** combin compar
compound effect enhanc high higher increas
level low perform rat rate ratio reveal risk
studi variabl

936: Galactose (41)

activ bind cerevisia condit differ function
gene high human identifi involv method mutat
product requir saccharomyc strain structur
suggest **yeast**

937: Fluorescent Dyes (253)

analysi arrai assai cell **detect** develop express
fish fluoresc **hybrid** label
method oligonucleotid perform **probe** sensit
signal situ specif techniqu

939: Lupus Coagulation Inhibitor (7)

associ dai develop gene mean method
patient phenotyp protein ratio
respons risk sampl studi subject test time treatment
valu year

941: Oligodeoxyribonucleotides (130)

cytokin **dna** effect human ifn
ifn-gamma il-10 il-6 immun induc interferon
macrophag model product replic respons
sequenc studi target

943: Immunoglobulin Isotypes (11)

base caus **cell** earli form identifi lead
lymphoma model **new patient**
plai product provid remain **role**
specif subject suggest **test**

938: Ribonucleoprotein, U2 Small Nuclear (9)

altern base cell **cluster**
complex develop **differ**
exon **function** gene growth
human identifi increas
protein receptor splice structur
studi **variant**

940: Immunoglobulin M (110)

antibodi antigen b-cell cell
detect famili high human igg immunoglobulin level
lymphoma mab model monoclon neutral patient
sera specif studi

942: Toll-Like Receptor 9 (47)

control cpg **cytokin** differ ifn
ifn-gamma il-10 il-4 il-6 immun induc
inflammatori interferon interleukin lps
macrophag odn product **respons**
stimul

944: Calcineurin (37)

activ analysi cell
control differ effect
function gene human interact
kinas mechan mutant **new**
phosphoryl **protein** provid
regul role transplant

945: NFATC Transcription Factors (47)

activ cell develop differ
express factor gene human identifi
inhibit plai promot protein regul requir
respons role studi target
transcript

947: RNA Replicase (51)

develop genom hbv hcv hepat host human identifi
infect larg melanoma protein replic rna
sequenc size small viral VIRU virus

949: Sulfonamides (110)

activ agent cell chemoprevent COX-2 differ drug
effect gene human increas inhibit
inhibitor mechan prevent reduc
select suggest target treatment

951: Transposases (40)

contain copi delet dna element end
gene genom host insert integr locat
mobil retrotransposon sequenc site termin
transpos transposit transposon

946: Disulfides (52)

activ chaperon character control dimer fold
form function group indic molecular nativ
protein residu site solubl
stabil stabl structur
suggest

948: Lamivudine (43)

associ clinic control differ genom group hbv hcv
hepat human infect level month mutat
patient replic viral VIRU virus
year

950: Phenols (96)

activ adduct cell chemic
compound deriv
determin differ effect exposur
extract fraction increas
inhibit liquid model oxid prepar respons
specif

952: Receptors, Interleukin-7 (19)

activ cell combin effect enhanc form gener
human increas lymphocyt mice number
patient product receptor select t-cell target
tumor vivo

953: RNA Nucleotidyltransferases (7)

acid analys analysi associ complex data earli
express **function** high level low
mice mous posit process rel reveal studi tumour

955: Prions (96)

cellular **degrad** finger function indic
ligas pathwai prion process proteasom
protein prp regul report requir
stabil suggest target ubiquitin zinc

957: Ethinyl Estradiol (12)

activ chang concentr control dai
decreas effect **express** gene
high hormon **increas**
level low measur sampl subject
tissu **treatment** women

959: Epirubicin (72)

advanc **chemotherapi** combin cycl
dai docetaxel gencitabin grade median
metastat month **patient** phase
rate receiv regimen respons surviv toxic
treatment

954: Uracil Nucleotides (3)

analys **analysi** cell complex element
enzym genom individu insert integr metabol
method patient perform
protein reveal rna specif studi techniqu

956: Estrogens (162)

activ associ **breast cancer**
endometri estrogen femal hormon increas male
mechan ovari **ovarian** periton reproduct
steroid studi suggest uterin women

958: Vincristine (125)

agent b-cell cell **chemotherapi** clinic combin
drug lymphocyt **lymphoma**
median month **patient** rate resist
respons surviv therapi toxic treatment year

960: Prednisolone (67)

associ **case** clinic dai diseas dose group
lymphoma month **patient** present
rare report respons sever studi surviv therapi
treatment year

961: RNA, Untranslated (94)

analysi chang chicken data differ function gene

genom identifi imprint **individu**
japanes melanoma methyl nucleotid
region rna **sequenc** studi
suggest

963: Hydroxyurea (72)

activ acut cell defici **dna** effect function
increas leukemia patient polymeras replic requir
respons role select strand studi suggest treatment

965: DNA, Single-Stranded (130)

analysi cell damag **dna** duplex effici fork
function helicase pol polymeras process repair replic
select single-strand strand studi synthesi templat

967: Pyruvate Kinase (11)

chang data effect enzym express famili
gene member mutant **mutat**
patient rate rel role sever specif **studi**
time treatment tumor

962: DNA, Fungal (275)

aspergillu bud cerevisia dna function fungal

fungi fungu growth isol pathogen

phylogenet produc requir saccharomyc

sequenc **speci** strain tree

yeast

964: Schizosaccharomyces pombe Proteins (114)

albican bud candida cerevisia encod eukaryot

fission function growth homolog involv mutant

pomb protein requir respons saccharomyc

strain suggest **yeast**

966: Methyl Methanesulfonate (35)

atm break damag differ **dna**
double-strand dsb effect excis exposur induc mutant
pathwai pattern protein rate repair respons strand
yeast

968: Iron Chelating Agents (27)

activ analysi assai barrier commun
connexin contact coupl defici detect effect

gap group indic **iron**
junction role sensit studi
suggest

969: Antigens, CD36 (25)

activ associ cell compar control
decreas develop effect group human
increas level lipid ratio receptor
risk select sequenc studi subject

971: mRNA Cleavage and Polyadenylation Factors (18)

associ bind chang decreas earli famili
function group increas
interact mrna number organ
patient **protein** rna select site studi
translat

973: Influenza Vaccines (34)

antigen care health human
immun individu infect
medic particip practic product protect rate
replc research respons **vaccin**
variabl viral **viru**

975: Phosphates (85)

activ analysi **bone** differ dna
enzym famili function gener human
increas level method model mutat product
role structur studi vitamin

970: Antigens, CD2 (4)

associ bind cancer carcinoma cell
combin effect flow gastric marker mutat patient
primari relat requir **respons** signific studi suggest
surviv

972: RNA Polymerase II (139)

activ complex demonstr elong factor function gene
genom melanocyt **melanoma** mirna
polymeras process promot ribozym **rna** rnase
suggest transcript vitro

974: Ribonucleoproteins, Small Nucleolar (12)

assembl associ **complex**
compon data encod evid express gene genom
melanoma **number** process
protein requir respons **rna** sequenc subunit
support

976: Urinary Plasminogen Activator (81)

activ associ cathepsin cell express
extracellular human inhibitor **invas**
matrix metalloproteinas migrat mmp
mmp-2 mmp-9 pai-1 plasminogen tissu upa upar

977: Gelatinases (12)

activ cell chang correl
develop effect express invas
level matrix model normal
patient process product
protein rate report studi tissu

979: Purines (59)

activ analysi arrest base cell control
cycl cyclin differ dna effect group
human identifi increas level phase studi
subject treatment

981: DNA, Superhelical (38)

activ analysi chang cluster dai dna duplex
fork gene helicas pol polymeras process protein replic
select single-strand strand studi synthesi

983: Blood Coagulation Factors (28)

bleed compar control develop differ effect
factor folat homocystein human
mthfr number patient platelet rel risk
studi thrombosi treatment venou

978: Uric Acid (30)

caus concentr control diseas effect failur
gene higher increas kidney level
mutat patient plasma rcc renal role
serum studi subject

980: Mucoproteins (10)

associ cell diseas domin
effect evid famili genet
genom inherit number phenotyp
protein provid region sampl
sequenc studi support time

982: Luminescent Proteins (93)

cell construct enhanc express fluoresc
form function gene gfp green interact mechan
model popul process protein report transfect
transient vector

984: Histocompatibility Antigens (34)

allele antigen cell class complex gene
genet group histocompat hla human major
mhc molecul new present provid role select
specif

985: Immediate-Early Proteins (179)

activ bind cell develop differ express
factor function **gene** human kinas
level phosphoryl **promot** protein regul
respons role transcript viru

987: Silver (10)

compar content detect determin extract
fish flow fluoresc higher
hybrid interact method
observ probe **rate** sampl situ studi
techniqu time

989: NADH Dehydrogenase (19)

associ complex develop differ dna
gene level mitochondri
mitochondria mtdna origin phylogenet rate
region rel relationship sequenc
speci suggest tree

991: Antibodies, Bacterial (54)

antibodi antigen assai associ
combin detect high igg immun mab method
monoclon neutral patient phenotyp protein
respons sensit sera specif

986: Cyclins (149)

activ arrest **cell cycl cyclin**
cyclin-depend express function gene inhibitor kinas
p21 p27 phase progress prolifer protein regul
retinoblastoma studi

988: Proto-Oncogene Proteins c-fos (83)

activ cell chang effect erk express
gene human increas induc inhibit kinas
mapk pathwai phosphoryl protein rat regul
respons signal

990: Chlorides (48)

activ asthma calcium caus
channel compar
concentr control current differ
effect famili increas mean measur rate
size studi test valu

992: Reagent Kits, Diagnostic (44)

assai base clinic compar **detect**
determin diagnosi evalu limit measur method monitor
patient posit rapid sampl sensit specif studi
test

993: Polyethyleneimine (37)

carrier cation complex conjug **deliveri**

dna **effici** formul gene liposom

nanoparticl **particl** poli polym prepar

properti releas scaffold solut **surfac**

995: Bacterial Vaccines (28)

adult antigen cell cti diseas express

group human **immun**

immunotherapi induc isol patient protect

recombin **respons** specif strain

vaccin year

997: Octamer Transcription Factor-3
(41)

adult cd34 cd34+ **cell** chang commit differenti

embryon gene hematopoiect hsc human increas lineag

mous popul potenti precursor progenitor stem

999: Gonadal Steroid Hormones (36)

associ children control cycl develop factor

femal hormon level **male**

popul reproduct risk sex sexual steroid

studi treatment tumor women

994: Polyglycolic Acid (16)

cation cell compar conjug **deliveri** dna

effect **effici** formul liposom method

normal **particl** polym prepar

properti rate releas **surfac**

tissu

996: Polymers (142)

cation conjug **deliveri** differ dna

effici formul liposom model nanoparticl

particl polym prepar properti releas

scaffold solut structur studi **surfac**

998: Ovalbumin (55)

antigen asthma **cell** compar control

cystic **differ** fibrosi gener genet

immun induc mice model

pattern **respons** select studi

treatment **vaccin**

1000: Desmin (16)

associ base cell chang **differ** effect

femal genom **high** level low male model

muscl mutat protein

rat sequenc tissu tumor

1001: Hepatitis B e Antigens (28)

combin control effect group hbv hcv hepat host
infect liver mutat patient replic respons
rna treatment viral **viru** virus year

1003: Cytochrome Reductases (2)

activ analysi approxim blot cancer
effect enzym express gener hepat
liver major mrna prevent protect protein reduc
reduct rel western

1005: Receptors, Interleukin-6 (16)

cell correl effect function gene high
human level **multipl**
patient rate receptor region
respons role sampl sequenc singl studi
treatment

1007: Guanine (169)

activ allele associ base control damag develop differ
dna gene genotyp human mutat patient
polymorph repair replic sequenc structur studi

1002: WT1 Proteins (46)

analysi cancer cell chang express gene genet human
increas malign patient posit progress protein report
solid studi suppressor target **tumor**

1004: Ankyrins (17)

contain enhanc express function gene interact
length long model new number patient
protein **repeat** role short suggest
tandem termin unit

1006: Cytokine Receptor gp130 (9)

analysi blot cell chang demonstr differenti
effect express famili **interact** level
mice model mous protein signal
specif **studi** subject transgen

1008: Oxidoreductases Acting on CH-NH Group Donors (9)

analysi clinic diagnosi enzym famili
group human identifi increas isol
new protein provid region respons
sampl **select** sequenc structur target

1009: Calmodulin-Binding Proteins (26)

activ cell chromosom differ express
gene genotyp human increas
individu level patient
polymorph posit predict protein rate
studi tumor variabl

1011: Mannose (19)

analysi cell control differ effect
famili function gene high
increas level low peptid plai
product protein residu role
site structur

1013: Antigens, CD79 (13)

associ case cell develop
differ distribut express
high increas level local low
lymphoma pattern requir respons
role studi suggest target

1015: Interferon Regulatory Factors (26)

analysi associ base bind case
cell detect express function gene
group increas lymphoma mutat
phenotyp protein region reveal
sequenc studi

1010: alpha-Cyclodextrins (3)

assai cation complex conjug deliveri detect
effici event formul gene involv
liposom particl polym PROCESS properti
regress sensit surfac variabl

1012: Neprilysin (40)

analysi b-cell carcinoma case cell cluster
develop differ diseas express group
increas larg level lymphocyt
lymphoma pattern
phenotyp role tissu

1014: Antigens, CD27 (18)

activ base caus cell compar control
decreas differ express gener group human
increas lymphocyt mice mous regul requir
respons t-cell

1016: Antigens, CD30 (23)

b-cell base case clinic cll diffus function hodgkin
immunoglobulin increas larg leukemia lymphocyt
lymphoma malign nhl
non-hodgkin patient rituximab treatment

1017: Paraquat (11)

activ caus decreas determin effect
exposur gene high **increas** level
low number oxid oxygen posit process
reactiv reduc stress valu

1019: Cysteine Endopeptidases (69)

activ analysi cell cleavag control degrad
express function genom group indic level
process proteas **protein** residu role sequenc
site tissu

1021: Hepatitis C Antibodies (8)

adult analysi blot chang detect
differ genet **group** incid
infect new patient preval risk test time
viru western women **year**

1023: Interferon-Stimulated Gene Factor 3 (4)

activ cell cluster decreas **express**
follow **gene** gener includ
increas inhibit invas kinas level
mice promot rang requir transcript wide

1018: Antigens, Polyomavirus Transforming (44)

anim base cancer **cell** develop express function
human larg line **mice** model mous
number product respons size tissu transgen tumor

1020: Viral Structural Proteins (62)

analysi cell differ genom group hbv hcv hepat high
host human **infect** protein region replic
sequenc structur viral **viru** virus

1022: STAT2 Transcription Factor (10)

associ caus correl cytokin effect form format
gene genom induc induct lead mice
pathwai receptor reduc requir resist
respons signal

1024: Interferon-Stimulated Gene Factor 3, gamma Subunit (3)

activ bind brain combin effect express
gene identif identifi kinas novel
phosphoryl promot protein receptor screen site
transcript variant viru

1025: Interferon Regulatory Factor-7
(11)

activ chang cytokin enhanc express
gene human identifi new phenotyp promot
provid receptor region regul screen sequenc
signal studi viru

1027: Interferon-alpha (132)

activ cell **cytokin** express ifn
ifn-gamma il-10 il-6 immun induc
inflammatori interferon leukemia level
macrophag mutat patient product
respons treatment

1029: Antigens, CD86 (32)

activ antigen **cell** develop enhanc express
famili gene human immun lymphocyt product
respons role specif t-cell tissu treatment vaccin
vivo

1031: Anticoagulants (80)

associ bleed differ effect **factor** folat
homocystein increas level metabol mthfr
patient plasma platelet sampl
studi thrombosi treatment venou year

1026: Mercury (23)

air **concentr** contamin copper

correl environment genet high influenc

measur metal pollut popul respons

sampl Soil sourc speci tissu **water**

1028: Interferon-beta (73)

activ associ cell **cytokin**
effect express ifn ifn-gamma il-10 il-6
immun induc macrophag month
patient product respons time
treatment year

1030: Ciprofloxacin (22)

activ antibiot bacteri bacteria control dai detect
genet group host **infect** **isol** parasit
pathogen patient respons **strain**
studi type virul

1032: Phenprocoumon (3)

allel caus concentr dai effect gene genotyp mean
measur metabol **patient** plai
polymorph ratio reduc requir respect role studi valu

1033: HIV-1 Reverse Transcriptase (51)

aids antiretrovir control env gag herp hiv

hiv-1 hsv hsv-1 human

immunodefici increas **infect**

mutat replic revers simplex viral **viru**

1035: HIV Protease (47)

aids data differ estim herp hiv

hiv-1 hsv-1 human

immunodefici **infect** method

model mutat patient predict simplex variabl

viral **viru**

1037: Ganciclovir (59)

address clear cmv controversi cytomegaloviru
despit evid gene infect issu lack major patient

possibl question rais **remain**
unclear unknown viru

1039: Antibodies, Antinuclear (43)

antibodi antigen associ biolog
cell correl develop includ level mab mice
monoclon neutral **patient** posit signific
specif studi **System** test

1034: AIDS Vaccines (57)

antigen ctl data epitop herp hiv hiv-1 human

immun immunodefici

immunotherapi induc **infect** protect

respons simplex time **vaccin** viral
viru

1036: Fluorine Radioisotopes (11)

analysi assess cell develop differenti effect

evalu express **human**

imag magnet measur mechan mri
perform reson scan tissu valu volum

1038: Uridine Monophosphate (5)

activ algorithm analysi combin complex

data effect enzym method model mutat

network predict **region** regul

respons **sequenc** set state

structur

1040: Vidarabine (55)

activ allogene b-cell case chemotherapi combin

dai donor effect graft **lymphoma** new

patient rate recipi respons stem

studi surviv **transplant**

1041: Proline (116)

allele analysi associ domain effect
express form function gene genotyp human
mutant mutat patient
polymorph protein residu site
structur substitut

1043: Antibodies, Antineutrophil Cy-
toplasmic (16)

antibodi antigen associ blood
control correl differ express genet level mab
monoclon neutral patient phenotyp
polymorph posit size specif test

1045: Ifosfamide (36)

advanc case cell chemotherapi combin dai
dose median month patient phase
receiv regimen respons studi surviv therapi
toxic treatment trial

1047: Cytochrome P-450 CYP3A (12)

activ cyp1a1 cyp2c9 cyp2d6 cyp3a4 cytochrom
determin drug enzym famili human liver
metabol metabolit microsom
p450 patient respect studi test

1042: Glutamic Acid (106)

acid activ analysi associ chang effect enzym
famili function gene increas mutant
mutat neuron number
protein rate role site suggest

1044: Protective Agents (10)

activ anim approach cell compar control
differ effect health human larg
model number patient random rat
size studi treatment trial

1046: Mesna (7)

case compar control detect differ
high higher local low median month normal
patient pattern rate report
time tissu tumor year

1048: Omeprazole (20)

associ CANCER clinic determin effect express
gastric gastrointestin mucosa
number patient pylori repeat respect
respons sampl stomach studi system
treatment

1049: Proton-Translocating ATPases (17)

acid **activ** analysi bind chang
complex dai differ gener interact mechan
observ plai **protein** repeat reveal role
select site structur

1051: Benzimidazoles (52)

activ bind **cell** compar control dai
detect determin **differ** effect human
increas number patient rat resist size
studi treatment **tumor**

1053: Mixed Function Oxygenases (69)

activ cyp2d6 cyp3a4 cytochrom determin
develop differ drug **enzym** gene group human
interact **metabol** metabolit
microsom p450 protein respect substrat

1055: Antigens, Viral (114)

cell express group hbv hcv hepat high host human
infect isol level phenotyp replic sequenc
strain test viral **viru** virus

1050: Histamine H2 Antagonists (4)

associ chang clinic dai decreas diagnosi **differ**
frequent genotyp **increas** model observ occur
occurr **patient** pattern presenc risk
studi transmiss

1052: Famotidine (4)

cancer clinic cluster combin compar decreas
effect essenti gastric **group**
increas mutat new plai random **requir**
role studi treatment trial

1054: Adenylate Cyclase (36)

activ agonist alpha antagonist beta cell decreas effect
express function increas level ligand mediat mutant
receptor respons role studi tissu

1056: Mucins (72)

associ **CANCER** cell compar control differ
express famili **gastric**
gastrointestin gene group human mucosa
phenotyp pylori respect stomach studi tissu

1057: Dopamine (129)

affect anim associ astrocyt brain diseas disord
dopamin effect function gene glial hippocamp
increas model **neuron** schizophre
studi suggest synapt

1059: Ferredoxins (7)

chang complex conform crystal data differ dynam

express function interact local mitochondri

model pattern protein region sequenc simul

stimul **structur**

1061: Cyclophilin A (10)

chang data distribut event famili form gene
human local mutant new process
protein region requir resist sampl select sequenc
treatment

1063: alpha Karyopherins (18)

accumul affect complex cytoplasm differ export

function gene import local **nuclear**
nuclei nucleu protein receptor region sequenc
signal test transloc

1058: Carmustine (22)

base **cell** chemotherapi control develop

differ effect human increas month

patient **primari** rate

respons secondari studi surviv treat

treatment tumor

1060: Formate Dehydrogenases (1)

avail base data databas discuss domain dynam
element experiment field inform insert integr

model paramet predict recent simul
space tool

1062: RNA Caps (24)

activ express function gene genom initi
model **mrna** process protein region
requir ribosom rna sequenc site suggest

transcript **translat** trna

1064: E2F Transcription Factors (97)

arrest associ cdk2 **cell** cip1 **cycl**

cyclin cyclin-depend express gene inhibitor
kinas p21 p27 phase progress prolifer regul
retinoblastoma role

1065: E2F3 Transcription Factor (9)

activ arrest caus cell chain
cycl cyclin delet express gene induc p21
p27 p53 phase progress reaction requir respons
tumor

1067: Galactokinase (8)

associ cerevisia clone cluster encod express form
function gene gener identifi plai
recombin role saccharomyc screen select structur
suggest yeast

1069: Basic-Leucine Zipper Transcription Factors (36)

activ analysi cell dna express
factor function gene genom
human identifi induc protein regul requir
respons screen tissu
transcript treatment

1071: Carbon-Nitrogen Lyases (2)

distribut fluid gene genom
local nuclear plai produc product
protein recombin region role
sequenc site speci suggest variant vitro
vivo

1066: Polyproteins (8)

analysi combin contain differ
genom infect isol
number pattern plant process
protein recombin region repeat
reveal sequenc site strain viru

1068: Transcriptional Elongation Factors (16)

activ associ bind complex evid
genom human initi melanoma new organ
product provid report ina sequenc studi
suggest support transcript

1070: SUMO-1 Protein (41)

activ cellular degrad finger
function human ligas mutant pathwai prion
proteasom protein prp regul
requir stabil suggest target ubiquitin zinc

1072: GATA4 Transcription Factor (26)

associ cell develop differenti effect enhanc

express factor famili gene genet

heart human level member protein regul

respons role transcript

1073: E1A-Associated p300 Protein (21)

acetyl activ cell chromatin
control develop differ effect famili
function gene **histon** inhibit
mechan number pattern promot recruit
regul transcript

1075: Immunoglobulin J Recombination Signal Sequence-Binding Protein (18)

activ bind cell conserv
detect effect function gene group human
identifi interact mammalian new phenotyp
protein rate recombin reduc role

1077: Guanylate Kinase (6)

associ bind complex effect express
famili function gene gener genet
interact mechan model plai
protein role specif structur
studi test

1079: Multiprotein Complexes (204)

assembl bind biochem **complex**
compon compos consist contain essenti form format
function interact mediat process protein recruit requir
structur subunit

1074: Threonine (72)

activ analysi associ effect gene
genotyp group interact kinas mutant
mutat patient phosphoryl
polymorph protein region role sequenc
site suggest

1076: Macrophage Inflammatory Proteins (6)

activ analysi blot cancer cell enhanc event
express increas induc inhibit line
process produc product respons suggest
tumor tumour vector

1078: Nucleoside-Phosphate Kinase (11)

cell complex correl **develop**
enzym form function increas interact mechan
phenotyp protein regul role select structur
suggest system target time

1080: Phosphotyrosine (47)

activ cell express function human
inhibit kinas mechan pathwai phosphatas
phosphoryl protein receptor regul requir role
signal src stat3 tyrosin

1081: Phosphotransferases (Alcohol Group Acceptor) (90)

activ analysi associ enzym
express form function gene
human kinas mutant mutat
pathwai patient phosphoryl protein regul role
studi substrat

1083: TATA Box Binding Protein-Like Proteins (2)

activ analysi dna essenti express fragment
gene independ p53 pathwai predict promot
regress relationship requir signal signific transcript
variabl variat

1085: Toll-Like Receptor 4 (75)

control cpg cytokin ifn
ifn-gamma il-10 il-4 il-6 immun induc
inflammatori interferon interleukin lps
macrophag odn product receptor
respons stimul

1087: Allergens (71)

airwai allerg allergen analysi
asthma cftr cystic diseas
eosinophil fibrosi ige increas obstruct
patient pulmonari respiratori
respons sever studi ventil

1082: TATA-Box Binding Protein (29)

activ associ bind chang complex develop
element express factor gene human identifi
interact patient promot protein
region regul site transcript

1084: Interleukin-12 (134)

cell cpg cytokin gene ifn
ifn-gamma il-10 il-4 il-6 immun induc
inflammatori interferon interleukin lps
macrophag patient product respons
stimul

1086: HLA-B35 Antigen (3)

acid assai class clinic codon detect diagnosi
gener identifi identifi normal novel
patient peptid screen sensit
specif studi substitut tissu

1088: Antigens, Bacterial (115)

activ antibodi assai cancer cell detect differ
function gastric gene gener infect
isol protein sensit sequenc specif
strain studi test

1089: Gentian Violet (7)

adult cell chang clinic
distribut effect express
famili higher level local
method phenotyp presenc
protein rate requir select
valu year

1091: POU Domain Factors (11)

analysi approxim develop differ
evolut EXPRESS function human identifi
mechan molecular new period point rel
respons screen select studi time

1093: Viral Fusion Proteins (36)

cell complet demonstr differ express fusion
gene hcv human infect partial pattern
protein replic specif structur vector
viral viru virus

1095: Acetamides (24)

activ analysi case concentr
develop differ effect function gener
group human increas individu infect
inhibit model new patient respons
studi

1090: Phenazines (10)

cell combin determin
develop differ distribut
earli effect express form format
gene inhibit isol local
method strain studi subject
techniqu

1092: MicroRNAs (133)

demonstr elong express gene genom interfer melanocyt
melanoma microrna mirna pol polymeras
requir ribozym rna rnase sirna small transcript
vitro

1094: Insecticides (76)

carcinogen chemic control differ
drosophila effect expos
exposur fli health host insect
larva melanogast model mutagen speci studi
toxic wing

1096: Hemagglutinin Glycoproteins,
Influenza Virus (21)

acid activ alter associ bind chang develop
express gene group increas infect isol
model mutant replic strain viral viru
virus

1097: Iron (206)

activ barrier commun connexin contact
coupl demonstr dose form gap gene hfe
indic iron irradi
junction radiat studi
suggest tight

1099: Ribonuclease, Pancreatic (26)

differ endotherli factor famili gener growth
high identifi level melanoma member
number process product protein
requir RNA role stabil subject

1101: Amino Acid Transport Systems (15)

acid amino anim associ develop
earli express function gene human
increas interact membran model posit
protein role sampl studi transport

1103: DNA, Recombinant (66)

cell chang construct contain effici express
gene genet genom homolog human
increas method plasmid recomb
select sequenc transfer variant vector

1098: Eosinophil Cationic Protein (1)

absenc diverg divers duplic evolut evolutionari
famili histori identifi includ individu
member origin presenc rang region sequenc
suggest varieti wide

1100: Rosaniline Dyes (8)

analysi approach case cell chang
detect determin differ genom
larg lesion level light organ posit sequenc
size specif stain studi

1102: Starch (36)

access barlei crop cross cultivar differ
diploid gene grain hybrid line maiz parent
plant rice select ssr wheat
wild yield

1104: Deferoxamine (23)

activ associ barrier cell
chang detect effect form format gap
gene group iron junction model
requir role sampl studi suggest

1105: Smad4 Protein (51)

activ bmp cartilag cell chondrocyt collagen

express factor fibroblast

growth human induc regul

respons signal smad suggest tgf-beta

tgf-beta1 transform

1107: alpha-L-Fucosidase (1)

adapt coli correl dna element environ enzym
evolut fit index insert integr natur posit protein

relat relationship select signific stabil

1109: Indicators and Reagents (78)

activ allow analysi appli applic base cell
compound detect develop effici extract human

method procedur protocol rapid
simpl standard techniqu

1111: RNA Probes (23)

analysi cell detect differ express
famili fish fluoresc function gene

hybrid identifi method normal
probe screen situ specif studi tissu

1106: Sepharose (19)

analysi bind cell develop

dna domain effect express extract

form gene genom high human

interact method process protein site

structur

1108: RNA, Transfer, Amino Acyl (16)

acid bind chang codon control form

format function gene

genom initi level mrna

protein ribosom rna sequenc site structur

translat

1110: Fixatives (16)

biopsi combin detect develop express gene

genom histolog human hybrid

immunohistochem lesion

method number specif

specimen stain studi techniqu tissu

1112: RNA, Algal (6)

analysi compar content determin differ effect

enhanc flow gene genom higher

model rate reduc respons rna sequenc

speci specif subject

1113: Lipoproteins, HDL (35)

activ apoe apolipoprotein associ
atherosclerosi cholesterol diseas gene
group hdl increas ldl level lipid
lipoprotein metabol plasma studi total
triglycerid

1115: Lipoproteins, LDL (46)

apoe apolipoprotein associ atherosclerosi
cholesterol effect hdl increas ldl
level lipid lipoprotein low
metabol patient plasma studi subject total
triglycerid

1117: Buffers (44)

activ analysi associ chromatographi detect
determin differ dna effect extract
fraction liquid mass method
prepar protein sampl separ structur studi

1119: Fimbriae Proteins (11)

activ ASSOCI base cell detect dna
gene infect isol model mutant
number phenotyp plasmid rate recombin
role select strain studi

1114: Lipoproteins (110)

activ analysi apoe apolipoprotein associ
cell cholesterol develop differ
effect function increas ldl level
lipid lipoprotein metabol patient
plasma studi

1116: Phospholipases A (30)

acid activ analysi conserv decreas differ
effect express form
function group high increas
inhibit inhibitor level pattern reduc
structur studi

1118: Sodium Channels (98)

activ atp ca2+ calcium cam
channel current function gene
genet intracellular ion mutat potassium
potenti region releas respons sequenc sodium

1120: Pheromones (55)

activ control differ drosophila
femal fli fly gene group host insect larva male
melanogast mosquito select speci suggest wing
yeast

1121: Iron-Binding Proteins (26)

activ barrier bind contact function gap
gene group human indic
iron junction local mutat
patient respons select
structur studi suggest

1123: Methionine (96)

activ affect allel associ
control differ effect factor famili gene
genotyp increas mutat
polymorph risk schizophrenia
site structur studi suggest

1125: Valine (90)

acid activ affect allel analysi associ
clinic codon differ frequenc gene genet
genotyp mutat
patient polymorph
popul studi substitut suggest

1127: GTP Phosphohydrolases (54)

actin activ cell cytoskeleton enhanc
famili filament function identifi
interact member migrat mutat patient
polar protein regul rho role suggest

1122: Adenomatous Polyposis Coli Protein (37)

apc cancer cell colon
colorect control crc develop evid gene
increas instabl methyl mutat normal pathwai
repeat signal support tissu

1124: Powders (8)

differ earli effect energi field
measur mechan method model movement
new pattern product reduc reduct select
space structur type valu

1126: RNA, Fungal (107)

activ analysi cerevisia function gene

identifi isol mrna mutant pathogen protein

requir rna saccharomyc sequenc speci strain

suggest translat yeast

1128: Cytochromes (8)

analys analysi base case chang compar
effect gene higher increas
metabol mitochondri new number rate
reduc respons reveal speci time

1129: Succinic Acid (10)

acid activ amino behavior cognit
concentr condit develop earli
enzym higher increas model
perform phenotyp rate select structur
substrat valu

1131: 5'-Guanylic Acid (5)

activ concentr conform crystal decreas determin
develop dna effect fold form increas rang reduc
reduct repeat specif structur target
valu

1133: Chitinase (16)

aspergillu decreas effect express famili
function fungal fungi fungu
group increas isol
mutant pathogen plant produc
sampl sequenc speci time

1135: Ferrous Compounds (16)

activ assai concentr condit
degre detect express high
human increas method
patient process product
sensit specif state treatment
tumour year

1130: Ubiquinone (30)

base compar control cytochrom dna effect famili
function gene group increas involv level
mitochondri
mitochondria mtdna oxidas patient studi
suggest

1132: Antineoplastic Agents, Alkylating (124)

agent chemotherapi clinic combin dna drug
effect new patient primari
respons studi surviv therapi tissu toxic
transplant treat treatment tumor

1134: Ceruloplasmin (25)

associ case clinic control develop
diagnosi differ function increas liver
model mutat organ patient
popul process report role studi
treatment

1136: Fanconi Anemia Complementa-
tion Group Proteins (21)

activ bind cell complex control defect
defici dna factor form function gene
human increas interact mechan new
patient protein risk

1137: Saponins (16)

analysi cell combin compar
compound concentr
deriv **develop** differ earli
effect follow group increas
level persist rate respect studi variabl

1139: Prothrombin (70)

associ bleed coagul control diseas
factor folat gene group homocystein
increas mthfr patient plasma platelet risk
studi thrombin thrombosi venou

1141: Ribonuclease P (14)

cell combin complex control effect human
identifi interact **melanoma** method
polymeras product protein region requir
rna sequenc site structur transcript

1143: Kainic Acid (23)

anim brain chang control dai earli effect
increas mice model **neuron**
patient rat role stage studi time treat
treatment week

1138: Factor V (93)

associ bleed coagul control **factor**
folat homocystein leiden mthfr patient plasma
platelet reductas risk studi test thrombin
thrombosi venou vitamin

1140: RNA Precursors (87)

altern differ encod exon gene identifi

intron isoform lack melanoma mrna novel

report rna sequenc site **splice** suggest

transcript **variant**

1142: Excitatory Amino Acid Agonists (34)

acid astrocyt base bdnf behavior brain cell control
differ dopamin effect glial glutam hippocamp interact
neural **neuron** receptor suggest
synapt

1144: Antigens, Differentiation, T-Lymphocyte (32)

activ analysi associ **cell** compar control
data diseas express gene genet immun increas
lymphocyt number rate sampl studi t-cell
treatment

1145: HLA-DR Antigens (147)

allele antigen associ cell **class** complex
drb1 histocompat hla human kir leukocyt major
mhc molecul natur patient present specif type

1147: Serotonin (80)

activ adhd anxiety associ behavior bipolar control
depress differ **disord** find genet major
mental person psychiatr serotonin sleep studi
symptom

1149: Oxidoreductases Acting on CH-CH Group Donors (35)

acid activ analysi associ catalyt control differ
enzym express gene genom group
human increas level mutant new reaction studi
substrat

1151: Receptors, Antigen, T-Cell, alpha-beta (61)

cd4 cd4+ cd8 cd8+ **cell** develop differ express
famili group il-2 immun lymphocyt member natur
new protein receptor t-cell tcr

1146: Pregnadienediols (5)

analys analysi decreas **effect**
express **high** improv increas level low
new patient protect provid reduc reduct
reveal state treat **treatment**

1148: Protoporphyrinogen Oxidase (5)

abil clinic enzym high level low mechan mice
molecul mutant mutat **patient**
phenotyp region sequenc sever state studi
target wild-typ

1150: Galactosylceramides (10)

analysi bind **cell** compar determin differ
enhanc flow **group** higher increas mice
patient product rate structur studi system
vitro vivo

1152: Antigens, CD1 (35)

analysi case cd4 **cell** class decreas develop
express gene human immun increas lymphocyt
mechan mice molecul new respons role t-cell

1153: Electron Transport Complex IV
(76)

activ analysi cytochrom differ dna genet indic involv
mitochondri
mitochondria mtdna oxidas phylogenet popul
region relationship sequenc speci suggest tree

1155: Antimutagenic Agents (39)

assess carcinogen cell chemic concentr control
damag **effect** expos **exposur**
frequenc genotox increas indic induc mutagen
potenti reduc signific toxic

1157: Proprotein Convertases (6)

caus cell complex concentr evid **express**
factor famili form format **gene**
genom growth involv lead member process
residu site support

1159: Chitin (20)

activ cell chang complex defect effect
function fungal gene group
human isol **mutant** mutat
pathogen rat requir respons speci wild-typ

1154: Tryptophan Hydroxylase (21)

adhd anxieti associ behavior bipolar control
depress differ **disord** function genet
group patient person psychiatr sampl serotonin
sleep studi symptom

1156: Carotenoids (48)

concentr decreas determin effect
gene higher increas low lower measur **microg**
microm micromol min number plasma rang respect
salt valu

1158: Glucan Endo-1,3-beta-D-
Glucosidase (4)

adapt cell core data encod evid evolut fit
gene identifi mutant natur open protein read
report **select** studi suggest support

1160: beta-Glucans (16)

cell control decreas develop diseas **effect**
enhanc increas induc induct isol pathogen
produc product protein reduc
respons role sampl treatment

1161: Helminth Proteins (33)

caenorhabd dispers distribut ecolog
elegant express forest function gene
habitat model product region rel sampl sea
season sequenc **speci** studi

1163: Hemoglobin A, Glycosylated (39)

analisi assess associ control correl
diabet effect fast glucos group
increas **insulin** measur mellitu metabol
patient peroxisom score studi subject

1165: Phenylalanine (59)

associ bind chang code codon differ
function gene identif **identifi**
increas mutant **mutat** novel
protein role **screen** site
structur substitut

1167: Hemoglobin A2 (3)

clinic control defici diagnosi diagnost
differ factor genet healthi identif
method patient report **risk** screen
site studi **subject** techniqu
variant

1162: Antigens, Helminth (16)

analisi antibodi chang combin dai
decreas detect effect express gene high
increas infect level
patient popul **protein**
sampl test treatment

1164: Cyclohexanes (20)

activ cell compar compound control differ effect
group inhibit model rat respect select
signific **structur** studi **treatment** trial vitro vivo

1166: Ethylenes (20)

activ arabidopsi control develop flower gene
group leaf leav **plant** pollen product
region regul **respons** root seed sequenc **structur**
studi

1168: Opsin (37)

acuiti amd cone degener detach develop
function human local macular optic
photoreceptor pigment **retin** retina
rod studi time vision **visual**

1169: L-Lactate Dehydrogenase (62)

activ analysi associ **cell** compar
control decreas develop effect enzym
express function gene **group**
increas level
patient protein serum studi

1171: Aspergillus Nuclease S1 (8)

analysi cell clone data effect express form
format gene gener method model new
protein provid **region select**
sequenc structur studi

1173: Arginine (219)

activ allele associ cleavag codon domain famili
function gene genotyp increas mutant
mutat patient polymorph posit
protein residu site substitut

1175: Somatomedins (20)

chang control decreas effect **factor** famili function
group **growth** health height hormon
human igf-i **increas** insulin-lik level respons stimul studi

1170: Receptors, CCR5 (64)

aids associ differ earli gene group herp **hiv**
hiv-1 hsv-1 human
immunodefici **infect**
nf-kappab number respons **select** simplex
viral **viru**

1172: Tetrodotoxin (15)

adapt alter **chang** channel concentr
effect evolut **human** increas local
mechan model plai receptor resist
respons role **select** stimul
studi

1174: Nucleic Acids (28)

acid amino approach detect dna fatti
function gene human hybrid identifi method model new
nucleic number process protein respons retino

1176: Proliferating Cell Nuclear Anti-
gen (142)

brdu **cell** cellular **differenti**
dna express increas induc model patient pcna prolif
prolifer protein regul replic role studi suggest
termin

1177: Transcription Factors, TFII (25)

activ assembl bind **complex**
compon differ dna effect factor form function
gene interact promot protein requir subunit
target time transcript

1179: Transcription Factor TFIIH (9)

chang complex dna express **gene**
genom interact melanoma model new normal
patient process regul rna size small time
tissu transcript

1181: Cations (83)

cation channel complex conjug **deliveri**

differ dna **effici** formul gene human

liposom **particl** polym prepar properti

releas solut structur **surfac**

1183: Mannose-Binding Lectin (29)

demonstr deriv design differ displai gene genotyp group
identifi level novel patient **peptid**
polymorph recogn recognit role specif studi synthet

1178: Endonucleases (63)

activ assai associ break **damag** detect develop differ
dna element excis gene genom group method
polymeras **repair** replic sensit strand

1180: Vesicular Transport Proteins (71)

activ cellular complex function gene identifi
interact intracellular local mechan
membran mutat plasma
protein requir surfac traffick **transport**
uptak vesicl

1182: Polyubiquitin (19)

cell cellular **degrad** demonstr finger indic
ligas pathwai prion process proteasom
protein prp regul requir stabil
suggest target ubiquitin zinc

1184: Dacarbazine (74)

activ chemotherapi clinic glioblastoma glioma
group malign month new patient
primari respons secundari studi
therapi toxic treat **treatment** trial tumor

1185: Excitatory Amino Acids (2)

affect data event evid **genet** involv
mechan molecular p53 plai popul process
provid role schizophrenia studi suggest support
treat treatment

1187: Ceramides (39)

accumul activ
apoptosi associ bcl-2 cell
control death deposit diseas enhanc
express function genom **increas** induc
organ storag studi suggest

1189: Fenretinide (19)

activ apoptosi cancer **cell** control
drug effect enhanc factor famili growth
increas induc patient reduc respons risk role
tissu treatment

1191: Sialyltransferases (10)

activ **cell** chang develop earli express
famili increas line new promot provid region
role sampl sequenc stage studi treatment tumor

1186: Gene Products, tat (48)

activ bind effect **express** gene gener
hiv hiv-1 human immunodefici
infect peptid **protein**
target therapi Tissu transfer vector
viral **viru**

1188: Gangliosides (34)

accumul activ
antibodi antigen case caus
cell deposit **develop** diseas earli
effect express gene group level reduc
storag suggest tumor

1190: bcl-2 Homologous Antagonist-Killer Protein (42)

activ **apoptosi** apoptot bax
bcl-2 caspas caspase-3 cell control death induc
induct inhibit inhibitor pathwai proapoptot protein rate
releas surviv

1192: p300-CBP Transcription Factors (7)

activ bind complex effect identifi
induc induct interact mechan organ p53 protein
report **respons** screen site studi target time
transcript

1193: CREB-Binding Protein (41)

acetyl **activ** analysi cell
chromatin combin function
gene **histon** human interact
new protein rate recruit regul role studi
target transcript

1195: Proto-Oncogene Proteins c-abl (29)

activ associ cell effect **kinas**
local number p53 patient phosphatas
phosphoryl protein regul role sampl
signal stat3 structur target tyrosin

1197: Doxycycline (65)

carri cell chain **construct** contain control effici
express function **gene** group homolog human
mice plasmid **protein** **recombin**
respons transform vector

1199: Hypoxia-Inducible Factor 1 (94)

angiogen **angiogenesi** antiangiogen cell densiti
endostatin **endotheli** factor
growth hif-1alpha hypox hypoxia
hypoxia-induc induc microvessel respons
vascular vegf vessel vhl

1194: Nelfinavir (5)

assess **associ** children dai gene
genet haplotyp hiv-1 infect measur
patient polymorph popul ratio
resist risk score snp valu viru

1196: High Mobility Group Proteins (96)

activ cell develop differenti
express factor **femal**
gene growth human **male**
regul role sex signal specif tgf-beta time
transcript transform

1198: rap1 GTP-Binding Proteins (20)

actin **activ** associ cell effect enhanc
function induc inhibit mice migrat normal
protein rate regul **respons** role sampl suggest
tissu

1200: Hypoxia-Inducible Factor 1, alpha Subunit (190)

angiogen **angiogenesi** antiangiogen densiti
endostatin **endotheli** factor
growth hif-1 hif-1alpha huvec hypox hypoxia
hypoxia-induc induc microvessel **vascular**
vegf vessel vhl

1201: Radiation-Protective Agents (76)

beam biolog damag dose effect expos exposur
fraction gamma group ion ioniz irradi
radiat radiation-induc radiosensit
radiotherapi rai surviv x-rai

1203: Catechol O-Methyltransferase (48)

affect associ control effect evid
examin find implic influenc investig involv met
possibl relat report schizophrenia signific
studi suggest unafect

1205: Collagenases (25)

activ cell control effect express

extracellular function human inhibitor

invas level matrix

metalloproteinas migrat mmp mmp-2 mmp-9

normal rate tissu

1207: alpha-Tocopherol (23)

antioxid concentr dai damag
decreas effect express famili gene
group increas min number
oxid oxygen protect rate reactiv
respons stress

1202: DNA Probes, HPV (9)

associ cancer cervic cin cytolog
detect hpv human intraepitheli lesion
neoplasia normal papillomaviru posit presenc
squamous studi tissu type women

1204: Neuraminidase (22)

acid activ amino bind chang decreas
differ express famili function gene

group increas infect number
report respons studi treatment viru

1206: Thiobarbituric Acid Reactive Substances (32)

antioxid control damag decreas effect group

increas level oxid oxygen patient
peroxid protect radic reactiv reduc ros speci
stress superoxid

1208: Arsenites (24)

activ analysi associ cell control effect
express function gene human
identifi level major primari process rate
rel size specif treatment

1209: Oxidants (65)

activ antioxid damag free glutathion increas

induc level **oxid** oxygen peroxid
protect protein radic rate reactiv ros speci
stress superoxid

1211: Peptidylprolyl Isomerase (17)

activ affin anim **bind** cell develop domain
enzym gene genet genom **human** interact

model popul **protein** requir site
specif target

1213: Angiogenic Proteins (21)

activ angiogenesi effect

endotheli factor

function gene genet growth identifi

increas influenc **level** normal rat

repeat role tissu vascular vegf

1215: Receptors, Androgen (173)

activ androgen associ **cancer** control
differ femal function increas lncap male number patient
progress **prostat** psa receptor repeat sex sexual

1210: Fatty Acid Desaturases (15)

acid alter amino cell chang develop effect
fatti function gene high male mutat rate repeat respons
retino sampl select tissu

1212: Aromatase (41)

associ breast **CANCER** cycl

express follicl gene **hormon**

increas mutat ovarian pregnanc

reproduct risk steroid studi

time tissu treatment **women**

1214: Neuropeptides (107)

activ analysi associ brain **cell** control
develop differ **express** gene increas
mechan model **neuron** new number protein
rat receptor role

1216: Interleukin-4 (130)

cell control cpg **cytokin**
express ifn ifn-gamma il-10 il-4 il-6 immun
induc inflammati interferon interleukin
macrophag product **respons** role stimul

1217: Interferon-gamma, Recombinant (8)

cell chang control data decreas estim gene
high identifi increas level low
method **patient** product region
sequenc subject time treatment

1219: Exoribonucleases (19)

activ associ complex develop
express function gene human initi
level melanoma mrna plai process
protein requir rna role site
translat

1221: Zebrafish Proteins (112)

conserv **develop** embryo
embryon **express** function gene
human mammalian mechan morphogenesi
mous neural organ pattern regul requir
role vertebr zebrafish

1223: Adenylyl Imidodiphosphate (9)

analysi bind cell complex conform crystal
function genom identifi increas mutant normal
rate regul respons reveal specif state
structur tissu

1218: RNA Helicases (66)

analysi cell **dna** earli **express**
famili function gene genet group human
identifi interact melanoma patient protein
replic rna screen suggest

1220: Taurine (20)

acid activ **analysi** combin
concentr dai develop effect express
famili increas member oral patient
respons reveal studi time treat
treatment

1222: Glutamyl Aminopeptidase (2)

compar complex content data differ estim flow
form higher lower method patient peptid plai
rate recent **role** structur suggest
versu

1224: Pyrimidine Nucleotides (5)

activ allel code codon combin genotyp
new nucleotid plai polymorph provid region
regul repeat role select sequenc structur studi
substitut

1225: Lithium Chloride (12)

activ associ beta-catenin cell conserv enhanc
express form human increas involv
pathwai presenc process rat regul
signal suggest time wnt

1227: Progesterone (95)

activ assist cycl develop follicl fsh

hormon increas ivf number ovari

ovarian pregnanc progesteron

reproduct steroid stimul studi

testosteron women

1229: Follicle Stimulating Hormone (69)

activ art assist control cycl estradiol follicl

fsh hormon ivf ovari ovarian

pregnanc progesteron reproduct

steroid stimul studi testosteron

women

1231: Peptides, Cyclic (57)

activ bind cell compar control detect
develop differ function group human
increas method model number

patient peptid studi vitro vivo

1226: Amino Acids, Branched-Chain (9)

acid amino cluster control decreas fatti
high identifi increas length level low patient product
repeat retino role screen short substitut

1228: Drug Implants (9)

concentr condit dai data degre dose effect

follow genet genom higher initi origin patient

rate studi therapi time treat

treatment

1230: Amphotericin B (21)

activ aspergillu case children

combin concentr effect

fungal fungi fungu human isol pathogen

produc product reduc speci time treat

treatment

1232: Antifungal Agents (103)

aspergillu caus fungal fungi
fungu fusarium host human inocul isol
pathogen patient plant
produc product speci spore var wall
yeast

1241: Kruppel-Like Transcription Factors (64)

activ cell develop differenti earli express

factor function gene human increas mutat

number phenotyp promot regul repress respons

studi transcript

1243: RNA, Bacterial (116)

analysi bacteri bacteria

coli differ escherichia eukaryot
gene isol mrna organ rdna region

ribosom rrna sequenc

similar speci strain translat

1245: Acid Phosphatase (25)

acid activ analysi associ

cell combin develop differ

effect express gene

method model new number

rate respons stimul

structur studi

1247: Cysteamine (11)

case caus cell clinic codon differ effect

embryo inhibit method model

normal patient product rat sever

studi substitut tissu treatment

1242: Triparanol (1)

beta-catenin defect effect environment
express factor genet influenc mrna

mutant mutat pain

pathwai patient signal studi
trait twin variat wild-typ

1244: Cathepsins (38)

activ associ cell control earli
express function gene genet

increas invas matrix patient
popul protein requir select studi tissu

tumour

1246: Luteinizing Hormone (63)

assist control cycl follicl fsh group

hormon increas ivf ovari ovarian

pregnanc progesteron reproduct

steroid stimul studi testosteron

treatment women

1248: Anthracyclines (61)

activ advanc agent cancer chemotherapi

cisplatin combin dai drug effect median

patient phase rate regimen resist

respons surviv toxic treatment

1249: Bleomycin (90)

agent **CANCER** cell clinic compar control
dna drug effect gene group increas **lung**
lymphoma patient respons studi treat
treatment valu

1251: Spectinomycin (6)

base contain control core drug encod gene
genet identifi isol mutant **mutat** new open
recombin region research **resist**
sequenc strain

1253: Receptors, FSH (10)

control cycl event follicl gene
hormon involv model ovarian posit
pregnanc **process** receptor
repeat reproduct steroid studi test
women year

1255: GTP-Binding Protein gamma Subunits (13)

activ associ chang **complex**
effect express identifi increas level
phenotyp product protein
receptor repeat report
respons screen select studi suggest

1250: Xylosidases (2)

achiev **activ** approach assess biolog design
evalu limit measur mutant **new** optim provid recombin
scale **score** strategi success system test

1252: Complex Mixtures (29)

analysi associ compar data determin differ
effect extract **function** gel
group increas mass **model**
number ratio risk role sampl studi

1254: Qb-SNARE Proteins (3)

accumul affect alter area **chang**
complex data decreas evolut increas inhibit initi
mechan molecular mutant **mutat** origin specif
structur syndrom

1256: GTP-Binding Protein beta Subunits (12)

activ allele alpha **associ** beta bind
complex enhanc famili gene genotyp
increas interact polymorph protein
receptor respons role studi
suggest

1257: Pulmonary Surfactant-Associated Protein A (9)

activ allele associ **cancer** compar
control express frequenc
function **gene** genotyp individu
local **lung** new normal polymorph
risk tissu variant

1259: Pulmonary Surfactants (9)

associ **cancer** children combin compar
concentr control gene healthi **level**
lung measur mice model serum
studi **subject** tumour valu variabl

1261: Glutamine (61)

activ **enzym** anim associ chang diseas effect
famili genet **human**
increas interact model mutat product residu
site studi substrat suggest

1263: Cyclooxygenase Inhibitors (142)

agent anti-inflammatori chemoprevent COX-2
cyclooxygenase-2 drug effect increas **inhibit**
inhibitor mechan potent potenti
prevent prostaglandin reduc select suggest suppress
treatment

1258: Pulmonary Surfactant-Associated Protein D (6)

bind cancer express genet high
human larg **level** low
lung new posit product **protein**
region sequenc serum size small time

1260: Tissue Inhibitor of Metalloproteinase-1 (49)

activ cathepsin **cell** express extracellular
increas inhibitor **invas** matrix
metalloproteinas migrat mmp mmp-2 mmp-9
pai-1 plasminogen role tissu upa upar

1262: Pyrazoles (74)

activ agent analysi associ cell COX-2 decreas
drug effect increas **inhibit**
inhibitor prevent receptor
reduc resist select studi suggest treatment

1264: Leucovorin (103)

advanc **chemotherapi** combin cycl dai
docetaxel gemcitabin grade median metastat
month **patient** phase rate receiv
regimen respons surviv toxic treatment

1265: Monomeric GTP-Binding Proteins (32)

activ cell control
differ differenti express

function gene growth identifi kinas

new prolifer protein provid

regul respons signal structur studi

1267: Pyruvaldehyde (7)

analysi combin condit degre effect form gener

increas level patient produc
product random requir resist respons serum
studi subject trial

1269: Metalloproteases (37)

activ cell combin effect express
famili function high human identifi
invas matrix model number
protein respons site studi target tissu

1271: Glucuronidase (75)

activ arabidopsi develop express flower function
gene leaf leav metastasi metastat node

plant pollen primari root seed studi
tissu tumor

1266: Asialoglycoproteins (5)

acid cell clone enhanc express gene improv
increas life method normal number site
structur subject target therapeut therapi
tissu treatment

1268: Organoplatinum Compounds (132)

advanc agent cancer
chemotherapi cisplatin combin
dai drug grade median paclitaxel
patient phase rate regimen
respons surviv therapi toxic treatment

1270: Diphosphonates (71)

bmd bone cancer cell clinic densiti
effect famili fractur hip marrow miner multipl
osteoblast role studi therapi treatment trial
vitamin

1272: Onium Compounds (9)

activ caus cell combin earli enhanc evid
increas normal organ oxid plai product
region repeat role sequenc structur
suggest tissU

1273: Superoxides (59)

activ antioxidant cell damage glutathione human
increases induced level **oxid** oxygen
peroxid protect radical reactivity role ROS speci
stress superoxid

1275: NADPH Oxidase (56)

activ antioxidant damage enzyme genetic glutathione
increases induced level **oxid** oxygen
peroxid protect radical reactivity role ROS speci
stress superoxid

1277: Vasoconstrictor Agents (18)

arterial control coronary effect
enhance **group** hypertensive
increases inhibit model normal
pressure rat receptor
response study **subject**
tissue treatment vascular

1279: Aphidicolin (19)

activ analysis cell control **dna** family
function group high level low mechan
method molecular number process recombination
require role study

1274: Reactive Oxygen Species (305)

activ antioxidant damage enzyme free glutathione
increases induced level **oxid** oxygen
peroxid product protect radical reactivity ROS speci
stress superoxid

1276: Receptor, Serotonin, 5-HT2B (3)

acid **activ** case control deletion disorder
enhance health high identification level loss low
muscle **patient** receptor require
response screen subject

1278: Ascorbic Acid (75)

acid amino antioxidant concentration damage
effect gene group increases level **oxid**
oxygen protect rat reactivity reduce role speci
stress study

1280: NADH, NADPH Oxidoreductases (15)

analysis cause cell complex effect express
gene genetic genome human identification
mitochondrial **mutat** oxid population rat
rate select time treatment

1281: Adaptor Proteins, Vesicular Transport (36)

activ analysi bind cell cytokin
develop differ domain express
function **gene** genet human
identifi mutat **protein** role
structur suggest tissu

1283: Carboxylic Ester Hydrolases (28)

activ analysi associ cluster differ
enzym exposur express function gene
identifi metabol pattern popul product protein
structur studi subject substrat

1285: Acyltransferases (48)

activ associ **enzym** express
function gene gener increas model mutant
mutat number patient product protein role
specif studi substrat suggest

1287: Receptor, Fibroblast Growth Factor, Type 3 (29)

activ analysi cell condit **cultur**
express factor famili fibroblast growth human
medium method mutant mutat normal respons
tissu variabl vitro

1282: Dietary Carbohydrates (19)

acid bmi **bodi** diet dietari fat food
high increas index intak leptin level mass model
nutrit obes patient supplement **weight**

1284: Biopolymers (30)

activ analysi approach associ base data
dna dynam famili **form** format
human increas interact method
model predict select
structur surfac

1286: Armadillo Domain Proteins (12)

activ affect **associ** differ diseas
express famili gene genet **interact**
member model polymorph protein requir
role sampl studi suggest tissu

1288: Citrinin (3)

cdna cell clone **develop**
differenti **express** extract fraction gene
isol laser librari **light** marker method prolifer
receptor report sequenc studi

1289: Thrombospondin 1 (43)

activ angiogenesi cell endotheli
express factor
famili gene growth
increas model protein role studi
tgf-beta tissu transform treatment
vascular vegf

1291: Tablets (16)

base chromatographi compar data determin
develop extract fraction
function improv liquid method model
prepar rate respons separ studi time trial

1293: Endothelial Growth Factors (4)

area assai assess chain detect
differ diseas distribut evalu
gene local measur pattern plai
reaction risk role score sensit
studi

1295: Sulfites (34)

activ cpg dna epigenet gene hypermethyl
inactiv individu island methyl
methyltransferas mgmt p16 promot rassf1a
region sequenc silenc statu suppressor

1290: Antigens, CD47 (8)

apoptosi associ base cell cluster
death differenti human mice new
normal number organ plai rate role
studi tissu treatment tumour

1292: Sodium Chloride (97)

concentr condit control
degre differ effect gene heat higher
increas low microg microm min observ plasma
protein rat shock temperatur

1294: Receptors, Vascular Endothelial Growth Factor (60)

angiogen angiogenesi chang clinic diseas
endotheli factor growth
hif-1alpha hypox hypoxia hypoxia-induc increas
studi therapi treatment trial vascular
vegf vessel

1296: DNA Adducts (133)

activ adduct adenosin analog analogu chemic
compound damag deriv
dna new novel nucleosid potenc potent
repair ring structur synthes synthesi

1297: Deoxyguanosine (81)

antioxid compound control damag differ

dna increas level **oxid** oxygen
patient protect radic rate reactiv repair ros
speci stress studi

1299: Nucleic Acid Precursors (2)

activ approxim core data dna encod
enzym includ known major mitochondri

open rang rat read rel **studi** substrat
suggest wide

1301: DNA Gyrase (21)

base caus chang character codon differ dna gener

identifi **isol** model mutant mutat respons

sequenc speci specif **strain** treatment type

1303: rab GTP-Binding Proteins (44)

activ analysi associ chang express famili
function gene identifi intracellular

membran model mutat
protein regul role screen **transport**
tumor uptak

1298: Deoxyribonucleotides (18)

activ analysi cell compound data differ

dna enzym estim genet increas
method rate replic sampl select sequenc
structur studi substrat

1300: Nalidixic Acid (4)

adapt cluster coli complex distribut dna encod

enhanc gene **human** identifi induc

induct **isol** local mechan molecular

respons select strain

1302: ran GTP-Binding Protein (21)

cell chromosom complex cytoplasm develop

divis **famili** interact local member

microtubul mitot model **nuclear**
nucleu process protein respons role spindl

1304: ADP-Ribosylation Factors (26)

activ bind cell develop domain **famili**
form format function gene histori identifi interact

mechan member membran p53 patient protein requir

1305: Sucrose (53)

activ cell control develop differ
effect express gene increas indic local normal
number oral **plant** rate size studi suggest
tissu

1307: Actomyosin (12)

cell centrosom chromosom
combin **divis** genet interact mechan
microtubul migrat mitosi
mitot new process protein
regul requir segreg **spindl** studi

1309: Proto-Oncogene Proteins c-vav (18)

actin **activ cell** control
cytoskeleton differ **famili** filament format
group growth interact member migrat
polar process protein regul role signal

1311: Acetic Acid (16)

acid amino compar concentr data
differ gene group high higher incid increas
lesion level low mice rate test tissu valu

1306: Dynein ATPase (52)

analysi **cell** centrosom checkpoint
chromosom complex differ **divis**
function interact local meiotic
microtubul mitosi **mitot** organ
patient requir segreg **spindl**

1308: Adenosylhomocysteinase (3)

activ associ blood children compar enhanc
enzym factor **function** genom
increas inhibit mean methyl pathwai ratio risk
sequenc signal valu

1310: Cytochromes b (55)

analys base clade close data diverg evolut gene
genet genu molecular morpholog phylogenet
popul relat relationship sequenc **speci**
support tree

1312: Methylenetetrahydrofolate Dehydrogenase (NADP) (3)

acid allele approxim associ children control
differ enzym **gene** genet genotyp mechan
patient polymorph
popul rel risk studi subject test

1313: Superoxide Dismutase (216)

antioxid damag examin extent find increas
indic later level observ **oxid** oxygen
protect reactiv sclerosi speci stress studi
suggest survivin

1315: Glutathione (156)

activ antioxidant damag enzym free glutathion
increas induc level **oxid** oxygen
peroxid product protect radic reactiv ros speci
stress superoxid

1317: Cell Wall Skeleton (1)

actin cell character contain core encod frame
identifi mice migrat mitochondri novel open orf
protein put read suggest vitro
vivo

1319: Protein Methyltransferases (15)

activ bind cell **complex**
differ event gene group
interact involv normal pattern
process protein role
specif step target tissu type

1314: Eosine I Bluish (1)

assess compar content control cytometri
determin differ evalu flow healthi laser light
load measur methods observ signific studi
subject yeast

1316: Food Coloring Agents (3)

acid compar **control** differ effect
flow frequenc healthi higher light manag observ
produc product repeat signific studi
subject treatment yeast

1318: Rad51 Recombinase (56)

activ atm base break damag develop **dna**
double-strand dsb excis function gene genom induc
lesion process recombin **repair** respons strand

1320: Integrin alpha6beta4 (6)

adhes antibodi caus **cell** collagen decreas
differenti express extracellular **famili**
gene genet increas integrin matrix member
membran molecul phenotyp regul

1321: Cystatins (32)

activ analysi cell control detect
function gene group identifi increas
invas kidney level matrix
protein region renal sequenc studi
tissu

1323: Aromatase Inhibitors (80)

adjuv **breast cancer**
ductal effect estrogen femal form format function genet
hormon level male mcf-7 receptor reduc tamoxifen
therapi women

1325: Dipeptides (27)

bind cell data decreas **develop**
differ effect function gene
group human increas
method patient popul **protein** rat
structur **studi** treatment

1327: Mannitol (14)

chang concentr condit **effect** form
format kinet mass new plai produc
product provid reduc role **state**
switch time tissu transit

1322: Estrogen Receptor Modulators (23)

analysi **breast cancer** cell
chang compar differ express function human
increas line random rate resist role studi
treatment trial women

1324: Carnosine (3)

acid affect associ cell complex concentr data
differenti effect estim level plai point ratio
reduc regul risk **role** suggest time

1326: Symporters (73)

acid analysi cell express gene group high
human increas intracellular level local
membran patient protein
rat role studi **transport** uptak

1328: Sarcoglycans (21)

caus dystrophi exercis famili fiber function
gene increas lead level **muscl**
muscular **mutat** patient posit protein rate
skelet smooth time

1329: Aerosols (29)

concentr contamin develop differ distribut
group **human** increas local
measur method model new organ patient
sampl soil subject surfac **water**

1331: Verapamil (21)

activ associ cell concentr confer determin drug famili
genom increas level mechan multidrug patient
resist sensit studi suscept time transport

1333: Fluoresceins (43)

activ analysi assai **cell** detect
differ fish fluoresc hybrid increas mechan
method probe protein resist sensit situ specif
studi time

1335: Rhodamine 123 (11)

acid assess **cell** chang compar content
determin drug flow **human** hybrid
increas measur model normal observ product
rate **resist** tissu

1330: Calcium Channel Blockers (44)

activ associ channel clinic combin compar
control current drug **effect** function increas
model new patient **resist** studi test
treatment year

1332: RNA, Transfer, Val (1)

adapt administr **cell** dai dose drug evolut express
fit **function** month natur patient
question remain **resist** select transfect week
year

1334: P-Glycoproteins (22)

acquir confer drug gene human increas level mdr mdr1
mechan multidrug p-gp patient protein **resist**
revers sensit studi suscept transport

1336: Receptor, Adenosine A1 (6)

activ area combin compound
develop **effect** enhanc follow
inhibit method mutant persist plai posit
product **receptor** reduc
respons role score

1337: Insect Hormones (8)

bodi case caus decreas **drosophila**
enhanc express **human**
increas insect level mass
melanogast presenc receptor repeat stimul
suggest test weight

1339: FMRFamide (1)

analysi brain cell confirm demonstr
electrophoresi **express** find gel
identif identifi mass peptid previou proteom
report spectrometri spot studi suggest

1341: Solutions (98)

carbon conform crystal determin differ energi
extract fold form free level loop measur method properti
residu sampl solut **structur** surfac

1343: N-Methylaspartate (20)

behavior chang concentr decreas develop
disord **effect** function identifi increas
inhibit model **neuron** plai reduc
role screen **studi** suggest treatment

1338: Pyrrolidonecarboxylic Acid (8)

analysi cell compar decreas differ earli
form high **increas** level low
mass mechan model mutant normal peptid
process reveal **tissu**

1340: Delayed-Action Preparations (34)

clinic combin compar control **dai**
deliveri dose effect effici **group**
increas particl patient random respons
studi surfac treatment trial week

1342: Pharmaceutical Preparations (132)

agent avail care clinic cost current data
decis **drug** guidelin health
manag medic
metabol method model
practic provid recommend studi

1344: Receptors, N-Methyl-D-Aspartate (63)

analysi astrocyt bdnf brain chang control dopamin
function gene glial glutam group hippocamp increas
neural **neuron** process receptor
suggest synapt

1345: Sulfides (18)

affect analysi cell chang data differ famili
gene increas mechan morpholog
observ process region sequenc state
structur studi subject treatment

1347: Antigens, CD14 (44)

activ allele associ cell compar
control cytokin differ factor
frequenc gene genotyp il-6 macrophag
patient polymorph respons risk role studi

1349: Allyl Compounds (9)

activ analysi cell compar compound
control differ effect **express**
group high induc inhibit level
low mechan molecular rat respons role

1351: Bacterial Toxins (108)

bacillu bacteri bacteria cell **coli** effect
encod **escherichia** express gene group host
infect isol operon phage product protein
strain toxin

1346: Catalase (95)

activ antioxid damag **gener** glutathion
increas induc isol level **oxid** oxygen
peroxid protect radic reactiv ros speci strain
stress superoxid

1348: Cytochrome P-450 CYP2E1 (25)

activ assai cyp2d6 cytochrom detect determin
develop drug enzym gene human increas liver
metabol metabolit microsom
p450 patient respect studi

1350: Hemagglutinins (16)

acid activ associ **cell**
chang develop earli effect
express form individu interact
isol mutant normal region
sequenc strain studi
tissu

1352: Enterotoxins (30)

assai bacteri bacteria cell coli detect develop
effect escherichia function host
human infect isol pathogen role
sampl sensit strain studi

1353: Galactosyltransferases (24)

blood cell compar control decreas
effect enzym express function
group human
increas level mutat organ patient
respons site specif transplant

1355: HMGB1 Protein (17)

acid analysi bind cancer complex dna effect
express function gene group
human increas model phenotyp process rate
region sequenc structur

1357: Alkaloids (39)

activ adduct analog analogu analysi associ
cell chemic compound
deriv effect express increas inhibit mechan
protein resist role structur studi

1359: Opium (2)

allel chain control detect discuss disord
evolut genotyp healthi oral pcr
polymeras polymorph quantit
reaction real-tim recent revers studi
subject

1354: Blood Proteins (111)

activ analysi concentr detect differ elev gene
genet higher identifi increas level measur
patient plasma popul protein sampl serum
studi

1356: DNA Probes (140)

analysi arrai design detect fish fluoresc
gene genom hybrid label method
microarra oligonucleotid perform probe sequenc
signal situ specif techniqu

1358: Benzylisoquinolines (4)

cell data distribut drug effect estim evolut
flow local mice prevent produc product protect
reduc reduct regul requir resist speci

1360: Dideoxynucleosides (14)

detect effect evalu high higher imag
level low magnet measur method mri
number rate reson scan studi test tumor
volum

1361: Teratogens (31)

analysi case children control dai develop
effect gene group high human increas induc
induct rat report **respons** studi
treatment week

1363: Prostaglandin-Endoperoxide
Synthases (247)

agent anti-inflammatori chemoprevent cox-2
cyclooxygenase-2 drug effect increas inhibit
inhibitor mechan potent potenti
prevent prostaglandin reduc select suggest suppress
treatment

1365: Trypsin (87)

activ **analysi** analyz capillari control
differ electrophoresi gel identif
identifi **mass** pancreat protein
proteom secret separ spectrometri spot
structur studi

1367: Mitoguzone (1)

approach continu dai delai demonstr design disord
dose find follow hour long-term marker
patient persist previou recoveri
report strategi studi

1362: Cyclooxygenase 2 (233)

agent anti-inflammatori chemoprevent cox-2
cyclooxygenase-2 drug effect increas inhibit
inhibitor mechan potent potenti
prevent prostaglandin reduc select suggest suppress
treatment

1364: Cyclooxygenase 2 Inhibitors (74)

agent anti-inflammatori chemoprevent cox-2
cyclooxygenase-2 drug effect increas inhibit
inhibitor mechan potent potenti
prevent prostaglandin reduc select suggest suppress
treatment

1366: Cerebrospinal Fluid Proteins (4)

area bind breast cancer cell clinic compar differ
distribut fluid higher individu
local mechan **protein**
rate studi suggest time trial

1368: Sialoglycoproteins (113)

allele associ bone cell compar
control decreas **express** frequenc
gene genotyp
increas infect level model
polymorph rate studi
tumor viru

1369: Thiosulfates (2)

adult bind chemotherapi conform dose
elderli express old older patient primari
protein radiat respons secundari
structur studi toxic year
young

1371: Cyanides (6)

base **CAUS** combin compar dai
decreas effect form **function**
increas interact lead model
mutant rate reduc result site state structur

1373: Imidazolidines (3)

anim case clinic concentr control dai

diabet diagnosi **effect** follow increas
model patient potenti releas

stimul studi **subject** treat

treatment

1375: Tacrolimus (51)

acut allogene allograft autolog condit dai diseas

donor follow graft hematopoiet immunosuppress

new patient receiv recipi reject stem surviv

transplant

1370: Thiosulfate Sulfurtransferase (2)

acid amino cell clone coli conform domain form
function interact involv
mechan molecular peptid plai **protein**
role stabil **structur** suggest

1372: Iron-Sulfur Proteins (27)

analysi base caus **cluster**
complex differ dna enzym famili
function gene genet human increas
mitochondri mutat
protein select suggest time

1374: Minor Histocompatibility Antigens (12)

activ associ base cell class control
donor **express** graft identifi major recipi
rel risk sampl stem studi target
transplant tumor

1376: ABO Blood-Group System (50)

activ **blood** circul collect COUNT determin
donor group healthi leukocyt lymphocyt mononuclear
pbmc **peripher** platelet popul red sampl test
transfus

1377: Cholesterol (208)

apoe apolipoprotein associ atherosclerosi
chd **cholesterol** diseas effect hdl
increas ldl level **lipid** lipoprotein
metabol plasma statin studi total triglycerid

1379: Siderophores (11)

activ cell cluster compar control
differ effect evid **function**
gene genom group high identifi
level mutant rate **select**
structur support

1381: Nitrogen Isotopes (36)

acid approxim carbon determin electron
energi exchang experi fluoresc
free measur method model mol **protein**
proton solut spectra spectroscopi transfer

1383: Aspirin (67)

agent chemoprevent clinic COX-2 decreas diseas
effect group increas inhibit
inhibitor patient prevent reduc
risk select studi suggest treatment trial

1378: Protons (119)

carbon dose effect electron **energi**
exchang fluoresc free ion **irradi** measur
model mol proton **radiat**
radiotherapi solut spectra spectroscopi
transfer

1380: Gallium (5)

analysi assai decreas detect effect electron
increas layer light method microscop
microscopi morpholog observ reveal
sensit shape stimul **structur**
surfac

1382: Interleukin-3 (48)

activ apoptosi bone **cell** differ factor
function gene group growth induc macrophag
marrow mechan neutrophil normal patient
respons role tissu

1384: Human Growth Hormone (106)

adult effect **factor** final grow **growth**
height hormon igf igf-1 igf-i increas insulin-lik level
patient receptor statur stimul studi year

1385: Potassium Channels, Inwardly Rectifying (38)

activ associ atp ca2+ calcium
channel current diabet
function gene group insulin intracellular ion
mutat patient receptor rel sodium studi

1387: Toll-Like Receptor 2 (34)

analysi associ cell cpg **cytokin**
express ifn ifn-gamma il-10 il-4 il-6 immun
induc inflammatori interferon interleukin
macrophag patient product **respons**

1389: Fluorescein-5-isothiocyanate (50)

activ bind blood **cell** demonstr
develop differ express form format
function new patient peptid
protein rate role specif studi tissu

1391: Propidium (22)

analysi cell compar content
cytometri detect determin **differ**
effect evalu **flow** function high
human load **method** observ select
signific studi

1386: Formaldehyde (36)

activ biopsi case dai detect dna genom
histolog immunohistochem **lesion**
mice rate respons section sensit
specimen **stain** studi tissu year

1388: Quercetin (17)

activ adduct analog analogu cell chang
chemic **compound** concentr
deriv function gene genom **group** high
human model potent role studi

1390: Benzene (34)

assess carcinogen chemic effect expos
exposur frequenc genotox health
increas indic induc level mutagen observ potenti
signific studi toxic worker

1392: Quinolines (46)

activ cell chang compar
compound control dai
deriv differ earli effect **group**
increas new patient resist respons
studi test treatment

1393: Deoxycytidine Kinase (9)

activ analys analysi cell compound
deriv develop high level low malign plai
reaction role specif studi subject **tumour**
variabl vivo

1395: Retinol-Binding Proteins (21)

acid amino associ cell control differ
differenti earli effect express gene group identifi
increas mechan methyl number patient protein
role

1397: Thymidine Monophosphate (5)

activ assai cell codon concentr
control correl **detect** effect enzym **form**
format rat select sensit subject
substitut suggest synthesi tumour

1399: Apoproteins (9)

activ bind compar **control** form
format frequenc increas interact mechan model
moleculari mutant **protein** rat requir stabil
structur target test

1394: Thymidine Phosphorylase (32)

activ associ cell combin develop effect
express group high increas level low oxid
patient respons studi surviv
synthas synthesi tissu

1396: Carbon Radioisotopes (31)

acid activ adult affect associ cell
differ effect evid gene group high
human **imag** measur patient
role studi tissu year

1398: Plant Extracts (233)

cell chromatographi column compound contain
determin effect **extract**
fraction group hplc liquid method plant
prepar purif purifi respect separ treatment

1400: Peptide Initiation Factors (12)

complex distribut function **gene**
human initi local **mrna** number
protein **regul** ribosom rna select site
small specif tissu **translat** trna

1401: Eukaryotic Initiation Factor-4E (31)

activ cell codon contain effici eukaryot factor
initi **mrna** poli protein region ribosom
rna site synthesi termin **translat**
trna utr

1403: Retinoids (45)

acid amino cell effect fatti increas level
model nucleic number **receptor** reduc respons retino
role studi target therapi time treatment

1405: Aryldialkylphosphatase (46)

activ apoe apolipoprotein associ chang
cholesterol differ diseas effect
enzym increas ldl level **lipid**
lipoprotein metabol plasma studi total
triglycerid

1407: Interleukin-13 (44)

activ cell control
cytokin express function
gene genet ifn-gamma il-10 il-6
immun macrophag mice model
polymorph product respons role
studi

1402: Receptor, PAR-2 (8)

activ caus cell differenti effect
express gene growth health induc induct
inhibit inhibitor mice prolifer reduc
respons rna stimul variabl

1404: Retinal Dehydrogenase (3)

acid adapt amino cell concentr data
develop earli epitheli evid gener normal
number provid report select stage studi
support **tissu**

1406: Immune Sera (20)

activ analysi **antibodi** assai
associ bind cell control **detect** effect
express group human mice
respons role sensit specif
studi tumor

1408: RANTES (17)

activ allel analysi associ
control differ express factor
function gene genotyp
human identifi method
nf-kappab number
patient polymorph
screen studi

1409: Dinoprost (21)

adult anim bovin breed compar **dai**
decreas differ dose effect group
increas level milk pig product rate
treatment week year

1411: Salmonella Vaccines (8)

antibodi antigen cell **develop**
host immun improv infect local method
mice random recombin respons risk sampl
studi target trial vaccin

1413: Immunodominant Epitopes (34)

analysi antibodi antigen detect differ famili
function group identifi **immun**
induc number **patient** peptid protect
protein repeat **respons** specif
vaccin

1415: Alkylating Agents (35)

analysi anim compar control dai dna effect
exposur function gene **group** increas induc
inject level **rat** rate structur studi week

1410: Vaccines, Attenuated (34)

analysi antigen challeng ctl dendrit enhanc
epitop gener group **immun**
immunotherapi induc isol mice product protect
respons strain studi **vaccin**

1412: Recombinases (23)

activ carri **construct** contain cre dna effici form
gene gener homolog number **plasmid** process
protein **recombin** sequenc transform region repeat

1414: Diethylnitrosamine (21)

anim cell compar control dai develop earli
effect hepat hepatocyt induc inject liver mice
mous mutat product **rat** time tumor

1416: Ca(2+)-Calmodulin Dependent Protein Kinase (50)

activ associ cell control dna
epigenet famili function **gene** interact
kinas methyl normal pathwai
phosphoryl promot protein regul signal
tissu

1417: Benzamides (46)

activ cell combin control
dai develop differ effect human
increas inhibit normal popul
respons studi target time tissu
treatment vivo

1419: Phosphate-Binding Proteins (1)

bone compar differ enzym gene gener
mean measur mice mous mutant mutat paramet
protein rang ratio respect transgen valu
wild-typ

1421: Dextrorphan (3)

analysi assess collect concentr control data
determin differ estim evalu healthi measur
metabol method phenotyp popul
sampl score studi subject

1423: Amoxicillin-Potassium Clavulanate Combination (3)

assess combin compar control data differ
earli effect estim healthi measur method risk
score signific stage studi subject
trial variabl

1418: Receptor, Angiotensin, Type 1 (41)

ace angiotensin arteri associ blood
cad cardiovascular coronari gene genotyp
hypertens infarct ischem ischemia
myocardi pressur stroke vascular
vein vessel

1420: Dextromethorphan (9)

acid activ affect associ concentr enzym
human metabol metabolit
method model patient popul ratio respons
risk sampl studi subject time

1422: Benzoyl Peroxide (3)

activ analysi anim blot dai detect dose
express famili featur follow gene member model
protein requir reveal studi tumor western

1424: Anti-Inflammatory Agents (103)

activ administr case children clinic dai
differ diseas dose effect follow group increas
patient receiv studi treat treatment week
year

1425: Aminobutyric Acids (10)

adult analysi arabidopsi cell combin
effect gene increas leav **plant**
point popul product **respons** root
seed subject **time** treatment year

1427: Prostate-Specific Antigen (130)

androgen androgen-independ antigen benign bph
cancer carcinogenesi du145 effect
increas lncap men pc-3 pca progress **prostat**
prostate-specif prostatectomi psa tumor

1429: Dinoprostone (69)

activ agent chemoprevent COX-2 decreas drug
effect express human increas inhibit
inhibitor mechan prevent reduc
select studi suggest tissu treatment

1431: Fatty Acids, Omega-6 (6)

acid activ amino cell decreas detect
effect enhanc factor fatti genet growth increas
mice plai product reduc reduct role studi

1426: Floxuridine (25)

activ advanc cancer cell
chemotherapi combin control dai
express increas median month
patient phase regimen respons
surviv time toxic treatment

1428: Defensins (16)

activ analysi associ cell cluster data differ
differenti diverg duplic evolut evolutionari
express gene human origin
peptid select structur suggest

1430: Fatty Acids, Omega-3 (24)

acid amino bodi compar control develop
effect fatti fish gene group hybrid nucleic probe rat
retino risk studi subject weight

1432: Complement C1q (4)

adapt code codon copi correl determin enhanc
increas interact mutat **number**
patient posit process respons
select signific specif subject substitut

1433: Pyrimethamine (12)

adapt associ combin confer differ drug effect gene
high hypothesi level low mutat resist sampl
select signific studi test treatment

1435: Chloroquine (45)

carri compar comparison differ evalu exact falciparum

fisher hypothesi malaria parasit perform plasmodium

posit resist signific standard statist studi test

1437: HTLV-I Antibodies (2)

adult analysi blood blot cell detect differenti event
express number overexpress
patient process prolifer requir reveal
structur transform western year

1439: Ribavirin (40)

associ case combin effect hbv hcv hepat induc
induct infect liver patient rate replic report
respons treatment viral
viru virus

1434: Dihydropteroate Synthase (10)

clinic confer data diagnosi drug gene includ mutat
patient popul rang rate resist sampl
sensit suscept test treatment varieti wide

1436: Sulfadoxine (7)

combin develop drug effect genet high level low
number patient popul product
resist sampl select studi test time
treatment year

1438: Exonucleases (29)

activ analysi cell data detect differ dna
express gene genom identifi marker normal
polymeras protein replic sequenc studi tissu tumor

1440: Receptor, Melanocortin, Type 1 (5)

acid allel area associ code codon control
differ genotyp mice phenotyp polymorph
regul respons risk skin
stimul studi subject substitut

1441: Gene Products, pol (17)

differ gene hiv hiv-1 **human**
identifi infect isol **mutat** patient
popul protein resist respons sequenc speci
strain studi viral viru

1443: Adenosine Kinase (2)

acid adult collect data estim function
gene genet identifi inhibit method
modul popul protein regul
regulatori **sampl** screen year
young

1445: Adenovirus E1 Proteins (6)

activ adenoviru adult cell deliveri effici
express **gene** human increas
normal pancreat studi therapi tissu
transduct transfer **vector** vivo
year

1447: Alanine Transaminase (53)

bile biliari chronic cirrhosi dai differ dose effect genet
group hepat hepatocyt increas level
liver patient sampl serum studi treatment

1442: RNA-Directed DNA Polymerase (38)

activ associ cell clinic detect diagnosi
element gene genom hiv-1
human infect **insert**
integr mutat patient protein sequenc
site viru

1444: Adenovirus E3 Proteins (8)

abil associ **cell** chang control
differenti enhanc **express** gene
high level low method protein receptor
recombin **sampl** sequenc transfer **vector**

1446: Clobetasol (2)

applic **caus** child childhood
children keratinocyt lead
light **method** multipl
parent pediater protocol singl **skin** studi
syndrom techniqu transplant year

1448: Steroid 11-beta-Hydroxylase (12)

allel function **gene** genotyp hormon
human identifi increas **mutat** new patient
polymorph product region role sequenc studi
subject thyroid treatment

1449: Aldosterone Synthase (12)

activ allele analysi associ data **gene**
genom genotyp high level low plai polymorph
popul reaction role subject thyroid treatment
variabl

1451: Creatine (26)

activ **brain** central combin compar
control differ effect function imag increas
measur **muscl** nervou normal
patient studi subject test tissu

1453: Diuretics, Osmotic (2)

administr copi dai decreas dose effect effici
gene increas interact **number**
patient presenc state therapi
transfer treat treatment vector week

1455: Glycerol (49)

acid bind cerevisia chang concentr differ
effect **function** group increas involv level
number patient protein requir saccharomyc
strain suggest **yeast**

1450: Choline (21)

brain central chang control
develop earli **function**
group human identifi **imag** increas
interact measur **model** respons select
studi **subject** volum

1452: Aldosterone (24)

activ analysi arteri concentr correl differ
effect **function** gene group
human hypertens level patient pressur
receptor signific **studi** subject thyroid

1454: Organic Anion Transporters (17)

analysi differ express famili **function**
gene group high identifi level low
membran mutat **patient**
protein sampl screen studi tissu transport

1456: Ribulose-Bisphosphate Carboxylase (20)

16s analysi bacteria control develop differ
divers effect eukaryot famili **gene** increas
phylogenet plant protein rate rdna rrna
sequenc **speci**

1457: Brefeldin A (14)

cell chang combin compar detect distribut
effect express higher human increas local
membran new process **protein**
rate role tissu transport

1459: Drugs, Non-Prescription (11)

Care cell combin cost design
differenti effect health high
hospit low **manag**
medic new number patient
practic provid rate **studi**

1461: Geranyltranstransferase (2)

adapt chain control environ evolut famili fit
growth healthi member mutant natur reaction
report sampl **select** studi subject
target test

1463: Phosphoserine (31)

activ associ bind cell complex
domain earli erk express interact
kinas mapk mechan pathwai
phosphoryl protein regul
signal specif treatment

1458: Albumins (36)

cell chang concentr effect elev express group
higher human increas **level** liver lower
measur patient plasma protein rate serum studi

1460: Vascular Endothelial Growth Factors (33)

activ angiogenesi cell clinic combin
develop effect **endotheli**
express factor growth high hypoxia
level low patient respons **vascular**
vegf vessel

1462: tau Proteins (69)

alpha-synuclein alzheimer autoimmun caus common
dementia **diseas** disord fabri includ
neurodegen onset parkin parkinson pathogenesi patholog
progress studi symbol tau

1464: GTP-Binding Protein alpha Subunits, G12-G13 (6)

area cell chang data distribut express
function identifi interact local
model phenotyp plai **protein**
receptor regul role
screen select suggest

1465: Receptor, PAR-1 (17)

activ approxim bleed cell
factor folat function invas matrix
mthfr new phenotyp platelet receptor rel
respons role sampl tumor venou

1467: Intercellular Adhesion Molecule-1 (77)

activ **adhes** attach **cell** collagen
differ ecm express extracellular fibronectin
gene increas **integrin** matrix migrat **molecul**
role spread sulfat surfac

1469: Receptors, Platelet-Derived Growth Factor (27)

activ cell effect **factor** gene group
growth increas kit level receptor
role sarcoma stromal studi target time tissu
tumor tumour

1471: Immunoglobulins, Intravenous (30)

administr case dai diseas dose effect follow improv
month **patient** receiv report respons sever studi
therapi treat **treatment** week
year

1466: HLA-C Antigens (24)

allel antigen associ **class** complex
gene haplotyp histocompat hla major mhc
molecul patient polymorph present region
sequenc snp specif studi

1468: Proto-Oncogene Proteins c-crk (6)

activ area bind **cell** compar
control dai differ effect **express** mutant
pattern process protein report structur studi
time treat **treatment**

1470: Growth Inhibitors (91)

activ apoptosi block **cell** develop differ
differenti effect express group growth human
induc **inhibit** inhibitori mechan prolifer
suppress target treatment

1472: Chaperonin 60 (16)

cell combin condit correl degre
differ famili **gene** genet high
patient **popul** protein rate
respons role select studi subject
temperatur

1473: Karyopherins (23)

accumul anim cellular cytoplasm element export
import lamin local model **nuclear**
nuclei nucleu protein rate signal specif studi
subcellular transloc

1475: Mycophenolic Acid (24)

allogen allograft autolog condit diseas donor effect
follow graft human immunosuppress patient receiv
recipi reject respons stem surviv
transplant treatment

1477: Antigenes, Differentiation,
Myelomonocytic (34)

acut analysi associ bone case **cell**
content control correl differenti **express**
flow function leukemia level number observ
patient signific treatment

1479: Antigenes, CD13 (11)

anim associ **cell** cluster differenti
effect genet genom **mice**
model mous number **peptid**
popul protein sequenc studi transgen
treatment tumor

1474: Algal Proteins (23)

analysi cell compar control differ evolut
gene genom organ pathogen plant
protein rate region respons rna
sequenc similar speci studi

1476: Fusion Proteins, bcr-abl (116)

acut aml bcr-abl blast cell chronic cml fit3
imatinib leukaemia leukem
leukemia lymphoblast marrow
mds myelodysplast myeloid patient relaps
syndrom

1478: Salts (29)

activ analysi base **concentr**
condit degre differ dna
effect gene human increas interact
observ respons sampl
structur studi
temperatur time

1480: Cytosine Deaminase (38)

activ analysi cell **dna** effect express gene
group growth human mice model patient polymeras
protein replic strand vitro vivo xenograft

1481: Nucleoside Deaminases (23)

activ approach cell develop differ **dna**
enhanc herp hiv hiv-1 hsv-1 human
immunodefici **infect** interact mechan
replic simplex viral **viru**

1483: Uracil-DNA Glycosidase (18)

base damag decreas detect **dna** increas
method mutat plai polymeras product repair **replic** role
sampl sequenc strand structur target valu

1485: Oxygenases (42)

activ associ base cell develop differ
enzym gene group increas light mechan
metabol new rate role sequenc speci studi
substrat

1487: Monokines (3)

actin **associ** blood cell count
human link literatur
data lymphocyt mechan migrat molecular multipl
peripher publish relat studi **tumor** underli

1482: Aldehydes (30)

activ chang compound **effect**
enzym form format function increas mice oxid
patient plai product protect reduc reduct
role studi suggest

1484: DNA Glycosylases (91)

analysi atm base break checkpoint comet damag
dna double-strand dsb excis foci induc lesion
mutat number pathwai rad51 **repair** strand

1486: Antigens, CD56 (25)

case cd4 **cell** clinic dai diagnosi express gene
human identifi induc lymphocyt model new
phenotyp posit report respons studi t-cell

1488: Inositol Phosphates (18)

activ bind cell channel enzym evid
express human increas interact model new
number posit protein provid **receptor**
regul studi support

1489: Amiloride (11)

ca2+ calcium cell **channel** current
decreas detect effect enhanc **human**
increas level plai potenti reduc
releas respons role sensit test

1491: Dystrophin (61)

contract dmd dystrophi dystrophin exercis fiber
muscl muscular myoblast
increas myopathi region sequenc **skelet** smc smooth strength
tissu train weak

1493: Utrophin (11)

compar complex decreas dystrophi exercis express
fiber increas mice mous **muscl**
muscular myopathi normal promot rate skelet
smooth tissu transgen

1495: Heterogeneous-Nuclear Ribonucleoprotein L (3)

altern **associ** differ exon gene
high intron isoform level low mrna mutant
phenotyp requir specif splice
studi suggest translat variant

1490: Hematoxylin (4)

analysi blot **cell** compar
control dai differ express
frequenc higher line lower marker method
mice mous muscl **rate** regul
transgen

1492: Citrate (si)-Synthase (9)

alter **chang** compar data decreas
famili gener genom group increas
patient plai product protein
rate respons role select structur subject

1494: Dystrophin-Associated Proteins (7)

biolog caus cell complex dai decreas domain
dystrophi exercis **human** increas
muscl muscular produc product rat
skelet smooth specif system

1496: GTPase-Activating Proteins (43)

actin activ **cell** chang control differ
domain effect **function** increas interact
mechan mice migrat pattern polar
protein regul requir resist

1497: rac1 GTP-Binding Protein (44)

actin **activ** associ **cell**
cytoskelet cytoskeleton develop famili filament
gtpase human **migrat** motil polar protein
regul requir rho role studi

1499: Receptors, Dopamine D2 (73)

adhd affect allel associ behavior bipolar
depress **disord** effect genotyp
person polymorph psychiatr receptor
schizophrenia serotonin sleep studi suggest
symptom

1501: Drugs, Chinese Herbal (77)

activ analysi **cell** china chines
determin **differ** effect **group**
heterogen includ increas investig observ
rat respect signific **studi**
subtyp treatment

1503: Nigericin (3)

activ **cell** channel effect enzym factor field

growth indic inhibit investig marker *microscopi*

morpholog observ plant requir resist state

studi

1498: Ubiquitin-Conjugating Enzymes (43)

cellular **degrad** dna finger function
involv ligas pathwai prion process proteasom
protein prp regul respons stabil
suggest target ubiquitin zinc

1500: Receptors, Thyroid Hormone (39)

activ adren alpha analysi beta cell chang
develop express function hormon human
increas pituitari protein **receptor**
regul requir studi **thyroid**

1502: Ionophores (23)

activ associ **cell** chang channel
decreas differ effect function gene
human identifi increas inhibit level
patient protein **respons** sequenc
treatment

1504: Hydroxyeicosatetraenoic Acids (12)

acid analysi **cell** clinic compar

concentr control diagnosi gener high

higher increas low product rate

respons role specif studi

subject

1505: Fatty Acids, Monounsaturated (19)

acid activ amino associ base cell
distribut effect effici gene human increas local
process rat report specif studi suggest surfac

1507: Phospholipids (70)

acid amino apoe cell cholesterol
control effect function gene increas level
lipid lipoprotein membran mutant plasma
protein respons studi transport

1509: HLA-A1 Antigen (9)

allel antigen **class** complex control
diseas famili histocompat hla human major
mhc molecul patient peptid present product
resist structur type

1511: Dystroglycans (19)

activ adhes cell complex diseas
effect human interact mechan model
muscl mutant phenotyp plai
product **role** skelet smooth time tissu

1506: Palmitic Acids (1)

acid amino autosom cell domin elev famili fatti
induc induct inherit level mutat nucleic plasma
respond **respons** retino serum yeast

1508: Vitamin B 12 (39)

acid associ bleed differ **factor** folat
group high homocystein level mthfr new plasma
platelet rate risk studi thrombosi valu venou

1510: HLA-DR3 Antigen (9)

associ class compar **control** differ frequenc
gene genet group haplotyp healthi increas
patient polymorph popul risk
signific snp studi subject

1512: Leucine-tRNA Ligase (3)

associ complex confid control differ
enzym featur **interact** interv isol
larg mutat **protein** ratio risk size small
smoke studi subject

1513: Creatine Kinase (27)

compar differ dystrophi effect exercis express

gene group increas level **muscl**
muscular patient pattern site skelet smooth
structur studi subject

1515: HLA-DP Antigens (15)

allele antigen **class** complex control
genotyp histocompat hla human identifi major
mhc molecul patient polymorph popul present
sampl screen type

1517: Lamin Type A (40)

accumul analysi associ cellular cytoplasm differ
export famili gene heart human import lamin local
nuclear nuclei nucleu protein
mice transloc

1519: Protein Kinase C-delta (24)

activ cell differ enhanc erk express
famili induc inhibit inhibitor jnk **kinas**
mapk p38 pathwai **phosphoryl**
protein regul signal treatment

1514: Lysosome-Associated Membrane Glycoproteins (27)

activ associ cell detect differ
effect function high human identifi
level low membran patient **protein**
specif target transport treatment tumor

1516: Heterogeneous-Nuclear Ribonucleoprotein K (4)

alter bind case cell chang decreas differenti
increas
enhanc gener genet interact level nuclear promot protein regul
serum translat tumour

1518: 14-3-3 Proteins (41)

activ analysi associ control develop
famili function gene genet group high
identifi interact **kinas**
pathwai phosphoryl
protein role screen signal

1520: I-kappa B Kinase (59)

activ alpha chemokin constitut cxcr4
express factor human il-8 induc necrosi
nf-kappab nuclear receptor
role signal suggest tnf tnf-alpha tumor

1521: Tristetraprolin (8)

associ bind express **gene** initi
interact involv mechan **mrna** process
protein regul rel ribosom rna site target
transcript **translat** trna

1523: TNF Receptor-Associated Factor
6 (12)

activ **cell** demonstr enhanc
express factor fish fluoresc
gene gener **group** hybrid
interact nf-kappab posit probe sequenc situ
studi suggest

1525: Dental Impression Materials (3)

area case cleft compar condit
control data degre differ estim
frequenc locat mean **method** palat
patient predict studi temperatur valu

1527: Adenine (87)

analysi associ base bind detect differ dna effect
gene genotyp group increas **mutat**
observ pair patient polymorph respons studi
treatment

1522: Casein Kinase Ialpha (3)

activ analysi **bind** cell classific cluster kinas
mice mutat p53 pathwai phosphoryl plai
protein region regul **role** sequenc
signal site

1524: DNA Topoisomerases, Type II
(54)

agent anticanc cancer cell chemotherapeut
chemotherapi cisplatin cytotox dna
drug effect enhanc famili gene increas
paclitaxel patient sensit structur treatment

1526: Gold Alloys (1)

area condit degre differ extract
fraction hospit mean median **method**
month **patient** rang ratio
respect standard studi temperatur **valu**
year

1528: alpha Catenin (20)

analysi carcinoma **cell** differenti
e-cadherin effect **epitheli** epithelium
express gland interact junction mammari
mechan plai prolifer protein requir role signal

1529: Immunoglobulin Idiotypes (9)

approach clinic complex express genet immun
induc induct lymphoma patient process requir
respons sequenc strategi target
therapeut tumor vaccin vivo

1531: Angiotensinogen (24)

activ allel **arteri** associ blood
coronari effect function gene genotyp
group hypertens infarct
patient polymorph pressur
protein stroke subject vascular

1533: Fanconi Anemia Complementa-
tion Group D2 Protein (17)

activ anemia associ caus damag defect
defici dna high malign normal
patient process **protein** repair respons risk
time treatment **tumour**

1535: Hemagglutinins, Viral (10)

base **bind** cluster decreas enhanc
genom **high** human
increas individu
interact isol level low normal protein
select strain **tissu** viru

1530: Renin (27)

activ allel **arteri** blood
control coronari differ function
genotyp group **hypertens** infarct
level **patient** polymorph
pressur stroke studi subject
vascular

1532: Fanconi Anemia Complementa-
tion Group C Protein (7)

caus cell clinic defect **defici**
distribut dna featur form format
function lead local mechan
mutant **mutat** protein requir
treatment tumor

1534: Transcription Factor TFIIA (7)

bind caus complex enhanc evid gene genet
human model mutat nucleotid organ
plai popul product protein region role
sequenc structur

1536: BRCA2 Protein (47)

assess associ brca1 brca2 cancer carrier develop diseas
dna epidemiolog **factor** high high-risk histori identifi
incid includ increas prevent **risk**

1537: Fanconi Anemia Complementa-
tion Group L Protein (2)

abil approxim ^{capac} complex core defici
demonstr dna encod function gener indic
interact ^{known major open properti}
protein rel suggest

1539: Ligases (17)

associ cell clinic complex degrad
diagnosi dna express famili form format
function gene human
patient posit product
protein rate structur

1541: Amoxicillin (13)

cancer clinic compar concentr differ effect
gastric group high infect low
patient pylori rate studi test
therapi tissu treatment trial

1543: Stilbenes (52)

activ addit cell ^{compar} combin
dexamethason differ effect ^{enhanc evalu increas}
investig mechan plu resist result simultan singl studi
synergist

1538: BRCA1 Protein (76)

analysi assess associ brca1 brca2 carrier develop diseas

dna epidemiolog factor high high-risk histori identifi

incid includ increas prevent risk

1540: Cross-Linking Reagents (115)

activ cell damag dimer dna fold
form format function group increas nativ
protein repair solubl stabil
stabl structur studi suggest

1542: Clarithromycin (14)

cancer case compar control data differ
evid gastric group higher
patient random rate resist respect studi
support time treatment trial

1544: Hydrocortisone (69)

activ adenoma adren combin compar control
disord effect group healthi hormon increas
level patient pituitari ret studi
subject thyroid treatment

1545: Interleukin-15 (38)

activ cd4 cd4+ cd8 **cell** express il-2 immun
level lymphocyt mutant number product protein
respons select serum t-cell tcr tissu

1547: Protein C (36)

activ bleed clinic express **factor** folat group
human mthfr **patient** platelet
product **protein** risk sever structur treatment
tumor venou year

1549: Vitamin B 6 (12)

associ children compar **concentr**
dai data **develop** effect
genom group high higher
level method patient rate
ratio **risk** sampl studi

1551: Erythroid-Specific DNA-Binding Factors (72)

activ **cell** defect **defici** develop
differenti express factor function gene
interact mutat normal progenitor
promot regul site stem tissu
transcript

1546: Antithrombins (13)

activ associ clinic diagnosi **factor** high
identifi **increas** level measur mutant mutat
patient protein score screen select
test time tissu

1548: Chromium (27)

activ cell compar **concentr**
control develop effect exposur
express frequenc group higher human method
model rate studi subject treatment water

1550: Vitamin E (59)

activ antioxid associ bodi differ **effect**
function **group** **increas**
oxid oxygen patient protect reactiv
reduc role **stress** studi time treatment

1552: GATA1 Transcription Factor (40)

activ acut anemja **ASSOCI** caus **cell**
defect **defici** develop differ differenti
function hematopoiect interact leukemia normal
patient progenitor role **stem**

1553: BH3 Interacting Domain Death Agonist Protein (52)

activ **apoptosi** apoptot bax
bcl-2 caspas caspase-3 cell control death
famili human **induc** induct inhibit inhibitor mechan
pathwai protein studi

1555: Receptors, Somatotropin (14)

activ effect **factor** function gene genet
growth high higher human igf-i level
number patient rate receptor region respons sequenc
studi

1557: Peptide Elongation Factor 1 (21)

activ cell differ diverg earli evolut
evolutionari function gene organ patient
phylogenet popul region relationship
sequenc **speci** stage suggest tree

1559: Alcohol Dehydrogenase (30)

activ **alcohol** associ consumpt
depend drink **effect** ethanol examin
genet indic number **oral** possibl prefer
select signific studi substanc suggest

1554: Sulfur Dioxide (6)

activ **area** assess concentr correl
differ form format **group** locat
measur method popul sampl size studi
subject test valu water

1556: Asparagine (40)

acid **activ** cell develop express form
human increas model mutant mutat rate
residu respons select **site** state structur
studi time

1558: Thyroid Hormone Receptors al-pha (8)

alter chang effect **gene** hormon

human interact measur

mechan mice molecular mutat

patient receptor reduc regul

score thyroid treat

treatment

1560: Receptors, IgG (50)

activ allele antibodi associ **cell**
compar **control** develop differ
function **gene** genotyp
increas mice patient **polymorph**
popul receptor regul studi

1561: Proinsulin (21)

activ associ cell **diabet** differ
glucos increas **insulin** level metabol mice
new number produc **product** risk select studi
time tissu

1563: Simvastatin (16)

apoe apolipoprotein **ASSOCI** cell chang
cholesterol effect increas ldl
level **lipid** lipoprotein
metabol **patient** plasma random
respons role studi trial

1565: Free Radicals (77)

activ antioxid damag energi free glutathion
increas induc level **oxid** oxygen
peroxid product protect radic reactiv ros
speci **stress** superoxid

1567: Flavonoids (176)

activ cell compound deriv
determin effect **extract** fraction group
increas induc inhibit **kinas** liquid pathwai
phosphoryl prepar protein rat specif

1562: Protein C Inhibitor (4)

analysi blot **CAUS** detect
differ express gene lead
marker mechan molecular normal
pattern plai protein regul reveal **role**
tissu western

1564: Lovastatin (18)

analysi combin compar concentr
control effect enhanc enzym
genet healthi increas measur model
mutat patient product **respons**
role studi **subject**

1566: Proto-Oncogene Proteins c-myc (22)

activ cell develop differenti
effect express form format function human
identifi mutant **number** process prolifer
promot protein screen structur studi

1568: Proanthocyanidins (10)

activ analysi cell combin concentr
control dai data decreas effect **enhanc**
increas inhibit model reduc resist sampl
studi test treatment

1569: Sesquiterpenes, Germacrane (2)

abil acid **activ** analys
analysisi blot cell content delet
demonstr enzym flow indic properti reveal site
structur substrat synthesi western

1571: Paired Box Transcription Factors (77)

cell detect **develop** differ earli
embryo embryon **express** gene
mutat neural pattern regul requir role
signal specif tissu tumor zebrafish

1573: Neurofilament Proteins (32)

activ analysi associ cell
develop differ diseas express gene includ
injuri male nerv **neuron** patient
protein respons reveal **studi** year

1575: Propolis (6)

acid analysi cell compar
correl dai decreas **effect**
exposur higher incid **increas**
product rat **rate** reduc
signific studi women year

1570: MCM1 Protein (4)

adapt complex **dna** express genet genom
inhibit initi interact mutant origin plai polymeras
region replic resist role select sequenc target

1572: bcl-Associated Death Protein (28)

activ **apoptosi** apoptot associ
bax bcl-2 caspas caspase-3 **cell** chang death
decreas effect **increas** induc pathwai protein
rate sampl treatment

1574: Hair Preparations (5)

abil assess combin correl detect
effect health higher measur
method model potenti process properti rate
reduc reduc score studi test

1576: Deodorants (3)

adult differ **group** incid level
men model mortal period point popul
preval product repeat serum studi test
time women year

1577: Perfume (2)

assai compar **detect** higher incid
includ increas lower men mortal normal
number preval rang **rate**
sensit **test** tissu women year

1579: Leukocyte L1 Antigen Complex (3)

acid bind cell **earli** identif
identifi injuri
interact late nerv, novel
pathwai phase protein **region**
screen sequenc signal
stage tumor

1581: o-Chlorobenzylidenemalonitrile (1)

alter behavior cell chain **chang**
decreas detect includ increas line pcr polymeras
quantit rang **reaction** real-tim revers state
varieti wide

1583: GATA2 Transcription Factor (18)

cell differenti enhanc express famili
function gene hematopoiect human increas plai
progenitor promot protein respons role specif
stem tissu transcript

1578: P-Selectin (22)

activ adhes blood **cell** combin compar
control effect express factor function
gene **group increas** interact level
patient studi subject
treatment

1580: Riot Control Agents, Chemical (1)

care chain follow impact improv
inform interview knowledg **life**
nurs **particip** persist person
physic physician **qualiti**
questionnair reaction skin survei

1582: Interferon Regulatory Factor-3 (14)

activ analysi correl cytokin enhanc
gene il-6 induc interact mechan normal plai
product protein receptor respons rna role
target tissu

1584: Octamer Transcription Factor-1 (14)

activ associ bind diseas effect element
express factor famili **gene** mice
model **promot** protein region
regul respons sequenc site transcript

1585: Nucleocytoplasmic Transport
Proteins (16)

compar complex control cytoplasm express
famili gene level local model mrna new

nuclear nuclei nucleu protein
requir respons role structur

1586: Pyridones (11)

activ associ combin

concentr dai defici effect

exposur gener increas level method

normal number

patient product resist

specif target tissu

1587: Sp3 Transcription Factor (33)

activ assai bind effect element express factor

famili gene human promot region
regul regulatori report site sp1 studi transcript
upstream

1588: MutS DNA Mismatch-Binding
Protein (14)

activ bind chang coli data dna effect
escherichia estim famili function identifi
increas method model new popul protein
replc specif

1589: Taq Polymerase (33)

analysi assai chain detect
determin gene high human method number
pcr polymeras quantit
reaction real-tim revers rt-pcr
sampl sensit test

1590: Thymine Nucleotides (13)

compar complex control differ
dna gene higher human
method multipl mutat number
polymorph process rate role sequenc
structur studi suggest

1591: Chloramphenicol O-
Acetyltransferase (35)

activ bind cell differenti element express

factor gene human increas level

product promot recombin

region regul sequenc site studi

transcript

1592: Deoxyribonuclease (Pyrimidine
Dimer) (14)

activ break cell control damag dna
effect event form gene group human increas
involv process product repair sampl studi
subject

1593: Deoxyuracil Nucleotides (9)

base cell data **dna** estim evid form
format genom method mutant mutat pair
phenotyp protein provid replic size suggest
support

1595: Placebos (66)

advers arm assess baselin clinic compar effect
efficaci group improv phase placebo
random receiv safeti studi treatment
trial versu week

1597: Receptor, Melatonin, MT1 (3)

activ associ cell circadian control differ differenti
earli enhanc feedback function **group**
hamster loop phase receptor signific stage studi
suggest

1599: Ampicillin (7)

bacteri cell clinic decreas element
famili hospit host **increas**
infect isol pathogen patient
region repeat resist select
sequenc **strain** studi

1594: Ketoprofen (2)

arm clinic compar **control** dai differ
effect efficac event frequenc **group**
hybrid improv involv **process** random
signific studi treatment **trial**

1596: Acetylserotonin N-Methyltransferase (1)

develop development earli enzym
function impact improv includ known level life
loop mechan molecular physic plasma qualiti serum
underli understand

1598: Arylalkylamine N-Acetyltransferase (7)

activ circadian clock control
determin **develop** effect
feedback hamster light loop model
modif **modifi** mutat rat
regul studi suggest time

1600: Tetracycline (62)

activ carri cell construct contain control effici
express **gene** gener homolog human mice
plasmid **recombin** respons
select transfer treatment vector

1601: Mitochondrial Membrane Transport Proteins (14)

cell cytochrom dna involv larg
mitochondri
mitochondria mtdna mutant normal organ
patient phenotyp process protein role size
small suggest tissu

1603: Ryanodine Receptor Calcium Release Channel (39)

activ atp ca2+ calcium cam cardiac
channel current develop heart
increas intracellular ion mechan mutat protein
releas respons role sodium

1605: GATA3 Transcription Factor (25)

bind **cell** chang differenti express
factor famili function gene genom group
increas model mutant mutat prolifer promot
regul respons transcript

1607: Phosphotransferases (40)

activ cell differ express
famili function high increas
kinas level new phosphoryl
protein regul respons sequenc
signal structur target tyrosin

1602: Ruthenium (4)

base **cell** compar complex concentr
decreas effect follow higher increas
inhibit line occur p53 plai process rat
rate role state

1604: Ruthenium Compounds (3)

base bind complex compound concentr differ
effect follow inhibit isol larg number
pair prevent protect reduc reduct size small
strain

1606: Interleukin-7 (26)

assai caus cd4 **cell** detect develop express
gene human immun level lymphocyt number
patient requir respons sensit t-cell target tissu

1608: Kanamycin (7)

activ concentr contain effect
function gene identifi isol length
long mutant novel plasmid protein
recombin repeat resist
screen short studi

1609: Neomycin (18)

assai associ **cell** clinic detect
effect express form identifi mice
new protein screen **select**
sensit sequenc studi target tissu
transfect

1611: Toll-Like Receptor 3 (20)

activ associ cell cytokin
function human ifn ifn-gamma il-10 il-6
immun increas induc macrophag new
process product receptor respons structur

1613: Silicone Elastomers (9)

base cataract **control** glaucoma implant

increas len method model mutant new

patient popul select state studi

subject test treat **treatment**

1615: Fructosediphosphates (2)

activ assai **combin** compar concentr
decreas detect determin effect enzym
extract fraction **increas** mean
measur presenc respect sensit system valu

1610: Periplasmic Binding Proteins (5)

analysi approach cluster effect flow
genet identifi membran molecular
mutant mutat nucleotid organ protein rang
reduc **region** repeat sequenc yeast

1612: NAD(P)H Dehydrogenase (Quinone) (27)

activ control determin effect glutathion group
gst gstm1 gstp1 increas influenc involv **modif**
modifi null observ s-transferas
signific studi suggest

1614: Polychlorinated Biphenyls (25)

air cell clinic **concentr** contamin

control copper environment human

increas level metal pah patient pollut

popul sever soil sourc **water**

1616: Glucose-6-Phosphate (5)

activ **bind** complex enzym form
format imag initi interact model
mutat pathwai protein report select
state **structur** studi substrat
tumour

1617: Fructosephosphates (4)
acid area bind cell cluster coli determin
differenti enzym escherichia experi extract
gene initi intern **number**
origin regul second system

1619: Cytochromes c6 (1)
cleavag complement contain cystein demonstr determin
energi **function** glycosyl highli
known major posit proteas residu serin site solut
specif surfac

1621: Bile Acids and Salts (31)
acid activ aduit cholesterol chronic develop
hepat hepatocyt human increas level lipid
liver new organ rate resist role studi
year

1623: Aspartate Aminotransferases (34)
chang compar concentr control dai develop
dose earli effect group hepat hepatocyt
high level **liver** new patient rat studi
week

1618: Photosystem I Protein Complex (16)
analysi bind carbon chang
complex electron
energi exchang fluoresc free
measur mol plant protein proton rate
solut spectra spectroscopi transfer

1620: Ursodeoxycholic Acid (10)
acid case cell diseas effect enhanc
function high increas
level life liver low **patient**
product qualiti rat risk studi subject

1622: Chenodeoxycholic Acid (6)
acid amino cell character
characterist combin common control
decreas distinct **effect** featur
healthi increas process reduc regul
respons studi **subject**

1624: Docosahexaenoic Acids (15)
acid amino cell combin compar control dai
effect enzym fatti higher level nucleic rat rate retino
retinoid subject substitut test

1625: Cytochrome P-450 CYP1A2 (29)

activ cyp cyp1a1 cyp2c9 cyp2d6 cyp3a4 cyp3a5
cytochrom determin drug enzym human

metabol metabolit microsom
p450 patient respect risk studi

1627: Iron, Dietary (9)

associ barrier base bodi contact
control express form gap
gene high iron junction low
phenotyp ratio regul risk
studi test

1629: rac GTP-Binding Proteins (53)

actin activ cell control cytoskelet
cytoskeleton fak filament format function
gtpase migrat motil myosin polar
protein regul rho role suggest

1631: Nicotinic Agonists (12)

associ chang code
codon develop effect function
increas interv level measur nucleotid
posit rat ratio risk score
smoke studi substitut

1626: Charcoal (9)

activ approach area cell combin concentr copi
cultur effect extract increas larg measur

method number process score
soil studi water

1628: Rho Factor (5)

assai caus detect function
gene initi level method mrna mutat
number organ plai region
role sensit sequenc structur
studi valu

1630: Raloxifene (13)

associ breast cancer compar control
effect human increas ovarian
random rat ratio reduc reduct risk role
studi treatment trial valu

1632: Bicyclo Compounds, Hetero-
cyclic (19)

bind cell decreas distribut effect famili
function increas induc inhibit local model
protein receptor regul requir respons role
suggest time

1633: Conotoxins (5)

acid adapt anim approach bind caus **cell**
concentr **differ** evolut **function**
human inhibit lead model
neuron pattern remain **select** site

1635: DNA, Archaeal (28)

16s analysi bacteri **bacteria**
commun contain divers **dna**
eukaryot **gene** microbi novel organ
protein rdna repeat **rrna**
sequenc similar speci

1637: Mycolic Acids (3)

acid case condit degre extract famili
gener genet group indic isol member
method plai produc product report role studi
tuberculosi

1639: Lipase (42)

activ apoe apolipoprotein associ
cholesterol compar develop differ gene
increas level **lipid** lipoprotein
patient plasma produc product ratio
studi valu

1634: Acetylcholine (36)

activ anim associ chang develop effect
experiment human increas **model**
neuron protein rat rate releas select stimul
studi suggest treatment

1636: H-Y Antigen (6)

alter area bind **cell** chang complex
decreas enhanc femal gener **increas**
interact male mice open peptid **protein**
requir transplant variabl

1638: Endopeptidases (109)

accumul activ amyloid caus
cell control degrad deposit develop diseas
famili **function** lysosom process
protein report residu site storag
suggest

1640: Endopeptidase K (13)

activ cell complex decreas detect dna
effect enzym famili fragment
increas method number pcr
protein reduc select sequenc stabil
structur

1641: Muramidase (39)

acid **cell** chang dimer fold form
function gene high increas interact
level low **protein** respons
solubl **stabil** stabl structur
suggest

1643: Antithrombin III (7)

analysi control factor function gene identifi
level mice mutat **patient** posit
protein region risk sequenc studi subject test
time treatment

1645: Arachidonate 15-Lipoxygenase (9)

acid amino associ **cell** correl
effect express gene high **human** level low
marker mechan new phenotyp produc product
rat rel

1647: Hydroxylamine (3)

abil acid compar effect express gene higher
human lower neg organ posit
potenti properti rat **rate** receptor regul
stimul versu

1642: Tenascin (19)

adhes analysi associ cell control
develop differ **express** genom group
individu integrin molecu number organ
patient studi subject time
tumor

1644: Endothelin-1 (29)

cellular compar **control** differ effect express
function group human increas involv level
mechan modul product receptor **regul**
regulatori role studi

1646: DNA Polymerase III (31)

analysi approxim cell **dna** express function
gene helicas human mutat mutat pol polymeras rate
recombin rel replic reveal strand synthesi

1648: Receptors, GABA-B (22)

activ alpha **associ** chang control develop
effect famili gene **genet** haplotyp
mechan molecular neuron polymorph
receptor regul snp stress
studi

1649: Neurotransmitter Agents (41)

activ^{associ behavior clinic control}
develop^{disord effect}
function^{gene group mechan}
model^{neuron^{protein regul role}}
studi^{treatment^{tumour}}

1651: Receptors, GABA-A (47)

agonist^{alpha anim antagonist associ beta chang}
develop^{gamma gene genet increas ligand mediat}
model^{receptor^{respons stress studi}}
subunit

1653: GABA Agonists (9)

alpha^{beta concentr dai effect group higher}
level^{measur mice new rat rate}
receptor^{stimul stress studi}
subject^{test treatment}

1655: Dopamine Antagonists (14)

activ^{affect}
function^{associ^{case data evid}}
mutat^{group^{level model}}
neuron^{number rel report respons}
studi^{suggest year}

1650: Receptors, GABA (12)

activ^{alpha beta cell chang}
develop^{express function genet}
genom^{increas mechan model molecular neg}
posit^{presenc receptor^{regul}}
studi

1652: Cholinergic Agonists (3)

approach^{caus complex copi degre}
differ^{express}
function^{lead membran mice}
mrna^{number^{patient pattern}}
receptor^{residu site test^{type}}

1654: Carbachol (8)

abil^{cell control develop gene}
high^{human^{increas individu}}
level^{local low mechan molecular}
mutat^{neuron^{properti}}
receptor^{repeat time}

1656: Central Nervous System Stimulants (40)

alcohol^{associ behavior bipolar chang}
depress^{differ}
function^{disord^{effect}}
genet^{number oral person psychiatr}
respons^{studi subject symptom treatment}

1657: Receptors, Neuropeptide (17)

activ caus control effect factor
function gene growth human increas
lead life mechan model mutat qualiti rat
receptor role select

1659: Receptors, Dopamine (7)

acid activ associ differ disord
effect gene genet genom genotyp increas
individu model phenotyp polymorph
protein size state studi time

1661: Receptors, Purinergic P2 (31)

activ atp ca2+ calcium cam cell
channel current express group
human increas intracellular ion potenti
receptor region releas sequenc sodium

1663: Nitric Oxide Synthase Type I (24)

control decreas demonstr effect enos incorpor
increas induc level nitric oil oxid
product rat reduc role studi suggest
synthas synthesi

1658: Dopamine Agonists (18)

activ analysi clinic develop differ diseas
disord earli effect increas level model number
patient rat receptor
respons studi test treatment

1660: Aldehyde Reductase (8)

associ cell clinic differenti enhanc enzym
event express gene increas involv model
occur patient process
produc product repeat step
treatment

1662: Cyclic GMP-Dependent Protein Kinases (8)

base cell control differ differenti
effect express gene human
increas interact mutant pattern
protein rang rat reduc select
synthesi treatment

1664: Cyclic GMP (31)

activ cell control decreas effect
function gene increas induc
level mechan nitric oxid reduc regul
respons role suggest synthas
synthesi

1665: Nitric Oxide Synthase (246)

decreas demonstr effect enos incorpor
increas induc inos investig level nitric oil
oxid product reduc studi suggest
synthas **synthesi** thymidin

1667: Manganese (33)

activ caus combin differ **effect**
enhanc famili group high
human increas level low
patient reduc sampl site specif
structur studi

1669: Triiodothyronine (43)

adenoma adren braf control correl effect
gene hormon increas **level** normal
papillari pituitari reduc ret serum subject
thyroid tissu treatment

1671: HLA-A2 Antigen (50)

antigen cell challeng class ctl dendrit elicit
epitop function group **immun**
immunogen immunotherapi induc innat patient
protect respons **vaccin** t-cell

1666: Fura-2 (4)

anim care chain channel elev evolut exposur
function gene health level
model muscul **patient** plasma
produc product reaction serum studi

1668: PAX2 Transcription Factor (12)

activ analysi decreas **develop**
express famili gene identifi increas mechan
model molecular mutat previou protein renal
report screen select studi

1670: Glutamate Decarboxylase (34)

associ cell diabet differ **effect**
express function **gene** genet
genotyp group human increas
neuron patient polymorph
reduc risk **studi** subject

1672: Sodium Channel Blockers (11)

acid **activ** anim associ ca2+
calcium caus chang **channel** current
human identifi model mutat new rate
resist role studi subject

1673: Anti-Arrhythmia Agents (28)

activ analysi associ base
cardiac chain channel dai failur
gene heart left model patient
ratio reaction risk sampl studi
ventricular

1675: Aluminum Silicates (12)

compar differ effect form format
group high larg low mean measur
morpholog product ratio repeat respect size
small time valu

1677: Hepatocyte Nuclear Factor 1-beta (9)

caus compar dai diabet differ express
famili gene group higher
human increas level mutant mutat
pattern promot rate renal requir

1679: Hepatocyte Nuclear Factor 1 (17)

concentr dai diabet express famili
function gene glucos increas insulin
mutat patient rate region
respons select sequenc subject treatment year

1674: Tylosin (4)

area assess concentr differ
effect form format mean
measur mutant mutat ratio
reduc resist respect score select
specif valu water

1676: Water (200)

air carbon concentr condit contamin degre
determin electron energi free measur metal
model plant rate soil solut spectroscopi
structur water

1678: Sterol O-Acyltransferase (5)

acid allel amino associ
control differ diseas frequenc
function gene
genotyp increas mice
mutant polymorph
region role sequenc size valu

1680: Hepatocyte Nuclear Factor 1-alpha (17)

analysi associ clinic control develop diabet
differ express gene glucos human insulin
model mutat patient pattern
promot region select studi

1681: Photoaffinity Labels (4)

acid alpha approxim cancer cell codon
compar data differenti dna estim featur
major observ protein
receptor rel site substitut
valu

1683: Receptors, Gastrointestinal Hor-
mone (7)

acid amino bodi differ function gene
health human individu mechan method
molecular normal pattern receptor region
sequenc site studi tissu

1685: Prolactin (55)

activ adenoma adren associ cell develop
express function gene gland hormon
human mutat patient pituitari rat ret select
thyroid time

1687: Fatty Acids, Nonesterified (27)

acid amino bodi compar control diabet
effect glucos group human increas insulin level
normal patient process rat studi subject tissu

1682: Amino Acids, Acidic (2)

acid activ amino associ bind
critic domain enzym interv mutat plai protein
ratio residu risk role site smoke studi
suggest

1684: Transcription Factor Pit-1 (10)

analysi associ combin compar control
develop effect famili genom identif
identifi life member mutat novel
patient qualiti screen studi
thyroid

1686: Cytochrome P-450 CYP1A1 (61)

activ allele associ cyp1a1 cyp2d6 cyp3a4
cytochrom determin differ drug enzym genotyp
human metabol metabolit
microsom p450 polymorph risk studi

1688: Diglycerides (12)

acid activ amino differ effect
express function
group high human increas
inhibit level mice model rate regul
requir respons tissu

1689: Cholesterol Esterase (5)

acid amino bind cell demonstr enhanc
fusion **human** increas interact
mice mutant **number** protein
receptor regul **specif** structur suggest
treatment

1691: ADP Ribose Transferases (12)

analysi assai blot cell chang detect dna
effect **gene** genom **human** increas
individu new patient **protein**
respons role sensit western

1693: Antigens, CD19 (37)

analysi b-cell blood case **cell** develop
function high larg level low lymphocyt
lymphoma normal number
phenotyp rate role studi tissu

1695: Androgen-Binding Protein (7)

base **cancer** cell compar control decreas differ
express group increas induc induct interact
mice posit prostat rat **respons**
target tumor

1690: Adenosine Monophosphate (16)

activ chang compar ENZYM
function gene genom increas level mechan
mutat phenotyp process protein rate region
respons select sequenc substrat

1692: Nuclear Pore Complex Proteins (36)

clinic control cytoplasm demonstr differ
function fusion gene local mice new
nuclear nuclei nucleu partial
process protein requir studi transloc

1694: Receptors, Nerve Growth Factor (32)

analysi **cell** control express famili
function gener increas level lymphocyt neuron
phenotyp receptor requir role sampl studi
suggest t-cell tumor

1696: Androgen Antagonists (48)

analysi androgen associ **cancer** cell
combin differ effect group lncap organ patient progress
prostat psa rate repeat respons studi treatment

1697: Antigen-Antibody Complex (13)

activ analysi antibodi blood cell determin
express gene group identifi level new normal
patient screen select serum
specif structur tissu

1699: Herpes Simplex Virus Protein Vmw65 (16)

analysi cell complex data
domain enhanc express gene
increas interact level mutat number
presenc process protein rel
reveal studi suggest

1701: Interleukin-5 (23)

asthma chang compar control cytokin decreas
develop function group identifi
increas level mechan molecular
patient protein rate
respons screen tissu

1703: Ribonucleotide Reductases (14)

cell combin differ dna effect
enzym evid form format gene increas level
model number phenotyp protein provid requir
support time

1698: Ions (72)

activ analysi bind
channel differ dna
effect energi gel group identifi
increas level mass mechan
model protein radiat structur
studi

1700: Granulocyte-Macrophage Colony-Stimulating Factor (90)

antigen bone cell demonstr effect factor
granulocyt immun induc macrophag marrow
matur mice monocyt mucl neutrophil patient
respons studi vaccin

1702: Acetals (2)

approxim avail base caus cell compound data
databas death develop
development lead major methyl observ occur pair
program rel state

1704: Ribonucleotides (15)

activ approach cell chang complex dna
enzym extract group
high mice new region requir sequenc
structur studi substrat tissu treatment

1705: Phosphoprotein Phosphatase (79)

activ cell chang develop express
function gene human increas interact
kinas pathwai phosphatas
phosphoryl protein regul role
signal stat3 tyrosin

1707: Fluorides (15)

activ analysi children compar concentr data
detect differ effect estim group
health high human increas level local protein
rate respons

1709: Ophthalmic Solutions (25)

aberr conclusions corneal correct develop
effect evalu examin group implant
increas mean measur methods ocular
patient perform studi tissu visual

1711: Sodium Selenite (4)

acid concentr correl determin
effect exposur higher increas measur microg
microm microscopi min morpholog observ plai
plasma reduc respect role

1706: Cariostatic Agents (8)

cleft combin compar concentr dai data differ effect
estim group increas method model
number sampl signific studi time treatment year

1708: Fluoroquinolones (14)

chang character clinic differ gene gener group infect
isol model mutant mutat patient presenc
respons select sequenc strain studi type

1710: Glutathione S-Transferase pi (66)

associ control determin enzym glutathion gst
gstm1 gstp1 gstm1 increas influenc involv
modif modifi null observ
s-transferas signific studi suggest

1712: HIV Envelope Protein gp41 (25)

activ aids antiretrovir detect fusion gag group
herp hiv hiv-1 hsv-1 human
immunodefici infect replic
sampl select simplex viral viru

1713: Cyclin-Dependent Kinase 9 (8)

activ cell compar complex control
develop differ earli form format
function melanoma pattern
polymeras report **rna** stage studi target
transcript

1715: Poly A (31)

base develop differ dna factor **gene**
genom human initi interact **mrna**
protein region repeat ribosom rna role
sequenc **translat** trna

1717: Bicarbonates (12)

activ **concentr** determin
differ earli express gene genom group
increas microg microm min mutant mutat
pattern plasma resist size system

1719: Adenovirus E1B Proteins (10)

adenoviru analysi bind **cell** deliveri
develop differ earli effici evid express **gene**
product requir support test therapi transduct
transfer **vector**

1714: Positive Transcriptional Elongation Factor B (7)

activ bind caus complex **human**
interact lead melanoma polymeras
product protein region regul repeat
rna select sequenc site specif transcript

1716: Biological Products (15)

activ anim cell control function gener group high
human increas level mix model process
produc **product** studi therapi
treatment yield

1718: alpha-Crystallin B Chain (10)

analysi cell chang condit **degre**
differ differenti **express** gene
genom identifi muscul **mutat** new
protein region sequenc
temperatur time tumor

1720: Adenovirus E1A Proteins (37)

activ adenovir adenoviru cell deliveri effici
express famili **gene** human protein role
select therapi transduc transduct transfer
transgen **vector** vivo

1721: Idarubicin (19)

acut analysi associ compar differ group
high higher leukemia myeloid number
patient rate respons studi
surviv transplant treat treatment year

1723: Micrococcal Nuclease (9)

alter chain chang correl detect dna
event high involv level low model
mutant mutat per popul
process protein reaction
structur

1725: Glycosides (17)

activ adapt adduct analog analogu analysi
chemic compound deriv
form format function mechan natur new
respons reveal select sequenc structur

1727: Lectins (57)

activ antibodi bind cell develop differ
express gene group increas level
mice patient peptid respons role
select site specif studi

1722: Fenfluramine (3)

associ bodi chines complex differ
dna form format function
heterogen identif identifi novel
produc product recombin
screen studi subtyp weight

1724: Anti-Ulcer Agents (28)

activ adenocarcinoma aim associ cancer detect
gastric gastrointestin group
helicobact human mucosa patient pylori rat
respect stomach studi subject treatment

1726: Amides (36)

activ alter analysi cell chang
compound decreas deriv effect
gene group increas inhibit new
novel role structur studi
target treatment

1728: Carbohydrates (42)

acid cell chang concentr
differ earli express form
function group new plant process
product protein rate residu
site structur studi

1729: Coated Materials, Biocompatible (40)

activ cation cell conjug **deliveri effici**
express formul function high increas
liposom **particl** polym prepar properti
solut studi **surfac** tissu

1731: Fucosyltransferases (14)

cell character conserv **express**
gene genom **group** high human
identifi mutat new **phenotyp** popul
protein **region** repeat select
sequenc suggest

1733: Disaccharides (16)

adult **cell** chang **develop**
differ **express** function gener
human increas isol line method
patient pattern process site strain structur
year

1735: Lysophospholipids (38)

acid actin activ analysi **cell** chang
differ earli human inhibit migrat **pancreat**
process regul respons role secret studi
suggest target

1730: Lactose (14)

activ analysi differ effect **express**
function gene genet **high** identifi
influen level low posit **protein**
rate recombin sampl screen valu

1732: Fucose (11)

conserv **differ** distribut effect
express **human** increas level local
mammalian new **patient**
pattern plai region role sequenc site studi
suggest

1734: Okadaic Acid (15)

activ analysi **cell** domain **express** gene
high induc kinas level model phosphoryl
process protein regul **respons**
select signal tissu treatment

1736: Antithyroid Agents (12)

activ compar concentr
control dai decreas develop
differ **diseas** effect **group** human
increas level protein rat
respons signific studi thyroid

1737: Thyrotropin (45)

activ adenoma adren alter braf chang

control endocrin group hormon identifi

increas papillari patient pituitari ptc respons

ret screen thyroid

1739: RNA Polymerase III (20)

activ bind control differ element
express function gene human increas
level melanoma promot protein rna
sequenc site studi time transcript

1741: Heparin (71)

activ adhes analysi associ
cell effect factor gene human
integrin molecu patient process rate risk
sampl specif studi time treatment

1743: Steroids (83)

activ analysi case cell control cycl follicl gene
hormon increas method new patient
pregnanc reproduct steroid studi treat
treatment women

1738: Thyroxine (44)

adenoma adren braf case compar control

develop differ effect group growth hormon

increas papillari patient pituitari rat rate ret

thyroid

1740: Thrombin (51)

associ bleed coagul factor folat
gener homocystein increas method model mthfr
plasma platelet protein risk structur studi
thrombin thrombosi venou

1742: Steroid 21-Hydroxylase (29)

activ adenoma adren analysi control

gene genet genotyp group hormon

increas mutat patient pituitari

polymorph popul ret studi subject

thyroid

1744: 11-beta-Hydroxysteroid Dehydrogenase Type 2 (6)

activ analysi associ
chang express factor gene
growth level mechan methyl
mutat process ratio reveal risk role
studi tumour year

1745: Creatinine (78)

associ compar concentr correl decreas develop
differ diseas failur group increas **kidnei**
level patient rcc **renal** serum signific
studi subject

1747: Tetrahydrocortisol (3)

activ bladder caus cluster compar
express femal genet higher lead lower male
morpholog mutat **patient** popul
rate studi thyroid urinari

1749: Cyclooxygenase 1 (26)

agent associ cell chang chemoprevent cox-2
effect express function gene increas inhibit
inhibitor mechan prevent
protein reduc select suggest treatment

1751: Dihydrotestosterone (21)

activ analysi **cancer** cell combin
detect effect enhanc express identifi increas normal
prostat protein receptor screen time tissu
treatment trial

1746: Receptors, Mineralocorticoid (13)

alpha beta combin effect express gene high
human increas level ligand new rate
receptor risk role select serum
structur studi

1748: Lipoxins (5)

compar **effect** enhanc evid gener
higher identifi increas inhibitor lower
mechan model new potenti provid
rate reduc screen subject test

1750: Gels (38)

analysi cell differ effect effici
electrophoresi gel group
identif identifi **mass** method
model partiel process proteom
spectrometri spot studi surfac

1752: eIF-2 Kinase (30)

activ cell effect express function gene high
infect level low mice model patient
phenotyp **protein** regul
respons treatment viral viru

1753: CCAAT-Enhancer-Binding
Protein-alpha (24)

activ acut adult bind cell combin differenti
element express famili gene leukemia
mutat patient promot
region respons site transcript year

1755: Antitubercular Agents (43)

addit basi data defin demonstr directli gener
includ indic lead mycobacterium new possibl report
repres result specif studi tuberculosi virtual

1757: Secretin (5)

acid activ approach area assess
caus children cluster enhanc inhibit measur
method model peptid popul residu
score site studi subject

1759: Polyethylene Glycols (86)

cation cell conjug deliveri dna effect effici
formul gene liposom particl patient polym
prepar product properti respons surfac
treat treatment

1754: Ethambutol (9)

assai associ data detect gener indic isol
method mutat patient phenotyp report resist
sensit specif strain studi subject time tuberculosi

1756: Olfactory Marker Protein (3)

analysi blot cell confirm detect express function
injuri mice model mous neuron northern plai
protein recombin reveal role transgen
western

1758: Hydrogels (15)

cation cell chang conjug deliveri
effici formul gene group increas
liposom method particl polym
prepar properti protein size structur

surfac

1760: Alendronate (9)

bmd bone cell clinic densiti effect
fractur high hip improv level low miner
osteoblast patient random studi treatment
trial vitamin

1761: Pregnenediones (5)
approxim children compar control dai

detect effect famili level major

measur method patient process reduc rel

sever test treat treatment

1763: Sterol Regulatory Element Binding Protein 1 (18)

acid activ apoe associ
cholesterol evid express
famili gene level lipid lipoprotein
mechan model patient plasma
provid role studi target

1765: Triamcinolone Acetonide (13)

acuiti amd cone dai degener dose level

macular number optic photoreceptor

pigment retin retina rod studi

treatment trial vision visual

1767: Ribonuclease H, Calf Thymus (16)

activ approach bind dna effect
element gene insert model region repeat
requir rna sequenc site size small

structur subject target

1762: Glucose Transporter Type 2 (7)

analysi associ compar complex concentr control

diabet form format glucos higher
insulin lower mice protein rate risk
studi subject time

1764: Chromium Compounds (3)

dai discuss dose effect environment exposur

factor genet induc influenc microscopi

morpholog mutant observ research

respons studi treat

treatment tumor

1766: Poly Adenosine Diphosphate Ribose (22)

activ analysi apoptosi assai caus cell chang
cytotox dna effect growth human induc inhibit
line prolifer protein rate role treatment

1768: Radiopharmaceuticals (138)

assess comput dose evalu imag irradi
magnet measur mri patient perform radiat
resolut reson scan techniqu therapi tomographi
ultrasound volum

1769: Radioisotopes (65)

antibodi antigen cell differ dose effect
exposur group irradi method model new
number radiat radiation-induc
radiotherapi studi therapi treatment tumor

1771: Yttrium (3)

acid analysi anim area case correl
effect life model radiat rat
reduc rel reveal specif structur studi
treatment tumor vivo

1773: Somatostatin (34)

dai develop effect group high islet level
model pancrea pancreat
patient protein rat rate receptor sampl
secret studi time treatment

1775: Ethylnitrosoarea (19)

analysi cell defect detect develop function gene
identifi mechan mice mutant
mutat phenotyp process rat reduc requir sampl wild
wild-typ

1770: Lutetium (1)

addit combin differ dose effect

larg larger level method number plasma plu

radiat serum size small smaller synergist techniqu

tumor

1772: Octreotide (24)

associ compar control differ effect follow

group imag improv increas normal number

pancreat patient rat studi therapi

tissu treat treatment

1774: DNA, Intergenic (73)

align analysi code consensu conserv contain differ flank
genom homolog ident identifi locat motif nucleotid
region segment sequenc
site speci

1776: Receptors, Adrenergic, beta-2 (39)

agonist allele alpha antagonist associ beta chang
differ frequenc gene genet genotyp group human

ligand polymorph receptor
respons sampl subject

1777: Isoproterenol (31)

cardiac caus cell decreas differ effect
express function group heart
human increas mice
mous rat receptor role size
studi treatment

1779: Urocanic Acid (3)

abil base CAUS chain enhanc featur gene
identifi inhibit lead mutat novel
pair potenti properti reaction SCREEN skin
state studi

1781: Myogenin (13)

activ combin develop dystrophi effect
exercis express factor fiber
function growth human increas mechan
muscl muscular process role skelet
smooth

1783: Virginiamycin (1)

approxim assai cell concentr
detect differenti effect increas major
microg microm min observ plasma prolifer rel
releas sensit specif stimul

1778: Sunscreening Agents (16)

alter behavior care caus chang cutan differ
effect genet health keratinocyt model observ
pattern popul respons signific skin
studi subject

1780: T-Box Domain Proteins (57)

cell develop embryo
embryon evolut express
function gene genom human mous mutat
neural pattern regul role studi transcript
vertebr zebrafish

1782: Rifabutin (15)

approach cell combin differ
differenti effect express growth level
mechan model patient pattern process
resist role serum size time tumor

1784: Teichoic Acids (5)

acid cell compar control cytokin differ frequenc
group higher host individu infect level
pathogen receptor serum signific site stimul structur

1785: Ceftriaxone (5)

activ assai clinic detect differ diseas
infect isol larg level method model month
patient sensit size small stimul strain year

1787: Prealbumin (31)

abeta **accumul** alzheimer
amyloid biochem caus deposit diseas enzym
group lead level lysosom patholog popul
precursor report storag studi suggest

1789: Hydroxymethyl and Formyl
Transferases (4)

contain core **develop** effect
encod **gene** hybrid identifi
mechan molecular open read recombin
reduc residu screen site
structur studi transcript

1791: Receptors, Peptide (30)

activ alpha beta bind cell cerevisia gene group
involv marker mutant peptid process rate
receptor requir saccharomyc
structur test yeast

1786: Thienamycins (5)

acid **analysi associ** base concentr
earli effect **group** increas infect
level random region **resist**
respons reveal sequenc studi
treatment trial

1788: Ubiquitin-Protein Ligase Com-
plexes (50)

activ cell chromosom **degrad**
divis ligas local microtubul mitosi mitot
pathwai proteasom **protein**
regul role spindl stabil suggest ubiquitin zinc

1790: Inositol 1,4,5-Trisphosphate (12)

activ caus cell chang channel
effect enhanc increas loss mechan
pathwai receptor reduc reduct regul requir
respons sampl signal treatment

1792: Receptors, Growth Factor (40)

affect associ cancer cell develop
express factor famili function
gene growth
human mutat receptor
regul respons studi target therapi
treatment

1793: Antisense Elements (Genetics)
(16)

analysi base cell chang compar
control develop differ
effect **express** gene
group posit rat regul rna small
subject target valu

1795: Receptors, Somatostatin (22)

adult associ bodi cell control differ express
function group increas islet pancrea
pancreat patient receptor
respons **secret** studi tumor year

1797: Glycoprotein Hormones, alpha
Subunit (6)

activ case caus cell chang
complex decreas **express** gene
human increas lead promot
region report risk sequenc studi test vector

1799: Procollagen-Lysine, 2-
Oxoglutarate 5-Dioxygenase (4)

clinic cultur event **express** gene incid involv
length mutat normal **patient**
preval process recombin repeat syndrom
system **tissu** women year

1794: Hydrolases (35)

activ analysi associ control
enzym event express gene genet
identifi involv mutat patient polymorph
popul process product role studi
substrat

1796: Fibrin (18)

activ analysi behavior compar
control differ earli effect
factor function human increas inhibit
organ requir sampl studi time tissu tumor

1798: Thyrotropin, beta Subunit (1)

chang circadian clock delai feedback
follow hamster long-term loop
month occur **patient**
period persist signal **state**
suggest synchron **time** year

1800: Kv Channel-Interacting Proteins
(4)

acid cell complex differenti dna enhanc
event **famili** gene genet increas
marker member **normal** process
promot rat receptor **tissu**
transcript

1801: Receptors, Dopamine D1 (13)

activ affect analysi associ chang
depress develop disord express function
gene high level low neuron polymorph
receptor respons select
studi

1803: DNA, Circular (41)

analysi construct contain develop dna
element gene genom group
human insert new plasmid
recombin region repeat replic
sequenc structur studi

1805: Acrylamides (11)

acid activ bind blood cell
chang complex develop effect
hybrid increas induc model number
process product radiat respons select
studi

1807: Mineral Oil (2)

care center conclusions dai design
develop dose field health
hospit isol main medic objective patient
record requir servic strain studi

1802: 2,3,4,5-Tetrahydro-7,8-
dihydroxy-1-phenyl-1H-3-benzazepine
(1)

affect alpha alter behavior beta caus
chang cognit decreas develop
development effect increas ligand memori observ
receptor signific treat treatment

1804: Chlorobutanol (1)

adapt associ care effect event exposur
health interv involv nurs particip process
protect radiat ratio reduc reduct risk select
studi

1806: Petrolatum (1)

associ center conclusions confid design
exposur factor hospit interv main marker
medic methods objective patient ratio record
risk smoke studi

1808: Lanolin (2)

approxim care design earli exposur
health hospit late light major medic nurs
phase progress rel servic stage studi
treat treatment

1809: Receptors, Transferrin (44)

analysis barrier cell commun contact
content coupl cytometri determin flow
gap gene increas indic iron
junction level measur select
studi

1811: Antigens, Thy-1 (12)

activ analysis area cell chang earli effect
express gene mice model organ
patient phenotyp report respons role studi
suggest vector

1813: Propranolol (16)

acid cardiac cell dai
differenti effect heart left
level method patient
popul rate receptor
respons size studi subject ventricular
year

1815: Titanium (36)

base compar control data
deliveri differ effici function
group increas light mean
method model new particl
patient studi surfac valu

1810: Integrin alpha6 (7)

activ adhes adult cell cluster
differenti enhanc express form format includ
integrin molecul number phenotyp process
prolifer studi treatment year

1812: von Willebrand Factor (46)

associ bleed coagul control effect
factor folat group homocystein
increas level mthfr patient plasma platelet
risk sampl studi thrombosi venou

1814: Troponin I (14)

assai cardiac control detect develop differ
failur gene heart human
increas left model normal patient sensit test
tissu tumor ventricular

1816: Fluorine (6)

assai compound deriv detect electron
energi form format light method
microscopi morpholog posit repeat resist
sensit structur techniqu
time variabl

1817: Phosphorus Isotopes (7)

cell chang combin dai develop famili
genom **group** high imag level low
number popul posit process product
report **studi** test

1819: KCNQ Potassium Channels (15)

atp ca2+ calcium **channel**
clinic current diagnosi intracellular ion long
model **mutat** process rel releas repeat
role sodium test time

1821: Anion Transport Proteins (15)

associ bone **differ** express famili gene
genet genotyp high **human**
mutat patient pattern
phenotyp polymorph popul sampl
structur studi valu

1823: RNA Ligase (ATP) (6)

acid **complex** dna earli element
enhanc enzym **genom** improv initi
life melanoma new organ qualiti
region rna **sequenc studi**
tumour

1818: Potassium Channels, Voltage-Gated (68)

activ analysi atp ca2+ calcium cam
channel current function gene
group human individu intracellular ion
potassium potenti releas sodium studi

1820: Calmodulin (48)

activ associ atp ca2+ calcium cam cell
channel current differ function
genom human intracellular ion popul rat region
sequenc sodium

1822: Receptor, Melanocortin, Type 2 (4)

associ compar dai **decreas** dose
group high higher
increas interact level low mice
phenotyp posit **rate** studi suggest thyroid
week

1824: Plant Lectins (14)

analysi assai cancer **cell** detect effect
express genom increas
marker model number **peptid** plai
plant role sensit specif studi test

1825: Kanamycin Kinase (9)

abil cell express famili **function**
gene high increas plant product
properti protein rate recombin repeat
resist **select** studi tissu tumor

1827: Quinoxalines (27)

bodi cell control dai detect diet differ
effect group increas larg model new
number patient product
reduc **studi** treatment weight

1829: Indocyanine Green (13)

analysi ASSOCI cone degener gene
group identifi incid level macular
methods optic organ patient photoreceptor
pigment **retin** retina visual year

1831: Indolizines (4)

alter analys **analysi** anim chang
compound data **function** genet model
perform produc product reveal select
structur **studi** variabl vitro vivo

1826: Pyrones (8)

activ caus cell compar compound effect
higher identifi lead lower new produc
product **rate** role studi time treat
treatment versu

1828: Phenylenediamines (8)

acid **activ** analysi assai combin dai
detect develop differ dose effect human
new patient pattern popul posit sensit specif
treatment

1830: Phenanthrenes (16)

activ assai associ **cell** combin
CONCENTR correl develop effect
human increas inhibit mechan
new product signific studi time vitro vivo

1832: rhoA GTP-Binding Protein (49)

actin **activ** **cell** cytoskelet
cytoskeleton filament format function gene
gtpase **migrat** motil myosin polar process
protein regul rho role signal

1833: Integrin alpha4beta1 (11)

adhes blood **cell** demonstr differ
differenti enhanc **EXPRESS** factor
function genet group growth integrin
invas matrix pattern receptor specif structur

1835: Selenoproteins (14)

analysi chang **data** evid express
function gene identifi increas mice
model mrna **mutat**
predict protein **region** sampl
sequenc structur translat

1837: Antigens, CD4 (61)

cd4 **cell** develop express function group
hiv hiv-1 immun immunodefici infect lymphocyt
model new posit t-cell tumor viral viru year

1839: Peptide Hormones (28)

acid bodi control **diabet** function
gene glucos growth healthi
human insulin number obes
rate receptor regul role studi subject
weight

1834: Iodine Radioisotopes (96)

activ adren cell **dose** effect group
hormon imag increas **irradi** measur
patient **radiat** radiotherapi studi
therapi **thyroid** treatment tumor year

1836: Tetanus Toxoid (5)

activ analysi **base** **cell**
cluster differ **differenti** effect
immun **increas** interact local organ
pair plai **prolifer** role **select**
time vaccin

1838: Upstream Stimulatory Factors (18)

activ assai associ bind element enhanc evid
express factor famili **gene** normal number
promot region regul **select** site
tissu transcript

1840: Acrylates (10)

activ compar control develop differ
effect follow **group** higher mechan
model patient pattern **process** produc
product rate requir stimul treatment

1841: PrPC Proteins (12)

caus cell chang **degrad** effect
express finger includ interact involv
ligas pathwai process proteasom
protein rang regul stabil
ubiquitin zinc

1843: DNA, Ribosomal (235)

16s analys analysi bacteri bacteria base close
divers eukaryot gene genu microbi phylogenet
rdna relat relationship rrna sequenc
speci tree

1845: Myosins (48)

actin activ **cell** develop differ
express famili format function loss migrat
mutant rate regul requir **role** small specif
studi time

1847: Metallothionein (29)

cell chang concentr control correl effect
express gene increas
induc level local mice observ
respons select signific studi
time water

1842: Flap Endonucleases (17)

activ content **dna** flow function gene genet
increas mechan model molecular polymeras process
product protein replic role strand studi target

1844: Wnt2 Protein (6)

beta-catenin bind cancer cell conserv effect
express gastric gene genom induc induct
pathwai rat reduc **respons**
signal target tumour wnt

1846: RNA-Induced Silencing Complex (14)

antisens express famili gene genet inhibit
interf interfer knockdown oligonucleotid
protein rate **rna** rna silenc sirna
small studi suppress target

1848: Cullin Proteins (20)

activ complex compon **degrad**
develop finger **function** human ligas
number pathwai phenotyp proteasom
protein regul requir stabil suggest
ubiquitin zinc

1849: Cotinine (9)

associ compar concentr differ
exposur factor genet high higher
increas influenc interv
level measur metabol **rate**
ratio **risk** score studi

1851: Cycloheximide (74)

activ apoptosi **cell** death decreas
differenti effect express human increas induc
inhibit level plai protein respons role studi
suggest treatment

1853: Monosaccharides (9)

bind **cell** compound distribut extract
famili genom local member
method mutat new phenotyp popul
sampl site **studi** subject test time

1855: Receptor, Insulin (44)

activ analysi **diabet** differ
function gene glucos improv increas
insulin larg life pathwai qualiti rate role
signal size small studi

1850: Nicotine (40)

arg associ **code codon** confid
interv nicotin nucleotid odd posit ratio
result **risk** singl smoke stop studi
substitut suggest usag

1852: Puromycin (6)

cell combin concentr decreas
effect express genom
increas life marker model
predict **product** region rel requir
sequenc studi vitro vivo

1854: Serum Albumin, Bovine (26)

analysi concentr detect develop effect
function **group** human increas interact
level model patient produc
product **protein** serum studi
surfac test

1856: Metals (55)

complex concentr condit contamin
degre differ effect **gene** high light
number product protein region
sequenc soil **structur**
studi time water

1857: Starch Synthase (5)

analysi cultivar **differ** distribut
function gene group human hybrid
line local maiz map pattern plai plant rice
role type wheat

1859: Plasminogen Activator Inhibitor
2 (4)

activ affect cancer caus cell copi correl effect
famili invas lead matrix member
number **protein** reduc signific studi
tumor tumour

1861: Anesthetics, Inhalation (28)

case **complic** differ effect follow group
increas manag oper **patient**
perform postop preoper procedur rat
resect risk **surgeri** surgic
underw

1863: Solvents (72)

analysi conform crystal data determin differ effect

energi expos **exposur** extract fraction measur method

rate reduc residu reveal solut

structur

1858: CCAAT-Enhancer-Binding
Protein-beta (34)

activ assai bind cell effect element express
factor gene human increas **promot**
protein rate region regul regulatori site
transcript upstream

1860: Gene Products, nef (15)

cell **express** gene gener herp **hiv**

hiv-1 human immunodefici

infect mechan mutant mutat

region regul sequenc simplex time

viral **viru**

1862: Methyl Ethers (11)

complic concentr dai decreas follow group
increas model oper **patient**
perform postop procedur rate report respons
studi surgeri surgic test

1864: Epoxide Hydrolases (24)

allel associ compar cytochrom develop enzym
gene genet genotyp human increas

metabol metabolit p450
patient polymorph rate risk select studi

1865: Proto-Oncogene Proteins pp60(c-src) (20)

activ associ bind cell demonstr effect
enhanc function inhibit interact **kinas**
peptid phosphatas phosphoryl protein signal
stat3 studi target tyrosin

1867: Anthocyanins (21)

analysi blue captur cell color composit develop
differ effect function gene intens laser
light plant red reduc shed studi time

1869: Corticotropin-Releasing Hormone (20)

alter anim chang compar control
effect high low **model** plai
process **rat** rate receptor respons
role select studi subject thyroid

1871: Cyclin-Dependent Kinase 2 (73)

activ arrest cdk cdk2 **cell** cell-cycl cip1
cycl cyclin cyclin-depend inhibitor
kinas level p21 p27 phase progress prolifer regul
retinoblastoma

1866: Coumaric Acids (9)

acid **activ** cell compar determin effect
enzym gene higher line lower **rate** regul
rice **sampl** specif structur **studi**
tumour wheat

1868: Interleukin-18 (47)

combin **cytokin** develop effect
gene group ifn ifn-gamma il-10 il-6 immun
increas induc inflammatori interferon level
macrophag patient product **respons**

1870: CDC2-CDC28 Kinases (75)

activ arrest cdk cdk2 **cell** cell-cycl cip1
cycl cyclin cyclin-depend inhibitor
kinas p21 p27 phase progress prolifer protein
regul retinoblastoma

1872: Cyclin E (74)

analysi arrest cdk2 **cell** cell-cycl cip1
cycl cyclin cyclin-depend express
inhibitor kinas p21 p27 phase progress prolifer
regul retinoblastoma surviv

1873: Amino Acid Transport System
X-AG (13)

activ associ brain compar control detect
level measur mice **neuron** observ
phenotyp popul protein regul rel score
studi suggest time

1875: Activating Transcription Factors
(3)

adapt **bind** combin domain effect evid
express famili gene induc
member promot protein provid recombin
respons select site
support transcript

1877: Hepatocyte Nuclear Factor 4 (29)

cell compar control diabet differ express
famili **function** **gene** hepat
increas insulin liver mutat patient
promot risk role studi transcript

1879: Emulsifying Agents (2)

absenc approach bodi compar design **effect**
extract higher lipid lower modifi presenc
protect **rate** reduc reduct strategi studi
surfac versu

1874: Glutamate Plasma Membrane
Transport Proteins (7)

alter cell chang control **develop**
differenti express famili
function member modul neg
neuron plai posit **regul**
regulatori role variabl variat

1876: Cyclin A (63)

arrest **cell** **cycl** **cyclin**
cyclin-depend effect express gene high inhibitor
kinas level p21 p27 patient phase progress
prolifer regul retinoblastoma

1878: Glucose-6-Phosphatase (5)

adult cell combin compar **dai** dose
effect form format **group**
interact length mice mutat rat **rate**
repeat score studi year

1880: Membrane Lipids (24)

acid activ amino associ bind cell
chang control distribut famili
group high human increas level
local low membran structur
transport

1881: Sterols (23)

activ associ chang cholesterol develop
famili function group high
human identifi level lipid
model mutat **protein**
rate studi subject time

1883: Ubiquitins (41)

activ cell cellular **degrad** finger
human indic ligas pathwai prion proteasom
protein prp regul requir stabil
suggest tumour ubiquitin zinc

1885: Oleanolic Acid (8)

apoptosi **cell** chang death differenti earli
high human induc level low model new
rate report respons role select studi suggest

1887: Nitrous Oxide (12)

chang **children** concentr
control effect function group increas
min parent potenti produc product select
stimul studi subject test treatment year

1882: Rhodamines (17)

cell determin differ express genet
group high identifi larg level
number posit product role
screen size small **studi** time valu

1884: Gene Products, vpr (10)

analys analysi **associ** cell domain
express **function** gene genet hiv
hiv-1 **human** infect interact
model mutant protein reveal studi viru

1886: Chlorhexidine (6)

alcohol clinic depend design **effect**
estim gener hospit includ medic oral patient
random reduc reduct repeat signific **studi**
subject trial

1888: Butylated Hydroxytoluene (2)

activ assai concentr dai decreas detect
dose extract fraction **increas** induc induct level
mice organ **protein** respond **respons**
sensit week

1889: Free Radical Scavengers (61)

activ antioxidant cell damage free glutathion
increas induc level oxid oxygen
peroxid product protect radic reactiv ros speci
stress superoxid

1891: Picrates (12)

acid activ combin differ dna effect estim
extract high lesion level low method normal oxid
process product stain stress tissu

1893: Analgesics, Non-Narcotic (14)

activ case chain chang children decreas
effect estim follow increas number
patient period reaction risk role
sampl studi time year

1895: Epoxy Compounds (31)

activ analysi base cell chemic
compound concentr
deriv develop dna effect expos
exposur human increas
model product rate structur studi

1890: Edetic Acid (22)

activ analysi assai cell compar
concentr data detect determin differ function
group measur number patient protein
respect sensit site valu

1892: Butadienes (51)

activ cell chang control erk express famili
high human inhibit kinas level mapk
pathwai phosphoryl protein
regul respons sampl signal

1894: Dexmedetomidine (3)

acid assess child children compar
concentr control dai differ evalu
group healthi measur parent
receptor score studi subject trial year

1896: Benzopyrenes (5)

chang code codon combin detect effect estim
exposur gene group interact
model mutat nucleotid region
respons sequenc studi subject substitut

1897: Nicotinic Acids (8)

adapt cell control data effect estim
gene gener improv method multipl
plant process product select
skin studi subject therapi
treatment

1899: Vascular Endothelial Growth
Factor Receptor-1 (46)

angiogen angiogenesi antiangiogen cell
effect endostatin endotheli
express factor growth hif-1alpha hypox
hypoxia hypoxia-induc plai receptor role
vascular vegf vessel

1901: Dinitrobenzenes (7)

anim blood cell concentr densiti form format
function group high
human individu level low model
normal studi tissu treat treatment

1903: Desmoglein 3 (3)

alter assai chang decreas detect differ
effect environment express gene
genet group increas individu
influenc mice mutant mutat reduc sensit

1898: Tetrahydronaphthalenes (10)

associ cell clinic experi express gene
high identifi improv low model organ
receptor respons sampl size studi
therapi time
treatment

1900: HIV Fusion Inhibitors (10)

adapt alter cell chang correl effect
high hiv hiv-1 immunodefici infect isol
low patient reduc resist
select time viral viru

1902: Desmogleins (9)

alter antibodi case cell chang
develop famili gene high
human increas low member mutant mutat
number skin studi test tumour

1904: Desmoglein 1 (9)

analys analysi antibodi assai caus detect diseas
earli form format fusion gene number organ
patient reveal risk skin stage
tumour

1905: Desmoplakins (29)

activ alter analysi associ **cell**
chang develop earli **epitheli**
epithelium **express** function gene
gland group mammari normal patient
select studi

1907: Lymphokines (13)

activ **cell** combin compar control differ
effect **express** featur gene **group** growth
higher human level multipl rate recombin
studi tumor

1909: Fatty Acid-Binding Proteins (19)

acid allel amino analysi associ bind
cell chang concentr **express** fatti gene genotyp
increas polymorph popul protein rate sampl studi

1911: Thyroid Hormones (40)

adenoma adren adult braf control evolut
function group hormon increas level method
normal papillari patient pituitari ret studi
thyroid year

1906: Chemokines, C (2)

cell compar data databas differ enhanc
express **group** identif identifi
increas level mean measur ovarian respect
screen serum therapi valu

1908: Isoquinolines (44)

activ analysi associ **cell** chang
develop drug effect **express** group growth
human increas induc inhibit
respons select tissu treatment tumor

1910: Monocarboxylic Acid Transporters (5)

analysi compar control correl data distribut
evid **express** genom higher **human**
individu local membran mutat rate reveal
state **studi** support

1912: Estrone (23)

activ associ cell develop
express function gene group high
human level mutat **normal**
patient resist role studi **tissu**
tumor variabl

1913: Hematopoietic Cell Growth Factors (10)

analys analysi care cell clinic dai health
inform new particip **patient** regul
respons reveal specif studi target therapi
treatment tumour

1915: Organic Anion Transporters, Sodium-Dependent (7)

cell clone compar control decreas express
genom high higher **human**
increas level low map membran
rate resist respons role subject

1917: Hyaluronoglucosaminidase (15)

analys **analysi** associ cell
express gene genet identifi increas
method product promot
respons reveal role sequenc
studi time trial tumor

1919: Psychotropic Drugs (26)

behavior bipolar children depress differ
discuss **disord** ethic group inform
issu medic model person practic process rate
research studi symptom

1914: HSC70 Heat-Shock Proteins (14)

activ analysi associ cell complex
condit **degre** domain express
famili form function increas
level mutant product **protein**
respons temperatur time

1916: Linoleic Acids, Conjugated (9)

acid amino associ bodi cell control
differenti effect genom group human phenotyp
presenc product prolifer risk sequenc size studi
subject

1918: alpha 1-Antichymotrypsin (8)

cancer **clinic** compar
diagnosi diagnost differ gene
genotyp higher inhibitor level model
patient pattern process rate
select specif treatment valu

1920: Central Nervous System Depresants (25)

abus **alcohol** behavior consumpt control
depend drink drug effect ethanol examin
group increas indic **oral** prefer signific
studi substanc suggest

1921: Cocaine (18)

alcohol behavior caus chang consumpt
depend effect enhanc ethanol increas
method number **oral** prefer role signific
studi substanc suggest system

1923: Tetrahydrofolate Dehydrogenase
(28)

activ confer develop drug famili gene group high level
mdr1 model multidrug mutat patient **resist**
sensit structur suscept test transport

1925: Collagen Type VII (7)

affect base caus cell develop gene human identif
identifi individu muscul **mutat** novel
patient region screen sequenc skin
treatment tumor

1927: Oligoribonucleotides, Antisense
(7)

approach chang decreas differ express
function gene growth
increas muscul new pattern plai provid rna
role strategi target treatment valu

1922: Oxidoreductases Acting on Sul-
fur Group Donors (10)

analysi case cell cluster differ
function gene genet **group**
isol model **phenotyp** protein
respons rrna sequenc size strain
structur test

1924: Protoporphyrins (14)

case cell compar concentr **control**
differ effect enhanc express **gene**
high identifi increas level liver low mice
screen **studi** treatment

1926: Fibroblast Growth Factor 1 (8)

assai cell cluster **cultur** decreas
detect dna fibroblast **function**
increas level mechan medium model
organ product protein structur valu vitro

1928: Methiocarb (1)

anim concentr develop effect establish
experiment exposur human includ method microg
microm min **model** provid rang studi
techniqu varieti wide

1929: Dimethoate (3)

anim cluster compar **control**
develop differ dna effect frequenc
induc inject life model patient point qualiti
rat respons **studi** time

1931: Curcumin (39)

activ assai **cell** construct effect enhanc
express fluoresc genom gfp green increas
inhibit protein report studi **transfect** transient
treatment vector

1933: Butyric Acid (5)

abil acid **assai** carcinoma **cell** chromatin
combin demonstr **detect**
effect enhanc gene histon interact mutant
popul resist sensit vitro vivo

1935: Urea (54)

associ cell **concentr** dimer
effect fold **form** function group high
increas indic low nativ **protein**
solubl **stabil** stabl studi suggest

1930: Sodium Dodecyl Sulfate (18)

activ cell clinic compar control determin
extract form fraction **function** human
increas mean method number protein
requir respect **structur** valu

1932: Dentin-Bonding Agents (12)

blue captur color composit cure dark differ dye
group intens laser **light** method
observ red shed studi test time unit

1934: Surface-Active Agents (30)

activ assai caus clinic detect effect effici
form function group **high** level low
method particl **sampl** sensit
structur surfac test

1936: Polyglutamic Acid (8)

dai differ effect enhanc factor
famili gene high low member
model new patient protein rate repeat
risk studi surviv treatment

1937: Acetylcholinesterase (30)

activ assess carcinogen chemic concentr effect
expos **exposur** frequenc
function genotox increas induc interact mechan
mutagen number organ signific toxic

1939: Protein Synthesis Inhibitors (76)

activ apoptosi **cell** chang death
effect express function gene group
increas inhibit level new **protein**
rate requir studi suggest treatment

1941: Nitrogen (108)

activ compar concentr develop differ
enzym function gene higher increas
measur method plant produc **product**
rate rel speci water yeast

1943: Ecdysteroids (7)

chang characterist decreas detect
develop drosophila
earli express featur femal **gene**
gener genom increas level male
number popul product
respons

1938: Fenitrothion (1)

anim bodi develop dynam ethic experiment
human membran **model**
new paramet predict provid rat research simul studi
technolog transport weight

1940: Fertilizers (13)

concentr data **effect** estim evid
genet **group** increas organ
popul product rang reduc
respons sampl select speci studi
subject water

1942: N-Acetylglucosaminyltransferases (37)

activ bind **cell** conserv develop differ
earli famili **function gene** group
identifi increas **mutat** protein requir
residu role **site** studi

1944: Eukaryotic Initiation Factor-1 (5)

assai **cell** **complex** correl
detect express form format **high**
level low mrna phenotyp plai
regul **role** sensit stimul translat
tumor

1945: Hydrazines (16)

cell compar complex concentr correl
differ drosophila effect function
higher increas **interact** number
pattern protein **rate** specif
structur target treatment

1947: Fluorocarbons (17)

associ compar control dai effect
group imag increas mice normal
number rat rate retin **sampl**
structur studi tissu **treatment** visual

1949: Androstadienes (59)

activ akt breast cancer
cell effect egfr factor growth
increas inhibit kinas new plai
receptor **respons** role
signal studi **treatment**

1951: Barium (7)

cell channel compar **control**
correl dai decreas distribut dose featur
increas local method model
respons **sampl** signific structur
studi subject

1946: Deuterium (22)

analysi base carbon chang compar
control data effect **energi** extract
group higher level measur **method**
protein rate solut state
structur

1948: Peroxynitrous Acid (15)

antioxid compar concentr **control**
dai earli effect function higher increas
mechan molecular **oxid** oxygen
rate reactiv stage stress subject
synthesi

1950: Narcotic Antagonists (7)

alcohol consumpt decreas depend
effect ethanol **increas**
interact level new **oral** provid receptor
reduc region risk sequenc signific studi time

1952: Carbonic Anhydrases (29)

carbon **cell** chang correl electron
endotheli **energi** **express** group
high level low measur number
patient **protein** reaction solut tumor
tumour

1953: Itraconazole (10)

area case chain clinic concentr dai detect femal
group isol male method mutat number
patient reaction respons sequenc
sever treatment

1955: Heme Oxygenase-1 (21)

analysi ASSOCI cell chang compar
control correl decreas differ
gene group higher increas induc
level oxid **respons** role
signific treatment

1957: Poly G (4)

activ analysi clinic cluster
differ distribut enhanc featur
genom local mechan **model**
moleculer pattern **region** repeat
sequenc similar speci target

1959: Calcifediol (11)

bone cell clinic concentr correl dai
develop express **function**
group higher **human** incid individu
level mortal rate treatment women year

1954: Heme Oxygenase (Decyclizing)
(32)

antioxid associ cell damag effect gene
increas induc level mechan **oxid**
oxygen protect radic reactiv reduc respons
ros speci stress

1956: Phosphorus Radioisotopes (14)

cell combin compar complex differ dna
effect famili form **group** higher
organ plai rat **rate** role select
structur test tissu

1958: Poly T (10)

activ associ base control dna effect
form format function gener genet
model plai region role
select sequenc studi subject test

1960: 25-Hydroxyvitamin D 2 (1)

analysi analyz **assai** collect correl
detect determin evalu extract index
mass method monitor relationship
sampl sensit signific specif
techniqu test

1961: Hydroxycholecalciferols (2)

approxim clinic correl **develop**
distribut extract incid level local major
method period point random rel
techniqu therapi **time** treatment trial

1963: Antisickling Agents (4)

adult base care correl defici differ diseas
genet **group** health inform method
new nurs particip patient provid
signific treatment year

1965: NF-kappa B p52 Subunit (4)

activ cell chemokin complex
express factor gene induc
inhibit mechan molecular necrosi
nf-kappab nuclear plai requir **role**
target tnf tnf-alpha

1967: Antigens, Protozoan (40)

analysi differ effect evalu hypothesi infect isol malaria

method parasit perform posit region sampl sequenc

signific statist strain studi **test**

1962: Factor VII (33)

analysi associ bleed chang coagul effect
factor folat homocystein leiden
mthfr mutat plasma platelet risk studi
thrombin thrombosi time venou

1964: Fetal Hemoglobin (15)

analysi anemia cell chang codon defect
defici gene genom level model
normal patient plai respons role sampl
select sever treatment

1966: Racemases and Epimerases (18)

acid analysi **cancer** clinic correl
diagnosi differ express gene group marker
normal patient product prostat protein report
signific studi tissu

1968: Malaria Vaccines (18)

adapt antigen differ genet high human hypothesi
immun model new provid respons sampl select
signific specif studi **test** vaccin valu

1969: Platelet Factor 4 (5)

caus concentr **develop** effect factor
group high inhibit lead level low
method model normal **patient**
tissu treat **treatment** tumor valu

1971: Placental Lactogen (3)

affect alter cell **chang** codon
decreas **differ** diverg duplic
evolut evolutionari express **gene**
growth **increas** observ pattern
state substitut suggest

1973: Pregnancy Proteins (34)

activ birth cell develop differ express factor
fetal function fusion gene growth
human matern pregnanc protein
region sequenc structur studi

1975: Heparin, Low-Molecular-Weight (16)

caus chang clinic cluster develop diagnosi
factor folat high lead level low model
number **patient** platelet risk
studi therapi **treatment**

1970: alpha-Fetoproteins (59)

associ cell compar control differ effect express
gene group hepat hepatocyt high increas
level **liver** marker method normal
patient Tissu

1972: Pregnancy-Specific beta 1-Glycoproteins (3)

activ bind cell element essenti express factor
gene **high** level low method
necessari **promot** protein
requir risk site transcript vivo

1974: HMGA Proteins (6)

cell chang copi data form format gene group
high increas **interact** low map model
number protein specif studi
suggest tumour

1976: Factor Xa (10)

activ approach base control data
error estim express factor gener interact
method model mutant new **patient** power
presenc simul statist

1977: Dalteparin (3)

abil approach approxim bodi clinic cluster combin
compar differ effect genet major
patient pattern popul properti rel
similar structur therapi

1978: Lamin Type B (9)

apoptosi base **cell** distribut
earli effect evid form **gene**
increas interact level **local**
nuclear phenotyp process
rate region sequenc support

1979: Morpholines (99)

activ akt cell egf **egfr**
epiderm express **factor** function
growth increas inhibit
inhibitor kinas pathwai pi3k
receptor select signal target

1980: Chromones (79)

activ akt cell egf **egfr** epiderm
factor gefitinib **growth**
increas inhibit inhibitor kinas pathwai
phosphoryl pi3k **receptor** signal
surviv tyrosin

1981: Fetal Proteins (11)

activ associ base cell
domain evolut form
format **function**
gene human local
mechan model molecular
protein regul respons specif
suggest

1982: Nucleic Acid Synthesis Inhibitors (38)

activ cell develop dna earli
effect enhanc function group high level
low plai process **protein** rate role
specif studi suggest

1983: Carboxypeptidase U (8)

adult associ compar **control** detect factor
function **group** level
measur new patient plasma platelet posit risk
serum surviv treatment year

1984: Coagulants (8)

approach cell compar **control** differ
event express frequenc gene **group**
level mechan **mutat** normal number
patient process protein time tissu

1985: Hemostatics (7)

analysi area care CASE clinic data diagnosi
factor gener health increas method
model new process provid studi
subject time valu

1987: Phenytoin (13)

activ cell concentr correl express gene
increas induc metabol patient plai presenc
report resist **respons** role stress
studi suggest treatment

1989: Integrin alpha Chains (15)

activ analysi **cell** chang develop
enhanc **express** featur function
human increas number phenotyp
plai protein regul **role** sampl
select tissu

1991: Platelet Membrane Glycoproteins (11)

allel associ cell correl detect
express form format genotyp
group human plai polymorph
protein ratio receptor respons risk
role studi

1986: Thromboplastin (28)

activ analysi **associ** cell
factor folat human identifi
increas level normal **patient** platelet
product respons role screen studi tissu
valu

1988: 6-Aminonicotinamide (3)

addit caus cell **combin**
demonstr effect endogen **enhanc**
high increas lead level line low map mice
rat report studi suggest

1990: Integrin beta Chains (17)

activ adhes associ **cell** chang
compar decreas differ express
group higher increas integrin local
molecul observ phenotyp rate surviv tumor

1992: Vesicular Inhibitory Amino Acid Transport Proteins (1)

acid amino analysi cdna cell clone code
conserv contain develop **express** fatti
gene ident identifi locat metabol nucleotid region
sequenc

1993: Platelet Glycoprotein GPIIb-IIIa Complex (23)

activ adhes associ bind blood cell
factor famili flow folat form format
function mutant platelet protein receptor
rel requir risk

1995: DNA, Algal (13)

analysi associ base cluster contain differ express
famili **gene** genom high identifi
increas multipl **region** repeat respons
sequenc speci studi

1997: Vasodilator Agents (42)

activ arteri blood coronari dai develop
effect function group hypertens increas
inhibit mutat **patient** pressur
rat respons studi treatment vascular

1999: Oxazoles (24)

activ cell chromosom develop dose
effect gene **gener** **group**
human irradii metabol model new
number product protein radiat rat
target

1994: Phospholipase D (15)

acid activ cell decreas develop
function high human identifi
increas interact level
new produc **product**
provid regul role signal size

1996: Nadroparin (3)

bone cancer case characterist common dai
effect evolut factor featur mean mice
microscopi morpholog **test** treat
treatment valu vitro
vivo

1998: Central Nervous System Agents (9)

analysi combin data differ
effect enhanc gener
genet method model popul
predict **product** research
role select signific studi
variabl variat

2000: E2F1 Transcription Factor (52)

analysi arrest **cell** chang **cycl**
cyclin cyclin-depend express group inhibit
inhibitor kinas p21 p27 phase progress prolifer
rate regul respons

2001: Angiotensin II (51)

ace activ **arteri** blood
cardiovascular CORONARI human
hypertens increas infarct ischেম
ischemia myocardi **pressur** protein
respons stroke vascular vein vessel

2003: Histidine (106)

activ analysi bind cell function gene genom
human increas interact mutant
mutat patient protein rate
residu sequenc **site** structur studi

2005: Nucleic Acid Heteroduplexes (28)

assai associ base bind complex control detect differ
dna hybrid interact number popul probe
replic select sequenc structur studi time

2007: Cysteine Proteinase Inhibitors (73)

activ **apoptosi** apoptot
cell death degrad differ effect
bcl-2 **cell** death degrad differ effect
enhanc express gene increas induc inhibit
inhibitor pathwai **protein** studi suggest

2002: Receptors, Angiotensin (12)

analysi arteri control dai effect function
gene genet human hypertens measur
respons model patient pressur receptor
score specif studi treatment

2004: Sex Hormone-Binding Globulin (12)

activ control cycl effect femal follicl

hormon increas influenc

level male ovarian patient

pregnanc reproduct steroid

stimul studi subject **women**

2006: Leupeptins (34)

activ cell **degrad** enhanc finger gene
high increas level ligas low mechan pathwai
process proteasom **protein** stabil
suggest ubiquitin zinc

2008: Diacylglycerol Kinase (6)

acid codon control enhanc
function gene high identifi
increas inhibit level low mice model
patient plai role screen specif suggest

2009: HIV Core Protein p24 (11)

cell correl express gene gener genom
group hiv hiv-1 infect inhibit protein
regul repeat select signific studi variabl
vector viru

2011: Synaptotagmin II (3)

abil approxim cell decreas demonstr
develop development enhanc
essenti express gene high increas level low
major mice mous rel requir

2013: Anisoles (8)

anim compound concentr data determin
exposur extract flow fraction genet level
model organ possibl product region
sequenc studi time valu

2015: Antibodies, Protozoan (21)

activ antibodi antigen area assai cell compar

detect develop differ gene higher infect level

method number rate sensit studi test

2010: Ethyl Methanesulfonate (14)

analysi caus cell combin control dna effect
exposur function identifi increas
level mutant mutat
patient respons sampl screen studi
wild-typ

2012: Antilipemic Agents (23)

associ cell cholesterol clinic effect factor

human identifi increas level lipid

lipoprotein new patient product

respons risk studi treat

treatment

2014: Protozoan Vaccines (5)

anim assai combin compar control
detect effect experiment immun infect life
method mice model resist sensit
specif studi subject treatment

2016: Antigens, Human Platelet (17)

base blood circul control count detect
determin differ donor gene group healthi human
lymphocyt method mononuclear pbmc peripher
popul respons

2017: Streptavidin (19)

activ antibody associ **bind** detect
enhanc fish fluoresc high
hybrid increas new normal posit
probe protein situ target tissu
treatment

2019: Proto-Oncogene Proteins c-met (38)

activ block cell chang effect factor function gene
growth hgf induc **inhibit** inhibitor
inhibitori mechan patient prevent role suggest
suppress

2021: Antigens, CD38 (31)

cell combin develop differ differenti
express flow gene group increas individu level
lymphoma normal **patient** phenotyp
progenitor stem surviv tissu

2023: GABA Modulators (12)

alcohol associ clinic cluster combin compar
differ disord effect function gene group
inhibit oral **patient** pattern
receptor stimul studi year

2018: Biotin (47)

activ analysi bind cell defici **detect** enzym
fish fluoresc function **hybrid**
label method number patient probe
protein situ specif studi

2020: Proto-Oncogene Proteins c-cbl (21)

analysi bind **cell** degrad express
famili form gene interact involv patient
protein
PROCESS proteasom
receptor regul respons role suggest
ubiquitin

2022: ADP-ribosyl Cyclase (31)

activ adult analysi **cell** correl differenti
express flow high human increas level low
lymphoma normal **patient** prolifer stem tissu
treatment

2024: Dopamine Agents (7)

activ adult associ combin
control data differ disord effect
express individu model neuron popul
produc **product** size studi
treatment year

2025: Serotonin Uptake Inhibitors (39)

adhd affect anxieti associ behavior bipolar chang

depress **disord** find major mental
person psychiatr respons serotonin sleep studi
symptom treatment

2027: MutS Homolog 2 Protein (102)

adenoma adenomat apc **cancer**
colon colorect crc dna famili genet
instabl microsatellit mismatch mmr msi polyp polyposi
protein repair studi

2029: Water Pollutants (30)

area caenorhabd concentr contamin dispers

ecolog **elegan** forest habitat method

natur nematod region rel sea season soil

speci studi water

2031: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (4)

base compar dai data differ **gene** high

higher level low lower mice multipl mutant pair

rate respect specif time versu

2026: Immunoglobulin kappa-Chains (23)

analysi assai associ **cell** detect differ dna

evolut **gene** genet genom high level

measur process score sensit sequenc studi

tissu

2028: Ammonia (19)

associ base **cell** chang concentr

develop effect function

gene genet high human increas

level popul product risk select **time**

water

2030: Carbon (117)

carbon chang determin develop **dose**

effect electron **energi** free **irradi**

measur model number **radiat**

radiotherapi rate solut time water yeast

2032: Tyrosine 3-Monooxygenase (51)

associ brain cell data detect evid express

function **gene** high level model mutat

neuron number rat sampl studi

suggest synapt

2033: Calcitonin (20)

alter associ cell **chang** children clinic
decreas develop earli increas **level**
marker measur **patient** risk sampl serum
stage studi year

2035: Carboxypeptidases (16)

ASSOCI base cell develop differ
effect express function **gene**
genom group human increas mice new
process protein rat select studi

2037: Antigens, CD31 (59)

angiogenesi **cell** combin control dai
differ **endotheli** factor gene
group growth human hypoxia mice role
tissu tumor vascular vegf vessel

2039: beta-Synuclein (4)

approxim **diseas** evid form format
function inhibit length long mechan protein
provid region rel repeat sequenc short specif
suggest support

2034: Diazinon (6)

allel assai assess cell chemic dai detect dose
effect expos **exposur** gene
genotyp increas **mutat** polymorph region
sequenc **studi** toxic

2036: Vascular Cell Adhesion Molecule-1 (53)

activ adhes angiogenesi **cell**
chang control develop
endotheli express factor
growth **human** level model
patient studi **subject** tissu
vascular vegf

2038: Complementarity Determining Regions (37)

analysi antibodi **cell** clone control differ
gene genet group human identifi nucleotid
patient popul **region** reveal role
sequenc structur tissu

2040: gamma-Synuclein (5)

bind delet diseas effect femal **function**
gene interact male mechan mice molecular
mutant potenti presenc **protein**
recombin reduc tumor tumour

2041: Aspartic Endopeptidases (52)

abeta **accumul** activ amyloid
caus cell character deposit diseas enzym
express gene lead lysosom precursor report
residu site storag suggest

2043: MAP Kinase Kinase Kinase 5
(13)

activ apoptosi cell death detect erk
express form format identifi induc inhibit
kinas mapk pathwai
phosphoryl protein regul screen
signal

2045: Semicarbazides (2)

applic assai avail chain concentr data detect
follow includ mass **method** produc
product rang reaction sensit
sourc techniqu wide yield

2047: 4-Butyrolactone (18)

acid **activ** bind chang compar
complex concentr **control** dai **differ**
express **group** identifi increas
protein rate respons select studi time

2042: Erythropoietin, Recombinant
(37)

abnorm anemia caus defect **defici**
disord epo erythrocyt erythroid erythropoietin g6pd
group hemoglobin normal patient product report
respons sever studi

2044: Cantharidin (4)

approach cell complex data differ dna famili human
induc induct member mice receptor respond
respons studi subtyp tumor vitro
vivo

2046: Benzaldehydes (5)

behavior concentr **differ** experi extract fraction
gener individu mix model mutant pattern
phenotyp popul produc
product risk select studi yield

2048: Depsipeptides (23)

activ cell chromatin
effect enhanc express gene high
histon human inhibit
mutat presenc **product** protein requir
time transcript treatment tumor

2049: Steroid 17-alpha-Hydroxylase
(27)

allel associ cancer control cycl
follicl **gene** genotyp
group hormon human
number ovarian
polymorph pregnanc
reproduct risk steroid studi
women

2051: Pyrimidinones (14)

associ chang clinic compar differ famili increas
infect level month mutat **patient**
random role studi subject target treatment
trial viru

2053: Parathyroid Hormone (44)

alkalin analysi bmd **bone** calcium
densiti fractur high hip human level miner
osteoblast osteoporosi **patient** skelet spine studi
treatment vitamin

2055: Linoleic Acid (9)

acid activ amino bind cell express fatti
function human increas inhibitor level mean model
protein retino sequenc subject target valu

2050: Ritonavir (9)

clinic compar **differ** event
group involv mean number
patient process
random **resist** respons risk
studi test **treatment**
trial valu viru

2052: Herpes Simplex Virus Vaccines
(7)

compar **effect** express gener higher
hiv hiv-1 incid infect lower mice new protect
provid **rate** reduc reduct state viru
women

2054: Phenylacetates (11)

activ analysi compar control correl
detect develop **effect** enzym higher
identifi increas level **patient** rate receptor
reduc respons screen specif

2056: Arachidonic Acid (29)

acid activ amino analysi cell control
cox-2 effect fatti form format gene inhibit inhibitor
level plai product reduc role subject

2057: Neural Cell Adhesion Molecule
L1 (16)

caus cell chang differ express
function gene lead local mice
mutat neuron normal
patient pattern plai requir
role suggest tissu

2059: Oligoribonucleotides (13)

acid base bind chang
complex decreas differ express
famili function increas
mutat observ region rel rna role
sequenc site target

2061: Antigens, CD11b (25)

activ analysi bone cell develop
differenti effect express factor macrophag
marrow mice number patient process protein
receptor role studi tumor

2063: Zidovudine (24)

analysi associ data develop effect group
herp high hiv hiv-1 human
immunodefici infect level new
popul simplex studi viral viru

2058: Cadmium Chloride (8)

bind caus cell chang combin compar concentr
control earli effect induc induct lead mechan
process protein requir respons
stage time

2060: Antigens, CD11c (19)

activ analysi case cell chang effect
express function high identifi induc mice
model popul process rate requir
respons screen treatment

2062: Zalcitabine (4)

cell dai dose earli
element gene growth high
hybrid insert late level low method
new organ phase presenc resist stage

2064: Annexin A5 (60)

activ apoptosi apoptot associ cell death
develop effect express function human increas
induc inhibit line method number role size
treatment

2065: Calpain (57)

activ associ cell decreas develop effect exercis
express famili gene human increas model
muscl muscular plai role select
skelet smooth

2067: Carbamazepine (20)

associ attempt children condit epilepsi follow
gene gener includ level number patient rate
report resist respons seizur **stress**
studi suicid

2069: Phosphonoacetic Acid (3)

acid aggreg **bind** combin complex
differ distribut effect **form**
format local mutant observ
pattern **phenotyp** protein
region sequenc structur suggest

2071: HIV Antibodies (32)

aids antibodi antiretrovir express gag gene herp
hiv hiv-1 hsv-1 **human**
immunodefici increas **infect** popul
replic simplex subject viral **viru**

2066: Trifluridine (1)

aggreg cell compound densiti deriv
develop development dna
express form format **high** level line low
month new patient technolog year

2068: Transforming Growth Factors (3)

anim correl develop diseas experiment express
featur gene genet isol larg **model**
new paramet provid signific size small specif
studi

2070: SAIDS Vaccines (4)

anim cluster compar control dai dose enhanc
experiment frequenc gene gener growth
human model plai role studi
transfer treatment vector

2072: Seminal Plasma Proteins (9)

analys **analysi** control differ
famili function gene genom
group identifi member number
patient protein region reveal screen
sequenc sperm variabl

2073: Isoantigens (25)

allele analysi blood cell clinic correl develop
diseas express function gene genotyp
group increas level **patient**
polymorph popul studi transplant

2075: Aminosalicic Acids (1)

chronic clinic compar concentr determin differ diseas
inflammatori intestin mean measur methods microm min
paramet **patient** rang ratio respect
valu

2077: Plant Growth Regulators (56)

arabidopsi chloroplast express flower gene genom
germin leaf leav **plant** pollen respons
root seed seedl speci thaliana tobacco tomato
transgen

2079: Cyclophilins (15)

activ analysi chang develop express form gene
genom **human** identifi interact
model **protein** rat role structur target time tissu
treatment

2074: Calgranulin B (7)

analysi cancer carcinoma cell chain
differenti express gene
level neg **patient** popul posit prolifer
protein reaction reveal sampl
studi treatment

2076: Fluorodeoxyglucose F18 (36)

assess comput detect evalu **imag**
magnet measur mri patient perform perfus pet
resolut reson scan studi techniqu tomographi
ultrasound volum

2078: Antigens, CD147 (8)

activ caus cell decreas express function
human increas inhibit invas matrix
new normal plai posit protein respons role tissu
tumor

2080: Angiopoietins (10)

activ angiogenesi complex control
correl endotheli factor **interact**
marker measur normal **number**
product studi **subject** target
tissu valu vascular vegf

2081: Cytosine (88)

allel analysi associ control develop differ
dna epigenet frequenc gene
genotyp human hypermethyl
inactiv methyl mutat
polymorph promot
sequenc studi

2083: Receptors, Endothelin (5)

alter cancer caus cell chang data
distribut growth high lead level local low
point receptor regul target
therapeut therapi time

2085: Thymosin (14)

activ analysi cell chang develop
diseas express gene identifi increas
mice plai product protein receptor role
screen structur studi time

2087: Sialic Acids (18)

acid amino cell control differ
differenti effect express form group
human mechan plai protein rate
respons role studi suggest test

2082: Arabinofuranosyluracil (4)

activ assai base clinic detect diagnosi diagnost
gene human imag magnet
method mice pair rat regul reson sensit techniqu
volum

2084: Serine Proteinase Inhibitors (26)

activ analysi cell control differ enhanc
express gene genet high
inhibitor level low normal number protein
repeat residu site tissu

2086: Proto-Oncogene Protein c-fli-1 (17)

cell decreas develop differ express
famili function gene identifi increas
level plai protein regul role sarcoma studi
suggest target tumor

2088: Nitroprusside (17)

concentr develop effect
enhanc gene human increas induc microg
microm min nitric oxid rat reduc respons
role studi synthas synthesi

2089: omega-N-Methylarginine (8)

activ cell control earli effect express
human increas mice normal oxid rat studi
subject synthas synthesi target test tissu
treatment

2091: SKP Cullin F-Box Protein Ligases (16)

chang control **degrad** develop
growth identifi interact involv ligas
mechan molecular mutant new number
pathwai proteasom **protein**
signal ubiquitin zinc

2093: Polyesters (18)

activ area cell cluster deliveri develop
effect effici enhanc enzym gene identifi liposom
particl patient polym product protein surfac
time

2095: HSP40 Heat-Shock Proteins (13)

caus cell combin condit control **degre**
develop earli **effect** enhanc
increas interact level mice
normal patient protein reduc
temperatur tissu

2090: NADPH Dehydrogenase (15)

activ chang compar **control** develop
function gene **human** increas
modifi neuron number product rate region
respons role sequenc signific studi

2092: G-Box Binding Factors (3)

cluster compar **control** critic differ
essenti frequenc interact larg mutant normal
number plai requir respons
role site size small tissu

2094: Hydroxybutyrates (8)

activ analysi **clinic** combin compar
control diagnosi diagnost effect
enzym extract group
mutant new organ presenc reveal structur
studi substrat

2096: DNA-(Apurinic or Apyrimidinic Site) Lyase (33)

atm base break checkpoint comet **damag**
dna double-strand dsb excis foci gene human
increas induc lesion pathwai **repair** strand studi

2097: DNA-Formamidopyrimidine Glycosylase (7)

activ break cell compar concentr **damag**
differ **dna** higher larg model
patient phenotyp rate repair size
small state subject test

2099: Deoxyadenine Nucleotides (5)

assai compar control detect differ **dna**
enhanc group high higher
increas level low **rate** rel respect select
subject suggest valu

2101: Sulfur (30)

analysi cell cluster concentr data differ
effect function **gene** group organ
patient protein rate rrna **sampl**
select similar speci water

2103: Phosphorus (42)

bone compar concentr data differ
group higher level mean measur
method organ patient popul
rate respect respons speci valu
water

2098: Holliday Junction Resolvases (1)

absenc compar **control** differ
dna endogen enhanc frequenc head higher
increas indic modul observ **presenc** promot regul
regulatori replic suggest

2100: Framycetin (1)

chromatographi column **concentr** contain
determin **extract** fraction
high-perform hplc light liquid method microg
microm min **prepar** purif purifi respect separ

2102: Arsenic (21)

area cell concentr data differ
effect examin form format gener high
increas individu locat mechan **primari**
sampl secondari **studi** suggest

2104: Disinfectants (14)

analysi area compar **control** dai data
differ effect exposur larg
method number rate sampl
size small **studi** test time tissu

2105: Trihalomethanes (3)

approxim area base care data
develop distribut health
human identifi includ local
major pair program rat rel screen
studi treatment

2107: Cyclosporine (91)

acut allograft autolog condit dai diseas

donor follow graft gvhd hematopoiet

immunosuppress patient receiv recipi reject stem

surviv **transplant**

2109: Nucleocapsid Proteins (32)

acid activ analysi dna express genom hbv hcv
hepat host increas **infect** protein replic reveal
sampl studi viral **viru** virus

2111: Follicle Stimulating Hormone,
beta Subunit (4)

analysi chain children combin complex conserv
effect encod **gene** genom identifi
mammalian **mutat** number predict
promot region sequenc studi women

2106: Air Pollutants, Occupational
(27)

area assess carcinogen chemic differ effect expos
exposur field function gene
genotox increas indic induc mutagen observ studi
toxic valu

2108: Interferon Alfa-2b (28)

associ clinic compar control dai express
group human month **patient** rate
respons risk signific studi surviv treat
treatment trial viru

2110: Receptors, Thromboxane A2,
Prostaglandin H2 (7)

associ caus **cell** decreas differenti
evid express **function** gene
group increas inhibit method
patient plai promot receptor
requir respons role

2112: Caveolin 1 (37)

activ cell cellular control effect endoplasm
express gene human intracellular local
membran plasma product
protein surfac traffick **transport** uptak
vesicl

2113: Caveolins (43)

activ cellular effect endoplasm express function
gene human intracellular local
membran plasma protein
role studi surfac traffick transport uptak
vesicl

2115: Protein S (11)

activ approxim cell clinic diagnosi
differ factor **famili** health life member
patient platelet **protein** qualiti rel risk
specif subject test

2117: Xenobiotics (55)

activ chemic cytochrom develop drug effect
enzym expos **exposur** function gene
identifi increas mechan **metabol**
metabolit model p450 studi toxic

2119: Dehydroascorbic Acid (5)

acid amino compar concentr
control data detect genom measur
method mutat plai product
rat role score sensit sequenc structur
techniqu

2114: Insulin-Like Growth Factor Binding Protein 3 (49)

autocrin control effect **factor** final grow
growth height hormon igf igf-1 igf-i
igf-ii igfbp-3 increas insulin-lik receptor role statur
stimul

2116: Fibrinogens, Abnormal (5)

assai **ASSOCI** chain character characterist
clinic common detect diagnosi distribut
featur local morpholog mutat
patient pcr reaction receptor
sensit test

2118: Photosystem II Protein Complex (32)

activ carbon electron **energi**
exchang fluoresc free **gene** increas
measur mol mutant properti proton solut
spectra spectroscopi state studi transfer

2120: Molsidomine (3)

acid amino chines concentr dai decreas differ
endogen **enhanc** heterogen
increas level oxid reduc region
sequenc studi subtyp suggest target

2121: Bronchodilator Agents (22)

airwai allerg analysi **asthma**
cftr cystic dai data effect estim
fibrosi genet ige method
pulmonari **respiratori** respons
studi test treatment

2123: Cholesterol, Dietary (13)

analysi bodi cholesterol concentr
function gene high higher
human level lipid low
mice patient plasma rate time tissu
treatment weight

2125: Trihexosylceramides (12)

accumul activ caus clinic control design
diseas form function hospit individu
level measur normal **patient** serum studi
subject tissu treatment

2127: Lipoprotein Lipase (31)

apoe apolipoprotein associ atherosclerosi
chd **cholesterol** concentr effect hdl
increas ldl level **lipid**
lipoprotein metabol plasma studi total
triglycerid variabl

2122: Tetrahydrofolates (8)

acid **activ** analysi correl differ factor
form format human
increas interact mutant normal
patient product protein risk
size tissu variabl

2124: Edeine (1)

continu declin delai **express** expression
follow infect initi long-term mrna occur occurr persist
protein recoveri remain spontan sustain
translat viru

2126: Vasotocin (2)

acid alpha beta bind brain code codon evid
hospit mean nucleotid peptid posit provid
receptor singl substitut
suggest support valu

2128: Transferrin (48)

barrier clinic commun connexin contact
coupl form function **gap** genet hfe indic
iron junction
patient protein site studi suggest tight

2129: Endoribonucleases (46)

activ develop express famili function gene
melanoma member mrna mutat patient
polymeras process protein respons **rna**
structur studi target translat

2131: Glutaryl-CoA Dehydrogenase (5)

analysisi caus children cluster
concentr decreas **develop**
enhanc **increas** mice month
normal patient product report
reveal **specif** studi tissu year

2133: Glutarates (13)

acid amino assess children clinic earli
evalu fatti group measur normal patient popul
retino score stage structur studi time tissu

2135: Nitric Oxide Synthase Type III (95)

decreas demonstr effect enos incorpor
increas induc inos investig level nitric oil
oxid product reduc studi suggest
synthas **synthesi** thymidin

2130: Carnitine (37)

abnorm **acid** anemia caus concentr control defect
defici epo erythrocyt erythroid
erythropoietin express group hemoglobin normal
protein sever studi tissu

2132: Receptors, Glutamate (14)

affect bind chang control
function gene identifi larg
mutant neuron new normal patient receptor
respons sampl screen size small tissu

2134: Tryptophan Oxygenase (9)

blood cell combin compar control differ
earli effect express function **gene**
genet **increas** local observ pattern protein
region sequenc transfect

2136: Nitric Oxide Synthase Type II (108)

decreas demonstr effect enos incorpor
increas induc inos investig level nitric oil
oxid product reduc studi suggest
synthas **synthesi** thymidin

2137: Ubiquitin Thiolesterase (14)

analysi **associ** diseas famili form
format function gene genet group identifi
mechan method model protein repeat
respons reveal role studi

2139: Baclofen (11)

alpha beta compar control dai differ effect
follow **group** human inhibit oral
patient persist **receptor** requir
respons signific studi time

2141: Californium (4)

area compar **dose** effect enhanc exposur
fraction higher ioniz **irradi** lower new
radiat radiation-induc radiosensit
radiotherapi **rate** rel variabl versu

2143: Cholinesterase Inhibitors (33)

carcinogen chemic control correl diseas effect
expos **exposur** genotox group
increas level mutagen patient rate respons
signific studi toxic treatment

2138: Muscle Relaxants, Central (10)

children **condit** **degre**
delai effect follow high low oral
patient persist phenotyp requir resist
sampl select studi temperatur
time **treatment**

2140: Drugs, Investigational (27)

base cancer **clinic** effect health improv
new provid random research resist
respons role select studi **target**
therapeut therapi
treatment trial

2142: Phorbol Esters (17)

activ cell chain effect enhanc express
function gene human interact kinas phosphoryl
promot protein reaction report role studi suggest
target

2144: Tosylphenylalanyl Chloromethyl
Ketone (3)

activ apoptosi caus content determin enzym
evid flow **human** inhibitor lead
mean measur organ provid receptor site
support system valu

2145: Tosyllysine Chloromethyl Ketone
(3)

activ apoptosi case cell compar
control effect enzym evid
exposur famili frequenc inhibit
member provid releas remain stimul substrat
support

2147: Contrast Media (73)

assess comput detect evalu imag
magnet measur method mri patient perform
perfus pet resolut reson scan techniqu tomographi
ultrasound volum

2149: Potassium Chloride (28)

activ associ base cell chang
concentr develop differ effect function
gene group human increas level
product rat respons structur studi

2151: Smad2 Protein (45)

beta bmp cartilag chondrocyt collagen
express factor factor-beta fibroblast
growth induc regul signal
smad smad4 sox9 tgf-beta tgf-beta1
tgfbeta transform

2146: Botulinum Toxin Type A (24)

bacillu bacteri coli compar control
correl escherichia group increas
operon phage product protein rate respons
strain studi toxin treat treatment

2148: Gentamicins (22)

combin compar control differ express
gene group high higher host
infect low new pathogen plasmid rate
recombin resist sequenc
treatment

2150: Activin Receptors, Type I (24)

analysi chondrocyt data express factor function
growth increas involv patient
process rate receptor role signal studi tgf-beta
tgf-beta1 transform tumor

2152: Methyl-CpG-Binding Protein 2
(42)

abnorm analysi anomali associ congenit cpg
defect dna epigenet femal gene hypermethyl
inactiv male methyl
methyltransferas p16 promot statu
syndrom

2153: Receptors, Dopamine D4 (27)

adhd anxiety associ behavior bipolar depress

disord find gene group major mental
person psychiatr receptor sampl serotonin sleep
studi symptom

2155: Phosphatidylethanolamines (27)

activ complex control deliveri
effect effici gene group **high** increas level
low method partiel produc product properti
size studi surfac

2157: Retinaldehyde (10)

acid amino analysi base combin data **differ**
effect form light new period point provid rate
regul retin size **time** visual

2159: Malate Dehydrogenase (9)

activ allel analysi associ core
correl encod enzym femal function
genom genotyp identifi male open
polymorph rat read reveal sequenc

2154: DNA (Cytosine-5)-
Methyltransferase (67)

aberr cpg demethyl dna epigenet gene
hypermethyl inactiv island mechan
methyl methyltransferas mgmt p16
promot rassfla region silenc statu suppressor

2156: Vitamin A (35)

acid **activ** associ care **concentr**
control develop function group health
higher human increas **level** measur
plasma product role serum studi

2158: Pentylenetetrazole (3)

adult approxim behavior compar control dai differ
enhanc **group** high higher level low
mice normal rat rel signific tissu year

2160: Freund's Adjuvant (10)

acid **activ** analysi area cell dai
develop dose **express**
group high level low
mice mous plai protein **rat**
receptor **role**

2161: Antibodies, Helminth (11)

analysi antibodi area assai bovin clinic
collect detect diagnosi differ group incid
patient product **sampl** sensit
specif studi test time

2163: Mannose-Binding Protein-Associated Serine Proteases (6)

complex function gene gener genom individu
larg **level** patient peptid
plasma rang role sampl serum size studi
subject surviv tumour

2165: Anthelmintics (14)

anim case data develop differ effect famili
group improv model number patient rate
report select studi therapi treat
treatment year

2167: Nuclear Receptor Coactivator 2 (17)

activ analysi bind cell chromatin
function gene histon increas
interact involv model posit
process protein **receptor** respons
studi transcript tumor

2162: Complement C4 (8)

analysi chang clinic dai
diagnosi effect function gener
group high level low
model mutant peptid popul produc
product respons specif

2164: Albendazole (6)

approach **case chain** clinic
data detect famili health method
organ **PCR** phenotyp polymeras
quantit **reaction** real-tim
report revers **therapi**
treatment

2166: Antiparasitic Agents (8)

activ bind concentr data
differ effect
function identifi inform mechan
model new phenotyp process
provid reduc research **resist**
risk target

2168: tRNA Methyltransferases (9)

activ **analysi** cell complex effect
function gene genom
human model modifi mrna
mutant mutat product protein requir
reveal suggest translac

2169: RNA, Transfer, Lys (10)

activ american develop ethnic evid express
gene genet mrna mutant number
patient phenotyp popul region
sequenc **structur** suggest
support translat

2171: Vitamins (32)

associ **bodi** chain data develop diet effect
evid **group** health increas patient
provid reaction risk studi support treatment
weight year

2173: Receptors, Purinergic P1 (8)

associ chang compound dai diseas dose
effect evid **group** high low
new process protein provid rat
receptor reduc role treatment

2175: Potassium Channel Blockers (23)

activ atp ca2+ calcium cam
channel control current differ
effect group intracellular ion potassium potenti
protein releas sodium stimul treatment

2170: Peptide Termination Factors (13)

activ chain codon differ high increas
initi level mechan **mrna** **protein**
reaction ribosom rna role select suggest time
translat trna

2172: Methylcellulose (4)

assai assess base cell detect genet
human initi length measur
method origin pair **popul** repeat
resist **sampl** score sensit tumour

2174: Diacetyl (1)

CAUS channel compar consequ data death decreas
evid follow hypothesi **increas** lead
level mechan persist provid reduc regul result
support

2176: Theophylline (17)

activ cell control earli
effect function gene group
inhibit **metabol** method mice process
protein rat reduc role size small time

2177: Antigens, CD15 (13)

analysi case **cell** chang clinic
control diagnosi differ express form format
group lesion posit presenc report
stem **studi** subject test

2179: Eflornithine (10)

activ adapt cell correl dai decreas dose
effect human increas inhibit mice mous posit
relationship sampl **select** signific studi test

2181: Cyclin-Dependent Kinases (170)

arrest cdk cdk2 **cell** cell-cycl cip1 **cycl**
cyclin cyclin-depend gene inhibitor kinas p21
p27 phase progress prolifer protein regul
retinoblastoma

2183: Cholagogues and Cholaretics (5)

base case enhanc hepat high level liver low
marker mean mechan molecular
patient presenc rat ratio report
respect risk valu

2178: Spermidine (10)

adapt compar competit control differ direct effect
environ evolut evolutionari fit gener group **natur**
respons risk sampl **select** tissu treatment

2180: Putrescine (11)

activ adapt cell competit concentr control dai decreas
environ evolut evolutionari fit gene gener increas level
natur **select** studi tissu

2182: Receptors, Bombesin (10)

activ alpha antagonist assai beta cell detect
express inhibit ligand normal number posit
protein **receptor** sensit studi
target tissu treatment

2184: Antacids (5)

approach base compar **data** effect error
estim increas inform method
new number particip provid random
rate specif statist studi trial

2185: Proton Pumps (20)

activ affect analysi assess associ base case
clinic cluster data gastric group measur
model **patient** report score
studi time treatment

2187: Sulfhydryl Compounds (36)

activ concentr correl effect high level
model **oxid** oxygen patient product
protein reactiv reduc residu role sampl
site stress studi

2189: Pyrimidine Dimers (31)

activ assai associ break control **damag** detect
dna form format group increas involv
lesion process **repair** respons sensit skin studi

2191: Cytochromes f (2)

blood color compar composit data differ
enhanc estim higher intens laser **light**
lower method mutant plant **rate** red
studi versu

2186: Carboxypeptidase B (3)

acid area case clinic conform crystal diagnosi
diagnost level locat patient region report residu
sequenc sever site **structur** studi
treatment

2188: Glycophorin (13)

activ bind blood **cell** develop differenti
form format gene **human** increas
model peripher process prolifer protein respons
specif studi subject

2190: Lyases (11)

acid **activ** analysi associ base
chang combin **differ enzym** famili
genom identifi mutant observ pair
plant protein screen **studi**
substrat

2192: Chemotactic Factors (19)

activ **cell** chang duplic **evolut**
evolutionari **express** famili
function gene genet genom
human larg protein receptor respons
size suggest tissu

2193: Receptors, Odorant (24)

control differ diverg drosophila
duplic evolut evolutionari
evolv express famili function gene
genom human lineag origin receptor
respons speci suggest

2195: Sulfones (37)

activ cell chain cox-2 develop effect group
increas inhibit inhibitor
number rat reaction resist role structur studi
target treatment trial

2197: Histone-Lysine N-Methyltransferase (34)

acetyl activ chromatin complex
deacetylas develop gene hdac
histon mechan methyl modif
nucleosom recruit regul remodel repress role
silenc transcript

2199: Aspartate-Ammonia Ligase (5)

cell cluster correl differ enzym express
high insight level low mechan new
pattern provid requir select site studi tumour
understand

2194: Insulin-Like Growth Factor II (53)

bird chicken determin differ effect factor gene
growth height hormon igf-i imprint
includ individu insulin-lik japanes level risk studi
suggest

2196: Lactones (61)

activ cell chain
compound deriv effect
enzym human inhibit
inhibitor method model
product reaction sampl select structur
studi time treatment

2198: Receptor, Endothelin B (12)

cell clinic effect express
famili genom high identifi interact
member mice mutat new product random
receptor regul studi subject
trial

2200: Glucosylceramides (7)

accumul ASSOCI cell children correl
diseas enzym express form
format genet model patient presenc product
ratio risk studi subject therapi

2201: Receptors, IgE (27)

activ analysi **cell** develop differ express famili
function gene genet human increas lymphoma mechan
patient receptor regul respons studi tissu

2202: Amphibian Venoms (2)

acid analysi cell china chines clone
determin **differ** gene heterogen
mechan model
molecular observ respect sequenc
signific **studi** subtyp underli

2203: Bufanolides (1)

analysi cell chines determin differ express
heterogen independ **new** predict
produc **product** provid
regress relationship signific studi subtyp
variabl variat

2204: Protein Kinase C-alpha (24)

activ analysi associ cell concentr
control earli effect erk express inhibit
kinas mapk mutant pathwai
phosphoryl protein reduc signal
studi

2205: Carbazoles (23)

activ **cell** clinic decreas effect enhanc
express identifi increas inhibit
inhibitor kinas **patient** process
reduc risk screen studi therapi treatment

2206: Benzeneacetamides (2)

associ case cell cycl follow-up gener
kinas link median month **patient**
protein rang recurr relat report studi therapi
treatment year

2207: Piperidones (3)

activ cell copi demonstr effect find
gener increas inhibit marker month multipl
number patient peptid previou report
stimul studi tumor

2208: Filgrastim (24)

advanc cell chemotherapi clinic dai diagnosi
dose effect **patient** phase rate
receiv regimen respons surviv therapi time toxic
treatment week

2209: Isoprostanes (4)

anim concentr control **high** larg
level local low method model
organ plai produc **product** rat
remain role size small subject

2211: Receptor, Fibroblast Growth Factor, Type 4 (6)

allel analysi associ case develop enhanc
express gene genotyp increas
polymorph popul rate rel report risk role
studi suggest tumor

2213: Tegafur (47)

advanc **chemotherapi** combin cycl
dai docetaxel dose grade median metastat
month **patient** phase receiv
regimen respons studi surviv toxic
treatment

2215: DNA, Chloroplast (36)

analys base data divers gene genet genom group
phylogenet plant **popul** region relat
relationship sequenc **speci** structur
support tree variat

2210: Glutamate-Cysteine Ligase (12)

base **cell** differenti **express**
gene inhibit level measur mice modifi mrna
mutant new oxid plant protein serum stress
target test

2212: Organophosphorus Compounds (46)

activ assai **base** clinic
combin detect develop
differ **effect** exposur
genet human increas
method patient sequenc size
structur studi treatment

2214: Uracil (44)

activ chemotherapi combin compar control
correl differ **dna** effect group high
patient phenotyp process rate
respons studi surviv toxic treatment

2216: Bilirubin (32)

activ analysi bile chronic compar concentr detect
hepat hepatocyt higher increas level
liver measur patient rate respect
sensit serum valu

2217: Dihydrouracil Dehydrogenase (NADP) (31)

cancer case **cervic** correl
develop gene group hpv human
marker normal **patient** posit
sampl signific studi **surviv** time
tissu treatment

2219: Inositol (13)

acid **activ** anim condit decreas degre
detect diseas effect enzym genom imag
increas level model reduc **respons**
sampl specif studi

2221: Prostaglandins (19)

cell cox-2 effect form format function gene
inhibit **inhibitor** mechan
potenti prevent produc product role stimul
suggest time tissu treatment

2223: Platelet Activating Factor (8)

activ alter **chang** combin decreas
effect group human **increas** length long
model patient protein **repeat**
respons short tandem time
treatment

2218: Gastrins (18)

analysi **cancer** cell compar differ effect
express **gastric** group higher
increas mice mucosa new pylori rate respect
studi Tissu treatment

2220: Thromboxane B2 (6)

acid blood combin compar concentr dai effect
enhanc **group** high **increas** level
low method rat receptor serum time treat
treatment

2222: Arachidonate 12-Lipoxygenase (6)

acid analysi approxim cell decreas enhanc
form format **human**
increas inhibitor level line
method mutat produc product protein rel
reveal

2224: Proto-Oncogene Proteins c-mos (7)

activ associ caus cell children
chromosom divis evid inhibit larg
microtubul mitot organ remain **requir**
risk size small spindl support

2225: Nocodazole (43)

associ **cell** centrosom chromosom
cycl detect **divis** earli function human
increas local meiotic **microtubul** mitosi
mitot protein role segreg spindl

2227: Hydralazine (10)

africa **african american** asian
black caucasian differ **ethnic**
european frequenc genom group indian
north origin **popul** preval race
south **white**

2229: Cardiovascular Agents (11)

african american asian black
caucasian develop differ **ethnic**
european genom group **number**
patient popul preval
race respons south studi **white**

2231: Benomyl (6)

assess **caus cell** concentr condit dai
degre **develop** electron **gene**
human isol lead measur
microscopi morpholog pathogen rat score
treatment

2226: Contractile Proteins (34)

actin analysi associ **cell** cytoskeleton
filament function gtpase human interact
mechan **migrat** polar protein regul
respons rho sampl studi suggest

2228: Isosorbide Dinitrate (8)

africa **african american** asian
black caucasian differ **ethnic**
european frequenc group india indian north
origin **popul** preval race south
white

2230: RNA, Ribosomal, 23S (35)

16s analysi bacteri bacteria commun divers
eukaryot **gene** group **isol**
microbi number rate rdna region rRNA
sequenc similar speci
strain

2232: Peroxidase (44)

activ analysi antioxid cell chang differ
genotyp group **increas** level
oxid oxygen patient polymorph
product reactiv risk role stress studi

2233: Poly I-C (20)

analysi assess **cell** chang cytokin immun
increas induc level measur organ patient
process protein **rat** requir respons
score specif viru

2235: Casein Kinase II (36)

activ analysi cell control develop erk gene
genom inhibit inhibitor jnk **kinas**
mapk p38 pathwai **phosphoryl**
process **protein** regul signal

2237: RNA, Transfer, Ala (2)

adapt differ dna element evolut
genom insert integr isol larg
mutat number plant **select** sequenc
size small speci strain structur

2239: Cyclin-Dependent Kinase 4 (45)

activ arrest associ **cell cycl** cyclin
cyclin-depend delet famili increas inhibitor kinas
level mutat p21 p27 phase progress prolifer regul

2234: Sodium-Hydrogen Antiporter (31)

activ associ ca2+ calcium cell
channel combin current differ
effect function **human** level
membran number **protein** size
studi suggest time

2236: Antifreeze Proteins (3)

associ bind compar condit degre differ
higher indic **larg** larger modifi number
plant **protein** rate rel **size**
small smaller state

2238: Anti-Asthmatic Agents (17)

airwai analysi **asthma** cfr
children cystic fibrosi
genet method new parent popul
random research respiratori role studi
treatment trial year

2240: RNA, Transfer, Leu (13)

activ associ **differ** gene genom
group high human level low mitochondri
mutat **pattern** select sequenc similar speci
structur studi type

2241: Anticholesteremic Agents (34)

activ apoe apolipoprotein associ
cholesterol, diseas effect increas ldl
level lipid lipoprotein
metabol new patient plasma random
studi total trial

2243: Streptomycin (17)

assai cell chang concentr confer detect drug gene
group isol level mutant mutat number region
resist respons sensit sequenc test

2245: Pigments, Biological (26)

complex control develop differ effect
evolut gene genet isol larg laser
light mutant number regul role
sequenc size small speci

2247: Pterins (2)

activ analysi blot cell condit core degre
demonstr detect encod enzym
function gene identifi map
mitochondri open reveal specif western

2242: Malondialdehyde (38)

activ antioxid damag glutathion human
increas induc level oxid oxygen
peroxid protect radic rat reactiv ros speci
stress studi superoxid

2244: Ketocholesterols (3)

acid activ affect amino cell channel

chromosom effect enzym expos

exposur induc inhibit interact oxid

receptor studi toxic treat

treatment

2246: Polyketide Synthases (13)

analysi aspergillu caus chang decreas
fungal fungi fungu gene group
increas isol pathogen plant
produc product repeat
sampl score speci

2248: Coenzymes (20)

activ associ concentr correl dna
effect enhanc enzym famili gene group
interact plai protein reduc role select
substrat suggest time

2249: Methane (28)

activ associ bacteria field form
format **gene** high increas low
measur movement rel rna sequenc
space speci test **time** water

2251: Chondroitin Sulfates (16)

acid activ adhes **cell** compar
develop effect extracellular group high
higher human integrin model molecu
rate sampl select time treatment

2253: BCG Vaccine (25)

addit area children data defin demonstr
gener group includ indic model
mycobacterium new patient report repres respons
specif studi tuberculosi

2255: Brain-Derived Neurotrophic Fac-
tor (70)

activ astrocyt bdnf brain develop differ dopamin glial
glutam group hippocamp neural **neuron**
new olfactori protein report studi suggest synapt

2250: Dry Ice (1)

analysi area **associ** differ direct
electrophoresi experi field forc gel light locat mass
motion movement orient proteom relat space studi

2252: Tropolone (2)

activ affect anim bind develop diseas
earli experiment **function** late methyl
model phase plai progress regul
role stage studi suggest

2254: Tuberculosis Vaccines (6)

area combin data famili femal **gener**
genet immun includ male organ plai possibl remain
report respons role studi tuberculosi vaccin

2256: Poly(A)-Binding Protein I (6)

decreas diseas embryo enhanc estim form
format **function** gene
increas larg matur mechan model
mutant nuclear oocyt size small specif

2257: Elastin (26)

adhes analysi **cell** chang children
correl detect express extracellular **human**
integrin matrix mice molecul protein rate
respons role **studi** tissu

2259: Anthraquinones (15)

activ cell chang
compound decreas deriv dna earli
effect express gene increas **inhibit** level
method select size studi subject target

2261: Indole Alkaloids (2)

content design determin diverg divers evolut
evolutionari flow genet hospit **inhibitor**
medic phylogenet **popul** rice sequenc
speci structur tree wheat

2263: Macrocyclic Compounds (6)

compound conform crystal dna featur fragment
level mechan method model molecular potenti
produc product receptor releas resist stimul
structur studi

2258: Bridged Compounds (24)

activ advanc associ cancer
chemotherapi combin drug effect high number
patient phase presenc **respons**
structur studi surviv test toxic treatment

2260: Nortropanes (1)

analys base clade close cultivar differ genu
hybrid **individu** lesion maiz phylogenet
plant relat relationship rice sequenc
speci tree wheat

2262: Aza Compounds (9)

activ dai differ effect
gener high isol larg low mutant
new product provid rat role
select size small specif studi

2264: Ozone (23)

air analysi concentr contamin copper data
differ effect function gene life measur
metal model protein qualiti
respons soil studi water

2265: Sesquiterpenes (54)

activ adduct analog associ **cell**
combin **compound** deriv
group human increas
effect inhibit new patient product role studi
target test

2267: Arginase (12)

alter cell **chang** control differ
diseas gene **group** high increas
level mechan model normal patient
respons role select tissu tumor

2269: beta-Endorphin (4)

alcohol anim dai depend **effect**
ethanol factor growth hospit level model
oral patient rat reduc regul serum
studi treat treatment

2271: Eukaryotic Initiation Factor-2B
(4)

affect associ cell combin complex data
differenti diseas effect factor gene gener high
level low map **mutat** risk studi
translat

2266: Toxins, Biological (26)

analysi case clinic data develop
diagnosi effect express gene genom group
high model normal **patient**
respons select sequenc structur tissu

2268: Boron Compounds (9)

approach cell compound develop discuss
gener **group** method mutant
new provid recent research role
sequenc structur studi suggest treatment
understand

2270: Dental Enamel Proteins (25)

analysi analyz collect data detect determin dna
femal fragment group male method new patient pcr
region **sampl** sequenc studi test

2272: Risperidone (14)

affect associ case control effect evid
examin find implic influenc involv met possibl relat
report schizoprenia signific studi suggest
unaffect

2273: HLA-DR4 Antigen (8)

allel antigen associ **class** complex
group high hla increas level low
major mhc molecul mutat polymorph produc
product specif syndrom

2275: Transcription Factor TFIID (15)

activ analysi assembl cell chang
complex compon differ famili
function human increas interact model
number pattern promot requir subunit
transcript

2277: Benzocycloheptenes (2)

acid alcohol alpha amino beta concentr depend
differ effect enhanc **group** increas
inhibit model oral rat receptor signific
stimul studi

2279: Benzylamines (13)

chang compar concentr **control**
differ effect frequenc **group** human
increas inhibit model mutant rat receptor
requir respons signific site studi

2274: TATA-Binding Protein Associated Factors (15)

activ associ **complex**
compon differ express function gene
identifi interact mutant process promot requir
respons role screen specif subunit transcript

2276: Diazepam (16)

alcohol chang dai depend develop effect
ethanol express **group** human
increas oral patient rat receptor report
signific studi suggest treatment

2278: Phosphinic Acids (3)

acid **activ** alter anim base chang compar control
correl differ **group** interact larg model
observ pair signific size small studi

2280: GABA Antagonists (15)

acid activ differ effect **group** inhibit
mechan mice model neuron potenti process
receptor releas respons signific stimul studi
treat treatment

2281: Butylene Glycols (5)

acid **analysisi** base bladder
clinic compound concentr
diagnosi diagnost differ effect
interact rat receptor residu
reveal select site
structur studi

2283: Sodium Oxybate (4)

activ base cell cluster compar
control data differ differenti effect
evid **group** health p53 posit
prolifer provid rat resist support

2285: DNA, Satellite (43)

cag contain differ direct length long longer
number region **repeat** reveal sequenc
short similar singl suggest tandem term termin
unit

2287: Benz(a)Anthracenes (9)

blood cell compound differ effect
form format **group** high
human induc level low model
normal product rat **respons**
sequenc tissu

2282: Dithiothreitol (11)

activ analysi approach bind cell
decreas domain flow form format **function**
group increas oral oxid protein select site state
studi

2284: Ribose (4)

alter bind cell **chang** condit conform dna
dynam enzym **form** format indic kinet
model occur region sequenc site
state **structur**

2286: Xanthine Oxidase (12)

activ cell concentr dai decreas effect enzym
gene **human** increas induc
modifi oxid reduc respons sampl specif stress
treat **treatment**

2288: Azoxymethane (15)

acid administr anim cancer cell colorect compar
control dai decreas effect increas induc
inject level mice **rat** reduc respons week

2289: Antirheumatic Agents (51)

arthriti associ attack chronic clinic diseas
effect fever headach joint methods migrain
objective pain patient respons
rheumatoid sever synovi treatment

2291: Early Growth Response Protein
1 (45)

activ analysi bind cell differ element express
factor function gene human level plai
promot region regul respons role
site transcript

2293: Adenovirus E4 Proteins (12)

cell chang control dna effici
express function gene growth
high nuclear plai protein
requir respons role sampl specif
transfer vector

2295: cdc42 GTP-Binding Protein (47)

actin adhes cell cytoskelet
cytoskeleton exchang fak filament focal format
gene gtpase migrat motil myosin polar
protein regul rho role

2290: MAP Kinase Kinase Kinases (46)

activ cell erk express increas induc
inhibit inhibitor jnk kinas mapk
mitogen-activ p38 pathwai phosphoryl
protein regul respons role signal

2292: Collagen Type I (82)

activ adhes bone cell collagen
differ express factor fractur growth human
matrix miner normal osteoblast studi tgf-beta
tissu transform vitamin

2294: 2-Acetylaminofluorene (9)

activ analysi bind blot compar decreas effect
form format group increas
model modifi normal protein rat respons
studi time tissu

2296: Receptor, trkA (25)

associ brain caus cell enhanc evid express
factor gene growth high level line low model
neuron product receptor suggest
support

2297: Thalidomide (61)

addit combin convent data demonstr highli includ
multipl myeloma novel patient
potenti provid rate result simultan **singl** studi suggest
thalidomid

2299: H(+)-K(+)-Exchanging ATPase (5)

alter base bind biolog case cell **chang**
form format **group** involv
mechan model molecular
report specif studi **system** underli
understand

2301: Caffeine (46)

activ associ cell chang concentr
detect develop differ dna earli effect human
inhibit metabol model repair specif studi test
time

2303: HTLV-I Antigens (1)

assai code codon contain demonstr deriv
detect fusion length long method
peptid repeat **sensit** short
specif substitut suggest synthet test

2298: Antigens, Viral, Tumor (26)

activ associ **cell** degre evid function
human infect level line mechan
model number phenotyp produc product risk
size tumor viru

2300: Cations, Monovalent (2)

adapt base cell chines differ famili
heterogen includ member mutant observ pair
possibl previou report select structur
studi subtyp yeast

2302: Retroviridae Proteins, Oncogenic (14)

activ analysi **cell**
compar **control** detect enhanc
express famili function
gene **human** increas
level mice posit rat rate repeat
respons

2304: Ribosomal Protein S6 (7)

activ adult ASSOCI cell evid gene
increas larg local mrna **number**
rate region sequenc size small state suggest
translat year

2305: Azetidines (12)

apoe arm associ cholesterol clinic

compar dai effect improv lipid

lipoprotein patient product

random respons studi target tissu

treatment trial

2307: HMGA1a Protein (9)

analysi case cell compar differ express flow
form function gene group method mice observ

pattern process product protein
role specif

2309: Substance P (26)

cell concentr dai effect increas
interact mechan method model number
oral plai rat rate receptor respons

role stimul studi suggest

2311: Ribosomal Protein S6 Kinases,
90-kDa (25)

activ effect erk form format gene inhibit

interact kinas mapk mechan
molecular pathwai patient

phosphoryl protein rate regul
respons signal

2306: Protein-Arginine N-
Methyltransferase (16)

associ cell cpg dna epigenet gene

hypermethyl inactiv interact mechan
methyl mice promot protein
receptor regul sampl site target time

2308: Antibodies, Antiphospholipid
(15)

activ antibodi antigen associ compar
control earli effect factor group month mutat

patient risk signific studi subject
system time treatment

2310: Neurofibromin 1 (14)

broad common divers gene group includ

larg limit major mutat nfl patient rang

repres spectrum tumor type vari varieti

wide

2312: Antiporters (20)

activ analysi class cluster data differ express

function gene high identifi interact

isol mutat protein recombin role strain
structur variant

2313: Malates (7)

abil activ effect enzym famili
genom high increas level
low mechan member normal potenti
process properti respons sequenc
structur tissu

2315: Benzyl Compounds (4)

abil approach concentr decreas form
format improv increas inhibit
level life mean patient potenti properti
qualiti serum strategi target valu

2317: Equilibrative Nucleoside Trans-
porter 1 (3)

approach associ cell compound
deriv design effect express factor gene growth
line lymphoma normal patient releas resist
stimul strategi tissu

2319: Riboflavin (16)

activ analysi compar control
develop earli enzym gene
genom group increas level
mutant new organ provid risk stage
studi subject

2314: Ethers (10)

acid activ adduct analog caus
compound deriv estim
genom high lead level low new
novel product provid select target
tumor

2316: Galectin 3 (23)

activ assai associ carcinoma cell correl
detect develop express famili
function gene model normal
peptid specif studi
thyroid tissu tumor

2318: Glucuronides (16)

activ compar control cyp2d6 cytochrom dai
determin differ drug enzym human level
metabol metabolit p450 popul
resist respect sampl studi

2320: Technetium Tc 99m Sestamibi
(13)

clinic detect differ evalu function genet human
imag increas magnet mean measur model
multipl patient resist respons
studi valu volum

2321: RNA, Transfer, Met (5)

area base chromosom **complex** compon
differ dna express flow fragment **gene**
human mechan mitochondri
molecular mutant pair per **protein** rna

2323: Chloramphenicol (8)

cell chang children **control** dna
gene infect **isol** mechan mutant
new normal posit product recombin region
risk sequenc **strain** tissu

2325: E2F2 Transcription Factor (9)

activ arrest **cell** cycl cyclin
differenti effect express famili identifi
interact mutant new normal p53 phase
phenotyp prolifer studi tissu

2327: Receptors, Calcitriol (67)

allele bmd **bone** calcium densiti develop
fractur gene genotyp hip human miner
osteoblast osteoporosi polymorph risk skelet
spine studi vitamin

2322: Sigma Factor (35)

coli activ analysi bacillu bacteri bacteria
encod escherichia form format
gene mutant new operon phage phenotyp
presenc regul strain toxin

2324: Retinoblastoma-Like Protein p107 (12)

arrest **cell** correl cycl cyclin
develop earli express famili mechan new p21
patient phase product progress prolifer regul
role size

2326: E2F5 Transcription Factor (3)

abil **activ** caus cell compar
control differenti express factor
famili featur frequenc interact lead
member point prolifer properti **time**
transcript

2328: Silicones (18)

case cluster data differ effect effici estim examin
group induc interact method
number **rat** respons select studi surfac
treat treatment

2329: Hair Dyes (6)

assess associ data effect evalu extract increas
light measur method mutat popul ratio
repeat risk sampl studi techniqu
treatment variabl

2330: Tryptophan (78)

acid activ allel associ bind
cell chang control differ
enzym function gene
genotyp mutat patient
polymorph site structur
studi substrat

2331: Relaxin (11)

analysi differ duplic effect
evolut evolutionari femal
human increas male
mice model rat rate receptor
respons role suggest
system yeast

2332: Receptors, AMPA (24)

adult astrocyt brain differ dopamin function glial
glutam hippocamp increas interact level mutant
neuron pattern receptor specif
subject suggest synapt

2333: Receptors, Biogenic Amine (3)

acid algorithm alter amino approach base
chang cluster concentr data
drosophila method network normal
predict receptor regul
respons set tissu

2334: Androstenedione (8)

associ clinic concentr correl cycl group higher
hormon level patient rate
reproduct risk size steroid studi test time
treatment women

2335: Inhibin-beta Subunits (11)

cell complex differ differenti express
factor growth human increas line model
number pattern process receptor role studi
suggest tgf-beta transform

2336: Activins (23)

activ cartilag cell chondrocyt differenti
express factor function growth
human increas induc prolifer regul
respons role signal
tgf-beta tgf-beta1 transform

2337: Inhibins (19)

associ cell **control** cycl develop
famili follicl **hormon** level ovarian
patient posit pregnanc protein
reproduct steroid studi tumour valu

women

2339: N-Acetylneuraminic Acid (14)

acid alter amino analysi associ cell
chang complex decreas express increas new
number product protein sampl select site
structur tumor

2341: Inhibitor of Differentiation Protein 1 (26)

associ cancer **cell** correl detect develop
differenti earli express factor famili
function gene **human** identifi prolifer
regul screen specif **transcript**

2343: Acetylcysteine (51)

activ antioxid caus cell damag
effect function increas induc
oxid oxygen prevent protect protein
reactiv reduc stress **time** tissu
treatment

2338: HN Protein (6)

cell cluster **gene** **group** high
human individu infect level local
low new popul posit recombin site structur
studi treatment viru

2340: Ganglionic Stimulants (7)

activ associ chang code **codon**
complex **differ** effect express form
format **gene** nucleotid posit ratio
respons risk studi
substitut treatment

2342: Activin Receptors, Type II (9)

adult autosom **cell** clinic combin diagnosi
domin factor **famili** growth includ
inherit member mutat **patient**
plai primari risk role year

2344: DEAE-Dextran (3)

cell differenti effici express fluoresc gene high
human level line low prolifer protein
recombin remain **transfect** transfer vector vitro vivo

2345: Polyethylene Terephthalates (6)

case **cell** chang cultur evid form format
level **method** microscopi
morpholog normal organ procedur standard
techniqu time tissu tumor valu

2347: Butylhydroxybutylnitrosamine
(3)

analys analysi cancer compar earli femal

higher incid male malign mice mutant

mutat progress protein rate

stage studi tumor **tumour**

2349: Aurintricarboxylic Acid (2)

area bind control femal **gene** healthi
male model normal presenc protein
region sequenc site structur studi
subject **tissu** transfer vector

2351: Nerve Growth Factor (45)

activ analysi brain cell control develop effect
express gene group growth increas level mice
neuron product rat regul studi
tumor

2346: Silver Compounds (4)

area **case** children concentr
electron layer microscop **microscopi**
morpholog new observ provid
report reveal shape skin structur studi surfac
valu

2348: Receptors, Thrombin (6)

analysi concentr correl detect effect form

format **function** high increas
interact level local low model **patient**
potenti protein releas stimul

2350: Apolipoproteins A (30)

apoe apolipoprotein associ atherosclerosi
chd **cholesterol** control hdl human
increas ldl level **lipid**
lipoprotein metabol plasma polymorph
studi total triglycerid

2352: Glycerolphosphate Dehydroge-
nase (4)

alter **chang** data decreas direct divers
evid function genet
hypothesi **increas** mice mous
popul provid specif state
suggest **support** transgen

2353: 17-alpha-Hydroxyprogesterone
(11)

children compar concentr control detect
differ healthi high hormon level mean
measur **patient** posit respect
studi **subject** treatment valu women

2355: Terpenes (35)

activ analysi **cell** decreas
differ effect **enzym** express
famili form group **increas**
inhibit isol mutant produc product
rat studi substrat

2357: Phthalimides (2)

bind caus direct dynam experi
field find forc lead **model**
motion movement **organ** orient peptid
previou report site space studi

2359: Receptors, Pituitary Hormone-
Regulating Hormone (4)

anim cancer combin effect factor **gene**
growth human impact improv
life **model** mutant patient
physic **qualiti** rate studi time variant

2354: Receptors, Pituitary Hormone
(2)

allel associ bodi children gene genotyp
haplotyp mean measur mutant plai
polymorph ratio receptor **role** snp
studi suggest valu weight

2356: Glycerides (9)

activ alpha beta combin correl decreas
degre effect enhanc ethic express form format
increas inhibit method model
receptor research target

2358: Lipid A (6)

acid **activ** cell complex inhibit
length long mice model peptid presenc
product protein repeat **respons**
short **structur** time vitro vivo

2360: Glucosylceramidase (26)

activ alter alzheimer autoimmun case chang
diseas disord enzym function gene human
mice parkinson pathogenesi patholog patient progress
studi tau

2361: Anions (28)

activ cell concentr control enzym
form format function
identi level model new
protein rat rate resist respons
structur studi test

2363: Dehydrocholesterols (2)

approach characterist common design
experi featur femal follow initi
level male morpholog origin
random second serum sex skin strategi trial

2365: Borohydrides (3)

analys analysi assai assess compound detect
develop evalu isol measur mix produc
product resist reveal score sensit
sourc test yield

2367: Glycolipids (22)

accumul associ cell chang
complex control decreas diseas
express group human increas
level patient peptid
product report serum studi suggest

2362: Vitamin D (66)

activ bmd bone calcium densiti effect
fractur hip human level miner osteoblast
osteoporosi patient skelet skin spine studi
vitamin year

2364: gamma-Glutamyltransferase (16)

associ case concentr decreas effect enhanc
express famili gene genet increas
level plasma popul protein ratio risk
sampl serum studi

2366: Sphingomyelins (14)

accumul activ approxim caus
chang effect famili function
high increas lead level low major
model protein rel role studi suggest

2368: Hexosaminidases (11)

activ analysi chain children
clinic data detect diagnosi
diagnost differ diseas enzym
express level marker model
pcr polymeras reaction
studi

2369: Dopamine beta-Hydroxylase (5)

associ caus correl decreas diseas effect evid
gene genet identifi increas influenc
level measur mechan receptor reduc score screen
studi

2371: Homovanillic Acid (5)

abil affect analysi children clinic
condit degre detect diagnosi **earli**
gene identifi **level** measur new screen
stage studi **treatment**
tumor

2373: Nitrobenzoates (5)

alter caus **chang** clinic diagnosi
effect famili local mechan molecular
mutant new normal rate reduc
respons stimul test tissu
treatment

2375: Dietary Proteins (32)

associ bmi **bodi** develop diet dietari
fat fed feed food index intak leptin mass nutrit
obes patient studi supplement **weight**

2370: Vanilmandelic Acid (2)

affect bladder case caus data develop diseas
earli electron late lead microscopi
morpholog phase progress report **stage**
structur studi therapi

2372: Cyclohexanones (8)

abil adapt cell children combin compar
develop effect higher inhibit
lower mechan **number** properti
rate select **treatment** tumor vitro
vivo

2374: Phytic Acid (14)

activ cell compar differ effect
higher increas level mean normal rat
rate respect **respons**
rice role studi tissu valu wheat

2376: Phenylalanine Hydroxylase (7)

base bind candid condit degre form format
gene identif **identifi** level local
model mutant novel organ protein
screen select structur

2377: Catecholamines (25)

affect case concentr **effect** express
genom group human increas larg level
mechan number **patient** posit
rat reduc respons size studi

2379: Tetragastrin (1)

contain core **distribut** encod exposur
fish fluid hybrid identifi indic **local**
open probe read receptor **region**
residu **sequenc** site vector

2381: Levamisole (8)

analysi caus clinic compar data effect
function gene identifi improv model
patient random rate regul studi
surviv treat **treatment** trial

2383: Tachykinins (9)

activ analysi caus cell
data **differ** evid famili
function gene major **peptid**
provid rate rel respons role
specif studi support

2378: Biopterin (10)

concentr differ form format group identif
identifi incid increas level mortal
novel plai preval role **screen**
synthesi time women year

2380: Receptor, Cholecystokinin A (4)

allel associ control correl
develop genotyp healthi
interact measur mechan mutat
polymorph ratio **receptor**

repeat risk score signific studi

subject

2382: Dioxoles (15)

activ bind cell clinic combin effect express
gene human induc mechan rate
respons sampl sarcoma select
studi subject test tumor

2384: Receptors, Opioid, delta (7)

activ alcohol alter assai
chang depend detect
develop effect gene **group**
human model mutant
oral receptor role select
sensit studi

2385: Eukaryotic Initiation Factors (8)

base compar discuss effect function higher
human interact mrna number
organ process protein **rate** structur studi
suggest test time translat

2387: Biocompatible Materials (86)

cation complex conjug **deliveri** differ

dna **effici** formul high liposom

nanoparticl **particl** polym prepar

product properti releas solut studi

surfac

2389: Oligodeoxyribonucleotides, Anti-sense (41)

activ antisens **cell** effect
express function gene group
growth human increas inhibit interf
interfer **rna** rna silenc sirna small
target

2391: Parasympatholytics (4)

arm clinic cluster compar concentr correl
effect higher improv random **rate** respect
select signific specif **studi** subject
treatment trial valu

2386: Polyethylene (15)

compar concentr **control** develop
dose group irradi level
measur method normal number
patient **radiat** rate respons sampl
studi subject **tissu**

2388: Polyethylenes (14)

compar deliveri differ effici enzym **group**
higher light lower model normal number
particl plant **rate** sampl studi
subject surfac **tissu**

2390: Phenethylamines (8)

base compar control dai dose effect famili
genom increas induc induct level **model**
patient predict **respons** role
select **treatment** week

2392: Antitoxins (4)

alter approach assai **chang** cluster
construct detect **develop** gene
high homolog level low model plasmid
recombin sensit site strategi
time

2393: Measles Vaccine (7)

analysi associ classif **cluster**
differ express gene high immun low
model posit profil set size **target**
therapeut treatment vaccin viru

2395: Methylene Blue (10)

chang chromosom dai decreas effect enhanc
increas individu lesion light method normal
patient **rat** region respons sampl stain
test tissu

2397: Oxyhemoglobins (6)

alter **chang** compar disord higher
imag increas interact light measur model
number plai rate receptor releas role
state stimul subject

2399: Palmitic Acid (16)

acid **activ** amino associ cell
chang enhanc enzym famili function growth
human induc model regul **respons** site
specif studi suggest

2394: Cholesterol 7-alpha-Hydroxylase (9)

activ associ cholesterol decreas factor
gener genet genotyp **increas**
level lipid lipoprotein new polymorph popul
ratio respons risk select studi

2396: Lignin (12)

activ chang **correl**
differ distribut express
function gene level local
map pattern popul product **rate**
respons rice signific speci tissu

2398: Glucans (12)

activ associ cell complex
concentr correl effect enzym **gene**
high low method **organ** plant produc
product **protein** sequenc specif state

2400: Sitosterols (8)

effect gener health improv inhibit inhibitor
level life lipid mechan mutat
number patient plant plasma qualiti
sampl serum studi tumour

2401: Phytosterols (9)

analysi bind cholesterol combin correl
earli effect **level** lipid mechan
mutant mutat phenotyp plant plasma regul
reveal serum stage studi

2403: NG-Nitroarginine Methyl Ester (23)

chang control decreas effect group

human incorpor **increas** induc level

nitric oxid product rat reduc respons role

suggest **synthas** **synthesi**

2405: Anilides (21)

activ **cancer** case cell chang
decreas differ effect famili group increas inhibit
line prostat receptor report **respons** studi
therapi treatment

2407: Minocycline (14)

case caus clinic differ diseas famili
follow gener isol model present product
report respons strain studi target **test** time
treatment

2402: Phenylephrine (11)

adult compar concentr control decreas
differ effect extract famili function
group **increas** member mice
product rat reduc select studi year

2404: Endothelium-Dependent Relaxing Factors (1)

arteri blood coronari demonstr effect **express**
function hypertens impair increas
level nitric oxid physiolog pressur reduc stroke **synthas**
synthesi vascular

2406: Kinetin (4)

abil assai cell combin demonstr detect

effect express high level low

potenti properti reduc reduct report sensit

studi treat **treatment**

2408: Micronutrients (13)

bodi chang compar control develop differ
effect factor function **genom**
group level multipl new provid
respons sequenc studi trial weight

2409: Isoantibodies (35)

antibodi antigen associ **blood** chines
circul count determin differ donor healthi
heterogen lymphocyt mononuclear peripher
recipi sampl studi subtyp transplant

2411: Ribonucleases (52)

analysi bind cell develop dna effect
function gene high increas level
mechan melanoma mutant
protein regul rna site
structur studi

2413: Convulsants (9)

analysi bind compar **control**
detect effect frequenc genom high inhibit low
mice neuron number **respons**
state stress studi test treatment

2415: Inorganic Pyrophosphatase (5)

analysi character concentr contain

core encod enzym

express frame genet identifi

novel **open** orf put read

region reveal sequenc

structur

2410: Site-Specific DNA Methyltransferase (Cytosine-Specific) (11)

activ analysi control cpg dna epigenet gene
hypermethyl identifi inactiv island
methyl methyltransferas model
p16 patient promot region statu treatment

2412: Osteonectin (16)

analysi blot cell chang
confirm detect effect enhanc
express human
mechan protein rate reveal role surviv
time tissu tumor western

2414: Flumazenil (4)

approxim **associ** bind combin
concentr effect featur **group**
mutat observ organ **patient**
popul presenc process **receptor** rel
studi suggest treatment

2416: Heme (49)

activ antioxid cell enzym **human**
increas mitochondri model new oxid
oxygen patient process protein reactiv role
stress **structur** studi suggest

2417: 5-Aminolevulinat Synthetase
(13)

activ approxim defici diseas enzym event
gene human involv major mechan
model molecular mutat new **process** rel
structur studi treatment

2419: Lactoglobulins (8)

anim bovin breed cell compar data express
gene hybrid identifi mice **model** new
number pig process **protein**
rate requir specif

2421: Adrenergic alpha-Antagonists
(14)

associ cancer chang
combin correl dai decreas develop
differ effect express group
increas number rate
receptor respons studi **time**
treatment

2423: Doxazosin (3)

analysi blot **cancer** cell cluster
dai decreas effect **express**
gene **increas** inhibit
microarra profil prostat system treat
treatment tumor western

2418: Diterpenes (27)

activ adduct analog analogu **cell**
chemic **compound** concentr
deriv differ effect enhanc increas induc
inhibit mechan new respons role structur

2420: Neural Cell Adhesion Molecules
(27)

adhes analysi approach assai associ cancer
cell detect develop differ effect
express gene molecu patient role sensit
sequenc studi treatment

2422: Antigens, CD146 (9)

analysi cancer cell compar content control
dai decreas develop dose express flow
increas marker mice normal
specif studi **tissu** treatment

2424: Benzoic Acids (6)

activ clinic combin concentr
develop diagnosi discuss effect
extract mice patient rat recent receptor
residu site **studi** therapi treat
treatment

2425: Glucosides (29)

activ analysi cell compound
detect determin develop differ effect express
extract fraction function group
increas method rat sequenc structur studi

2427: Mechlorethamine (12)

activ associ differ dna earli
effect group high initi level low

model patient pattern rate respons stage

therapi treat treatment

2429: HIV Antigens (7)

antibodi assai cell children combin detect
differ individu infect parent
pattern peptid plai role select sensit specif
target type viru

2431: Lymphoid Enhancer-Binding
Factor 1 (27)

activ beta-catenin cascad compon develop
downstream gene high intracellular involv mechan
mediat molecular pathwai regul select
signal transcript transduct wnt

2426: Chlorambucil (7)

compar dai dose earli effect follow gener
increas month patient product random
rate receiv respons studi treat
treatment trial week

2428: Cyclin-Dependent Kinase In-
hibitor p15 (19)

activ alter associ cpg dna epigenet gene
human hypermethyl inactiv individu island loss
methyl methyltransferas number
p16 promot region statu

2430: Phenolsulfonphthalein (1)

analys analysi assess content
evalu flow imag measur method
perform period point rat reveal scale SCORE
standard techniqu time valid

2432: LDL-Receptor Related Proteins
(33)

activ analysi associ beta-catenin bone cell
human increas pathwai patient plai
protein receptor regul role signal
studi transduct vitamin wnt

2433: Neurofibromin 2 (12)

cell delet develop differ **express**
famili find function gene genet human identifi
includ loss mutat previou report studi suggest
tumor

2435: Inhibitor of Differentiation Protein 2 (16)

activ cell correl develop differ differenti earli

express factor function gene initi interact

pattern prolifer protein regul repress test

transcript

2437: Lactoferrin (24)

activ anim bovin cell dai differ **express** function

gene **human** identifi increas interact
level mice patient pig role screen studi

2439: Citric Acid (20)

acid activ base combin **concentr**
differ effect function group increas low microg
microm min mitochondri patient plasma
product respect studi

2434: Butyric Acids (9)

acid associ **cell** cycl dai decreas
differenti effect **express** **gene**
increas individu inhibit level **mice**
prolifer treat **treatment** vitro vivo

2436: Inhibitor of Differentiation Proteins (12)

cell combin develop **differenti**
earli **express** **function** gene high **human**
low methyl number phenotyp product **prolifer**
promot **protein** select subject

2438: Nitrobenzenes (18)

agent cell chemoprevent COX-2 effect gene high

inhibit **inhibitor** isol level low
prevent product reduc role select strain suggest
treatment

2440: Trace Elements (17)

activ **analysisi** bodi compar data
differ high improv level life low
pattern process qualiti reveal
sampl select studi
subject time

2441: Flavones (9)

activ cancer cell compound
detect effect form format
function identifi inhibit line method
process reduc report screen specif
studi treatment

2443: Receptors, Opioid, mu (23)

abus alcohol associ consumpt depend
drink effect ethanol examin function gene
indic oral patient polymorph prefer
signific studi substanc suggest

2445: Tobramycin (6)

analysi assai base data detect
effect gene high identifi increas infect
level low method number
patient role screen sensit
specif

2447: Ribonucleoproteins (50)

activ altern bind complex exon
famili gene human intron isoform
mrna patient protein requir
rna sequenc site splice translat
variant

2442: Antidiarrheals (6)

acid bind chronic diseas effect event
function gener identifi involv
level oral process reduc screen studi subject test
therapi treatment

2444: Caseins (21)

anim bodi bovin cell control differ effect
express gene human
method model pig polymorph process
region role sequenc site studi

2446: Tissue Extracts (9)

activ analysi base cell differ express
extract form fraction group increas
model patient process protein
select studi subject test therapi

2448: Chemokines, CX3C (3)

activ allel chemokin concentr express factor gene
genotyp necrosi neg nf-kappab
patient polymorph posit resist
tnf-alpha tumor vector vitro vivo

2449: Collagen Type IV (36)

adhes analysi **cell** collagen data
express extracellular femal human integrin
invas male matrix migrat model molecul
mutat patient studi surfac

2451: Receptor, Serotonin, 5-HT2A (10)

affect allel assess **associ** chain
correl disord gene genotyp group
measur **patient** polymorph reaction
respons score signific **studi** test time

2453: Telomere-Binding Proteins (25)

activ cap cell cellular chromosom end htert
human length mainten normal protein
revers senesc shorten suggest
telomer telomeras
transcriptas trap

2455: Materia Medica (8)

avail care cell cost current decis
effect extract function group
guidelin health **manag medic**
method practic recommend reduc reduct
studi

2450: Glyceraldehyde-3-Phosphate Dehydrogenase (Phosphorylating) (7)

bind cell chang correl express gene gener
genom human increas interact level mrna
phenotyp plai protein regul respons
role suggest

2452: ATP Synthetase Complexes (1)

chromosom code codon copi determin duplic
evolut increas individu isol larg map
number particip patient singl
strain substitut suggest surviv

2454: Chromium Radioisotopes (7)

antigen assai **associ cell**
class **concentr** detect evid immun
induc inhibit major mechan ratio rel
respons risk sensit target tumour

2456: Dimethylnitrosamine (10)

activ cell concentr correl dai detect develop
differ effect exposur gene mice
pattern process rat role signific time
treatment tumor

2457: Complement C3 (18)

activ analysi cell compar control develop differ
evolut express **group** level model
normal patient requir signific specif studi test
tissu

2459: Carbon Tetrachloride (7)

adult base **cell** differ effect genet
hepat individu **liver** local marker
mice mous phenotyp **respons** studi
subtyp treatment valu year

2461: Interferon Alfa-2a (19)

associ bind case clinic combin dai effect infect level
patient posit ratio **respons** risk
studi treat **treatment** trial viral viru

2463: Glutathione Reductase (13)

antioxid decreas enzym **high**
increas induc level low method
oxid oxygen protein rat reactiv **respons**
role stress studi subject treatment

2458: Insulin-Like Growth Factor Binding Protein 2 (10)

bind bodi cell control differ **factor** gene group
growth igf-i individu level model
normal patient protein role studi tissu valu

2460: Chloral Hydrate (3)

acid bind children concentr effect exposur
high hybrid induc level loss low
method period rat releas
respons stimul techniqu
time

2462: Interferon Inducers (8)

activ analysi cell dai detect effect
express form **high** induc induct level low product
protein receptor **respons** role select time

2464: 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase (6)

allel associ cell compar decreas factor
gene genom genotyp **group**
increas level normal
polymorph ratio rel risk tissu valu year

2465: Cystathionine beta-Synthase
(13)

activ associ caus effect factor
folat gene gener genet level measur
mechan mutant mutat plasma
platelet risk studi subject time

2467: Pectins (9)

activ area detect differ gene genom
group mechan molecular pathogen
plai plant protein repeat role sampl studi test
therapi tumour

2469: Synaptosomal-Associated Pro-
tein 25 (9)

affect analysi bind complex data
differ distribut evid genet local
number patient pattern
protein provid respons
role studi suggest support

2471: Botulinum Toxins (11)

assai chang children cluster
coli dai detect effect
escherichia gene isol mechan
repeat requir sensit stimul
strain time
treatment year

2466: Signal Recognition Particle (11)

analysi associ cell complex
element genet high initi level low
melanoma origin protein region repeat
reveal rna sequenc structur
suggest

2468: R-SNARE Proteins (13)

analysi chang control data develop earli
effect featur function gene level
membran mice mutant
mutat protein site size structur
transport

2470: Tetanus Toxin (7)

accumul assess cell coli combin
decreas differ effect
function high increas
level low marker mice pattern reduc
repeat requir score

2472: Qa-SNARE Proteins (6)

affect compar differ
function fusion genom
individu interact membran
mutant mutat pattern phenotyp
process protein rate requir studi
suggest transport

2473: Catechol Oxidase (8)

acid cdna clone drosophila encod extract
form **gene** genom mechan method
plai plant point product **role**
sequenc structur **time** tumour

2475: Dapsone (3)

addit code codon **combin** compar
effect gener higher lower multipl organ point
rate reaction result singl studi substitut synergist
time

2477: Asbestos (18)

associ cell esophag **frequent**
includ investig italian mesothelioma
observ **occur** **occurr** possibl
probabl relat report sampl
studi suggest transmiss
transmit

2479: Complement Factor B (4)

anim approxim base bind duplic evolut
factor **gene** growth model mutant
observ pair patient presenc rel requir
studi suggest test

2474: Poly(A)-Binding Protein II (5)

abnorm ataxia atroph **CASE** caus
control differ **diseas** disord
expand expans genet includ **motor**
neuron **popul** progress report studi
subject

2476: STAT4 Transcription Factor (17)

cell combin cytokin gene high
ifn-gamma il-6 immun increas induc macrophag
mechan normal patient rate receptor
respons structur studi tissu

2478: DNA Topoisomerases (7)

activ area cell complex develop
dna effect enhanc gene
human inhibit mutat normal
recombin replic requir specif studi target
tissu

2480: Haloperidol (13)

affect associ chain control
activ effect examin **group** increas involv met
patient reaction report **schizophrenia** sever
signific studi suggest unafect

2481: Pesticide Synergists (1)

concentr determin effect endogen
enhanc higher increas low lower measur microg
microm min plasma potenti rang respect suggest
target therapeut

2483: Tritium (39)

activ compar control correl dai
develop differ effect express human
measur model mutant normal plai
receptor role state studi
tissu

2485: Gelatin (15)

activ analysi anim bind cell
compar control deliveri **differ**
earli effect effici express individu
model pattern product role
sampl surfac

2487: Hormones (53)

activ chang control **develop**
differ effect factor function gene group
growth hormon increas model patient
receptor studi subject treatment
women

2482: Ivermectin (14)

adult chang determin effect extract famili
fraction high includ number phenotyp popul
resist respons select studi treat
treatment vivo year

2484: Piperonyl Butoxide (1)

compound **concentr** determin
effect higher increas induc induct lesion low measur
microg microm min plasma rang respect respond
respons stain

2486: Eukaryotic Initiation Factor-2 (19)

associ cell develop express function gene
high initi mechan model **mrna**
protein region respons ribosom rna
sequenc site **translat** trna

2488: Epitopes, B-Lymphocyte (10)

abil **antibodi** bind **cell**
demonstr famili interact mutat
normal peptid potenti product properti
requir **select** size **specif**
subject test tissu

2489: Hemoglobin, Sickle (11)

allele associ case cell clinic defect
defici diagnosi gene genet genotyp
human method patient
polymorph popul sampl select studi
test

2491: Elapid Venoms (4)

assai caus **cell** cluster dai data detect
differ estim **function** gene
group lead protein rat sensit state
structur transfer vector

2493: Polystyrenes (18)

assess associ cell control **deliveri** dna
effici identifi liposom measur
method normal **particl** polym prepar
sampl score screen **surfac**
tissu

2495: Oxides (60)

apoptosi **cell** chain combin compar
death detect effect flow glioma human imag
increas leukemia patient **primari**
product reaction secundari studi

2490: beta-Lactamases (48)

analysi antibiot aureu bacteri bacteria biofilm
function gene host **infect** isol
mutat parasit pathogen protein salmonella
select strain structur virul

2492: Aminoimidazole Carboxamide (7)

acid activ alter base cell **chang**
decreas enzym **express**
increas individu inhibit kinas
lymphoma **mechan** method
molecular product protein
sampl

2494: Methylnitrosoourea (22)

administr anim cell chang compar control dai decreas
effect group increas induc inject model **rat**
studi time treat treatment week

2496: Vascular Endothelial Growth Factor C (26)

angiogenesi correl effect
endotheli express factor
group growth hif-1alpha hypoxia
patient plai prognost role sampl signific
surviv vascular vegf vessel

2497: Biological Factors (16)

approach dai data develop function
identifi model **new** novel provid
recent research resist respons screen select
studi subject target year

2499: Clenbuterol (3)

area assess concentr correl dai decreas differ
group increas inhibit mean
measur mechan method molecular
respect score signific **time** valu

2501: Calcimycin (14)

activ analysi cell channel compar
concentr **control** detect differ effect frequenc
gene increas level model process protein reduc
role studi

2503: Phytohemagglutinins (19)

abil activ associ blood cell differ effect express
femal group **human** increas male
number patient radiat respons studi
treatment valu

2498: Proto-Oncogene Proteins c-sis (10)

activ analysi cell chang compar decreas
differ evid gene genom growth
increas level mice model number
pattern regul support tissu

2500: Methanol (26)

chromatographi combin compar determin
effect enhanc **extract** fraction
group higher **human** increas isol
liquid **new** prepar product provid **rate**
sampl

2502: Anti-Allergic Agents (3)

adjust associ blood **cell** children
confid control dai detect effect interv odd
peripher **rat** ratio **risk** sensit
smoke studi treatment

2504: Antigens, Dermatophagoides (7)

analysi associ asthma effect enhanc fibrosi
gene genet genotyp human individu
patient polymorph popul reduc
region sequenc studi therapi treatment

2505: Phospholipases (8)

activ alter analysi blood cell chang
group compar control differ famili
increas isol mechan member
product protein receptor strain studi

2507: Apolipoprotein A-I (34)

apoE apolipoprotein associ atheroscleroti
chd cholesterol hdl human increas
ldl level lipid lipoprotein
metabol number plasma studi time total
triglycerid

2509: Glycoconjugates (6)

assai correl detect develop form
format group human
organ peptid plai process protein region
role select sensit sequenc specif tumour

2511: Fatty Acid Transport Proteins (5)

acid cell complex delet develop express
famili featur gene identifi includ larg
member mice mutat resist respons risk size
small

2506: Apolipoproteins (35)

analysi apoE apolipoprotein associ
cholesterol control effect gene
genet human increas ldl level
lipid lipoprotein metabol
plasma polymorph protein studi

2508: Receptors, LDL (79)

apoE apolipoprotein associ
cholesterol detect diseas identifi
increas ldl level lipid
lipoprotein metabol pathwai patient
plasma signal studi total triglycerid

2510: RNA, Protozoan (36)

analysi cdna clone contain develop earli
element encod express gene genom
identifi insert melanoma region reveal rna
sequenc studi test

2512: Trypanocidal Agents (4)

acid activ alter analysi case chang
cluster combin effect
extract genom open popul protein reduc
region resist sequenc target treatment

2513: Chlorophenols (2)

adduct analog chemic **compound** deriv differ
effect genet **group** length long
popul protect reduc reduct repeat short site
speci structur

2515: Scavenger Receptors, Class B (5)

activ cluster control effect
famili form format lipid member
mice mous plai reduc regul requir
role studi subject test tumour

2517: Flavodoxin (3)

affect analys **analysi** data differ
enzym evid growth indic mutant perform
protein provid requir reveal state structur
studi support variabl

2519: Norfloxacin (3)

adapt dna **earli** effect **isol** late mutant
mutat natur phase progress rat resist
select stage strain studi
system treat treatment

2514: Phosphatidylcholine-Sterol O-Acyltransferase (4)

activ bind cholesterol detect diseas
evid fish fluoresc form format higher
hybrid lipid mutant probe protein
rate risk situ support

2516: Receptors, Scavenger (16)

ASSOCI cancer chang differ famili
increas interv level lipid
patient plai product ratio

receptor region **risk** role select sequenc

studi

2518: Betaine (8)

acid approach **chang** concentr condit
degre dose **effect** factor male
mice **mutat** radiat reduc reduct
requir **structur** studi
treatment tumour

2520: Flagellin (13)

analysi character cluster **differ** element genom
identifi infect **isol** method number
pattern phenotyp product region respons
sequenc **strain** type valu

2521: Corticosterone (33)

adren anim compar **differ** effect
function hormon increas level male mechan
mice **model** new pattern pituitari
rat repeat studi **thyroid**

2523: Insulin Antibodies (8)

activ anim children compar diabet earli
function genom high higher mice
model patient
popul posit process **rate** select
stage studi

2525: DNA Modification Methylases (45)

aberr cpg demethyl dna epigenet gene
hypermethyl inactiv island mechan
methyl methyltransferas mgmt p16
promot rassfla region silenc statu suppressor

2527: Cortactin (7)

actin adult **analysi** breast
cancer cell data delet **enhanc**
estim gene **high** level low **method**
migrat neg **posit** reveal year

2522: Uroporphyrinogen Decarboxylase (6)

activ case enzym find function gene
genet identifi method mutat organ popul previou
produc product rat report screen studi substrat

2524: Macrolides (43)

activ cell character detect develop differ enhanc gene
genet identifi increas **isol** model popul resist
select sequenc **strain** treatment type

2526: Amino Acid Transport System ASC (2)

activ brain central densiti enzym gene high
human level low membran monkei
nervou primat receptor resist substrat transfer
transport vector

2528: Organic Cation Transport Proteins (28)

associ cell control develop
famili gene genet **haplotyp**
human interact nucleotid patient
polymorph risk role singl snp studi
suscept tissu

2529: Water Pollutants, Radioactive (21)

air area chang **concentr** contamin

copper environment high level low measur

metal pah pollut sediment soil sourc studi

subject **water**

2531: Levonorgestrel (9)

care chang combin dai effect ethic
group health hormon increas issu
medic number patient practic research studi
subject **treatment** women

2533: Methylcholanthrene (9)

activ associ cell compar concentr
control degre differ earli express gene high
human individu low respons sequenc stage
treatment tumor

2535: Fatty Acids, Unsaturated (34)

acid activ amino bind control differ
express fattl function gene group high human local
model nuclear organ protein studi subject

2530: Carbolines (14)

activ adduct analog analogu chemic
cluster **compound**
concentr deriv **effect** express
form format genom human
product protein reduc **respons** select

2532: Contraceptives, Postcoital, Hormonal (3)

care case conclusions **design** discuss
femal hormon **hospit** main
male manag **medic** objective
patient rat recent research studi
women year

2534: Argon (7)

analysi cell cluster decreas **dose** effect
form format **human** increas individu
irradi method **model**
radiat radiotherapi reduc sampl
treatment tumour

2536: Calcium Compounds (8)

assess **cell** combin data develop effect
evalu form imag incid measur mechan
molecular number product site studi treat
treatment year

2537: Root Canal Filling Materials (2)

cell compar content control
cytometri determin differ enhanc flow
form format increas level light load new
observ report studi time

2539: Silicates (6)

adult base cell concentr dose famili
femal field increas irradi male
movement observ radiat report
respons space specif studi
year

2541: DNA Nucleotidyltransferases (15)

base carri construct contain differ earli effici famili
gene gener homolog mice number plasmid
recombin requir respons role
select structur

2543: Dextranase (1)

activ chain detect diverg domain duplic
enzym evolut evolutionari isol origin per
polymeras protein quantit
reaction real-tim revers strain substrat

2538: Aluminum Compounds (3)

abil analysi content
cytometri demonstr determin effect
enhanc flow increas indic light load
observ potenti properti reduc reveal studi
target

2540: Chlorine Compounds (2)

approxim bovin compar differ electron express
gene length long major microscopi morpholog
observ pig primari rel repeat short test
water

2542: Antigens, CD24 (9)

activ associ cancer cell correl
express gene gener high
higher level low mice patient
prognost rate report studi
surviv tumor

2544: Lipoproteins, VLDL (14)

apoE apolipoprotein associ
cholesterol growth increas ldl
level lipid lipoprotein metabol
plasma presenc protein rate sampl size
studi total triglycerid

2545: Sex-Determining Region Y Protein (19)

cell determin develop earli **femal** gender
identifi **male** mate offspr patern patient
process protein reproduct sex sexual stage steril
time

2547: Exotoxins (22)

analysi **cell** concentr develop effect gene
human increas individu infect **isol**
level **patient** protein rate
respons **strain** studi subject
treatment

2549: Protein Disulfide-Isomerase (9)

chang class complex data enzym
evid famili **form** format
initi interact mutant
mutat process produc
product protein residu
site support

2551: Fibroblast Growth Factor 8 (20)

cell **develop** development earli
embryo embryon express gene morphogenesi
mous neural pattern rate requir respons
treatment tube tumor vertebr zebrafish

2546: Pentosyltransferases (16)

analysi associ cell **chang** dna
enhanc enzym **gene** gener
group increas isol local model
regul resist select **state** strain time

2548: Isomerases (4)

acid amino cell **class** differenti event gene
genom initi mhc molecul mutant nuclear
phenotyp process **protein**
repeat stabil structur variabl

2550: Calreticulin (14)

activ analysi associ cell chang develop differenti
effect function gene high human mass
patient prolifer **protein** reduc
sampl studi tissu

2552: Radioactive Pollutants (15)

area differ effect examin function group
health human increas japan live locat main margin
rate region relat resid studi zone

2553: Polynucleotide 5'-Hydroxyl-Kinase (2)

bind complex dna enzym event form format
induc involv length mix neg posit process
produc **product** repeat
respons treat treatment

2555: Receptors, Neurotransmitter (12)

activ affect analysi blot **cell** chang
develop differ express famili
increas pathwai plai posit protein
receptor respons **role signal** western

2557: Pentamidine (3)

adapt approxim broad cell children divers
evid **includ** interact major mechan
protein provid rang rel **select**
spectrum support varieti wide

2559: Busulfan (15)

allogen autolog chemotherapi control dai differ

diseas donor follow graft month patient

product receiv recipi reject select stem surviv

transplant

2554: Protamines (16)

activ assai complex control **correl**
deliveri detect develop **differ**
effici femal **interact** male pattern
protein role signific sperm surfac
target

2556: Antiprotozoal Agents (10)

activ assai associ caus children
concentr detect differ effect human
includ interv lead model rang ratio **risk**
sensit **studi** tissu

2558: GAP-43 Protein (10)

adult analysi **ASSOCI** compar decreas
develop enhanc express **function**
higher **increas** interact lower
neuron rate rel role suggest
treatment year

2560: Peroxisome Proliferator-Activated Receptors (11)

activ analysi complex effect function gene
genet group **human** improv life
mutat plai qualiti rat **receptor**
regul respons **role** time

2561: Aldose-Ketose Isomerases (5)

activ clone dna enhanc enzym
gene genom **human** isol larg
methyl process sampl sequenc size small
specif strain substrat target

2563: Acetylglucosamine (13)

activ bind develop differ earli increas indic
interact level mutant normal presenc
protein residu **site** suggest
tissu treatment tumor wild-typ

2565: Heterogeneous-Nuclear Ribonu-
cleoprotein U (3)

affect bind complex dna gene inhibit map
method **mice** mous mutant network nuclear
nucleotid predict recent **region**
sequenc transcript transgen

2567: Ofloxacin (6)

assai compar **detect**
differ higher **human** hybrid isol
lower new pattern probe provid **rate**
sensit specif strain **studi**
treatment trial

2562: Glucosamine (8)

analysi anim **cell** chines develop
differ effect enzym express function gene
group increas model posit **protein**
reveal site **studi** subtyp

2564: Phosphorylcholine (16)

analysi associ cell combin compar control effect
function gene human increas
light mechan model number rate rel
respons structur treatment

2566: Phosphoenolpyruvate Sugar
Phosphotransferase System (3)

chromosom complex delet dna
element **gene** genom insert integr isol
linkag loci locu map **mutant**
mutat region sequenc strain wild-typ

2568: Ethacrynic Acid (3)

acid caus concentr effect
experi gener increas inhibit
initi intern lead method modifi
origin potenti regul releas
second **stimul** subsequ

2569: Cellulase (16)

activ analysi cell clone control earli effect
fungal fungi **gene** genom isol
pathogen plant produc product select
sequenc stage time

2571: Thiohydantoins (2)

acid amino assai chemic compound
deriv detect exposur immun metabol plai
regul regulatori respons **role** sensit
specif suggest tumor vaccin

2573: Receptors, Cholinergic (21)

alpha alter cell chang develop diseas
enhanc express function gene increas
model muscl neuron patient
receptor suggest test time
tissu

2575: Pulmonary Surfactant-Associated Proteins (2)

analys cancer **diseas** examin factor length
long lung malign mutat plai progress
repeat risk **role** short speci studi
suggest tumour

2570: Indoleamine-Pyrrole 2,3-Dioxygenase (7)

analysi base cell concentr **differ**
enhanc **express**
function gene larg mechan
molecular pattern promot **protein** size
small target tumor variabl

2572: Quinolizines (5)

acid **activ** analysi area cell
chang condit degre **differ** observ
pattern period point resist reveal studi
test time tumor tumour

2574: Amino Acyl-tRNA Synthetases (17)

acid bind cell enzym function
genom human initi interact
level mrna new **protein** provid
region ribosom sequenc site
structur **translat**

2576: Phosphotransferases (Phosphomutases) (5)

activ analysi assai case compar control
detect genet increas indic interact
patient protein remain report
residu reveal sensit **site** studi

2577: Eicosapentaenoic Acid (7)

acid amino blood cell cluster compar
concentr decreases differenti high higher increas
level low organ period point rate **time**
treatment

2579: Megestrol Acetate (4)

a**ctiv** approach bodi breast cancer dai differ
exposur extract **group** model patient
period point random target **time**
treatment trial weight

2581: Lithium (29)

bipolar chang depress develop differ
disord effect express gene group
increas level patient person psychiatr signal
studi symptom treatment valu

2583: Flavins (8)

activ bind cell effect enhanc
enzym higher kinet level
method plai rapid rate remain
role site state subject substrat techniqu

2578: Appetite Stimulants (1)

approach cancer cours design durat end fish hybrid
improv limit method period point probe random
strategi success techniqu **time** trial

2580: Sparteine (1)

activ base chemic compound data deriv
dynam energi enzym experiment literatur
model paramet publish report
review search simul solut term

2582: Styrenes (2)

acid amino compar compound deriv
differ factor growth map mass mutat
pattern peptid period point similar stabil surfac
time type

2584: Flavin-Adenine Dinucleotide (13)

activ bind chang **effect**
enzym form format metabol
mutant mutat normal prevent product protect
protein reduc reduct role substrat tissu

2585: Methylprednisolone (44)

administr associ clinic **dai** dose effect
follow group month **patient**
rate receiv sever studi system therapi time
treat **treatment** week

2587: Activated-Leukocyte Cell Adhesion Molecule (3)

adapt adhes base cancer **cell** content
express flow **gene** identifi
microarra multipl **normal** observ pair
profil regul screen **select** **tissu**

2589: Penicillins (15)

activ analysi antibiot associ bacteri cell
clinic control gene group host human
infect number parasit pathogen
patient risk studi
treatment

2591: Testosterone 5-alpha-Reductase (15)

allel **cancer** cell compar control
differ effect femal gene genotyp group male
patient polymorph prostat rate repeat sex
studi treatment

2586: Cytidine Triphosphate (4)

abil **activ** alter anim bind cell chang
complex differenti enzym genet model mutant
phenotyp potenti properti rna system target tumour

2588: Lithostathine (3)

abil affect analysi **associ** base blot
cell differenti evid **express**
gastric mean pair prolifer properti provid studi
support surviv valu

2590: Medroxyprogesterone 17-Acetate (19)

activ breast cancer cell compar
dai develop **express** group
human increas **level** number
patient **respons** studi subject
treatment trial tumor

2592: Binding Sites, Antibody (23)

antibodi antigen bind cell
differ effect group **interact** mab model
monoclon neutral new number peptid protein
sampl specif studi tumour

2593: Ornithine (4)

activ approxim associ concentr dai evid
form format high level low month patient rel
suggest support target time tumor valu

2595: Caffeic Acids (4)

acid alter amino **cell** chang concentr
differ effect enhanc growth higher human
increas induc inhibit mutant new process rate
treatment

2597: Acetylglucosaminidase (15)

alter blood **chang** compar
concentr **control** decreas differ
effect famili form human
increas individu level observ
patient reduc signific time

2599: Aziridines (14)

activ assess cell compound
concentr **effect** express high
level **measur** normal
patient rate score select specif
studi **tissu** treatment valu

2594: Glycosylation End Products, Advanced (32)

associ cell detect develop **diabet**
express form function glucos human identifi
insulin level mellitu metabol patient protein
sensit studi subject

2596: Phenylethyl Alcohol (7)

acid amino analys **analysi**
cell concentr data determin differ extract
famili model perform respect reveal role
sampl studi test valu

2598: Formazans (9)

assai cancer **cell** compar detect differ

express group high higher induc

level low normal rate respons

sampl select studi **tissu**

2600: Phosphopyruvate Hydratase (39)

cell combin compar develop differ
express gene genet higher **level**
neuron patient plai protein rate
role serum studi treatment tumor

2601: Dehydroepiandrosterone Sulfate (13)

associ bodi differ elev group high higher
hormon human individu **level**
patient plasma rate sampl serum studi
subject tumour women

2603: Hallucinogens (8)

clinic concentr **effect** function high
increas method normal oral patient
period point reduc sampl sever studi
symptom **time** tissu year

2605: Bufotenin (1)

absenc addit blood combin compar correl
disord effect enzym **function** head
index modifi normal observ presenc
relationship signific studi **tissu**

2607: Nickel (33)

activ cell compar concentr
control develop **effect**
exposur group high level low model
patient reduc **respons** sampl
studi time water

2602: DNA, Z-Form (8)

anim base differ dynam experiment genotyp
high human mechan **model**
molecular normal pattern product state
structur studi subject time tissu

2604: Receptors, Serotonin (20)

activ associ bipolar control depress differ
disord function genet group
patient person popul psychiatr receptor
serotonin sleep studi symptom tissu

2606: N,N-Dimethyltryptamine (1)

analysi bladder brain chronic complement demonstr
determin diseas electrophoresi enzym gel highli
human identifi intestin mass proteom
specif tract urinari

2608: Aquaporins (34)

activ cell **develop** express famili function
gene group human increas intracellular
membran model new plai
protein renal role studi transport

2609: Aquaporin 2 (5)

approxim CAUS chain clinic complex
develop development enhanc
express lead major mass membran p53 pcr random
reaction rel studi trial

2611: Adrenergic beta-Agonists (36)

analysi cardiac concentr decreas develop
effect group heart **human** increas
level method number patient
receptor releas
respons stimul studi treatment

2613: Pyridazines (7)

analysi cell compar compound
concentr dai differ dose **group**
higher **identifi** increas level
model novel rate screen
studi test time

2615: Acyl Carrier Protein (5)

acid amino analysi base complex
concentr cultur dai effect enzym evid fatti **gene** reduc
regul residu reveal risk site support

2610: Felodipine (3)

analysi **ASSOCI** chang
compar control extract healthi high
higher level low mean **rate** respect
reveal studi **subject**
treatment trial valu

2612: Hydrazones (6)

approxim cell combin compar **dai**
decreas differenti dose effect
human increas major mice
new observ product provid rel trial
week

2614: Phosphorylase Kinase (4)

caus clinic complex diagnosi **differ**
evid genet lead mechan method molecular
morpholog multipl **mutat** pattern
popul presenc provid **structur**
support

2616: Glycosaminoglycans (36)

accumul activ adhes **cell**
compar control differ diseas group
increas integrin level molecul
normal **patient** process sequenc
studi tissu treatment

2617: N-Acetylgalactosamine-4-Sulfatase (4)

accumul amyloid case clinic
concentr criteria dai deposit diagnos
diagnosi diagnost diseases dose
laboratori lysosom patient random storag test
trial

2619: Succinate-CoA Ligases (1)

activ condit defect defici degre dna heat
indic mitochondri mitochondria mtdna mutant
mutat residu shock site suggest syndrom temperatur
wild-typ

2621: Electron Transport Chain Complex Proteins (7)

activ case compar complex
condit decreas degre differ diseas effect
gener group identifi
increas mitochondri new
rate reduc screen year

2623: Thiocarbamates (14)

activ base cell differ effect
factor group high involv low mechan
nf-kappab pair process produc
product report studi subject
treatment

2618: Thymine (50)

allele analysi associ base develop
differ dna famili gene
genotyp human increas
member mutat observ pair patient
polymorph protein studi

2620: Transcortin (4)

associ correl dai determin elev higher increas
level lower measur observ plasma popul
relat relationship risk serum signific studi thyroid

2622: Calcium Chloride (7)

activ analysi assess associ develop
effect evalu featur function measur model
mutant organ patient reveal score sequenc
studi treatment valu

2624: Digoxigenin (6)

cell chain detect develop dna fish fluoresc
genet genom group hybrid
individu method popul posit probe
reaction sampl select situ

2625: Oncogene Proteins v-erbB (15)

associ cell control decreas degre develop
express factor genet growth increas
level model neg patient plai posit
receptor role tumor

2627: Hydroxysteroid Dehydrogenases (2)

allel blood cancer cell differ express extract
fraction function genotyp larg
larger mice mous mutant number polymorph
prepar size small

2629: Copper Sulfate (6)

bodi compar correl earli group
increas level local model
normal number plai protein rel
role stage studi test tissu
treatment

2631: Dicarboxylic Acids (12)

acid activ amino concentr control
data effect enzym error estim
level measur method model
organ product protein statist structur
studi

2626: Cardiolipins (7)

apoptosi cell detect enhanc factor
famili growth identifi includ mechan
mitochondri process rang screen select
sensit time tumor valu vivo

2628: 3-Hydroxysteroid Dehydrogenases (12)

activ bind cell concentr effect
express gene genet group
hormon inhibit mechan mutat
patient popul rate sequenc specif
treatment women

2630: Lysophosphatidylcholines (6)

approxim bind bodi compar control decreas
differ high increas level low
major number observ patient protein rel
studi valu weight

2632: Dimyristoylphosphatidylcholine (7)

abil associ combin compar concentr
determin differ domain interact
measur pattern posit properti rate regul
residu sampl site structur
valu

2633: Lipoxygenase (7)

acid amino analysi approxim
differ express form major
mutat new observ pattern region rel
respons select sequenc size specif
tumor

2635: Fish Proteins (22)

activ analysi associ base conserv develop
differ duplic evolut evolutionari
express function gene
genom increas protein region
sequenc speci suggest

2637: Protein Inhibitors of Activated
STAT (14)

activ control degrad express famili
function identifi interact involv mechan process
proteasom **protein** regul requir
suggest transcript treatment ubiquitin variant

2639: Trimethoprim-Sulfamethoxazole
Combination (3)

adult approach clinic design diagnosi high level
low method older **patient** presenc
recombin resist strategi studi tumour variabl
year young

2634: Egg Proteins (15)

clone develop dna earli embryo
enhanc express function gene genom
high increas matur oocyt
protein role sequenc site
stage transfer

2636: Vitellogenins (13)

analysi assai base detect develop
differ **drosophila**
femal gene identifi insect male mean
melanogast protein region sequenc
speci time valu

2638: Silver Nitrate (4)

analysi **chines** correl design determin
differ gene genom
heterogen hospit isol mechan plant
respect signific strain **studi**
subtyp time variabl

2640: Plicamycin (6)

activ analysi assai bind decreas element
express factor gene increas level mutant
produc product **promot** region
regul reveal site transcript

2641: Proto-Oncogene Protein c-ets-1
(23)

activ analysi bind cell control develop
express gene group increas
invas normal **promot** protein
regul role site studi tissu transcript

2643: Acetophenones (7)

cell combin dai decreas effect form
format **human** increas new plai
point provid **role** studi suggest target
test **time** treatment

2645: ral GTP-Binding Proteins (10)

activ analysi assai bind
cell detect effect
function inhibit migrat
number overexpress phenotyp
process regul requir **role** sensit
suggest transform

2647: Ornithine Carbamoyltransferase
(6)

abil **activ** area caus chang decreas
defici demonstr enhanc group **human** increas
mechan model plai properti rat report role studi

2642: Benzopyrans (21)

activ apoptosi **cell** compound
decreas detect function high
human identifi increas
level mechan molecular produc
product sampl screen select studi

2644: Sphingosine (25)

activ apoptosi **cell** differ earli evid
express gene **human** identifi model
pattern protein regul requir resist role stage
studi support

2646: Acetyl-CoA C-Acetyltransferase
(1)

caus clinic defect defici develop exon **gene** inform
insight methods missens mitochondri **mutat**
new novel **patient** provid surgeri
surgic understand

2648: Valerates (1)

analys **analysisi** caus clinic
experi extern follow indic **initi** intern lead
origin patient perform reveal second seri
sever subsequ symptom

2649: Carbon-Carbon Ligases (2)

activ analysi blot brain child
children clone experi **express** initi
intern origin parent patient region second
sequenc target western year

2651: Transaldolase (1)

acut administr **clinic** complic cultur dai
defici dose **gener** liver manifest mild
patient present residu
sever sign site symptom week

2653: Acyl-CoA Dehydrogenase (12)

acid **activ** analysi anemia clinic
concentr defect **defici** diagnosi
gene group identifi level mutant protein role
sampl screen sever trial

2655: Guanylate Cyclase (25)

activ analysi **cell** effect express
gene identifi increas
marker mutat number
organ **patient** rel role screen
studi suggest synthas synthesi

2650: Keratan Sulfate (7)

blood cell compar **control** detect differ
diseas express famili genom higher mass
method mutat **new** product provid
rate specif tumor

2652: Galactosephosphates (4)

activ alter bodi chang concentr control
effect exposur featur **group** increas interact rat
report signific studi subject treat **treatment**
yeast

2654: 3-Hydroxybutyric Acid (5)

analysi base character complex concentr
extract improv life **mechan** molecular
phenotyp produc product
qualiti receptor regul report reveal risk studi

2656: Vehicles (5)

acid amino assess cell concentr detect
differenti evalu gene **group** level
local **measur** mechan posit repeat
requir score valu vector

2657: Deoxycholic Acid (7)

acid **activ** amino apoptosi caus cell
chang cluster dai decreas earli health
human increas line measur method protein
score studi

2659: Angiotensin II Type 1 Receptor Blockers (30)

adult **arteri** blood cardiovascular
clinic coronari effect **hypertens**
identifi infarct myocardi **patient**
pressur screen stroke studi
treatment trial vascular year

2661: Indoleacetic Acids (27)

acid arabidopsi cell differ flower gene leaf leav
model **plant** pollen regul root seed
seedl speci thaliana tobacco tomato transgen

2663: Hormone Antagonists (20)

compar control differ effect express gene
group higher **human** increas
inhibit level mechan patient rate receptor
reduc respons treat **treatment**

2658: Losartan (10)

arteri blood case coronari
dai form format **hypertens** larg
pressur product remain report
respons size stroke studi
treatment valu vascular

2660: Polydeoxyribonucleotides (7)

activ bind dna enhanc form format
gener **group** human includ
interact **multipl** region
repeat sequenc singl **specif**
structur therapi treatment

2662: 8-Bromo Cyclic Adenosine Monophosphate (9)

alter **cell chang** differenti
express function gene increas level mice
normal process product prolifer rate
respons select studi tissu treatment

2664: Mifepristone (15)

cell chang **combin** compar condit
control degre develop **effect** enhanc
express human increas mice
model observ rate **receptor** role
studi

2665: Wiskott-Aldrich Syndrome Protein (21)

actin activ cell compar congenit control
diseas express **gene** higher migrat
number patient phenotyp polar rate regul
respons select syndrom

2667: Nitrites (34)

activ associ decreas develop effect
function gene group **increas**
induc level nitric oxid product reduc
role studi suggest **synthas**

synthesi

2669: Antigens, CD98 Light Chains (2)

action **activ** basi data decreas elucid
express includ **increas** involv level
mechan molecular poorli
provid remain **studi** underli
understand understood

2671: Chlorothiazide (2)

associ combin condit dai degre dose
effect gene link **mechan** molecular **mutat**
patient protein rat relat studi suggest treat
treatment

2666: Oxidants, Photochemical (10)

activ compar decreas develop
effect express **high** higher
increas level low mean
mechan model molecular
rate reduc select treatment
valu

2668: Citrulline (12)

arthriti clinic concentr diseas gene genom
increas level **mechan** molecular pain
patient period point protein rate
serum studi subject **time**

2670: Diazoxide (5)

acid alter analysi blot case **chang**
concentr **differ** event fusion **increas** involv
mutat **patient** pattern plai
process role treatment western

2672: Sodium Chloride Symporter Inhibitors (5)

associ clinic effect enhanc function gene
identifi **mechan** **mutat** organ
patient phenotyp plai
polymorph repeat **role** screen sever suggest
variabl

2673: Nevirapine (9)

ASSOCI dai detect dose gene hiv hiv-1
immunodefici infect model mutat
patient report resist select
sensit specif studi viral viru

2675: Iodide Peroxidase (20)

activ associ cell combin compar
control develop diseas effect express
higher hormon level
patient rat rate serum
studi subject thyroid

2677: G(M3) Ganglioside (4)

abil accumul acid cell demonstr deposit differ
differenti effect enhanc genet growth
human inhibit interact mice
pattern reduc requir suggest

2679: Mouthwashes (4)

anim ASSOCI compar control form
format genom group
healthi human light method
model normal posit sampl
studi subject test tissu

2674: Thyroglobulin (26)

adenoma adren adult analysi braf endocrin
famili gland hormon level normal papillari
patient pituitari ptc ret studi
thyroid tissu year

2676: Glutathione Disulfide (9)

antioxid caus cell damag decreas enzym
event follow group increas
level measur mice mous oxid oxygen
process reactiv score stress

2678: RNA, Ribosomal, 5S (19)

activ analysi bacteria base
bind differ dna fragment gene
genet genom increas mechan
molecular pcr region repeat rna
sequenc speci

2680: Salicylates (10)

activ assai compar control detect effect genet
high higher induc induct level low method
product rate recombin respons
sensit test

2681: Fibrinolytic Agents (24)

arteri associ cell clinic factor function
human increas larg **patient** rate
remain risk role size small studi therapi
time treatment

2683: Aptamers, Nucleotide (10)

adult caus dna identifi insight method
new provid region repeat resist retin
screen sequenc state structur studi
treatment visual year

2685: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine (5)

activ anim cell **effect** factor inhibit
inhibitor mice **model** mous prevent
protein rat reduc reduct remain
risk site **specif** studi

2687: Humic Substances (7)

acid chain **concentr**
effect estim function
increas mechan **method**
model organ pcr polymeras product
reaction sampl select **studi**
time valu

2682: Ethidium (27)

activ caus **cell** chang combin detect
effect enhanc function gene identifi increas
method **mitochondri** new number
patient product respons studi

2684: Diphosphates (15)

activ analysi **bind** combin
effect **enzym** human mutant
mutat number product protein rate requir
reveal select site structur studi
treatment

2686: Pesticides (40)

assess carcinogen chemic differ effect expos
exposur famili genotox human
increas indic induc mutagen observ potenti signific
studi test toxic

2688: Neuromuscular Agents (17)

analysi associ care clinic coli dai differ
escherichia featur function **group**
health increas manag **patient** rate studi
therapi treat **treatment**

2689: Ouabain (11)

activ bind ca2+ calcium cell
chang channel codon
current decreas effect famili
function increas mechan
mutat new provid studi substitut

2691: Leprostatic Agents (2)

dose gene intermedi irradi kinet lesion
marker melanoma mutat primari radiat
resist rna skin speci stain state switch transit
vector

2693: beta Karyopherins (19)

complex cytoplasm export function gene larg
local method new nuclear nuclei
nucleu number process protein regul signal
structur transloc treatment

2695: Lepromin (1)

allele associ gene gener genotyp
haplotyp interact kinet link mean measur
polymorph ratio respect singl snp state studi
suscept valu

2690: Antihypertensive Agents (60)

arteri associ blood clinic control
coronari dai effect hypertens
increas methods number
patient pressur stroke
studi subject treatment vascular year

2692: S-Adenosylmethionine (16)

activ alter chang control decreas
develop differ dna effect enzym function
gene group human
increas level methyl
promot studi treatment

2694: Oxazolidinones (9)

case compar concentr
develop gener higher
infect mean method new organ
patient rang rat rate respect select
therapi time valu

2696: Misoprostol (8)

birth dai fetal gestat improv
infant life matern neonat
new physic pregnanc prenat
presenc qualiti respons
studi subject week women

2697: Arachidonate 5-Lipoxygenase
(11)

associ cell control effect
express form format human increas
inhibit inhibitor mechan plai rat regul
risk role studi subject suggest

2699: Carboxyhemoglobin (3)

approxim compar correl dai decreas defici elev
higher human increas **level**
patient plasma produc product rel serum
signific subject system

2701: Emetine (2)

absenc algorithm cultur decreas express gene genet
increas induc induct level method network predict
presenc promot resist respond
respons transcript

2703: Thallium (4)

absenc analysi approach collect compar
concentr decreas determin differ higher
increas lower presenc rat **rate**
regress **sampl** studi variabl versu

2698: Orotic Acid (4)

concentr detect distribut dna genotyp
local male method model
mutant number
polymorph recombin rel requir
sampl select sensit specif tumour

2700: Immunoglobulin A (43)

adult **antibodi** antigen assai
chang detect differ group human monoclon
multipl number patient sampl sensit specif
studi test time year

2702: Amebicides (3)

activ broad divers gene health includ
interact level major new presenc provid rang
recombin serum spectrum test type varieti wide

2704: Bacteriocins (24)

acid activ bacillu bacteri bacteria **coli**
escherichia gene group identifi infect
mutant operon phage product region sequenc
strain structur toxin

2705: Bupivacaine (10)

case compar effect gene **group**
higher increas inhibit injuri level patient rate
reduc report respons serum stimul surgeri
therapi treatment

2707: Proto-Oncogene Proteins c-bcr (8)

analysi cell compar differ differenti diseas express
famili high identifi leukemia level low model
patient pattern product protein
rate treatment

2709: Integrin alpha3 (2)

activ adhes bind **cell** effect extracellular
inhibit integrin interact kinas kinet matrix
migrat molecul protein receptor specif state
treat treatment

2711: Pravastatin (9)

alter apoe chang cholesterol clinic compar
effect genet **group** increas level
lipid lipoprotein mutat **patient**
plasma process signific studi subject

2706: Anesthetics, Local (26)

activ case control develop effect gene increas
inhibit model **patient** potenti rat
releas respons stimul studi surgeri surgic
treat treatment

2708: Mitogens (55)

activ bind **cell** differenti effect express
function gene growth human increas induc
induct inhibit mice prolifer rate region
respons sequenc

2710: tert-Butylhydroperoxide (5)

activ alter cell chang concentr dna
express gene increas inhibit mice mitochondri
organ oxid plai role suggest telomer telomeras
test

2712: Myristic Acid (7)

bind cell chang complex differ enhanc
famili fusion gener local member
model pattern region requir sequenc site
structur target treatment

2713: Excitatory Amino Acid Antagonists (34)

analysi behavior brain cell combin develop
differ effect function genet group increas
neuron patient perform rat
receptor reduc studi treatment

2715: Glycoside Hydrolases (37)

enzym ^{activ} cell clone differ earli
express famili function
gene high human low product protein residu
sequenc site substrat tissu

2717: beta-Fructofuranosidase (11)

cerevisia clone concentr **develop**
domain earli enzym **gene**
group identifi level
patient plant posit
region screen **sequenc** specif
studi yeast

2719: Paxillin (19)

actin activ adhes **cell** chang earli
function high increas level low migrat
molecul point polar protein regul role
time tissu

2714: Apigenin (15)

activ adduct analog analogu **cell**
compound decreas deriv
effect express extract fraction **increas**
level method rate rel role specif
treatment

2716: Cellulases (3)

differ ^{area bind chain} **combin**
effect enzym fungal fungi
genet interact isol mutant pathogen pattern
plant reaction speci studi type

2718: Myosin Light Chains (30)

actin analysi **cell** express format
human identifi increas local **migrat**
model **muscl** number patient polar
process protein regul requir
respons

2720: Actin-Related Protein 3 (13)

actin **cell** complex control
cytoskeleton distribut filament form format
local **migrat** new phenotyp polar protein
regul rho select small suggest

2721: Chylomicrons (7)

apoe apolipoprotein cholesterol function
high **human** ldl level lipid
lipoprotein low mutat normal plasma product
rel resist respons studi tissu

2723: Integrin alpha6beta1 (1)

cell code codon conserv cultur function human
identifi mammalian nicotin nucleotid overexpress
posit **protein** singl stop substitut
suggest transform usag

2725: Collagen Type X (12)

analysi cell chang combin
concentr earli effect express
factor **function**
growth individu
mutat protein rat
select signal stage studi test

2727: Bicuculline (12)

activ alpha approxim chang effect
gener increas inhibit major measur
neuron potenti rat **receptor**
reduc rel releas respons stimul suggest

2722: Receptors, Vitronectin (10)

adhes cell differ effect express
extracellular **function** gene
integrin molcul normal organ pattern
receptor report studi tissu treat
treatment vector

2724: Gene Products, vif (10)

activ correl dna domain herp hiv
hiv-1 human immunodefici
infect male **patient**

protein replic requir simplex specif target

viral **viru**

2726: Phenobarbital (15)

activ associ chang compar develop
differ effect gene increas
metabol mice mous normal
rat rate rel studi time tissU variabl

2728: Dizocilpine Maleate (15)

acid anim behavior cell cognit control
effect group high mice **model**
neuron product **rat** receptor reduc
role select time treatment

2729: Hazardous Substances (15)

approach assess base cell concentr
differ effect exposur factor
human measur model new
number provid remain risk specif
strategi studi

2731: Complement C3c (1)

accumul activ aggreg altern carrier coloni
convers diseas effect exon factor form
format inhibit nuclear risk
splice suggest suppress variant

2733: Hydroxybenzoic Acids (6)

acid cell concentr determin differ extract
gene identifi larg model number organ
process rel screen size small studi support
time

2735: Dioxygenases (25)

activ cell decreas effect enzym
express famili gene group identifi increas
level plai process reduc region role select
sequenc substrat

2730: Complement Membrane Attack
Complex (6)

bind case cell compar complex compon
control differ form format
frequenc level method polymorph regul repeat
signific specif test time

2732: cis-trans-Isomerases (4)

activ cell compar concentr data differ enzym
essenti gene higher lower mice protein
rate requir respect retin test versu
visual

2734: Gentisates (1)

affect critic encod essenti factor function gene
growth involv maintain mainten membran necessari
pathwai requir schizophrenia signal studi suffici suggest

2736: Glutaral (6)

activ cell compar differ dna effect evid
exposur group light patient
protein provid rate role studi support test
treatment trial

2737: Chlorine (6)

alter approxim **chang**
concentr data distribut extract life
local major method model
normal observ organ process
qualiti rel sampl tissu

2739: Cesium (11)

associ compar control differ dna effect famili
group increas initi level measur
method model normal number origin radiat
signific tissu

2741: Dextrans (20)

cell chang compar concentr control decreas
differ effect **group** higher
human **increas** level lower mice protein
rate reduc studi tissu

2743: CDPdiacylglycerol-Serine O-
Phosphatidyltransferase (1)

activ associ character concentr constitut
ebv exhibit factor growth inact microg microm min
mitochondri phenotyp plasma protein residu site
suggest

2738: Tetrachloroethylene (1)

approxim compar differ discuss greater **higher**
hospit larg lower major number particip **rate**
recent rel respect similar size small versu

2740: Tetraethylammonium (3)

abil activ anim calcium channel children
combin concentr effect genom
induc inhibit microm **model** organ
phenotyp properti **respons**
sequenc studi

2742: Cathepsin D (25)

activ assai associ cancer cell
control detect express gene group human
invas matrix model patient protein
respons sampl surviv target

2744: Phosphatidylglycerols (10)

acid **associ** detect determin differ
form format **gene** identifi increas indic
observ phenotyp presenc report site
structur **studi** suggest vivo

2745: IMP Dehydrogenase (9)

caus cell chang enzym express featur gene
high identifi level low method model
mutat patient rel
sampl select size test

2747: alpha-Linolenic Acid (7)

acid amino analysi bodi cluster
concentr data decreas effect gene human
increas level **model** product rat reduc
respons specif weight

2749: Glycine Hydroxymethyltrans-
ferase (5)

activ assess children compar control degre develop
gene larg measur
evalu evid express mechan risk score size small studi support

2751: Dopamine Plasma Membrane
Transport Proteins (31)

analysi associ bipolar depress develop
disord express gene genotyp human
neuron patient person polymorph psychiatr
respons risk sleep studi symptom

2746: Guanine Nucleotides (7)

ASSOCI bind caus chang compar
control correl delet express
famili frequenc individu interact lead
region rel respons sequenc signific tumor

2748: Ferredoxin-NADP Reductase (8)

cell children compar control **differ**
dynam factor form format mechan
model paramet pattern product rel
select simul size **STRUCTUR** valu

2750: Platelet Membrane Glycoprotein
IIb (12)

analysi base **cell** complex detect differ
factor **function** gene mutant
mutat pair **patient** product **protein**
receptor respons stem studi subject

2752: Levodopa (26)

affect analysi clinic develop differ
diseas earli effect group human
level mutat neuron **patient** progress rel
respons stage studi treatment

2753: Phosphorylase a (2)

activ addit affect alter **chang** decreas effect
endogen **enhanc** increas inhibit
modul month patient rat reduc regul site
suggest year

2755: Adenosine Diphosphate (44)

activ bind cell channel complex
effect express function gene human
interact mutant mutat region respons role
sequenc specif state **structur**

2757: Uridine Diphosphate Glucose (4)

absenc **activ** bind combin distribut effect
enhanc enzym express function **gene**
higher human local presenc rate requir site
structur time

2759: Xylenes (6)

analysi area blot concentr
decreas differ enzym follow increas
level model number pattern product
region reveal sequenc serum
studi western

2754: Phosphorylase b (2)

activ affin **bind** compound
concentr deriv effect enzym inhibit
interact microg microm min plasma protein
regul residu respect site structur

2756: Glucosephosphates (3)

activ analysi **associ** blot
concentr effect enhanc enzym express form
format **gene** increas inhibit microm min
protein substrat suggest western

2758: Thyrotropin-Releasing Hormone (9)

analysi case **cell** clone differenti gene
identifi increas isol **level** mechan
point product screen **sequenc** serum
state studi thyroid **time**

2760: Benzene Derivatives (16)

acid analysi cell chemic compound data
effect estim expos **exposur**
inhibit level method model mutant new
rate respons select toxic

2761: Clozapine (13)

affect associ control differ effect evid
examin find group implic influenc involv met
possibl report **schizophrenia** signific studi
suggest unaffected

2763: GTP-Binding Protein alpha Sub-
units, Gq-G11 (14)

acid **activ** alter cell chang
decreas express gene high increas inhibit level
pathwai protein receptor **respons** signal
stimul studi tissu

2765: Sulfates (31)

activ analysi cell
chang concentr
differ effect gene genom
local **model** pattern process
product role sampl **select** test
treatment water

2767: beta 2-Microglobulin (26)

antigen **class** combin control develop effect
express hla increas level major mhc mice
molecul **patient** renal studi
treatment vitro vivo

2762: Antigens, CD43 (6)

activ adult blood **cell** combin data
decreas express **increas**
interact lymphoma mice multipl phenotyp
process regul rel risk tumour year

2764: Cytochrome P-450 CYP2B1 (8)

activ adapt area base compar
control differ enzym famili increas level
metabol normal product rat region
select studi subject tissu

2766: Sulfur Isotopes (4)

adult area bind **cell**
concentr conserv earli evolut form
format increas mean measur **number**
receptor respect speci stage valu year

2768: Furin (16)

activ analysi caus cell data differ
effect event express gene genom involv lead
mutat **process** protein rate residu
sequenc **site**

2769: Myosin Type V (8)

abil analysi associ bind cell
differ domain
function interact isol mice
mutat pattern properti protein reveal
select **strain** structur system

2771: Tropoelastin (13)

adhes cell collagen control
develop effect extracellular integrin interact
matrix model molecul organ plai process
requir **role** studi surfac tissu

2773: Myosin-Light-Chain Kinase (11)

actin activ **cell** chain combin control
effect enhanc growth migrat muscl mutat
process protein reaction regul requir studi
test treatment

2775: Nonmuscle Myosin Type IIA (7)

bind chain content determin
experi flow inhibit initi mechan
muscl organ origin pcr polymeras
product reaction regul report
studi **target**

2770: Congo Red (11)

accumul analysi cell chang **form**
format genom human indic light
microscopi model morpholog observ
protein reveal stabil state
structur time

2772: GATA6 Transcription Factor (17)

activ analys **analysi** cell express
factor function gene genom mechan model
normal protein regul repress reveal role studi
tissu **transcript**

2774: Serum Response Factor (20)

chang differ gene induc induct interact level muscl
mutant pattern phenotyp promot protein requir respond
respons sampl studi suggest
transcript

2776: Nonmuscle Myosin Type IIB (4)

analysi blot chain compar **control**
differ express frequenc higher induc local rate
reaction report **respons** splice
studi valu variant western

2777: Myosin Type II (15)

actin activ associ **cell** form
format genom migrat mutant
mutat new polar popul posit process
protein regul requir specif suggest

2779: Phosphoric Acid Esters (12)

activ assess base **cell** concentr dai data
differ **enzym** estim human
measur method multipl new score studi
substrat test tumour

2781: Viral Hepatitis Vaccines (3)

base caus clinic current data initi lead length
origin pair **patient** protein
rat recombin repeat second short therapi
treatment viru

2783: Amino Acids, Aromatic (5)

acid bind carbon cluster determin
electron **energi** exchang free
higher measur mutat **rate** regul
solut specif spectra spectroscopi state
structur

2778: 2-Methyl-4-chlorophenoxyacetic Acid (1)

broad cell data divers effect evid exposur
gene hypothesi includ major provid
rang spectrum support type varieti vitro
vivo wide

2780: Lanthanum (3)

cell chain dai delet detect differenti
express fish fluoresc follow form format **gene**
hybrid marker presenc probe prolifer reaction situ

2782: Amantadine (10)

assai combin data detect differ
function gene high individu model
mutant mutat new patient protein respons
sensit **studi** therapi
treatment

2784: Alkenes (4)

assess cell cluster compound concentr decreas
degre differ express gene **group**
increas inhibit interact line measur model
resist score structur

2785: Insulin-Like Growth Factor Binding Proteins (18)

analysi bind cell control develop factor famili
genom **growth** human igf-i increas
level member mutat number phenotyp protein risk
tissu

2787: Cytidine (14)

activ caus cell control **dna** form gene
gener lead level mechan methyl mice patient
promot region replic respons sequenc target

2789: Gadolinium (12)

activ combin compar dai
differ dose effect
express group imag increas
irradi **patient** popul radiat
rat rate studi time treatment

2791: Nucleoside-Triphosphatase (5)

activ biolog dai dna dose enhanc enzym
famili includ mean member per popul rang region
respect sequenc subject system valu

2786: Pyrimidine Nucleosides (4)

activ cluster compar complex
control earli enzym form
format genet genom multipl region risk
sequenc stage structur studi subject target

2788: Heterocyclic Compounds, 1-Ring (6)

assai caus cell concentr **correl** data
detect determin **develop**
model posit rat rel sampl
sensit specif **studi** target therapi
tumor

2790: Pentetic Acid (7)

analysi case compar **control**
dai dose famili high higher
human imag low method
rate rel role **target** tumor vivo week

2792: Metformin (15)

base clinic combin design **diabet** differ
effect estim glucos group hospit
human insulin patient reduc reduct studi
therapi **treatment** trial

2793: Collagen Type II (45)

cartilag cell chondrocyt collagen develop
differ express factor group
growth mutat role signal
studi suggest **tgf-beta** **tgf-beta1**
time tissu transform

2795: Hematinics (14)

anemia chang **combin** dai defect
defici differ dose effect
function high increas level normal
patient product role studi tissu
year

2797: Hydroxyapatites (1)

associ **CONCENTR** deliveri effici gene haplotyp
light microg microm min mix particl plasma
polymorph produc **product** snp
sourc surfac yield

2799: Clathrin (18)

cell cellular control endoplasm express
intracellular local **membran**
method nuclear plasma **protein** reticulum role size
surfacc traffick **transport** uptak vesicl

2794: Receptors, Oxytocin (5)

area **ASSOCI** chang
children decreas detect earli
gener high **increas** level low mean
model new peptid presenc receptor studi
valu

2796: Phosphodiesterase Inhibitors (26)

activ adult cell combin differ
effect gene group human increas mechan
mutat **patient** protein respons
structur studi subject treatment year

2798: Durapatite (17)

bone chang compar control decreas
effici form format higher
human increas level
method **protein** rate sampl
structur surfacc time treatment

2800: Folic Acid Antagonists (19)

base chemotherapi combin dai data
differ **enhanc** human increas
model month observ
patient pattern resist studi
suggest target therapi **treatment**

2801: Cryoprotective Agents (17)

alter cell **chang** develop egg
embryo fertil function germ
increas matur normal number oocyt
protein sampl sperm testi transfer vitro

2803: Propylene Glycol (3)

alter analys **analysi** caus
chang data estim increas lead
multipl new predict provid regress reveal
signific sperm treatment variabl variat

2805: MAP Kinase Kinase 5 (3)

activ anim cancer cell character characterist
common complex diseas distinct featur includ
kinas model pathwai phosphoryl signal
studi target vivo

2807: Phosphoric Triester Hydrolases (1)

basi bind conform crystal element enzym form
insert integr interact involv **mechan** modifi
molecular oral residu site **structur**
underli understand

2802: Chromogranins (16)

adren assai associ cancer concentr detect
express featur gene hormon increas level
marker new **patient** role sensit
serum thyroid tumor

2804: Mitogen-Activated Protein Kinase 7 (14)

activ cell function high increas
induc inhibit **kinas** level low mice
new pathwai **phosphoryl** popul
protein rat respons signal **studi**

2806: HIV Integrase (10)

analysi cell domain
element famili genet
genom hiv-1 infect **insert** integr
plai protein reveal **role** select
specif suggest **time** viru

2808: Casein Kinase Iepsilon (2)

algorithm circadian clock clone delet discuss
enhanc feedback hamster increas loop
method network period predict
protein recent signal suggest
time

2809: Mannich Bases (2)

abil **base** condit degre differ
effect **express** imag
interact mean measur observ pair properti
reduc reduct structur temperatur test valu

2811: Inosine (16)

analysi **ASSOCI** compar
compound **control**
deriv differ function gene
human product region role sampl
sequenc size small **structur**
studi **tumour**

2813: Phenylalanine Ammonia-Lyase (9)

acid **activ** biosynthesi catalyt chang develop
effect **enzym** gene genom identifi
level **protein** resist **respons** role screen
substrat time treatment

2815: Methylphenidate (10)

assess behavior bipolar children cognit
depress develop **disord** effect
function male measur person psychiatr sampl
score studi subject symptom time

2810: Methylamines (9)

analysi associ base compar control
data differ **gene** higher increas lower
model organ phenotyp **rate** reveal
sequenc specif studi versu

2812: Avidin (15)

approach bind cell control detect
develop express fish fluoresc group
hybrid method new normal
probe **protein** provid rate situ
tissu

2814: Desmosine (2)

acid adhes amino analysi blot
develop express form
format gener **genom** multipl protein
sequenc site speci **specif** structur test
western

2816: Amphetamine (11)

associ behavior cognit dai **effect**
femal **function** impair improv
increas life male model oral perform rate
requir studi test **treatment**

2817: Ellagic Acid (5)

acid activ cell compar dai decreas effect
enhanc extract group **human**
increas inhibit malign normal rat studi tissu
tumor tumour

2819: Abscisic Acid (23)

activ analysi arabidopsi differ flower function
increas leaf leaf **plant** pollen respons
root seed seedl thaliana tobacco tomato transgen
treatment

2821: Glycine Dehydrogenase (Decarboxylating) (2)

area case common delet differ express featur
gene **high** identifi larg level
low **mutat** novel number
screen site size small

2823: Amino Acid Transport Systems, Basic (43)

alpha-synuclein alzheimer autoimmun caus common
diseas
dementia disord fabri gene includ
neurodegen onset parkin parkinson pathogenesi patholog
patient progress tau

2818: Arachidonic Acids (8)

acid alpha associ beta effect enhanc form high
increas inhibit level low number potenti
receptor role subject suggest
target therapeut

2820: Cyclopentanes (21)

activ analysi arabidopsi cell chang compound
effect enhanc gene increas induc induct leav
plant product rat reduc
respons root seed

2822: Amino Acid Oxidoreductases (14)

activ cell effect express **gene**
group high identifi level plant
produc **product** region repeat
residu sampl screen sequenc **site**
studi

2824: Erucic Acids (3)

acid amino analys analysi chain
decreas detect **genet** increas
molecular number pcr plai produc product
reaction resist reveal role studi

2825: Triolein (2)

acid amino cell clinic codon cultur effect exposur
express improv individu organ
patient random receptor studi
substitut treat treatment trial

2827: Sugar Acids (6)

chang compar differ dna **group**
interact level plai process product rel role
select serum signific site studi suggest
treatment valu

2829: Glucosyltransferases (36)

activ analysi cell chang effect
enzym express function **genē** increas
patient plant product protein resist role
sequenc site studi substrat

2831: Thioinosine (1)

approxim compar concentr decreas delai
increas level long-term
follow major min minor mutat observ occur persist
reduc rel suggest synthesi

2826: Galactitol (2)

alter area bodi chang control differ effect
group increas level presenc produc
product rat serum signific studi treat treatment
yeast

2828: Phloroglucinol (7)

analysi compar concentr **control**
data differ effect enhanc frequenc interact
isol level random sampl select specif
strain studi trial valu

2830: Equilibrative-Nucleoside Trans-
porter 2 (1)

decreas **effect** endotheli gene incorpor
increas induc level methyl nitric oxid prevent
product protect **reduc** reduct suggest synthes
synthesi vegf

2832: Clonixin (1)

area bovin compar dai differ dose effect
element higher insert interact locat lower pig
rate respect studi treat
treatment versu

2833: Hydroxyproline (13)

compar control decreas develop differ effect
express function **group** identifi
increas level mass mice normal number rat
structur time tissu

2835: 3',5'-Cyclic-Nucleotide Phosphodiesterase (14)

associ cell compound detect enhanc
gene genom high hybrid level mutant
polymorph protein rate receptor sampl select
structur suggest treatment

2837: Hepatitis B Antibodies (12)

clinic induc induc infect liver method number
patient posit product rate
respons risk specif test time
treatment variabl viral viru

2839: Osmium Tetroxide (1)

administr algorithm dai data **distribut**
dose fluid imag inject **local** manag medic
method network pain predict
rat set techniqu week

2834: Rolipram (2)

activ compound control effect experi
healthi **high** imag inhibit initi level low
magnet origin rat releas second stimul subject
volum

2836: Pituitary Adenylate Cyclase-Activating Polypeptide (5)

alter bind **chang** combin decreas
disord effect factor flow gener hybrid
increas new pathwai protein
provid receptor risk signal surviv

2838: RNA, Small Nuclear (48)

altern complex differ encod **EXON** gene

human identifi intron isoform melanoma

novel rna site size small **splice** structur

transcript **variant**

2840: Yttrium Radioisotopes (17)

clinic control dai dose effect famili group
lymphoma month new **patient**
posit radiat respons therapi treat treatment
tumor valu year

2841: alpha-Glucosidases (12)

accumul
activ amyloid case
deposit diseas function gene gener
increas mice model muscl patient
posit report respons storag studi suggest

2843: Staphylococcal Protein A (4)

alter assai base cell chang correl dai detect
gene gener infect mutat patient
repeat report sensit studi target valu vector

2845: Juvenile Hormones (16)

analysi cell drosophila
effect express gene increas insect larva life
melanogast mutant popul produc product
rate role specif suggest treatment

2847: Poly C (5)

base cell differ effect express
gene genet genom high length level low
mechan molecular mutat pattern repeat
select treat treatment

2842: Creatine Kinase, MM Form (4)

analys analysi bind caus control
gene indic individu mice
mutant region report reveal risk
sequenc site structur studi
subject vector

2844: Toothpaste (3)

administr combin compar control dai differ dose
effect group organ signific studi
subject test treat treatment variabl vitro vivo
week

2846: Endotoxins (44)

analysi coli control correl differ
drosophila effect express gene
increas individu level measur protein
resist respons strain studi test time

2848: Ether-A-Go-Go Potassium Channels (28)

activ associ atp ca2+ calcium cell
channel concentr current
develop express famili increas intracellular ion
mechan model respons sodium subject

2849: Egtazic Acid (17)

activ alter analysi bind cell
chang channel enhanc
function genom high
increas level low model
popul protein regul studi
valu

2851: Epinephrine (29)

activ cell chang control dai detect effect
group human increas level patient
receptor releas respons risk stimul studi test
year

2853: Hippurates (1)

acid amino analysi care class cost divers
electrophoresi gel genet identifi manag mass
medic month patient popul
practic proteom year

2855: Cardiac Myosins (10)

cardiac chain evid express gene
genet heart increas interact
mutat patient posit
process provid reaction sampl sequenc
studi support target

2850: Myosin Type I (2)

associ confid demonstr energi enzym evolut
find form interv kinet previou protein
ratio report risk smoke stabil
state studi suggest

2852: Protein-Lysine 6-Oxidase (6)

assai cell data detect enhanc enzym
express identifi measur
mechan model plai recombin region
role score screen sensit sequenc test

2854: Chlorogenic Acid (3)

activ adult blood compound divers
genet genotyp inhibit loci patient phenotyp
polymorph popul rat speci specif
therapi variat year young

2856: Alkanes (8)

activ area base case data differ
energi enzym mean measur method
model observ pair ratio rel report respect
studi valu

2857: Alkane 1-Monooxygenase (3)

acid activ adult approach design effect enzym
famili growth induc induc member receptor
recombin reduc respond **respons**
strategi structur year

2858: Tolonium Chloride (2)

approxim chain cultur induc induc injuri known
major minor observ pcr plai polymeras reaction
rel respond **respons** role skin
suggest

2859: Roxithromycin (4)

activ analysi blot cell combin
decreas effect **express** factor gastric gene
increas inhibit level produc
product protein resist risk western

2860: Fibrillar Collagens (5)

analys **analysi** anim chang effect
enhanc **express** gene gener increas
model protein rat reveal role sequenc
studi treat **treatment**
tumor

2861: Tropomyosin (16)

activ cell chang
develop differ
express function
gene level muscul mutat
normal number protein
rate sampl select speci
structur **tissu**

2862: Tropomodulin (2)

abil analys **analysi** bind domain
earli mice mous mutat perform period
phase point properti protein reveal stage
structur time transgen

2863: Trinitrotoluene (3)

abil adjust adult associ confid expos
exposur factor increas induc interv modifi
odd potenti ratio **respons** **risk**
smoke studi year

2864: Emulsions (23)

activ approach case data deliveri differ
dna effici form format **genom**
increas method partiel polym properti
sequenc structur studi surfac

2865: Biogenic Polyamines (4)

adapt alter anim chang induc induct mice
model mous natur normal
respons select structur
studi tissu treatment variabl vitro vivo

2867: Azo Compounds (16)

acid **activ** base cell concentr
differ effect enhanc identifi increas
light method model observ protein rat
rate sampl studi time

2869: Acridine Orange (5)

compar control **differ** earli enhanc
increas isol larg local method new
number pattern regul size small
strain studi subject treatment

2871: Tyrphostins (26)

activ akt **cell** differenti egfr factor
growth human increas inhibit inhibitor kinas
phosphoryl plai protein receptor respons
role signal suggest

2866: Trypan Blue (14)

activ apoptosi **cell** combin differ effect
human increas induc level light line measur model
number protein respons role studi treatment

2868: Bromphenol Blue (1)

concentr effect
increas lesion light measur microg microm min
phenotyp plasma potenti prevent
protect reduc reduct respect stain target
therapeut

2870: Lissamine Green Dyes (1)

cataract cell **concentr** determin
effect glaucoma higher implant increas len measur
microg microm min optic plasma rang respect
retin visual

2872: Suppositories (4)

arm clinic compar dai effect evid
group hormon interact method
new provid random stimul studi support
target treatment **trial** women

2873: alpha-MSH (22)

activ bodi control develop effect
express function genet group human
increas mice model plai **rat** receptor
role select test weight

2875: Alcian Blue (2)

cell dai degre demonstr **develop**
differenti find form format
function indic observ previou
prolifer regress report studi suggest variabl
variat

2877: Fibroblast Growth Factor 7 (24)

administ administr cell cultur **dai** daili
dose effect express factor growth hour
human increas infus interact intraven oral receiv
week

2879: Perchloric Acid (7)

base compar **concentr**
control differ effect
form format high higher
imag low process protein
rate respons size
stabil state treatment

2874: Receptor, TIE-1 (5)

angiogenesi behavior cell **complex**
compon **endotheli** express factor
growth hypoxia **normal** organ plasmid
protein receptor recombin subunit
tissu vascular vegf

2876: G(M2) Ganglioside (6)

accumul **activ** antibodi base **cell**
diseas express growth line major mechan
mice normal **patient** regul rel
specif studi test tissu

2878: Sodium Compounds (13)

area **associ** concentr decreas
develop **effect** exposur function
gene health **increas** plai primari reduc
reduct rel role specif studi tissu

2880: Hydrogen (40)

carbon determin differ **energi** field high
measur **model** movement patient
product rate region sampl sequenc solut
space **structur** studi valu

2881: Phosphoric Diester Hydrolases (25)

activ associ base cell dna
express famili gene increas
mutant mutat **new** provid rat region
requir **respons** role sequenc studi

2883: Deoxyuridine (6)

analys **analysi** compar decreas
differ dna express genom
identifi includ **increas** larg pattern
product reveal screen size structur
studi type

2885: Idoxuridine (7)

cell **combin** compar decreas detect

differenti dna dose effect **increas**

induc irradi model number organ presenc

radiat rate **respons studi**

2887: Methyl Parathion (4)

analys **analysi** assai base coli
detect effect enzym escherichia expos
exposur express gene
indic methyl mutat pair reveal sensit
toxic

2882: Integrin beta4 (4)

assess **ASSOCI** base case cell complex
data domain estim form format measur
model pair pancreat process
protein score structur tumour

2884: Phenylbutyrates (9)

acid assai **combin** concentr dai
decreas detect effect express
gene increas inhibit
new number provid sensit
structur target test tumor

2886: Glycerol Kinase (5)

adult **analysi** children cluster concentr
express gene gener **group**
interact isol method **mice** mous
mutat reveal strain studi year yeast

2888: Polysaccharides, Bacterial (30)

activ analysi bacteri express gene group
high host **infect isol** mutant new
pathogen patient produc
product respons
sampl sequenc strain

2889: Goserelin (6)

breast cancer case earli **effect** express

follow **patient** receptor reduc

reduct report **RESPONS** risk stage subject

surviv time treat **treatment**

2891: Ointments (13)

activ anim clinic dai effect higher keratinocyt
loss manag method model

patient product rate sampl

skin studi test treat **treatment**

2893: Fluorobenzenes (4)

compar control differ **effect** genotyp
healthi marker plai popul reduc reduct
respons role signific state studi

subject treatment trial variabl

2895: Amyloid beta-Protein (93)

abeta **accumul** alzheimer
amyloid app biochem caus character deposit
diseas enzym glycogen lead lysosom
patholog precursor reduc report storag suggest

2890: Receptors, Calcium-Sensing (29)

bmd **bone** calcium densiti diseas
enhanc fractur function high hip level low miner
mutat osteoblast osteoporosi receptor spine
studi vitamin

2892: Ethylene Glycols (2)

activ bodi compar concentr dai differ effect
enhanc enzym exposur **group**

higher increas lower rat **rate** respect
substrat versu weight

2894: 2',5'-Oligoadenylate Synthetase (12)

activ assai associ detect differ gene
genom haplotyp **number** polymorph popul
risk role sampl sensit singl snp specif treatment
valu

2896: Iron Compounds (4)

approxim compar concentr decreas high

higher imag **increas** initi level
low lower major observ rang **rate** rel risk
state time

2897: Calcium Phosphates (21)

analysi **bone** cell compar
differ high higher improv increas level
measur method number **patient**
random rate **studi** surfac
treatment trial

2899: Carboxypeptidase H (2)

bodi data evid genet **high** identif
identifi incid level low marker
mass method **popul** provid
risk screen support weight women

2901: Oxonic Acid (21)

advanc chemotherapi combin cycl dai
develop docetaxel dose grade median month
patient phase receiv regimen
respons surviv toxic treatment week

2903: Collagen Type III (8)

approxim associ caus cell correl enhanc
express gene human increas interact major
mechan mutat **patient** popul
region rel sequenc subject

2898: Eukaryotic Initiation Factor-4F
(3)

complex demonstr enhanc
event factor growth **initi**
interact mrna origin **process**
protein report requir ribosom rna
studi suggest **translat** trna

2900: Neuronal Apoptosis-Inhibitory
Protein (5)

control correl delet differ enhanc **famili**
gene includ inhibit interact loss member
mutat number **patient** plai
process role studi subtyp

2902: Ventricular Myosins (5)

anim compar **control** dai dose
enhanc express frequenc gene identifi
increas mice model **mous** mutat
region screen sequenc studi week

2904: Insulysin (8)

accumul associ control diseas enzym
express find gene genet high identifi model
mutant popul region report role sequenc
studi suggest

2905: Street Drugs (7)

alter **chang** data detect differ earli
function gene group
method model new oral phenotyp
provid **sampl** select stage studi
test

2907: Chromans (28)

activ analysi associ **cell** combin
diabet **effect** enhanc growth
increas inhibit insulin model new patient
rate reduc respons **studi** subject

2909: Triazenes (7)

activ assai chang data
detect differ estim gener
group inhibit method patient
pattern popul process resist sensit
subject therapi variabl

2911: Amikacin (8)

antibiot bacteri case dai differ host
human identifi **infect** level
parasit pathogen phenotyp repeat resist
sampl strain studi time treatment

2906: Dactinomycin (40)

activ cell differ effect
express factor famili form gene high
human increas inhibit level mrna
number **protein** role studi transcript

2908: Furans (19)

activ analysi associ base
chang compound
data effect estim group
identifi increas method model
new number respons structur **studi**
treatment

2910: Transcobalamins (5)

allel analysi associ carrier case chang diseas
effect factor gene genotyp health increas
normal **patient** polymorph
ratio reduc **risk** tissu

2912: Cilastatin (1)

case clinic confirm demonstr diagnosi effect
find improv **isol** present previou rare **report**
rna strain studi suggest therapi treat
treatment

2913: Imipenem (5)

analysi caus cluster core differ
effect encod identifi infect interact
isol mutat open pattern region
resist reveal sequenc strain
treatment

2915: Glyburide (8)

cell channel combin
concentr dai develop dose
effect experi follow initi mechan
mutant mutat origin regul second studi
subject trial

2917: Cationic Amino Acid Trans-
porter 1 (4)

acid amino analys analysi
cluster compar concentr decreas differ
genom group higher
human increas
number plai rate reveal role sequenc

2919: Polygalacturonase (7)

abil allel assai base chang demonstr
detect express function
fusion gene genotyp observ
phenotyp plant polymorph potenti
properti sensit tumour

2914: RNA, Transfer, Phe (2)

alter approxim chang compar control form
function group increas
major neg observ posit protein regul rel signific
site stabil structur

2916: Radium (16)

activ air area concentr contamin
copper correl dose effect high irradi
low metal radiat risk sampl soil
studi target water

2918: Eukaryotic Initiation Factor-4G
(9)

base bind differ enhanc factor increas initi
mrna protein requir ribosom rna site
size state structur termin translat
trna utr

2920: Ecdysone (8)

cell chang decreas develop
drosophila genet increas
induc insect interact model new phenotyp
protein provid respons structur studi
suggest time

2921: Lipofuscin (11)

adult brain caus effect
exposur gene high initi
level low new origin rate
releas retin stimul studi
treatment visual year

2923: Dust (19)

analysi compar concentr data
develop differ effect estim
exposur higher increas measur
method polymorph rate respons
risk sampl studi water

2925: Selectins (4)

abil anim cell clinic demonstr diagnosi
differ express larg mice
model normal number patient pattern
properti size small specif tissu

2927: Vaccines (26)

adult antigen challeng compar control famili
health higher immun interact new
number popul protect rate research
respons studi vaccin year

2922: MAP Kinase Kinase 3 (6)

activ cell drug erk essenti event
express inhibit involv kinas mapk overexpress
p38 pathwai phosphoryl process protein
requir signal target

2924: Vitamin K (11)

base control design effect enhanc
factor famili hospit main medic objective
patient plai protein reduc requir
risk role studi time

2926: Enzymes, Immobilized (18)

acid activ chang compar
control data deliveri effect
effici enzym function method new
normal particl provid rate sampl surfac
tissu

2928: Nasal Decongestants (2)

african american brain central children
collect earli ethnic field hear imag late loss
parent phase popul progress sampl
stage white

2929: Lanosterol (8)

activ adduct analog analogu approach
assai base caus compound deriv detect enzym
group interact method model potenti respons
target tumour

2931: Alginates (17)

activ cation concentr conjug control
deliveri effect effici formul higher liposom
particl polym prepar protein rate surfac target
time tumor

2933: Hexuronic Acids (11)

acid **activ** analysi degre deliveri differ
effici evid **group** increas particl
protein requir role speci structur subject
support surfac time

2935: Hydrochloric Acid (4)

activ cell compar data densiti **develop**
earli enhanc enzym **high** higher
increas level light **low** lower rate
repeat stage structur

2930: Ergosterol (10)

analysi correl dai data decreas differ dose
effect **gene** genet identifi
increas method model mutant resist
respons screen signific test

2932: Glucuronic Acid (9)

compar concentr condit degre deliveri effect
effici higher increas lower measur new normal
particl **rate** releas stimul surfac tissu
versu

2934: Xylose (5)

activ chronic combin diseas effect
enzym **function** gene genom
interact intestin **patient**
produc product protein region repeat
sequenc substrat yeast

2936: Capsaicin (7)

analysi combin concentr differ effect
gene gener increas induc laser light reduc
region releas **respons** reveal
sequenc specif stimul studi

2937: Isoflavones (17)

associ **cancer cell** chang
compar differ effect estrogen
express form high interact new
ovarian rate ratio respons
risk studi treatment

2939: Fushi Tarazu Transcription Factors (2)

chines determin differ famili **femal**
function genotyp **interact**
male mate member offspr protein
reproduct sex sexual specif studi subtyp trial

2941: Glucose Transporter Type 4 (11)

anim **diabet** distribut fast glucos
imag **insulin** local mellitu metabol mice
model normal peroxisom protein rat region
requir sequenc **TISSU**

2943: Receptors, Antigen, T-Cell, gamma-delta (34)

cd4 **cell** detect develop differ express
function gene genom lymphocyt mechan mice model
normal region respons role sequenc t-cell tissu

2938: Exodeoxyribonucleases (53)

activ associ bind break cell complex **damag** develop
dna genet human interact polymeras protein
rate recombin repair replic respons strand

2940: Thiamine (7)

administr assai **dai** defici detect diabet
dose **effect** inhibit level oral organ
plai **rat** reduc **role** sensit specif target
week

2942: Superantigens (14)

bind cell compar **control**
detect enhanc **express**
gene identifi infect isol
patient plai protein respons role
screen sensit strain **studi**

2944: Tuberculin (4)

activ adult area associ caus
cell children clinic **develop**
locat model new organ phenotyp plai role
studi target **test** year

2945: Methoxychlor (4)

analys **analysi** caus cell
children decreas **express**
gener growth **increas** lead
mechan mice molecular recent report
research reveal **studi** tumour

2947: Bronchoconstrictor Agents (6)

adult asthma clinic correl cystic design evid
fibrosi hospit level **patient** period
point respiratori **respons** studi test **time** trial
year

2949: Tocotrienols (6)

analysi caus cell data evid
function gene high includ
individu level low model protein rang repeat
reveal studi target wide

2951: Synaptophysin (20)

activ **associ** case cell chang clinic
develop diagnosi **effect**
express featur human mice
neuron primari reduc
role **time** tumor tumour

2946: Salivary Proteins (10)

activ analysi children cluster **differ**
effect **express** gene high
identifi model number phenotyp
protein role **sampl** select
specif studi subject

2948: Methacholine Chloride (6)

asthma compar concentr
control correl data estim
genom mean measur normal **plai** ratio
respons **role** site studi subject
tissu valu

2950: Macrophage Migration-Inhibitory Factors (19)

associ compar **control** depress
disord enhanc **express**
gene haplotyp identifi **increas** level method
patient polymorph risk role **sampl**
studi tumor

2952: Ketoglutaric Acids (12)

activ area biosynthesi catalyt catalyz cell
combin dehydrogenas effect **enzym**
gene group **increas** involv **metabol** model
reaction regul studi **substrat**

2953: Oxygen Isotopes (7)

activ analys **analysisi** chang
combin data energi evid famili form gel
identifi mass method perform provid reveal
speci support valu

2955: Gliadin (8)

activ associ bodi chronic cultivar differ diseas
group intestin maiz number
patient popul process product rice specif
studi time wheat

2957: Aminoquinolines (10)

activ alter case cell chang effect enhanc follow
improv increas interact male patient report test
therapi time treat **treatment**
tumor

2959: Piroxicam (3)

analisi area assai blot concentr detect
develop differ includ
individu level metabol multipl mutant
mutat pattern rat sensit studi tumor

2954: Polynucleotide Ligases (1)

activ adapt area chain characterist
common detect featur inhibit isol pcr plai
polymeras quantit reaction real-tim revers role
select strain

2956: Plant Preparations (26)

anim associ bodi compar
control dai differ effect
express **group** human increas
model phenotyp protein rat reduc
studi time treatment

2958: Dosage Forms (6)

avail dai data databas dose
group identifi manag medic model
number patient product
sampl screen studi test treatment
week year

2960: Thiolester Hydrolases (10)

abil acid **activ** amino demonstr
high level low measur model mutat new normal
patient potenti properti protein rate respons
tissu

2961: Bacterial Capsules (16)

analysi cluster coli control differ

escherichia express function gene

identifi increas **isol** level mutant

region reveal role select sequenc

strain

2963: Myogenic Regulatory Factor 5
(7)

bind cell **control** develop

famili gene hybrid identifi life

mice muscl mutant **new** nuclear

organ pathwai protein provid

screen **signal**

2965: Trichothecenes (10)

activ aspergillu base concentr

control dai effect **fungal**

fungi fungu gene host **isol** new

pair **pathogen** produc

product speci studi

2967: Butanols (3)

approach **cell** defect densiti develop extract

famili **high** higher level low lower

member mutant mutat rel site strategi suggest
wild-typ

2962: Cyclic AMP Receptor Protein (4)

bind enhanc express **famili**

gene gener identifi increas level

mechan member molecular mutant mutat
regul report studi suggest time transcript

2964: MyoD Protein (33)

bind cell chang contract develop differenti dystrophi
exercis express fiber function gene increas

muscl muscular myopathi respons
skelet smooth transcript

2966: Muromonab-CD3 (2)

cell complex demonstr densiti essenti

express find follow **high**

level low method persist previou

report requir studi suggest target
techniqu

2968: Potassium (63)

activ atp ca2+ calcium cell

channel concentr current

decreas human increas intracellular ion level
membran model size sodium structur studi

2969: Lysosomal-Associated Membrane Protein 1 (9)

activ assai **cell** detect
function interact larg local normal number
patient posit process **sensit** size small
specif target test tissu

2971: Amine Oxidase (Copper-Containing) (4)

activ allel bind domain enzym **express** form
function gene genotyp
human light normal polymorph
protein remain site stabil **tissu** tumour

2973: Chlorpromazine (9)

affect associ behavior chromosom
concentr differ effect examin find **function**
protein rat rate recent report schizophrenia
select studi suggest treatment

2975: Antitussive Agents (5)

affect chang chromatographi compar
concentr condit **control** degre
determin differ effect **extract**
fraction frequenc interact liquid method
prepar separ treatment

2970: Tyramine (11)

activ base detect duplic **effect** evolut
famili fish **function**
hybrid member **method** new origin
probe reduc select **studi** tissu year

2972: Primaquine (2)

approxim **CASE** caus combin
concentr condit degre effect lead major
mechan **method** molecular month
patient recombin rel report vivo year

2974: Quinidine (7)

chang compar concentr decreas differ group
increas new normal observ popul product rate
rel **resist** respons sensit subject **test**
tissu

2976: Amifostine (35)

beam cell **dose** effect expos exposur fraction
gamma group increas ion ioniz **irradi** patient
radiat radiation-induc radiosensit
radiotherapi surviv x-rai

2977: 6-Ketoprostaglandin F1 alpha (4)

anim cluster control dai discuss
effect inhibitor level mechan
method model molecular rat
recent reduc region sequenc studi
subject target

2979: Trypsin Inhibitor, Kazal Pancreatic (4)

clinic control correl express **famili**
frequenc genom high level low member mice
pancreat **patient** popul requir
sever signific site surviv

2981: Calcitriol (46)

activ bmd **bone** cancer cell densiti
differenti effect express fractur increas level
miner new osteoblast patient provid reduc studi
vitamin

2983: Naphthoquinones (25)

associ base **cell** develop
dna effect gene group increas level
mutant new number protein provid
rate resist respons **studi** target

2978: Apyrase (4)

assai base blood combin decreas
detect determin
develop distribut effect
enhanc increas
local peripher product repeat select
sensit specif suggest

2980: Ethylene Oxide (8)

assai compar control detect differ
exposur high higher increas mean
measur product rang **rate** ratio
respect sensit tissu treatment **valu**

2982: N-substituted Glycines (1)

assai complex demonstr detect find function novel
peptid potenti previou **protein** report
sensit specif studi subunit suggest target test
therapeut

2984: Lipoprotein(a) (15)

cholesterol compar control differ group healthi
higher human level lipid methods
patient plasma sampl sequenc serum
signific studi **subject** year

2985: Chromomycin A3 (3)

base correl embryo fertil fish
germ health hybrid method
observ pair probe protein
region sequenc situ sperm
studi system techniqu

2987: Ribosomal Protein S6 Kinases
(17)

activ analysi cell correl
differ individu interact kinas
mechan mice molecular number
phosphoryl protein regul signal signific
studi treatment tyrosin

2989: Diphenylamine (2)

acid assai cell chain detect
differenti includ mix NEW per popul produc
product prolifer provid rang
reaction sensit specif wide

2991: Cinnamates (18)

acid activ analysi associ base cell
control express group identifi induc
inhibit number rat recombin region
repeat respons sequenc
studi

2986: Maleimides (20)

activ compound differ express
group human identifi kinas new novel
pattern phosphoryl protein receptor regul
role screen structur studi target

2988: Collodion (5)

analysi approach cluster control differ
effect factor growth high identifi isol level
low method protein
reduc sampl screen techniqu variabl

2990: Adamantane (11)

activ cell combin concentr correl
decreas effect evid
function group growth increas
inhibit patient provid reduc support
treatment vitro vivo

2992: Thioredoxin Reductase
(NADPH) (9)

activ affect alter analysi bind
chang compar complex
control data decreases effect
enzym frequenc genom increas oxid
specif studi suggest

2993: Guanidine (18)

cell character dimer fold **form** function
group high human level low model mutat
nativ **protein** solubl
stabil stabl state structur

2995: Glutamates (30)

advanc **chemotherapi** combin cycl dai
function median month mutat
patient phase protein regimen
respons studi surviv therapi toxic treatment
trial

2997: Immunoglobulin A, Secretory (3)

activ antibodi compar corneal correct dai
data decreas differ dose estim **group** increas
level method period point segment serum **time**

2999: Anesthetics (13)

care data **earli** ethic gener genet
genom health high inform issu
new number particip patient provid
research stage studi surgeri

2994: Electron Transport Complex III
(12)

caus **complex** control diseas dna form gene
gener high increas
mitochondri
mitochondria model mtdna phenotyp protein
respons studi subunit suggest

2996: Mannose-Binding Lectins (15)

associ case cell **correl** express famili
function gener **human** level
mice mutat number phenotyp popul
protein signific site studi tissu

2998: Acetaldehyde (15)

alcohol compound decreas depend effect
extract high human increas level mechan
oral produc product rat reduc risk select
signific **studi**

3000: Hydrocarbons, Fluorinated (6)

compar compound data **develop**
differ estim flow form **group**
higher mean measur new **rate** ratio
respect role **structur** subject **valu**

3001: Amines (28)

activ adduct analog analogu chemic
compound control deriv
famili function group high identifi increas new
novel number potent size target

3003: Platinum Compounds (16)

agent cancer chemotherapi cisplatin cluster
combin cytotox **drug** effect express high
increas **patient** product rate
therapi time toxic treat **treatment**

3005: Sodium Nitrite (5)

activ alter cell chang combin compar
concentr decreas **effect** higher increas lower oxid
rat rate reduc risk select treatment versu

3007: Receptor, Adenosine A2A (6)

associ compound deriv
differ diseas effect enhanc **gene**
genotyp pattern plai polymorph popul
process **receptor** reduc **role**
select studi suggest

3002: Melphalan (41)

allogen autolog cell **donor** effect follow graft
level multipl **patient** rate receiv recipi reject
respons stem surviv time
transplant treatment

3004: Phalloidine (5)

abil bind capac cell data demonstr domain
gener initi larg morpholog plai potenti
properti report **role** size small
studi tumour

3006: 1,2-Dimethylhydrazine (9)

anim cell compar control dai decreas differ effect
function **group** increas induc inject larg mice
model number **rat** size week

3008: Dextran Sulfate (15)

anim bodi cell chronic data diseas **effect**
estim express increas intestin **mice**
model mous process **rat** time transgen
treatment tumour

3009: Phosphoranes (2)

associ bind compound demonstr expos
exposur find hybrid imag indic individu
interact observ previou ratio report
risk state **studi** suggest

3011: Acetylene (3)

behavior **CAUS** dna dose effect essenti
event express fragment **genet**
inhibit involv irradi lead mrna
process radiat requir step
surfac

3013: Carbodiimides (4)

chang complex data direct dynam evid
hypothesi kinet light **model** organ
predict propos provid specif state suggest
support switch transit

3015: Alkynes (3)

approxim assai **cell** correl detect
develop effect express major
receptor reduct reduct rel requir resist sensit
signific state structur target

3010: Phosphoglucomutase (7)

activ base cell chang divers famili **gene**
genet genom high interact level low
phenotyp popul select
studi suggest variabl variat

3012: RNA, Ribosomal, 5.8S (14)

analys **analysi** base cluster data differ gene
group human **isol** new phylogenet
popul relationship reveal sequenc **speci**
specif **strain** tree

3014: Alkadienes (4)

activ compound data differ distribut
evid form format **group** kinet light local
produc product provid risk state studi
suggest support

3016: Imines (6)

acid approxim bind caus **chang**
compound deriv detect **effect**
form format model point process reduct
region rel sequenc state **time**

3017: Phenyl Ethers (9)

behavior chang control decreas detect
evid genom identifi **increas** larg
level provid rat sampl screen select size
small support time

3019: Cyclin-Dependent Kinase 6 (16)

analysi arrest associ **cell** chromosom
complex **cycl** cyclin delet detect
genom level loss phase protein rate regul
respons sampl variabl

3021: Receptor, Adenosine A3 (7)

activ algorithm **cell** combin
compound data **develop** effect enhanc
event method model network normal
number predict process rate
receptor tissu

3023: Polyurethanes (10)

activ cell combin compar control
effect effici femal higher **human** light
male particl popul protein **rate**
sampl state surfac **treatment**

3018: Polybrominated Biphenyls (7)

adult anim behavior concentr dai
effect **exposur** high **increas**
level low model **new** normal
provid size speci **tissu** water year

3020: Thyroid Hormone Receptors beta (17)

activ adenoma adren alpha clinic complex
express function gene growth hormon
mice mutant **mutat** phenotyp pituitari
receptor ret
thyroid treatment

3022: Acrylic Resins (28)

analysi approach cataract differ effect
effici glaucoma group **implant** **increas**
len light mass **method** number popul
studi surfac time treatment

3024: Dental Amalgam (3)

adapt competit data databas environ evolut
evolutionari fish fit fluoresc hospit hybrid method
natur probe **select** situ skin studi
techniqu

3025: HMGA1b Protein (3)

acid approxim cell chain circadian data featur
inhibit line loop major **protein**
reaction region rel sequenc suggest tumor vitro
vivo

3027: Deamino Arginine Vasopressin (11)

children clinic cluster data
differ evid express increas
kidnei **patient** protein rat
renal sampl sever studi support
test time year

3029: Gramicidin (2)

activ associ bind concentr
effect field **function** gener
hybrid includ model predict produc product
rang reduc regul signific space variabl

3031: Haptens (7)

antibodi approxim base combin **effect**

enhanc **human** level major new

normal provid rang rel **respons** serum

surviv tissu treat **treatment**

3026: Nystatin (3)

alter **associ** chang cluster
decreas enhanc form format **gene**
increas individu initi mice
organ posit region regul risk sequenc
suggest

3028: Vasopressins (19)

activ alter analysi **chang** decreas
express famili function gene group high
identifi **increas** individu level low
patient **receptor** renal role

3030: Amino Acid Isomerases (2)

algorithm alter approach bind **chang**
decreas **function** gene identifi increas
method network novel plasmid predict
recombin screen site target test

3032: VDJ Recombinases (13)

assai cell **combin** detect
diseas effect express **gene** high
multipl organ plasmid process
recombin region rel role
sensit sequenc specif

3033: Peptide Elongation Factor G (5)

acid **activ** combin correl effect
initi interact mrna **mutant**
mutat phenotyp protein regul
report ribosom **select** structur studi
translat wild-typ

3035: Chemical Warfare Agents (7)

analysi anim **control** data exposur
gene includ individu level mass **model**
patient process rang repeat reveal
risk **sampl** studi year

3037: Carbenicillin (1)

analysi blot cell confirm
content cytometri detect determin **express**
flow identif **identifi** northern novel
plant protein reveal **screen** transfect
western

3039: Immunoglobulin Joining Region (11)

cell chang children dna **express** famili
gene **group** human interact
mutat phenotyp plai protein **region**
respons **role** sequenc studi tissu

3034: Mustard Gas (7)

compar compound concentr **control**
express extract **gene** **group**
higher **level** mechan method **new**
number **patient** provid rate
role sampl studi

3036: Tin Compounds (4)

approach assai cancer chromosom compar
data **detect** exposur **high** higher
level low lower presenc **rate**
reaction **sampl** sensit
treatment tumor

3038: Antigens, Plant (4)

antibodi data **differ** dna extract
fragment **gene** health isol mice
pattern **plant** **protein** region rice
sequenc strain test type wheat

3040: Immunoglobulin Constant Regions (7)

differ dna effect human
increas kinet mechan number pattern
process rate region resist respons role
sequenc specif **state** switch transit

3041: Cytochrome b Group (8)

amplifi cell compar dna effect famili
fragment model mutat pcr
plai primer product protein rate
reaction restrict **role** tumour
valu

3043: Guanine Nucleotide Dissociation
Inhibitors (9)

activ assai bind cell complex correl detect
differ earli function human
interact mutat number pattern
phenotyp protein receptor site test

3045: Receptor, trkB (18)

cell demonstr enhanc **express** genet
increas line **neuron** number
patient phenotyp process protein receptor
sampl specif studi suggest surviv tumor

3047: Benzazepines (4)

assai **concentr** detect estim
extract **famili** form
format gener inhibit measur
method model plai presenc
role score sensit target valu

3042: Acetic Acids (16)

activ caus cell compound
effect enhanc express form
format gene human increas product
receptor reduc resist respons
studi suggest treatment

3044: Tetrachlorodibenzodioxin (26)

air associ **concentr** contamin
content copper dai develop effect environment
human measur metal pah pollut
respons sediment soil sourc
water

3046: Receptors, Formyl Peptide (5)

abil base bind capac **cell** effect high
identifi level low mice potenti produc product
proporti reduc regul screen **studi**
treatment

3048: Amlodipine (4)

analys **analysi** clinic dai data determin
estim **extract** form format fraction
method **patient** perform plai
product reveal **role** studi
variabl

3049: Hepatitis A Antibodies (2)

associ common compar control delet esophag
frequent gene haplotyp healthi hepat
hepatocyt **liver** occur occurr polymorph
snp studi **subject** transmiss

3051: H-2 Antigens (25)

antigen bind cell class detect gene hla identifi
immun major method mhc **mice**
molecul mous respons specif studi transgen
vaccin

3053: Cystine (9)

area chang compar control
develop differ **effect**
function gene higher
includ loss patient protein
rang rate reduc structur valu
wide

3055: Silymarin (11)

activ apoptosi associ cell chang clinic compar
control decreas **effect** increas prevent
protect random rate reduc reduct role studi
trial

3050: Hygromycin B (13)

assai associ correl **detect** develop
form gene genom mutant new
number posit protein rate recomb
report resist select sensit **studi**

3052: Immunologic Factors (52)

clinic control develop differ effect famili
gene human immun model multipl
respons role select studi target
therapeut **therapi**
treatment vaccin

3054: Plectin (5)

associ base clinic diagnosi diagnost
differ gene identifi marker measur mechan
model molecular **mutat** pattern
requir score screen skin subject

3056: Salicylic Acid (22)

acid activ arabidopsi control flower gene increas
induc induct leaf leav model number **plant**
pollen resist **respons** root seed
treatment

3057: Anthranilic Acids (3)

analysi approxim compar compound develop
differ isol major mutant number
pattern plai recombin rel role similar speci
strain type variabl

3059: Receptors, Cannabinoid (4)

bodi caus diet **effect** enhanc
estim event factor growth increas
involv lead mechan **process**
rat **receptor** reduc **risk** target
weight

3061: Sterol Regulatory Element Binding Protein 2 (8)

acid cholesterol combin control earli
express gene **group** increas
level lipid mice new plai plasma
protein regul **respons** **role**
subject

3063: PPAR alpha (24)

activ chang cluster data develop
diabet effect express famili
function gene glucos **insulin** metabol mice
patient protein **respons** sampl year

3058: Quinaldines (1)

abil american analysi approxim capac
differ gene major plasmid popul predict
properti **recombin** **region**
regress **rel** relationship
sequenc **variabl** variat

3060: Electrolytes (11)

activ analysi children compar
concentr data **differ**
effect function **group** higher
model pattern protein rate reduc reduct
respons role valu

3062: Hydroxymethylglutaryl CoA Reductases (9)

activ associ base cell chang
detect effect enzym **group**
high increas level lipid low new
pair popul regul specif treatment

3064: Xanthines (9)

base chang concentr correl data dna enzym
function individu male mechan metabol
method modifi mutant rat receptor remain
repeat **studi**

3065: Enkephalin, Ala(2)-MePhe(4)-Gly(5)- (1)

administ administr alcohol **dai** depend
dose effect ethanol hour inject linkag locu map
oral rat receiv receptor signific studi week

3067: Poloxamer (6)

chang deliveri differ earli **effect**
effici express gener life mechan new normal
pattern protect reduc reduct stage surfac
tissu tumor

3069: Mannosyltransferases (18)

analysi associ combin detect **gene** group
mechan model molecular mutant **mutat**
organ **patient** peptid protein
region sensit sequenc specif syndrom

3071: Concanavalin A (26)

associ case **cell** combin compar differ
effect gene group increas method mice
number posit protein **rat** rate region
sequenc vivo

3066: Transcription Factor TFIIA (5)

activ assembl associ **complex**
compon defect **express** function gene
gener interact **mutant** mutat presenc
promot protein site subunit
transcript wild-typ

3068: Excipients (8)

area assai deliveri **detect**
develop effici factor
gene increas mechan method
model new particl rel **risk** score
sensit surfac vector

3070: Carboxypeptidase C (6)

complex control core dai encod follow
gene identifi mutat **new** normal
novel **number** open region
screen sequenc target tissu **treatment**

3072: Mercuric Chloride (4)

assess **concentr** earli exposur
express form format gene **high**
human level low measur
microm min network predict protein score
stage

3073: Calcium Channels, P-Type (2)

atp ca2+ calcium channel complex
compon current environment factor function
genet influenc ion modul mutant plai regul
role subunit suggest

3075: S-Nitrosothiols (10)

activ approach area cell
effect increas inhibit initi level
mechan normal plai potenti reduc releas
role stimul **studi** subject
tissu

3077: Nucleosides (35)

activ adduct analog analogu base cell
chemic **compound** deriv
differ dna gene human mechan new patient
select structur studi viru

3079: Retinoid X Receptor alpha (10)

acid alpha amino beta cell compar **control**
develop express high increas level
low mechan new process **receptor**
respons sampl subject

3074: Calcium Channels, Q-Type (2)

ca2+ calcium channel complex compon critic
current defect mice mous mutant mutat
neuron plai receptor **role** subunit
suggest transgen wild-typ

3076: Didanosine (8)

alter **chang** combin dna event
gener **group** hiv hiv-1 individu
infect mutat **patient** process
resist therapi time treatment trial viru

3078: Etodolac (3)

apoptosi approach cancer cell chain
correl effect **express** factor
growth inhibit inhibitor method multipl
produc **product** reaction receptor
signific strategi

3080: Fertility Agents, Male (1)

administr affect associ dai dose **effect**
factor gene methyl platelet prevent protect reduc
reduct schizophrenia signific studi suggest
transplant week

3081: 5,10-Methylenetetrahydrofolate
Reductase (FADH2) (4)

activ associ case control develop differ
effect enzym healthi new pattern
prevent protect provid reduc reduct report
studi subject year

3083: Amiodarone (6)

associ case chang dai differ dose famili
larg number protein radiat rate ratio
risk sampl size
small studi time treatment

3085: Aldehyde Dehydrogenase (24)

activ alcohol allel associ cell
consumpt depend detect effect enzym
ethanol gene genotyp human number
oral polymorph popul signific
studi

3087: Cations, Divalent (26)

associ cell channel concentr
data differ dna effect form
function group high identifi interact
pattern phenotyp protein respons
studi suggest

3082: Origin Recognition Complex (17)

assembl bind **complex** compon
dna domain earli essenti form function human initi
interact mutant origin protein requir second
structur subunit

3084: PQQ Cofactor (2)

blood cell clone demonstr enhanc express find
gene **human** includ increas mice
observ previour rang report sequenc studi
suggest wide

3086: L-Aminoadipate-Semialdehyde
Dehydrogenase (1)

adult cdna clone elderli enzym express gene
human insight level librari mrna new
novel old older provid sequenc year young

3088: Plasminogen Activators (15)

activ cell control develop express
extracellular function imag inhibitor **invas**
level matrix metalloproteinas mmp mmp-2
mmp-9 patient process sampl treatment

3089: gamma Catenin (14)

activ analysi **associ cell**
chang control differ **effect**
epitheli express human
increas interact mechan
mutat phenotyp protein reduc
sampl tumour

3091: Acetyl Coenzyme A (9)

analysi bind chang
characterist common **complex**
enzym **featur** gener indic larg
method model **mutant**
phenotyp rel **requir** reveal
size **structur**

3093: Sorbitol (12)

activ associ cell compar
control effect **gene group**
growth high higher low **patient**
protein rate reduc **respons** role
studi suggest

3095: LDL-Receptor Related Protein 1 (9)

bind cholesterol develop differ diseas famili
high human interact level
lipid **low** model mutat normal phenotyp
protein site studi tissu

3090: Glycerol-3-Phosphate O-Acyltransferase (3)

acid amino clinic compar **decreas** diagnosi
effect **gene** identifi
increas level liver map mean
model predict reduc **sampl** screen valu

3092: Angiotensins (4)

activ alter anim assai **chang**
combin **decreas** detect develop experiment
increas level mice **model** new
provid report sensit studi test

3094: Ionomycin (20)

activ analysi cell chang demonstr
distribut effect **function** inhibit kinas local
number promot protein receptor report respons
stimul studi treatment

3096: Dimethylpolysiloxanes (12)

assai **control** deliveri **detect** dna
effici **high** human identifi
level liposom low method
particl polym prepar report sensit studi

surfac

3097: Fluconazole (13)

associ case caus chang children clinic
combin effect fungal
fungi gene isol new pathogen
patient **resist** strain studi
year yeast

3099: Nuclear Matrix-Associated Proteins (18)

activ **associ** cell complex
cytoplasm develop diseas enhanc evid
express famili local model **nuclear** plai
protein role suggest target time

3101: Cladribine (13)

adult case **combin** compar compound
control dai dose effect follow higher increas
month **patient** rate respons
studi time tumor year

3103: Antigens, CD5 (16)

b-cell case clinic cll express gene gener high
hodgkin larg leukemia level low lymphocyt
lymphoma malign nhl
non-hodgkin recombin rituximab

3098: Hemocyanin (10)

cell chang diverg duplic **evolut** evolutionari
genom immun interact length
level model new origin repeat sequenc
specif structur suggest vaccin

3100: Cholesterol Esters (5)

acid alter amino case chang cholesterol
compar concentr decreas enhanc extract featur
increas level lipid number
process rat subject valu

3102: 4-Nitroquinoline-1-oxide (11)

acid activ anim compar
develop effect exposur
gene increas induc level model
popul protein **rat** rate respons studi
test tumor

3104: Terbutaline (3)

alter **chang** combin compar
control detect **develop** effect gener
genotyp **group** higher increas male
polymorph popul rate receptor subject
treatment

3105: Biphenyl Compounds (17)

activ cell combin compar effect enhanc
famili function high **increas** level
number patient protein rate risk
studi subject test treatment

3107: Receptors, Adrenergic, alpha-1
(6)

acid alpha amino beta concentr effect induc
induct inhibit level popul
receptor region resist
respons sequenc serum site specif
time

3109: Adrenergic beta-Antagonists
(54)

associ **cardiac** cardiomyopathi
clinic control data effect failur **heart**
improv left new **patient** receptor studi
subject treatment trial ventricular year

3111: Receptors, Oxidized LDL (8)

acid activ analysi blot cell cholesterol cluster
express function **human** larg
level lipid protein rel respons size specif
structur western

3106: Tetrazoles (17)

adult arteri associ cell concentr
decreas effect function high
increas inhibit pressur
respons sampl studi subject time
treatment trial year

3108: Receptors, Adrenergic, beta-1
(11)

allel alpha analysi bodi cardiac cell children
combin genotyp heart high **increas** interact
level low **patient** polymorph
receptor studi time

3110: Scavenger Receptors, Class E (8)

apoe ASSOCI base cell cholesterol correl detect
express **human** lipid lipoprotein
mechan plai popul protein rel requir
role structur suggest

3112: Pituitary Hormones (16)

activ **analysi** associ base bodi
combin effect **famili** femal
group increas **level** male
mutat number **patient** rate serum
studi thyroid

3113: Cyclin-Dependent Kinase Inhibitor p57 (21)

analysi arrest **cell** chicken control
cycl cyclin differ differenti express gene
individu level methyl normal
patient prolifer respons studi tissu

3115: Chalcones (11)

analysi base **cell** chang effect express
famili function gene gener group growth
human inhibit level mice model **vitro**
vivo xenograft

3117: Octoxynol (22)

activ cell chang complex express
function gene high
form interact membran mutat plai
product protein rate
role sampl stabil suggest

3119: Angiopoietin-2 (16)

analysi angiogenesi associ correl
endotheli **express** factor
form format growth level rate
receptor respons reveal role serum tissu
vascular vegf

3114: Chalcone (13)

bind **cell** concentr effect enzym famili
function gene growth **human** increas
mice model rate resist respons time
treatment **vitro vivo**

3116: Purine Nucleosides (9)

cell compound
deriv detect differenti dna enhanc
famili function gene
level mechan region rel resist role
select sensit sequenc tumor

3118: Receptors, Calcitonin (5)

analysi children cluster control determin
differ express function gene
measur predict protein
receptor regress relationship
signific studi subject **variabl**
variat

3120: Trisaccharides (4)

base clone concentr dai differ distribut
genet larg local mean produc
product region respect
select sequenc size small test valu

3121: Flucytosine (20)

activ associ cell combin develop effect express
gene group growth human inhibit inject
mice model studi vector **Vitro**
VIVO xenograft

3123: Phosphoribosylglycinamide
Formyltransferase (2)

acid adapt allele clone contain core encod
gene genom genotyp identifi initi marker
open origin polymorph read recombin select
sequenc

3125: Cholestanols (10)

activ affect chang concentr data
enhanc estim famili function genom increas
level mutant plant regul rice sequenc studi
subject wheat

3127: Receptors, Interleukin-3 (4)

analysi case cell content core determin differ
featur flow initi marker normal **number**
open **patient** process report
requir **TISSU** valu

3122: RNA, Ribosomal, 18S (47)

analys analysi associ base chain clade close differ
gene genu group molecular pcr phylogenet
reaction relat relationship sequenc
speci tree

3124: Protein Hydrolysates (2)

adapt approxim avail cell concentr
correl cultur dai **data** databas
evolut gene inform major peptid program
rel **select** tool vector

3126: Deuterium Oxide (5)

area conform crystal data determin dynam earli estim

form function high level loop low model popul rel

residu sampl **structur**

3128: Capsules (23)

cell chain compar control detect
determin differ flow group mutant
patient pcr polymeras ratio
reaction studi surfac time treatment
valu

3129: Selenium (30)

concentr decreas determin
effect higher increas level low lower measur
method microg microm min plasma reduc respect
risk studi time

3131: Erythromycin (23)

activ character differ divers gene genet human ident
identifi infect **isol** method pathogen phenotyp
rate resist sequenc serotyp **strain** type

3133: Proto-Oncogene Proteins c-ret (72)

adenoma adren adrenocort braf carcinoma
cortisol endocrin follicular gene gland hormon
mechan molecular mutat neuroendocrin
papillari pituitari ptc ret **thyroid**

3135: Receptors, Drug (19)

acid associ base channel combin concentr
data effect **function** genet group human identifi
mutat **patient** potenti protein
studi target

3130: Chorionic Gonadotropin, beta Subunit, Human (22)

birth deliveri estim **fetal** fetu
gestat high infant level low marker
matern mother neonat
newborn **pregnanc** pregnant
prenat week women

3132: Tetracyclines (8)

bind cell chang construct data dynam effect
isol mechan **express** function gene gener
model new plasmid predict
provid recombin treatment

3134: Phosphatidylserines (24)

activ apoptosi bind cell compar
concentr **control** **differ** effect frequenc inhibit interact membran
mutant mutat pattern region sequenc
studi test

3136: Antigens, CD98 Heavy Chain (1)

actin adhes analysi apoptosi assai cell chain
detect express migrat overexpress pcr polymeras **protein** quantit reaction
real-tim revers rt-pcr transform

3137: Prostaglandins F, Synthetic (3)

acid case concentr conclusions design
differ high hospit level low medic
method patient pattern phenotyp posit
report similar studi type

3139: Pro-Opiomelanocortin (17)

associ bodi chang control
decreas effect evid high hormon
increas level mechan
molecular polymorph region
respons sequenc subject
thyroid weight

3141: Antibodies, Blocking (15)

activ **cell** dai effect enhanc famili
function human induc inhibit patient rat
regul report respons role studi
suggest treatment tumor

3143: Lipid Peroxides (15)

acid activ antioxid associ concentr correl
decreas differ **increas** induc
oxid oxygen patient product rate
reactiv respons stress time treatment

3138: Histamine (25)

activ asthma cell compar cystic
detect differ fibrosi group high increas
level low normal respiratori respons sensit
studi subject tissu

3140: Immunoglobulin Fab Fragments (23)

activ **antibodi** antigen clinic
develop effect gene high higher
human inhibit low monoclon
number patient rate receptor specif
structur studi

3142: Digoxin (4)

analysi case cell clinic
diagnosi diagnost fish fluoresc
gener hybrid life perform probe qualiti
report reveal situ **specif** studi
treatment

3144: Miconazole (2)

adolesc associ autism child childhood
children confid incid interv odd
parent patient pediatri ratio risk smoke
studi system women year

3145: Bone Morphogenetic Protein Receptors, Type II (10)

develop **famili** form function gene
growth identifi mechan member mutant
mutat new normal novel phenotyp
plai role screen suggest tissu

3147: Factor X (5)

analysi assai blot detect disord express factor
gene improv life **mutat**
patient period point qualiti
requir sensit site **time** western

3149: Receptors, Neurokinin-1 (12)

activ alpha assai beta **cell** concentr detect
effect group human line method
model oral **receptor** role sensit
specif structur tissu

3151: Technetium (15)

analysi clinic concentr dai detect
develop effect evalu human identifi
imag magnet measur
patient perform reveal screen
specif studi volum

3146: Isothiocyanates (13)

activ apoptosi assai **cell** cytotox develop
effect enhanc human increas induc inhibit level
line mechan model number prolifer protein
treatment

3148: Contraceptives, Oral, Hormonal (8)

base chang clinic combin correl data diagnosi
effect factor higher hormon increas level
number **patient** rate reproduct
risk serum women

3150: RNA-Binding Protein EWS (8)

case cell express famili
function gene genet
interact method neg normal plai
popul posit **role** sarcoma specif
studi tissu tumor

3152: Organotechnetium Compounds (11)

analysi cell dai data detect evalu high
imag magnet mechan method
model mri perform posit reson scan select
studi volum

3153: Glial Cell Line-Derived Neurotrophic Factor (28)

activ analysi astrocyt brain cell
develop earli effect express famili
genom mechan member mice mutant
neuron new rat renal synapt

3155: Glutaminase (8)

activ analys **analysi** blot cell
detect differenti effect enzym
express increas level plai regul rel reveal
role test tumour western

3157: Cellulose 1,4-beta-Cellobiosidase (5)

analysi compar decreas determin flow gene
high higher **increas** individu level
low method product protein rate reveal risk
specif test

3159: Pyrans (13)

assai cell compound detect **effect**
express form gener high human
model **new** plai process provid
reduc role select sensit specif

3154: Colchicine (29)

activ arthriti bind case differ diseas
effect famili level member model pain
patient popul rate
respons role target time
treatment

3156: Beta-Globulins (4)

american chain cluster **control**
differ effect ethnic frequenc identifi
neg pcr polymorph **popul**
posit reaction requir screen time
tumour valu

3158: Phosphoramidate Mustards (3)

anim **concentr** dai
develop earli effect mean
measur microg microm min model mutat
protein rang ratio respect stage tumour
valu

3160: Mercaptoethylamines (2)

administr assai blood dai
detect dose effect extract
fraction inject irradi method peripher
radiat rat sensit site specif test
week

3161: Penicillin Amidase (3)

alter approach chang design **differ**
improv larg life observ pattern physic
product qualiti rel requir size small strategi
studi treatment

3163: Plutonium (22)

concentr contamin data develop
differ dose effect estim exposur
group **human** increas irradi
measur metal model **radiat** rate
soil water

3165: Large-Conductance Calcium-Activated Potassium Channels (8)

ca2+ calcium chang **channel**
current effect express
function interact larg
normal phenotyp popul releas size specif
stimul structur time tissu

3167: Scorpion Venoms (8)

bind cell chain **channel**
concentr domain effect evid
inhibit interact protein rat
reaction requir structur support
time treatment tumor
tumour

3162: Ribonucleoside Diphosphate Reductase (2)

analys **analysi** cell data
differenti enzym evid express **gene**
hybrid microarraai peptid perform profil prolifer
provid regul resist reveal support

3164: Activating Transcription Factor 3 (9)

activ associ **cell** combin
differenti effect express function
gene identifi induc inhibit mutant
overexpress prolifer regul respons screen
transcript transform

3166: Potassium Channels, Calcium-Activated (22)

activ associ atp ca2+ calcium cam
channel current express
function intracellular ion phenotyp popul
potassium potenti rate releas respons sodium

3168: Monoiodotyrosine (3)

activ aggreg chromosom coloni conform convers data
differ diseas enzym estim form format
group method plai role
structur substrat suggest

3169: Americium (5)

administr assess **dai** data dose effect
estim evalu follow literatur measur method
model oral score studi treat
treatment valu week

3171: Chlortetracycline (4)

adapt compar condit degre **differ**
effect fertil follow germ mean pattern
period point reduc **select** sperm testi
time treatment valu

3173: Carbonic Anhydrase I (4)

acid assai complex conform *crystal* decreas detect

dimer energi fold form genom increas interact

protein sensit stabil stabl state

structur

3175: rap GTP-Binding Proteins (4)

bind chines differ featur heterogen interact
modifi mutant *pathwai* **plai** protein

requir **respons** **role** signal state
structur studi subtyp suggest

3170: Sulfamethazine (1)

collect concentr **correl** data determin
effect gener index infect microm min
prevent protect reduc reduct relationship
sampl signific studi water

3172: PAX7 Transcription Factor (8)

analysi **associ** base caus **cell**
data evid **famili** find follow gener growth
muscl phenotyp report reveal score studi
suggest support

3174: Mitochondrial Proton-
Translocating ATPases (22)

analysi complex differ dna function genom

human identifi mice **mitochondri**
mitochondria mtdna mutat **region**

reveal role select **sequenc**
suggest target

3176: Oxytocin (10)

activ anim children differ express
function group health mice model
number patient **plai** provid **receptor**
regul **respons** **role** select
studi

3177: 19-Iodocholesterol (1)

assai clinic design **detect**
diagnosi diagnost evalu gel hospit imag
light main mass objective patient sensit
specif studi test **tumor**

3179: Harmaline (1)

activ adduct analog analogu arabidopsi chemic
complet **compound** contain deriv
flower fusion leaf leav partial **plant**
pollen potent root seed

3181: Phospholipid Transfer Proteins
(12)

activ bind control effect express
function gene high level lipid local low
membran mice mous plasma regul select
studi transport

3183: Adenosine Diphosphate Ribose
(8)

activ cell damag dna effect famili
gene gener human induc line plai potenti
rate region releas repair role sequenc stimul

3178: Lindane (4)

alter approach **chang** children
decreas design effect exposur improv increas life
observ parent qualiti rat report signific strategi
studi treatment

3180: Receptors, Interferon (34)

cell combin control **cytokin** develop
function genet ifn-gamma il-6 immun induc
interact level number patient process rate
receptor **respons** subject

3182: RNA Polymerase I (18)

activ assai bind cell chang detect express
gene **melanoma** model number
polymeras protein regul requir respons
rna role studi transcript

3184: Interferon Regulatory Factor-2
(4)

activ associ cell class densiti earli
enhanc event growth **high** larg level
low mice mous process regul size small stage

3185: Phenylurea Compounds (9)

activ assess cell determin differ
extract fraction high level low
measur period point posit resist sampl
score select time treatment

3187: Cosyntropin (3)

case compar concentr dai differ follow
group higher isol level lower
model organ posit presenc rate report
respect serum strain

3189: Telomeric Repeat Binding Protein 1 (11)

analysi cap cell cellular end gene httert
human increas length repeat respons
reveal revers senesc shorten suggest
telomer telomeratrap

3191: Cholecalciferol (11)

analysi associ base bone cell
chang children differ differenti
express increas interact
method observ prolifer protein studi
subject treatment valu

3186: O(6)-Methylguanine-DNA Methyltransferase (49)

cell cpg dna epigenet gene human
hypermethyl inactiv island methyl
methyltransferas mgmt p16 promot rassf1a region
silenc statu suppressor treatment

3188: DNA Polymerase beta (30)

analysi cell damag dna duplex effect group
helicase increas normal pol polymerase receptor repair
replisome role single-strand strand synthesi tissu

3190: Phenylhydrazines (3)

analys analysi base blood defect
defici diseas form format isol level
mutant mutat number
pair region regul reveal sequenc wild-typ

3192: Toll-Like Receptor 7 (7)

absenc activ associ
combin correl cytokin dai effect
enhanc form format increas individu
presenc rat receptor respons studi
suggest treatment

3193: RNA-Binding Protein FUS (7)

activ combin differ dna earli
express featur **gene** genet interact
pattern phenotyp point presenc process
region regul sequenc specif **time**

3195: 3-Iodobenzylguanidine (8)

activ analysi case cell clinic combin
compar effect increas mutat normal
patient phenotyp rate reveal
studi target test time tissu

3197: Receptor, Cholecystokinin B (10)

activ bind cell compar
control decreas differenti effect
express frequenc function gene growth
high human increas level normal
receptor tissu

3199: Diamines (7)

activ base caus **cell** compound
effect form format gener inhibit
interact mass phenotyp protein reduc
site structur **studi** target tumor

3194: Calcium, Dietary (12)

adult alter analysi **bodi**
chang diet differ effect famili
femal group increas male mass
number obes **patient** studi
weight year

3196: Azaserine (1)

analysi **cell** differenti event express
gastric gel initi involv mass mice mous occur
pancreat **process** prolifer receptor secret step
transgen

3198: Osteocalcin (35)

alkalin bmd **bone** calcium combin
decreas densiti develop fractur function group hip
increas miner osteoblast osteoporosi phosphat
skelet spine vitamin

3200: Cadaverine (4)

activ adult analysi apoptosi assai cell collect
detect function induc month normal patient
respons **sampl** sensit test tissu
tumor year

3201: Rabies Vaccines (5)

assess combin complex effect **express**
human incid infect initi measur
mice produc product protein repeat replic
score target viral **viru**

3203: Enalapril (5)

alter anim arteri **chang** content
decreas **effect** evid flow growth hypertens
increas inhibit model pressur rat reduc
signific support treatment

3205: Bisbenzimidazole (14)

activ analysi assai cell
chang content detect determin
effect flow genet increas larg mechan
model **number** process sensit
signific time

3207: Atropine (3)

abil assess chang demonstr effect extract
field increas kinet measur mice mutant
potenti releas requir score
state stimul switch
transit

3202: HLA-A3 Antigen (3)

class clinic complex diagnosi diseas
famili genet includ mechan
member molecul molecular peptid
phenotyp point popul rang structur
studi time

3204: Antigen, CD57 (4)

associ case cell chain
children decreas detect **develop**
enhanc express genet health
increas normal pcr polymeras
reaction requir specif tissu

3206: Hexylresorcinol (1)

administr blood cell chromosom **dai**
differ dose effect examin exposur inject larg
larger number observ peripher rat **size**
small week

3208: Peptidyl Transferases (1)

compar contain control differ divid drosophila
gene **group** insect melanogast
nucleotid pancreat **region** respect secret sequenc
signific speci studi translat

3209: Antimony Sodium Gluconate (2)

adult case data design distribut evid
hospit incid local normal provid rat
respons studi support
tissu treatment tumour
women year

3211: Uroporphyrinogen III Synthetase (3)

children clinic defici diseas enzym improv
life marker mutant mutat **normal**
pain patient qualiti report sever state
studi **tissu** transplant

3213: Pyrophosphatases (23)

acid **activ** analysi compar
differ dna famili function gene
genom group identifi increas mutant
new open patient pattern studi tissu

3215: Receptors, Invertebrate Peptide (3)

acid **activ** alpha amino cell chines differ
domain drosophila express function heterogen
methyl protein **receptor** regul signal studi
subtyp transfect

3210: Ferrochelatase (8)

cell **develop** function
gene gener high higher level liver
low method **mice** mous mutant
patient rate region requir
sequenc wild-typ

3212: Guanosine (16)

activ base bind cell chang
differenti dna effect gene group increas level
number observ pair product protein sequenc
site structur

3214: Dynamins (14)

cell chang correl develop earli effect
function interact local
mutant patient phenotyp **protein** regul
respons select stage studi subject tissu

3216: Destrin (7)

actin caus **cell** form format growth
lead mice migrat mutant mutat patient
phenotyp plai process regul repeat
respons role suggest

3217: Actin Depolymerizing Factors (19)

actin analysi anim **cell** cytoskeleton
differ filament function genet gtpase identifi
migrat model motil polar process protein
regul respons rho

3219: Pregnancy-Associated Plasma Protein-A (18)

birth develop **fetal** gestat
human identifi infant larg matern
mother neonat patient
pregnanc prenat screen
size small test week women

3221: Vitamin K 3 (11)

activ cell chang combin
effect enhanc enzym **function**
gener genet increas inhibit level model
number oxid product rate reduc
treatment

3223: Bibenzyls (2)

bind cancer cours drug **effect** end event initi

involv lead occur period point

process protect reduc reduct step

target **time**

3218: STAT Transcription Factors (4)

activ **cell** essenti event femal identifi
involv kinas male mutant pathwai phenotyp
PROCESS region requir sequenc sex signal
step tyrosin

3220: Uncoupling Agents (7)

associ cell **concentr** detect earli

effect evolut gener genotyp

method

mitochondri normal

polymorph process **protein** risk

role stimul suggest tissu

3222: Rotenone (10)

activ bind cell combin compar
control decreas differenti earli effect increas
mitochondri model mtdna organ oxid
phenotyp rat repeat subject

3224: Gases (24)

cell correl data develop dynam

estim **field** forc group human

larg measur method **model**

movement number

patient size space water

3225: Antigens, CD26 (9)

cell chang dai dose effect gene
line mice **patient** peptid rat
repeat specif studi subject
treatment trial vitro vivo week

3227: Oncogene Proteins v-abl (5)

abil capac **cell** children demonstr
effect **function** identif
identifi level
mechan model molecular
novel potenti properti protein report
screen studi

3229: G(M1) Ganglioside (10)

accumul associ bind cell children earli experi
form format **function** high initi
low mice model origin second size specif
treatment

3231: Aldicarb (1)

analysi base categori classifi cluster differ
distinct examin **gene** identifi mutant
mutat pancreat profil **protein** set structur
subgroup wild-typ

3226: Amyloid beta-Protein Precursor (56)

abeta **accumul** alzheimer
amyloid app biochem caus character deposit
develop **diseas** enzym glycogen lead
lysosom patholog precursor report storag
suggest

3228: 1-Naphthylisothiocyanate (1)

administr anim bodi compar control dai decreas
dynam effect experiment increas induc inject model
rat reduc simul treat week weight

3230: Androstenes (1)

cell chain content cytometri densiti determin
drug flow **high** higher level line load
low pcr polymeras reaction resist revers
tumor

3232: Tissue Inhibitor of Metalloproteinase-3 (13)

analysi **associ** cell develop effect
express gene genom human identifi invas
methyl mutat role screen sequenc studi subject
tissu tumour

3233: beta-Defensins (14)

cell cluster differ distribut evolut express gene
group **human** identifi local
method number **patient** peptid phenotyp
region sampl sequenc tissu

3235: Adrenergic alpha-Agonists (9)

associ control data **function** gene
genet healthi human interact mice model
mutant **patient** product receptor
respons **studi** subject target
treatment

3237: Ephrin-B1 (4)

alter cell **chang** evid express
form format gene growth high
human individu inhibit interact
level low mice **receptor** repeat support

3239: Oxytocics (7)

acid cell decreas demonstr effect evid find
function increas level previou
process releas report role stimul studi
suggest time treatment

3234: alpha-Defensins (6)

assai **cell** data detect evid
express group individu
local marker model mutat normal
patient protein sampl
sensit studi tissu tumour

3236: Clonidine (3)

acid combin compar **concentr** determin differ
effect extract fraction **group** mean
patient ratio reduc respect risk signific studi
test valu

3238: Receptors, Prostaglandin E (10)

cell chang cox-2 decreas earli effect enhanc
increas inhibit **inhibitor** level normal
patient receptor reduc risk
role studi suggest tissu

3240: Blood Group Antigens (40)

blood cell circul count determin differ
donor genet **group** healthi human leukocyt
lymphocyt mononuclear pbmc **peripher** popul red
sampl transfus

3241: Receptors, Complement 3b (8)

blood cell combin complement correl demonstr
determin develop dna genom larg method
natur receptor select sequenc size
specif studi test

3243: Kallikreins (19)

altern associ **Cancer** cell chang differ
effect exon famili **function**
gene human model normal prostat
rate splice studi **tissu** variant

3245: Paroxetine (11)

behavior bipolar chang clinic compar control
dai depress **disord** dose enhanc
function genom metabol number random
respons sampl studi trial

3247: Propylamines (4)

activ combin concentr dai dose
effect enhanc enzym
gene identifi level metabol popul
produc product rat reduc rel screen
studi

3242: Hypothalamic Hormones (8)

alpha analysi beta blot **bodi** diet differ
effect express famili function increas
individu mass obes pattern
receptor role suggest weight

3244: N-Methyl-3,4-methylenedioxyamphetamine (8)

alcohol assess case clinic depend
effect ethanol group incid
measur method **oral** process
product risk score studi test women year

3246: Hydrocarbons, Chlorinated (11)

concentr contamin decreas differ
extract gener human
increas mechan molecular
product rate **sampl** size soil
specif studi target treatment water

3248: Adrenergic Uptake Inhibitors (5)

bind control dai disord dose effect famili
healthi member metabol **patient**
plai reduc reduct requir role studi subject
treat treatment

3249: Clodronic Acid (7)

breast cancer cell dai dose
enhanc event method mice mutant
patient plai process risk role
studi surviv treatment trial week

3251: Propanolamines (12)

activ analys analysi cardiac
concentr dai data differ effect
express function heart number receptor
reduc reduct resist reveal studi
trial

3253: Phosphatidylinositol Phosphates (18)

activ associ cell cluster earli
effect factor genom growth kinas
membran mice process protein reduc
regul respons sequenc signal studi

3255: Benzofurans (15)

acid associ caus cell concentr control differ
express extract group human
lead measur mice model mutant rat soil studi
water

3250: Lomustine (4)

adult chemotherapi dai dose group imag
median month organ patient
period point radiat rat receiv recurr time trial
tumor year

3252: RNA, Small Nucleolar (18)

core detect encod famili function gene identifi
interact melanoma open organ
phenotyp polymeras process region requir
rna screen sequenc tissu

3254: Transducin (10)

demonstr detect express find
interact mechan molecular mutant optic previou
protein receptor report retin retina select
structur studi tumour visual

3256: Niflumic Acid (2)

acid amino case chromatographi
extract fraction liquid metastasi metastat
method node prepar primari
procedur report separ standard syndrom
techniqu tumor

3257: alpha-Galactosidase (30)

activ alzheimers analysi autoimmun clinic data
diseases disord express genet level
parkinson pathogenesi patholog patient product
progress reveal select studi

3259: Parvalbumins (8)

affect alter brain chang featur increas
neuron mice mous mutant mutat
protein provid rat risk transgen vitro vivo

3261: Sphingolipids (21)

accumul acid associ base
cell combin deposit diseas
effect enzym famili **function**
gene increas local rel respons role storag
suggest

3263: Ibuprofen (7)

associ chang cluster compar data
differ high higher hospit
inhibitor level low patient pattern
rate ratio respons risk
studi treatment

3258: Calcium-Binding Protein, Vitamin D-Dependent (17)

activ analysi case **cell** detect
differ differenti gene high lesion level
neuron patient plai
protein respons role stain studi
treatment

3260: Contraceptives, Postcoital (12)

benefit **care** control cost current decis
ethic guidelin **health** issu
manag medic medicin
need physician **practic** provid
recommend research time

3262: Phytoestrogens (12)

cancer combin compar concentr data earli
effect famili higher increas
number ovarian rate reduc risk role
studi time treatment vivo

3264: Luminescent Agents (9)

cell control correl enhanc express form
gene high identifi improv life low
method promot **protein**
qualiti recombin techniqu tumour vector

3265: Lymphocyte Function-Associated Antigen-1 (19)

activ adhes attach **cell** collagen
express extracellular flow increas integrin
marker matrix migrat molecul normal process
surfac test time tissu

3267: Plastoquinone (3)

avail bind cluster **data**
databas decreas effect evid http
increas inform **interact** model
program provid reduc set site support tool

3269: Benzoates (15)

anim associ cell effect express group
high level low measur mechan
model number patient
product **respons** role score
studi target

3271: Ficusin (8)

activ alter bind cell chang damag
dna effect gene genet mechan molecular
mutant number process repair skin specif state
treatment

3266: Warfarin (24)

activ caus clinic cytochrom drug enzym factor
gener human **metabol**
metabolit method p450 patient popul risk
studi test treatment trial

3268: 4-Hydroxyphenylpyruvate Dioxygenase (2)

avail base concentr **data**
databas enzym event inform initi
literatur origin pair **PROCESS** program
report search second speci state tool

3270: Insulin-Like Growth Factor Binding Protein 5 (12)

activ associ base bind cell differenti enhanc
express factor gene **growth**
increas individu level mechan mice process promot
protein structur

3272: Acute-Phase Proteins (18)

activ adult associ cell chang children
differ effect express function
increas **level** pattern protein
respons serum studi tissu tumour year

3273: Ginsenosides (10)

activ analysi cell compound
control dai deriv develop
effect express function
gene group inhibit number
product reduc structur time
treatment

3275: Phenanthrolines (6)

activ chain enhanc evid famili
function human
identifi mechan model new process provid
reaction recombin region requir
sequenc structur time

3277: Hepatitis B Vaccines (17)

activ antigen associ children diseas effect
factor immun incid induc method number
parent patient process rate
respons risk vaccin year

3279: Dopa Decarboxylase (5)

absenc assess cell concentr develop head
indic individu induc induct measur model
new presenc requir respons
sampl score studi suggest

3274: Integrin beta3 (26)

adhes analysi associ cell
chang enhanc factor gene haplotyp
increas integrin model
mutat number polymorph
rate respons risk studi year

3276: Basic Helix-Loop-Helix Leucine Zipper Transcription Factors (14)

analysi assai bind case cell
detect famili function gene genet
genom increas interact process
protein report sensit specif studi valu

3278: Methamphetamine (19)

affect alcohol behavior chang data
depend develop disord effect
function gene group oral product
respons signific studi suggest time
treatment

3280: Nandrolone (1)

brain compar content data differ direct evid
femal flow higher hypothesi lower male
provid rat rate receptor sex
support versu

3281: Phosphocreatine (4)

activ analysi caus detect earli
effect form format gener genet high
level low rel reveal studi subject test
time treatment

3283: Phosphonic Acids (23)

acid **activ** analysi clinic effect enhanc
extract function **group** human
increas infect **patient** random
resist respons studi treatment trial viru

3285: Bradykinin (11)

analysi arteri **cell** chang control
coronari differenti effect function hypertens
mechan pressur reduc remain repeat reveal site
specif stimul vascular

3287: Fluorescein (22)

activ associ chang combin
concentr control correl detect develop
distribut effect group hybrid local observ
signific structur studi subject target

3282: Antigens, CD18 (9)

adhes cell differ extracellular
function gener inhibit
integrin level molecul phenotyp plai popul
receptor regul rel **respons** role size
specif

3284: Povidone (3)

approach combin compar concentr differ effect
embryo **group** higher lower mean
method **rate** ratio receptor requir respect
specif valu versu

3286: Kininogen, High-Molecular-Weight (2)

accumul bind bodi compar **control**
function
differ diseas frequenc
higher **mechan** microscopi molecular morpholog
observ pain patient rat underli variant

3288: Nitrogen Dioxide (5)

activ area **associ** correl dai
exposur form gener **human**
identifi interact level measur model
region screen sequenc studi tumour valu

3289: Nitrofurazone (2)

administ administr cell compound concentr

correl dai **effect** gene infect inject light
rat receiv reduc reduct signific week

3291: 1-Alkyl-2-acetylglycerophosphocholine Esterase (6)

allele **associ** function group level local mutat patient
brain cell gene genet genotyp plai polymorph popul remain role serum test

3293: Antidepressive Agents, Tricyclic (14)

activ analysi chain chang children **patient**
effect group metabol pcr polymeras rat rate reaction
respons role studi treatment valu year

3295: Isotopes (18)

acid activ **analysi** approach associ base
concentr detect develop **differ** effect energi genom
group mass method product sampl select
target

3290: Calcitonin Gene-Related Peptide (15)

cell compar **control** differ express frequenc human injuri level mean
measur mechan model nerv rat repeat role spinal studi valu

3292: Mianserin (4)

affect analys **analysi** concentr cost drug effect gene genet genotyp influenc level manag
medic **patient** schizophrenia serum studi polymorph reveal

3294: Complement C4b (7)

chang children compar complement control demonstr determin differ famili genet group
highli increas isol mutat patient pattern popul **specif** type

3296: Papain (3)

acid adapt amino blue color composit **light** method red region
decreas differ increas intens laser sampl select sequenc studi
techniqu

3297: Coenzyme A (11)

acid amino avail data databas develop
enzym fatti gener genom mutant popul process
product protein select sequenc **structur** test treatment

3299: L-Serine Dehydratase (1)

activ allow complement demonstr determin
enzym gener highli marker
method plant procedur protocol simpl
specif standard studi substrat
techniqu util

3301: Sodium Azide (10)

assess compar condit degre differ
effect event exposur higher
increas involv light **model** new
observ **process rate** reduc
studi system

3303: Antigens, Tumor-Associated,
Carbohydrate (24)

antibodi antigen cancer cell develop
differ express increas level marker
new **patient** pattern peptid
posit site studi tumour type variabl

3298: Pantothenic Acid (6)

acid amino assess cluster data detect
enzym estim experi extract fatti fraction initi measur
method origin product score second sensit

3300: Thermolysin (5)

conserv domain **effect** enzym evid hospit
inhibit mutant process **protein**
provid reduc **region** residu **sequenc**
site structur support test valu

3302: Receptors, Lipoprotein (6)

analysi assai assess data **detect** earli evid
factor form genet level measur method
mice mous phenotyp repeat risk
sensit transgen

3304: Gonadal Hormones (4)

cell combin compar differenti
effect epitheli express featur femal growth
higher male mechan produc **product**
prolifer **rate** regul tumor valu

3305: Peptide Elongation Factor Tu (8)

analys **analysisi** base blot cluster
control correl express genet
interact mrna organ phenotyp product
protein requir reveal sampl speci translat

3307: Phorbol 12,13-Dibutyrate (4)

activ approxim case character enhanc
express featur high inhibit level
low mutant patient **phenotyp**
plai rel resist role sampl suggest

3309: Receptors, Prolactin (8)

bind **cancer cell** data detect
develop factor gener growth
increas individu interact local malign
receptor region repeat sequenc studi

tumour

3311: E-Selectin (25)

activ adhes associ **cell** correl
develop effect extracellular factor function
gene **human** increas integrin
level molecul patient risk studi subject

3306: Arginine-tRNA Ligase (1)

abil abl capac **Correl** demonstr endogen
enhanc increas index methyl microscopi
morpholog **normal** nuclear observ potenti
properti relationship signific **tissu**

3308: Activating Transcription Factor 2 (14)

activ **cell** effect **express**
factor gene **group** high identifi kinas
low network phenotyp phosphoryl
promot protein region regul
structur transcript

3310: Core Binding Factor Alpha 1 Subunit (31)

alkalin bmd **bone** calcium densiti
develop femor fractur hip miner osteoblast
osteoporosi phosphat phosphatas role skelet spine
studi vdr vitamin

3312: Myelin Basic Proteins (26)

associ axon caus **cell** control cord heal increas
injuri myelin nERV neuropathi
number peripher regener respons spinal
structur trauma wound

3313: Hemiterpenes (3)

acid alter area **chang** compar defect
distribut enhanc higher increas initi local
method model **mutant**
mutat **rate** specif techniqu wild-typ

3315: Nitrogen Oxides (10)

acid **chang effect** genom improv
increas level life oxid period point qualiti
rat rate reduc select site **time**
treat **treatment**

3317: Lidocaine (8)

activ compar **CONTROL** dai decreas
effect function gene
increas larg measur
patient potenti rat reduc
releas size small **stimul** subject

3319: Skatole (2)

affect approach arm associ clinic compar

data design effect estim gener

genet improv method **random** ratio

risk studi treatment **trial**

3314: Pentanes (3)

analysi defect differ **group** level
measur method **mutant** mutat organ predict
regress serum signific speci test variabl variat
water wild-typ

3316: Thiones (7)

analysi apoptosi correl data demonstr
effect enzym estim famili **function**
level method **model** organ plai reveal
role specif studi subject

3318: Lauric Acids (4)

acid amino analysi **ASSOCI** blot
detect express featur femal **gener** includ
infect male multipl produc product protein
rang studi western

3320: Androsterone (3)

ASSOCI collect compar concentr correl
decreas enzym femal genom higher increas
lower male map **rate sampl** sex
signific studi subject

3321: 11-beta-Hydroxysteroid Dehydrogenases (4)

activ associ cell clinic defici
develop development diagnosi
gene link mechan mice molecular period
point recombin studi test time understand

3323: Neurotrophin 3 (11)

activ assai cell decreas detect earli enhanc
function group increas loss
mutant neuron normal organ
phenotyp rat sensit tissu treatment

3325: Amygdalin (2)

adapt adult associ content determin
extract flow fraction genet imag neg popul
posit prepar receptor select site studi year
young

3327: Fertility Agents (2)

address approxim bodi environment factor
femal genet induc influenc major male
question rel remain respons
studi trait twin variat weight

3322: Cerulenin (3)

cell cluster compar differenti gene high
higher identifi level low lower mechan
molecular produc product prolifer rate
screen target versu

3324: Proline Oxidase (6)

affect assai associ complex
concentr detect enzym gene
identifi patient phenotyp
polymorph report risk schizophrenia screen
sensit site studi suggest

3326: Benzyl Alcohols (3)

activ compar complex determin
differ extract fraction higher lower mean
measur morpholog prepar rang rate ratio
respect select studi valu

3328: Receptor-CD3 Complex, Antigen, T-Cell (5)

activ alter biolog cell chang
delai earli follow long-term mutant new organ
persist plai regul role stage system target
tumor

3329: Lymphocyte Specific Protein Tyrosine Kinase p56(lck) (13)

activ analysi **cell** develop
differenti express famili gener high interact
kinas low mice phosphoryl receptor recombin
role signal studi tyrosin

3331: Phosphoglycerate Kinase (7)

activ base **cell** combin
develop effect function
group level **mutant** mutat
number product rate respons role state
treatment tumour wild-typ

3333: KCNQ1 Potassium Channel (14)

activ atp ca2+ calcium
channel clinic current develop gene ion
mechan model mutat new **patient** releas
sampl studi test year

3335: Delayed Rectifier Potassium Channels (1)

action **activ** adapt complex dynam
effect experiment fit gener increas **model**
natur paramet potenti predict regul releas
select simul stimul

3330: CCAAT-Binding Factor (30)

activ assai bind develop element express factor
gene human increas **promot**
region regul regulatori report role site sp1
transcript upstream

3332: Carnitine O-Palmitoyltransferase (11)

acid anemia case combin defect
defici differ effect famili identifi
mutat **patient** phenotyp protein
report sever size studi subject treatment

3334: Receptors, Adrenergic, beta (14)

acid alpha base beta cardiac data differ gene
genet group heart ligand mechan mice model
receptor select specif studi trial

3336: Desoxycorticosterone (4)

acid correl determin **develop**
differ effect express flow
function gene heart increas
level model **rat** regul signific structur
studi trial

3337: Sodium Chloride, Dietary (13)

associ **concentr** dai determin
differ effect gene group **high** increas
isol level low min normal number **rat**
respons sampl **tissu**

3339: Dithionite (2)

acid base bind content
determin differ flow inhibit mean
measur **mechan**

molecular mutant observ pair
protein respect stabil state **valu**

3341: Porins (24)

analysi associ differ famili function identifi
isol membran mutant mutat protein
region regul resist respons reveal screen
sequenc **strain** type

3343: Receptor, Melanocortin, Type 4 (8)

approxim **bodi** control develop
diet dietari **express** fat genet human
intak mass obes **patient** polymorph
popul rel respons studi **weight**

3338: HSP47 Heat-Shock Proteins (2)

algorithm cell chromosom data **delet**
differenti element **express**
gene loss map method
network pancreat predict prolifer
rat region set **tumor**

3340: Dichlorodiphenyl Dichloroethylene (5)

correl differ **high** higher human increas
larg **level** low lower mechan molecular
number rate select serum **size** small studi time

3342: Thioglycolates (3)

group ^{activ affect analysi blot cell differ effect}
human inhibit isol mice mous
^{signific strain target transgen treatment vitro vivo}

3344: Parabens (3)

adult analysi combin compar
differ ^{concentr dai effect}
extract fraction infect method
older pattern prepar reveal studi subject
year young

3345: Preservatives, Pharmaceutical (3)

children concentr dai
defici dose effect event experi follow initi
organ origin process rat
regul requir stabil treat
treatment week

3347: Core Binding Factor Alpha 3 Subunit (17)

cancer cell detect develop differenti
dna express famili gastric gene
identifi mechan methyl phenotyp promot
pylori respons role select studi

3349: Tartrates (1)

analys analysi arm behavior clinic
compar differ improv indic larg number
perform random reveal size small studi
therapi treatment trial

3351: Anilino Naphthalenesulfonates (7)

acid concentr dimer express fold form
format function high increas level low
nativ number protein solubl stabil
stabl state structur

3346: Mefloquine (3)

acid amino decreas effect gene high increas level
low mice mutant mutat organ patient reduc
resist signific Studi test wild-typ

3348: Diazepam Binding Inhibitor (2)

abil acid aggreg alter amino cell
chang concentr demonstr
differenti form format
increas metabol peptid potenti prolifer
properti remain stimul

3350: Physostigmine (3)

adult clinic effect exposur high
includ level low multipl mutat produc
product random rat risk studi
treatment trial vivo year

3352: Factor VIIa (13)

activ associ bleed cell coagul develop
differenti factor folat form gener
homocystein mthfr platelet report studi
suggest thrombosi treatment venou

3353: Asialoglycoprotein Receptor (3)

assai bind cell chain complex detect
differenti **function** gene
length level liver rang reaction receptor repeat
sensit serum site surfac

3355: Activin Receptors (5)

activ cell concentr control develop enhanc
famili growth healthi identifi
mechan member mice normal posit regul
screen subject tissu transform

3357: Meglumine (3)

acid clinic diagnosi differ effect
genom imag larg map number
period point rat receptor sequenc **size**
small test **time** trial

3359: Platinum (18)

activ agent cell chang clinic concentr differ
dna drug effect gene **group** high
number **patient** popul rel resist structur
treatment

3354: Poisons (1)

american assess associ carrier countri european
factor impact improv increas interv life nation
physic popul qualiti ratio **risk** state
studi

3356: Carbon Disulfide (1)

administr anim compar content cytometri dai
determin dimer dose effect flow form increas
inject load protein **rat** stabil stabl week

3358: Neurokinin B (3)

approxim cell clinic diagnosi diagnost
differ differenti express fish fluoresc
gene **human** hybrid individu
mutat pattern probe rel situ target

3360: Deoxycytosine Nucleotides (10)

cell compound **dna** human increas
new normal process protein rate region replic
respons sequenc size small state studi target
tissu

3361: Coenzyme A Ligases (11)

acid enzym gene
activ amino cell differ
express function
genom hybrid isol mutant
mutat product region sequenc specif substrat
test

3363: Propanols (5)

cell chang dai differ dose express
group individu intermedi kinet
new popul rat size small state
structur switch transit variabl

3365: Azides (7)

approxim compar detect differ enzym
function group
level major new provid rel resist sequenc serum
size small studi time

3367: Pneumococcal Vaccines (7)

adult associ caus chang combin
effect genet health human increas
isol mice number particip popul
produc product strain studi
year

3362: Thionucleotides (35)

activ apoptosi cell
clinic combin differ effect
express function gene induc
inhibit local number patient
protein respons structur therapi
treatment

3364: Galanin (14)

activ cell develop differ
differenti effect express gene
human increas larg neuron
number pattern rat respons
role size small studi

3366: Ion Pumps (3)

abil approxim cell coli condit contain degre
domain drug encod enzym major open
properti protein region rel
resist sequenc similar

3368: Glucose-6-Phosphate Isomerase (12)

activ area complex develop differ
enzym human increas isol new
normal number patient popul
protein role structur substrat tissu
treatment

3369: Autocrine Motility Factor (5)

base **cell** correl differ enhanc
enzym factor **growth** identifi increas
method model novel organ pattern
phenotyp regul screen target tumor

3371: Diphtheria Toxin (13)

cell dai develop express femal health high
level low male mice model
patient product rat tissu
treatment tumor vitro vivo

3373: Methylazoxymethanol Acetate (3)

activ adult anim behavior compar data
gene high higher level low lower model
mutat older rate state studi
year young

3375: Small Ubiquitin-Related Modifier Proteins (17)

abil assess associ bind degrad evalu
factor **function** interact
measur patient protein requir risk
role scale SCORE subject ubiquitin valid

3370: Peptide Elongation Factor 2 (6)

associ cell control
correl diseas evolut famili form
format initi member mrna
phenotyp presenc requir rna speci
suggest target translat

3372: Tryptophan Synthase (2)

chang defect enzym evid intermedi kinet
marker **mutant** mutat
protein provid receptor residu site
state structur support switch transit
wild-typ

3374: Guanosine 5'-O-(3-Thiotriphosphate) (11)

activ alpha approxim base beta bind
cell differ function interact major observ
receptor rel select specif studi
suggest test time

3376: Collagen Type XI (11)

activ analysi caus cell compar
control develop earli express frequenc
gene group lead level mice model
mous specif stage transgen

3377: Troponin (3)

absenc anim ASSOCI base featur field
function genom heart
marker model mutant new pair
presenc properti provid rang sequenc studi

3379: Epoprostenol (11)

acid analysi associ chang cox-2 effect high
increas induc inhibit inhibitor
level low mechan prevent rat respons select
suggest treatment

3381: Bacteriochlorophylls (3)

anim cancer compound dai demonstr differ dose
essenti experiment gener group indic
individu isol light model requir site strain
studi

3383: Guanethidine (1)

accumul bone cardiac caus compar
control differ effect frequenc
heart higher increas loss observ prevent protect reduc
reduct signific vitamin

3378: Neuropilin-1 (13)

angiogen angiogenesi cell differ
endotheli enhanc express
factor gene growth hif-1alpha human
hypox hypoxia interact line pattern
vascular vegf vessel

3380: Sodium Hypochlorite (6)

activ combin compar control
differ effect evolut group
light measur method microscopi
morpholog observ pattern product rel
score stimul studi

3382: Sympatholytics (3)

adenoviru bone cell compar copi deliveri diseas
distribut effici express gene higher
local lower number rate recombin
transfer vector vivo

3384: Naphthalenes (41)

activ chang compound concentr deriv
develop effect gene genom group increas
model patient protein respons
structur studi target time treatment

3385: Antiemetics (7)

activ agent area base blood condit degre

determin differ drug effect metabol number

patient popul specif studi temperatur treat

treatment

3387: Enkephalin, Leucine-2-Alanine (3)

analysi blot cell combin condit

distribut effect follow gene impact

improv life local phenotyp physic

qualiti rat reduc state treatment

3389: Thrombomodulin (13)

cell children control
differ earli enhanc factor
group high human

inhibit level low marker

patient plai popul protein

role stage

3391: Wiskott-Aldrich Syndrome Protein, Neuronal (6)

actin activ analysi bind cell

cytoskeleton famili filament

member migrat mutant

phenotyp polar produc product

protein regul requir rho test

3386: Thiotepa (8)

chemotherapi concentr dai donor dose effect human

median metabol month patient plai
process regress requir role studi toxic transplant
variabl

3388: Receptor, EphB2 (7)

analysi bind cell correl express

famili genet member model mutant

new normal popul posit protein
provid ratio receptor risk tissu

3390: Anti-Anxiety Agents (21)

activ alcohol behavior cognit develop

differ disord effect group human impair

learn memori oral patient

perform rat studi test treatment

3392: Receptors, LHRH (17)

assist base cycl effect express follicl

gene hormon human

identifi new ovarian patient

pregnanc reproduct respons

steroid stimul studi

women

3393: Diamide (7)

analysi blot **cell** concentr control
demonstr follow initi,mechan mutant
mutat oxid protein rat requir reveal
structur treatment western wild-typ

3395: Casein Kinase Idelta (3)

cho circadian clock cycl cyclic
develop disord feedback genet
hamster **human** isol loop
mammalian oscil period strain suggest synchron
time

3397: Receptor, Galanin, Type 2 (1)

activ alpha antibodi beta block **cell**
differenti domain effect express induc
inhibit inhibitori ligand mechan
prolifer protein **receptor** skin
suppress

3399: Receptors, Aryl Hydrocarbon
(33)

activ cell chang concentr contamin
develop endotheli enhanc express gene
increas interact protein receptor respons role
soil studi suggest water

3394: Aminohydrolases (6)

data evid famili
function gener identifi
network predict process product provid
region screen select
sequenc specif studi subject
support test

3396: Receptor, Galanin, Type 1 (2)

approxim carcinoma cell **function**
high human incid level low
major men mice mortal mous preval rel requir
transgen women year

3398: Receptor, Galanin, Type 3 (1)

absenc aim content cytometri data determin evalu
flow head indic investig load malign modifi observ
possibl presenc signific **studi** tumour

3400: Aryl Hydrocarbon Receptor Nu-
clear Translocator (12)

activ angiogenesi associ cell correl
detect endotheli factor function growth
human increas new regul signific specif studi
transcript vascular vegf

3401: Glycosyltransferases (32)

activ base cell cluster develop differ express
function **gene** group human
identifi model mutant residu sequenc site
structur studi test

3403: Oxprenolol (1)

analysi chromatographi condit degre
determin **extract** form
format fraction **level** liquid
measur predict prepar regress relationship
separ serum **variabl** variat

3405: Propylene Glycols (5)

assai **ASSOCI** cell concentr detect
embryo high **human** level low
multipl rat requir sensit structur studi
system treatment tumor valu

3407: Flutamide (4)

adult bodi **CANCER** children condit control
correl degre **develop** examin
level patient prostat radiat signific specif
studi subject vector year

3402: Sulfonylurea Compounds (10)

associ children clinic control diabet
effect function glucos **group** insulin
level mechan molecular
patient period point studi
subject **time** treatment

3404: Neurocalcin (1)

adhes carcinoma **cell** conserv cours durat
end function genet human invas longer mammalian
matrix molecular period point **protein**
start **time**

3406: Arylsulfotransferase (9)

activ analysi associ cancer chang compar
control differ effect **genom** group
metabol normal **patient** region
risk sequenc studi **tissu**
tumour

3408: Oncogene Protein p65(gag-jun)
(4)

activ anim cell famili genom
light mechan member **model**
molecular mutat plai promot report requir
role select studi suggest system

3409: Procetofen (4)

activ concentr control differ enhanc
increas larg level mutant presenc produc
product rat risk size small specif structur
studi subject

3411: Carbamoyl-Phosphate Synthase
(Ammonia) (3)

allel **analysi** data effect enzym estim
express factor function
gene genotyp **human** mutat
polymorph protein reduc reveal risk
structur transplant

3413: Dihydroxydihydrobenzopyrenes
(3)

abil activ analys **analysi** base
concentr effect enhanc increas indic inhibit
inhibitor **mechan** **metabol** mice
molecular pair properti reveal studi

3415: beta-Transducin Repeat-
Containing Proteins (11)

activ **cell degrad** differenti
express **human** inhibit level ligas
mice normal number pathwai process
prolifer proteasom **protein**
repeat tissu ubiquitin

3410: Bromides (4)

area base compar differ form format greater
rate
higher lower mean measur patient
ratio respect similar stress studi valu versu

3412: Myeloablative Agonists (1)

clinic compar content cytometri determin donor evalu
flow induc induct methods month multipl
patient random respons studi
transplant trial year

3414: Cytidine Diphosphate Choline
(1)

anim bovin breed compar content cytometri **decreas**
determin differ evalu flow implant
increas level load milk observ pig
reduc signific

3416: Antigens, CD94 (10)

allel antigen area **cell class**
combin complex correl express hla
human major mhc molecul
receptor regul respons select size time

3417: Thorium Dioxide (1)

alter **case caus chang**
codon consequ decreas **express gene increas**
lead **mechan** molecular patient present
report result sever substitut underli

3419: Ephrin-A1 (4)

cell ^{cancer} **express** ^{decreas event}
factor gene growth
human increas **normal** patient
posit process prognost **sampl** signal surviv
tissu tumour

3421: Carboxylic Acids (19)

acid amino approxim associ chang detect
differ famili fatti gene **group** human level major
method observ organ rel respons sampl

3423: Bicyclo Compounds (4)

activ adduct analog analogu approach
chemic **compound** deriv
design **mechan** molecular multipl new novel
number potent presenc strategi structur
target

3418: Fatty Alcohols (7)

activ assai base chang combin concentr
detect effect **express** femal
group local male mice normal rat receptor
risk sensit **tissu**

3420: Silicon (16)

activ analysi base **cell** differ
electron high human hybrid imag method
microscopi morpholog new number
observ radiat rat reveal surfac

3422: Tannins (4)

adult chang determin effect experi
genet **level** mean measur **organ**
ratio resist respect **sampl** serum
specif tumor **valu** variabl
year

3424: Hydrocarbons, Cyclic (1)

activ adduct adenosin analog analogu chemic
compound deriv **effect** ^{new}
novel oxid potent prevent protect reduc reduct
ring synthes **synthesi**

3425: Dioxanes (2)

cell **concentr** dai differenti
effect exposur form format marker mice
microg microm min normal plasma potenti
protein **target** therapeut **tissu**

3427: Alum Compounds (4)

american cell determin differ experi
express extract fraction incid
individu **organ** popul possibl preval
process report respect studi treatment valu

3429: Chromogenic Compounds (9)

adult fish fluoresc her-2 hybrid method neg
normal number **posit** probe product
protein rate role sampl situ test tissu year

3431: Thorium (15)

air concentr contamin copper dose exposur
human irradi measur metal
method **model** radiat rang rate soil
sourc **time water** year

3426: Proto-Oncogene Proteins c-pim-1
(5)

cancer confirm demonstr distribut enhanc
find **human** identifi indic local
patient previou regul report
sampl screen structur **studi** suggest
vivo

3428: Vitamin D-Binding Protein (4)

assai assess bone detect evalu factor genet
identifi measur method polymorph
protein receptor region score
screen sensit sequenc specif structur

3430: Industrial Waste (23)

activ air analysi assai **Concentr**

contamin copper detect effect increas

measur metal **model** process respons

sampl sensit soil sourc **water**

3432: Lead Radioisotopes (3)

analysi classif **cluster** compar
differ higher **level** lower mean
measur normal **rate** respect serum
set studi system **tissu valu** water

3433: Luciferases, Firefly (20)

acid activ assai **cell** detect effect
express fluoresc function gene
green imag protein report respons sensit specif
transfect vector vivo

3435: Gibberellins (22)

acid arabidopsi differ flower function gene
genet interact leaf leav organ pattern **plant**
pollen protein root seed thaliana tomato transgen

3437: Tellurium (1)

advanc allow appli applic approach biologi **cell**
chicken develop discoveri imprint individu japanes
method new protocol research techniqu technolog tool

3439: Receptors, Serotonin, 5-HT2 (4)

activ assai **detect** disord earli
environment factor **genet** genotyp
influenc interact model plai polymorph
popul product role sensit trait variat

3434: Myelin-Associated Glycoprotein (12)

activ axon cord differ featur function
heal **injury** nerv produc
product protein region **sampl**
sequenc spinal **studi** subtyp
time wound

3436: Cadmium Compounds (12)

activ codon differ effect electron
gene genom larg microscopi morpholog
observ polymorph process protein regul
select size small state treatment

3438: Methylmercury Compounds (8)

ASSOCI bodi care data differ evid
exposur famili **health** level measur
mechan model molecular posit provid
studi support test water

3440: Factor Va (2)

activ analysi base cluster code
codon complex data decreas differ evid
growth **increas** inform new pair particip
provid substitut support

3441: Molluscacides (1)

characterist common compar cultivar densiti
differ featur **high** higher level light
low lower maiz **rate** respect rice
similar versu wheat

3443: Vesicular Glutamate Transport Protein 1 (2)

characterist common **decreas** express featur
fish fluoresc high hybrid impact improv
increas level life low physic
probe qualiti situ **studi**

3445: Isoniazid (21)

addit data defin demonst **gener** includ
indic isol mutat mycobacterium new report repres resist
select specif strain studi treatment tuberculosi

3447: Captopril (7)

bladder chang clinic control **decreas** effect
extract femal **group** increas inject level
male **patient rat** receptor reduc
serum studi treatment

3442: Vesicular Glutamate Transport Protein 2 (4)

affect common distribut donor evid evolut
express featur follow form
format identifi local neuron provid rat
screen suggest support transplant

3444: Terphenyl Compounds (3)

activ apoptosi base bind cell conform
control crystal differenti **express** healthi new
p53 pair prolifer provid region sequenc
structur subject

3446: Ethane (2)

addit analysi **combin** effect electrophoresi extract
form gel **human** imag magnet mass
muscl produc product **protein**
proteom stabil **structur** volum

3448: Thiopronine (1)

averag calcul compar curv determin differ lower
mean measur paramet predict rang ratio refer
respect standard structur treat treatment

valu

3449: Penicillamine (5)

abil caus cluster **dai** demonstr differ

dose effect **function**

gene individu mean measur model

proporti ratio respect system

treatment **valu**

3451: Granulocyte Macrophage
Colony-Stimulating Factors, Recombi-
nant (9)

adult bone **cell** clinic combin

detect differ earli gener individu marrow

measur **patient** requir size studi

test therapi **tumour** year

3453: HLA-DR1 Antigen (3)

activ analys analysi blood cell

class compar **control** frequenc

interact mhc **mice** molecul mous
patient presenc reveal sever transgen vivo

3455: CDC28 Protein Kinase, S cere-
visiae (9)

arrest caus **cell** cost cycl cyclin form

format **function** interact manag medic
mutant new phase plai provid requir role yeast

3450: Mitochondrial ADP, ATP
Translocases (6)

acid base code codon dna enzym
express gene gener genet

mitochondri normal organ **region**

risk **sequenc** structur

substitut **tissu** yeast

3452: HLA-DR5 Antigen (1)

acut associ chines class **clinic** diabet

differ haplotyp heterogen liver mild

patient polymorph present

sever sign snp studi subtyp

symptom

3454: HLA-DR2 Antigen (5)

analysi assess combin decreas diseas estim evalu
genom increas measur mice neg

patient posit product region resist

respons score sequenc

3456: Alfentanil (1)

analysi concentr determin differ factor genotyp

group growth measur metabol patient

polymorph predict **protein** regress relationship
sever signific variabl variat

3457: Ondansetron (1)

allel clinic compens COP1 determin express gene genotyp

high includ increas larg limit **number**
patient polymorph possibl sever singl total

3459: Silanes (5)

chang decreas dna effect form **group**

high identifi **increas** initi laser
level **light** low observ product reduc
screen structur treatment

3461: Receptors, Erythropoietin (26)

abnorm anemia caus cell control defect

defici develop express increas interact
level mechan normal report respons sever size
studi treatment

3463: Chorismate Mutase (3)

activ children concentr conform core
famili gene identifi larg member mix
number open produc **product** size small
structur yield

3458: Fluorine Compounds (4)

algorithm approach case
concentr data differ
effect estim **exposur**
featur health includ isol
method network
predict rang set studi water

3460: Nitrosoguanidines (2)

apoptosi cell chromosom complement death

densiti determin dna domain express extract

gene genotyp **high** highli level low

mutat polymorph **specif**

3462: Cellulose (22)

activ compar **control** determin differ

evolut **extract** fraction

function isol method mutant

number prepar product rate

sampl sequenc size **time**

3464: Trinitrobenzenesulfonic Acid (5)

cell compar **control** correl dai differ diseas

enhanc **group** interact larg phenotyp
plai rat role signific size small target treatment

3465: DNA Polymerase II (14)

activ analysi associ condit degre distribut
dna famili gene human increas local
product promot recombin replic requir rna role
suggest

3467: Cannabinoids (5)

alpha bodi cluster **control** data direct
evid find frequenc hypothesi plai
provid receptor releas role
stimul suggest **support** therapi
weight

3469: Arrestins (9)

affect alpha analysi associ beta cell complex
effect mechan mice new patient protein provid
receptor reduc select specif
structur studi

3471: Methylmethacrylates (2)

applic base compar **control** data
differ frequenc laser light microscopi morpholog
new observ pair patient **protein** research
studi surfac technolog

3466: Neuropeptide Y (23)

anim data differ direct effect **evid** find
gene group hypothesi model neuron popul
provid rat respons studi suggest
support test

3468: Cyclohexanols (7)

abil **activ** compar earli effect evid higher
increas induc potenti process **provid rat**
rate receptor releas respons stimul
support test

3470: NFI Transcription Factors (16)

activ cell complex control
develop express factor function
gene includ inhibit mrna promot protein
region repeat sequenc site transcript translat

3472: Potassium Dichromate (2)

avail biolog dai data databas dose event gene
involv length long period point **process**
renal repeat short studi system
time

3473: Proto-Oncogene Protein c-ets-2
(8)

associ correl decreas differ earli
express gene human
increas level new patient
process promot protein region sequenc size
telomer transcript

3475: GroES Protein (3)

activ assai bind detect enzym form
includ major multipl predict protein
rang remain sensit specif stabil
state structur varieti wide

3477: Polycarboxylate Cement (3)

analysi blue cell color composit evid
identifi intens laser light measur
process protein red regul reveal score screen
studi support

3479: Magnesium Oxide (3)

clinic composit cultur diagnosi differ
extract fraction impact
improv laser level life
light liquid physic prepar
qualiti risk serum studi

3474: GroEL Protein (11)

activ complex data effect estim form gene
isol measur method model
protein rate role select speci
stabil strain support valu

3476: Bacteriorhodopsins (10)

approxim base carbon chang conform crystal
electron energi form free gene genom measur
method model new protein sequenc solut

structur

3478: Dental Cements (2)

abil approach electron laser length light long
microscopi morpholog observ plai properti red
repeat role short strategi studi suggest
trial

3480: Dental Alloys (3)

approach concentr dai data design differ effect
group incid laser light method
network observ popul predict rat sampl
strategi studi

3481: Zinc Oxide (2)

acid adapt amino differ effici electron extract find
group light method microscopi
morpholog observ previou report select studi
surfac techniqu

3483: Receptor, trkC (6)

activ adult associ cell earli evid
express identifi local **mechan**
molecular plai provid receptor
role screen suggest
treatment tumor year

3485: Adenine Nucleotides (13)

activ approach bind compar
control data effect enzym famili
higher new produc product **rate** regul
respons specif studi time year

3487: gamma-Glutamyl Hydrolase (3)

activ anim carcinoma concentr
continu dai delai dose **express** follow gene
long-term marker **model** multipl persist studi
therapi vector vivo

3482: Aspartate Kinase (1)

activ avail current data databas densiti dimer
discuss enzym form **high** inform level
low program protein recent stabil stabl tool

3484: Arabinonucleosides (5)

abil **activ** acut administ administr
aml cancer characterist chronic **dai** dose
featur leukemia month myeloid patient
properti receiv transplant week

3486: beta-Cyclodextrins (13)

analysi cell concentr **dai**
determin dose effect form format genom
initi metabol number plai process rat rate
role suggest week

3488: Xanthophylls (13)

approxim concentr correl differ
energi express form format **human**
increas **level** major measur model
observ plasma rel **respons** select
serum

3489: Anabolic Agents (11)

analysi associ dai data effect estim
extract factor gene **group**
growth increas method new
number organ product protein
studi subject

3491: Contraceptive Agents, Female (8)

associ care clinic compar control cost differ
group guidelin health manag
medic new practic provid random studi
subject treatment trial

3493: Antibiotics, Antifungal (15)

analysi control detect enhanc
express extract fungal gene isol
method mice model
mutant organ pathogen
patient process research
select time

3495: Subtilisins (9)

activ area base data differ earli
express human identifi region residu
role select sequenc site speci stage
studi subject test

3490: Trenbolone (1)

administr compar condit dai degre differ dose
effect heat high higher lower oral **rate**
respect shock temperatur time versu week

3492: Streptothricins (3)

analysi bind cerevisia cluster construct contain
data drug **gene** homolog identifi
identifi mutat novel plasmid
recombin resist
saccharomyc screen yeast

3494: Chymotrypsin (12)

activ complex control differ domain
effect **express** form format
function gene human
identifi **protein** residu role
screen site structur test

3496: Receptors, Granulocyte-Macrophage Colony-Stimulating Factor (4)

assess bind bone **cell** chain detect
develop fusion measur mutant
normal partial pcr polymeras
protein reaction receptor requir
score **tissu**

3497: Immunoglobulin lambda-Chains (8)

analysis associ cell clinic evolut
flow gene increas larg mice model normal
number origin patient
respons reveal studi subject tissu

3499: Sympathomimetics (7)

associ clinic compar CONCENTR
control determin differ famili measur normal
patient predict signific specif studi test
tissu valu variabl year

3501: Fludrocortisone (5)

clinic correl effect evid femal group
high identifi level low male normal
patient reduc screen sever signific
support tissu treatment

3503: Cyanogen Bromide (3)

acid clinic conserv develop
diagnosi event form level mammalian
mutant presenc process protein receptor
remain serum site stabil structur suggest

3498: GRB2 Adaptor Protein (19)

activ associ Cell chang develop
express form format identifi
interact kinas mutant
pathwai phosphoryl protein
screen signal time tumor tyrosin

3500: Midodrine (2)

affect blood case characterist effect

famili featur imag member mutat neg

patient posit reduc reduct report state surviv

treat treatment

3502: Glycopeptides (13)

assess clinic data differ famili improv

measur model organ random

respons role sampl score

select sequenc site structur studi

trial

3504: Antibiotics, Antitubercular (10)

area chang differ gene gener genom

high indic isol mutat produc product resist role
sequenc specif strain structur studi tuberculosi

3505: Homoserine O-
Succinyltransferase (1)

accumul achiev activ addit approach catalyt
coli **combin** design effect
ENZYm escherichia limit optim strain strategi
substrat success synergist transcript

3507: Aflatoxins (13)

anim associ case **control** differ
function fungal gene individu
model mutat number
pathogen produc **product** ratio
risk sampl **studi** time

3509: Maf Transcription Factors, Large
(6)

activ associ base bind cell
control enhanc express gene increas islet mice
pancreat popul promot protein respons
secret studi transcript

3511: Silicone Gels (3)

breast cancer cataract
data error estim ethic examin glaucoma implant
len marker method perform power research statist
studi tamoxifen women

3506: Methionine Adenosyltransferase
(2)

activ affect alter cancer **chang**
concentr decreas ENZYm hybrid increas
involv **mechan** methyl molecular mutant
prostat schizophrenia studi substrat suggest

3508: Polynucleotides (3)

associ base bind cluster compar
differ dna genom individu isol
model observ pair pattern regul sequenc
similar strain structur type

3510: Radioactive Fallout (29)

area base concentr data differ dose
effect live locat measur new radiat region relat
resid risk sampl studi water zone

3512: Perylene (8)

activ bladder cell concentr control
determin express form identifi mutat normal
plai role sequenc structur studi
suggest tissu tract urinari

3513: Mannosephosphates (6)

accumul alter bind cell chang complex
cultur **human** identifi interact
membran mutat process protein requir
residu screen **site** specif treatment

3515: Clindamycin (10)

bacteri clinic **combin** compar
effect gene **group** hospit host **human**
infect **isol** pathogen phenotyp
popul rate resist **strain** studi
subject

3517: Methicillin (3)

acid amino antibiot bacteri **combin**
concentr dai differ dose effect gener host
infect **isol** pathogen resist **strain** studi
subtyp week

3519: Phosphodiesterase I (7)

activ **assai** cell chain codon
decreas **detect** differ
femal growth identifi **increas**
male per **phenotyp** reaction
sensit sequenc substitut time

3514: Mannans (11)

assai bind **correl** detect
develop differ exposur
high identifi interact level low
mutant product sensit signific site
specif **studi** target

3516: beta-Lactams (14)

antibiot bacteri bacteria data featur gene
group host **infect** isol parasit
pathogen produc product resist specif
strain target treatment virul

3518: Glutamate Carboxypeptidase II (13)

activ androgen antibodi base **cancer**
cell control earli enhanc express gene increas
mechan molecular **patient** product progress
prostat recombin tumor

3520: Sulfur Hexafluoride (5)

anim **case** concentr correl
differ distribut effect larg light local
model observ pattern **rat** report
size small studi target tumor

3521: Monoamine Oxidase (43)

adhd affect anxieti associ behavior bipolar
depress **disord** genet group major
patient person polymorph psychiatr sampl
serotonin sleep studi symptom

3523: Activating Transcription Factor 1 (3)

compar condit degre enhanc femal **high**
higher level low male mice mutant organ
produc **product** rate rel
report resist studi

3525: Phenylpropanolamine (2)

bladder chines cost determin
differ electron manag medic
microscopi mobil morpholog observ
practic **specif** studi subtyp
surfac tract urin urinari

3527: Fumarate Hydratase (8)

activ **famili** autosom clinic develop domin
enzym **famili** gener group identifi
individu inherit member mutat patient plai
produc product rate role

3522: Vancomycin (13)

activ antibiot aureu bacteri bacteria compar
control **group** host increas
infect isol mutant parasit
pathogen rat salmonella specif strain virul

3524: Macrophage-1 Antigen (10)

activ adhes anim base bone **cell**
detect genet improv increas interact life
mice **model** physic qualiti receptor
respons studi treatment

3526: Mineral Fibers (3)

associ caus cell confid control domain factor
human increas interv lead odd plai
rat ratio **risk** role site smoke studi

3528: Aconitate Hydratase (8)

cell chang effect evid
famili gene gener
identifi increas inhibit
mitochondri model
oxid phenotyp **product** provid
rate respons suggest
support

3529: Glyoxylates (5)

activ adapt alter bladder case cell chang
distribut enzym evolut express **gene** local
mutant natur protein respons
select studi variabl

3531: Hydroxymethylbilane Synthase (6)

arthriti associ case **clinic** complex diagnosi
diseas express famili
function gene member
month mutant **mutat** pain
patient report requir sever

3533: 3,4-Methylenedioxyamphetamine (1)

analysi bladder carrier collect data detect determin
extract factor fraction increas loss oral oxid
phylogenet risk **sampl** speci studi
urinari

3535: Sulfuric Acid Esters (3)

acid cell concentr differenti dna exposur
genom induc initi length mean measur
origin rat ratio repeat requir respect
respons valu

3530: Platelet Glycoprotein GPIb-IX Complex (7)

bind blood cell control correl decreas flow form
function healthi increas level
patient phenotyp produc
product repeat signific studi subject

3532: Nonheme Iron Proteins (1)

affect carbon condit degre effect energi

experi free heat loop observ schizopshrenia shock

solut studi suggest temperatur therapi treat

treatment

3534: Barium Sulfate (6)

anim cancer case children chronic clinic demonstr
diseas find function intestin model number
patient previou report studi
suggest valu variabl

3536: Neuromuscular Blocking Agents (3)

associ condit degre differ enhanc
increas **mechan** molecular multipl
period point random studi subtyp temperatur
time treatment trial underli understand

3537: Elements (1)

demonstr diverg duplic **embryo**
evolut evolutionari extract find fraction
matur **multipl** oocyt origin previou
report segment singl **studi**
suggest transfer

3539: Antibodies, Catalytic (1)

base correspond differ discuss diseas enzym
expect extens match observ pair plai possibl
propos **protein** recent region
role sequenc similar

3541: Hypoxanthines (2)

anim case complex compon damag data dna
experiment form individu model produc
product protein repair stabil **studi**
subunit vitro vivo

3543: D-Amino-Acid Oxidase (4)

activ approach compar concentr decreas
evid **gene** higher identifi increas lower
normal rate respect screen strategi
subject support **tissu** versu

3538: Fluoxetine (12)

adhd affect associ bipolar chang depress
differ **disord** effect increas level
patient person psychiatr respons serotonin sleep
studi symptom treatment

3540: RNA, Transfer, Gln (2)

acid activ amino **base** codon enzym essenti
form format involv mechan
mitochondri molecular observ pair plai
requir **role** substitut suggest

3542: Receptor, Serotonin, 5-HT1B (7)

associ bipolar data depress
disord gene genet haplotyp
human increas map model person
polymorph psychiatr select snp studi symptom
tumor

3544: RGS Proteins (12)

affect alter analysi associ brain
chang control effect
express **gene** genet human
level normal protein region
sampl select studi tissu

3545: Galectins (14)

activ bind cell compar
control develop **express**
famili high interact **model**
peptid protein rate regul
select specif studi target tumor

3547: Diethylstilbestrol (12)

cancer concentr **develop** effect
express femal **human**
improv life **male** model new posit
process qualiti rat sex studi treatment
tumor

3549: NF-E2-Related Factor 2 (20)

activ analysi antioxid damag function
increas induc level mechan **oxid**
oxygen promot protect radic rate reactiv
regul respons speci stress

3551: Voltage-Dependent Anion Channel 2 (2)

abil cell **complex** compon dimer effect
form plai potenti properti protein rat
releas **role** stabil stabl stimul
subunit suggest therapi

3546: Galectin 4 (3)

bind cell **chain** dai **express** initi
new origin pcr polymeras provid quantit
reaction real-tim **region** regul
revers **sequenc** specif
structur

3548: Gene Products, tax (22)

analysi c-myc **cell** cellular deregul **express**
human induc malign myc **oncogen**
overexpress patient
prolifer promot respons role studi
transform tumorigenesi

3550: Formamides (2)

analysi blot clone contain core detect encod gene
identifi induc induct open **protein**
recombin region **respons** reveal
sequenc speci western

3552: Voltage-Dependent Anion Channels (5)

activ apoptosi **chang**
express form format genom identifi
interact male mechan morpholog organ
plai protein role screen specif structur
suggest

3553: Formyltetrahydrofolates (1)

differ distribut dna element enzym fluid form
format fragment **gene** indic larg
larger local mutant number site **size**
small suggest

3555: Formate-Tetrahydrofolate Ligase (2)

activ continu delai **enzym**
follow form format initi
interact long-term mutant
mutat occur persist recoveri
remain site **specif** spontan
substrat

3557: Hippocalcin (1)

allel analysi associ **chines**
chromosom **differ** gene
gener genotyp haplotyp
heterogen linkag loci locu
map polymorph
presenc snp **studi**
subtyp

3559: beta-Crystallin B Chain (3)

affect alter blood chain **chang**
complex control famili featur gene gener
healthi method mice multipl reaction₄₄₅
region sequenc studi
subject

3554: Carbon-Nitrogen Ligases (10)

alter **ASSOCI** case caus
chang concentr decreas
enhanc evid express function
human increas lead
plai **PROCESS** protein **role**
suggest support

3556: Thrombopoietin (28)

adult **cell** dai differenti embryon
hematopoiet high hsc isol level lineag low model
number patient progenitor **STEM** studi time
treatment

3558: Crystallins (11)

activ analysi **ASSOCI**
chang effect enhanc express famili
gene genet high identifi implant
len popul protein sampl **specif**
studi system

3560: HIV Envelope Protein gp160 (8)

cell **chang** combin differ enhanc famili
fusion high hiv-1 **human** infect
isol level low region sequenc **specif**
structur studi viru

3561: Thebaine (1)

alcohol assess chromatographi
combin
effect evalu extract fraction
liquid measur method oral prepar scale
SCORE separ valid

3563: Receptors, Serotonin, 5-HT1 (1)

assess current discuss environment evalu factor
genet
recent scale SCORE stress studi trait twin
understand valid variat

3565: Receptor, EphB4 (5)

bind cell chang correl decreas develop
effect factor growth increas
level mice mous normal peptid rat
receptor reduc target tissu

3567: Arrestin (6)

cell chromosom decreas delet hybrid
identifi increas level locu map
mechan plai process retin role screen site
specif target visual

3562: Codeine (5)

assai associ combin control dai
data detect differ effect estim extract
follow gene method pattern sampl
sensit size studi treatment

3564: Ephrin-B2 (6)

activ alter cell chang
express growth human
interact mice model mous
mutant normal posit region sequenc
subject test tissu year

3566: Retinal Pigments (9)

acid activ analysi associ
concentr data detect differ form
high human light low measur
pattern phenotyp retin size state
visual

3568: Fumonisin (7)

area cell compar concentr
control differenti enhanc
extract fraction gene health
normal plant posit prolifer rang rice
test tissu wheat

3569: Gliclazide (1)

articl chromatographi data determin
extract fraction improv
inform life liquid literatur method physic
prepar publish qualiti report research
review search

3571: Collagen Type VIII (2)

autosom character characterist clinic codon
common diseas dna domin famili featur gene
inherit length long morpholog **mutat**
patient repeat short

3573: Hypoxanthine (10)

activ analysi associ **base**
cell combin compound cultur detect
differ enhanc enzym **group**
hybrid increas method pair
probe size structur

3575: Mephenytoin (2)

bind demonstr femal find indic male
metabol metabolit mutant
mutat network predict presenc previou
protein recent report
studi suggest wild-typ

3570: Lisinopril (3)

adult alter chang chromatographi
determin elderli **extract** femal fraction
liquid male method old older prepar sex studi
year young younger

3572: Xanthine (5)

acid approxim **associ** bind
compound dai dna express famili isol member
new rel residu select site state strain studi
surviv

3574: Contraceptives, Oral, Combined (5)

associ case combin correl data estim factor gene
group increas level **patient** posit
ratio risk serum signific studi variabl women

3576: RNA, Small Cytoplasmic (9)

analysi bind cell compar control differ
element **gene** high human
insert integr low melanoma rate recomb
region rna sequenc site

3577: Asbestos, Crocidolite (5)

analysi associ compar earli **effect**
higher **level** model normal point rate
ratio reduc risk role sampl studi
time tissu **treatment**

3579: Antennapedia Homeodomain Protein (6)

cell data enhanc flow form format includ
indic interact larg mechan model peptid
requir select size small structur **studi**
tumor

3581: Saccharin (6)

activ alcohol chang decreas
depend **effect** gene
human increas method
mice oral protein rat **requir**
respons select studi test time

3583: Thiazines (2)

adapt cell differenti **extract** fraction
high induc larg level low method
normal prepar rat **respons**
select size small system tissu

3578: 5-Methylcytosine (7)

base bind dna enhanc epigenet gene
genom hypermethyl inactiv level
method **methyl** pair promot
region requir respons sampl select
sequenc

3580: Spiro Compounds (13)

cell compound differ effect inhibit level
multipl number **patient** process
produc **product** rat region
respons sequenc **structur**
tumor vitro vivo

3582: Cyclamates (1)

chromatographi column contain detect determin
develop development effect
extract fraction gel inhibit liquid mass method
oral prepar purif purifi separ

3584: Aspartame (1)

aggreg chromatographi column contain
determin **extract** form
format fraction high-perform hplc liquid
method mixtur oral prepar purif purifi separ
solut

3585: Diterpenes, Kaurane (8)

activ analysi cell chang concentr
content cytometri determin effect evalu
flow high human increas load
measur observ percentag signific studi

3587: Succinimides (11)

cell class combin data effect gener
genom growth high human low model
normal protein sampl specif target tissu
vitro vivo

3589: Sugar Phosphates (1)

activ differ element enzym factor gene
genom growth hypothesi insert integr isol mice rna
sequenc strain substrat test vitro vivo

3591: Lignans (17)

activ cell concentr
develop effect human increas induc
inhibit microg microm min model product
resist structur studi time vitro vivo

3586: Glycyrrhizic Acid (5)

acid activ adjust amino associ caus confid

effect extract fraction gener initi interact

interv odd process ratio risk smoke

studi

3588: Erythritol (1)

critic demonstr depend deplet enzym essenti
establish function indic maintain mainten

mutant necessari plai requir

role signal suffici suggest wild-typ

3590: N-Glycosyl Hydrolases (12)

activ adapt analysi assai chang
detect dna effect enhanc enzym express
genom increas model mutant select
sensit sequenc specif tissu

3592: 2-Propanol (3)

acid activ allel cancer cell concentr

divers drosophila genet genotyp high level

low new normal polymorph

popul prostat state tissu

3593: 1-Propanol (4)

acid cluster **concentr** determin divers
enzym evolut form format genet increas
microg microm min normal **popul**
sampl state structur tissu

3595: NADPH-Ferrihemoprotein Reductase (21)

activ analysi cyp2d6 cytochrom determin differ
drug enhanc enzym express gene high human
increas **metabol** metabolit
mutat p450 patient regul

3597: Thioridazine (2)

case compar control **differ** frequenc
function gener length mechan membran
moleculat observ **pattern** repeat report short
signific similar surviv type

3599: N-Acetyllactosamine Synthase (2)

activ biolog code codon compound cultur
determin **enzym** gene major
nucleotid primari **PROMOT** question remain
specif substitut substrat system
transcript

3594: Haemophilus Vaccines (2)

approach care design form format health
hospit **isol** level main mean medic
method objective patient serum **strain**
studi type valu

3596: Flavanones (14)

activ analysi **cell** compound deriv
effect form format **gene** group inhibit new
number pathwai patient produc
product signal structur treatment

3598: Biogenic Amines (4)

acid **associ** cell chromatographi
compound **extract** fraction
gener includ inhibit liquid new
prepar produc **product** properti provid
rang resist system

3600: Phosphothreonine (9)

acid analysi **ASSOCI** bind cell combin
extract gel high identifi kinas low mass
method nuclear **protein**
respons sequenc site specif

3601: Xanthones (5)

analys **analysisi** cell compound
decreas **effect** enhanc increas
model organ phenotyp produc **product**
protect reduc reduct reveal sampl structur
studi

3603: Xeroderma Pigmentosum Group
A Protein (17)

activ assai atm break **damag** detect
dna dsb earli excis genom mice model
patient **repair** role sensit specif stage studi

3605: Glutamate-Ammonia Ligase (19)

activ analysi biosynthesi catalyt cell chang
control develop **enzym** gene genet
human increas interact metabol product
protein sampl size substrat

3607: Methenyltetrahydrofolate Cyclo-
hydrolase (1)

activ activat cell constitut differenti
embryon encod enzym enzymat exhibit **gene**
hematopoiect inact line **mutat** progenitor skin stem
substrat tpa

3602: Kinins (2)

administr assai care cell chain dai detect dose
effect health **human** line manag
medic protect reaction reduc reduct sensit week

3604: Ammonium Chloride (5)

abil class correl data diseas **effect**
enhanc **enzym** method mutant
potenti properti **protein**
reaction reduc region risk sequenc
studi time

3606: Fusion Proteins, gag-pol (5)

analys **analysisi** compar
control decreas express
famili fusion genom
human increas interact
member normal partial produc
product reveal subject tissu

3608: Lamins (23)

activ associ cell cytoplasm diseas form gene
high human includ local low **mutat**
nuclear nuclei nucleu phenotyp
protein studi transloc

3609: Thymopietins (10)

analysi associ bind cell complex cytoplasm
detect form format local mechan molecular
nuclear nucleu number **protein**
rate requir risk target

3611: Quinine (6)

adapt alcohol depend effect measur mice mous
mutant oral product rat resist score select
signific studi subject **test** transgen
wild-typ

3613: Leukotriene C4 (3)

antibodi cluster compar differ
function human induc
induct mean normal period point
respons site state time tissu trial
valu vivo

3615: 3,4-Dihydroxyphenylacetic Acid (6)

anim base condit **control**
degre differ earli effect femal
increas male mice
model mutant neuron pair rat
reduc studi test

3610: Opioid Peptides (3)

activ alcohol alter chang
depend effect evid length **level** long
oral plai repeat role serum short
specif studi suggest support

3612: Antigens, Ly (27)

activ antigen **cell class**
complex develop differ differenti express
function high hla human major mhc
mice molecul mous **number** stem

3614: Hydroxyindoleacetic Acid (5)

alcohol blood condit decreas degre depend

distribut effect **increas** level local loop

oral organ patient process studi suggest

treat **treatment**

3616: Serotonin Agents (3)

activ approxim base compar condit decreas degre

differ higher **increas** level observ
oral pair rate receptor reduc rel requir respons

3617: Thiazepines (3)

adapt bind character characterist common
concentr decreas distinct effect featur
increas organ peptid
receptor select target treat
treatment trial tumor

3619: Reactive Nitrogen Species (12)

cluster express famili form function
gene high level low mechan model
molecular normal oxid product protein
requir sequenc time tissu

3621: Maleates (6)

activ cell differ enhanc enzym
gene group larg mutant oxid protein role
site size small specif state studi subject test

3623: Psilocybine (1)

behavior cell cognit concentr
impair learn level line measur memori
microg microm min perform period plasma
point serum task time

3618: Benzoxazines (3)

abil activ compar control dai differ
distribut group higher includ local
properti rang rate ratio respect subject
test valu wide

3620: Buthionine Sulfoximine (10)

cell combin concentr effect enhanc
gene high increas level low mice normal
number oxid risk role select studi test tissu

3622: Receptor, Serotonin, 5-HT1A (10)

associ behavior bipolar chang combin
decreas depress disord effect
increas number person psychiatr receptor
sleep studi subject symptom test time

3624: Phosphoglycerate Mutase (6)

acid activ assai blood chang detect earli
enzym function
hospit mean mutat phenotyp plai role sensit
stage subject substrat valu

3625: Carboxyl and Carbamoyl Transferases (1)

complex compon demonstr **effect**
enzym find fusion mutant **mutat**
partial prevent previou protect
protein reduc reduct report
specif studi suggest

3627: Propionic Acids (16)

acid activ amino cell
children **control** earli effect
gener high human level mutant produc
product rat requir select structur
treatment

3629: Indomethacin (22)

activ cell cox-2 develop effect express
group induc inhibit **inhibitor**
mice model prevent rate reduc **respons**
studi test time treatment

3631: alpha-Mannosidase (5)

accumul **activ** cell control enhanc
famili **human** individu inhibit
level normal phenotyp protein region sequenc
specif suggest time tissu treatment

3626: Methylmalonyl-CoA Decarboxylase (1)

cell complement complet conform crystal defect
demonstr determin domain fusion gene highli
mutant **mutat** partial protein
receptor specif structur wild-tyt

3628: Carbonyl Cyanide m-Chlorophenyl Hydrazone (3)

absenc anim earli event follow head indic
induc inhibitor involv level model neck
presenc process
respons serum stage studi
suggest

3630: Methylmalonic Acid (12)

acid amino chang children clinic combin
concentr develop differ diseas fatti increas nucleic
patient process receptor retino retinoid sever symptom

3632: DNA Topoisomerases, Type II, Archaeal (1)

absenc code codon conform enzym form indic
insight kinet multipl **new** presenc
provid singl stabil state **structur**
substitut suggest transit

3633: Dynamin II (4)

base cell **diseas** gene initi membran
origin pair popul previou protein receptor
remain report second structur studi
transport **tumor** vector

3635: Transient Receptor Potential Channels (4)

analysi complex data **distribut** estim
includ larg **local** membran
mutant new **number**
phenotyp rang releas repeat stimul
suggest wide wild-typ

3637: Receptors, Lysosphingolipid (14)

actin **activ cell express**
function growth human inhibit
interact level migrat process
protein **receptor** rna role sampl
studi suggest tumor

3639: Collagen Type XVIII (12)

angiogenesi bind **cell chang**
endotheli enhanc
factor famili gener genom
growth **increas** interact
process **product** protein
rate specif vascular vegf

3634: Sulfate Adenylyltransferase (4)

acid caus cluster **differ** element
enhanc evid identifi increas insert
mutant mutat pattern region risk
sequenc site subject suggest support

3636: Chimerin Proteins (1)

actin affect associ cancer cell construct dna gene
methyl migrat **mutat** ovarian plasmid
promot **protein** recombin report
schizophrenia studi suggest

3638: Acyclovir (20)

aids case chang clinic diagnosi
group herp hiv hiv-1 hsv-1
human immunodefici **infect** mutat
new remain simplex **studi** viral
viru

3640: Muscarinic Agonists (11)

abil analysi case caus compar differ gener
human identifi inhibit mutat
patient properti rat rate
receptor studi subject test time

3641: Pilocarpine (9)

analysi compar control
design earli gene group high higher
hospit identifi model rat rate
resist reveal risk stage studi time

3643: Glucuronates (6)

associ compar concentr effect follow
form higher human incid increas level
lower metabol new rate ratio risk site
studi women

3645: Recoverin (9)

antibodi antigen assai bind
caus cell dai detect earli enhanc larg new
rat respons retin score sensit size
small visual

3647: Antigens, CD22 (12)

activ antibodi
antigen associ cell combin differ
express gener lymphoma model month
patient phenotyp rate respons
studi subject target year

3642: Sodium-Potassium-Chloride
Symporters (11)

ca2+ calcium caus chang
channel combin current
decreas effect featur increas
intracellular ion mechan membran new
phenotyp rat respons treatment

3644: Polysaccharide-Lyases (10)

activ base cell chang correl
decreas featur gene genet
genom increas interact mutat
patient posit rat respons role
site structur

3646: Rhodopsin Kinase (3)

alter analysi bind blot chain chang
earli function mice period
point protein reaction receptor retin site stage
system time western

3648: Antigens, CD58 (8)

cell compar differ earli express gener
genet human immun model patient
pattern rat rel respons stage target trial tumor
variabl

3649: Sulpiride (6)

activ **affect** analysi associ base
data decreas differ effect **group**
increas inhibit pair schizophrenia
sequenc signific **studi** suggest test year

3651: Pimozide (3)

affect associ effect examin find implic
induc induct involv met **patient** random report
respons schizophrenia signific
studi suggest trial unffect

3653: Receptors, Complement 3d (8)

cell cluster correl develop high
individu low mice new normal phenotyp
popul posit produc **product** protein
receptor role specif tissu

3655: HSP72 Heat-Shock Proteins (9)

anim cell condit degre differ express
group heat model mutant number
protein rat requir resist role studi temperatur
treatment tumor

3650: Perazine (1)

affect associ control effect evid examin
find implic influenc involv like met possibl relat
report schizophrenia signific **studi** suggest
unffect

3652: Cyclin-Dependent Kinase 5 (16)

arrest associ **cell** **cycl**
cyclin diseas **function** group kinas
mutant **new** p21 p27 phase progress provid
report role studi suggest

3654: Complement C3d (2)

apoptosi **cell** concentr death
decreas delet divers dna **genet**
increas level loss microg microm
min pathwai plasma **popul** signal stabil

3656: Light-Harvesting Protein Complexes (16)

alter **chang** complex
control differ electron energi function
interact morpholog number observ
plant protein requir **respons** role sampl
solut structur

3657: Isoflurane (9)

concentr data decreas follow group increas
mean microm min model **patient**
rat rel respect studi surgeri surgic time
treatment valu

3659: Antidepressive Agents, Second-
Generation (11)

assess associ dai depress disord dose
effect group measur organ
process rat reduc reduct research score
studi time treatment week

3661: Ergolines (2)

abil addit approxim capac cell

combin compar effect event involv

major occur potenti **process** properti

random rel studi trial **tumor**

3663: Tryptophan-tRNA Ligase (3)

aggreg allele associ bind enzym **form**
format function gene
gener genet genotyp haplotyp interact
polymorph popul protein ratio risk snp

3658: Thapsigargin (22)

activ apoptosi associ ca2+
calcium cell chang **channel**
combin current effect **express**
gene high human increas interact product
protein **respons**

3660: Bromocriptine (3)

anim blood **case** clinic cluster compar
decreas earli factor growth
increas level model patient
present report sever stage test valu

3662: Dynorphins (2)

collect **correl** demonstr dna factor find genet
includ influenc marker **peptid** previou rang
receptor report **sampl** signific
studi suggest wide

3664: Microtubule Proteins (16)

associ cell complex express **function**
gene genet high human increas
level mutat number **protein** rate
regul sampl sequenc structur studi

3665: Stathmin (7)

analysi **cell** chang combin decreas
develop differenti express
famili increas new plai process
product prolifer protein provid **role** sampl
time

3667: Gluconates (4)

acid approach approxim compar condit dai
degre higher initi lower mutant process produc
product **rate** rel strategi therapi versu
yeast

3669: Measles-Mumps-Rubella Vaccine (13)

antigen associ cancer caus chang child
children health
childhood hospit immun model parent pediater rate
respons studi subject vaccin year

3671: Receptors, Somatomedin (7)

activ cell combin compar decreas differ
effect enhanc factor genet
growth higher increas mechan
molecular pattern rate repeat studi subject

3666: Heptanol (2)

cell concentr control differenti
effect express follow healthi increas
measur microg microm min potenti prolifer
reduc reduct releas stimul subject

3668: Nootropic Agents (5)

affect behavior cell cognit **differ**
diseas express **group** growth
mechan **method** pattern perform report
resist specif state studi target
treatment

3670: Alkanesulfonic Acids (2)

absenc acid **activ** assai defect
detect determin experi initi intern
mutant mutat origin presenc second sensit
site specif test wild-typ

3672: Chlorofluorocarbons, Methane (2)

affect anim chain concentr data dynam event
experiment exposur form format involv length
model patient
process reaction repeat simul studi

3673: Flame Retardants (6)

activ analysi collect concentr continu dai
data decreas delai detect determin follow
increas level long-term persist rat recoveri

sampl water

3675: Chlorobenzenes (5)

compar concentr control correl growth high

higher level local low mice model
multipl normal plasma risk serum studi
tissu tumor

3677: Polytetrafluoroethylene (11)

base case compar control
differ express group healthi high
higher individu larg rate size
small studi subject time
treatment variabl

3679: Hexadimethrine (2)

blood cell chines concentr dai differ dose
gene level method microg microm min organ

plasma serum studi subtyp test vector

3674: Antiparkinson Agents (19)

assess cell clinic develop diseas disord earli
effect evalu function increas measur

patient reduc respons risk scale
score studi treatment

3676: Vinculin (8)

adhes analysi biolog cell
chang compar control earli
express higher interact level model
phenotyp process rate requir reveal
studi system

3678: 17-Hydroxysteroid Dehydrogenases (14)

activ analysi associ CANCER cell effect
enzym express form format larg
patient product rate role sampl size
small studi substrat

3680: Plastics (17)

base cell clinic correl data differ dose
effect field group high irradi level
light manag medic model radiat
studi valu

3681: Cholera Toxin (11)

analysi **cell** correl dai express form
immun larg line mechan method molecular
number produc **product**
respons risk role size studi

3683: Cytochalasins (6)

actin **activ** analysi blot cell complex
migrat model mutant pathogen pathwai protein
regul requir resist signal specif structur tumour
western

3685: Receptors, Leukotriene (2)

allele **associ** compar data
differ evid genotyp link mice mous
mutant pattern polymorph provid similar
suggest support transgen type wild-typ

3687: Xylitol (4)

activ analysi correl **enzym**
gene identifi isol mean plasmid random
recombin screen signific strain studi
substrat test trial tumour valu

3682: Antibodies, Anticardiolipin (9)

antibodi associ compar **control**
data detect differ diseas factor frequenc
genet hospit includ increas loss
patient risk studi test
year

3684: Leukotrienes (4)

current **discuss** diseas domain
famili gene involv
mechan member molecular
organ plai polymorph **process**
recent region research role
sequenc understand

3686: Follicle Stimulating Hormone,
Human (7)

clinic compar **control** cycl dai dose
follicl hormon increas
number ovarian **patient**
pregnanc random reproduct respons
steroid studi trial WOMEN

3688: Sugar Alcohol Dehydrogenases
(5)

activ assai caus concentr condit degre
detect earli **enzym** express
gene genet isol mice rel sensit
stage strain substrat time

3689: D-Xylulose Reductase (2)

activ analysi blot chain degre detect
determin **enzym** experi
follow hybrid **initi** intern
origin reaction recombin
second structur subsequ
western

3691: MSX1 Transcription Factor (10)

analysi **associ** develop earli
express famili form format genet identifi initi
interact mechan regul report
reveal role studi suggest time

3693: Cephalosporins (12)

antibiot bacteri caus chang combin effect
host **infect** isol model parasit
pathogen select specif **strain** stress studi
test treatment variabl

3695: Ceftazidime (4)

administ administr bacteri cell **dai** daili
dose effect host hour infect inhibit level
mutant pathogen patient posit receiv resist
week

3690: Pipecolic Acids (4)

caus clinic diagnosi distribut enhanc induc
level local mean measur new patient ratio
residu respect **respons** serum site
test valu

3692: Shiga Toxins (4)

bacteri base bovin children **coli**
escherichia essenti gene gener incid
indic pair pig **requir** sampl
strain target toxin women year

3694: Colistin (3)

children clinic conclusions design develop
hospit host infect isol main medic objective
pathogen **patient** strain studi
therapi treat **treatment** year

3696: Malonates (5)

acid cell correl defici dose effect enhanc
genet includ irradi process radiat rang
reduc report **structur**
studi suggest varieti wide

3697: Glutathione Synthase (5)

activ chang cluster compar correl determin

differ **function** gener higher

level mean measur multipl paramet predict

ratio respect subject **valu**

3699: Chlorpyrifos (7)

activ analysi chang combin compar

concentr **control** effect
estim expos **exposur** femal
frequenc **group** high low male mice
respons role

3701: Pyrenes (15)

activ area associ

determin differ **dna**

exposur express gene

group human

increas interact level

number region sampl select

sequenc studi

3703: gamma-Tocopherol (2)

adult african american asian black bodi
dai differ ethnic **express** group

mean methyl popul preval **sampl**
south valu white year

3698: Sodium Chloride Symporters (7)

associ cluster compar concentr

control differ express frequenc
function gene genet individu level

local mutat new patient pattern structur studi

3700: Pyrethrins (9)

detect **differ**

drosophila effect follow

function increas inhibit initi

insect mutat **number** pattern

product **rat** sampl sequenc

studi time treatment

3702: Tocopherols (10)

adult concentr **control**

determin effect express extract form

includ increas method oxid patient

product rang rat sampl studi valu

year

3704: Receptors, Muscarinic (11)

activ alpha alter beta bind bladder chang clinic
function identifi ligand mice model rat

receptor role select stress studi
time

3705: Receptor, Cannabinoid, CB1 (9)

activ alpha anim beta develop effect enhanc
experiment function human increas inhibit life
ligand mechan **model** qualiti
receptor stimul studi

3707: Profilins (6)

activ analysi base bind cell
control domain earli
function method
number organ protein report requir
reveal risk select structur studi

3709: Chloride-Bicarbonate An-
tiporters (2)

acid alter analysi cancer cell **chang** codon
collect delai effect epitheli follow genet influenc
long-term persist recoveri **sampl** treat
treatment

3711: Neurophysins (3)

associ caus children clinic core dai
diagnosi encod evid larg lead open parent
patient size small studi suggest
support test

3706: Glycosphingolipids (9)

case **cell** clinic cultur differ diseas
effect featur **human** larg local method
patient pattern process reduc sever size small
stem

3708: Iodides (10)

assai **cell** content control
detect determin **develop**
differ flow **group** high
imag level low method repeat
sensit signific **test** time

3710: Ornithine-Oxo-Acid Transami-
nase (1)

allel american care clone effect ethnic gene genotyp
inform interview mutat nurs particip person
polymorph popul therapi treat
treatment variant

3712: Glial Cell Line-Derived Neu-
rotrophic Factor Receptors (11)

activ alter chang develop
distribut enhanc express famili genet
high identifi increas interact level
local **mechan** molecular neuron
new suggest

3713: Meningococcal Vaccines (4)

anim **children** distribut
effect genet immun individu **isol**
local membran model mutant parent
reduc region sequenc state **strain**
studi vaccin

3715: Cholecystokinin (8)

affect associ cell compar concentr control
differ express **group** higher normal
rate ratio **receptor** risk signific studi
subject time tissu

3717: Disintegrins (15)

adhes **cell** chang develop evid
express function **gene** genom
interact invas model normal patient product
protein specif support tissu tumor

3719: Herpesvirus Vaccines (5)

combin concentr dai **effect** high
immun induc level low mice prevent protect
reduc reduct report requir **respons** risk
studi vaccin

3714: 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide (14)

associ cell compar control
differ dna form format
increas level metabol
product rate ratio respons **risk**
role sampl studi time

3716: Receptors, Antigen (11)

cell clone **data differ** diverg
duplic effect evid **evolut**
evolutionari **express** gene
mice origin pattern protein provid
suggest support system

3718: Neopterin (6)

assai associ concentr detect elev group higher
identif identifi **level** measur novel
patient plasma popul sampl screen sensit
serum studi

3720: Paraoxon (5)

activ adult associ degre distribut effect
enhanc exposur form format gene genom
genotyp **group** local polymorph reduc reduct
respons year

3721: Salicylamides (1)

bind cell evalu **express** imag line
magnet measur mice mous mri mrna perform
protein reson scan site transcript transgen volum

3723: Palmitoylcarnitine (1)

acid amino contain defect defici enzym
fusion gene **mutant** mutat partial plasmid
recombin **region** residu
sequenc site splice variant
wild-typ

3725: Aminopyrine (2)

abil **activ** alter capac chang concentr dai
decreas dose effect factor increas inhibit microg microm
min mitochondri potenti properti risk

3727: Methoxyhydroxyphenylglycol (5)

assess associ concentr effect elev evalu
express form format higher **level**
measur plasma receptor respons scale score
serum trial variabl

3722: Diacylglycerol O-Acyltransferase (3)

analys **analysi** bind enhanc
express featur form format genet
genotyp includ isol plai polymorph region
reveal **role** sequenc speci test

3724: Microbial Collagenase (1)

assai cell **detect** dynam fish hybrid identif
identifi method **microscopi** model
morpholog **normal** novel probe screen
sensit specif techniqu **tissu**

3726: Benzhydryl Compounds (7)

activ assess bladder chang depress detect
differ disord evalu measur
model observ pattern role scale score
studi target treat
treatment

3728: Thioacetamide (3)

approxim **cell** data differenti effect
enhanc estim event **express**
gene inhibit involv major microarra neg
posit process profil rel treatment

3729: Metoprolol (14)

associ cardiac clinic compar dai dose effect
group heart human improv increas life
patient qualiti random studi
treatment trial week

3731: Antibodies, Fungal (8)

adapt allel antibodi antigen base chronic clinic
develop diseas effect genotyp intestin isol
patient plai polymorph role select
strain studi

3733: Aniline Compounds (27)

acid activ assess associ cell channel
compound dai deriv develop
effect exposur **human**
measur model organ **receptor** requir
sampl structur

3735: Organic Anion Transporters,
Sodium-Independent (7)

associ concentr evid gene
human individu interact involv
level mechan **membran**
patient plasma popul process
promot **protein** respons support
transport

3730: Metronidazole (11)

associ base cancer chang data differ
gastric **group** incid isol
mutat rate **resist** risk signific strain
studi treatment women year

3732: Pseudouridine (9)

cell code codon combin contain **gene** genom
increas level mrna nucleotid **region**
residu respons **sequenc** site
structur substitut time translat

3734: Aminolevulinic Acid (14)

cell chang clinic **combin** compar
control determin differ effect flow
group laser **light** local observ
rate signific skin studi subject

3736: Benzothiadiazines (9)

activ **ASSOCI** cell compar
control differ effect frequenc gene
genotyp initi method number polymorph
predict process role signific treatment valu

3737: Naphthyridines (4)

acid activ amino base bind
cell compound decreas deriv increas isol
mutant organ pair requir select strain
structur vitro vivo

3739: Indazoles (11)

analysi cell chang combin compound correl
effect event identifi increas induc induct involv
mechan model new process rat
respons signific

3741: Hemoglobin H (4)

african american approxim associ chromosom clinic
defici diseas ethnic observ patient
popul presenc receptor rel sever studi suggest syndrom
white

3743: Norgestrel (1)

arm assai clinic compar concentr
detect effect efficac evalu improv
marker phenotyp random sensit
specif studi test treat
treatment trial

3738: Heterocyclic Compounds (15)

associ bind bodi chang compound
data deriv develop differ effect form
format group human multipl
patient studi target weight year

3740: Trypsinogen (24)

associ cell famili function group human identif
identifi islet level mutat new novel pancrea
pancreat patient risk SCREEN
secret studi

3742: Galantamine (2)

diseas earli growth impact improv late
life mechan molecular patient phase physic
posit progress qualiti regul stage
studi test treatment

3744: Ethisterone (1)

arm base clinic compar dai disord
dose effect efficac hormon improv observ
pair random receiv studi treatment
trial week women

3745: Oximes (6)

abil **associ** caus compound
concentr deriv **develop** diseas **function**
group growth isol mechan model
properti random signal strain studi trial

3747: Cortodoxone (3)

children condit degre elev enzym hospit improv
level life marker plasma previou
produc **product** qualiti report requir serum
studi thyroid

3749: GATA Transcription Factors (7)

alter analysi **cell** chang classif
cluster data decreas
function increas mice
mutant process product **protein**
requir **respons** set specif transcript

3751: Peptidoglycan (22)

acid **activ** bacteri cell chang coli
detect escherichia famili **gener** identifi
infect mutant **protein** rat rate respons
select sequenc state

3746: Xylan Endo-1,3-beta-Xylosidase (3)

analysi base bind clone combin conform differ
effect enzym gene larg pair produc
product repeat sequenc size small
structur time

3748: Mineralocorticoids (1)

alpha beta cardiac cerevisia compound condit
degre **function** heart heat hormon
interact involv protein
receptor saccharomyc shock temperatur
thyroid yeast

3750: Zymosan (6)

abil adapt approach bind cell complex evid
express **function** gene inhibit
mutat natur presenc provid **receptor**
select specif support vector

3752: Histidine-tRNA Ligase (2)

chain code codon dna encod express fragment
gene level microscopi morpholog **mrna** per
polymeras protein reaction ribosom substitut transcript
translat

3753: Glutamate-tRNA Ligase (1)

absenc algorithm code codon compar complet data dna
gene **genom** method neg
network posit predict presenc sequenc set
structur substitut

3755: Polypropylenes (7)

analysi clinic cultur design differ earli hospit
human **level** measur method
model **patient** perform plasma
reveal select serum specif studi

3757: Procollagen N-Endopeptidase (5)

alter base **chang** compar decreas
evid express form format includ **increas**
normal **patient** provid rang
rate specif support tissu treatment

3759: Pregnanes (2)

alter breast cancer **chang** compar complex
compound decreas **differ** effect form
format **increas** interact observ pattern
resist treat **treatment** type

3754: Serum Amyloid P-Component
(6)

caus combin effect express **gene** genet
group inhibit **level** measur
method plai plasma presenc protein repeat
role serum studi suggest

3756: Aquaporin 1 (8)

analysi cell chines compar
control determin **differ**
express function
gene heterogen membran
product protein rat respons
specif studi subtyp transport

3758: Umbelliferones (7)

activ cell decreas **differ** effect enzym
express **human** increas level
metabol method pattern presenc product
protein reduc studi treatment variabl

3760: Clomiphene (11)

assist compar cycl dai follicl
hormon new number ovari
ovarian pregnanc rate reproduct
steroid stimul studi subject testosteron
trial **women**

3761: Fertility Agents, Female (18)

assist **control** correl cycl famili follicl

fsh **hormon** number ovari ovarian

pregnanc rate reproduct steroid

stimul studi testosteron treatment

women

3763: Buserelin (3)

compar control differ function **group**
higher hormon level lower mean measur

patient **rate** receptor respect serum
subject valu versu women

3765: Toremifene (6)

assai **breast cancer** case detect
follow-up median month mutat

patient rat recurr report resist
sampl sensit studi surviv tumour year

3767: Collagen Type IX (9)

analysi bone caus cluster compar **control**
famili gene healthi identifi increas loss mice

mutat patient phenotyp
respons role screen subject

3762: Rhenium (9)

compar control dai differ dose
group high higher human increas

mice normal **rate** respect **studi**
tissu tumor valu vitro vivo

3764: Menotropins (8)

administr control cycl **dai** dose follicl

group hormon hospit **human**
patient popul pregnanc reproduct respons
size steroid studi week women

3766: Solanaceous Alkaloids (1)

base copi correspond cultivar differ increas infect

larg normal **number** observ
pair pathogen possibl rice singl therapi **tissu**
total wheat

3768: Glucokinase (20)

activ associ caus **diabet** differ fast
function gene genet glucos high identifi

insulin isol level low mellitu metabol
mutat strain

3769: ets-Domain Protein Elk-1 (14)

activ analysi bind caus cell
complex develop enhanc famili gene
kinas lead new pathwai phosphoryl
process protein respons signal time

3771: Lactase (9)

activ control differ effect environ
environment factor genet
genotyp herit individu influenc patient
polymorph product studi trait twin variat
year

3773: Rheumatoid Factor (12)

affect arthriti associ chang control diseas
famili genotyp group joint mice model
mous pain patient polymorph
posit specif test variabl

3775: Heroin (3)

analysi assai avail dai data
databas degre detect dose
ethic inform model previou rate
region report research sensit
sequenc studi

3770: Carbonyl Cyanide p-
Trifluoromethoxyphenylhydrazone
(4)

abil activ anim area case cell dna
effect mechan mice mitochondri
model molecular potenti rat releas specif
stimul studi tumour

3772: Calcium Channels, L-Type (24)

activ atp ca2+ calcium cam cell
channel current gene
intracellular ion mice mutat patient
potenti region releas sequenc sodium studi

3774: 11-Hydroxycorticosteroids (2)

care case caus chain develop
genet health high lead level low
manag medic need nurs practic reaction
research servic structur

3776: Allopurinol (7)

associ case compar condit
control dai decreas degre effect
increas mutat patient plai rat reduc
report role studi tumour valu

3777: Procollagen (13)

bone caus cell compar earli factor
growth loss mechan mutant normal
number **patient** product
promot rate role studi subject tissu

3779: Esters (30)

activ adduct analog analogu associ cell chang
chemic compar **compound**
control decreas deriv enzym increas level
new novel target test

3781: Nifedipine (7)

analys **analysi** data differ effect
evid human individu metabol month muscul
patient pattern perform provid
receptor reveal studi support treatment

3783: Phenanthridines (11)

cell compound concentr differ differenti
effect express genom human isol line new pattern
provid strain test time treat treatment valu

3778: Troponin C (9)

activ base caus cell complex differ
distribut evolut function **gene** heart
local muscul normal pattern protein receptor
structur time tissu

3780: Activating Transcription Factor 4 (11)

analysi cell express factor gener increas
induc induct **interact** mechan patient
promot protein regul **respons**
reveal role stress suggest transcript

3782: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (6)

acid affect alter caus cell **chang**
control decreas factor function
growth increas mice neuron
plai rat receptor role studi subject

3784: Xanthenes (12)

assai assess **cell** channel concentr
correl detect differ **effect** express
measur **method** mice popul
posit reduc requir score sensit techniqu

3785: Receptors, Metabotropic Glutamate (14)

base behavior complet dai data form fusion
gene genom mechan mice model
neuron partial phenotyp receptor requir
respons sequenc suggest

3787: Choline O-Acetyltransferase (15)

astrocyt brain cell differ express famili function
glial interact mice mous **neuron**
new pattern product protein rat synapt
treatment variant

3789: Biogenic Monoamines (5)

adult anim caus combin correl decreas
disord effect enhanc **group**
increas lead mechan mice
model rat risk signific studi year

3791: Azepines (10)

base cell **concentr** correl dai determin
effect function human level
method patient product protein
resist signific **studi** subject techniqu
variabl

3786: Dipeptidases (7)

assess concentr **express**
function growth level measur
mutant normal number
patient phenotyp
popul repeat score select **studi**
subject test tissu

3788: Vesicular Acetylcholine Transport Proteins (4)

bind compar **control** copi correl differ
frequenc increas larg mutant neuron
number pattern presenc regul
signific site size small structur

3790: Diphtheria-Tetanus Vaccine (1)

acut adolesc aml autism boi child childhood
children chronic girl leukemia
lymphoma mds myeloid parent patient pediater
stress studi year

3792: Neuropilin-2 (1)

actin carcinoma cell complet demonstr
endotheli fusion **gener** includ indic
migrat occur occur partial regul report result
studi transmiss tuberculosi

3793: Clusterin (20)

cell cholesterol control detect develop
differ earli effect **express**
function gene growth high level lipid
low model posit vitro vivo

3795: Cyanates (2)

case combin compar control copi determin
differ effect exposur **group** healthi
increas individu mechan molecular
number sampl stimul studi subject

3797: Toluene 2,4-Diisocyanate (1)

blood carcinogen chemic damag dna
effect expos **exposur** genotox length
long mutagen peripher repair
repeat short tandem termin toxic
unit

3799: Plasminogen Inactivators (5)

activ analysi blot cell cluster
concentr correl detect express invas matrix
method normal patient presenc regul
target techniqu **tissu** western

3794: Laccase (10)

activ aspergillu associ detect
fungal fungi fungu host **isol** model new
pathogen process produc protein region
sequenc speci spore strain

3796: Isocyanates (5)

assai care caus **clinic** concentr detect
diagnosi exposur **health** identifi
individu interact level liver
number patient
respons risk screen sensit

3798: Patulin (6)

analysi area cell collect concentr detect
determin extract fraction **gene** human
liquid method prepar produc product
respons **sampl** studi tumour

3800: Isoxazoles (10)

affect assess cell correl dai effect
evalu **function** increas inhibitor
measur **new patient**
provid receptor score signific size
studi target

3801: Receptors, Neurokinin-2 (2)

acid affect alpha beta cell effect enhanc
increas inhibit light oral plai
receptor releas **role**
schizophrenia state stimul studi suggest

3803: Trimethyltin Compounds (1)

assai collect detect earli effect increas
late phase potenti progress releas
sampl sensit stage stimul test
treat **treatment** vitro vivo

3805: Ca(2+) Mg(2+)-ATPase (8)

activ alter base blood cell chang
combin control **effect** genom inhibit
model observ protein reduc region sequenc
state subject treatment

3807: Pyruvate Carboxylase (3)

analysi assess bind blot **combin**
decreas effect **increas** measur
mechar method molecular new organ
posit provid remain risk score **target**

3802: Steroid Hydroxylases (30)

activ bone combin compar
control detect differ effect express
function gene increas level protein rat
rate receptor respons studi vitamin

3804: Aflatoxin B1 (13)

activ analysi **cell** compar dai
data dose **effect** higher increas
method model popul **rate** reduc
respons reveal time tissu treatment

3806: Dental Porcelain (14)

assess blue captur color composit control
differ evalu intens laser **light** measur
method number observ red shed studi test time

3808: DNA Primase (10)

associ **dna** famili genom human interact
member mice model new normal origin polymeras
protein replic sequenc strand structur test tissu

3809: Hetastarch (4)

blood cell clinic compar control dai differ distribut
fluid function **group** high increas
level local low method signific subject treatment

3811: RNA, Transfer, Ser (7)

chang codon data **differ** gene genom
high low model **mutat** pattern
popul previou report respons sequenc
studi suggest test type

3813: Carbaryl (4)

assai care case chines detect differ
drosophila effect expos **exposur**
health heterogen method
new popul provid sensit servic studi
subtyp

3815: Abortifacient Agents, Nons-
teroidal (6)

birth caus control dai degre dose
earli fetal gestat **group**
infant matern mother neonat
pregnanc prenat respons
treatment week women

3810: Plasma Substitutes (6)

blood cell compar dai differ dose **effect**
factor follow **group** higher lower
model **patient** process rate
ratio reduc reduct risk

3812: Carbofuran (2)

chines compar determin differ extract follow
heterogen higher lower mean
method protocol rate
respect standard studi subtyp system
techniqu valu

3814: Mercury Compounds (5)

acid **analysi** caus compar
concentr **control** dai data
effect frequenc **function**
lead mice mutant rat recombin reduc
reveal **sampl** studi

3816: Natriuretic Agents (4)

analysi assai blot caus detect
enhanc express **gene** gener level
method model mutant patient rat reveal
select sensit treatment western

3817: Ubiquitin-Activating Enzymes
(5)

acid amino bind degrad enzym
function genet initi interact
ligas marker origin plai proteasom
protein rang role structur
suggest ubiquitin

3819: Strontium (12)

alter area caus **chang** concentr
develop differ embryo group lead
observ organ pattern plai rate region role
studi treatment water

3821: Dantrolene (6)

activ children clinic condit dai
degre effect **high** larg level
low region sequenc size small
specif temperatur test treatment
tumour

3823: Myoglobin (14)

base characterist common compar differ
experi featur higher initi model mutant
mutat origin **protein rate** second
similar state structur test

3818: Ethylene Glycol (7)

base blastocyst cell develop effect egg
embryo fertil imag interact
matur oocyt phenotyp rate somat stage
transfer tumour vitro year

3820: Glass Ionomer Cements (6)

analysi approach area assess data
design estim gener hybrid light measur
patient primari reveal score
strategi studi target test trial

3822: Halothane (6)

affect analysi approach cell
children clinic concentr condit
degre **gene** gener genet individu parent
patient sever strategi **studi** test
variabl

3824: Tyrosine-tRNA Ligase (3)

acid **activ** altern assai base bind detect
featur mutant pair presenc region select
sensit sequenc similar splice
structur tumour variant

3825: Collagen Type VI (3)

analys **analysisi** caus **cell**
control epitheli event involv lead mutant
mutat plai process **protein** regul
respons reveal **role** specif
subject

3827: Oncogene Protein v-cbl (1)

aggreg **bind cell** coloni contrast convers
demonstr depend endogen **enhanc** essenti
famili **form format** increas indic necessari
requir suffici suggest

3829: Cholinergic Antagonists (6)

associ case children clinic combin
differ effect **function** number
patient pattern posit report
respons role studi subject therapi
treatment trial

3831: Liver Extracts (5)

anim **associ** chang
chromatographi concentr correl determin
extract fraction liquid method
model prepar process rat respect separ studi
time valu

3826: Apolipoprotein A-II (6)

analysi **ASSOCI** code codon
develop group high includ
level low mutat nucleotid number phenotyp
posit repeat reveal **studi** substitut suggest

3828: Adhesins, Escherichia coli (2)

african american character coli delet differ domain
element escherichia ethnic gene insert integr **isol**
loss popul sequenc **strain** type white

3830: Acetonitriles (7)

analysi assai chromatographi decreas
detect determin **extract** femal
fraction high **increas** level liquid male
mechan method prepar sensit separ time

3832: Sulfonic Acids (5)

acid amino **base** differ
extract gener hybrid interact mechan
mutant pair produc **product**
region residu select sequenc site size
test

3833: Sodium Benzoate (1)

acid amino chromatographi concentr determin differ
extract fraction **group** liquid method
microg min prepar produc **product** resist respect
separ yield

3835: Ephedrine (4)

analys **analysi** associ
chromatographi concentr determin
extract fraction liquid
method perform prepar
procedur region reveal risk separ sequenc
studi techniqu

3837: Anion Exchange Protein 1, Erythrocyte (11)

analysi associ blood blot cell
chang **concentr** confirm detect differ
express gene interact membran methyl
mutat **protein** respons reveal
western

3839: Cyanamide (2)

adult bind chain encod **gene** mean
older open plant presenc produc
product ratio reaction recombin resist
respect valu year young

3834: Benzoic Acid (5)

acid amino combin compar control degre
differ extract function gener high higher
level low lower method product **rate**
respect versu

3836: Chlorpheniramine (2)

analysi associ chromatographi **condit**
degre determin **extract**
fraction gene heat liquid method patient
prepar ratio regress risk shock
temperatur variabl

3838: Hydro-Lyases (11)

activ associ bind complex encod enzym
famili featur **gene** mechan melanoma
molecular mutant normal popul product
recombin rna studi tissu

3840: HMGB2 Protein (2)

addit affect alter bind cell **chang**
combin complex effect enhanc gene
gener increas interact line
phenotyp region sequenc suggest
tumor

3841: YY1 Transcription Factor (14)

analysi bind cell develop element enhanc
express function gene high identifi level low
mutant number **promot** screen
site tissu transcript

3843: Vinyl Compounds (3)

algorithm approach base condit data energi
featur intermedi kinet **method** model
network **plai** predict **role** set state
switch target transit

3845: Urease (9)

activ assai detect form gastric
gene genet **isol** method morpholog
new **patient** provid regul sensit size
strain structur studi treatment

3847: Sugar Alcohols (4)

acid analys analysi cell compar differ higher
hybrid lower presenc protein **rate** repeat
respect reveal similar **structur** studi valu versu

3842: Adenine Nucleotide Translocator
1 (5)

acid code codon conserv **develop**
express **gene** growth identifi interact isol
mice mitochondri **mutat** presenc
protein region sequenc substitut
suggest

3844: Reticulin (3)

acut CASE cell children correl develop fetal
insight leukemia **new** parent pregnanc
provid random relationship report signific state
studi trial

3846: Receptors, Granulocyte Colony-
Stimulating Factor (12)

activ analysi bone **cell** develop
differenti effect express factor function gene
genom growth human macrophag marrow
normal product respons tissu

3848: Guanidinoacetate N-
Methyltransferase (3)

affect alter anim behavior **chang** clinic
defici diagnosi diagnost experiment level mice
model muscl produc product
serum specif studi treatment

3849: Glucose Transporter Type 5 (1)

activ arm baselin clinic compar compound deriv
efficaci evalu gene improv membran metabol
mutat random signific studi test
treatment trial

3851: 3-O-Methylglucose (3)

anim assai concentr dai data detect
distribut enhanc estim genet group
local method model mutat produc product
resist sensit studi

3853: Glycopyrrolate (3)

characterist children common compar
control differ experi featur follow
frequenc initi intern light origin parent
respons risk second treatment year

3855: Acrylamide (18)

assess carcinogen chemic compar concentr decreas
effect expos exposur form
genotox increas indic induc method mutagen
observ rate respons toxic

3850: Glucose Transporter Type 3 (5)

analysis area blot concentr
distribut express high imag level
local low phenotyp protein rat region
rel reveal sequenc tumor western

3852: Luteolin (5)

activ apoptosi apoptot blood cell
combin concentr death develop effect
individu induc inhibit ligand microm min necrosi
pathwai sensit trail

3854: Butorphanol (1)

action compar concentr control
correl differ distribut effect frequenc higher
increas local observ potenti puls record releas
respons signific stimul

3856: Lipoxygenase Inhibitors (11)

activ associ combin control
cox-2 effect express function
genom human increas
inhibit inhibitor mechan
model reduc role specif studi time

3857: Linoleic Acids (7)

acid **activ** amino cell compound
control data differ estim growth larg method
number product rat size small system time
treatment

3859: Cobamides (5)

acid **activ** amino bind cell clinic compar diagnosi
effect enzym group high higher
human inhibit level low rate
reduc substrat

3861: Cobalt (23)

activ base cell decreas differ effect express
form format **function** gene
group human increas mutat protein
respons structur subject valu

3863: Isotonic Solutions (10)

alter **chang** compar concentr
condit control degre develop differ gene
group higher **human** increas mice
model **rate** respons sampl tissu

3858: Glipizide (2)

alter assess **chang** clinic diabet
effect evalu increas measur patient
potenti random reduc releas score signific
stimul **studi** trial variabl

3860: Methylmalonyl-CoA Mutase (9)

acid **activ** amino bind diseas enzym estim
fatti gener human model mutat nucleic number
patient produc product retino sever substrat

3862: Rubidium (5)

base bind **chang** combin compar differ form
format higher individu model posit
rate repeat resist role size
structur studi suggest

3864: Kynurenic Acid (2)

acid **activ** anim chines combin dai
develop differ earli effect inhibit model
receptor regul stage studi subtyp system
target test

3865: Lactalbumin (5)

activ effect extract featur high
human level low mechan mice new product
protein provid rel sampl select site structur
tumor

3867: Apatites (3)

adult bind cell children **differ**
differenti femal gene individu male
older pattern popul protein regul studi
system test year young

3869: Hydrocarbons, Iodinated (4)

acid amino analysi base compound
differ famili gener indic isol
member method pair **patient**
pattern residu reveal site state strain

3871: Neurotoxins (27)

alter caus cell **chang**
develop effect exposur
increas mechan mutat neuron new
number **protein** receptor region
role sequenc structur suggest

3866: Uridine Diphosphate Galactose
(4)

absenc **activ** bind caus control
enhanc enzym form format identifi
indic lead mutat organ presenc protein
screen structur substrat suggest

3868: Calcium Oxalate (8)

acid **associ** bladder detect
determin genet genom genotyp
human mobil model
polymorph protein structur studi
subject time tract tumour urinari

3870: Peptide-N4-(N-acetyl-beta-
glucosaminy) Asparagine Amidase
(9)

acid amino blood cell cleavag contain effect
extract form format group product proteas
protein residu role sampl **site**
studi treatment

3872: Trypsin Inhibitor, Kunitz Soy-
bean (6)

activ **associ** caus
develop effect evid factor
genet growth inhibit invas
level local mechan molecular site studi
suggest tumour variabl

3873: Streptozocin (10)

analys **analysi** anim combin dai diabet
dose **effect** function gene **group** insulin
mice model rat reveal **studi** treat
treatment trial

3875: Quinone Reductases (9)

activ alter cell chang compar **control**
decreas effect enzym express frequenc
human increas modifi observ
patient signific structur studi time

3877: Vaccines, Conjugate (10)

antigen associ **children** combin
concentr differ **effect** identifi
immun **isol** parent particip **patient**
product protect reduc **respons**
strain test vaccin

3879: Receptors, Histamine H3 (3)

activ anim approach correl data develop
diseas drug estim experiment method
model phenotyp provid receptor
resist strategi structur studi target

3874: Selenocysteine (12)

activ code codon element initi mechan
model **mrna** new nucleotid number
organ protein ribosom rna site substitut
synthesi **translat** trna

3876: D-Aspartic Acid (1)

acid adapt amino compar comparison competit
differ domain environ evolut
compound fit membran natur neuron observ **pattern**
select similar type

3878: Histamine Agonists (2)

affect design **develop** diseas
earli hospit late loss main objective patient
phase progress receptor stage studi target treat
treatment year

3880: 15-Hydroxy-11 alpha,9 alpha-
(epoxymethano)prosta-5,13-dienoic
Acid (7)

alter approxim arteri cell **chang**
clinic **concentr** dai decreas
differenti **effect** increas inhibit major
observ prolifer rat rel requir synthesi

3881: Myosin-Light-Chain Phosphatase (3)

activ adapt alpha cell chicken data direct
enhanc evid increas **individu**
kinas muscl primari protein provid
receptor **select** suggest
support

3883: Vinca Alkaloids (4)

abil affect agent caus cytotox develop drug
effect **high** lead level low novel potenti
proporti **target** therapeut therapi
treatment tumour

3885: Hymecromone (5)

activ assai correl demonstr detect
differ find method observ organ
pattern previou product rat repeat report
sensit **studi** suggest type

3887: Organosilicon Compounds (2)

abil abi **activ** agent cancer capac
compar cultur demonstr drug higher lower potenti
proporti radiat **rate** stabil target therapeut
versu

3882: Tubercidin (2)

associ behavior confid demonstr exposur
factor find follow interv multipl **new**
persist previou provid ratio report risk
smoke **studi** suggest

3884: Saline Solution, Hypertonic (6)

assess complex detect **earli** effect form
group **high** level low mean
measur number phase rat respons score
stage treatment valu

3886: Nitroreductases (4)

agent cancer caus cell chromosom delet drug
enzym gastric **gene** genotyp induc induct
isol lead protein recombin resist respons
strain

3888: Thiobarbiturates (1)

acid affect amino benefici decreas **effect**
fatti kinet modif modifi potenti prevent primari
protect reduc reduct signific state switch transit

3889: Oleic Acid (15)

acid activ amino cell compar complex
control correl famili fatti form format high higher level
low new rate select studi

3890: Vitamin B Complex (7)

concentr dai decreas factor gene group
high increas larg level low mechan
plasma remain risk serum size small studi
variabl

3891: Methylglycosides (1)

absenc chines determin differ effect
head heterogen indic investig neck observ
presenc prevent protect reduc
reduct signific studi subtyp suggest

3892: Alcohols (11)

activ base compound detect differ
method new number observ pair pattern
produc product select
sequenc similar specif studi time type

3893: Immunoglobulin D (16)

alter arthriti associ caus cell chang
combin dai diseas effect human increas
number pain patient
phenotyp popul respons sampl specif

3894: Linolenic Acids (1)

addit biolog combin concentr decreas
determin effect increas microg microm
min plasma prevent protect protein reduc
reduct respect studi system

3895: Amidines (11)

acid cell chang complex concentr dai
decreas effect increas induc
model normal number product protein
rat reduc respons select tissu

3896: Naphthols (4)

analysi compar dai decreas develop
enhanc enzym gener higher hospit increas
lower patient plai presenc rate regul
role suggest versu

3897: Hexosamines (6)

analysi base blot bodi concentr data differ
distribut group growth human induc induct
local mechan pattern **respons**
specif treatment western

3899: Phthalic Acids (5)

acid assai case caus collect compar concentr
control detect **develop** express
gene model organ rat report
sampl sensit state studi

3901: Arsenates (6)

cell chang **control** dai differenti dose
gene larg level male **mice** mous
popul primari recombin report size small
studi transgen

3903: Polyisoprenyl Phosphates (4)

acid **activ** cell decreas diseas effect find
gene increas inhibit inhibitor level plasmid previou
rat recombin regul report studi suggest

3898: Dialysis Solutions (1)

bodi cell compar control diabet diet differ
enzym healthi methods mix obes pancreat
produc **product** sourc studi
subject weight yield

3900: Clofibrac Acid (11)

acid activ amino cell compar control
differenti effect function gene increas induc
male model process **rat** rate
respons studi treatment

3902: Mevalonic Acid (7)

activ cell concentr effect enzym
function health inhibit inhibitor
level mice model multipl organ plasma
protein serum studi vitro vivo

3904: Dioxins (14)

air analysi cell concentr contamin copper
correl dna exposur indic metal normal
number regul role soil sourc
studi tissu water

3905: Hydrocarbons, Brominated (9)

air concentr^r conditⁿ contaminⁿ copper

degre^e distribut^e earli^e extract^e increas^e
level local metal popul^e respons^e
risk sampl^e soil time water

3907: Luteolytic Agents (1)

densiti^e design^e endogen^e enhanc^e high^e higher^e
hormon^e hospit^e increas^e level^e low^e lower^e
multipl^e objectiv^e p53^e patient^e singl^e studi^e suggest^e women^e

3909: Antimycin A (11)

activ^e analysi^e caus^e dna^e enhanc^e express^e
genom^e increas^e induc^e mitochondri^e
mitochondria^e model^e mtdna^e process^e protein^e
respons^e subject^e suggest^e test^e
variabl^e

3911: Imides (3)

activ^e adduct^e affin^e aggreg^e bind^e chain^e
compound^e deriv^e dna^e form^e format^e peptid^e polymeras^e
protein^e reaction^e replic^e site^e speci^e vitro^e vivo^e

3906: Triptorelin (4)

associ^e combin^e compar^e earli^e
effect^e high^e higher^e level^e life^e low^e
number^e patient^e product^e
rate^e receptor^e specif^e studi^e test^e treatment^e
tumor^e

3908: Isopropyl Thiogalactoside (11)

activ^e analysi^e coli^e compar^e control^e data^e dynam^e
experiment^e gene^e group^e higher^e model^e
paramet^e predict^e rate^e recombin^e respons^e sampl^e
simul^e test^e

3910: Mycotoxins (24)

aspergillu^e caus^e effect^e fungal^e
fungi^e fungu^e fusarium^e host^e human^e
inocul^e isol^e pathogen^e
plant^e produc^e product^e
sampl^e speci^e spore^e subject^e wall^e

3912: Viper Venoms (10)

activ^e bind^e compar^e complex^e conserv^e famili^e
higher^e level^e lower^e mammalian^e marker^e model^e
mutant^e normal^e number^e peptid^e rate^e
studi^e test^e tissu^e

3913: Interleukin-11 (9)

blood **cell** combin differenti effect
express form format **function** genet
improv mechan mice peripher protein studi
therapi treatment trial valu

3915: Saxitoxin (3)

activ area assai caus decreas
detect event famili **human**
increas involv method mutat
process receptor rel requir resist
sensit studi

3917: Antipyrine (2)

analys **analysisi** anim cell compar control
differ effect experiment **function**
group human indic line model
perform rat reveal studi tumor

3919: Receptors, Lysophosphatidic Acid (6)

base bind **cell** dna **effect** factor
fragment gene growth interact mechan
molecular pancreat pcr **receptor**
reduc reduct regul **respons** secret

3914: Marine Toxins (7)

analysisi blood **cell** chang condit
decreas degre detect express
group identifi **increas**
method observ product rat screen
speci target test

3916: Oxocins (2)

analysisi assai caus cell correl detect
exposur includ lead line mass method
normal rang **sampl** sensit
signific speci **tissu** wide

3918: Antilymphocyte Serum (17)

acut allogene autolog cell control diseas **donor**
follow graft immunosuppress mice patient rate
receiv recipi reject stem surviv
transplant treatment

3920: Sulfasalazine (6)

activ behavior cell cognit compar
control develop differ genom
group higher model new patient
provid rat **rate** respons
subject treatment

3921: Phosphate Transport Proteins (7)

area **associ** bone concentr correl
decreas evid **express** growth **increas**
level mice model organ process region repeat
select sequenc studi

3923: Veterinary Drugs (7)

care cost countri **effect** european
genom health manag
medic medicin nation organ practic
recommen reduc regul **research** sequenc
subject time

3925: Phthalazines (10)

cell clinic combin **control**
correl effect endotheli factor
increas inhibit model **patient**
signific therapi **treatment** trial
tumor tumour vascular vegf

3927: Glutamate Dehydrogenase (NADP+) (3)

activ copi **enzym** form format
genom isol length metabol **new**
number provid repeat report
sequenc strain studi substrat suggest yeast

3922: Teniposide (2)

arm clinic develop dna drug effect efficaci improv
insight marker **new** patient provid
random remain studi surviv treatment trial
understand

3924: Aldosterone Antagonists (3)

arm clinic combin compar dai discuss dose
effect improv **patient** protein
random rat recent remain studi test
treatment trial week

3926: Xylazine (3)

analysi assess caus combin
concentr dai dose effect
follow gener growth measur perform
popul rat reveal score studi test
time

3928: Glutamate Dehydrogenase (10)

acid activ base clinic **enzym**
gene genet isol number pancreat
patient popul protein region respons
sequenc sever strain substrat time

3929: Iduronidase (10)

accumul blood children deposit
differ diseas effect group high identifi
includ model mutat patient product screen
studi target therapi treatment

3931: Leukocyte Migration-Inhibitory Factors (1)

activ adhes block blood cell class count differ effect

evalu hypothesi inhibit inhibitori lymphocyt molecul

perform peripher signific suppress test

3933: Paromomycin (6)

cell chang compar control decreas enhanc
gene increas level mrna mutant
mutat organ plai presenc rat ribosom role
suggest translat

3935: Lewis Blood-Group System (8)

antibodi bind chang compar control differ diseas
express gene group high higher level
low product rate respons signific studi subject

3930: Matrix Attachment Region Binding Proteins (4)

cell develop famili initi larg
member mice origin plai posit previou
protein report resist role second
size small studi suggest

3932: Penicillin G, Benzathine (1)

adhes antibiot apoptosi bacteri cell condit
cultur cytotox effect fibroblast host
human induc infect inhibit line medium pathogen
viru vitro

3934: Kidd Blood-Group System (3)

allele associ blood class control differ distribut
genotyp group hospit local peripher
polymorph popul posit ratio region risk sequenc
studi

3936: Small-Conductance Calcium-Activated Potassium Channels (2)

analys analysi cell compar
control differ frequenc gene
genet indic individu induc inhibit mechan
molecul report respons reveal
studi test

3937: Leucine-Responsive Regulatory Protein (4)

cell enhanc event **express** famili
form high **increas** involv
level low new phenotyp
process product protein
regul report studi suggest

3939: Site-Specific DNA-Methyltransferase (Adenine-Specific) (14)

analysi associ bind decreas develop
dna form format function gene
genom **increas methyl** process
promot protein regul reveal specif test

3941: Sizofiran (3)

abil abl aggreg capac caus condit degre
demonstr exhibit extract **form**
format genom hybrid lead
mice potenti **properti** sequenc translat

3943: Ketamine (7)

area associ chang **combin** compar
concentr control decreas differ effect enhanc
group high increas level
number rat studi time treatment

3938: Hydrogenase (4)

activ adult anim bacteria complex enzym form
format **gene** model mutant produc
product protein rrna select sequenc speci studi
year

3940: Motilin (3)

alter area **associ** chang flow
gastric gene identifi increas investig isol
model mutat novel observ rat screen
strain **studi** variant

3942: Shal Potassium Channels (1)

analysi assess blot cell detect **effect** evalu
function line measur
express prevent protect protein reduc reduct scale SCORE
valid western

3944: Receptor, EphB3 (3)

analys **analysi** bind cell decreas defect
develop development express
function increas level
mutant mutat perform regul reveal role vivo
wild-typ

3945: Nitrofurantoin (1)

determin drug elev enzym femal level
male mate metabol mice modif modifi
mous plasma reproduct resist serum
sex sexual transgen

3947: Antigens, T-Independent (2)

antibodi bind cell compar data develop
differ differenti estim gene method
mice mous mutat pattern plai role select
similar type

3949: HMGB3 Protein (2)

analysi assess blot caus cell
chain chines detect differ differenti express
lead measur prolifer reaction score
studi subtyp tumor western

3951: Neon (7)

analysi data dose effect estim exposur
fraction function human ioniz irradi
light number process product radiat
radiation-induc radiosensit radiotherapi surviv

3946: Kynuramine (2)

analys analysi cluster compar decreas
differ environment factor genet higher
increas influenc level lower
mutant rate reveal site studi variat

3948: MNSs Blood-Group System (5)

associ blood chines differ genet genotyp
group heterogen increas level
patient peripher phenotyp polymorph
popul respect signific studi subtyp test

3950: Helium (3)

blood differ dose effect field
individu irradi laser light measur
movement point radiat reduc report
space structur studi time valu

3952: Dansyl Compounds (1)

assai calcul compar detect determin differ
extract fraction hybrid mean measur
method paramet predict rang ratio respect
sensit standard valu

3953: Rimantadine (1)

affin **bind** detect determin extract
fish fluoresc fraction hybrid interact mean
measur probe protein rang ratio respect site
situ **valu**

3955: Isovaleryl-CoA Dehydrogenase (1)

analysi **assai detect** determin
electrophoresi enzym extract gel identif identifi
mass method monitor novel proteom sampl SCREEN
sensit specif test

3957: Eosine Yellowish-(YS) (4)

abil bind cell clinic concentr diagnosi flow
improv life **method** mice mous
patient phenotyp properti
qualiti **sampl** site target techniqu

3959: Smad7 Protein (20)

bmp cartilag chang chondrocyt collagen
develop effect express **factor** famili
function **growth** induc inhibit
respons signal smad **tgf-beta**
tgf-beta1 transform

3954: Memantine (5)

assai assess caus clinic concentr detect
diseas evalu extract hospit mean measur
medic neuron repeat respect score sensit
studi valu

3956: Ribonucleoprotein, U1 Small Nuclear (9)

altern antibodi complex diseas earli **EXON**
gene identifi intron isoform novel organ
produc product protein screen site
splice test **variant**

3958: Receptors, Serotonin, 5-HT4 (2)

alpha beta consist enhanc evid experi extern
final follow **human** initi intern
origin promot provid **receptor**
second seri subsequ support

3960: Sarcosine (3)

abil analys **analysi** bind biolog cell
compar concentr condit degre higher lower
method **rate** regul reveal site state
studi system

3961: Gold (25)

analysi assai deliveri detect develop dna
effici electron high hybrid low
method microscopi model
morpholog partiel sensit studi surfac
techniqu

3963: Toluidines (6)

adult compar concentr differ dna exposur
group higher lower model plai
plant product **rate** respect role studi
tumor versu year

3965: Hepatitis Antibodies (1)

analysi chain content detect determin
famili flow identif identifi
isol member novel pcr polymeras
quantit reaction real-tim revers SCREEN
strain

3967: Acarbose (2)

addit aggreg allel associ carrier caus **combin**
diabet effect factor form format **gene**
genotyp increas lead polymorph ratio **risk**
studi

3962: Palladium (7)

alter assai base cell chang compound
detect differ dose effect
function gener irradi product
radiat repeat sensit studi test valu

3964: Cobalt Radioisotopes (10)

analysi base differ dose effect energi estim
exposur **group** irradi model new
normal patient **radiat** radiotherapi
rat rate studi tissu

3966: HLA-B7 Antigen (2)

activ allel associ bind cell chromosom
class data element follow gene gener genotyp
haplotyp linkag loci locu map polymorph snp

3968: Fatty Acids, Essential (4)

acid alter amino chang children
combin concentr effect evid **group**
increas individu provid requir studi support
treat **treatment** variant yeast

3969: Linoleoyl-CoA Desaturase (1)

acid amino conduct data endogen enhanc
enzym fatti includ increas investig mice mous nucleic
pool potenti retino studi suggest transgen

3971: Dibenzothiazepines (7)

affect associ clinic effect evid examin
find implic includ influenc involv measur met
report schizophrenia score signific studi
suggest unafect

3973: DNA Restriction-Modification Enzymes (6)

contain core detect develop dna
encod gene includ major methyl number open
posit read region rel repeat sequenc specif
structur

3975: 5'-Nucleotidase (9)

activ cell combin compar
compound control deriv detect differ effect
enzym group human new normal
patient role subject time tissu

3970: Canavanine (4)

analysi approxim blot cell clone differenti dna
express function gene health
inhibit interact major mutant protein
region rel risk sequenc

3972: Receptors, Vasopressin (11)

acid activ alpha analysi assai beta cell complex
detect determin distribut genet local mutant
mutat number popul product
receptor sensit

3974: beta-Naphthoflavone (6)

activ cell data decreas
develop enzym estim
increas inhibit metabol
metabolit method new popul rat region rel
sampl select sequenc

3976: Cystamine (4)

compar control demonstr
differ effect find gener inhibit
number pattern previou produc
product protein reduc
report stabil structur studi
suggest

3977: Heterocyclic Compounds with 4 or More Rings (9)

cell chain compound detect effect fish
function **high** hybrid identifi increas
level low model probe produc
product reaction resist situ

3979: Amdinocillin (1)

bodi cell code codon coli develop electron
factor **growth** layer microscopi
morpholog nucleotid observ posit reveal
substitut suggest surfac weight

3981: Hydrolyzable Tannins (5)

activ apoptosi bind caus **cell** death effect
human
enhanc extract form format
induc **inhibit** invas larg size small specif
suppress

3983: TNF Receptor-Associated Factor 1 (6)

assai **cell** combin detect differenti
distribut effect enhanc **express** form
format local lymphoma mice mutant new
prolifer receptor sensit suggest

3978: Prodigiosin (2)

carcinoma cell densiti express **famili**
follow form format **high** histori level line low
member persist produc product protein
requir resist

3980: Butyrate Response Factor 1 (2)

activ cell characterist common
differenti event express featur induc induct initi
involv line mrna presenc process prolifer
protein **respons** translat

3982: Pyrazinamide (4)

assai case caus clinic dai delet detect form
format **function gener** level
mutat patient report resist respons sensit
specif studi

3984: Chlorzoxazone (2)

activ analysi assai assess blot
concentr correl detect determin evalu express
flow isol measur mice score sensit signific system
western

3985: Heterogeneous-Nuclear Ribonucleoprotein D (7)

chang cluster distribut end **famili**
human local member mrna nuclear process
protein region rna sequenc
stabil structur telomer telomeras translat

3987: Endopeptidase Clp (5)

base cell condit degre differ distribut
gene gener length local long mechan
molecular **mutant** protein
repeat requir short
structur valu

3989: Antidotes (3)

alter anim **area** assess
chang characterist common dai
data distinct dose **featur** locat measur
model radiat rat score site studi

3991: TRPP Cation Channels (23)

activ analysi caus diseas express failur famili
function genet **kidnei** mutat normal number
phenotyp rcc **renal** reveal studi tissu
tubular

3986: Heterogeneous-Nuclear Ribonucleoprotein Group A-B (12)

analysi assai **associ**
bind blot cell control detect
famili increas mechan nuclear
patient protein region reveal sampl
sequenc studi tissu

3988: Protease La (3)

cell earli infect involv late **mechan**
mitochondri **molecular** multipl mutant phase
protein residu site stage target
treat **treatment** underli understand

3990: Potassium Permanganate (2)

anim case construct **dna** experiment
gene homolog includ inhibitor marker
model particip plasmid rang
recombin replic report studi
varieti wide

3992: Myelin Proteolipid Protein (21)

axon cord demyelin effect gene heal
injuri mechan mice myelin nerv
neuropathi number oligodendrocyt peripher
regener spinal studi trauma wound

3993: Guanosine Diphosphate (14)

activ bind **cell** chang cluster differ express

form format gene number product protein

region requir resist sequenc site state

structur

3995: Razoxane (4)

agent **cell** code codon

combin cytotox decreas dna

drug effect genet

increas inhibit nucleotid posit

singl substitut treatment vitro vivo

3997: Mandelic Acids (3)

acid amino approxim assess bladder clinic

compar evalu **group** higher

measur mutant **number** rate

receptor rel SCORE select specif state

3999: Esterases (21)

activ adapt analysi cell compar control

develop differ enzym evolut femal gene

group human male new number provid rate

select

3994: Amsacrine (3)

acid analysi blood chain cluster data

dna donor exposur **mechan** molecular

month mutant **mutat**

patient reaction regul surviv

transplant year

3996: Phenylalanine-tRNA Ligase (1)

achiev algorithm **approach**

code codon design dna express field

method mrna network optim

peptid predict problem set

space strategi substitut

3998: ets-Domain Protein Elk-4 (2)

bind bodi cell complex conform data

enhanc form increas interact level line

protein residu serum site stabil

structur studi transcript

4000: Antibodies, Anti-Idiotypic (21)

antibodi antigen cell detect

express high human immun mab mechan

monoclon neutral number **patient** rel

respons sampl specif treatment vaccin

4001: Ryanodine (4)

adult calcium channel concentr
develop domain effect
express function high inhibit
level low presenc protein receptor reduc
regul serum year

4003: Thioredoxin (19)

analysi associ decreas
develop effect function
gene identifi increas
interact level oxid
protein reduc region
role sequenc stress time
tumor

4005: Pyridostigmine Bromide (1)

biolog bodi concentr data differ direct evid find
group hypothesi microg microm min
patient plasma provid respect
suggest support system

4007: Polyphosphates (9)

activ catalyt chain complex effect
enzym function gener group
high human level low model new pcr product
reaction respons substrat

4002: Limonins (2)

adduct algorithm compound contain
core deriv effect encod length long method
network new novel open predict
provid rat repeat short

4004: HIV Integrase Inhibitors (3)

analys analysi approach
avail data databas design develop inform
mutat new novel predict provid reveal
strategi structur target therapeut
tool

4006: Neodymium (1)

apoptosi base cell death differ electron
extens induc layer match microscop microscopi
morpholog observ pair reveal shape structur surfac
wall

4008: Propionates (6)

activ analysi cell combin concentr
enzym express gene high
increas level low model mutat
region resist sequenc specif studi variabl

4009: Fibroblast Growth Factor 5 (2)

area **cell** compar control differ
differenti **enhanc** express
higher increas larg multipl prolifer rat
rate size small studi subject
vector

4011: Isoflurophate (1)

activ anim compar compound control
develop enzym experiment fish fluoresc healthi
hybrid **model** mutant mutat
probe situ studi **subject** wild-typ

4013: Emodin (5)

activ cancer **cell** content control
differ effect enhanc evid flow
human inhibit mice pattern
phenotyp regul subject support time
tumor

4015: E2F7 Transcription Factor (4)

adult bind **cell** children cycl estim factor
famili growth larg member
phenotyp plai role size small specif
suggest transcript year

4010: Mitomycins (4)

acid analysi clinic compar **control**
distribut effect frequenc initi local mutat
patient popul releas **sampl** specif
state stimul therapi **treatment**

4012: PrPSc Proteins (15)

anim assai **degrad** detect diseas
larg level ligas model pathwai product
proteasom **protein** rate regul
sensit size small ubiquitin zinc

4014: Thiouracil (3)

adapt approach core **develop**
distribut encod **genom** improv isol life local
method natur open organ predict qualiti
select sequenc **structur**

4016: E2F6 Transcription Factor (2)

addit **cell combin** cycl cyclin domain effect
express gene methyl novel plai
potenti promot protein **role** suggest target
therapeut transcript

4017: Cofilin 1 (1)

actin **cell** compar conserv defect differ function
higher lower mammalian migrat mutant mutat
polar **rate** regul respect similar versu
wild-typ

4019: alpha-Amylase (11)

activ analysi chang correl
develop differ earli gene higher
individu level plant popul product
protein **rate** rice select studi wheat

4021: Aroclors (1)

caus compar control differ effect elev exposur
group higher lead level plasma random
rat serum signific studi thyroid treatment trial

4023: Receptors, Adrenergic, alpha-2
(8)

alpha **ASSOCI** cell combin dai effect famili
function gene genet genotyp haplotyp
polymorph product **receptor**
respons snp subject test treatment

4018: Transketolase (2)

acid anim blood bovin breed cattl chain
concentr earli effect factor **gene**
growth inhibit method milk pig porcin
reaction stage

4020: Kangai-1 Protein (10)

analysi bind cancer case **cell** combin
complex differ effect **express** increas
interact level mechan molecular mrna
patient pattern posit protein

4022: Aroclor 1254 (5)

activ alter chang clinic dai
decreas effect exposur express increas
level measur normal patient protein
rat serum sever tissu year

4024: Thallium Radioisotopes (2)

adapt administr analysi **area** care clinic
collect **dai** data diagnosi dose estim
flow health method **sampl**
select state studi week

4025: Rho(D) Immune Globulin (4)

children china **chines** determin
develop differ **gene**
heterogen high includ level low observ
phenotyp product respect
select studi subtyp tumour

4027: Potassium Radioisotopes (6)

activ compar concentr **control**
differ extract factor **group** higher
includ level method rang rate respect risk
sampl valu water wide

4029: Endo-1,4-beta Xylanases (10)

cluster compar condit **control**
degre differ effect **extract**
featur fraction gene high increas
method prepar protein
respons sampl tissu treatment

4031: Receptor, Muscarinic M2 (6)

activ combin compar **control** differ effect
express famili **function** gene
higher increas product protein rate
receptor risk specif studi
subject

4026: Radon Daughters (4)

compar concentr correl **distribut**
dose estim higher irradi larg
local normal organ popul
radiat **rate** rel risk size
tissu valu

4028: Thiourea (7)

adapt anim combin differ dna effect
function group high
human level low model new process product
provid select specif studi

4030: Tocolytic Agents (2)

birth **case** data fetal gestat infant
literatur matern neonat pregnanc prenat
present publish report review target
test treat **treatment**
women

4032: Exfoliatins (2)

accumul acid **assai** base compar
detect determin differ dna level
mean measur pair recombin **sensit**
serum specif structur test valu

4033: Purine-Nucleoside Phosphorylase
(9)

compound correl deriv detect
differ dna express gene
human methyl number
pattern plai promot rate resist
role specif synthesi tumor

4035: MAP Kinase Kinase 6 (6)

acid activ amino associ cell induc
interact kinas pathwai peptid
phenotyp phosphoryl protein
requir respons risk signal studi
system target

4037: Hemoglobins, Abnormal (44)

abnorm anaemia anemia associ caus defect
defici disord epo erythrocyt erythroid
erythropoietin g6pd hemoglobin mutat normal report
sever sickl test

4039: Hemoglobin E (9)

anemia assai ASSOCI case chang combin
common defect defici detect
famili featur identifi level member
method mutat normal sensit tissu

4034: Nordihydroguaiaretic Acid (7)

acid amino assai cell decreas detect
differenti growth increas inhibitor level model
normal protein requir sensit studi tissu
tumor valu

4036: 2,3-Diphosphoglycerate (1)

aggreg algorithm bind case code
codon form format gene
genet method mutat
network nucleotid predict report set
structur substitut vector

4038: Hemoglobin A (5)

analys analysi base compar control differ
effect group method new normal
pair patient provid respect reveal
specif studi subject tissu

4040: Lutein (6)

adult base concentr data delet distribut evid
gene hospit local organ patient plai
provid regul role studi support trial year

4041: Prostaglandins E (3)

biolog blood cancer compar **control**
develop distribut effect frequenc
gastric growth health inhibit local
patient presenc studi system
target treatment

4043: Receptors, Adrenergic, beta-3 (7)

activ **allele** associ bodi chang
compar **control** differ express
frequenc gene **genotyp**
group **polymorph**
ratio receptor risk studi subject weight

4045: Hydantoins (2)

approxim assess base compound **correl**
evalu major measur mutant observ pair
previou rel report requir resist
respons score studi suggest

4047: Ficoll (2)

bone cell **correl** effect factor genet induc induct
marrow **model** mutant new provid recomb
reduc respond **respons** signific stabil
structur

4042: Hexosyltransferases (4)

area caus **differ** evid **famili**
genet **human** member mice mutant
normal pattern phenotyp protein residu
select site support test tissu

4044: Receptor, Melanocortin, Type 3 (2)

bodi chromosom copi diet **gene**
increas level linkag loci locu map mass
mutat number obes
region serum **studi** test weight

4046: Picibanil (3)

bind breast cancer case **cell** differenti earli
inhibit length long **patient** period
point primari repeat report short stage **time**
tumor

4048: Trinitrobenzenes (1)

cell complex copi data determin direct evid
hypothesi includ increas larg limit **mice** mous
number possibl provid support
total transgen

4049: Fosinopril (1)

arm bodi clinic compar effect efficaci improv
particip **patient** prevent protect
random receiv reduc reduct studi treat
treatment trial weight

4051: Drugs, Generic (7)

avail base care cost data decis
develop estim gener genet
guidelin manag medic method model
practic recommend specif studi treatment

4053: Filaricides (3)

anim area blood correl data develop
experiment incid mechan **model**
molecular presenc provid regul speci state
studi target therapeut women

4055: gamma-Globulins (5)

associ blood cell compar differ diseas
gene group increas mean measur
method **patient** ratio rel report
respect score studi valu

4050: GTP Cyclohydrolase (11)

activ associ base cell decreas diseas disord
enzym featur genet high increas level low
new **patient** studi synthes
synthesi test

4052: NF-kappa B p50 Subunit (16)

activ associ cell compar
control differ express factor
frequenc gene group haplotyp
human necrosi nf-kappab
polymorph rate role snp studi

4054: Coagulase (6)

area associ chang clinic data design evid
identifi infect isol model organ plai process
role screen select strain **studi**
support

4056: Artemisinins (5)

analysi associ care differ health induc
induct mechan model phenotyp presenc
product resist **respons** reveal
servic studi subject suggest test

4057: Chloroguanide (2)

adapt **associ** clinic codon combin
effect gener link reduc reduct relat select signific
speci studi suggest system **test** therapi
treatment

4059: Amylose (5)

assai decreas **detect** differ effect
function identifi increas
level mechan recombin reduc repeat rice
screen sensit system valu variabl wheat

4061: Cyclopropanes (4)

bind decreas effect enzym evolut
identif **identifi** includ
increas inhibit novel rang
screen skin specif structur
studi **treatment** valu wide

4063: Podophyllotoxin (3)

bind caus cell death decreas densiti
high includ increas lead level
low properti rang resist risk
structur target varieti wide

4058: Glutamate Synthase (6)

acid activ concentr decreas dna **enzym**
form format fragment **genom**
increas mice model mutant new pcr
peptid produc product sequenc

4060: Indans (6)

activ behavior bind cell cognit
combin effect impair learn memori normal
perform popul select **target** test therapeut
tissu tumour variabl

4062: Aminophenols (1)

assess **bind** current discuss dynam
function gene gener genet
impact improv life model physic plasmid
qualiti recent recombin simul understand

4064: Receptors, Thyrotropin-
Releasing Hormone (3)

analys **analysi** compound
concentr data deriv differ factor gener
growth indic model produc
product receptor regul report
reveal risk studi

4065: Smad6 Protein (5)

activ blood cartilag cell chondrocyt
collagen develop express factor growth
individu induc invas matrix receptor resist signal
tgf-beta tgf-beta1 transform

4067: Diazooxonorleucine (1)

activ biosynthesi cancer catalyt catalyz cell
dehydrogenas effect enzym
enzymat metabol ovarian p53 prevent protect
reaction reduc reduct reductas substrat

4069: Thimerosal (4)

case children combin data develop
direct earli estim evid genet
hypothesi incid mice popul preval
provid risk support women
year

4071: Poliovirus Vaccine, Inactivated (3)

adult area children cohort data differ
group incid men mortal older
period popul preval rate registri studi trend
women year

4066: Fatty Acids, Volatile (8)

acid amino analysi cell chang
children compar concentr control correl
differ follow group human larg signific
size small studi variabl

4068: Lactoylglutathione Lyase (4)

activ alter analysi blot cell chang condit
decreas degre demonstr detect enhanc express
factor increas plant protein
respons risk western

4070: Diphtheria-Tetanus-Pertussis Vaccine (3)

adult children data earli experi
featur incid initi late men mortal organ
origin phase preval risk second stage
women year

4072: Imidoesters (1)

alter bodi brain chang decreas
densiti diseas experi extract high increas
level low observ organ possibl rat signific
test weight

4073: Oxidopamine (14)

analysi area cell diseas earli express **gene**
level **neuron** number process
product protein rat requir respons studi
target transfer vector

4075: Benzalkonium Compounds (2)

acid adapt approach characterist common
cultur detect exposur extract featur fraction
hybrid imag includ limit mass rang
select strategi wide

4077: Complement Factor D (1)

antibodi antigen differ evalu **factor**
growth height hormon hypothesi igf-i
immun insulin-lik malaria perform signific statist studi
test transcript vaccin

4079: Bentonite (3)

alter chang compar **control** differ
earli exposur frequenc mean measur multipl
patient produc product properti
ratio respect **respons** stage valu

4074: Sodium Hydroxide (7)

assai **detect** determin differ dna
effect extract **function**
group initi **method** new
normal origin **sampl** select sensit
studi time tissu

4076: Wasp Venoms (4)

case discuss earli **effect** flow isol
mechan molecular peptid presenc recent
reduc report **respons** stage
strain **target** therapeut **treatment**
vector

4078: Picloram (1)

activ analysi antibodi assai compar
decreas detect determin differ **group**
increas level predict regress relationship sensit
signific specif variabl variat

4080: Casein Kinase I (8)

analysi assai bind blot chang **complex**
detect **develop** express famili
genom **interact** new posit protein
region regul repeat sequenc site

4081: Factor XI (7)

affect analysi ASSOCI base defici differ
effect **gene** group interact
mutant **mutat** number reduc
region repeat report sampl sequenc studi

4083: Integrin alpha1beta1 (4)

adapt adhes bind **cell** collagen
differenti diseas express extracellular integrin
interact molecul new prolifer protein provid
receptor regul role select

4085: Magnesium Sulfate (4)

blood care caus channel collect complex
dai data event health involv lead level
process rat report **sampl**
serum studi target

4087: Receptors, Thyrotropin (22)

activ adenoma adren braf chang diseas
function genet hormon interact mutat
papillari patient pituitari plai receptor
respons ret role **thyroid**

4082: Peptones (3)

acid **activ** anim ASSOCI cultur decreas
field growth incid **increas** level
model movement produc **product**
space **studi** test women year

4084: Integrin alpha1 (4)

activ bind **cell** conserv decreas
increas inhibitor invas lymph matrix
metastasi metastat mutant node organ peptid
primari receptor requir tumor

4086: Immunoglobulins, Thyroid-Stimulating (3)

compar **control** data diseas effect
estim frequenc gener incid induc inhibit
organ popul preval receptor
respons structur
treatment women year

4088: 2',3'-Cyclic-Nucleotide Phosphodiesterases (4)

activ cell cluster copi data form format
gener genet mice model multipl mutant
number plai presenc role
suggest tumor valu

4089: Testicular Hormones (8)

cell combin control differ

express femal gene

individu level male organ

period point protein rat respons sex

studi test time

4091: Resorcinols (5)

acid **activ** bodi cell compar
control differ extract **group**
higher incid line model product rate
rice select specif wheat women

4093: Receptors, HIV (11)

cell genet herp hiv **hiv-1** human identifi
immunodefici **infect** level mechan
molecular **patient** process
resist size **studi** time viral viru

4095: Iridoids (3)

activ associ cell decreas
effect increas kinas level modif modifi
mutant phosphoryl protein reduc reduct studi
suggest treat **treatment** vivo

4090: beta-N-Acetylhexosaminidase
(10)

activ assai cell chang control detect
develop effect enhanc gene group increas inhibit
level measur reduc respons score select sensit

4092: Acitretin (2)

acid assess case cell decreas evalu express
factor **increas** induc induct inhibit
lesion level line measur **patient**
respons risk score

4094: Imipramine (8)

anim associ **bind** children
compar **control** disord effect
express extract gene **group** isol
metabol **model** number
protein rat risk studi

4096: Amino Acid Transport Systems,
Acidic (1)

express addit confirm consist demonstr effect
find increas indic loss
neuron nitric observ oxid previou report studi
suggest synthas synthesi

4097: Vesicular Glutamate Transport
Proteins (1)

assess **correl** demonstr dynam find
impact improv life membran
model paramet physic previou
qualiti relationship report signific simul
studi suggest

4099: Calcium Channels, N-Type (9)

atp ca2+ calcium **channel** complex
current differ high increas ion level low
mechan **mice** mous patient pattern
properti role transgen

4101: Trazodone (2)

arm **clinic** compar earli **effect**

efficaci gener genet improv organ patient

phase **random** reduc sever stage studi

symptom treatment **trial**

4103: Thrombospondins (12)

activ bind cell develop
effect express genet group human
increas interact model normal
number rate specif **studi** therapi
tissu tumour

4098: Early Growth Response Protein
2 (4)

care **cell** complex domain encod follow
health indic injuri larg mutat nerv number
protein requir size small speci
state transcript

4100: Receptors, Atrial Natriuretic
Factor (4)

area characterist common control differ
featur **gene** genotyp **human**
mice modul polymorph presenc **regul**
regulatori repeat studi subject variabl
variat

4102: Sodium-Calcium Exchanger (9)

associ compar decreas evid
function gene higher **increas** mechan
rate ratio regul requir respons risk role
sequenc **studi** suggest support

4104: Phytochrome (14)

activ base blue clone color composit differ
express gene group intens laser **light**
new observ pair plant red **respons**
studi

4105: Tetrapyrroles (3)

bind determin differ energi enzym
express gene genotyp interact
mean measur mutant recombin remain residu
respect **sampl** site test valu

4107: Maf Transcription Factors (3)

bind decreas develop event **express**
famili gene increas induc induct
involv level member **process** promot
protein remain **respons**
state transcript

4109: Viral Tail Proteins (1)

algorithm **children** coli
complex data electron escherichia
imag **mechan** method
microscopi **molecular** morpholog
network parent predict problem set
structur underli

4111: Annexin A7 (2)

cancer cell distribut epitheli essenti
express factor fluid indic local
loop malign **marker** multipl **protein**
requir risk studi suggest tumour

4106: Phycocyanin (2)

bind cell conserv cultur domain energi
event initi involv kinet laser **light** occur
process protein question remain
state step transplant

4108: Vindesine (11)

chemotherapi combin dai distribut earli effect
increas level local lymphoma **patient**
phase prognost respons stage **surviv** toxic
treat **treatment** trial

4110: Receptor, Notch2 (9)

activ cell conserv earli express famili
function genom high human
level low mammalian **mechan** new plai
resist role stage target

4112: Annexins (9)

analysi **cell** clinic compar detect diagnosi
drosophila earli factor famili **growth**
higher patient protein **rate** role
sequenc stage test therapi

4113: Indium (2)

abil accumul bind capac demonstr enzym
field find imag mechan microscopi
molecular morpholog potenti previou
proporti report **structur**
studi suggest

4115: Tumor Necrosis Factor Receptor-Associated Peptides and Proteins (10)

activ apoptosi associ **cell** data
death develop enhanc evid famili
induc interact mechan **protein**
provid role suggest support system
treatment

4117: Amino Acid Transport Systems, Neutral (32)

alpha-synuclein alzheimer autoimmun caus common
dementia develop **diseas** disord gene
group human membran mice onset parkinson
pathogenesi patholog progress tau

4119: cdc25 Phosphatase (21)

activ arrest associ bind **cell** compar
control cycl cyclin differ
human kinas phase protein respons
role select studi target time

4114: Sulfur Radioisotopes (12)

activ analysi bind condit dai
degre form format group mass mechan
mutant phenotyp process **protein**
receptor studi time vitro vivo

4116: Anisomycin (7)

adult **associ** caus cell chang
dai detect growth kinas level mechan
method **model** mutant
protein receptor **respons**
time valu year

4118: Amino Acid Transport System A (2)

analys **brain** central cerebr condit degre diseas
enzym extract fraction gene malign membran
mutat nervou progress protein
temperatur transport tumour

4120: Hepatocyte Nuclear Factor 3-alpha (10)

chang dai decreas develop
effect evid express gene
genom **increas** mechan
new presenc process promot
protein provid
respons support
transcript

4121: Betamethasone (5)

administr case cell **dai** dose effect
femal high level low male new patient
period point provid rat **time**
treatment week

4123: Polyvinyl Chloride (6)

associ **dai** effect exposur factor
high identifi **increas**
influen isol level **light** low
model product ratio **risk** screen
studi tumour

4125: Antigens, CD98 (2)

absenc cell chines compar **control**
differ epitheli express frequenc heterogen observ
patient plai presenc receptor **role** signific
studi subtyp suggest

4127: Deoxyribonucleosides (5)

activ adult **analysi**
approxim combin compar control detect
differ dna high low major
pattern rel specif structur studi
subject year

4122: Pancreatic Polypeptide (3)

bind compar **control differ**
evid frequenc lesion normal observ pattern
presenc process region sequenc stain studi
support **tissu** tumour type

4124: RNA Cap-Binding Proteins (5)

bind compar complex **control**
end featur initi **mRNA** new protein
requir ribosom risk rna **select** site
telomer telomeras **translat** trna

4126: Deoxyribose (6)

adult approxim complex **differ** dna
energi form format **human** improv
individu life pattern qualiti radiat rel state
structur studi year

4128: Forssman Antigen (1)

carri compar comparison consid differ evalu exact

falciparum fisher hypothesi malaria parasit perform

plasmodium posit signific standard statist studi

test

4129: Antibodies, Heterophile (5)

approach assai caus cell clinic detect diagnosi

differenti evalu express lead method number

phenotyp popul prolifer research sensit studi

test

4131: Nitroso Compounds (10)

algorithm analys **analysis**
approach cell concentr data effect form
format **human** identifi method
network predict respons reveal set
studi target

4133: 1-Deoxynojirimycin (4)

accumul activ clinic degrad degre diseas
effect enzym method mutant
prevent protect protein reduc reduct regress
substrat **therapi** treatment variabl

4135: Amide Synthases (2)

activ assai catalyt CAUS cell death detect
dna **enzym** examin fragment **gene**
lead metabol modifi rice sensit specif substrat
wheat

4130: Peracetic Acid (2)

acid amino chromatographi collect concentr

detect determin effect expos exposur extract

fraction liquid method perform prepar

sampl separ studi test

4132: Oxidoreductases, O-Demethylating (2)

analisi concentr determin differ enzym gel

genet hospit mass mean measur metabol

method popul protein ratio

respect **sampl** standard

valu

4134: Phosphatidate Phosphatase (4)

acid amino anim cell clone decreas event genet
human increas interact involv line
model pathwai **PROCESS** repeat signal step system

4136: Dihydrolipoamide Dehydrogenase (3)

activ clinic criteria design diagnos diagnosi

diagnost enzym follow **gene** gener

genom hospit mutat patient produc product

sequenc structur studi

4137: Pyruvate Dehydrogenase Complex (5)

alter case **chang** clinic complex design
enhanc **gene** gener hospit increas
modifi **mutat** plai product
role **structur** studi time
variabl

4139: Desipramine (3)

anim behavior bind concentr effect experiment field
function induc inhibit metabol
model rat regul respons space stimul studi treat
treatment

4141: Nitrite Reductases (5)

abil analysi assai associ caus compar detect
differ **gene** higher individu isol
method pattern properti rate risk sampl sensit
strain

4143: Nitrate Reductase (8)

activ analysi develop enzym
famili **gene** gener genet high
inhibit level low mutant popul posit
region regul sequenc size studi

4138: Ketoglutarate Dehydrogenase Complex (4)

acid bind caus characterist common evid featur
gene genom isol mutant new normal
produc product provid repeat sequenc
support tissu

4140: Immunoglobulin Fc Fragments (13)

antibodi assess cell dai dose effect
express **function** gener
group high human increas level
measur patient score select signific
studi

4142: Nitrate Reductases (10)

approxim develop differ enzym gene
gener group inhibit isol level
measur mutant mutat rel sequenc
structur studi subject synthesi valu

4144: Leukocidins (5)

analysi antibiot bacteri combin data
design effect hospit host individu **infect**
isol number parasit pathogen
patient reveal strain
studi test

4145: Diethylcarbamazine (2)

analisi categori caus classif classifi
cluster correl data differ
health incid includ lead profil rang rat set
subgroup women year

4147: Placental Hormones (2)

cell dai dose effect express **human**
inhibit mice mous period point radiat **studi**
time transfect transgen tumor vector vitro
vivo

4149: Siloxanes (4)

alter blue **chang** color composit data
differ function group intens laser
light method process red region
sequenc studi surfac variabl

4151: Dinitrogenase Reductase (1)

approxim bodi differ indic known **larg**
larger major minor number observ rel rna
similar **size** small smaller speci
substanti weight

4146: Phosphotransferases (Phosphate Group Acceptor) (3)

base cancer dna event express identif identifi
induc induct involv mutant novel pair
process produc **product** requir
respons screen yeast

4148: Formic Acid Esters (1)

compar compound control core differ divid dna encod
enzym event **group** initi involv occur
open **process** read respect signific step

4150: Cryoglobulins (5)

acid activ bind cell condit degre
develop diseas distribut growth
heat investig local observ peptid report
studi temperatur treatment tumour

4152: Uridine (19)

activ base compound effect express
function high higher initi level
method origin patient process rate
region sampl **sequenc**
structur **studi**

4153: Tricarboxylic Acids (1)

acid activ amino **base** character
core design differ encod enzym frame
hospit identifi isol open pair patient read
strain variant

4155: Thymic Factor, Circulating (1)

adhes affect alter cell **chang** cultur
decreas effect epitheli express increas
interact observ protein rna signific therapi
transfect treat **treatment**

4157: Piperacillin (2)

assess compar concentr control dai differ divid donor
group higher initi measur origin point
respect score second signific **time** transplant

4159: Antigens, CD11 (4)

activ adhes analysi cell content
cytometri determin domain effect evalu flow
load mice organ protein reduc region regul
sequenc state

4154: Choline-Phosphate Cytidylyl-transferase (3)

data develop estim express form format gene
genom hybrid imag malign method mutant
organ phenotyp rat risk target
tumour variant

4156: Penicillanic Acid (2)

compar control data differ estim **group**
host induc induct infect length long method
patient rat repeat respons short signific statist

4158: Dietary Sucrose (4)

alcohol bodi **children** compar
concentr decreas depend differ effect
higher **increas** oral popul
rate risk specif studi valu
variabl weight

4160: Antigens, CD11a (6)

activ bind cell clinic correl
diagnosi differ differenti **enhanc**
express function identifi increas multipl
mutat phenotyp region screen sequenc
suggest

4161: Phytochrome A (3)

acid amino approxim cell clone compar
enzym gene higher light lower major multipl
observ **rate** rel report sequenc studi
suggest

4163: Antigens, Fungal (10)

analysi antibodi detect earli event follow
fungal fungi **gene** genet isol level mice
pathogen **process** produc product
size **specif** subject

4165: Bucladesine (9)

analysi caus **cell** clone concentr decreas
differenti effect evid **express** famili gene
increas lead line mutat protein
role studi valu

4167: Amber (3)

cell cluster control data design differenti

discuss enhanc evolut hospit

normal phenotyp popul

recent remain speci

structur studi subject

tissu

4162: Chitin Synthase (9)

area compar **control** form format

gene high higher interact level low

mutant **normal** pathogen plai rate

requir role speci **tissu**

4164: Receptor, Nerve Growth Factor (12)

approxim associ brain cell **express**
form format **group** growth major mutat
neuron plai protein receptor rel respons
role site suggest

4166: Prazosin (3)

activ anim associ decreas **increas** initi
level model origin previou protein receptor report
stabil **studi** suggest system therapi treat treatment

4168: Hemoglobin J (1)

altern associ **chain** defici detect

exon gene haplotyp intron isoform

mutat pcr polymeras

polymorph quantit **reaction**

real-tim revers splice **variant**

4169: rhoB GTP-Binding Protein (9)

cell combin concentr cox-2 effect
enhanc express growth high induc inhibit
inhibitor level low model mutant region
respons sequenc tumor

4171: Complement C3 Nephritic Factor (2)

ASSESS bodi carcinoma defect defici diseas
evalu **kidnei** measur mice mous
mutant mutat rcc **renal** scale
score **specif** valid wild-typ

4173: Deoxyribonuclease HpaII (5)

analysi base detect
differ dna fragment genet
pattern pcr polymorph popul primer
product region restrict reveal
sequenc **speci** **studi**
subtyp

4175: NF-E2 Transcription Factor (5)

analysi base cell compar **control** decreas
defici differenti express gene
increas interact level number
observ **patient** promot rat rel test

4170: Sex Attractants (16)

acid activ chang complex
drosophila femal ffi fly
host increas insect larva male melanogast
mutant number sex speci target wing

4172: Methimazole (5)

activ adult assai compar detect
develop differ diseas higher
metabol protein rat rate report risk sensit studi
target thyroid year

4174: Receptors, Prostaglandin (5)

bind cancer **cell** combin earli
effect inhibitor initi larg line mutant
posit produc **product** regul size small
stage state **tumour**

4176: NF-E2 Transcription Factor, p45 Subunit (4)

associ cell compar data decreas defici evid
express **function** gene hypothesi
increas level mice mous number
provid reduc remain support

4177: Niacin (3)

acid approach care complex data design
estim factor growth health manag
mechan medic method molecular presenc
provid **risk** specif strategi

4179: Thioctic Acid (7)

activ base compar correl dai differ effect
group higher human inhibit level
mutat oxid rate risk serum signific time treatment

4181: Selegiline (2)

abil adapt alter assai **chang** complex
concentr decreas detect effect genet increas
inhibit method natur patient properti rat
select sensit

4183: Galactosides (23)

cell chang diseas effect
express form format function
gene high increas level low
method mice observ process size
treatment vector

4178: Peptide Elongation Factors (14)

activ associ bind data domain
function gene **interact** melanoma
mutat number plai **protein** regul
requir rna **role** structur suggest
transcript

4180: Saquinavir (2)

alter arm **chang** clinic compar
develop differ effect
efficaci **gene** improv initi month patient
pattern random studi treat
treatment trial

4182: Berberine (4)

analysi blot **cell** demonstr determin
effect high inhibit level low modif
modifi presenc previou process
reduc report **studi** suggest western

4184: Europium (3)

assai bind compar **control** demonstr
detect enhanc fish
fluoresc hybrid increas interact new probe
resist **sensit** situ specif studi suggest

4185: Lanthanoid Series Elements (2)

allow applic approach **assai** bind data
design **detect** enhanc estim limit
method procedur repeat
sensit specif strategi **studi** techniqu
test

4187: Guanosine Tetrphosphate (2)

bodi **complex** compon conduct data design dna
essenti evalu includ investig neg pool **posit** promot
publish replic requir **studi** subunit

4189: Receptors, Eph Family (8)

activ alpha beta cell clinic combin
complex diagnosi event famili function
interact involv new process rate
receptor requir size specif

4191: Ephrins (7)

alpha beta bind cell **develop**
famili function high individu larg level
low member plai posit **receptor**
role size tumour year

4186: Enkephalins (5)

affin assai **bind** combin detect **high**
higher level low method mice mous process
protein rate repeat sensit site structur studi

4188: Fungal Vaccines (2)

anim cerevisia **decreas** experiment exposur
host imag immun **increas** infect
isol level **model** pathogen strain studi
vaccin vitro vivo yeast

4190: Endothelins (7)

activ cell compar **decreas** **develop**
differ earli effect express femal
increas inhibit interact level male
product rat receptor subject valu

4192: Epothilones (14)

activ agent cancer chemotherapi
clinic combin drug effect gener growth
human new patient rang studi
therapi time treatment vitro vivo

4193: Photosynthetic Reaction Center
Complex Proteins (16)

combin differ discuss **effect**
energi famili gene high identifi laser
light plant rate recent
respons sampl screen **select**
solut state

4195: Progestins (12)

activ ASSOCI breast cancer chang

clinic control earli effect express factor

organ requir **respons** risk stage

studi therapi treat **treatment**

4197: Caproates (1)

anim bovin breed cattl cow dai differ dose
duplic evolut milk **phenotyp**
pig porcin sheep sperm splice suggest variant
week

4199: Androstane-3,17-diol (1)

activ aggreg block **CANCER** coloni convers
effect exposur **form format** induc
inhibit inhibitor inhibitori invas
matrix mechan prostat suggest suppress

4194: Gonadotropins, Equine (2)

anim biolog bovin breed **effect** experi
milk organ pig possibl prevent protect reduc
reduct remain system treat
treatment vitro vivo

4196: Pyruvic Acid (13)

activ **analysi** children clinic
compar concentr **control**
diagnosi effect **enzym**
function organ rat rate reduc reveal
substrat time tissu year

4198: Asbestos, Serpentine (4)

analysi area **cell** compar
control dai electron evid field
high level low microscopi morpholog
observ **sampl** space structur studi
support

4200: Phosphoenolpyruvate Carboxy-
lase (1)

coli defect disrupt enzym exhibit function impair lack
mice mous **mutant** mutat phenotyp
reduc rescu rice transgen wheat wild-wild-typ

4201: Oxaloacetic Acids (1)

activ biosynthesi catalyt catalyz coli cytochrom
defect dehydrogenas **enzym**
membran **metabol** metabolit mice
mous **mutant** mutat p450 substrat
transgen wild-typ

4203: Proto-Oncogene Proteins A-raf
(3)

activ approach **cell** design **effect** growth
inhibit kinas novel organ overexpress pathwai
potenti reduc reduct signal strategi
target therapeut transform

4205: Peptide Synthases (13)

activ analysi associ data enhanc
enzym famili gene
identifi increas interact local member
predict rate **select** studi substrat
suggest time

4207: Inosine Monophosphate (4)

activ analysi bind biosynthesi blot
catalyt catalyz complex dehydrogenas
enzym enzymat metabol reaction
reductas report structur studi substrat test
variabl

4202: Phosphoenolpyruvate (2)

activ condit core degre domain encod
enzym exon identifi metabol
mutant mutat open peptid
recombin splice **structur** substrat
variant wild-typ

4204: Adenylosuccinate Synthase (2)

activ cell compound contain core differenti effect
encod **enzym** **express** light open
prolifer protect recombin reduc reduct region
sequenc substrat

4206: Ribonucleosides (6)

activ alter **bind** cell chang
complex compound decreas **differ**
dna enzym estim extract fraction
increas inhibit method
model new pattern

4208: Pentoxifylline (6)

analysi compar control dai differ dose
earli form format **group** higher
increas level patient rat rate stage
studi subject week

4209: Stearates (1)

carbon complement complex compon demonstr
determin divers domain energi free genet highli
measur multipl **popul** singl solut
specif subunit variat

4211: Oxazepines (1)

absenc apoptosi **associ** cell examin
head hypothesi investig link malign neg observ posit
presenc relat signific studi suggest **test**
tumour

4213: Betaxolol (1)

affin alpha bacteri **bind** channel coli
escherichia interact ligand outcom patient
prognosi prognost protein **receptor** site
strain SURVIV synthesi toxin

4215: Aconitine (1)

action activ block calcium channel coli
effect escherichia increas **inhibit**
inhibitori mechan ovarian potenti puls reduc
releas stimul suppress synthesi

4210: Receptors, Glycine (10)

acid activ analysi bind
correl detect effect express famili
genom group interact
mutant neuron popul
receptor respons
sequenc signific site

4212: Coal Tar (3)

analys analysi care children data exposur
health impact improv includ life need perform
physic qualiti reveal sampl **studi**
therapi tumour

4214: Veratridine (2)

absenc alpha channel **earli** effect express
field increas late level mrna phase presenc
primari progress promot rat
receptor stage synthesi

4216: Atenolol (5)

adult caus **CONCENTR** correl dai decreas
effect enhanc high **increas** induc
level low **patient** rat
respons select stimul surviv year

4217: Lactate Dehydrogenases (5)

anim chang control dai decreas enzym
femal increas larg level male model
patient protein rat size small
subject treatment tumor

4219: Nitrogen Mustard Compounds (4)

base biolog cell combin dai decreas
effect gene high increas level
low mice new protein provid studi
system vitro vivo

4221: Vascular Endothelial Growth Factor B (2)

cancer carcinoma cervic correl delai develop earli
express factor follow gene growth
initi late occur persist phase progress signific stage

4223: Paraproteins (2)

adult anim combin differ effect event experiment
group involv lymphoma model
multipl older plai process role site studi year
young

4218: Glycols (2)

african american antibodi cell compound
conform deliveri dna effici ethnic modifi
mutat neg overexpress particl popul
posit structur surfac white

4220: Squalene (4)

acid african american assai cell combin
detect **develop** differ effect
ethnic extract individu popul rel requir
select sensit subject valu

4222: Receptors, Neuropeptide Y (6)

bind cell chang data direct **evid**
famili function hypothesi member
model peptid product provid receptor
studi suggest **support**
treatment tumor

4224: Phenol (9)

analysi chang dai data demonstr earli enzym
group indic model mutant new
previou process report requir reveal specif
studi test

4225: Dichlororibofuranosylbenzimidazole (7)

associ compar complex
differ genom human
larg melanoma pattern popul rate
region rna role sequenc size small
structur time transcript

4227: Cyclooctanes (3)

abil approach base chain compar complex compound
control differ drug enhanc group increas
mice pair potenti properti reaction resist signific

4229: 6-Cyano-7-nitroquinoxaline-2,3-dione (7)

adult alter cell chang cultur earli
flow increas mechan method molecular
neuron produc product rat
receptor repeat stage state
year

4231: Shiga Toxin (3)

african alter american asian black
chang coli dna escherichia ethnic
evolut gene isol origin popul south strain
tumor vector white

4226: Ketones (8)

chang compar compound correl deriv differ
gener genom group higher increas
method model new patient provid rate
select studi subject

4228: Indican (1)

accumul cell cultur dose effici elegan gener irradi mix
natur plant process produc
product pure radiat season sourc
speci yield

4230: Cytochalasin D (10)

activ cell compar correl differ
effect famili field measur mechan model
pattern point rate repeat requir role signific
time variabl

4232: Trifluoroethanol (3)

analysi bind blot chain condit conform crystal

degre determin follow form format level multipl

protein reaction reveal serum state

structur

4233: Kynurenine 3-Monooxygenase
(3)

acid **cell** combin diseas
disord effect follow gene genet genotyp
inhibit mice motor mous **mutant**
mutat polymorph **protein**
recombin wild-typ

4235: Raclopride (4)

affect allel area **associ** case
decreas diseas effect genet genotyp imag
increas model polymorph receptor reduc
report schizophrenia studi suggest

4237: Receptors, Interleukin-4 (13)

activ allel associ compar control differ
distribut effect **express** famili gene
genotyp **group** local
polymorph protein rate receptor studi
tumor

4239: Propafenone (1)

administ administr **dai** daili discuss
dose effect hour includ infus inhibit month
oral patient rang receiv recent sever week wide

4234: Glycogen Phosphorylase, Muscle
Form (2)

autosom caus children clinic conclusions control
diseas domin famili gene healthi hospit inherit
mutat patient phenotyp
site state studi subject

4236: Dihydroxyphenylalanine (8)

associ caus chang children clinic concentr
decreas **diseas** effect famili
function human identifi imag increas
member mutat repeat **studi** treatment

4238: SNARE Proteins (13)

cellular complex function identifi interact
intracellular level **membran**
new plasma process protein provid regul
specif surfac traffick **transport** uptak vesicl

4240: Spider Venoms (6)

activ cell channel combin complex
duplic effect evolut evolutionari
famili high increas level low
member potenti protein releas **stimul**
structur

4241: Fos-Related Antigen-2 (3)

analysi bind blot caus cell decreas differenti enhanc

express famili growth **human**
increas induc lead level member presenc repeat
respons

4243: Y-Box-Binding Protein 1 (8)

acid analysi associ cell **correl**
develop express factor inhibit initi
mrna mutant **protein** regul
ribosom rna signific specif **translat**
trna

4245: Sodium Cyanide (2)

compar concentr delai determin differ earli

express follow level long-term

mean measur persist ratio respect serum

specif stage stimul **valu**

4247: Oxazolone (2)

analys **analysi** blot concentr
data event **function** initi
involv microg microm min **model** occur
perform **process** reveal step vivo
western

4242: 4-(3-Butoxy-4-methoxybenzyl)-
2-imidazolidinone (1)

affect approach cell design elev endogen enhanc

express higher increas **level** limit lower
measur plasma schizopshrenia **SERUM** strategi studi
suggest

4244: Sensory Rhodopsins (2)

abil analysi **base** blot capac
demonstr energi includ

interact mutant pair
potenti properti protein rang
requir structur

tumour western wide

4246: Neurturin (2)

compar data **differ** diseas fusion gene
includ neuron pathwai pattern **protein** signal

similar specif **studi** transfer type
vector vitro vivo

4248: Barium Compounds (3)

carbon chain concentr condit core dai degre

dose effect energi **function**
inhibit measur mechan method molecular
open reaction solut temperatur

4249: Nitro Compounds (13)

cell complex differ exposur featur genet
group mean mechan mice
microscopi model molecular
morpholog process regul studi
treatment tumour valu

4251: Clathrin Heavy Chains (5)

associ bind chain
complex concentr diverg duplic
evolut evolutionari express
interact membran origin
pcr polymeras protein reaction
real-tim revers transport

4253: MAP Kinase Kinase Kinase 1 (4)

activ cell express interact involv kinas
mechan molecular neg novel pathwai phosphoryl
plai posit potenti protein role suggest target
therapeut

4255: Magnesium Chloride (3)

approach complex data design dna evid
factor form function genom
group growth inhibit mice mutant
protein provid stabil strategi support

4250: Receptors, Corticotropin-Releasing Hormone (10)

abil adapt bind cell combin complex dai effect
human induc interact mice properti protein
receptor respons risk select
studi treatment

4252: MAP Kinase Kinase 7 (1)

activ blood candid count detect identif
identifi injuri kinas known
lymphocyt nerv neuron novel peripher phosphoryl
program protein screen spinal

4254: Tacrolimus Binding Protein 1A (4)

activ complex data differ evid
factor form format growth inhibit larg
pattern peptid provid receptor
regul size small support target

4256: Ethylenediamines (5)

data effect express extract form
format fraction genom initi
level method model new
origin process product provid region
sequenc structur

4257: Salicylic Acids (5)

activ caus cell effect express gene
health high interact lead level life low
overexpress qualiti reduc requir structur studi
transform

4259: Dimethylallyltranstransferase (3)

activ cell decreas differenti effect
enzym **function** increas inhibit larg
patient number produc product
size small structur substrat target tumour

4261: Guanidines (15)

acid cell chang compar differ effect express
group higher increas level normal
number plai protein rate role structur tissu
treatment

4263: Ethylmaleimide (6)

activ affect concentr copi enzym inhibit measur
mechan method molecular new
number product region repeat
requir score sequenc site studi

4258: Econazole (1)

cancer cell colorect content cycl cytometri
demonstr determin evalu find **flow** indic
load observ percentag previou **report**
studi suggest **tumor**

4260: Urethane (7)

adult correl dai decreas express form
format increas **mice** mous observ
product resist signific studi transgen tumor
tumour variabl year

4262: Pit and Fissure Sealants (2)

approach arm clinic compar effect higher
identifi improv incid light lower random
rate screen studi treat
treatment trial versu women

4264: Porfiromycin (1)

absenc clinic diseas head indic manag
month neck outcom **patient**
presenc prognosi prognost
random recurr stage studi **surviv** trial
year

4265: Phenylmercury Compounds (1)

analysi differ independ larg larger
nuclear number patient predict predictor
prognost radiat regress relationship signific
size small surviv
variabl variat

4267: Calcium Sulfate (2)

care commun condit data degre dose educ
estim health irradi method need
nurs program public radiat sampl
servic student temperatur

4269: Farnesol (12)

activ associ cell control distribut
effect express gene human
improv inhibit life local phenotyp
qualiti respons role sampl studi tissu

4271: HSP30 Heat-Shock Proteins (1)

aggreg condit degre earli form format
function gene heat indic
late marker observ phase physiolog progress shock
stabil stage temperatur

4266: Dicumarol (2)

cell combin compar decreas effect
express increas interact level
line mean measur organ primari ratio respect
tumor valu vitro vivo

4268: Phosphatidylinositols (20)

activ analysi associ bind
cell chang famili function high
level low mechan mutat
protein receptor regul
requir role signal site

4270: Dioxolanes (2)

apoptosi cell chemotherapi compar decreas earli
effect improv increas late level
patient phase progress random reduc stage treat
treatment trial

4272: Amphibian Proteins (3)

abil analysi blot condit degre demonstr detect
determin gene human lesion
potenti properti regul renal sampl
specif target temperatur western

4273: Gallic Acid (4)

activ analysi base cell compound concentr
data determin differ estim famili gene growth member
pair region sequenc specif target variabl

4275: Soybean Proteins (9)

acid associ blood **bodi** cell diet
differ **effect** evid function
gene mechan molecular **protein**
rat rate reduc support time weight

4277: Clotrimazole (3)

enhanc event incid increas involv men mortal
mrna plai preval process rat rate rna
role suggest system translat women
year

4279: Filipin (4)

activ alter case cell chang
demonstr evid find induc membran observ
previou provid **report**
respons specif studi suggest
support transport

4274: Thiadiazoles (8)

activ cell chang compound data
effect measur mechan method network
normal plant predict respons signal studi
subject **TISSU** treatment variabl

4276: Moclobemide (1)

adapt case copi depress **develop**
development disord evolut fit includ increas larg
limit natur **number** possibl report
select studi total

4278: Benzoflavones (2)

activ area cytochrom determin differ drug
effect enzym exposur extract fraction inhibitor live
locat **metabol** metabolit p450 rat resist studi

4280: Adaptor Protein Complex beta
Subunits (2)

biolog chines clone complex conserv differ element
encod **express** function **gene** heterogen
mammalian morpholog **protein** rna state studi
subtyp system

4281: Adaptor Protein Complex 3 (3)

absenc affect complex conserv data determin
differ distribut fluid **human**
investig local mutant mutat observ presenc
rna **studi** suggest system

4283: RNA, Chloroplast (2)

allele arabidopsi defect event factor genotyp
growth involv map melanoma
mutant mutat plant
polymorph **process** rna stabil step
test wild-typ

4285: Clonazepam (1)

case control dai dose earli epilepsi healthi late
methods **patient** phase progress
report seizur stage stress studi subject suicid
week

4287: Adjuvants, Anesthesia (4)

assai **children** dai demonstr detect earli
evolut find method parent
patient previou rat report
sensit stage **studi** suggest test time

4282: Mesylates (9)

abil assai data detect effect famili
function gene increas induc model
properti protein rat **respons**
role sensit specif state treatment

4284: Intramolecular Transferases (2)

affect alter arabidopsi caus **chang**
decreas defici diverg duplic evolut evolutionari
increas lead observ oxid pathogen plant rna speci
yeast

4286: Vascular Endothelial Growth Factor D (14)

angiogenesi associ cancer control
endotheli factor flow
function growth hif-1alpha
human hypoxia level normal role
subject tissu vascular vegf vessel

4288: Oils, Volatile (8)

analysi chines concentr determin differ
drosophila express growth identifi increas
method new plant **respons**
sampl size studi subtyp synthesi valu

4289: Monoterpenes (9)

acid cell chang combin

effect enhanc enzym

extract factor form format

growth increas method new

organ process receptor reduc

respons

4291: Pentosephosphates (3)

activ analysi compar conserv control decreas
enzym frequenc gene identifi increas

nucleotid region repeat report screen

sequenc specif studi variabl

4293: Selenomethionine (6)

approxim bind clinic compar

control differ increas normal

patient pattern protein

random rel specif structur studi

subject tissu treatment trial

4295: Uranium Compounds (2)

analys analysi characterist

compar electron evolut featur form format

indic mean measur microscopi morpholog

presenc ratio respect reveal speci

537

valu

4290: Nitrogenous Group Transferases
(3)

activ combin effect enzym factor gene
growth interact involv mechan metabol

mice molecular mous mutant organ
plant regul transgen wild-typ

4292: 3',5'-Cyclic-GMP Phosphodi-
esterase (7)

combin compound control
distribut effect follow genom increas
individu interact local mechan new
persist retin studi subject synthas
synthesi target

4294: Amobarbital (2)

assess attent behavior
behaviour cognit deficit disabl impair
improv interact learn life measur memori
patient perform qualiti score task test

4296: Alloys (7)

chang condit data degre
estim evid mechan method mice
model observ organ provid
region rel sequenc structur studi
suggest support

4297: Hepatitis C Antigens (2)

acid addit chines combin differ effect enhanc gene
heterogen **human** increas induc induct mice
open recombin respond **respons**
studi subtyp

4299: Polyenes (8)

analysi cell chang combin decreas
develop effect express **gene**
increas inhibitor posit protein receptor
resist select specif studi test
tumour

4301: Quinolinic Acid (5)

anim dai diseas dose effect form format
gener inhibit **level** model neuron
phenotyp plasma process reduc select
serum specif valu

4303: Waxes (7)

acid caus cell differ diseas drosophila
extract **group** mass method
period plai point region role sequenc size
small **time** valu

4298: 12-Hydroxy-5,8,10,14-
eicosatetraenoic Acid (1)

aggreg Cell coloni convers demonstr differenti enzym
exon express form format **function**
gene impair known mutat physiolog prolifer
structur transfect

4300: Carbon-Oxygen Ligases (5)

actiy associ bind children cluster
contain **function** identifi infect method
nucleotid number recombin **region**
resist **sequenc** site specif
structur tumour

4302: Eicosanoic Acids (5)

abil abl acid capac caus
chang combin demonstr
effect evid express femal gener genet
influenc male metabol potenti
properti support

4304: Ethanolamine (3)

abil acid analysi approxim blot capac cell
codon compar demonstr express higher line
major potenti **rate** rel
structur substitut

4305: Streptokinase (3)

group identifi improv incid interact life
men method mortal **patient**
physic popul preval qualiti rate report screen
studi women year

4307: Toxoids (2)

approxim assai assess cell compar
control detect differ individu
major mean measur mice normal rel
score sensit specif **tissu** valu

4309: Fanconi Anemia Complementa-
tion Group G Protein (4)

african american asian **bind** black complex
data defici ethnic evid genet identifi **mutat**
popul preval sampl screen support
test white

4311: Enoyl-(Acyl-Carrier-Protein) Re-
ductase (NADH) (1)

acid activ amino biolog block develop
effect enzym fatti **inhibit** inhibitori novel nucleic
potenti retino studi suppress system **target** therapeut

4306: Carbon-Sulfur Lyases (4)

acid **activ** amino cell coli combin
effect factor growth infect initi mutant

new origin provid reduc reduct second speci

studi

4308: Keto Acids (5)

acid amino approach bodi caus cell
children cluster codon data differenti
effect patient presenc reduc requir
strategi substitut **target** tumour

4310: Organothiophosphorus Com-
pounds (3)

analysi approach dai data decreas differ
distribut **increas** level local
method model network plai predict
resist reveal role studi techniqu

4312: Chloroform (8)

analysi differ effect extract gel genom

group human mass

model popul produc **product**

rat sampl **select** size studi

time treatment

4313: Diterpenes, Clerodane (2)

analys analysi approxim assai compound
deriv detect indic insight major **new**
novel organ possibl provid rel remain reveal
sensit **structur**

4315: Androstenols (1)

anim **bovin** breed calv cattl
correl cow differ evalu index lactat
marker milk **mutat** pig porcin
relationship respect sheep signific

4317: Estrogens, Conjugated (USP) (6)

adult compar control decreas **differ**
extract fraction **group** increas mean
studi subject trial
mutat pattern rat
type valu women year

4319: GTP-Binding Protein Regulators (2)

alter **chang** consist data direct distribut
function high
hypothesi increas level local low observ
provid receptor remain suggest **support**

4314: Cytochromes b5 (6)

chang complex decreas **effect** express
function high identifi increas interact
level low mechan model point reduc screen
structur studi time

4316: Receptor, Parathyroid Hormone, Type 1 (6)

associ **cell** combin decreas effect
evid **express** gene growth
haplotyp **increas** nucleotid
peptid polymorph **receptor**
region sequenc snp support target

4318: Nucleotides, Cyclic (1)

cell
arg chang code codon compound cultur
loop nicotin nucleotid posit pro result sequenc singl
stop substitut suggest synthesi usag

4320: Deoxyribodipyrimidine Photo-Lyase (15)

bind damag differ **dna** express
gene genom **group** mean
number process product regul repair
sequenc **skin** specif **studi**
treatment valu

4321: Ergothioneine (2)

adapt **cell** condit cultur decreas degre dna
effect **increas** induc induct light
observ presenc reduc reduct
respons select skin studi

4323: Hepatocyte Nuclear Factor 3-beta (11)

assess cell dai **differ** effect
evid express factor femal **high**
level low male measur
mice pattern score select
structur support

4325: Receptors, Colony-Stimulating Factor (1)

achiev approach blood clinic design drug improv
limit optim **patient** problem provid
random resist strategi success target therapeut
treatment trial

4327: gamma-Crystallins (6)

analysi approach associ cluster earli electron
famili gene high human
identifi interact low member microscopi
model morpholog mutat **protein** structur

4322: Hepatocyte Nuclear Factor 3-gamma (6)

activ bind children dai distribut
dose essenti **express** famili
gene level local member new promot
protein receptor regul **requir**
transcript

4324: Designer Drugs (3)

approach blood care design drug health
hospit incid mortal mutat novel patient
potenti **resist** strategi studi
target therapeut women year

4326: Styrene (3)

bind carcinogen caus chemic demonstr
effect expos **exposur** find
function lead plai previou
regul remain report role studi suggest
toxic

4328: Aminoisobutyric Acids (2)

acid alter chang compar **control**
decreas differ effect frequenc genotyp higher
human increas multipl observ presenc reduc
reduct signific studi

4329: 1-Methyl-3-isobutylxanthine (6)

activ alpha analysi area case cell
enhanc express inhibit inhibitor isol
method pancreat produc product protein
receptor strain structur vector

4331: Niobium (1)

arrai condit degre detect dna fish fluoresc
fragment function heat
hybrid label oligonucleotid per peptid probe
shock situ techniqu temperatur

4333: Leuprolide (9)

assess children compar control data
differ effect evalu famili higher
increas measur patient pattern rate reduc
score signific studi treatment

4335: 1-Naphthylamine (3)

activ analysi blot cell detect dna
effect express gene genet human induc
inhibit protein resist reveal target telomer
therapeut western

4330: Adenosylmethionine Decarboxylase (4)

activ adult alter cell chang dai dose
earli enhanc event increas mutant patient
process stage subject time tumour week year

4332: Carboxylesterase (12)

activ analysi cell concentr effect encod
enzym famili function gene
genom human identifi member novel protein
reveal sequenc substrat target

4334: Heterocyclic Compounds, 2-Ring (3)

activ approach base complex differ distribut

effect inhibit inhibitor invas level local

normal observ pair rice serum strategi

suppress tissu

4336: Thiadiazines (1)

analys cancer clinic compar control differ divid form
group inject malign ovarian protein rat
signific stabil studi therapi treatment tumour

4337: Sinalide (2)

alter chang concentr condit decreas degre
express function **human**
increas level membran microg microm min observ
plasma radiat receptor resist

4339: Oxotremorine (3)

affect caus chines compar **control**
differ enhanc frequenc
function heterogen increas
inhibit lead **mice** mous rat receptor
studi subtyp transgen

4341: Cytochrome b6f Complex (6)

alter **bind chang** combin complex
decreas effect energi **increas**
kinet mechan mitochondri model mutant
site **state** structur studi switch transit

4343: Chaperonins (17)

analysi associ complex correl detect
effect express function gene
gener genom **human**
method product protein rate
respons specif stabil target

4338: Receptor, Muscarinic M4 (1)

absenc **activ** alpha antagonist beta critic
essenti head indic lack ligand **mice** mous necessari
neck presenc **receptor** requir suffici
transgen

4340: Trypsin Inhibitors (8)

chang combin **control** data develop
function gene high mice normal pancreat
patient posit protein respons
secret structur studi tissu treatment

4342: Procarbazine (13)

clinic compar group higher improv lymphoma
median month number **patient**
rate select studi therapi time Tissu treat
treatment valu year

4344: Factor XIII (13)

activ associ bleed chang coagul express
factor famili folat homocystein
mthfr platelet process rat ratio rel **risk** studi
thrombosi venou

4345: Spironolactone (7)

cell chang children combin effect enhanc famili
gene larg mutat **patient** protein
receptor remain size small studi treat
treatment trial

4347: DNA Nucleotidylexotransferase (9)

activ apoptosi **cell** death develop
differenti **dna** express famili gene
genom **group** identifi interact prolifer
replc report sequenc studi test

4349: RNA, Transfer, Pro (3)

arg code **codon** decreas
increas interact mrna nicotin
nucleotid posit residu result sequenc
singl site stop **substitut** suggest
translat usag

4351: Contraceptives, Oral, Synthetic (3)

alter cell chang compar control dai dose effect
expos exposur frequenc increas oral patient plai
role signific suggest treat treatment

4346: Iron Isotopes (2)

blood bodi determin elev higher iron junction
level mass mean measur mutat
peripher **phenotyp** plasma radiat ratio
respect serum valu

4348: Tryptophanase (1)

code codon critic dna essenti gene induc induct
methyl nucleotid peptid plai promot requir
respond **respons** role substitut
suggest translat

4350: Alpha-Globulins (6)

activ analysi **associ** bind cluster
control detect earli enhanc **function**
gene identifi marker method mice mutat
protein rang remain site

4352: Norpregnenes (3)

associ clinic compar concentr decreas
effect group
increas level mean protein ratio
reduc reduct respect studi therapi
treatment trial valu

4353: Blood Coagulation Factor Inhibitors (4)

cluster compar concentr control differ factor famili
group identifi level member mutat
patient phenotyp product protein respect screen
signific subject

4355: Coproporphyrinogen Oxidase (3)

activ alter anim **chang** domain enhanc
enzym factor increas induc inhibit marker
model peptid produc
product respons risk
specif studi

4357: Cholestenone 5 alpha-Reductase (4)

alter **cancer** cell **chang**
effect express femal **gene**
level male method normal plai
prostat rat reduc regul **role** tissu
treatment

4359: Polynucleotide Adenylyltransferase (8)

chain compar **control** evid **express**
frequenc **gene** genet mrna mutat
new pcr polymeras **protein** provid reaction
repeat rna system translat

4354: Histidine Ammonia-Lyase (1)

alter candid chain chromosom delet detect essenti
gene identifi identifi loss mutat
novel pcr polymeras reaction region requir
screen sequenc

4356: Coproporphyrins (3)

adult **case** clinic criteria data
diagnos **diagnosi** diagnost estim inhibit
method patient present rare report sever skin
symptom year young

4358: Steroid 12-alpha-Hydroxylase (3)

activ addit alter approxim case
chang **combin** compar effect
express increas liver major mean mice mutant
receptor regul rel valu

4360: Coenzyme A-Transferases (2)

case **cell** clinic defici **diagnosi** diagnost
express find gene insight
mechan molecular mutat **new**
previou promot provid report studi
transcript

4361: Acyl-CoA Dehydrogenases (2)

acid amino cardiac compar comparison
defect defici differ effect enzym fatti gene
heart muscl mutat pattern similar treat
treatment type

4363: Dipeptidyl Peptidase I (9)

activ analysi develop diseas
earli function gene identifi includ larg
mutat normal number patient
phenotyp reveal risk sampl stage tissu

4365: Pentanoic Acids (4)

acid assai children combin concentr dai

detect effect enzym follow increas

method mutant produc product rat risk

sensit treat treatment

4367: Dolichol (3)

activ associ chang compar detect differ
femal genet group high level low
male normal pattern phenotyp sensit signific
test tissu

4362: Electron-Transferring Flavoproteins (3)

associ concentr dai defect defici enzym
factor form format includ induc patient
rang ratio respons risk sever
state test wide

4364: Ketone Oxidoreductases (2)

assai clinic complex detect
diagnosi diagnost enzym isol mechan method
molecular mutant region resist sensit
sequenc specif strain test underli

4366: 3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide) (1)

assai clinic compar complex control
detect determin diagnosi diagnost
evalu express extract healthi method monitor
sensit specif studi subject test

4368: Proto-Oncogene Proteins c-fyn (12)

activ associ cell control develop
express famili form format increas
inhibit kinas mechan member process
protein rat signal tissu tyrosin

4369: Oxalic Acid (3)

acid approxim compar concentr
express genom growth known
major mean minor mutant observ plant
rel requir respect sequenc suggest valu

4371: Glucan 1,3-beta-Glucosidase (6)

correl develop express **gene**
group identifi increas model mutat
patient region rel repeat respons
screen sequenc site speci treatment
variabl

4373: Acetyldigoxins (1)

atrial **cardiac** cardiomyocyt
cardiomyopathi condit dilat epilepsi failur gener
heart hypertrophi left respons right
seizur **stress** studi suicid valv ventricular

4375: Complement C5 (4)

chang **complex** compon
decreas effect evid famili gene
genet increas level method
mutat plai reduc region role sequenc serum
specif

4370: Phosphorus, Dietary (2)

adapt bodi bone chicken diet differ imprint
individu initi japanes men
mortal origin preval second **select** weight
women year

4372: Thymol (3)

activ affect concentr data determin
diseas dna effect extract **human** level microg
microm min plasma rat respect serum studi trial

4374: Disopyramide (1)

cardiac cardiomyocyt cardiomyopathi
clinic condit **diseas** epilepsi failur
gener **heart** includ left patient
respons seizur sever **stress** suicid
symptom ventricular

4376: Diiodotyrosine (1)

abnorm anomali **chromosom**
compound congenit depress deriv diseas
disord effect incorpor increas nitric oxid
reduc retin studi **syndrom**
synthas synthesi

4377: Iodoproteins (1)

abnorm adhd anxieti associ behavior bipolar
chromosom defici depress **disord**
person psychiatr serotonin sleep studi symptom
syndrom synthas synthesi thyroid

4379: Porphyrinogens (1)

activ affect complex critic enzym
essenti event function initi involv necessari
occur **PROCESS** requir
residu schizophrenia site step studi substrat

4381: Uroporphyrinogens (2)

activ densiti **diseas** dynam enzym
find **gene high** level low model
patient previour report residu sever site studi
substrat suggest

4383: Dicloxacillin (1)

allel **correl** evalu genotyp grade
higher index mean measur paramet polymorph
posit ratio relat relationship **resist** respect
signific studi valu

4378: Calcium Radioisotopes (3)

case cell children clinic condit
degre diagnosi growth incid period point present
random rare report studi time trial women
year

4380: Hexachlorobenzene (2)

analys **analysi** compar concentr
control differ enzym form
format frequenc higher indic **level**
lower plasma **rate** reveal serum state
studi

4382: Adenovirus Early Proteins (1)

abil abl capac current demonstr discuss displai
exhibit **function** induc induct
potenti promot properti **protein** recent research
respond **respons** understand

4384: Zeolites (5)

combin compar concentr determin effect
electron energi form format **group**
higher level morpholog **number** observ
rate region sequenc specif time

4385: Receptors, Mitogen (7)

area cell compar control
differ famili frequenc function high
increas level low mice patient process
protein region regul rel studi

4387: Thiamine Pyrophosphate (1)

blood chronic compar defect defici densiti diseas

elev high higher inflammatori intestin
level low lower normal peripher
plasma serum tissu

4389: Haptoglobins (14)

analysi base defici differ
famili gel gene group human identifi
increas level mass mice
patient phenotyp popul
protein sampl studi

4391: Naphthalenesulfonates (4)

affect analysi chain concentr detect
differ effect electrophoresi gel
identif identifi laser light mass
proteom reaction reduc spectrometri
spot structur

4386: Pyridoxal Phosphate (9)

activ associ detect
enzym gene high imag mean
measur mutat ratio respons
risk sampl select stress studi
time treatment valu

4388: Calcium Carbonate (10)

chang data determin differ
distribut elegan high individu low
multipl pattern product random sea
season signific speci studi
trial variabl

4390: 6-Phytase (4)

activ bodi concentr diet
differ effect form
individu pattern plai presenc properti
protein reduc reduct role stabil suggest
valu weight

4392: alpha-Crystallin A Chain (2)

affect analysi associ blot condit decreas
degre examin express function hospit implant
increas interact level protein
studi suggest transcript western

4393: Focal Adhesion Kinase 2 (5)

activ analys analysi compar control frequenc
function gener human identifi
interact mechan mice molecular
mutant number presenc protein reveal target

4395: Cerebroside-Sulfatase (9)

base case clinic combin cord diagnosi
earli **injury** mutat nerv new
normal patient phenotyp popul report
spinal studi tissu wound

4397: Neurotensin (3)

abil case cell combin demonstr
differ effect enhanc fusion high
increas level low model
number pattern potenti
properti risk test

4399: Reducing Agents (2)

abil analysi capac classif cluster compound
domain evolut **famili** form identifi
member potenti properti **protein**
residu set site stabil structur

4394: Pulmonary Surfactant-Associated Protein C (12)

acid analysi **ASSOCI** cancer caus
cell diseas express gene genet **lung**
mice model mutat new produc product
protein role studi

4396: Nuclear Cap-Binding Protein Complex (2)

altern approach assembl **complex**
compon essenti exon form function inhibit
interact involv mechan molecular
protein requir splice strategi subunit variant

4398: Cathepsin E (3)

adapt analysi approach bladder cell cluster
develop development differenti
express gene mice patient prolifer select
structur surviv target treatment tumor

4400: Keratolytic Agents (4)

approxim children clinic compar data
decreas diagnosi distribut estim featur
includ **increas** local major
method **number** observ rel
risk skin

4401: Receptor, Angiotensin, Type 2 (12)

activ analysi arteri associ decreas detect
express **gene** genom high increas
level mechan process rat **receptor** regul
sampl studi treatment

4403: Amaryllidaceae Alkaloids (3)

apoptosi **cell** compar complement
cancer

compound develop earli individu late **normal**

phase progress prostat recent specif stage target

therapi **tissu**

4405: Silicon Compounds (6)

activ analysi assess **differ** extract
intens laser **light** measur mechan
method model morpholog observ pattern
protein regul rel reveal studi

4407: Affinity Labels (14)

analysi **bind** cell complex differ effect
genom human identifi **interact** mass
model mutat product **protein**
resist select sequenc time tissu

4402: MafB Transcription Factor (4)

cell compar **control** dai
develop differ differenti frequenc gene high
interact level low pancreat plai produc product
prolifer role select

4404: Air Pollutants, Radioactive (24)

air **area** concentr contamin

copper data develop dose estim genet

irradi measur metal method radiat

select soil sourc valu **water**

4406: T Cell Transcription Factor 1 (3)

analys **analysi** bind cell data
databas indic **interact** melanoma mice
pathwai perform presenc reveal rna signal
speci **structur** surviv transcript

4408: Polycyclic Compounds (10)

cell data **develop** effect
form format metabol **method**
mice model **number** rate reduc
requir resist **respons** risk structur
studi treatment

4409: Dihydropyridines (5)

analys analysi assai cell compound detect
determin drug extract gener interact method
new provid receptor **resist** reveal
sensit specif system

4411: Butyryl-CoA Dehydrogenase (3)

acid amino associ combin
differ diseas effect enzym **group**
human identif identifi mutat
novel point screen signific studi test time

4413: Hirudins (4)

activ compar demonstr differ earli
effect enhanc form format higher
mean model rate reduc respect specif
stage subject test valu

4415: Plakins (1)

activ control diseas effect function induc induct
inhibit interact involv mechan modul protein
regul regulatori respond **respons**
role suppress transcript

4410: Phytanic Acid (4)

acid adult amino associ cancer enzym
factor fatti genet level mean nucleic ratio retino risk
serum studi transplant valu year

4412: Adenylosuccinate Lyase (1)

activ avail data databas design enzym extract
inform mechan molecular patient produc
product **studi**
provid sever sourc
tool underli yield

4414: Gossypol (3)

apoptosi assess cancer cell
evalu includ mean **measur**
mice predict rang regress resist score
target valu variabl vitro
vivo wide

4416: Tars (3)

adjust associ case compar confid cost
decreas increas interact interv level
manag medic model odd **ratio**
risk smoke studi valu

4417: Receptor, Serotonin, 5-HT2C (13)

affect allel analysi associ
control effect examin function gene genotyp
polymorph receptor report respons sampl
schizophrenia select signific studi suggest

4419: Ketone Bodies (4)

acid approxim caus clinic design diagnosi
gene growth hospit lead life major month
patient qualiti rat rel sever
studi year

4421: Carboxy-Lyases (8)

analysi anim develop differ dna
express famili **gene** genom
hybrid methyl **model** produc product
protein rat respons select studi variabl

4423: Natriuretic Peptide, C-Type (3)

compar differ diseas **express** factor
gene growth higher level lower
organ pattern peptid phenotyp plai rat rate
role serum similar

4418: Receptors, Laminin (7)

adhes analysi case **cell** famili genet
group includ inhibit member mice molecul
plai region reveal role sequenc
studi time tumor

4420: Bone Substitutes (14)

analysi **bone** compar control earli
format **group** high level new osteoblast
patient plai rate role sampl stage studi
treatment vitamin

4422: Agrin (2)

anim cell differenti distribut experiment
famili form gener genet inherit
local model muscl prolifer
protein releas stabil stimul studi suggest

4424: Fibroblast Growth Factor 4 (2)

analysi assai bind cell cluster degre
detect differenti effect form format mean
presenc **rat** recombin **sampl**
sensit treat **treatment** valu

4425: Polymyxin B (2)

caus concentr differ enzym experi extract factor
follow **group** growth initi intern laser
lead light origin **protein** red respect second

4427: FMN Reductase (3)

chain cluster concentr differ express
gene health larg larger level membran
mitochondri **number** reaction
regul serum set **size** small yeast

4429: 1-Phosphatidylinositol 4-Kinase (7)

activ bind caus **develop**
enhanc form format **function**
interact lead mice mutant pathwai
presenc protein requir signal subject
target tumor

4431: Tissue Adhesives (6)

cell complic concentr distribut level local
month oper **patient** perform
postop procedur rel resect serum surgeri surgic
time underw year

4426: Agmatine (2)

activ adapt cell concentr differenti
effect inhibit mean measur prolifer
ratio receptor reduc reduct respect
select tumour valu vitro vivo

4428: 2-Aminoadipic Acid (2)

acid aggreg alter chang clinic compar control
diagnosi differ diseas form format
group healthi observ protein signific
state studi subject

4430: Bone Cements (9)

bone caus combin data dna **effect**
human method model new
normal **patient** provid rang reduc reduct
rel studi tissu vitamin

4432: Enbucrilate (2)

anim **correl** develop experiment method
model month new patient
period point provid relationship signific state
studi techniqu **time** vitro vivo

4433: Receptors, Neurotensin (2)

abil adult anim approxim **effect** high
inhibit level low major model potenti
proporti **protein** receptor reduc
rel stimul studi year

4435: Silicone Oils (5)

assess case **correl** form format
health **high** larg level low
measur new popul rat resist retin
score size small **treatment**

4437: 1-Acylglycerol-3-Phosphate O-Acyltransferase (3)

activ analysi classific cluster diabet dna
drug interact involv mechan molecular month
mutant patient **resist** skin state underli understand
understood

4439: Aldehyde Oxidase (1)

absenc addit caus concentr data determin
enzym head indic investig lead microm min
modifi neck observ plant **presenc**
studi suggest

4434: Digitonin (4)

base bind cell critic differenti essenti genom
hybrid inhibit mainten necessari neg pair
posit receptor **requir** resist
structur suffici **treatment**

4436: Shaker Superfamily of Potassium Channels (6)

ca2+ calcium channel compar comparison current
differ express follow increas level
model mutant **pattern** regul similar specif
structur type valu

4438: Dimethylhydrazines (7)

activ administr anim cancer colon colorect compar
control dai decreas **effect** experiment increas induc
inject **rat** reduc risk treat week

4440: Pteridines (8)

absenc activ **analysi** chang clinic
develop diagnosi **enzym**
level method mutant **mutat**
phenotyp **presenc** regul role studi
substrat suggest time

4441: 8,11,14-Eicosatrienoic Acid (4)

acid analysi blot carcinoma **cell** channel
combin effect enhanc express human
increas inhibitor mechan **metabol**
metabolit molecular system tumor western

4443: 7-Alkoxy coumarin O-Dealkylase (2)

acid adapt alter analysi assai blot caus cell
chang decreas detect express form
format gene increas inhibit lead **select**
sensit

4445: Heterocyclic Compounds, 3-Ring (6)

base compar compound control differ
enhanc identifi initi interact mean
new normal rat
receptor **requir** screen
subject **tissu**
treatment valu

4447: Palmitoyl-CoA Hydrolase (5)

acid activ alter amino analysi
chang effect enzym express **gene**
mechan molecular mutat rat reduc regul
repeat reveal site structur

4442: Riluzole (2)

anim clinic depress **develop** differ
diseas disord experiment larg mechan model
molecular number **patient** random
size small studi target trial

4444: Acenaphthenes (1)

compound contain core cultur data design encod
frame identifi includ investig kidnei novel **open** pool
put read receptor renal **studi**

4446: Xylans (6)

analysi classif **cluster** data differ
famili genom identifi increas isol
local member new profil reveal **sampl** set
strain structur test

4448: Cytidine Diphosphate (1)

biolog carbon compound determin develop
electron energi free includ **interact**
involv measur protein pten receptor sle solut
spectroscopi studi **system**

4449: Thiocyanates (10)

activ apoptosi **cell** chang combin
concentr cytotox decreas effect express gener
human increas induc inhibit requir risk
specif studi test

4451: Antivenins (3)

abil acid **activ** adapt antibodi complex
CONSERV demonstr mammalian mice mous natur
proporti rang recombin report select studi suggest
test

4453: Adaptor Protein Complex 2 (3)

activ cell complet delet demonstr dna factor
form format fusion growth neuron
partial plai promot rat **role**
suggest treat **treatment**

4455: Iron-Regulatory Proteins (6)

activ **children** control delai
follow gene genet healthi increas model
mutat number parent persist product
protein remain studi **subject**
treatment

4450: Desmocollins (1)

affect alter cell **chang** decreas
element epitheli gastric increas insert integr
mice MOUS murin observ pathwai signal
signific transgen wild-typ

4452: Monensin (5)

caus cell concentr earli effect enhanc
high inhibit **level** low new
popul process rat repeat site stage
studi time treatment

4454: Tunicamycin (11)

activ analysi **cell** effect
enhanc famili function gene
group high increas indic level
product rel requir **resist** sampl site
suggest

4456: Hexoses (4)

adult assess blood **case** combin
compar effect higher measur **method**
mice model patient peptid **rate**
report score studi **subject** year

4457: Cuprizone (1)

anim control cord develop distribut effect
experiment fluid induc inhibitor inject injuri
local model ^{nerv} rat
spinal studi suggest wound

4459: Virulence Factors, Bordetella (1)

apoptosi cell cellular chronic coli control diseas
function inflammatori intestin involv mechan
mice modul mous regul regulatori
role transgen wild-typ

4461: Phosphorus-Oxygen Lyases (3)

abil acid base case dai data
distribut dna dose enhanc
enzym estim identifi local new
pair plai role screen valu

4463: Eicosanoids (10)

activ cell cox-2 effect enhanc famili
featur gener genet human inhibit
inhibitor mechan member model plai
requir respons role studi

4458: Pertussis Vaccine (2)

adult chronic diseas earli effect
factor inhibit intestin late mice older phase
prevent protect reduc reduct risk stage year
young

4460: Potassium Channels, Tandem Pore Domain (5)

analysi cell channel distribut effect enhanc
express gene human inhibit
interact local mechan method model
mutat reduc regul requir studi

4462: Renal Agents (5)

children clinic compar
concentr control
develop differ
distribut kidnei local mutant parent
patient pattern product rat renal
repeat therapi year

4464: Iodoacetamide (2)

analysi approach compound electrophoresi gel identif
identifi MASS metabol nuclear oxid oxygen
protein proteom residu site
spectrometri spot stress technolog

4465: Smallpox Vaccine (7)

clinic effect **gene** genom
human immun individu
infect **isol** mice process reduc
respons specif strain therapi
treatment trial vaccin viru

4467: Plakophilins (4)

differ distribut earli **famili** gene
human includ life local member
model mutat new organ pattern rang stage
structur target wide

4469: Iopamidol (4)

assess brain compar correl differ evalu
group **imag** individu life
magnet mean measur normal qualiti studi
tissu tumor valu volum

4471: Benzodioxoles (4)

alter anim assess caus chang combin effect
enhanc evalu experiment exposur increas
measur **model** potenti produc product score
studi system

4466: Azure Stains (13)

abnorm area blood chang
chromosom compar
concentr control correl differ effect **group**
human mean method **patient** signific
studi treatment valu

4468: Pancreatic Elastase (13)

cell compar develop differ effect
enhanc increas induc month normal number
pancreat **patient** protein rat rate reduc
respons tissu tumour

4470: Ochratoxins (5)

combin dai detect dose effect function
genom identifi improv increas life
mechan method **number** popul
process qualiti screen studi treatment

4472: Technetium Tc 99m Sulfur Colloid (2)

chain compar data determin differ estim mean
measur method neg normal
patient posit predict ratio
reaction respect tissu valu variabl

4473: Epoetin Alfa (11)

administr anemia associ **dai** defect
defici dose effect follow high
human level low patient rate reduc
select time treatment week

4475: Hydrogensulfite Reductase (2)

conserv discuss **enzym**
examin extent find function human
indic mammalian mous observ recent
rrna sequenc similar **speci**
structur suggest survivin

4477: Citalopram (10)

adult assess **ASSOCI** behavior bipolar children
depress **disord** high measur organ
patient person process **sampl** score studi
symptom tissu year

4479: Nitrosourea Compounds (3)

cancer compar **control** differ
dna **express** frequenc gene higher
interact lower methyl **number**
patient **primari** **rate** studi subtyp
system tumor

4474: Transferases (Other Substituted Phosphate Groups) (7)

activ case **combin** effect enzym form
format **gene** identifi mutat
patient phenotyp protein receptor
recombin region screen select sequenc time

4476: Sertraline (4)

associ children clinic concentr dai data disord
enzym interv **patient** period point
ratio respons risk select state **studi**
time vivo

4478: Nimustine (6)

cell distribut drug effect **express**
gene **group** local methyl new
patient **primari** requir studi surviv
target **treatment** trial tumor valu

4480: Ketolides (4)

adult analysi compar degre distribut drug
effect genet higher infect level local lower
mutat phenotyp **rate** **resist**
reveal versu year

4481: Camphor 5-Monooxygenase (1)

activ aggreg **associ** enzym essenti
form format indic link metabol methyl mutant
mutat necessari relat **requir** studi suffici suggest
wild-typ

4482: Camphor (2)

absenc care content cost evolut flow
form format guidelin hospit indic
interact manag medic
mutant neg posit practic
presenc **requir**

4483: Lithium Compounds (6)

alter approach **chang** composi
differ discuss dose irradi laser
light observ pattern produc
product radiat recent red size studi
valu

4484: Maltose (4)

alter bind **chang** **differ** duplic evolut induc
induct interact mechan mutant pattern
presenc produc **product** region regul
respons sequenc structur

4485: Organ Preservation Solutions (6)

approxim **associ** combin compar condit
degre **develop** effect heat
increas major method normal observ
protein rel sampl temperatur time **tissu**

4486: Munc18 Proteins (5)

bind complex decreas **differ** earli gene
increas interact mechan **mice** model
mous mutant pattern phenotyp
protein recombin **requir** stage
wild-typ

4487: Tissue Kallikreins (7)

altern cancer compar control correl earli exon express
famili gene **human** identifi isoform
normal rat role splice subject tissu variant

4488: Polonium (4)

analysi behavior cognit compar data
distribut estim higher local lower model neg
number perform posit **rate** rel
studi time valu

4489: Glycogen Debranching Enzyme System (5)

activ control data differ
function gene gener incid
interact men mortal popul preval
process product protein risk subtyp
women year

4491: Oncogene Protein p55(v-myc) (2)

abil abl capac cell demonstr discuss domain
essenti exhibit mutant mutat
overexpress potenti properti recent
requir structur suffici transform
wild-typ

4493: Receptor, IGF Type 2 (7)

cell express function gene
genet identif identifi incid individu
mechan mutat novel process produc
product role screen size
treatment women

4495: Benzophenones (6)

activ cell compar control detect
determin famili flow form function
gene group level mechan
model molecular process specif studi
subject

4490: Mercaptoethanol (3)

activ caus combin effect
environment enzym evid
factor genet influenc lead
model provid studi substrat
support test trait twin variat

4492: Glucan 1,4-alpha-Glucosidase (7)

accumul affect alter associ bind
case chang differ diseas
effect express gene group high
low mice model mous site specif

4494: Receptors, Pheromone (11)

chang diverg duplic evolut
evolutionari express femal form gene
larg male model origin
receptor respons role
size small specif suggest

4496: Insect Repellents (5)

activ assai care concentr detect
drosophila inform insect manag
medic particip period person physician
point popul practic sensit studi
time

4497: DEET (3)

activ anim clinic develop diagnosi differ
drosophila effect exposur extract fraction
heterogen hybrid includ inhibit method
model open **studi** subtyp

4499: Proto-Oncogene Proteins c-maf
(5)

analysi bind evid express **gene**
model network predict **promot** provid
region regul report requir sequenc specif
studi support system transcript

4501: Aquaporin 3 (4)

analysi blot cell differ distribut epitheli express
famili **function** gene human
local member membran mice mous pattern rat skin
test

4503: Bisoprolol (2)

allele channel **effect** genotyp induc
induct initi origin polymorph prevent protect rat
receptor reduc reduct regress **respons** second
signific variabl

4498: Psoralens (5)

abil **activ** effect ENZYME event gene
human inhibit involv kinet light
metabol point process properti protein
reaction state substrat **time**

4500: Carbonic Anhydrase II (4)

adapt case cell data direct evid evolut induc
induct inhibit mechan molecular mutat new
number provid renal **respons**
select support

4502: Nitroglycerin (6)

analysi blot correl detect **effect**
follow initi level model normal patient
ratio reduc risk test therapi tissu
treatment trial western

4504: Nucleoside Transport Proteins
(5)

activ analysi cluster
compound data distribut enhanc estim level
local mechan phenotyp report reveal
sampl site studi suggest test time

4505: Medical Waste Disposal (3)

avail care cost current decis
develop effect form format gener
guidelin manag medic method organ practic
process recommend reduc strategi

4507: Astemizole (1)

assess **correl** evalu identif
identifi includ index malign
measur multipl novel potenti relationship
scale score **screen** signific target
tumour valid

4509: Fructose-Bisphosphate Aldolase (6)

analysi cell children **develop** differ
differenti enzym express famili
function genom light pattern
popul process prolifer reveal **structur**
studi target

4511: Gonanes (1)

affin aggreg **bind** bound cell complex
famili form format indic interact intermedi
kinet member protein site specif state switch
transit

4506: Butyrophenones (1)

acid african altern american amino enzym
ethnic exon identif **identifi** isoform metabol
novel **plai** popul recombin **role**
screen splice variant

4508: Acenocoumarol (5)

allele associ clinic dai diagnosi differ genet
genotyp **group** metabol
patient polymorph ratio
requir **risk** studi test treatment valu
variabl

4510: Promegestone (2)

absenc cancer **cell** cycl epitheli
examin express head indic line observ
presenc primari promot **receptor**
studi suggest transcript vitro vivo

4512: Daptomycin (3)

administr **associ** base
combin concentr dai dose
effect isol muscul observ organ pair patient
possibl remain strain studi test week

4513: Albuterol (9)

analysi assai data decreas detect genet
increas interact level method
plai popul process receptor
respons role sensit
subject suggest variabl

4515: Stilbamidines (3)

densiti differ distribut effect evid
group high level light
local low neuron posit potenti provid
releas specif stimul suggest support

4517: Gelsolin (11)

cancer cell clinic diagnosi express
famili form format gene genet high
interact level low member patient protein
sampl subject tumor

4519: Leucyl Aminopeptidase (3)

approach compar data enzym evid extract gene
higher isol new peptid period plant point
provid rate respons strain support

time

4514: Synaptotagmin I (5)

acid alter analysi cell chang
cluster data differ evid new
pattern provid region repeat
sequenc specif structur
support tumour variabl

4516: Terfenadine (2)

area associ compar control differ gene
genotyp healthi mean measur polymorph
predict ratio resist respect studi subject
treat treatment valu

4518: Technetium Tc 99m Pentetate (2)

case caus clinic confirm demonstr diagnos
diagnosi diagnost diseas failur find kidnei lead
present previour rare renal report studi
suggest

4520: Cycloheptanes (2)

assai chang correl detect differ
distribut effect gener length life local long
method pattern reduc repeat resist
sensit short signific

4521: Scavenger Receptors, Class F (1)

analysi cataract cdna cell class clone defect
express **gene** glaucoma implant
len microarra **mutant** mutat
profil sequenc transfect translat wild-typ

4523: Amodiaquine (5)

allel area combin dai detect dose effect genotyp
local new **patient** polymorph
provid **resist** sensit structur studi test
treatment tumour

4525: Polymethacrylic Acids (7)

blue captur color complex composit concentr
correl differ effect increas intens laser
light observ rate red role shed studi
treatment

4527: cdc42 GTP-Binding Protein,
Saccharomyces cerevisiae (4)

actin bind cell complex domain **famili**
function growth identifi member migrat
modul **phenotyp** protein **regul**
regulatori requir role screen signal

4522: Fanconi Anemia Complementa-
tion Group F Protein (1)

brca1 broad carrier damag defici divers dna
factor includ major multipl muscl
rang repair **risk** singl spectrum type
varieti wide

4524: Carbonates (7)

analys **analysi** data group
human impact improv includ life new
number perform physic **qualiti** rang
reveal sampl select speci **studi**

4526: Carbon Compounds, Inorganic
(2)

blue captur color composit dai differ effect
extract follow intens laser **light** observ
presenc red shed studi time treat treatment

4528: Thymus Hormones (2)

adult environment evid express factor gene
genet **human** influenc mechan
molecular presenc provid support telomer
telomeras tumor variabl variat year

4529: RNA, Spliced Leader (7)

altern **differ** exon form

genom **group** identifi

intron isoform melanoma mutant new

pattern process protein region **rna**

sequenc splice

variant

4531: Biomedical and Dental Materials
(2)

activ avail biolog chain condit content data
databas degre determin enzym flow per **plai**

reaction **role** stabil substrat system
target

4533: Leukotriene Antagonists (4)

analysi caus clinic decreas effect form format

genet increas induc induct measur

respons reveal score specif studi

therapi treat **treatment**

4535: Bombesin (9)

alpha associ beta cancer cell effect express
growth ligand mechan model molecular new

prostat protein **receptor**
respons target treatment tumor

4530: Eukaryotic Initiation Factor-4A
(4)

area bind complex concentr **control** densiti
dna domain famili growth **high** level

low member new **protein** remain
report studi tumor

4532: Polyvinyls (5)

adult **analysi** chain decreas

delai dna follow **gener** increas

mass method persist **popul** posit rat
reaction receptor reveal **sampl** year

4534: Methylprednisolone Hemisuccinate (2)

analys **analysi** chain clinic combin compar
decreas effect **increas** level loss

patient perform rat reaction
reveal studi system therapi treatment

4536: Guanine Nucleotide-Releasing
Factor 2 (1)

activ assembl **complex** compon
control function leukemia mechan melanoma

metabol **mice** modul mous promot
regul regulatori rna role subunit
transgen

4537: Uridine Diphosphate Glucose Dehydrogenase (3)

absenc activ assai combin detect differ
effect enzym gener head human
mechan mice mutat pattern popul
presenc respons sensit studi

4539: Quinolinium Compounds (5)

activ analysi base bind cell
complex concentr decreas dna express
human increas initi line pair produc
product requir resist valu

4541: Cyclin-Dependent Kinase Inhibitor p19 (5)

activ analys analysi base cell
cluster concentr control differ differenti
express gene identifi interact popul profil
prolifer protein reveal target

4543: Rutin (2)

anim approach bind bodi chines compound
deriv differ effect inject larg light number
rat size small strategi studi subtyp
weight

4538: Methoxsalen (5)

control differ gene group human
level mechan method pathwai
patient promot rat report
respons select signal skin structur studi
treatment

4540: Proton-Phosphate Symporters (2)

activ analys analysi compar
control data differ domain follow
frequenc gene imag larg membran number
perform reveal size small stimul

4542: Gastrin-Releasing Peptide (6)

alpha alter beta chang combin decreas effect
gener growth human increas level ligand new
receptor reduc subject
treatment vitro vivo

4544: Acetylgalactosamine (2)

adapt breast cancer cell densiti follow
high individu level line low
malign persist resist select studi
test tumour vitro vivo

4545: Factor XII (2)

assai base clinic copi dai delet detect diagnosi
form format genotyp mutat **number** pair
patient protein resist sensit
surviv test

4547: Vanadates (14)

alter analysi blot cell chang compar

dai decreas detect differ effect high

increas level normal

observ patient protein reduc **tissu**

4549: Host Cell Factor C1 (2)

base cell core differenti earli encod **gene**
inhibit late marker muscl open pair phase progress
prolifer regul stage transcript tumor

4551: Emollients (2)

articl author avail dai data decreas definit
gener includ **increas** inform literatur
patient publish report review
search structur systemat target

4546: Vanadium (3)

approxim assess dai **develop**
dna **effect** exposur interact major
marker measur observ **rat** reduc rel report
score studi suggest system

4548: Diphtheria Toxoid (2)

adapt adult approxim compar **effect** femal
function individu major
male normal reduc reduct rel **select**
speci studi **tissu** trial year

4550: GA-Binding Protein Transcription Factor (4)

anim **cell** combin complex
differenti domain effect
express gene induc mice
model multipl prolifer promot receptor
regul **respons** structur
transcript

4552: Gene Products, vpu (1)

acid amino cell confirm consist demonstr
drosophila find her-2 her2 indic kinas neg neu
posit previou report studi
suggest surfac

4553: PolI Transcription Initiation
Complex Proteins (7)

complex earli evid **express** factor
growth mechan new protein provid
region **regul** regulatori repeat rna
sequenc state structur
transcript variabl

4555: 2-Naphthylamine (5)

acid **activ** alter base chang code
codon compound concentr dna estim method
organ region report sequenc stabil structur
studi substitut

4557: Sulfadimethoxine (1)

care conserv copi delai **effect** follow
increas inform inhibitor larg long-term
number particip persist prevent protect
recoveri reduc reduct total

4559: Norepinephrine Plasma Mem-
brane Transport Proteins (10)

affect associ bipolar chang depress
disord enhanc **gene** identifi
increas mutat number person polymorph
popul psychiatr rate screen **studi** symptom

4554: Cycloserine (1)

assai compound data **detect**
direct domain **evid** fusion hypothesi
mutant mutat partial provid residu
sensit site specif suggest
support wild-typ

4556: Exodeoxyribonuclease V (8)

activ bind coli dna escherichia evid
famili form format function
identifi member mutant number product
provid rate respons screen support

4558: Receptors, Purinergic (2)

avail **cell** damag data databas dna earli
late line nuclear phase potenti progress
receptor releas repair signal stage stimul
tumour

4560: Ribosemonophosphates (1)

behavior chang cognit conserv damag
dna gene homolog intermedi kinet learn
mammalian memori **mutat** plasmid
recombin repair state switch transit

4561: Betahistine (1)

adapt clinic design diagnosi earli
hospit late main mean objective patient
phase ratio **select** stage studi surviv
treat **treatment** valu

4563: Alcohol Deterrents (5)

alcohol dai decreas depend effect gener
group health increas month mutat oral
patient phenotyp rat select
studi treatment tumour year

4565: Abortifacient Agents, Steroidal (1)

administr care cost **dai** data dose
estim guidelin hour incid manag medic men
method mortal practic preval week women
year

4567: Receptors, Dopamine D3 (7)

affect allel alter associ chang differ evid
famili gene genet genotyp **group**
neg polymorph posit receptor schizoprenia
signific studi suggest

4562: Homocystine (1)

articl brain cataract current discuss effect ethic
follow glaucoma implant improv issu len recent
research studi therapi treat
treatment understand

4564: Enzyme Activators (12)

activ analysi bind cell dai dose enzym
function identifi increas induc induct level mice
patient phenotyp protein **respons** role treatment

4566: Hypertonic Solutions (3)

cell concentr condit decreas degre evolut gene
genet imag **increas** level modul
popul regul regulatori resist seizur stimul stress
volum

4568: Endothelin-3 (4)

chromosom copi decreas **develop** domain
factor growth increas initi larg mice mutant
mutat **number** point produc
product signal system time

4569: Amino Acids, Diamino (2)

activ anim associ caus death develop
dose enzym establish experiment human irradi lead
model muscul mutant provid radiat
studi suggest

4571: Chickenpox Vaccine (6)

adult cell children elderli immun incid
mean men mortal old older popul preval risk
studi test women year young younger

4573: Glycogen Synthase (5)

acid activ adult amino chain
concentr condit degre enzym gene
human larg reaction region
report sequenc size small studi year

4575: RNA, Messenger, Stored (4)

analysi base cluster differ
distribut femal form format genom local
male mice mutant new pattern plai
protein respons reveal
role

4570: Serine C-Palmitoyltransferase (2)

cell clone continu delai differenti experi
follow function
initi intern long-term origin
persist phenotyp recoveri regul remain
second seri subsequ

4572: Creatine Kinase, Mitochondrial Form (1)

cellular control dimer fold form function
gene involv mechan modul muscul nativ
protein regul regulatori role solubl stabil
stabil structur

4574: Early Growth Response Transcription Factors (1)

continu declin delai enhanc
field follow increas initi long-term
movement occur pathwai persist recoveri
remain signal space spontan sustain time

4576: Organic Cation Transporter 1 (2)

abil bind conserv differ function
highli human mammalian mechan membran
molecular mous pattern potenti promot
proporti releas similar stimul type

4577: Hydroxyzine (1)

adolesc child childhood **children**
dai dose field mutant parent pediater peptid
period **phenotyp** point random studi
time trial week year

4579: Oncogene Protein p21(ras) (13)

activ **cell** detect express gene high
induc level low mutant mutat normal
overexpress protein requir respons specif
tissu transform treatment

4581: 5-alpha-Dihydroprogesterone (2)

approxim bind combin compar effect
express **gene** genet higher imag influenc
lower major **model** mutant **rate**
receptor rel site versu

4583: Poly(A)-Binding Proteins (15)

activ **analysi** bind control famili
function gene identifi initi
interact mrna number
patient protein regul
ribosom rna site **translat** trna

4578: Sulfoxides (2)

determin domain effect exposur extract
fraction human insight **metabol** metabolit
mice **new** peptid produc
product provid rat site vitro
vivo

4580: Galectin 2 (3)

analys **analysi** data function
human indic larg level method peptid
perform protein regul remain reveal size small
studi surviv tumour

4582: Cholic Acids (2)

abil **activ** assai care cell demonstr
detect health isol larg number previou properti
report sensit size small strain studi system

4584: Pyruvate Dehydrogenase (Lipoamide) (3)

approxim complex correl earli enzym gene
gener induc induct major mutat patient predict
region rel respond **respons**
sequenc site stage

4585: Phosphatidylethanolamine N-Methyltransferase (3)

develop distribut effect embryo
function gene induc induct
interact local mechan mice molecular mous
protect reduc reduct **respons** transgen tumour

4587: Mydriatics (4)

case **develop** experi follow initi
intern mean measur method origin patient
produc product rang ratio requir respect
second treatment valu

4589: Nitrophenols (7)

analysi approxim cell compar concentr
detect enzym higher initi lower new phenotyp
rate rel respect reveal sampl select
specif versu

4591: Qc-SNARE Proteins (3)

autosom cell clinic **complex** data
domin estim evolut famili form
fusion inherit **interact**
membran method mutat
organ patient protein
transport

4586: Valinomycin (2)

caus **cell** cultur **effect**
event field forc inhibit involv larg lead
movement number prevent **process**
reduc reduct **size** small space

4588: Gold Colloid (2)

approach assai design **detect**
effect endogen **enhanc**
fish fluoresc **hybrid** increas neg
posit probe reduc reduct sensit situ
specif strategi

4590: Proto-Oncogene Proteins c-rel (4)

activ alter bind cell chang
characterist **differ** distinct distribut
featur **gene** genom local pattern
repeat requir **respons** similar site
target

4592: Carbon-Carbon Lyases (3)

activ alter analysi **chang** children
compar complex **control** enzym
gener **high** increas level low mutant
number organ state
structur treatment

4593: Amido Black (1)

acid amino assess compar determin evalu
extract imag magnet mean
measur modifi mri perform ratio reson
respect scan valu volum

4595: p120 GTPase Activating Protein (5)

associ bind cell complex correl
express form format inhibit
level membran mice mutant protein requir
signal structur suggest target tumor

4597: Propylthiouracil (7)

concentr dai decreas determin
dose effect famili increas level
measur mechan molecular
patient predict rat regress
signific treatment variabl variat

4599: Thymine DNA Glycosylase (5)

activ base bind concentr correl
determin dna form format identifi interact
methyl produc product protein requir screen site
specif structur

4594: Ferrosoferric Oxide (5)

cell combin condit control degre differ effect
gener genom group high human
induc level light low rat respons
studi subject

4596: Snake Venoms (8)

activ cell conserv
delta differ function highli homolog
human identifi mammalian mice
model mous notch pattern protein similar
structur treatment

4598: Pepsin A (6)

analysi assai complex detect
differ electrophoresi famili
function gel high identifi
mass member protein proteom sampl
sensit spectrometri structur subject

4600: TRPM Cation Channels (9)

blood cell channel develop
differenti enhanc express
human male mechan
molecular mutant region select
sequenc site splice state time variant

4601: Phospholipid Ethers (2)

anim assai base case detect differ
experiment flow **gene** mean measur
model pair patient protein sensit
studi surviv tumor valu

4603: ATP Citrate (pro-S)-Lyase (1)

activ **associ** character chromosom
compound enzym light link mitochondri new observ
phenotyp relat relationship research speci studi
substrat suggest technolog

4605: Azoles (11)

assai detect drug express fungal fungi
fungu gene isol larg method mutant new
pathogen produc **resist** sensit size
small speci

4607: DNA, Kinetoplast (4)

analys **analysi** data distribut dna
fragment indic isol local organ **patient**
perform popul presenc region reveal sequenc
strain structur studi

4602: Cetrimonium Compounds (3)

adapt collect dai determin dose fit mean
measur model natur paramet predict ratio
resist respect **sampl** select
specif surfac valu

4604: Glycosylphosphatidylinositols (15)

cell control develop effect
express form function
gene growth increas mechan number
protein region role select sequenc site
stress tissu

4606: Tacrolimus Binding Proteins (20)

activ apoptosi **bind** cell dai effect
express form function gene
interact mice normal
protein rate receptor respons
stabil structur **tissu**

4608: Loperamide (3)

assess **effect** express
function identifi improv larg life
measur normal qualiti reduc reduct score
screen size small **tissu** trial tumor

4609: Anti-Obesity Agents (7)

alter bodi care **chang** children
chines differ earli **effect**
health heterogen high neg
posit product reduc stage studi
subtyp treatment

4611: Myelin P0 Protein (8)

cell cord enhanc identifi injuri loss map mice
mous mutat nerv **patient**
phenotyp protein region screen select sequenc
spinal wound

4613: Potassium, Dietary (1)

african american **area** asian black bodi
control differ ethnic european group healthi
popul produc **product** south
studi **subject** weight white

4615: Neuroendocrine Secretary Protein 7B2 (1)

contribut decreas **develop**
development elev environment factor genet
increas influenc **level** modifi observ
phenotyp plasma serum studi suggest trait variat

4610: Metmyoglobin (2)

abil acid decreas demonstr **effect** follow
form format increas indic phenotyp potenti
prevent properti protect **reduc** reduct result
state suggest

4612: Netropsin (2)

adapt apoptosi approxim **bind** cell
embryo enhanc express gene genotyp
increas major polymorph receptor recombin
rel **select** site suggest target

4614: Estrogens, Non-Steroidal (9)

assess base cell data **effect** expos
exposur express gene genet
health increas induc new **popul**
respons studi subject toxic
treatment

4616: Proprotein Convertase 2 (1)

compar decreas determin elev higher
increas isol **level** mice modif
modifi mous null observ plasma reduc serum signific
strain studi

4617: Phenylpropionates (6)

acid **activ** analysi blood compar
concentr **differ** **gene** higher mice
new number pattern plasmid
product provid rate recombin
respons reveal

4619: Fluoroacetates (3)

analys **analysi** cell chain defect delet
enhanc **express** **gene** genet
indic induc mitochondri **mutant**
mutat plant reaction **respons**
reveal wild-typ

4621: Mustard Compounds (1)

agent cancer develop drug elicit endotheli induc
induct malign novel potenti respond
respons solid strategi target
therapeut **tumor** vascular vegf

4623: Ketoconazole (9)

activ alter **chang**
concentr dai **differ** enzym gene increas
metabol metabolit new p450
patient pattern popul region
regul sequenc **studi**

4618: Amylopectin (6)

access analysi barlei cultivar diploid
gene genom high hybrid indic line
low maiz model mutant parent plant **rice**
wheat wild

4620: Lactams (2)

analys **analysi** cell compar
correl **differ** enhanc higher increas indic
rate lower respect reveal signific
stimul studi subtyp **tumour** versu

4622: Indinavir (4)

caus data **differ** drug evid function high level
low metabol mutant mutat **patient**
pattern provid resist sampl select **studi**
support

4624: Budesonide (2)

activ chang **COURS** data **differ** durat end follow long
longer median month **patient** period point real
signal start **time** year

4625: Cathartics (7)

chronic compar concentr develop
diseas extract higher intestin level mean
normal patient rat rate requir
respons studi subject **tissu** valu

4627: Steryl-Sulfatase (9)

activ analysi associ **cell**
combin **develop** differ
differenti effect enzym gene inhibit
new normal phenotyp prolifer role
specif target **tissu**

4629: T-2 Toxin (1)

anim apoptosi biopsi cell death delai effect
express follow gene histolog induc inject lesion
long-term persist **rat** recoveri specimen
stain

4631: Pyruvates (2)

adapt **associ** cell character
characterist common complex factor featur
gener growth inhibit phenotyp region
resist **select** sequenc site suggest yeast

4626: Bisacodyl (1)

bodi copi determin differ extract includ increas larg
larger length long multipl **number**
patient repeat short singl size
small total

4628: Nicotinamide N-Methyltransferase (4)

activ analysi assai clinic complex
detect earli enzym genet genom influenc level
mechan molecular **patient** sensit stage
substrat variabl variat

4630: Benzoxazoles (8)

acid activ amino analys
analysi base caus concentr data
high increas low method normal process
product reveal sampl **tissu** variabl

4632: Integrin alpha5 (9)

adhes **cell** correl decreas effect
express form format gener increas integrin
molecul popul protein receptor reduc signific
state studi variabl

4633: Aquaporin 6 (2)

acid amino channel conserv diabet failur fatti
function impair insulin kidnei
known loop mammalian membran rec renal retino
syndrom transport

4635: Hydrocarbons, Acyclic (2)

acid activ affect amino blood
compound data densiti dna evalu exposur high
investig level low peripher specif
studi test tumour

4637: Anticestodal Agents (2)

analysi care chines clinic cluster differ elev
health heterogen hybrid injuri level
plasma random serum studi subtyp therapi
treatment trial

4639: Naloxone (7)

alcohol clinic effect express gene high
increas level low mechan mice mous
mutant oral region regul
respons risk sampl sequenc

4634: Phosphines (5)

acid bind combin dna effect experi genom
human individu initi larg oral
origin requir risk second site size small studi

4636: Oligomycins (6)

activ analysi approach bind
cell dna femal gener human male
mitochondri mitochondria
mtdna ORGAN region resist reveal sequenc
strategi studi

4638: Fadrozole (3)

alter CAUS chang
develop effect femal interact
lead level loss male plai prevent reduc
regul role serum test tumor valu

4640: Hemosiderin (3)

associ blood characterist common
condit degre factor featur imag lesion malign
multipl ratio region risk sequenc stain studi
test tumour

4641: 4-Aminopyridine (3)

activ channel concentr data demonstr
effect essenti ethic factor function
inhibit issu nuclear patient peptid requir research
sever studi transcript

4643: Agrochemicals (3)

activ approach cancer clinic
diagnosi diagnost effect exposur femal
genet male normal ratio reduc regress risk
signific state tissu variabl

4645: Shaw Potassium Channels (2)

analysi anim ca2+ calcium channel classif
cluster continu current delai experiment
follow long-term mice model
persist recoveri regul spontan studi

4647: Plastocyanin (3)

area assai compar decreas detect differ
element higher increas integr larg
mutant organ rate requir
sensit site size small state

4642: Trioxsalen (4)

activ analysi approxim assai blot cell detect
dna group histon major melanoma mutant
plai rel remain rna role sensit suggest

4644: Oxazepam (1)

approxim compar control decreas differ
dna effect frequenc group higher
increas level liver major mutant observ rel
signific treat treatment

4646: Schiff Bases (6)

base case decreas differ dna effect form
increas individu larg pair posit product
protein reduc site size small
structur tumor

4648: Glycolates (3)

approach blood cell compar dna express femal
gene gener higher isol lower male normal
patient rate recombin strain
tissu treatment

4649: Fibrin Tissue Adhesive (4)

approach complic dai decreas **differ**
discuss estim increas **method**
normal oper patient pattern perform
procedur repeat **surgeri** surgic techniqu
tissu

4651: Retroviridae Proteins (9)

associ cell control **effect** famili
genet genom high **human**
interact low member model product
protein reduc role state subject suggest

4653: Kv1.2 Potassium Channel (1)

address autosom coli cord dōmin electron
famili inherit **injuri** major
microscopi morpholog mutat
nerv question rais **remain**
spinal tumor wound

4655: Cnidarian Venoms (6)

associ coli enhanc evid
express form format identifi local
model mutat peptid **rate** region
screen sequenc studi suggest system
tumour

4650: Arthropod Venoms (2)

avail conserv data databas
drosophila fli function host
inform insect larva mammalian **mechan**
melanogast molecular **protein**
provid site tool wing

4652: Mitogen-Activated Protein Kinase 6 (4)

activ analysi blot degrad demonstr
differ express form format gene gener
high level low nuclear pattern
protein report studi suggest

4654: KCNQ2 Potassium Channel (3)

assess concentr **diseas** effect evalu
famili gene inhibit measur
member mutant mutat recombin region
resist score sequenc stress target tumor

4656: Griseofulvin (6)

cell chromosom content diseas enhanc
express famili flow gene identifi life
method **new** observ popul protein
provid screen **studi** suggest

4657: beta-Alanine (3)

adapt defect effect enhanc fit gene
human interact marker membran
mutant mutat natur organ popul reduc
reduct regul **select** wild-typ

4659: Oncogene Proteins v-fos (2)

compar data direct evid express
higher hospit hypothesi length loop lower
patient provid **rate** remain repeat
respons state suggest
support

4661: Periplasmic Proteins (8)

activ coli control enhanc escherichia
express form format function gene larg
mutant mutat number requir respons size
small structur wild-typ

4663: Demecolcine (3)

approach cell compar **control** delai
differ follow frequenc **group** higher
long-term lower model mutant normal
patient persist rate tissu
versu

4658: Novobiocin (3)

approach caus cell complex copi dna gene
increas individu inhibit isol larg lead limit
normal **number** plasmid
recombin strain tissu

4660: Glycine Plasma Membrane Transport Proteins (2)

affect data delet differ distribut evid
function inhibit local mice
mous provid regul resist studi subtyp suggest
support tumour vivo

4662: Etomidate (1)

children clinic dai differ dose hospit
improv isol larg **level** life
number patient physic qualiti serum
size small strain studi

4664: Steroids, Heterocyclic (7)

analysi chang clone concentr effect
enhanc express **gene** gener
growth high increas inhibit interact level
low mutant plant protein receptor

4665: Dinitrophenols (2)

abil **activ** caus cell chain **function** induc
induct initi lead mice mutant origin presenc
proporti reaction receptor respond
respons second

4667: Receptors, Melatonin (3)

bind caus combin determin effect extract **group**
induc interact lead loop model neg
patient posit presenc **respons**
structur suggest system

4669: Maleic Hydrazide (3)

data direct effect **evid** expos
exposur find hypothesi neg
plant posit provid report studi
suggest **support** system **test** toxic
treatment

4671: Toxaphene (1)

concentr data determin effect
expos **exposur** increas literatur measur microg
microm min neg plasma **posit** publish
report respect search toxic

4666: Iron Regulatory Protein 2 (3)

cancer cell demonstr diseas enzym find
gene indic interact iron junction
previou protein receptor remain report
requir studi suggest tumour

4668: tert-Butyl Alcohol (1)

chromatographi determin disord effect experi
exposur **express** extract follow
fraction initi intern liquid methyl origin prepar
rat second subsequ **test**

4670: Zearalenone (4)

acid bind cell compar complex content
control differ **effect**
exposur flow frequenc **gene** growth
health mutant presenc reduc signific
treatment

4672: Nitrogenase (3)

activ cell code codon decreas differ
domain featur **group** incid increas
inhibit nucleotid posit **protein** requir rrna
sequenc substitut women

4673: PII Nitrogen Regulatory Proteins
(2)

absenc **activ** addit codon combin
defect effect extract head indic multipl
mutant mutat presenc singl studi
suggest vitro vivo wild-typ

4675: Pregnenolone (1)

carri caus detect exon **express** expression gene
germlin heterozyg homozyg identifi iron junction missens
mutat novel point sequenc somat thyroid

4677: Quartz (4)

compar determin differ form format **mean**

measur model paramet predict rang ratio

region respect respons sequenc standard

structur treatment **valu**

4679: Natriuretic Peptides (3)

biolog blood cell experi field **function**
includ marker multipl new organ plai provid

rang **role** space studi suggest system
transplant

4674: Phenylmethylsulfonyl Fluoride
(2)

compar **control** degre differ
distribut enhanc factor femal frequenc
growth increas indic inhibit local
male observ presenc risk **sampl** suggest

4676: Sulfathiazoles (1)

aggreg coloni compar **control** cultur differ
effect expos exposur extract **form**
format fraction healthi mean methods
signific studi **subject** surfac

4678: Granisetron (2)

affect **concentr** consist data determin
effect estim experi follow
individu **initi** intern origin
reduc report **second** studi
subsequ suggest trial

4680: Fibroblast Growth Factor 9 (3)

adult analysi approxim blot **cell**
cluster cultur **differenti** express

featur gene major **mechan**
molecular prolifer receptor rel report
studi year

4681: Serum Amyloid A Protein (16)

accumul compar control develop diseas
express famili gene group human

level mice number patient plasma
polymorph popul risk serum subject

4683: Receptor, Anaphylatoxin C5a (7)

analysi cell classif cluster complex
data effect enhanc evid express
function gene identifi interact peptid
receptor reduc reveal studi support

4685: Excitatory Amino Acid Transporter 3 (1)

adjac area brain central compar differ examin japan
live locat muscl neuron normal region relat
resid skelet studi tissu zone

4687: Uridine Diphosphate Glucuronic Acid (1)

activ clearanc cyp cyp1a1 cyp1a2 cyp2c9 cyp2d6
cyp3a4 cyp3a5 cytochrom determin drug enzym

human metabol metabolit
microsom p450 respect studi

4682: p-Methoxy-N-methylphenethylamine (1)

alcohol analysi asthma blot confirm demonstr detect

electron embryo examin express human
microscopi morpholog northern oral peptid protein
reveal western

4684: Complement C5a (4)

activ caus cell data earli estim express
gener human induc induct late lead mice
peptid phase protein respons
stage variabl

4686: Excitatory Amino Acid Transporter 1 (4)

analysi area assai blot cell confirm
demonstr detect find neuron presenc
previou rat regul report requir sensit
studi suggest western

4688: Synapsins (4)

anim bind cell data decreas element evid
express gene growth

increas model phenotyp popul
provid rat sampl support transfer vector

4689: Immunoglobulin Allotypes (3)

antibodi caus cell decreas donor **gene**
high increas interact lead level low mice neg
patient posit rang remain transplant wide

4691: Diclofenac (11)

analysi assai compar **detect**
determin differ **human** mass
metabol **method** model new product
protein rate respons **sampl** sensit
test valu

4693: Immunoglobulin gamma-Chains (2)

cell chain compar delet detect enhanc
gene higher lower **mutat** pcr period
point polymeras quantit **rate** reaction
resist **time** versu

4695: DNA Topoisomerase IV (11)

chang character complex differ dna form infect
isol mutant **mutat** new posit rate resist role
sequenc specif **strain** structur type

4690: Scopolamine (5)

adult associ behavior children compar
control decreas differ **group** increas
older organ report signific stimul studi subject
trial year young

4692: I Blood-Group System (1)

antibodi **associ** blood differ larg
larger link **mechan** molecular number peripher
relat residu site size small smaller speci studi
underli

4694: Immunoglobulin epsilon-Chains (1)

antibodi antigen apoptosi **cell** chromatographi
death determin **extract** fraction human induc line
liquid lymphocyt method monoclon prepar purifi separ
t-cell

4696: Tryptamines (4)

adapt adult compar detect enhanc evolut famili
fit genet manag natur rate receptor region
select sensit sequenc specif
treatment year

4697: Octopamine (6)

activ^{diverg} drosophila
duplic^{enhanc} evolut^{evolutionari}
express^{insect male origin process}
product receptor^{rel}
respons^{score suggest test}
treatment

4699: Chromium Alloys (1)

absenc^{cost data evalu event follow-up involv}
manag^{median medic month patient practic}
presenc^{PROCESS random recurr} studi
trial^{year}

4701: Galactans (7)

acid^{activ} bind^{cell distribut}
enzym^{form format}
gener^{indic local produc product}
region^{residu sequenc}
site^{structur surfac target}

4703: TRPV Cation Channels (10)

activ^{anim calcium cell}
channel^{condit current degre}
effect^{larg mechan mice}
model^{normal number}
receptor^{SIZE small studi}
tissu

4698: Pyruvate Dehydrogenase
(Lipoamide)-Phosphatase (1)

acid^{affect amino autosom demonstr}
disord^{domin enzym famili find inherit}
metabol^{mice} mous^{mutat pancreat}
previou^{report studi}
suggest

4700: Oligosaccharides, Branched-
Chain (3)

analysi^{bind case cluster differ}
form^{format high inhibit level low}
pattern^{peptid produc product}
report^{residu site treatment type}

4702: Resins, Synthetic (5)

area^{differ dna form format group health}
improv^{larg method number}
patient^{period point rel size small}
studi^{techniqu time}

4704: Receptors, Leukotriene B4 (4)

blood^{cell develop earli experi}
inhibit^{initi interact lung marker neuron origin}
phase^{produc product receptor second specif}
stage^{trial}

4705: Leukotriene B4 (2)

alpha beta case elev induc induct interact
level mice month mous neuron patient plasma
receptor report respond **respons**
serum year

4707: Soman (1)

compar decreas dna effect elev enzym exposur gene
increas level month
higher patient plasma serum therapi treat
treatment vector year

4709: Receptor, Endothelin A (9)

activ cell compar **control** differ
effect express gene **human**
increas inhibit model number regul
respons role select **studi** subject
treatment

4711: Receptors, Opioid, kappa (4)

activ adult alcohol alter assess
chang decreas effect evalu express
famili increas measur mice mutat oral posit
scale SCORE year

4706: Cholinesterase Reactivators (1)

activ caus correl deliveri effect effici
enzym expos exposur gene grade index lead posit
relat relationship signific studi transfer vector

4708: Glutamine-Fructose-6-Phosphate
Transaminase (Isomerizing) (3)

alter associ bind **chang** decreas element
gene haplotyp **human**
increas insert integr nucleotid
polymorph protein region
sequenc site snp target

4710: Alkalies (4)

acid adult care children enhanc
health higher **human** mice
mutant new phenotyp plai provid **rate**
risk role select servic year

4712: Carboxypeptidases A (4)

area case **cell** combin data effect enhanc
estim flow **human** increas
normal patient plai rat role structur
studi **tissu** tumour

4713: Amino-Acid N-Acetyltransferase
(3)

case **clinic** concentr criteria defici diagnos
diagnosi diagnost domin earli famili
includ laborator **patient** produc
product rang recombin stage test

4715: Heptanoates (2)

analysi analyz clinic collect detect diagnosi gel
gene genotyp identif identifi mass mechan
method molecular novel polymorph
sampl screen techniqu

4717: Nitric Acid (1)

acid activ amino cleavag contain cystein form
glycoprotein glycosyl indic **pathwai** posit proteas
protein residu serin signal **site** stabil
substitut

4719: Flurbiprofen (1)

anim apoptosi cell compar **control**
death develop differ experiment frequenc gene
higher human **model** mutat p53 residu signific
site studi

4714: Botulinum Antitoxin (1)

antibodi chain delay **effect** extract follow
induc induct **mice** mous per peptid persist
prevent protect reaction reduc reduct
respons transgen

4716: Oxadiazoles (9)

activ analysi bind cell
compound detect develop group identif
identifi local mechan **new** novel protein
provid screen site structur target

4718: Diethylamines (1)

affin behavior **bind** cleavag cognit cystein
glycosyl impair interact learn memori oxid posit
proteas protein recognit residu serin **site**
task

4720: Maturation-Promoting Factor
(4)

abil children compar complex control demonstr
human method new potenti
properti provid random regul repeat report
studi subject target trial

4721: Aminoacridines (2)

cell content cycl cyclin cytometri
delai determin dna effect flow follow gene
load long-term malign methyl persist
promot radiat tumour

4723: Receptor, EphA4 (2)

activ alpha beta cell dna factor form
kinas ligand mice phosphoryl protein receptor
residu signal site stabil tyrosin vitro vivo

4725: Cyproterone Acetate (4)

analys analysi cancer caus
express femal gene genet growth liver
loss male patient popul prostat
protein rat reveal sex test

4727: Hydroquinones (16)

activ cell effect expos
exposur follow
function induc mechan model
oxid patient product rate regul respons
role select studi time

4722: Angiostatins (14)

angiogenesi cell develop effect
endotheli express factor form
format growth level protein repeat
studi tissu tumor vascular vegf
vitro vivo

4724: Transferases (6)

adult chain develop effect
interact level mechan new normal pcr
polymeras process provid reaction reduc
reduct studi tissu tumor year

4726: Tosyl Compounds (3)

bind cancer cell compar decreas detect dna
fish fluoresc hybrid increas inhibit
level probe prostat receptor situ studi vitro
vivo

4728: Dihydroxycholecalciferols (3)

adjust analysi associ combin confid correl
effect factor increas interv level odd ratio
risk serum signific smoke studi treat
treatment

4729: Toll-Like Receptor 8 (2)

code codon conserv element function
highli human identifi **individu**
length long mammalian nucleotid posit
receptor repeat short
specif substitut suggest

4731: Prokaryotic Initiation Factor-1 (1)

analysi categori classif **cluster** data defect
express field gener **genom**
mrna **mutant** mutat profil sequenc
set subgroup vitro vivo wild-typ

4733: Bismuth (6)

alter cell **chang** control dose
earli **effect** exposur gener increas irradi
model **patient** process product
radiat rat respons sequenc therapi

4735: Angiotensin I (6)

affect arteri **associ** combin
control effect enhanc
function high level local low
mechan number **patient**
rat receptor role suggest treatment

4730: SOS1 Protein (2)

analysi blot cell chromosom decreas
detect genet **increas** level
linkag loci locu **map** marker qtl
quantit region serum trait western

4732: Ranitidine (2)

alter cancer **chang** cours earli end event
gastric hybrid increas initi involv late occur period
phase point process stage **time**

4734: Threonine-tRNA Ligase (1)

acid amino analys cdna clone domain
examin extent fatti gene indic investig malign nucleic
observ retino sequenc studi suggest **tumour**

4736: 8-Hydroxy-2-(di-n-propylamino)tetralin (2)

allele behavior bind cognit condit distribut
genotyp **human** impair learn local mechan
memori molecular perform polymorph state
studi task test

4737: Fanconi Anemia Complementa-
tion Group A Protein (4)

adult american caus cell defici dna earli
enhanc ethnic evid factor **group**
mutat patient popul risk stage support
transplant year

4739: Uridine Triphosphate (6)

activ ^{ca2+} calcium cell channel current
decreas differenti diseas dna enzym **human**
increas ion line model neg plant posit receptor

4741: Pseudorabies Vaccines (2)

anim approach bind bovin dai **famili**
gene incid member mortal pig preval produc
product rat specif strategi vector women year

4743: Integration Host Factors (5)

activ assai **bind** detect enhanc high
identifi level low mechan molecular popul
process protein regul requir screen sensit site
specif

4738: DNA Probes, HLA (1)

antigen **cell chain** class detect
differenti hematopoiect hla mhc molecul **pcr**
polymeras progenitor quantit
reaction real-tim revers rt-pcr
stem transplant

4740: Uridine Diphosphate (1)

activ **analysi blot** calcium
channel confirm detect effect express
inhibit membran metabol northern
pancreat protein **receptor** reveal
secret suppress **western**

4742: F2-Isoprostanes (3)

analysi caus concentr correl enhanc
famili high increas lead level low
member patient predict rat regress relationship
signific **studi** variabl

4744: Sorbic Acid (6)

associ **chang** compar decreas detect
differ effect expos **exposur**
higher **increas level** observ
protein rate ratio risk specif
studi time

4745: Annexin A6 (2)

analysi **cell** collect concentr
develop find individu induc induct
interact mass microm min previou report
respons sampl studi suggest target

4747: Fluvoxamine (4)

allel assess depress disord evalu
function genotyp interact measur
patient plai polymorph rat role
sampl scale score subject valid variabl

4749: Hexokinase (10)

assess **enzym** express
function high imag **level**
measur product protein rate
region respons role score
sequenc **studi** time
tumor yeast

4751: HLA-DR7 Antigen (1)

class clinic compar conclusions **control**
differ frequenc healthi higher increas lower methods
observ **patient** respect sever signific studi
subject symptom

4746: Metanephrine (1)

affect anim assai **concentr**
control **detect** determin effect enzym
increas inject metabol microg microm min
plasma **rat** schizophreria **sensit** specif

4748: Dihydrotachysterol (3)

abil abl apoptosi capac cell concentr defici demonstr
elev level oxid **patient** plai plasma
potenti properti role serum treat treatment

4750: Phosphofructokinases (2)

analysi anim blot compar **control**
differ enhanc **femal** frequenc **high**
higher increas level low lower **male**
model **rate** sex western

4752: Receptors, Dopamine D5 (4)

adapt allele analysi content determin disord
evolut flow gene genet genotyp influenc natur
polymorph sampl **select** signific
studi variabl variat

4753: PPAR delta (7)

activ anim cell differ differenti
effect **express** famili individu
interact model normal pattern prolifer
protein sampl structur studi tissu tumor

4755: Creatine Kinase, BB Form (1)

activ bind element factor gene glioblastoma glioma
induc induct malign **primari** promot region regul
respond **respons** secundari site studi
transcript

4757: Hu Paraneoplastic En-
cephalomyelitis Antigens (7)

analys **analysis** associ bind
cell data differenti earli evid gene
increas neuron new number polymorph
protein provid reveal sampl support

4759: Acetylmuramyl-Alanyl-
Isoglutamine (5)

bone caus cell chronic diseas femal form
format **gene** inflamm inflammatori
intestin lead male mice period point report
studi time

4754: Hydrogel (6)

adult combin earli effect experi form
format gene **group** human
method organ produc
product region repeat sequenc
stage structur year

4756: Aminopropionitrile (2)

activ biolog dai effect enzym form format
function genet inhibit open plai
popul rat remain role structur suggest system week

4758: Diosmin (1)

assess clinic compar **decreas** design evalu hospit
impact improv includ **increas** level life
methyl perform physic qualiti random
studi trial

4760: Cholesterol Oxidase (1)

approxim area compar densiti elev enzym
high higher **level** locat low
major mass minor observ plasma rel serum studi
suggest

4761: Vitamin K 1 (1)

agreement anim assess bone bovin compound evalu
express expression instrument lipid
mean measur membran pig reliabl scale score total
valid

4763: Pepsinogen A (2)

approxim **associ** cancer compar control
group healthi higher
differ gastric level link observ rel relat serum signific studi
subject suggest

4765: N-Acetylmuramoyl-L-alanine
Amidase (3)

absenc **activ** defect dna enzym genet
head includ induc infect **mutant** mutat
presenc rang remain **respons** site
target wide wild-typ

4767: Receptors, Estradiol (2)

activ analysi clinic genom improv
independ lesion method patient predict
regress requir sequenc stain surviv target
therapeut **therapi** treatment variabl

4762: Protein D-Aspartate-L-
Isoaspartate Methyltransferase (5)

associ chang compar decreas
develop effect form format higher
increas individu measur protein
rate receptor reduc score select test tumor

4764: Triclosan (2)

adapt analysi cell codon compar **control**
differ **effect** frequenc
human laser light mass new
protect protein reduc reduct select
substitut

4766: Streptolysins (8)

associ cell data differ dna express fragment

gene genet **group** human infect

isol mechan **patient** pattern product specif

strain **studi**

4768: Menthol (2)

avail **base** cell dai data
databas dose effect follow improv
inhibit **life** pair physic **qualiti**
rat receptor trial **tumor** week

4769: Guanylyl Imidodiphosphate (2)

cell conform crystal differ differenti express factor
famili growth imag larg member mrna
number prolifer size small state
structur vivo

4771: Nitroimidazoles (10)

caus cell chang compar differ effect
express high higher human increas level
lower model plai presenc rate
role studi tumor

4773: Teriparatide (2)

adapt bone caus compar concentr control differ
effect group lead patient potenti regul
releas select signific stimul test treat treatment

4775: Stavudine (9)

activ dai differ genet
group herp hiv hiv-1
immunodefici infect level new
number patient pattern
phenotyp therapi treatment viral
viru

4770: Etidronic Acid (5)

bind clinic compar control
design discuss effect famili improv
interact method random recent rel rna
studi subject therapi treatment
trial

4772: GATA5 Transcription Factor (5)

analysi anim data develop
enhanc express factor famili gene
includ inhibit member model new
provid requir reveal select studi
transcript

4774: Acetanilides (2)

acid amino caus compound condit decreas
degre deriv effect lead level prevent
produc product protect rat reduc reduct
serum stress

4776: Acrolein (5)

assai caus cell chain concentr
detect determin form format initi lead
pcr polymeras quantit
reaction real-tim revers rt-pcr
sensit studi

4777: Iodoacetates (3)

anim compound degrad develop effect
experiment **model** normal
pathwai peptid plai protect protein rat reduc
reduct role signal studi **tissu**

4779: Palmitates (9)

activ approach approxim combin
concentr dai design effect enzym form level
major membran new protein provid reduc rel
strategi time

4781: 1,2-Dipalmitoylphosphatidylcholine (4)

approxim caus deliveri **differ** effici
electron form format **function**
lead major method microscopi morpholog
observ particl pattern regul rel surfac

4783: Nitritriacetic Acid (3)

analysi approxim compar dai data **decreas**
electrophoresi express gel human
increas level major mass method
observ reduc rel **sampl** structur

4778: Dichlorvos (3)

carcinogen chemic condit degre differ effect expos
exposur famili **function** gene
member mutagen mutat pattern protein
temperatur test toxic type

4780: Methylhydrazines (1)

anim bodi core encod enzym experi frame
incid men mortal open **organ**
popul possibl preval **rat** rate read
women year

4782: Desmosterol (1)

calcul compar cultur defici differ domain
electron mean measur microscopi morpholog
paramet predict rang ratio respect standard
surfac telomer **valu**

4784: 2-Amino-5-phosphonovalerate (3)

action alter **associ** chang
effect enhanc express increas inhibit mrna
plai potenti puls **receptor** releas respons
role **stimul** stress suggest

4785: Serine O-Acetyltransferase (1)

activ cdna character clone coli encod enzym
gene librari melanoma mitochondri novel
oxid protein residu rna sequenc site substrat
tag

4787: Ergot Alkaloids (1)

activ analysi avail base classif cluster
compound core data databas densiti encod
enzym high identifi level low
open read set

4789: Zinostatin (2)

cell chain compar differ differenti
express field function fusion
muscl pattern per prolifer rat reaction similar
structur type vitro vivo

4791: Cytosine Nucleotides (2)

affin associ bind complex domain factor identifi
interact mass p53 patient period
point protein risk site specif target therapeut
time

4786: Carbon-Oxygen Lyases (2)

analys analysi cell clone content
determin flow gene indic interact
level presenc reveal sequenc serum splice
stimul studi suggest variant

4788: Integrin alpha2 (6)

acid amino cell compar control
differ genet group level new
normal pattern phenotyp popul regul
serum similar tissu treatment type

4790: Chromates (2)

analysi cell dna effect elev exposur
level measur plasma predict previou
regress report serum signific state studi
surviv variabl variat

4792: Procollagen-Proline Dioxygenase (19)

activ angiogenesi cell chang
complex control endotheli
enzym express factor function group
growth mutat protein receptor select
substrat vascular vegf

4793: Manganese Compounds (3)

assai **chain** detect determin dna
domain initi mechan molecular origin pcr
polymeras presenc quantit
reaction real-tim repeat
revers rt-pcr valu

4795: Sodium Fluoride (3)

activ analysi area children dai data differ
estim level method model predict regress
respons signific **studi** subtyp treat
treatment variabl

4797: Excitatory Amino Acid Transporter 2 (7)

acid adapt caus concentr diseas **effect**
express gene genom induc mice model
neuron **rat** reduc respons
select studi treat treatment

4799: Enkephalin, Methionine (3)

absenc addit anim cell combin effect
enhanc **group** head increas indic
inhibit mice model point posit presenc
studi suggest time

4794: Cycloleucine (4)

acid **CAUS** complex concentr differ
effect fusion interact larg lead
level metabol new number receptor
reduc **respons** size
small test

4796: Son of Sevenless Protein, Drosophila (1)

activ alter anim **cell** chang compar
decreas develop effect experiment express
increas inhibit level model mrna observ
reduc signific studi

4798: Tropanes (2)

aggreg **CASE** coloni convers disord electron examin
form format **gene** indic light
microscopi morpholog observ
patient phenotyp report
studi suggest

4800: Flavonols (3)

area **cell** chines clinic
complex diagnosi differ
growth inhibit isol line
nuclear popul **rat** remain skin
speci strain **studi** subtyp

4801: Aminobiphenyl Compounds (6)

approach assai damag detect develop dna
high **human** identifi individu
level low mice model requir screen sensit
serum studi treatment

4802: Hydroxychloroquine (3)

adult children cohort dai data follow identifi
incid men mortal mutant
patient popul preval rate
respons screen treatment women
year

4803: Acriflavine (2)

acid amino approach assess complet electron evalu
follow gastric **genom** marker measur
microscopi morpholog **patient** scale
score sequenc strategi vivo

4804: Cacodylic Acid (5)

activ cell compar concentr
control dai differ dose
effect exposur gene inhibit
normal primari reduc respect **specif**
tissu valu week

4805: Sulfhydryl Reagents (6)

activ approxim bind caus
concentr dna effect gene
group inhibit mechan mice microg
microm min primari rel **respons** structur
treatment

4806: Iloprost (1)

cell chain detect differenti express fish fluoresc
growth hybrid induc induct per polymeras
probe prolifer reaction respond
respons situ tgf-beta

4807: Phosphorus Compounds (2)

associ base compar differ **function**
genet **group** inhibit marker mean
measur organ pair **popul** predict signific studi
valu variabl variat

4808: Potassium Compounds (6)

analysi base compar **concentr**
control correl dai determin differ **group**
higher measur microg microm min popul
respect **sampl** signific valu

4809: RNA, Guide (2)

activ assembl behavior **complex**
compon element enzym form **gene**
inhibit insert integr melanoma remain residu rna
site substrat subunit vector

4811: beta-Adrenergic Receptor Kinase
(4)

activ cell differenti diseas enhanc express
featur gener interact kinas mutant nuclear oral
receptor regul report signal
studi suggest treatment

4813: Butylated Hydroxyanisole (2)

activ affect block **CAUS**
concentr effect increas induc
inhibit inhibitor lead mechan
oxid oxygen prevent stress studi suppress
vitro vivo

4815: Chloroplast Proton-
Translocating ATPases (2)

analys base clinic code codon complex diagnosi
famili genu inhibit member phylogenet
popul receptor relat relationship sequenc
speci substitut tree

4810: Receptor, Muscarinic M1 (4)

affect alpha anim beta cell **complex**
compon concentr effect gene individu induc
model phenotyp rat **receptor**
respons studi subunit suggest

4812: Transposon Resolvases (1)

alter **chang** construct decreas differ
dna gene increas kinet **larg** larger number observ
plasmid recombin site **size** small stabil
state

4814: RNA, Transfer, Thr (4)

analysi area **CAUS** data divers estim evid
genet lead **model** mutant mutat organ
popul provid region sequenc
speci support test

4816: Cyclosporins (3)

associ case compar develop differ higher
larg lower number patient **rate** requir
risk **size** small surviv therapi treat
treatment versu

4817: Protein Kinase C-epsilon (9)

activ analysi apoptosi **cell** death
featur gener induc kinas **mechan**
mice molecular mous number
phenotyp phosphoryl process receptor
respons transgen

4819: Fats (7)

bodi chang correl detect **differ effect**
femal **function** individu male organ
patient pattern product reduc
resist risk time treatment weight

4821: Crotalid Venoms (4)

acid character clone
conserv function highli
homolog identifi length long
mammalian **mechan**
molecular remain
repeat requir sequenc short
speci suggest

4823: Chlorophyllides (5)

analysi bind determin earli
effect **function**
human level mean measur
protein reduc respect reveal serum stage
structur studi subject valu

4818: Irritants (5)

acid assai associ concentr **detect** health
induc induct model multipl report
respons risk sensit signific specif
studi **test** treatment variabl

4820: Interleukin-17 (13)

activ **associ** clone develop effect factor
gene growth haplotyp identifi induc induct
inhibit nf-kappab **patient**
polymorph region **respons**
sequenc snp

4822: Isothiuronium (1)

assess compar densiti domain effect **high**
impact improv increas induc inhibit level life
low normal physic qualiti rat
synthesi **tissu**

4824: Nitrofurans (5)

analysi **assai** assess caus concentr
correl **detect** determin dna evalu
exposur extract gener life measur
new rang score sensit **studi**

4825: Magnesium Compounds (2)

care **CAUS** extract form
format fraction genet health lead
length mechan **model**
molecular plai presenc repeat
role state structur suggest

4827: Aclarubicin (4)

adult **case** caus chang combin
concentr dai data differ
effect estim **express** increas
microm min pattern produc
product report year

4829: Progesterone Congeners (2)

acid **activ** amino breast cancer cell
demonstr differenti endotheli **enhanc** essenti
express fusion increas inhibit line prolifer receptor
requir suggest

4831: Emetics (1)

compar control dai differ dna dose effect
group higher lower mice protect rat
rate reduc reduct respect signific **versu** week

4826: N-Formylmethionine Leucyl-
Phenylalanine (4)

bone cell compar concentr **control**
differ differenti effect event frequenc healthi
increas multipl **patient** process
protein releas stimul studi subject

4828: Aquaporin 4 (3)

approach compar complex
control differ **enhanc**
frequenc genet increas induc mice **new**
pattern provid requir **respons**
strategi **target** therapeut type

4830: Norethynodrel (2)

acid amino breast cancer cell complex

effect form format improv ovarian p53

prevent protect rat reduc reduct therapi treat

treatment

4832: Polypyrimidine Tract-Binding
Protein (12)

activ altern bind exon express

function gene human intron

isoform mrna new protein region

sequenc site **splice** structur translat

variant

4833: Octanols (2)

clinic content data determin diagnosi
dose estim flow genet **high**
incid irradi level low measur
model radiat specif valu
women

4835: Acridines (9)

activ alter case caus **chang**
compound dna gene high lead level
low new properti rate report
structur studi time treatment

4837: Phytol (1)

activ bodi compar decreas defici diabet diet enzym
glucos **increas** insulin level liver mice
mous obes receptor reduc transgen weight

4839: Plasmalogens (1)

altern **cell** defect exon isoform isol line
multipl **mutant** mutat normal
phenotyp reduc singl splice strain **tissu**
variant wild wild-typ

4834: Inulin (7)

anim base blood **chang** combin correl
decreas **effect** increas level
mean measur mice model product
receptor reduc **studi** system valu

4836: Fibroins (3)

acid cdna **clone** dai drosophila evolut gene
high length level long low measur origin
protein **repeat** score sequenc
short valu

4838: Arabinofuranosylcytosine
Triphosphate (1)

acut assai cell compar comparison detect
differ dna express leukemia line observ
pattern sensit similar specif syndrom test
transfect type

4840: Glycerophospholipids (2)

acid **activ** amino approxim defect
enzym isol length level long major mutant
mutat rat rel repeat serum short strain
wild-typ

4841: Peptide YY (3)

base caus code codon control decreas gener
genet increas lead level nucleotid
pair patient peptid posit resist
serum subject substitut

4843: Adenine Nucleotide Translocator
2 (3)

acid amino associ cell characterist
common event express factor featur
gene involv line microarra PROCESS profil
protein risk thyroid tumor

4845: Carrageenan (7)

anim combin control effect experiment high
increas induc inject level low mice model
number rat respons studi time treat
treatment

4847: Succinate Cytochrome c Oxidore-
ductase (2)

care complex dose effect extract fraction
health irradi mice mitochondri oxid period point

protect radiat reduc reduct time treat

treatment

4842: Cytochalasin B (6)

assai cell detect differ effect
exposur form format genom increas
method model pattern popul
requir respons role studi techniqu
treatment

4844: Methyltyrosines (2)

activ affect concentr condit data
degre disord effect estim extract femal fraction
inhibit male method methyl sex suppress
techniqu therapi

4846: Pulmonary Surfactant-
Associated Protein B (4)

associ caus cell children complex

famili flow gene gener haplotyp lead

member mice mutat polymorph presenc

produc product protein
studi

4848: Norisoprenoids (1)

arabidopsi assess content cytometri determin
divers evalu flow genet isol load measur
plant popul root scale score
strain valid variat

4849: Vesicle-Associated Membrane Protein 3 (1)

acid amino bind compar **control**
differ event frequenc higher initi involv membran
occur PROCESS protein question remain signific step
transport

4851: Receptor, EphB1 (1)

addit affin alpha beta **bind**
combin complet demonstr effect
fusion interact ligand partial peptid
protein **receptor** replac result site specif

4853: Waste Products (4)

anim **associ** dai data extract
form format fraction gener growth interact
method **model** patient prepar region
sequenc studi surfac water

4855: Heterogeneous-Nuclear Ribonucleoprotein Group F-H (5)

analysi **develop** earli
enhanc identifi mrna **number**
phenotyp product promot rat region
reveal screen sequenc splice stage studi
treatment variant

4850: Rehydration Solutions (4)

caus chang compar concentr control correl data decreas
differ distribut effect fluid **group**
increas local reduc reduct respect signific studi

4852: Delavirdine (1)

analys analysi compar control differ divid
group median month mutant mutat
patient perform respect reveal signific statist studi
test year

4854: Dicarboxylic Acid Transporters (3)

acid adapt amino bind case cell
compar concentr factor **famili**
higher lower member membran
mitochondri **rate** requir risk
select target

4856: Ribitol (1)

activ adduct analog analogu chemic chromatographi
compound contain deriv extract fraction **genet**
liquid method molecular **patient**
potent prepar separ synthes

4857: Cholestenones (2)

approxim compar compound control determin

differ extract healthi higher level major

measur methods patient phenotyp

rel serum state studi subject

4859: Deoxyribonucleases, Type I Site-Specific (2)

activ analysi blot compar detect enzym
express gene genom higher identifi

lower method new protein provid

rate screen sequenc western

4861: Nucleotidases (2)

activ compound continu delai dna

effect enzym follow includ

long-term mutant persist rang recombin

recoveri reduc reduct repair resist wide

4863: Dextrins (1)

accumul adapt chain detect domain encod environ

enzym evolut fit gene gener natur per

polymeras quantit reaction real-tim revers select

4858: Fusidic Acid (3)

adapt alter caus chang correl decreas diseas
genet increas isol mutant natur plai role

select signific strain structur valu
variabl

4860: Centromere Protein B (7)

associ contain differ dna gene group identifi

length long patient popul protein

region repeat sequenc short

studi tandem termin unit

4862: Syntaxin 1 (1)

absenc alter chang decreas experi follow
function gene increas initi

interact intern manag map observ
origin presenc protein second suggest

4864: rab1 GTP-Binding Proteins (2)

alcohol behavior carcinoma chain clone
demonstr domain express field find gene
marker oral per previou reaction report

structur studi suggest

4865: Acyl-CoA Oxidase (2)

acid amino bodi caus effect
express factor gene genet hybrid
improv influenc lead life physic prevent qualiti
reduc reduct weight

4867: Flavin Mononucleotide (5)

anim cluster effect enzym experiment
group interact larg method
model plai product region repeat
role sequenc size state structur
studi

4869: Transcription Factor Brn-3A (5)

activ blood cell compar control
develop development factor famili
frequenc function includ interact level member
plasma serum studi target transcript

4871: Transcription Factor Brn-3 (7)

area blood cell domain express
factor gene individu interact mechan
model mutant mutat promot protein requir
studi subject system transcript

4866: Ribonuclease T1 (2)

associ bind cell complex effect event experi gene
initi intern involv network origin predict process
protein reduc reduct requir second

4868: Prokaryotic Initiation Factor-3
(1)

complex compon encod examin extent function
gene initi interact involv mrna observ
protein ribosom rna stress subunit suggest translat
trna

4870: Transcription Factor Brn-3B (4)

activ affect analysi associ bind
biolog blot domain express factor gene
interact level patient protein
serum studi system transcript western

4872: Homoserine (5)

base evid express form format
group high host infect
level low mutant number peptid
rel report sampl studi suggest support

4873: Anthranilate Synthase (2)

code codon combin effect evid induc induct
inhibit interact nucleotid plant posit provid
respond **respons** singl substitut
suggest support target

4875: Iduronate Sulfatase (3)

abil abl accumul capac cell
cluster **correl** data
demonstr differ **enhanc**
increas inhibit **mechan**
molecular potenti **properti**
signific studi subtyp

4877: Phosphoenolpyruvate Carboxykinase (ATP) (2)

activ cell data differenti **enhanc** enzym
gene increas infect inhibit mutant
normal prolifer **protein** target
therapeut **tissu** transcript vitro vivo

4879: Biflavonoids (8)

analysi **cell** correl detect determin
develop differenti earli effect **group**
method mice number protein signific
specif stage stimul time treatment

4874: Fluorides, Topical (2)

approach assai **associ** base caus
data detect error **estim** insight lead
method **new** power provid resist
sensit set statist test

4876: Pyocins (1)

antibiot bacteri complet damag defect dna
element fusion genom host **infect**
insert integr **mutant** mutat
parasit partial pathogen repair wild-typ

4878: Corrinoids (1)

character conserv consist core data direct

encod enzym **evid** find frame

hypothesi identifi mutant open provid

read resist suggest **support**

4880: Uranyl Nitrate (1)

administ administr alcohol bone **dai** daii
dose effect exposur factor follow given hour
infus inject intraven oral receiv studi week

4881: Angiostatic Proteins (2)

abil **activ** capac demonstr distribut
domain evolut famili fluid **function** inhibitor
level local member peptid potenti properti regul
serum suggest

4883: Interleukin-16 (2)

allel analysi cdna clone cluster differ

express gene genom

genotyp identifi **normal** plai

polymorph popul profil **role**

sequenc therapi **tissu**

4885: 4,4'-Diisothiocyanostilbene-2,2'-
Disulfonic Acid (2)

acid amino approach cancer class colorect
concentr confer delai design drug follow
long-term microscopi morpholog persist residu

resist site strategi

4887: Thiram (1)

anim bone cell chang develop dna experiment
human intermedi kinet metabol

model multipl promot singl slow
state studi switch transit

4882: Adenovirus E2 Proteins (3)

adenoviru compar **control** deliveri
effici **express** famili frequenc gene
genom higher member promot
rate region regul sequenc
specif transfer vector

4884: Dental Materials (6)

area blood **cell** **control** determin
differ light local model new **number**
period point provid research studi
time treatment valu variabl

4886: Diterpenes, Abietane (4)

activ analysi blot cell concentr dai
detect dna effect exposur express form format
inhibit interact isol protein **resist** strain
western

4888: Cloprostenol (2)

administr case clinic compar **dai**
decreas dose effect higher incid **increas**
patient random rate receiv
treatment trial versu week women

4889: Secologanin Tryptamine Alkaloids (2)

activ analysi base bind classif cluster cultur data
enzym mechan mix model molecular multipl
produc **product** protein
requir sourc yield

4891: Aldehyde-Lyases (6)

acid amino clone coli enzym gene
group high level low phenotyp produc
product region regul rel
sampl sequenc speci valu

4893: Norleucine (1)

conform crystal data determin direct dynam energi
evid fold form hypothesi kinet loop provid residu
secondari solut state **structur**
support

4895: Piracetam (9)

clinic condit dai develop **effect** epilepsi
gener health includ patient rat reduc seizur
stress studi suicid test time treat
treatment

4890: Diethylhexyl Phthalate (5)

assai carcinogen chemic detect differ distribut
effect event expos **exposur**
field **group** local potenti PROCESS rat
select sensit studi toxic

4892: Oils (9)

activ analysi base chain
children data earli
increas method parent pcr
polymeras popul process product
reaction specif stage **studi**
target

4894: ras Guanine Nucleotide Exchange Factors (1)

acid activ amino compar compound CONTROL differ
function healthi methods
enzym mice modul mous regul regulatori role studi
subject transgen

4896: Zinc Isotopes (2)

anim bodi cell collect control data essenti evid
initi model origin phenotyp provid rang regul
requir **sampl** studi subject
support

4897: Lyme Disease Vaccines (1)

adapt approach copi dai data direct dose
effect evid increas larg limit
number protect provid reduc
reduct select strategi support

4899: Complement C3b (6)

allow complement compon correl defin demonstr
determin develop enhanc gener highli identifi known
major natur phenotyp **specif** tea uniku util

4901: Rodenticides (1)

alcohol broad chicken depend drosophila effect
exposur includ **individu**
interact method
oral protein protocol rang studi suggest
techniqu varieti wide

4903: Cyclohexanecarboxylic Acids (3)

bind compar complex **control**
differ drosophila evolut experi follow form
format individu **initi** intern light
method **origin** protein second
subsequ

4898: Sodium Glutamate (1)

administr **bodi dai** diet dietari
dose **femal** intak **male** mass
mice mous **multipl** obes **rat** sex
sexual singl week **weight**

4900: Macrophage Inflammatory Protein-1 (11)

activ combin compar **control** differ
famili frequenc function gene **high** level low
mice mutant new nf-kappab normal size studi
tissu

4902: Zinc Compounds (7)

analysi chang combin control
earli form **group** microscopi
model morpholog phenotyp plai
regul reveal **role** select size stage
state subject

4904: Sodium Acetate (1)

activ assembl bind chromatin
complex compon element essenti
factor form function gene growth histon **promot**
recruit regul site subunit transcript

4905: Dihydropteridine Reductase (1)

effect express **famili** **gene**
histori identifi insight member microarra new
oxid oxygen prevent profil protect provid reactiv
reduc reduct stress

4906: S-Nitrosoglutathione (5)

activ area bind case cell conserv
earli enhanc enzym express
form format **gene** interact
method presenc region
select sequenc stage

4907: Hemeproteins (5)

affect compar compound dna
express gene higher isol
method mice **new** phenotyp provid
rate regul requir **respons**
strain studi suggest

4908: Sulfinic Acids (2)

addit anim cell **combin** compar
effect enhanc **gene** increas investig malign model
plu result simultan singl studi synergist tumor
tumour

4909: Alprazolam (1)

acid addit amino avail **combin**
data databas design effect hormon hospit
inform main muscl objective patient program
studi tool women

4910: Cysteic Acid (1)

acid amino broad class ear hair hear
includ loss major **method**
patient procedur protocol rang spectrum
techniqu type varieti wide

4911: Carbonic Anhydrase IV (1)

antibodi **associ** cell compar **control**
differ epitheli frequenc higher mean measur
normal **patient** ratio respect
signific stress studi **tissu** valu

4912: Galactosylceramidase (5)

anim caus cell chang children clinic develop
earli experiment gene late
model patient phase protein
region sequenc stage studi treatment

4913: Oxepins (1)

analysis behavior categori classif classifi cluster
cognit delet differ distinct **gene** identifi
loss mutant mutat profil **protein** set
subgroup wild-typ

4915: Myristic Acids (1)

activ apoptosi cell diseas hiv hiv-1 human
immun immunodefici induc infect oncogen
overexpress pathwai **peptid**
signal transform vaccin viral viru

4917: Nitroblue Tetrazolium (3)

acid alter amino analysi bind blot cell
chang enhanc evid express gene
growth increas life mutat provid qualiti
support system

4919: Thromboxane-A Synthase (1)

^{cancer compar control CORREL densiti differ}
group high higher imag index level
low lung marker relationship respect signific statist
studi

4914: beta-Mannosidase (3)

area **CASE** clinic diagnosi
diagnost experi includ initi modifi origin
patient presenc present rang report second
state studi target wide

4916: Fructosamine (1)

accumul **assai** bodi chromosom **detect**
effect event initi involv modifi occur
prevent **process** protect reduc reduct
sensit specif step weight

4918: Noscapine (4)

applic assai cell compound concentr data
detect determin **develop** differenti
distribut estim extract fraction local mechan
method sensit techniqu variabl

4920: GRB10 Adaptor Protein (4)

adapt carcinoma chromosom delet factor
function gene **growth** individu
interact methyl mice mous
patient phenotyp promot select
signal **studi** syndrom

4921: Immunophilins (3)

activ analysi anim blot cell concentr
effect experiment express gene health
interact marker model posit
protein receptor reduc requir studi

4923: Carbonic Anhydrase III (1)

anim bovin cdna character clone complet conserv
energi **express** fusion gene homolog
level mammalian mrna partial phylogenet pig sequenc
speci

4925: Tablets, Enteric-Coated (5)

arm clinic combin compar donor effect
function graft high improv low random
receiv recipi stem studi test
transplant treatment
trial

4927: DDT (8)

children data detect
develop drosophila
famili insect isol larva melanogast
member modifi organ parent presenc
product protein rat studi suggest

4922: Cystinyl Aminopeptidase (1)

birth compar fetal **function** gestat
impair infant matern mother neonat normal
physiolog pregnanc prenatal primari promot receptor
tissu week women

4924: Adipic Acids (2)

bladder case conform crystal determin earli
enzym late mitochondri phase progress receptor
report residu site stage
structur surfac tract urinari

4926: Glucosinolates (6)

adapt arabidopsi base effect evolut famili
function genom high higher level low
organ plant posit rate regul root seed
select

4928: Insulin Antagonists (2)

activ cell character cultur distribut effect
enzym factor fluid fusion growth local
membran metabol phenotyp regul
site suggest treat treatment

4929: Sodium-Phosphate Cotransporter Proteins (9)

anim cell decreas densiti effect express fusion
gene **group high**
increas level low model process
promot **protein** reduc regul state

4931: Phosphatidylinositol Diacylglycerol-Lyase (4)

activ cell compar control
differenti effect enzym frequenc identifi inhibit
isol level multipl organ **protein** regul screen
serum strain suppress

4933: Large-Conductance Calcium-Activated Potassium Channel alpha Subunits (2)

channel compar decreas enhanc function identif
identifi **increas** inject
interact isol level mutat novel
protein rat reduc screen strain suggest

4935: Histamine N-Methyltransferase (4)

associ compar differ featur find genet
group higher **human** isol lower plai
polymorph popul rate report **role** strain
studi suggest

4930: Sodium-Phosphate Cotransporter Proteins, Type IIa (3)

approach common decreas featur find
increas level membran period plai point
previou **protein** rat renal report
role studi suggest time

4932: Homogentisic Acid (4)

acid activ dai **enzym** essenti experi
form format **human** indic initi
intermedi kinet origin **patient**
phenotyp requir second state substrat

4934: Receptors, Galanin (1)

abil abl alpha antagonist beta capac copi
demonstr determin **increas** injuri larg ligand limit
number potenti properti
receptor specif total

4936: Histamine Antagonists (3)

abil **activ** analysi anim capac cell
compound decreas demonstr experiment gener
genom **increas** isol **model** organ
potenti properti studi tumor

4937: Lactulose (2)

adult case compar control differ enhanc
group hepat increas level liver older rat
report serum signific treat treatment year young

4939: Histidine Decarboxylase (5)

acid **activ** cancer **concentr** earli

express **gene** **group** mice

microg microm min mrna new **normal**

produc product protein stage **tissu**

4941: Succinates (6)

bind combin **effect** experi extract
form format high initi interact
level low **method** organ
origin product second site specif
techniqu

4943: Carbanilides (1)

approach bird chicken design determin differ elev
imprint includ indic **individu**
japanes **level** manag plasma serum site
strategi studi suggest

4938: Pyrilamine (1)

absenc addit anim **combin** compar
effect enhanc head increas inject investig plu
presenc rat result simultan singl stress studi synergist

4940: Subtilisin (1)

activ catalyt cleavag contain deliveri effici
enzym initi mrna particl plant polym

proteas residu ribosom serin **site**
substrat surfac translat

4942: Nicarbazin (1)

approach bodi chicken **concentr**
design diet effect elev increas **individu**
level limit measur microm min plasma
rat serum strategi weight

4944: Coccidiostats (3)

caus chicken compar concentr **control** dai
differ effect express higher imprint
individu inject japanes level
lower **rat** rate reduc serum

4945: Amino Acids, Sulfur (3)

acid amino bodi event experi follow
function initi intern involy occur
organ origin **process** second site speci
step subsequ trial

4947: Xylulose (2)

acid affect amino analysi blot compar
condit **control** degre detect earli
famili frequenc **function**
mechan member molecular protein stage
western

4949: Peanut Agglutinin (1)

aggreg cell coloni compar **control** defect differ
form format healthi methods
mutant mutat pathwai signal
studi **subject** vitro vivo wild-typ

4951: Selenoprotein W (1)

analysi cell content cours cytometri determin differ
express flow **gene** load mice mous
overexpress period point promot **time** transform
transgen

4946: Apoenzymes (2)

base bind complex conform crystal dynam form
interact length long methyl **model** promot
protein repeat requir short simul site

structur

4948: Veratrum Alkaloids (10)

cell develop differ embryon express
function human
model mutant neural new pathwai
pattern provid regul requir signal studi
system treatment

4950: Cephalexin (1)

analysi categori cell classif **cluster**
combin data differ distribut dna
effect fluid local profil recombin set

subgroup transfect treat

treatment

4952: p-Dimethylaminoazobenzene (2)

acid blood compar concentr detect fish fluoresc
higher hybrid lower neg posit probe rat
rate respect situ structur studi versu

4953: Receptors, Proteinase-Activated
(2)

activ cell cultur distribut domain
express fibroblast fluid increas
kinas local oxid pathwai receptor residu
signal site suggest synthas synthesi

4955: Vesicular Biogenic Amine Trans-
port Proteins (6)

analys analysi cluster correl data
develop distribut express gene
identifi local novel number posit respons
reveal screen target tumour variabl

4957: Iron Regulatory Protein 1 (2)

caus cell defici demonstr essenti exposur

express fusion indic junction lead mitochondri

necessari normal oxid partial protein

requir result **tissu**

4959: S-Nitroso-N-Acetylpenicillamine
(3)

associ bind caus cell correl
experi hybrid interact isol lead organ
possibl relat signific specif strain studi suggest
synthas synthesi

4954: Mesalamine (3)

arm cell clinic compar dai diseas effect efficac
enhanc improv mutant presenc random resist
studi therapi treat **treatment**
trial week

4956: Receptor, Bradykinin B2 (9)

adult arteri associ cell **develop** diseas
effect genet identifi interact local plai
polymorph receptor reduc role screen
studi subject year

4958: Receptors, Amino Acid (2)

activ analys analysi base
complex event fusion **gene** gener
genom indic initi involv occur origin pair
process reveal sequenc step

4960: ral Guanine Nucleotide Exchange
Factor (5)

activ analys analysi cell effect enhanc
gene inhibit interact overexpress plai reduc regul
requir reveal role suggest test transform tumor

4961: MAP Kinase Kinase Kinase 3 (1)

activ affect belong **famili** histori identifi
includ kinas known larg **member** pathwai phosphoryl
protein rel report signal subfamili superfamili translat

4963: Rose Bengal (2)

assai **cell concentr** condit degre
detect differ drosophila exposur gener induc
induct light min **respons** sensit
studi subtyp target **test**

4965: 5-Methoxytryptamine (1)

acid cho circadian clock content
cyclic determin feedback flow
hamster length long **loop** oscil
period **repeat** short suggest
synchron time

4967: Poly U (3)

area **base** clinic correl diagnosi differ
enhanc featur form format
human mitochondri mutat observ
pair produc **product** region sequenc
structur

4962: Receptors, Eicosanoid (2)

acid activ alpha amino beta channel critic drug
interact involv kinas ligand metabol oral **plai**
protein **receptor role** suggest
transplant

4964: Receptors, Interleukin-8A (9)

activ alpha cell chemokin correl diseas
express **factor human**
induc necrosi **nf-kappab**
rate receptor respons
stimul studi tnf tnf-alpha tumor

4966: Receptor, EphA3 (1)

correl cours develop end gene grade index novel
period point posit potenti promot relat relationship
signific target **time**
therapeut transcript

4968: beta-Glucosidase (8)

activ analysi **cell** children correl differ
enzym express gene high low mutant
patient pattern plant protein
select speci state studi

4969: Fumarates (4)

activ agent cell clinic enhanc enzym
function gene gener genotyp
increas metabol polymorph primari state substrat
target therapeut therapi treatment

4971: Cystathionine (2)

activ aggreg coloni concentr convers
group differ domin effect famili form format
inherit inhibit microg microm
min mutat plasma respect

4973: Thiogalactosides (1)

class contain deliveri effici includ length
liposom liver long major particl polym rang
repeat short surfac tandem
termin varieti wide

4975: Kynurenine (1)

activ cell clinic cultur effect enzym fibroblast
inhibit **mice** mous overexpress
patient segment sever substrat suppress symptom
transform transgen wild-typ

4970: Betaine-Homocysteine S-Methyltransferase (1)

associ cleft **effect** gene haplotyp includ
multipl myeloma polymorph potenti prevent
promot protect reduc reduct signific singl snp
studi syndrom

4972: Cystathionine gamma-Lyase (1)

affect **associ** autosom caus clinic
diseas disord domin enzym famili gene genet
hereditari inherit link mutat radiat receptor
recess studi

4974: Duffy Blood-Group System (9)

analysi **associ** compar content
control cytometri determin **differ**
famili flow **gene** genotyp high
observ polymorph popul signific studi
subtyp **test**

4976: Fish Oils (15)

acid combin detect **effect** fish
fluoresc group **hybrid**
increas nitric oxid probe product reduc
respons risk situ studi synthas
synthesi

4977: Dihematoporphyrin Ether (2)

assai cancer **cell** chines cultur detect
differ drug exposur gastric heterogen human
laser light **line** resist sensit specif studi
subtyp

4979: Endocannabinoids (7)

alcohol anim develop earli effect enhanc
experiment genotyp mechan **model**
molecul oral posit potenti provid receptor
studi **target** test therapeut

4981: Fentanyl (8)

alcohol anim chang clinic combin
concentr effect function group
increas level microg microm min model oral
patient plasma report studi

4983: Acetate-CoA Ligase (2)

data databas differ environment factor
function genet histon influenc
mean method **model** mutat network predict
receptor regul trait valu variat

4978: Monoacylglycerol Lipases (2)

approach caus **develop** drug form format
inhibit lead molecul molecular new novel potenti
receptor regul select specif strategi
target therapeut

4980: Laurates (2)

activ approach bind chines compar
control demonstr differ enhanc
frequenc heterogen higher increas infect observ
requir signific strategi studi subtyp

4982: Bacterial Proton-Translocating ATPases (1)

adapt anim base compar differ experiment
genet higher influenc lower **model** neg
pair **posit rate** respect
select site studi versu

4984: Arabinose (5)

base character contain core encod
enzym frame **gene** indic mutant
mutat observ open pair protein read
residu sampl **site** substrat

4985: Chondroitin (2)

acid chines control data differ dynam genet
healthi heterogen **model** plai previou
repeat report role state **studi**
subject subtyp suggest

4987: Urate Oxidase (6)

compar **control** core differ encod
enzym form format frequenc gene genet high
higher level low new open rel studi tumor

4989: Bee Venoms (2)

analysi analyz collect compar conserv **control**
detect differ domain drosophila factor famili
frequenc member new **protein** provid
risk **sampl** site

4991: Kv1.3 Potassium Channel (3)

approach assess bind cell distribut femal
health high level local low male measur
organ **patient** peptid
respons risk score strategi

4986: Thionucleosides (3)

approxim cell conform crystal differenti dna effect
express fold form loop major produc product prolifer
reduc rel residu **structur** system

4988: Neuropilins (4)

biolog **develop** effect endotheli essenti express
function gene genet mutant
receptor reduc reduct regul remain requir role
system tumor vascular

4990: Intermediate-Conductance
Calcium-Activated Potassium Chan-
nels (4)

activ **cell** chain experi hybrid inhibit initi
larg multipl novel organ origin phenotyp
reaction second size small specif target
therapeut

4992: Prekallikrein (1)

concentr determin elev exon experi gene higher
level _{min} mutat **normal** organ
plasma possibl promot serum specif splice
tissu variant

4993: Shiga-Like Toxin I (4)

alter **assai** caus cell chang combin
compar complex **detect** effect follow
higher initi lead membran **rate** requir
sensit specif test

4995: Prostaglandins A (2)

apoptosi apoptot assess bcl-2 **cell**
compar **control** death differ disord
frequenc higher impact improv induc life marker
physic qualiti studi

4997: Aminoacyltransferases (3)

assess data evid form format identifi
measur mechan molecular mutant
normal organ provid regul score screen
state **studi** support tissu

4999: 3-Hydroxyacyl CoA Dehydrogenases (5)

acid adult analysi children clinic cluster
defici **develop** express gene
growth identifi **mutat** patient region
screen sequenc sever specif year

4994: Physalaemin (2)

activ alcohol defect depend effect
element ethanol insert **mutant** mutat oral
particip **plai** prefer rat reduc **role** studi
suggest wild-typ

4996: Suramin (6)

assai clinic **detect** determin
famili **function** high
initi level low mechan origin receptor
sensit specif studi time
treatment trial **tumor**

4998: Thiamphenicol (3)

analysi assess collect degre encod express
gene gener measur modul mutant rat
recombin regul regulatori resist **sampl**
score specif system

5000: Bromobenzenes (3)

abil adapt chromosom complex **concentr** dai
dose effect **express** gene **group**
induc induct inhibitor marker microm min
properti **respons** select

5001: Butanes (3)

activ approach cell children concentr
gene incid men mortal plai preval rate regul report
role state studi trial women year

5003: Chondroitin ABC Lyase (2)

adenoviru cell dai deliveri differenti dose

effici express form format gene

improv life physic prolifer qualiti therapi

transduct transfer **vector**

5005: Cresols (3)

affect assess bodi clinic
concentr cost decreas
diagnosi enzym **increas** manag
measur medic microm min practic radiat
report score studi

5007: Gallium Radioisotopes (2)

concentr confer determin diabet dna drug extract
femal male microg microm min plasma
resist respect sensit sex suscept transport
tumor

5002: Muscarinic Antagonists (8)

affect behavior bladder case chang
children compar control dai decreas
develop effect **group**
increas organ perform report signific
studi subject

5004: Palmitoyl Coenzyme A (1)

acid amino analys **analysisi**
confirm correl data effect fatti index indic mice
mous perform relationship **reveal** signific studi
treat treatment

5006: Colicins (4)

adapt alter bind **chang** coli combin
complex dna form format individu
intermedi kinet method protein rapid
select state switch transit

5008: Acetolactate Synthase (4)

acid **activ** amino distribut enzym
form format health high level local low measur
mechan **mutant** protein recombin score
structur studi

5009: Propane (2)

activ adapt analysi antigen case categori class
classif cluster compound enzym mhc molecul
natur oxid profil report **select** set
subgroup

5011: Endosulfan (3)

alter chang dai decreas **differ**
effect exposur improv **increas**
initi life patient pattern plai qualiti regul
resist role treat treatment

5013: Sulfurtransferases (3)

activ altern bind defici enzym exon
express gene genom induc induct
isoform **mutat** regul
respons sequenc specif splice
substrat variant

5015: Raffinose (5)

condit degre differ effect flow **group**
high identifi level low model new phenotyp
process rat sampl screen signific specif yeast

5010: Nitroparaffins (1)

activ aim antibodi cell compar control differ
enzym healthi intermedi kinet malign
oxid state studi **subject**
substrat switch transit **tumour**

5012: Purine Nucleotides (3)

associ cell code **codon** dna
gene haplotyp hybrid method
multipl nucleotid polymorph
posit region sequenc singl
snp stop **substitut** suggest

5014: Organoselenium Compounds (8)

activ analysi apoptosi cancer **cell**
combin decreas **develop** effect
express increas inhibit level presenc
reduc role sampl select serum tumor

5016: Cyclin-Dependent Kinase Inhibitor Proteins (1)

absenc assembl chromosom
complex compon divis form
head indic loss microtubul mitot neck
presenc protein spindl stabil
studi subunit suggest

5017: Carubicin (1)

agent cell compar cytotox **decreas** dna drug effect
gene human **increas** level line methyl
observ promot reduc reduct result treatment

5019: Prostaglandin Antagonists (1)

address advanc articl clinic current discuss effect
focu focus futur improv question recent remain
research therapeut **therapi** treat
treatment understand

5021: Coumestrol (1)

analysi blot cancer cell confirm detect differenti
express gel mass **mice** mous ovarian
pathwai prolifer protein reveal signal transgen
western

5023: Sumatriptan (2)

care **combin** concentr cost decis drug
effect **extract** fraction guidelin
manag medic **method**
practic prepar procedur recommend
standard techniqu trial

5018: Diprenorphine (1)

abil abl alcohol alpha capac demonstr depend
effect exhibit fusion indic oral partial potenti
proporti **receptor** residu site studi
test

5020: Hemoglobin C (3)

approxim assess combin data effect
estim evalu evid genet major **measur**
method popul recombin rel
score select support **test** valu

5022: Debrisoquin (2)

activ allel control correl cytochrom
determin enzym extract fraction genotyp
healthi metabol metabolit p450 polymorph
respect signific specif **studi** subject

5024: Glucose Oxidase (1)

case compar data **differ** dimer direct
evid form hypothesi **pattern** protein provid
rare report similar stabil support treat
treatment type

5025: Aminocaproic Acids (1)

activ adhes Cell effect extracellular
human imag inhibit inhibitor
integrin invas magnet matrix monkei multipl ovarian
singl studi suppress volum

5027: Calnexin (5)

activ assai complex detect
domain **gene** initi measur membran
mutant mutat origin protein
requir score second sensit site stabil
transport

5029: Adrenergic Agonists (2)

analys **analysi** bind chain clinic
data decreas diagnosi increas indic mutant per
perform polymeras reaction region reveal
sampl sequenc **studi**

5031: Trialkyltin Compounds (1)

activ administr cell dai develop **dose**
earli effect enzym irradi late liver
onset phase progress radiat radiotherapi
stage substrat week

5026: RNA, Transfer, Amino Acid-Specific (3)

differ enzym event incid includ initi marker
mice mous mrna process rang recombin
ribosom stimul **studi** subtyp
translat women year

5028: Pancrelipase (2)

caus compar **control** differ enzym
event evolut frequenc genet healthi involv
lead mice occur **process** signific step
studi subject trial

5030: Receptors, Cholecystokinin (3)

alpha decreas densiti enhanc evid follow
high increas level low multipl
peptid period point protein provid **receptor**
suggest support **time**

5032: Receptor, EphA1 (1)

algorithm behavior compar data **differ**
dynam environment factor genet influenc method
model network pattern predict receptor
set similar simul type

5033: Ketotifen (2)

abil analys **analysi** anim content
cytometri data determin flow follow indic
microscopi model morpholog observ perform
properti reveal state studi

5035: rab5 GTP-Binding Proteins (4)

cell code codon enzym initi interact
intracellular larg **membran**
multipl **NEW** origin protein provid second
size small substitut transport uptak

5037: Mannosidases (4)

caus cell differ differenti earli effect enzym
express form format **human**
increas mutat pattern reduc repeat report
stage studi time

5039: Holoenzymes (5)

assembl bind **complex** compon
essenti form function genom human region
regul requir sequenc site structur subunit
telomer telomeras test tumour

5034: Oncogene Protein pp60(v-src) (4)

cell complex earli event function
growth **interact** involv late
overexpress phase process progress rat
regul requir role stage state
transform

5036: Hydroxyprostaglandin Dehydrogenases (1)

action activ cancer cell cox-2 effect
enzym factor **growth** increas
inhibit **inhibitor** line potenti
prostat puls reduc releas **stimul**
transcript

5038: Acetone (7)

compar concentr determin express
extract famili fraction gene
increas light method
number organ prepar rate rel
respons system target **treatment**

5040: Receptors, Histamine H2 (2)

cell control extract factor growth healthi
interact level melanoma
phenotyp produc
product releas rna serum
stimul studi **subject** vitro vivo

5041: Guanosine Diphosphate Fucose
(2)

bind cell character conserv delta enzym
function highli homolog homologu human identifi
line mammalian membran mous notch ortholog

protein therapi

5043: Dienestrol (1)

avail concentr data databas decreas direct
essenti evid extract fraction hypothesi

increas inform level ovarian
program provid requir support tool

5045: Polyglactin 910 (3)

approxim assess cell evalu express factor
gene identifi major measur patient
rel risk scale score screen transfect valid vitro vivo

5047: Singlet Oxygen (8)

adapt caus condit effect form format

human interact kinet lead
light mechan method
molecular oxid protein reduc
select state structur

5042: Hexestrol (1)

data direct endogen enhanc
evid extract field find fraction
hypothesi increas marker

method movement prepar
provid space suggest support
techniqu

5044: Horseradish Peroxidase (9)

activ analysi effect gene genet

identifi interact method
potenti product radiat region screen
select sequenc stimul studi subject
techniqu time

5046: 2-Aminopurine (8)

activ bind cancer decreas dna effect
gener group high increas inhibit interact
level low marker mutant protein reduc structur
valu

5048: DNA, Concatenated (1)

approach base bia data differ error

estim method model
number organ pattern power probabl
propos region sequenc set statist structur

5049: Dequalinium (2)

agent apoptosi **cell** cerevisia death densiti
drug effect **high** induc level loss
low mitochondri novel potenti saccharomyc
target therapeut yeast

5051: Morphinans (2)

activ apoptosi apoptot bcl-2 care cell
commun educ express gene health induc inform need
nurs p53 particip protein servic survei

5053: Sorbose (1)

analys **analysi** chines compar condit
degre **differ** gene heterogen isol
new pattern perform provid reveal similar
strain studi subtyp type

5055: Estradiol Congeners (2)

cell concentr copi core correl **effect**
fusion includ increas larg morpholog
number open protect reduc
reduct signific **studi** vivo water

5050: Dimethylamines (3)

activ cell complex compon concentr dai dose
effect exposur field form format hybrid mix
presenc produc **product** sourc
space yield

5052: Ergocalciferols (3)

bone **cell** decreas differenti effect enhanc
express **increas** interact level
patient prolifer rat reduc reduct
serum treat treatment tumor vivo

5054: Pentoses (2)

acid activ analysi blot differ **effect**
enzym **gene** induc larg method
number reduc regress **respons**
size small substrat variabl western

5056: 4-Aminobutyrate Transaminase (1)

affect alter associ **chang**
chromosom delet gene haplotyp identif
identifi linkag locu map novel polymorph
region screen signific snp **test**

5057: Lutheran Blood-Group System
(1)

adhes allele associ blood cell consist diseas
embryo experi follow genotyp initi intern line
origin peripher **phenotyp**
polymorph second subsequ

5059: Tyrosine Decarboxylase (2)

activ address anim develop drosophila embryo enzym
experiment femal fusion **gene** male
model mutant question remain sex structur studi
substrat

5061: Yohimbine (2)

behavior cluster cognit copi depress disord
experi induc induct initi **number**
origin perform rat receptor
respons second studi test trial

5063: Esculin (3)

analys analysi combin data differ effect
factor **group** growth health indic
isol model phenotyp presenc rat
reveal state **strain** studi

5058: Chemotactic Factors, Eosinophil
(1)

cell condit degre heat hormon induc induct involv
mechan metabol molecular receptor respond
respons structur temperatur
underli understand understood women

5060: Organic Anion Transport Protein
1 (3)

alter associ chang control dai exon
express function
gene healthi identifi metabol
organ polymorph screen signific splice studi
subject variant

5062: Chlorpropamide (2)

data enzym error estim extract famili
fraction genet larg member metabol
method number power procedur
recombin size small statist techniqu

5064: Croton Oil (2)

bodi copi dai differ dose effect enhanc
exposur **group** increas irradi
number potenti radiat reduc reduct releas
signific stimul weight

5065: Vigabatrin (4)

data epilepsi follow **group** includ

inform larg literatur mice new publish report

review seizur size small **stress** suicid

treat **treatment**

5067: Immunosorbents (1)

antibodi approxim compar differ extract

higher **level** light major mean

measur observ plasma ratio recombin rel

respect serum state valu

5069: Membrane Transport Modulators (5)

affect bind cell disord effect increas level

mice model number **phenotyp**

process reduc resist role **studi**
subject suggest **treatment** valu

5071: Chlorofluorocarbons (1)

approach care condit **data** degre discuss

environment error **estim** factor
genet **health** influenc **method** model
power recent resist set statist

5066: Kv1.1 Potassium Channel (3)

assess condit degre **differ** gene
improv life measur mechan method mice mutant
mutat **pattern** qualiti repeat score similar
treatment type

5068: Hydrophid Venoms (1)

cdna cleavag **clone** contain diverg duplic
encod evolut evolutionari gene librari marker
molecular origin proteas residu sequenc serin

site speci

5070: Mitotane (3)

activ anim carcinom caus cell
decreas differenti diseas distribut featur

human imag increas lead local
model patient prognost prolifer surviv

5072: Sodium-Phosphate Cotransporter Proteins, Type I (1)

abil abl bone capac chromosom compar decreas

demonstr densiti exhibit **high**

increas level low modul
potenti properti regul regulatori role

5073: Sodium-Phosphate Cotransporter Proteins, Type II (1)

abil abl bone capac compar **decreas** demonstr displai
exhibit genet **increas** kidney level
observ peptid potenti properti reduc renal result

5075: Carbonic Acid (1)

affin **bind** bound complex compound conform
crystal determin field fold form interact loop movement
protein residu secundari site space

structur

5077: Vaccines, Combined (3)

avail caus characterist control data featur
healthi identif identifi immun includ inform
lead phenotyp rna screen specif
studi subject vaccin

5079: Mibefradil (1)

act addit contribut demonstr **effect** endogen
enhanc examin exogen extract
increas indic potenti prevent protect reduc
reduct result suggest therapi

5074: Sodium-Phosphate Cotransporter Proteins, Type III (2)

bone control factor function fusion growth
involv kei kidney kinas mechan modul
phosphoryl plai **protein regul**
regulatori renal **role** suggest

5076: Yellow Fever Vaccine (3)

caus chicken compar **differ** form
format higher **individu** lead light lower
method pattern produc **product rate**
research similar type versu

5078: Hepatitis A Vaccines (2)

compar condit control cost degre differ
distribut genotyp healthi **local** manag
medic polymorph produc
product random resist studi
subject trial

5080: omega-Conotoxin GVIA (1)

action addit channel demonstr **effect** endogen
enhanc examin extent extract
find fraction **increas** indic neuron potenti
reduc releas stimul suggest

5081: MafG Transcription Factor (3)

activ alter chang conserv
element enhanc express increas induc induct
multipl mutant mutat region remain
respons sequenc singl suggest
wild-typ

5082: Eugenol (5)

adult combin
compound data effect evid
improv level life
method physic process provid
qualiti rat repeat risk
support test year

5083: Isocitrates (3)

activ approxim concentr enzym form
format high level low major mean
measur new produc product
ratio rel respect specif valu

5084: ATP-Dependent Proteases (2)

acid affect anim complex differ event
improv involv life model organ pattern
process qualiti region sequenc site studi
subtyp type

5085: Azetidinecarboxylic Acid (1)

analysi base bind categori classif classifi cluster differ
express gene level month patient
plasma primari profil serum set subgroup year

5086: 3-Oxoacyl-(Acyl-Carrier-Protein) Synthase (1)

analysi arabidopsi base data dynam experiment express
factor gene growth microarra model
paramet plant predict profil root seed simul skin

5087: Mimosine (1)

cell compar critic cycl decreas
develop development essenti
increas kinas level loss mainten necessari p53
reduc requir resist role suffici

5088: Glucosidases (1)

adjust associ confid degrad event initi interv
involv membran occur odd
process protein ratio risk
smoke step structur studi transport

5089: Vesicular Monoamine Transport
Proteins (4)

analysi assai detect factor fish
fluoresc hybrid level mechan
method mice multipl phenotyp probe
product reveal risk sensit serum specif

5091: LDL-Receptor Related Protein 2
(3)

acid bind children express famili femal
function high human isol level
low male member mice organ produc product
report studi

5093: Benzodiazepinones (4)

activ cell concentr correl data decreas
estim evid express factor growth
increas level plai provid receptor
resist role support treatment

5095: Gastric Mucin (2)

alter approxim cell chang character
characterist common differenti distinct
earli featur lesion major observ
phenotyp prolifer rel similar
stage tumour

5090: DNA Topoisomerases, Type I,
Eukaryotic (5)

activ agent bind cell complex dna
drug estim express form format
function identifi interact mechan
mutant protein screen structur
time

5092: Ribonucleoprotein, U4-U6 Small
Nuclear (3)

base bind complex compon conserv event
function human interact involv multipl
mutant observ pair presenc process
protein recombin structur subunit

5094: Adrenergic Agents (6)

activ anim compar control decreas effect
express gene group increas model
neuron number patient rat
reduc studi subject test treatment

5096: Orotate Phosphoribosyltrans-
ferase (5)

acid activ approxim area cluster dai
extract genet mice mutant nuclear peptid
recombin region rel select sequenc tumor vitro
vivo

5097: Oxalates (4)

acid amino cluster compar data evid form
format genom mean method model normal
provid respect structur **studi** support
tissu valu

5099: Carbohydrate Epimerases (3)

abil acid **activ** amino enzym femal
form format gener male mechan molecular
mutant **number** properti residu site
structur substrat tumour

5101: Deoxyribonuclease EcoRI (8)

associ chang **dna** fragment
function genet genom
isol method mutant
patient pcr phenotyp plasmid
popul recombin
region role **sequenc**
strain

5103: Hypotonic Solutions (3)

cell character characterist clinic diagnosi differenti
famili featur fertil **function** germ
imag interact member multipl prolifer protein
recombin regul sperm

5098: UDPglucose 4-Epimerase (2)

bind conform crystal domain enzym express factor
form format **gene** insight loop new organ
possibl provid residu risk **structur**
yeast

5100: Triose-Phosphate Isomerase (2)

analysi chain character copi dimer fold form gel
gene identifi interact map mass nativ
number **protein**
reaction solubl stabil stabl

5102: Antibodies, Phospho-Specific (3)

activ assai bind detect earli effect form
format **human** inhibit method
receptor reduc reduct requir sensit specif
stage vitro vivo

5104: Vascular Endothelial Growth
Factor, Endocrine-Gland-Derived (5)

analysi associ blood cell
core encod express frame health identifi
indic open read region requir **respons**
reveal sequenc structur suggest

5105: Paraffin (5)

analysi cell compar decreas differ
earli effect **express** gene
high **increas** late level low pattern
phase progress rate reduc stage

5107: Hepatitis B Antigens (3)

compar differ **group** higher incid
interact lower morpholog mutant mutat patient plai
rate region role sequenc year signific surviv target

5109: Indolequinones (2)

abil analysi blot cell **combin**
concentr cultur dai demonstr differenti
effect enzym **express** **high** level
low properti regress variabl western

5111: Insulin-Like Growth Factor Binding Protein 4 (5)

analysi area cell cluster cultur differ
distribut factor **group**
growth inhibit level local
marker mechan mice molecular reveal serum
studi

5106: Cyclic AMP Response Element Modulator (11)

cell differ effect **express** gene
high increas involv level modul new plai process
product promot reduc **regul** regulatori role
specif

5108: Pentostatin (4)

cell clinic combin compar differ earli effect genet
genom **group** higher lower **patient**
random **rate** rel respect stage trial versu

5110: Carbapenems (5)

analysi assai character clinic cluster data detect
differ famili gener host identifi infect **isol**
member number pathogen resist sensit

strain

5112: Nucleotide Transport Proteins (2)

activ adduct analog analogu **area** chemic
coli **compound** deriv enzym escherichia
insight live locat **new** novel plant
provid resist studi

5113: Glucose-1-Phosphate Adenylyl-transferase (5)

activ cell complex
compon cultivar differ enzym express
gene hybrid larg maiz
number plant regul rice
size small structur wheat

5115: Dipyridamole (2)

accumul arteri chines coronari differ
effect heterogen hypertens insight
mechan molecular **new** pressur
provid reduc reduct remain studi subtyp
vascular

5117: Bone Morphogenetic Protein Receptors, Type I (8)

associ bind cell develop differenti
earli express famili gene growth mutant
mutat pathwai process protein receptor
requir signal specif wild-typ

5119: DNA, Catalytic (5)

activ associ cell character demonstr ebv element
exhibit function gener insert model normal
phenotyp plai role suggest
target tissu valu

5114: Milrinone (1)

alter approach avail base bia **chang**
data distribut error **estim**
inform manag **method** model power probabl
produc product set statist

5116: Graphite (4)

analysi data dna dose earli
electrophoresi extract gel identifi
irradi **mass method**
posit proteom radiat ratio risk
stage **target** valu

5118: Phosphofructokinase-2 (4)

activ analys **analysi** cell decreas
enhanc enzym **express**
increas indic inhibit level
mice plai promot regul requir reveal
role state

5120: o-Aminoazotoluene (2)

affect analysi differ effect exposur induc induct
light mice predict presenc regress
respons schizophrenia signific
studi suggest variabl variat vivo

5121: Son of Sevenless Proteins (1)

analysi assai chromosom codon
detect determin dna factor
fragment growth interact
predict regress relationship sensit
signific specif substitut variabl
variat

5123: Gastric Inhibitory Polypeptide (1)

case control decreas diabet effect increas
insight modif modifi new prevent protect provid
rat reduc reduct report signific treat
treatment

5125: Periodic Acid (3)

base cell compar dai differ
evolut marker mean microscopi morpholog
new observ pair pattern predict primari
provid tumor type valu

5127: Estrogenic Steroids, Alkylated (1)

analys analysi antibodi assai
detect identif identifi includ
indic method novel perform rang reveal
screen sensit specif techniqu test wide

5122: Cytokinins (9)

activ arabidopsi cell differenti express flower
function leaf leav number plant
pollen product prolifer protein rate risk root
seed transgen

5124: Carboxymethylcellulose (1)

addit apoptosi cell chromosom convent cultur
death delet demonstr endotheli includ induc invas
loss multipl myeloma region
simultan singl studi

5126: Androstanols (3)

caus concentr dai diseas earli follow identif
identifi initi lead median month new
novel origin patient provid
screen stage year

5128: Antiplasmin (3)

activ cell defici develop
development effect endogen enhanc enzym
imag increas inhibit inhibitor morpholog
normal residu site suggest suppress tissu

5129: Methylenetetrahydrofolate Dehydrogenase (NAD+) (3)

associ case clinic compar concentr confid
control factor genet increas interv
mutat odd patient ratio risk sever
smoke studi symptom

5131: Ruthenium Red (1)

acid amino brain channel chromosom dna effect
fragment gene increas linkag loci locu map
neuron per potenti releas restrict stimul

5133: Calcium Channel Agonists (10)

activ cell dai decreas differ differenti
diseas effect famili increas
member normal phenotyp product report
respons role studi test tissu

5135: Propoxyphene (2)

base combin conclusions control data design
effect estim evalu follow healthi hospit inhibit
metabol method objective pair
patient studi subject

5130: Antigens, CD7 (5)

approxim area blood cell compar cultur differ
express flow higher interact leukemia lower major
marker mrna patient rate rel tumor

5132: Octamer Transcription Factor-2 (2)

associ contain core encod express frame
gene human identifi open
promot put read region regul regulatori relat
sequenc site transcript

5134: Corn Oil (1)

approxim compar concentr differ
distribut known larg local major mean
measur minor number observ rel respect
size small suggest valu

5136: UTP-Hexose-1-Phosphate Uridyltransferase (4)

activ compar control defici differ
enzym frequenc genet group high higher interact
level low model mutat new presenc provid signific

5137: Luciferases, Renilla (5)

activ assai cell chang correl decreas
detect develop express featur
gene increas interact level protein risk
sensit specif test transfect

5139: Niclosamide (1)

antibodi area clinic incid infect insight
live locat men mortal **new** patient
popul preval provid rate sever studi women
year

5141: 5-Amino-3-((5-nitro-2-furyl)vinyl)-1,2,4-oxadiazole (1)

administr anim bovin dai develop dose effect infect
inform inject insight mice mous **new**
provid rat syndrom transgen understand week

5143: Hepatocyte Nuclear Factor 6 (3)

anim combin compar **control** differ
effect evid femal **group** high
interact level low male model promot
studi support transcript treatment

5138: Luminol (4)

activ assai detect effect fish fluoresc
gene **group** hybrid model plai
potenti probe releas **respons** role
sensit situ stimul studi

5140: Tungsten (1)

altern anim control dai effect essenti exon expos
exposur increas indic induc inject necessari
rat requir splice suffici variant water

5142: Steroid 16-alpha-Hydroxylase (6)

activ compar **control** determin
differ enzym express **famili**
featur liver member metabol metabolit
posit protein rat **respons** specif studi
subject

5144: Argininosuccinic Acid (1)

compar **develop** development
differ enzym follow-up malign median
month normal patient pattern recurr similar
therapi **tissu** treatment tumour type year

5145: Receptors, Mating Factor (6)

activ alpha beta bind **cell** cerevisia
enhanc express identifi increas level
number receptor
recombin **respons** saccharomyc screen
specif strain yeast

5147: Flunarizine (1)

adult african american avail bodi
data databas ethnic experi **initi** intern
older origin popul releas second stimul
white **year** young

5149: Picrotoxin (6)

anim approxim decreas detect effect
function increas individu
major mice model neuron rat
receptor rel repeat respons
stimul **studi** time

5151: Inosine Triphosphate (1)

activ **chromosom**
compound deriv diverg duplic effect
enzym **evolut** evolutionari increas
lineag nitric origin oxid phylogenet **speci**
suggest synthas **synthesi**

5146: Mitogen-Activated Protein Kinase 10 (1)

activ event **initi** involv kinas lead
mechan methyl molecular occur
overexpress phosphoryl **process**
question **remain** rna step underli understand
understood

5148: Hydrocarbons, Aromatic (8)

acid **analysi** approach combin compar
correl differ extract famili **gene**
genet group higher mean
method **model** rate repeat
respect valu

5150: Fructans (2)

acid analysi bone **children**
clone densiti gene genotyp **high**
level low parent period point regress
sequenc site **time** variabl variat

5152: Vasoactive Intestinal Peptide (12)

acid alter **chang** decreas **effect**
enhanc **increas** mice model
peptid rat recent receptor reduc
report **respons** studi time
treatment tumour

5153: Cholesterol Side-Chain Cleavage Enzyme (7)

approach associ caus cluster
function gene individu
interact male mitochondri model mutant
mutat neg posit protein recombin rel
structur variabl

5155: Bisphosphoglycerate Mutase (1)

acid activ amino biochem biosynthesi
catalyt catalyz dehydrogenas **enzym**
enzymat fatti metabol pathwai reaction reductas retino
step substrat synthesi synthetas

5157: Arylsulfatases (3)

accumul **activ** compar cord decreas
differ effect **group** increas injuri
level mean nerv ratio respect spinal treat
treatment valu wound

5159: Annexin A4 (1)

bind biopsi **cancer** cell
differenti epitheli event express histolog
immunohistochem initi involv lesion occur
process prolifer prostat
specimen stain step

5154: Pyridoxine (4)

acid base children clinic dai differ dose earli effect
larg level local new number **patient**
phenotyp size small stress studi

5156: Phenylethanolamine N-Methyltransferase (2)

activ biosynthesi catalyt catalyz cell
dehydrogenas delai **enzym** enzymat
express fluoresc follow metabol persist
protein reaction reductas substrat transfect
transient

5158: Annexin A1 (3)

alter apoptosi cancer carcinoma cell
chang dai death includ inhibit
initi origin plai rang regul report
role second studi suggest

5160: Argininosuccinate Synthase (3)

activ biosynthesi case catalyt catalyz
chromosom dehydrogenas disord **enzym**
enzymat express gene metabol microarra profil
promot reaction reductas report substrat

5161: Hemopexin (2)

anim bovin breed compar **develop**
differ distribut earli identifi local
mean pattern pig respect screen stage studi
system type valu

5163: Purinones (2)

adapt alter bind **chang** compound decreas differ
effect form format **group** increas
inhibit natur releas **select** signific specif stimul
synthesi

5165: Pterocarpans (2)

activ analysi breast cancer cdna chain
classif clone cluster compound express fusion gene
human plant reaction sequenc
structur treat treatment

5167: Beclomethasone (1)

concentr control dai determin
effect femal healthi hospit increas male
measur microg microm min plasma respect
stimul studi **subject** trial

5162: Seminal Vesicle Secretory Proteins (2)

analysi base chromosom genet identifi isol
linkag locat loci locu **map** marker mutat
pair popul qtl **region**
sequenc trait valu

5164: Parathion (1)

assess **correl** effect enzym expos
exposur gene impact improv index **life**
physic plasmid **qualiti** recombin relat
relationship rna signific studi

5166: Hydroxymethylglutaryl-CoA Synthase (2)

alter **chang** decreas differ
distribut fish fluid fluoresc hybrid
increas light **local** modifi observ
pattern probe **protein** recombin situ
suggest

5168: Coatomer Protein (3)

accumul **activ** analys **analysisi**
chain form format gene indic **individu**
inhibit mice patient reaction recombin requir
reveal studi suggest surviv

5169: Diatomaceous Earth (2)

adult cell compar cultivar differ field higher
lower maiz older produc product **rate**
respect rice surfac versu wheat year young

5171: O Antigens (10)

activ bacteri coli detect encod escherichia event
evolut **gene** genet group involv mechan
organ posit process requir strain structur toxin

5173: Photoreceptors, Microbial (4)

assai base children cluster concentr

control detect differ extract form light

mechan molecular mutant process

protein regul sensit stabil

structur

5175: Tin (2)

applic case compar control dai degre differ divid
electron **group** light method microscopi
morpholog observ organ respect signific site technolog

5170: Teprotide (1)

activ apoptosi **associ** cell death dna
elev fusion gene induc inhibit level link partial
plasma relat serum studi suggest vector

5172: Gene Products, rex (4)

anim bind cell compar **control** demonstr
distribut express frequenc **gene** local
model mutant nuclear phenotyp plai
requir role specif suggest

5174: Tin Fluorides (1)

alter assess **chang** color composit
effect evalu increas intens laser **light**
measur morpholog observ red scale SCORE
treat **treatment** valid

5176: Dentifrices (1)

compar comparison concentr **differ** effect
energi **group** laser light measur microg
microm min observ **pattern** plasma respect signific
similar type

5177: AGAMOUS Protein, Arabidopsis
(4)

arabidopsi cell data **develop** differenti
famili gene includ leav life
member mutant **number** plant
protein qualiti regul root seed target

5179: Amino Acids, Cyclic (3)

arabidopsi concentr **gene** induc induct level
mean measur mutant new plai plant provid
ratio receptor respect **respons**
role serum valu

5181: Adenylate Kinase (6)

base data dynam enzym express gene growth
identifi interact **model** new
phenotyp predict propos protein provid sampl
screen sequenc simul

5183: Porphobilinogen (2)

arthriti chain clinic discuss diseas domin famili
joint **method** pain patient period point
random reaction recent regul techniqu
time trial

5178: Aminoxyacetic Acid (2)

assai detect distribut **effect** function induc
induct local mechan mice molecular mous prevent
protect **reduc** reduct respond
respons sensit stress

5180: Phleomycins (1)

condit **degre** differ fungal fungi heat host
infect **isol** pathogen pathwai plant rice
shock signal speci **strain** temperatur
wheat yeast

5182: Sotalol (1)

cardiac distal dog **effect** failur hand
heart imag left limb magnet prevent protect
proxim **reduc** reduct right segment ventricular
volum

5184: Naproxen (1)

african american averag calcul compar determin

differ ethnic hybrid mean measur modifi

paramet popul predict rang ratio respect

standard **valu**

5185: Receptor, EphA7 (1)

cancer carcinoma colon colorect compar dna

effect gene loop malign methyl

normal prevent promot prostat protect

reduc reduct **tissu** tumor

5187: Proto-Oncogene Proteins c-fes
(4)

cell differ distribut domain featur

group **human** line

local mutat nuclear overexpress protein region

sampl sequenc structur target transform
tumor

5189: Ristocetin (2)

associ bind clinic condit degre evolut experi factor
form format genotyp initi length long origin

patient polymorph repeat second
short

5191: Galactolipids (1)

activ arabidopsi block cell develop effect

inhibit inhibitor inhibitori invas
mechan membran novel plant potenti root

strategi suppress **target** therapeut

5186: Metalloporphyrins (5)

alter assess bind chang **combin** decreas

dna effect increas **level**

measur mechan mitochondri model mutat
oxid reduc regul score serum

5188: Semaphorin-3A (2)

activ case cell **function** includ
inhibit microscopi morpholog pancreat plai rang

report **role** secret suggest test varieti vitro vivo
wide

5190: Isopentenyladenosine (1)

alpha bone **cell** cellular **differenti**
express frequent induc macrophag marrow occur

occurr pathwai **prolifer** promot

protein receptor signal studi
transmiss

5192: Complement C2 (1)

abil abl capac complement condit cultur degre

demonstr determin experi highli initi intern

membran origin potenti properti receptor

second **specif**

5193: Vanadium Compounds (1)

activ area **associ** bind cell develop
effect examin factor growth inhibit link locat
method potenti relat studi target techniqu
therapeut

5195: Triethylenetetramine (4)

acid **activ** approach cell clinic
concentr control dai diseas featur healthi mean
mechan molecular respect risk subject
therapi treatment valu

5197: Calcium Channels, R-Type (2)

compar elev higher inhibit **level** lower
mice mous **plai** plasma **rate** region releas
role sequenc serum state stimul
suggest versu

5199: Zinc Sulfate (5)

base case compar data differ earli effect estim
group level new normal primari
rat report requir serum studi tissu treatment

5194: Glucaric Acid (1)

acid aggreg amino bind cell coloni copi deliveri
determin effici **form** format increas larg
number partiel peptid site surfac
total

5196: Sesquiterpenes, Guaiane (1)

cell chines determin differ enzym extract
gene heterogen identif identifi
includ inhibit line novel produc
product respect screen studi
subtyp

5198: Pancreatic Hormones (2)

alter **chang** content decreas
effect express factor flow growth
increas inhibit inject observ pancreat plai
rat reduc reduct **role** state

5200: Oxo-Acid-Lyases (1)

altern anim develop exon experi experiment
gene initi intern intron isoform **model**
mutat new origin provid second splice
structur variant

5201: Selenoprotein P (1)

amplif chicken determin differ distribut effect

express fluid gene her-2 her2 individu local

neg neu **posit** statu suggest treat

treatment

5203: Globulins (1)

abil abl anim bodi capac demonstr displai
elev exhibit experiment higher inhibit

level model plasma potenti
properti protein serum studi

5205: Protochlorophyllide (1)

addit analys **analisi** approxim
compar data enzym indic major map mutat

observ perform plant produc **product**
rel reveal studi yield

5207: Enteropeptidase (1)

CAUS coli compar consequ death differ disrupt excess

higher **human** lead lower monkei
pancreat prevent rate respect result secret versu

5202: Trimethoprim (6)

activ analysi base case clinic
diagnosi effect express form **group** identifi
model **patient** phenotyp report
resist structur studi test treatment

5204: Phosphatidic Acids (4)

acid activ amino **cell develop**
development differenti event form format **gene**
involv new pathwai **process** region report
sequenc signal studi

5206: Betacyanins (3)

alter approach assai blood bodi cdna cell
chang clone detect enzym extract
gene increas **new** provid report sensit sequenc
studi

5208: Chlorobenzoates (2)

approxim caus cell compar **differ**
differenti enzym **high** isol lead level low major
observ **pattern** presenc rel similar strain type

5209: Eukaryotic Initiation Factor-3 (7)

analysi base clinic combin complex effect
express growth increas interact measur
mrna normal phenotyp respons
score stimul **tissu** translat tumour

5211: Receptors, Epoprostenol (2)

absenc addit **blood** condit content degre
determin endogen **enhanc** flow
follow increas indic observ peripher persist
presenc receptor resist suggest

5213: Timolol (2)

arm clinic compar concentr
control effect efficac frequenc
higher improv lower random
rate releas respect stimul studi
treatment **trial** versu

5215: Benzyl Alcohol (2)

cell condit dai degre dose **effect**
extract **form** format fraction impact improv
life membran **method** physic
qualiti reduc reduct techniqu

5210: Glycogen Synthase Kinases (2)

analysi blot diseas **enhanc** identif identifi
includ increas induc induct novel peptid
potenti protein rang **respons**
screen target western wide

5212: 25-Hydroxyvitamin D3 1-alpha-Hydroxylase (7)

associ bone cell compar control correl
decreas **enhanc** human **increas**
level mechan normal ratio regul risk
serum signific studi tissu

5214: Apomorphine (3)

approxim condit copi degre **develop** earli
effect evid increas larg mice neuron
number rat reduc regul rel risk
stage support

5216: Polyribonucleotide Nucleotidyl-transferase (2)

analys **analysi** apoptosi bind blot cell
confirm content detect determin dna express
flow malign mutat protein reveal rna
tumour western

5217: Complement C4a (2)

alter approxim associ biolog case
chang class evid gene
haplotyp major normal polymorph provid
rel risk studi support system
tissu

5219: Boron (7)

analysi combin concentr develop
dose earli effect genet irradi
method product radiat
radiotherapi region report sequenc studi
target treatment variabl

5221: Castor Oil (2)

acid amino cell compound correl decreas
differ find increas larg level map
number previou report signific size small
studi tumor

5223: Smooth Muscle Myosins (2)

alter bind case chang data
databas evid identif identifi kinet map
mutant novel provid screen state
structur support switch transit

5218: Gonadotropins, Pituitary (3)

analysi base caus cluster compar control differ
elev frequenc group higher level observ pair
patient plasma serum set signific
studi

5220: Cyclodextrins (8)

activ approach cell design form
format interact limit model plai product
rate role state strategi
structur studi
system target time

5222: Calcium Channels, T-Type (1)

activ concentr data effect error estim
femal inhibit male mate
method microg microm min offspr power
reproduct sex sexual statist

5224: Nicotinamidase (1)

achiev activ advantag
approach design effect
exposur histon inhibit limit modul optim
problem provid regul regulatori requir
strategi success transcript

5225: Pentagastrin (1)

achiev approach behavior cognit
current design discuss disord factor
growth learn limit memori optim
problem recent seizur strategi stress
success

5227: Propiophenones (2)

apoptosi assai **cell** cytotox decreas
effect growth human **increas** induc
inhibit level line nuclear plai potenti **role**
suggest target therapeut

5229: Thiosemicarbazones (2)

absenc **acid** activ amino chain
defect **defici** diabet **enzym**
head infect insulin pcr polymeras
presenc reaction revers
substrat viral viru

5231: Xenon Isotopes (1)

blood complet continu count delai energi follow
human imag long-term
fusion lymphocyt measur partial peripher persist rat recoveri
spontan volum

5226: Receptors, sigma (1)

affect approxim **cell** develop gener major
minor modifi new novel observ potenti receptor
rel specif strategi studi suggest **target**
therapeut

5228: Cyclobutanes (3)

acid **activ** approxim bodi cell complex
compound form format health larg major
plai rel **role** size small stabil suggest
therapi

5230: Ether, Ethyl (5)

alter carcinoma **chang** compound
dai effect gener **high** increas interact
level low phenotyp potenti **rat**
releas report **stimul** studi vector

5232: Methoprene (5)

activ affect bind cell cultur drosophila
gene insect isol larva mass mechan
melanogast molecular point site stimul strain **time** wing

5233: Flunitrazepam (1)

affin alpha approxim beta **bind** effect
famili interact known ligand major
member minor observ **receptor** rel releas
site stimul structur

5235: Holmium (1)

administ administr analysi compar complex control
dai differ dose effect **group** inject
predict rat receiv regress signific variabl variat
week

5237: Myeloma Proteins (7)

addit convent differ effect includ interact larg
level model **multipl** myeloma
product serum singl size small studi treatment
tumour valu

5239: Activating Transcription Factor 6 (4)

activ cell differenti epilepsi express
factor follow growth membran prolifer promot
protein region regul report seizur
sequenc stress suicid vivo

5234: Aminobenzoic Acids (2)

activ agent **associ** concentr drug
effect enzym factor growth inhibit inhibitor link
resist studi suggest telomer telomeras therapi
treat **treatment**

5236: Hydroxy Acids (1)

acid amino concentr effect fatti increas
inject microg microm min new nucleic
patient plasma rat research retino
technolog telomer telomeras

5238: Vidarabine Phosphate (2)

alter approach **cell chang** clinic
combin effect event increas involv
occur open period point **process**
step strategi therapi **time** treatment

5240: Sp4 Transcription Factor (5)

activ analysi area bind cell
combin complex effect gene
human promot
protein report resist **respons** reveal
select site studi transcript

5241: Iodine Isotopes (3)

alpha cell cultur differenti effect flow
function includ mean measur
mechan molecular peptid prolifer rang
receptor stimulat treat **treatment** valu

5243: Caveolin 3 (5)

activ case diseas express field forc
gene gener imag measur mice
microscopi morpholog movement muscul
releas risk space stimulat tumor

5245: Prostatic Secretory Proteins (3)

anim base cancer demonstr earli featur
find mice model new normal
previou rel report stage structur
studi suggest tissu tumor

5247: Methemoglobin (3)

analysi assess blood chang differ estim
genet **group** mean measur
mechan molecular predict radiat risk score
signific valu variabl variat

5242: Receptor, Melatonin, MT2 (1)

activ administr bone **cell** dai dose effect
express follow induc induc inhibit receptor
respond **respons** suppress therapi treat
treatment week

5244: Ramipril (3)

combin compar control **effect**
factor higher individu inhibit **new**
organ plai provid rat **rate** reduc risk
role studi subject treatment

5246: Cytochrome-B(5) Reductase (3)

activ **cell** effect **enzym** factor
genet identif identifi influenc
isol line metabol multipl mutant novel
primari **screen** strain studi substrat

5248: Aminopterin (1)

compar **control** differ effect
element express frequenc higher insert integr iron
junction mutant mutat radiat remain signific treat
treatment wild-typ

5249: Poliovirus Vaccine, Oral (6)

assai case data detect differ earli group
isol new nucleotid pattern popul
region sampl sensit
sequenc state strain
studi viru

5251: Anthrax Vaccines (5)

area bind dai_data dose estim famili
gener improv isol life mechan member mice
qualiti sampl strain studi therapi week

5253: Cyclic ADP-Ribose (1)

aggreg alpha antagonist beta cell coloni convers
elegan form format indic ligand loop
neuron occur pathwai receptor
signal speci suggest

5255: Aromatic-L-Amino-Acid Decarboxylases (3)

activ alter chang decreas diseas
enzym exposur gene increas level month
neuron patient serum signific substrat
test therapi transfer vector

5250: Receptors, Kainic Acid (3)

assai base channel combin complex detect
effect function interact mass
membran method network pair predict
receptor resist sensit subunit transport

5252: Integrin alpha3beta1 (5)

adhes area bind cell demonstr
enhanc express form format
high increas interact
level low protein receptor requir
suggest tumour valu

5254: Neurotransmitter Uptake Inhibitors (2)

absenc cell concentr cultur delai
effect enhanc follow head
increas indic induc long-term membran
microm neuron persist presenc
rat suggest

5256: Ethylamines (2)

algorithm analysi base classif cluster data
gene hybrid method neg network new
normal posit predict profil provid
rat set tissu

5257: Puromycin Aminonucleoside (2)

assai **base detect** exposur express
extract **gene** includ kidnei microarra pair
plai rang renal **role** sensit state
varieti vector wide

5259: Dinitrochlorobenzene (4)

cdna cell clinic clone control differenti
distribut **function** gene gener
healthi isol local modifi presenc **protein**
sequenc studi **subject**
test

5261: Bence Jones Protein (2)

assai **detect** characterist common compar
featur kidnei **method**
monitor normal **protein** protocol rapid renal
sensit specif standard techniqu test
tissu

5263: Cholestenes (1)

applic approach bind biologi design develop
limit molecular new novel peptid potenti
provid research specif strategi success
target technolog therapeut

5258: Uridine Diphosphate Sugars (1)

activ arabidopsi cerevisia chromosom complet
enzym fusion linkag loci locu map
metabol partial **plant** residu root
seed **site** substrat yeast

5260: Metal Ceramic Alloys (5)

bone compar **control** data differ effect
estim follow light method mutant **number**
repeat requir studi subject test treat
treatment tumour

5262: Androstenediol (2)

approxim compar control differ effect femal
group interact level major male radiat
rat receptor rel system treat **treatment** vitro vivo

5264: Receptors, Corticotropin (3)

caus dai dose effect elev factor gene growth
hormon imag inhibit lead **level** multipl
mutat plasma receptor serum
stimul thyroid

5265: Hypochlorous Acid (3)

activ complex correl **differ** enzym
exposur extract improv life pattern point
qualiti signific structur studi substrat subtyp
test time type

5267: Dicarbethoxydihydrocollidine (2)

administr aggreg bodi coloni **dai** dose
effect **form format**
genotyp hepat inject liver **mice** mous
polymorph **rat test** transgen week

5269: Poloxalene (1)

concentr determin effect higher
increas low lower measur **microg microm** micromol
microscopi **min** morpholog observ plasma rang
respect surfac **test**

5271: Phosphoribosyl Pyrophosphate (2)

activ analysi base conform crystal determin differ
enzym event **human** inhibit involv pair
predict process regress **structur**
substrat variabl variat

5266: Rubber (4)

analysi associ classif cluster data diseas essenti

exposur factor health includ initi mutant posit

produc product recombin requir risk

studi

5268: Acetylerase (2)

acid **activ** analys analysi anim
complex control dna element **group**
insert integr interact model perform produc
product regul reveal studi

5270: Aprotinin (5)

activ adult bind cell children collect concentr
condit decreas degre factor gener

increas interact level receptor
regul **sampl** site year

5272: Abortifacient Agents (2)

approxim articl caus data

develop drug identifi includ lead
literatur major publish receptor regul rel
report resist review search systemat

5273: Dynamin I (5)

abil cell demonstr diseas domain essenti
function fusion indic mitochondri
model potenti presenc properti **protein** regul
requir state structur target

5275: Integrin alpha4 (2)

adhes cell domain exposur express follow-up
gastric gene median molecul **month**
patient rang recurr structur
target therapeut vitro vivo year

5277: Nucleic Acid Probes (6)

acid amino **analysi** base chain combin
detect fish fluoresc **hybrid**
label method perform posit **probe** reaction
reveal situ structur techniqu

5279: Phosphoenolpyruvate Carboxykinase (GTP) (5)

caus data diabet enhanc fish fluoresc gene
hybrid probe produc **product** promot
ratio regul **respons** risk situ
specif transcript valu

5274: N-Ethylmaleimide-Sensitive Proteins (3)

approxim caus **develop** differ
enhanc **gene** identifi larg major
number phenotyp plai popul rel resist
role screen **size** small suggest

5276: Galactosamine (3)

activ alpha **cell** chemokin class express
factor field induc liver **mice** mous
movement necrosi nf-kappab **receptor**
space transcript transgen tumor

5278: Clathrin Light Chains (3)

chain complex
diverg domain duplic **evolut**
evolutionari follow **gene**
membran pcr plai polymeras
reaction region requir
role sequenc target variabl

5280: Elastomers (2)

alter **chang** concentr decreas differ
effect imag increas larg light model
number patient prevent protect reduc reduct
repeat size small

5281: Melengestrol Acetate (1)

anim collect dai dose effect experi experiment

follow improv initi intern model oral origin

sampl second studi therapi treat

treatment

5283: Collagen Type V (2)

bone chain characterist common detect featur
fish fluoresc genotyp hybrid includ mean

patient peptid probe rang reaction
situ valu wide

5285: Inorganic Chemicals (1)

activ class data direct discuss

enzym evid hypothesi

metabol modul multipl mutant

mutat provid recent regul

regulatori substrat support
wild-typ

5287: Ketanserin (1)

alcohol bipolar decreas depress disord

effect increas level oral

person potenti prevent protect psychiatr reduc
reduct studi symptom target therapeut

5282: Sodium Pertechnetate Tc 99m
(2)

cell compar differ express form format imag
induc induct magnet mean measur paramet

ratio respect respons stimul

transfect valu volum

5284: Parainfluenza Vaccines (2)

biolog condit construct contain degre delet

develop development domain form

gene homolog mutat plasmid protein

recombin stabil stabi system viru

5286: Eosinophil Peroxidase (1)

carbon compar compound control differ divid electron

energi free group intens laser light

measur modif modifi respect signific solut studi

5288: Serotonin Antagonists (9)

activ area develop disord

earli effect increas individu

patient protein rat

receptor risk select stage

studi subject test time treatment

5289: Penicillin G (4)

approxim bacteri data host infect **isol**
lymph major metastasi metastat node pathogen
presenc primari rel **respons strain**
stress syndrom tumor

5291: Phosphopeptides (2)

bodi chicken compar **control**
differ enhanc form format frequenc gener
imprint increas indic **individu**
japanes residu site studi suggest weight

5293: Beryllium (2)

combin dose effect field forc
imag irradi larg measur movement
new number orient provid radiat
size small space
structur system

5295: Insulin-Like Growth Factor Binding Protein 6 (1)

analysi breast cancer carcinoma effect elev
express expression gene higher
identifi level microarra ovarian plasma profil serum
therapi treat **treatment**

5290: Indenes (4)

analysi apoptosi **cell** cluster compound differ
human identif identifi induc
induct larg mechan molecular novel resist
respons screen size small

5292: Ibotenic Acid (2)

associ bind dog element enzym
examin insert integr link microscopi morpholog observ
peptid receptor relat segment site specif studi
suggest

5294: Streptonigrin (2)

assess cancer **cell** control effect
evalu healthi identif **identifi** inhibit
line **measur** modif modifi novel scale
score **screen** studi

subject

5296: Receptor, Ciliary Neurotrophic Factor (3)

activ american apoptosi bind cell
complex correl death factor growth line
membran mutant **phenotyp** popul **protein**
receptor resist signific tumor

5297: Bacteriochlorophyll A (1)

acid amino bacteria compar control differ

divers gene healthi **isol** mean methods

respect rrna sequenc signific speci **strain**

studi **subject**

5299: Diosgenin (2)

activ apoptosi **bind cell** dna effect
environment factor fragment gene genet
influenc kinas line methyl promot protein
stabil trait variat

5301: Antitrichomonal Agents (1)

analysi condit degre **differ** dna
fragment hybrid isol patient pattern pcr
predict regress relationship signific similar strain
type variabl variat

5303: Methandrostenolone (1)

aberr **CANCER** chronic conclusions cornea
corneal correct diseas evalu examin
gastric intestin mean measur
methods mucosa ocular pylori studi thick

5298: Medroxyprogesterone (3)

analysi cluster express factor **gene**
growth identifi mechan median microarra
molecular month patient phenotyp profil
set treat treatment **tumor** year

5300: Finasteride (7)

activ **CANCER** data differ distribut
error **estim femal**
function increas **male**
method model prostat rat role select
sex test **treatment**

5302: Clomipramine (2)

assai **chain** compar detect differ
group higher lower pcr polymeras
quantit random rate **reaction**
real-tim revers rt-pcr target trial versu

5304: Cholestyramine (1)

adult analysi carrier factor identifi
independ novel older **patient** predict
regress relationship **risk** screen signific variabl
variats year young

5305: Complement C7 (1)

affect **bind** characterist collect common
complement determin distinct environment
factor featur genet highli influenc regul
sampl site **specif** studi unigu

5307: Complement C5b (1)

approxim chain characterist common describ
discuss distinct featur gener major
method observ pcr procedur
protocol reaction recent rel simpl techniqu

5309: Triamcinolone (3)

analysi arteri **base** classific cluster
combin dai differ diseas dose
effect inject month pair patient pressur
rat set therapi week

5311: Isradipine (2)

analys **analysi** chain clinic
combin diagnosi effect extract initi
mechan molecular origin perform reaction
receptor reveal studi system treat
treatment

5306: Complement Factor I (2)

acid base bind chain character characterist
common distinct factor **famili** featur
gener inhibit member pair **patient**
reaction risk similar state

5308: Procainamide (2)

biolog **cell** chain decreas effect environment
factor genet **human**
increas influenc level pcr
polymeras quantit reaction studi system trait
variat

5310: GTP-Binding Protein alpha Subunit, Gi2 (4)

caus cell compar **control** frequenc
gene **human** inhibit initi
level map marker mechan mice molecular
produc product regul requir time

5312: Deoxyguanine Nucleotides (5)

activ decreas **dna** form format
function genom **group**
human increas mechan methyl
organ produc product protein report structur
studi valu

5313: Hydroxylamines (1)

absenc allele associ character characterist
common distinct enzym featur frequenc gene
genotyp head metabol metabolit p450

polymorph presenc **protein**
typic

5315: Factor XIIIa (4)

case data event evid form format

function individu initi involv

mean measur phenotyp plai

process respect role subject

support valu

5317: Opsonin Proteins (2)

absenc assai caus children detect elev
enhanc identifi increas isol lead

level plasma presenc screen sensit
serum specif strain suggest

5319: Shab Potassium Channels (1)

allow appli applic CAUS **cell** conserv
develop fish fluoresc hybrid lead

method probe procedur protocol
rapid simpl situ standard techniqu

5314: Electron Transport Complex II
(2)

activ anim blood bovin breed chicken differ
diseas impact improv individu isol life

patient physic pig qualiti strain
studi surviv

5316: rab3A GTP-Binding Protein (1)

critic data demonstr depend direct essenti

evid function hypothesi indic maintain
mainten necessari phenotyp protein

provid **requir** suffici suggest
support

5318: Ferricyanides (2)

activ contain core dna domain encod
event extract gene inhibit involv methyl neg open
posit process radiat read recombin step

5320: Chloramines (2)

activ assai chain detect
determin evid **patient** pcr point
polymeras provid quantit **reaction**
real-tim revers rt-pcr sensit specif support time

5321: Glycine N-Methyltransferase (1)

analysi data dna evid genet
genom influenc **mechan**
methyl molecular predict provid recent
regress sequenc support treat
treatment variabl variat

5323: Calcium Pyrophosphate (1)

activ bone cell elucid **famili** histori
identifi involv kidnei **mechan** member molecular
pathwai poorli provid renal signal underli understand
understood

5325: Phosphoric Acids (5)

acid amino approxim base bind
combin compar **high** higher level low
major mean method peptid **rate** rel
respect test **valu**

5327: Phosphatidylinositol 4,5-Diphosphate (9)

acid **activ** cell channel combin earli
gene gener **high** higher **human**
interact level low protein **rate** rel repeat
respons signal

5322: Luciferases, Bacterial (1)

cell chang enzym express insight intermedi
kinet **new** provid random rapid
residu shift site slow **state** switch
transfect transit trial

5324: Hexanoic Acids (2)

acid activ amino chain
develop development enzym inhibit
isol mice mix mous **produc**
product reaction sourc strain
vitro vivo yield

5326: Myosin Subfragments (2)

activ base decreas defect differ gene
increas level light **mechan** molecular mutant
mutat observ pair **phenotyp** protein reduc vivo
wild-typ

5328: Quinic Acid (1)

analysi **area** classif **cluster** differ
enzym express gene identifi **larg** larger
live number **organ** profil set **size**
small studi transcript

5329: Organotin Compounds (1)

character concentr contain copi core determin
encod frame identifi increas larg novel

number open orf predict put
read total water

5331: Iridium (1)

acid activ amino anim bind develop electron

enzym experiment layer microscop microscopi

model morpholog observ shape studi substrat

surfac test

5333: Tranquilizing Agents (1)

activ anim assess compar
concentr correl differ evalu
measur microg microm min model pattern
scale SCORE signific studi surviv type

5335: Bromates (2)

approxim compar concentr data decreas

effect estim exposur gener increas

larg major method number rat rel resist

size small studi

5330: Methyltestosterone (1)

assess bodi concentr evalu extract hybrid

incid measur men method
mortal preval scale SCORE standard techniqu
valid weight women year

5332: Potassium Cyanide (1)

apoptosi articl current discuss drug factor focu

focus genet knowledg lymphoma
mitochondri molecular nuclear recent research
resist suscept transcript understand

5334: Calsequestrin (3)

combin diseas domin effect famili
function gene high
hospit interact level low mutat potenti
protein releas stimul structur treat
treatment

5336: Atractyloside (1)

cell clone damag dna endogen
enhanc gene heart increas involv
line mechan mitochondri
molecular overexpress repair sequenc
suggest underli understand

5337: Bongkreikic Acid (2)

accumul acid affin amino apoptosi
bind cell clone conserv essenti
extract function inhibitor interact line
mitochondri protein **requir** site suggest

5339: Choline Kinase (2)

absenc activ alter cell **chang** copi data
increas kinas larg line malign mechan
molecular **number** observ
presenc tumor tumour vivo

5341: Angiotensin III (2)

alter anim **chang** combin dai
decreas dose **effect** enhanc genet increas
individu inject month patient **popul**
rat releas stimul week

5343: Vaccines, Contraceptive (1)

anim biolog bovin breed cattl compar cow
effect milk pig porcin prevent protect
random rat reduc reduct studi system trial

5338: Adenine Nucleotide Translocator
3 (2)

abil acid **activ** bind compar content
control demonstr differ factor flow
frequenc **human** interact isol
potenti properti risk strain structur

5340: Lysophospholipase (3)

acid analysi blot caus cell conform differenti
enzym **express** fusion lead mice
mutant prolifer residu reveal site state
structur western

5342: Fenthion (1)

area caenorhabd cell differ dispers
ecolog **elegan** habitat identif
identifi live locat novel region
screen sea season speci studi zone

5344: Oxyquinoline (2)

anim cell combin effect evalu experiment
exposur follow human marker mean **model**
persist ratio respect **studi** tumor valu
vitro vivo

5345: Dodecanol (1)

cell cho circadian clock cyclic
drosophila effect expos
exposur feedback hamster indic
insect **loop** melanogast oscil period
suggest synchron time

5347: Sterigmatocystin (3)

alter bodi cell chang combin compar concentr control
dai differ dose effect evid form format
group process signific support week

5349: L-Gulonolactone Oxidase (1)

avail bone cdna **clone** data databas
express gene inform librari
method modul mutant program regul
regulatori sequenc techniqu tool wild-typ

5351: Retinoid X Receptor beta (2)

analysi chain collect core detect element
embryo fusion hybrid isol **model** nuclear
open plai reaction **role sampl**
strain suggest system

5346: Copper Radioisotopes (1)

activ analysi blot detect determin
effect express neg posit prevent protect protein
reduc reduct reveal **specif tumor** vitro vivo
western

5348: Trichloroethylene (6)

analysi anim assess carcinogen chemic data
effect expos **exposur** function
genotox increas **model** mutagen new organ
provid risk studi toxic

5350: Oncogene Proteins v-erbA (1)

alpha cell chromatin conserv cytoplasm
dimer form function histon human local
mammalian **nuclear** nucleu
overexpress protein **receptor**
stabil stabl transform

5352: Retinoid X Receptor gamma (4)

abil alpha beta bind blood cluster compar
concentr control **differ** express
gene interact life pattern properti
receptor regul similar type

5353: Picolinic Acids (2)

bodi compound contain core diet extract
fraction **function** improv life
light obes open organ physic qualiti random
studi trial weight

5355: Norethindrone (2)

abil abl capac damag dna experi identif
identifi novel **organ** particip
plai possibl potenti process properti repair
role screen work

5357: Cytochrome c Group (1)

acid amino anim cell content cytometri determin
develop dynam experiment flow human line load
model provid simul **structur** studi
technolog

5359: AMP Deaminase (4)

activ alter chang compar **control**
copi correl differ femal frequenc **gene**
group higher increas male **mutat**
number patient sampl signific

5354: Betalains (2)

assai blood compar **detect**
differ evid extract higher larg lower
peripher provid **rate** report sensit
size small specif studi support

5356: Iridium Radioisotopes (1)

applic behavior **bind** cognit complic
develop learn memori **method**
new oper patient perform postop procedur
research surgeri surgic techniqu technolog

5358: Caerulein (5)

analysi cell combin compar degre
effect evid express higher
number pancreat rate reduc reduct
requir reveal secret studi subject treatment

5360: Anesthetics, Combined (2)

affect anim assess dai differ distribut effect
evalu **group** inhibit local measur
method procedur protocol rat score
standard techniqu valid

5361: 2,6-Dichloroindophenol (2)

associ cultur fungal fungi high isol
level low method mix network pathogen
predict produc **product**
receptor sourc studi tumour yield

5363: Azithromycin (5)

area care **cell** combin
effect femal infect inform
inhibit male manag medic nurs
particip person physician practic
resist **sampl** studi

5365: UDPglucose-Hexose-1-
Phosphate Uridyltransferase (2)

activ clinic common delet densiti diagnosi
essenti featur genet high identifi level low patient
popul requir sampl screen test yeast

5367: Zein (4)

activ analysi base bind chang contain
differ element **gene** genom insert
integr interact local pattern **region**
repeat reveal **sequenc** site

5362: Dibenzazepines (1)

absenc **cell** condit conserv current degre
differenti discuss express head
induc induc inhibitor mammalian neck **presenc**
prolifer recent suggest temperatur

5364: Selenium Compounds (6)

area cell chang **concentr**
dai decreas effect enhanc **increas**
individu male microg microm microscopi
min morpholog observ **structur** time
treatment

5366: Halorhodopsins (4)

anim assess case correl domain extract
featur identifi isol measur **model**
neg novel peptid **posit** protein score
screen **structur** target

5368: Hexanones (3)

adapt caus cell differ evolut femal form
format genet **group** interact male
mechan molecular mutant rang
select target valu variabl

5369: Galanin-Like Peptide (1)

behavior compar control differ femal
group higher inject level male mate
mutant normal rat reproduct serum sex sexual
signific tissu

5371: Host Factor 1 Protein (3)

analysi blot character coli express melanoma
model mrna phenotyp plai protein
region rna **role** sequenc structur
suggest transcript translat western

5373: Complement C3a (1)

activ alpha bone **cell** cellular chemokin
control factor function induc involv marrow
mechan modul necrosi nf-kappab
receptor **regul** regulatori role

5375: Lymphocyte Antigen 96 (3)

caus **cell** differenti dna follow
genotyp **interact** lead mean
measur **mechan** mice
molecular p53 polymorph prolifer
receptor surviv **valu** vivo

5370: Receptors, Glucagon (5)

chromosom dai express linkag loci locu
map mice new pancreat plai qtl
receptor region residu
role secret sequenc site tumour

5372: Glyoxal (2)

analysi approxim determin differ
distribut dna flow fluid form
format level **local** major method
observ point rel specif suggest **time**

5374: Heterogeneous-Nuclear Ribonucleoprotein Group M (2)

approxim bind **cell** complex express function
gene hospit identifi **interact** major
melanoma protein region rel rna sequenc
signal site suggest

5376: Diamond (2)

compar concentr current decreas discuss dose
effect **increas** irradi level light
organ radiat radiotherapi recent reduc research
rice understand wheat

5377: RNA, Transfer, Asn (1)

arg code **codon** dna
interact mutant mutat nicotin
nucleotid posit pro residu result singl
site stop **substitut** suggest
synonym usag

5379: Gemfibrozil (2)

cell content correl cours determin differ differenti

end event flow involv light line observ period

point process prolifer signific **time**

5381: G Protein-Coupled Inwardly-Rectifying Potassium Channels (1)

alpha analysi beta blot compar comparison

confirm detect **differ** express

ligand northern pattern protein **receptor**
reveal similar thyroid type western

5383: Cellobiose (1)

accumul **activ** aspergillu caus compound
deposit examin extent find fungal fungi fungu inact isol
observ pathogen produc speci suggest survivin

5378: Aspartate-tRNA Ligase (2)

algorithm base code **codon**

data databas **form**

format gener inform

method network nucleotid

posit predict produc **product**

set structur **substitut**

5380: Cardioplegic Solutions (1)

action content cytometri delai determin

effect enzym extract flow follow increas

load long-term measur persist potenti puls

record releas **stimul**

5382: Catechols (8)

activ affect compar compound concentr

control differ dna effect express
group increas level pattern plai

popul **role** studi subject suggest

5384: Protamine Kinase (1)

analysi blot **CAUS** cell

confirm death detect **express** factor

growth lead level mrna northern

overexpress protein reveal syndrom transform
western

5385: Tranexamic Acid (2)

activ anim blood cell combin data

differenti earli effect includ literatur model

number organ possibl publish report

search stage studi

5387: Hesperidin (1)

alter analysi bind chang decreas

event gel increas involv level mass mean
measur PROCESS protein ratio respect serum
site valu

5389: Diacylglycerol Cholinephospho-
transferase (2)

breast cancer cell clone concentr defici
differ express fluoresc form format
gene hybrid interact line pattern similar
tumour type vector

5391: Ruthenium Radioisotopes (1)

algorithm approach combin data

effect improv life mean measur

method mutat network

predict problem propos qualiti

ratio respect set valu

5386: Hydroxyestrones (2)

adapt CAUS cell compar compound death decreas
dna effect growth human

increas lead level metabol prevent
reduc reduct result select

5388: DNA, Catenated (1)

affin bind bound complex dna dynam
exon field interact model movement predict
protein residu simul site space specif splice variant

5390: Proadifen (2)

alter analysi approxim chang data

decreas evid hypothesi increas loss major

malign mechan molecular observ provid rel

suggest support tumour

5392: Pivampicillin (1)

analysi blot confirm detect determin
experi express extern final follow

initi intern membran origin
protein resist second seri subsequ
western

5393: Brucella Vaccine (2)

abil capac combin compar demonstr differ effect
group immun isol mean measur
properti ratio recombin respect signific strain
vaccin valu

5395: RNA, Heterogeneous Nuclear (1)

cardiac effect environ environment
express factor genet heart
herit influenc level melanoma mrna
protein rna studi thyroid trait twin variat

5397: Alzheimer Vaccines (3)

accumul **activ** analys analysi care
data **diseas** effect health immun indic
induc induct mice presenc **respons**

reveal therapi treat

treatment

5399: Chrysenes (2)

activ chines data deçreas determin
differ effect enhanc exposur **increas**
level light **method** rat region sequenc
specif studi subtyp techniqu

5394: Pyrrolizidine Alkaloids (2)

abil abl area **base** capac
cell demonstr differenti express
follow **form format** liver
pair patient potenti **properti**
rat requir speci

5396: Iron Radioisotopes (2)

analysi classif **cluster** defect dose effect
exposur field forc inhibit irradi movement
mutant mutat radiat
recent **resist** space vivo wild-typ

5398: Liver Glycogen (1)

acid amino anim bovin cell data
differenti direct effect evid express fatti
gene hypothesi prolifer provid rat
receptor suggest support

5400: Imino Acids (2)

activ approach bind control design differ
find **group** membran novel potenti
previou protein rat report site strategi studi
target therapeut

5401: Neptunium (3)

combin compar control data effect estim
form format healthi **human** method
normal reduc region requir sequenc structur
studi **subject** tissu

5403: Silicate Cement (1)

case cleft clinic complet condit criteria degre diagnos
diagnosi diagnost genom heat laboratorii novel
patient potenti sequenc target
temperaturi therapeut

5405: Pyrrolidinones (4)

action **activ** bind effect electr event
increas involv potenti process puls record releas
respons rest **stimul** threshold vitro vivo wave

5407: Appetite Depressants (1)

alcohol continu cost delai **effect**
factor follow long-term manag medic oral
persist practic prevent protect recoveri reduc
reduct **risk** spontan

5402: Sulfenic Acids (1)

acid activ amino chain concentr induc induct
kinas microg microm min oxid pcr polymeras quantit
reaction real-tim respond **respons**
revers

5404: (R)-2,3,4,5-Tetrahydro-8-chloro-3-methyl-5-phenyl-1H-3-benzazepin-7-ol (3)

adapt administr alcohol alpha beta concentr
dai depend dose effect mean oral
patient rat **receptor** regul
select target valu week

5406: Estrenes (3)

action **activ** domain **effect**
electr increas inhibit potenti produc
product puls record reduc releas respons
rest **stimul** test threshold wave

5408: Scopolamine Derivatives (3)

arm assess associ clinic compar **dai**
dose evalu improv interv measur
random ratio **risk** score studi
test treatment **trial** week

5409: rab4 GTP-Binding Proteins (1)

chang class embryo function host infect
intermedi kinet mechan membran modul
pathogen protein regul regulatori
role state switch transit transport

5411: Cefaclor (1)

analysi antibodi case chain chines collect
detect determin differ heterogen inhibit level
pcr polymeras reaction report sampl
serum studi subtyp

5413: Carnitine Acyltransferases (4)

acid amino assai concentr detect
gene high identif identifi level low
mutant novel rat recombin requir
screen sensit structur studi

5415: Toll-Like Receptor 1 (4)

adapt associ chang cluster data
evolut express gene genom identifi individu
plai product role screen select structur
studi subject suggest

5410: DNA Topoisomerases, Type I,
Bacterial (2)

activ character characterist common condit degre dna
enhanc enzym factor featur gene
growth increas plasmid recombin substrat
temperatur transfer vector

5412: Evans Blue (1)

activ cdna cell clone data elev encod enzym
gene includ investig level plasma pool
rice sequenc serum studi substrat wheat

5414: Acetylcarnitine (4)

acid amino chain dai dose effect
evid express method model pcr plai
polymeras provid reaction reduc role state
support test

5416: Receptor, Fibroblast Growth
Factor, Type 5 (2)

abil abl capac conserv copi cultur demonstr domain
evolut express gene highli
human increas larg mammalian
number potenti properti receptor

5417: Actinoid Series Elements (1)

analysi assess chines differ factor heterogen
impact improv life physic predict qualiti
regress relationship **risk** signific studi
subtyp variabl variat

5419: Trichloroacetic Acid (3)

acid amino analys **analysi**
anim chain dai decreas effect **high**
increas level low
model pcr rat reaction reveal studi
target

5421: Procaine (2)

associ caus compar content decreas degre
determin extract flow **increas**
interact lead mean measur method multipl
rat ratio risk valu

5423: Ninhydrin (1)

care **case** commun counsel experi home
hybrid inform interview knowledg nurs
organ particip person physician
questionnair rare report structur survei

5418: Shiga-Like Toxin II (3)

assai base chain coli **detect** dna
escherichia fragment **gene** isol method
pair pcr posit reaction **sensit** specif splice
strain variant

5420: Benzophenoneidum (1)

approach **assai** biopsi case design
detect evalu gener histolog
immunohistochem lesion limit neg **posit**
sensit specif specimen stain strategi test

5422: Epoxy Resins (2)

approach design enhanc experi
extract fish fusion hybrid incid increas
initi limit **model** origin probe
rang recombin situ strategi women

5424: Neurokinin A (2)

bind blood cell compar concentr control
differ famili group inhibit
line member pattern peptid receptor regul
signific similar site type

5433: Technetium Compounds (1)

analysi breast **CANCER** gel lesion lymph mass metastas
metastasi metastat new node **patient**
primari prostat proteom research stain technolog tumor

5435: Ovomucin (1)

african american anim black bovin breed differ embryo
ethnic extract includ mass milk pig popul
protein rang varieti white wide

5437: Estriol (5)

approxim **associ** birth compar
data detect fetal identifi increas level
major matern **patient** pregnanc
rate ratio rel **risk** screen studi

5439: Linseed Oil (1)

acid administr amino bodi code codon dai
dose elev **level** lipid nucleotid plasma
posit rice serum singl substitut week weight

5434: Egg Proteins, Dietary (1)

african alter american **chang** condit
decreas degre delai differ ethnic follow increas
long-term manag observ persist popul
protein temperatur white

5436: Amino Acid Transport System L (2)

cell codon copi enhanc enzym factor
growth includ increas larg light membran
number rang remain resist
substitut suggest transport wide

5438: Phosphogluconate Dehydrogenase (2)

african american asian black cluster
data differ ethnic european **genom**
group initi normal origin popul
preval sequenc south **tissu** white

5440: Carbon-Carbon Double Bond Isomerases (1)

allel delai electron essenti follow genotyp
layer long-term maintain microscop
microscopi morpholog observ
persist polymorph recoveri **requir**
shape surfac syndrom

5441: Bezafibrate (2)

adhes analys analysi blot **cell** detect
differenti express **level** lipid
malign plasma primari **prolifer** protein
serum signal transcript **tumour** western

5443: Antigens, CD164 (1)

analysi **CaUS** cell chromosom death delet express
gene identifi lead loss **mice**
microarraimous primari profil promot region
transcript transgen

5445: Nuclear Factor 90 Proteins (3)

acid cell chromosom cluster control differenti
function gene hybrid identifi
interact modul phenotyp protein **regul**
regulatori rna role translat tumour

5447: Factor For Inversion Stimulation Protein (2)

bind coli control **correl effect**
genet healthi mechan molecular neg
popul posit promot reduc
reduct requir signific studi
subject vivo

5442: Pyridoxaminephosphate Oxidase (1)

activ data **effect** enzym femal includ male
pool prevent protect reduc reduct sex sexual
splice **studi** substrat treat
treatment variant

5444: Nuclear Factor 45 Protein (1)

adjac cell compar cytoplasm gene induc induct kidney
lymphoma **normal** nuclear promot renal residu
respond **respons** rna site **tissu**
transcript

5446: Scavenger Receptors, Class A (3)

adjust **ASSOCI** confid data diseas earli
identifi **increas** interv odd popul
posit ratio residu **risk** screen
site smoke stage **studi**

5448: Gliotoxin (2)

anim area **base correl effect**
experiment **model** mutant pair
pathogen potenti produc **product**
reduc reduct regul signific stimul studi vivo

5449: PAX9 Transcription Factor (1)

associ case close compar control examin
find healthi investig link observ possibl relat
relationship report signific speci studi subject suggest

5451: Penicillinase (2)

acid bind caus compar differ flow **high**
higher individu infect larg lead level low
rate resist size small
treatment

5453: Caustics (1)

blood case **chain** clinic detect
mild patient pcr peripher polymeras
present quantit **reaction**
real-tim report revers rt-pcr **sever** sign
symptom

5455: 5-Hydroxytryptophan (2)

anim bodi **case** caus clinic dai
diagnosi identif identifi individu induc lead
mass **model** patient report
respons screen studi weight

5450: Viomycin (2)

associ defect drug encod form format gene
gener indic isol mutant mutat
open report **resist** strain studi suggest tuberculosi
wild-typ

5452: Talin (4)

adhes base bind cell compar decreas
differ evid increas new observ
pattern presenc provid rang regul similar
support type valu

5454: MafK Transcription Factor (2)

differ evid express includ induc induct larg
modifi **number** plai provid rang repeat
respons role size small support
test valu

5456: Oleic Acids (4)

administr **associ** case cell
combin dai domain dose effect
famili member mice multipl peptid
protein report singl studi surgeri week

5457: Permethrin (4)

approxim assai concentr detect determin
drosophila effect enzym **gene** inhibit
major metabol microm rel repeat resist
respect sensit treatment valu

5459: Toll-Like Receptor 10 (2)

abil **activ** associ cancer cell confid
interv mice new odd presenc properti prostat
provid ratio receptor risk smoke specif

studi

5461: Oncogene Protein v-crk (1)

activ cell embryo express human
imag invas kinas magnet
matur oncogen oocyt overexpress
phosphatas phosphoryl signal stat3
transform tyrosin volum

5463: Phosvitin (1)

bind compar conserv cours **decreas** gene
increas level mechan mice
moleculat mous mutat period point reduc time
transgen underli understand

5458: Peplomycin (1)

assai carcinoma **cell** data
detect direct evid her-2 human
hypothesi line neg **posit** provid
resist sensit specif support test
tumor

5460: Primidone (1)

addit alcohol alpha beta **combin**
depend effect ethic involv **mechan**
mice molecular mous oral
receptor research studi transgen
underli understand

5462: Tiapride (1)

adult **case** diagnosi elderli literatur lung
mean neg old older peopl posit present rare
report statu studi year young younger

5464: Phosphofruktokinase-1 (1)

abil abl activ analys **analysi**
capac codon data delet demonstr displai
enzym exhibit indic perform potenti properti
reveal substitut substrat

5465: Steel (2)

chain compar **differ** effect event hybrid mean
method organ pattern predict process reaction
specif techniqu therapi treat
treatment type valu

5467: Receptors, Lipoxin (2)

affect bone **cell** core encod express frame
gene identifi inhibitor line marrow
mice mous open read receptor specif
suggest transfect

5469: Cortisone (6)

activ allel case children clinic concentr
enhanc enzym genotyp growth level mechan
metabol method organ patient polymorph
subject thyroid valu

5471: Immunoglobulin mu-Chains (5)

associ caus dna earli form
format gene **genom** lead mice
normal process recombin regul
respons sequenc stage state
tissu variant

5466: Farnesyl-Diphosphate Farnesyl-transferase (1)

code codon compar concentr differ greater high
higher lower nucleotid observ posit **rate**
respect similar singl speci substitut suggest versu

5468: Azasteroids (3)

assess cancer evalu improv
inhibit life **measur** produc
product qualiti regul risk
score signific studi **test**
tumor variabl vitro vivo

5470: Pharmaceutical Solutions (2)

compar dai differ diseas dynam higher
individu lower manag mean medic
model paramet predict **rate**
respect simul specif tumor valu

5472: Digitalis Glycosides (1)

activ breast cancer **caus** cell consequ
death disrupt effect excess function inhibit
interact kinas lead phosphoryl
prevent protein result signal

5473: Cardiac Glycosides (1)

addit alpha basi better compound develop gain inform
insight involv mechan modifi molecular
new novel provid recent receptor underli
understand

5475: Butanones (2)

analys analysi cell critic demonstr depend
deplet essenti establish function indic maintain
mainten necessari normal **requir**
resist reveal suffici tissu

5477: Oncogene Proteins v-myb (1)

addit assai cell chicken **detect**
differenti endogen **enhanc**
express histon increas **individu**
multipl p53 prolifer **sensit** singl
specif suggest test

5479: Latex (4)

cluster compar concentr **control**
differ dna effect extract fraction
function gastric level mechan
mutant pattern presenc protein reduc
respect valu

5474: Anhydrides (2)

acid allow amino **concentr** dai
develop mechan **method** microg
microm min molecular **new** organ plasma
protocol provid rang techniqu wide

5476: Cimetidine (3)

allel concentr enhanc gastric **gene**
genet genotyp identif identifi increas level
novel polymorph primari rat **screen** serum
tumor vitro vivo

5478: Samarium (3)

allogen anim cell dai donor earli featur
graft mean method model multipl
patient recipi **sampl** stage stem
structur
transplant valu

5480: Alprostadil (3)

base dai decreas differ dose effect end increas
marker pair period point random receiv
studi time ^{treat} treatment trial
week

5481: Papaverine (2)

administr approxim compar concentr dai
dose effect improv life major mean
normal patient qualiti rat
rel tissu trial valu week

5483: Factor XIIa (2)

adhes aggreg event factor form format
identif identifi initi involv mass novel
nuclear occur platelet process
protein screen stabil step

5485: RNA Cap Analogs (2)

acid affin amino bind bound complex
domain interact mean mrna mutat plai protein
ratio respect role site structur translat valu

5487: Mitogen-Activated Protein Kinase 14 (1)

activ affect apoptosi autosom compar decreas domin
famili increas inherit kinas level
mutat nuclear pathwai phosphoryl protein recess
reduce signal

5482: Phentolamine (1)

administ administr approach copi dai
daili design dose follow hour limit
number period point random receiv
strategi time trial week

5484: Soluble N-Ethylmaleimide-Sensitive Factor Attachment Proteins (1)

assembl bind compar complex compon
decreas domain endotheli essenti factor form
function growth increas interact
level protein recruit reduce subunit

5486: Receptors, Adrenergic (2)

acid algorithm allel data develop
genotyp improv method network polymorph
predict random receptor region sequenc
set test treat treatment trial

5488: Ceramide Trihexosidase (1)

accumul activ barrier constitut densiti
exhibit extrem gap high higher inact iron junction
level low lower membran skin suggest synthesi

5489: AraC Transcription Factor (1)

caus cellular control critic function **gene**
involv kei lead mass mechan modul **mutant** mutat
plai regul regulatori **role** suggest wild-typ

5491: Trityl Compounds (1)

acid amino analysi channel determin differ
independ induc induct measur metabol predict
regress relationship respond **respons**
signal signific variabl variat

5493: Arbutin (2)

acid adapt complex compound differ earli
evolut genet **group** length long natur
neg phase **popul** posit repeat select short
stage

5495: Adaptor Protein Complex alpha Subunits (1)

achiev approach character design identif
identifi limit membran mutant
mutat novel optim **phenotyp**
protein **screen** strategi success suggest
transport wild-typ

5490: Apamin (2)

activ block channel compar control effect
healthi induc induct **inhibit**
inhibitori loss mechan molecular
respons structur studi
subject suppress underli

5492: Receptors, Neurokinin-3 (1)

absenc **concentr** dai determin
dose effect head increas microg microm min
modul observ ovarian plasma **presenc**
receptor regul regulatori week

5494: Testolactone (1)

abnorm anomali bone **cell** congenit defect ear
germ hear hormon kidnei loss malform marrow renal
report retard sperm **syndrom** women

5496: Polyribonucleotides (1)

aggreg anim area coloni convers differ
experiment **form format**
indic interact larg larger **model** number
recombin size small studi suggest

5497: Acetazolamide (5)

acid amino analysi blot children
develop development effect
express famili member mice mous mutat
patient respons test transgen treat
treatment

5499: Dianisidine (1)

analys **analysi** band blot
confirm demonstr detect determin examin
express iron junction northern oxid protein
residu reveal **site** southern western

5501: Dermatan Sulfate (2)

analysi cell determin differ diseas distribut
express independ local normal
predict receptor regress relationship
sampl signific **tissu**
transplant **variabl** variat

5503: Pergolide (1)

affect continu data delai disord evid find follow
hypothesi long-term pathwai **patient**
persist provid recoveri schizophrenia signal studi
suggest support

5498: Cyclotides (1)

abil abl adapt approach capac conform
demonstr design experi form limit natur
organ possibl potenti properti
select stabil strategi
structur

5500: Receptors, Polymeric Immunoglobulin (6)

caus cell chronic dai decreas diseas dose
enhanc evid express growth identifi
increas intestin mechan regul
rel screen site support

5502: Interleukin-9 (2)

abil associ biolog data direct **evid**
gene haplotyp hypothesi **level**
mice mous polymorph properti
provid serum snp **support**
system transgen

5504: Transcription Factor DP1 (3)

cell cycl data decreas direct enhanc evid
form format function hypothesi
increas induc p53 provid
regul requir **respons** suggest
support

5505: Oxacillin (1)

agent assai concentr **detect** determin drug

effect host infect light microg microm min

pathogen sensit specif **test** therapi treat

treatment

5507: ADP-Ribosylation Factor 1 (4)

abil abl acid **activ** bind capac cell
demonstr growth **interact** normal organ

plai potenti properti protein regul role
suggest **tissu**

5509: Hydroxytestosterones (2)

acid **activ** amino cell concentr
differenti enzym **express** identif identifi
inhibit metabol mix novel produc

product prolifer screen sourc yield

5511: Quinpirole (1)

chang event incid intermedi involv kinet
men mortal occur preval **process**

rate receptor slow **state** step switch
transit women year

5506: RNA, Nuclear (1)

bodi compar data **differ** drosophila evid
hypothesi isol larg larger number **pattern** provid
similar size small strain support type weight

5508: Syntaxin 16 (1)

allele chicken differ divers dna gene genet

genotyp imprint **individu**

japanes methyl polymorph **popul** promot
receptor studi suggest technolog variat

5510: Phencyclidine (5)

affect caus combin dai data effect featur
function high interact

level low neuron rat receptor report
schizophrenia stress studi suggest

5512: Dysprosium (1)

cell **condit** degre discuss dose
effect experi field heat irradi movement order
organ place possibl process radiat
shock space temperatur

5513: Cephalosporinase (1)

class concentr design determin
famili hospit main mean measur
medic member **model** objective paramet
patient ratio respect **specif** studi valu

5515: Phthalic Anhydrides (1)

activ antibodi associ bladder cell character
exhibit human includ keratinocyt line mice
phenotyp skin studi suggest tract urinari vitro
vivo

5517: Heptanes (1)

CAUS cell consequ death disrupt dose excess
express induc induct irradi **lead** line loss mechan
prevent radiat respond **respons**
result

5519: Ribonucleoprotein, U7 Small Nuclear (2)

altern analysi classif cluster
develop development domain
exon express iron isoform junction mrna protein
residu rna set site splice variant

5514: Proto-Oncogene Proteins c-yes (1)

activ apoptosi assembl cell **complex** compon death egfr
induc induct kinas oxid pathwai phosphoryl protein
respond **respons** signal stress subunit

5516: Monocrotaline (3)

administr anim compar **control** dai diseas
effect elev frequenc higher increas induc inject
level mutant plasma **rat** resist
serum week

5518: Receptors, Histamine (1)

assess delet diverg duplic evolut
evolutionari impact **improv**
individu **life** origin physic
qualiti region segment
sequenc studi suggest vitro vivo

5520: Pituitary Hormones, Anterior (2)

cell chromosom cycl elev **express**
expression gene germ lesion level line mitochondri
neg nuclear **patient** plasma posit
serum sperm stain

5521: Technetium Tc 99m Exametazime (1)

brain condit epilepsi evalu gener **imag** magnet measur
mri **patient** perform reson respons
scan seizur **stress** studi suicid tomographi volum

5523: Turpentine (1)

alter approxim **chang** compar
CORREL decreas differ increas larg larger
major number observ produc **product**
rat rel signific **size** small

5525: Lysostaphin (1)

activ affect alter caus **chang**
decreas defect effect increas **mutant**
mutat observ pancreat prevent protect reduc
reduct secret signific **wild-typ**

5527: Deltaretrovirus Antigens (1)

antibodi blood compound follow-up induc induct
lymphocyt lymphoma median month occur occur
patient peripher recurr respond
respons studi transmiss year

5522: Meptazinol (1)

anim compar core differ drug experiment find
higher hybrid lower model open previou
rate report respect similar studi suggest
versu

5524: Diaminopimelic Acid (1)

assembl cleavag coli **complex** compon
defect deriv escherichia metabol **mutant**
mutat **peptid** proteas recognit
residu **site** specif subunit synthet wild-typ

5526: beta-Crystallins (2)

clone core diseas electron encod **express**
famili gene identifi member
mice microscopi morpholog mous mutant
open reveal structur transgen wild-typ

5528: Tetrahydrocortisone (1)

decreas factor **femal** gender growth
incid increas level **male** mate
men mortal offspr preval reproduct sex sexual
thyroid women year

5529: Etiocholanolone (1)

associ compar **control** confid
decreas differ factor femal frequenc growth
increas interv level male ratio risk sex
signific smoke studi

5531: Taurocholic Acid (1)

alter anim **chang** compar decreas differ
effect genet higher increas infect inject lower
observ **rat rate** respect therapi treatment
versu

5533: Pentobarbital (2)

caus compar **control** differ earli
essenti frequenc independ indic lead necessari
produc **product** rat
requir signific stage suffici variabl yield

5535: Vaccines, Virosome (2)

antigen bind cell fusion immun impact improv
induc induct life line **new** organ physic possibl
protein provid qualiti **respons**
vaccin

5530: 11-beta-Hydroxysteroid Dehydrogenase Type 1 (3)

anim compar experiment femal form format
growth higher incid lower male men
model mortal preval **rate**
studi valu women year

5532: Anesthetics, Dissociative (2)

acid **activ** anim compar concentr
control differ effect femal
frequenc higher increas influenc level male
point **rat** report studi time

5534: Anesthetics, General (2)

behavior dai **develop** dynam
effect improv increas inject life
model number particip
qualiti **rat** releas simul state stimul studi
week

5536: Nitroarginine (6)

combin copi correl data dose effect evid
function increas larg measur mechan
number radiat rel score size
small studi tumor

5537: Myo-Inositol-1-Phosphate Synthase (1)

analysis blot clone detect duplic event evolut
evolutionari express gene involv multipl occur

process **protein** reveal
sequenc signal step western

5539: Pindolol (1)

adhd anxieti assess bipolar condit degre

depress **disord** impact improv
life person physic psychiatr qualiti serotonin
sleep studi symptom temperatur

5541: Ergotamine (1)

adapt anim care clinic compar cost experiment
higher lower manag medic **model** patient

practic random **rate** select studi
trial versu

5543: Procyclidine (1)

affect associ control effect examin healthi induc
induct met organ possibl report respond

respons schizophrenia signific
studi subject suggest unaffect

5538: Leukotriene D4 (2)

action characterist common complex data
distinct effect enhanc featur includ increas
investig potenti publish receptor releas respons

stimul **studi** suggest

5540: 2,4-Dichlorophenoxyacetic Acid (6)

arabidopsi area associ cell chang correl
dai dose earli effect exposur higher

plant product rate root seed stage
studi time

5542: Glycine-tRNA Ligase (3)

analys **analysisi** bind complex

differ domain enhanc increas
mrna pattern protein region reveal
sequenc site stabil stimul structur translat
type

5544: Diphtheria Antitoxin (1)

avail benefit care clinic COST current decis
devic emerg guidelin impact

manag medic medicin need
physician practic provid recommend safeti

5545: Tetanus Antitoxin (1)

avail benefit care clinic COST current decis
devic emerg guidelin impact
manag medic medicin need
physician practic provid recommend safeti

5547: Autoreceptors (1)

abil abl anim capac clinic dai demonstr
diagnosi diagnost dose effect experiment
inhibit **model** neuron potenti
properti specif studi week

5549: Carbamoyl-Phosphate Synthase
(Glutamine-Hydrolyzing) (2)

activ **associ** cell data differenti
enzym evid evolut experi factor growth initi
intern nuclear origin prolifer provid second
suggest support

5551: Complement C1r (1)

avail data databas dimer domain fold form
inform **plai** program protein receptor residu
role site stabil stabl structur
suggest tool

5546: L-Amino Acid Oxidase (1)

antibodi biolog **CONSERV**
data delta enzym function highli
homolog human identifi literatur
mammalian mous notch publish
report residu site **system**

5548: Aspartate Carbamoyltransferase
(5)

activ assai bind compar
control detect distribut enzym
express gener **human** local
mutant **normal** rat report sensit
structur studi **tissu**

5550: Dihydroorotase (2)

activ approach base copi data enzym evid
gene increas larg limit nuclear
number pair possibl promot
provid remain strategi support

5552: Creatine Kinase, MB Form (1)

area arteri concentr differ effect
examin investig japan live locat margin microg
microm min rat region relat resid studi zone

5553: Scavenger Receptors, Class C (1)

adapt cell class competit differenti direct duplic
environ evolut evolutionari evolv fit gener natur
plastic pressur prolifer **select** test trait

5555: Troleandomycin (1)

activ bone confirm cytochrom demonstr
enzym find gene indic **metabol** metabolit neg p450
plasmid posit previ recombin report studi
suggest

5557: Probucol (1)

apoe apolipoprotein cholesterol compar **decreas**
diseas **increas** induc induct ldl level
lipid lipoprotein membran observ plasma reduc respond
respons transport

5559: Fullerenes (3)

acid assess compar concentr differ dose extract
group higher interact irradi lower
measur oxid properti radiat **rate** respect score
versu

5554: Potassium Iodide (4)

area associ case clinic differ dose effect
gener irradi live locat **patient** radiat
ratio reduc region resid risk studi zone

5556: Mannosyl-Glycoprotein Endo-
beta-N-Acetylglucosaminidase (4)

activ assai detect enzym form fusion
growth hybrid isol plai **protein** releas residu
role sensit site stabil state stimul structur

5558: 3,3'-Diaminobenzidine (1)

aggreg cell coloni compar confer convers **decreas**
drug **form format** fungal
increas indic level line observ
pathogen **resist** result suggest

5560: Wheat Germ Agglutinins (1)

anim cancer cell delai demonstr develop
endogen **enhanc** experiment follow human
increas line long-term **model**
peptid persist recoveri rice studi

5561: Enoxaparin (1)

clinic compar differ effect
function gene mean measur
paramet predict random rang ratio respect
standard therapi treat **treatment** trial
valu

5563: Nitrogen Compounds (2)

condit **correl** degre
enhanc evolut factor **femal**
growth increas indic light **male**
mass **plant** relationship sex signific speci
state suggest

5565: Sulfamethoxazole (1)

brain data differ diseas kinet **larg** larger
literatur **number** pancreat publish report
search secret **Size** **small** smaller
state switch transit

5567: Neuroleukin (1)

copi determin embryo factor fungal fungi **growth**
includ increas invas isol larg limit
number pathogen possibl produc
singl total **tumor**

5562: Picryl Chloride (2)

activ cell chines dai differ dose
effect heterogen induc induct inhibit
prevent produc **product** reduc reduct
respons site studi subtyp

5564: Amitrole (2)

addit aggreg analysi **combin**
compound copi determin effect **form**
format gene increas **number**
patient predict recombin regress structur
variabl variat

5566: Arginine Kinase (1)

analysi **chain** code codon
detect metabol nucleotid pcr polymeras
posit quantit **reaction**
real-tim residu revers rt-pcr singl site stop
substitut

5568: Chlordiazepoxide (1)

behavior cognit condit dai decreas degre
disabl dose **enhanc** experi impair
increas learn level memori organ
perform random task trial

5569: Decanoic Acids (2)

assai blood cell clinic detect differenti
express **group** model new
patient regul report research sensit studi surviv
technolog treatment trial

5571: Receptors, Presynaptic (3)

activ earli effect genet
human incid larg mice neuron
protein rat regul report size
small stage stimul studi women year

5573: Complement C3 Convertase, Alternative Pathway (1)

accumul **activ** addit complement demonstr effect
endogen **enhanc** highli **human**
increas infect inhibit inhibitor peptid potenti reduc
specif suggest suppress

5575: Amphetamines (2)

alter analysi **chang** diseas
express **gene** gener level mice
microarra multipl mutat **normal** profil
regress serum signific technolog **tissu**
variabl

5570: Buprenorphine (4)

alcohol area data depend
develop drug effect identif
identifi method new novel oral provid
regul requir resist risk **screen** studi

5572: Danazol (3)

affect cancer **case** caus defect defici discuss domin
famili month ovarian **patient** period
point recent report state studi time year

5574: Sericins (2)

activ apoptosi **cell** compar
control cultur death differ domain
enhanc frequenc higher increas inhibit line
peptid protein stabil suggest variant

5576: Tromethamine (2)

analysi bind chines collect condit degre
differ **high** level low multipl open
regul residu **sampl** site
structur studi subtyp temperatur

5577: Phenylglyoxal (3)

activ assess concentr data **differ**
effect enzym form format gener insight
measur metabol **new** pattern provid
reduc resist score type

5579: Gallopamil (1)

action approxim chicken data dynam effect
increas **individu** major minor
model observ potenti puls rel
releas respons simul **stimul** suggest

5581: Receptors, Lymphocyte Homing (4)

blood **cell** differenti discuss earli
function induc induct phase
prolifer receptor remain **respons**
stage state surviv system target therapi vivo

5583: Minoxidil (1)

case compar **differ** effect **femal**
male mate offspr patern pattern
gender report reproduct **sex** sexual similar therapi treat
treatment type

5578: Carbonic Anhydrase Inhibitors (3)

diseas effect express find inhibitor mechan
mice modul molecular neg posit previou regul
regulatori report role studi therapi treat

treatment

5580: Ubiquitin C (1)

assai correl delai detect **develop**
development element express follow fusion
gene index insert long-term persist plant
relationship sensit signific specif

5582: Trypsin Inhibitor, Bowman-Birk Soybean (1)

code codon conserv **famili** function
highli homolog human identifi inhibitor mammalian
member mous nucleotid posit **protein**
region sequenc substitut suggest

5584: Xenon Radioisotopes (1)

analys **analysisi** characterist
common data distinct **effect** featur indic
manag **method** perform prevent protect reduc
reduct reveal studi techniqu water

5585: Amanitins (4)

abil **activ** cell compar **control**
demonstr domain effect frequenc
function inhibit interact
melanoma p53 properti protein region rna
sequenc treatment

5587: Nuclear Respiratory Factors (5)

combin demonstr enhanc famili **function**
gene gener increas member neg
number posit promot protein regul
report respons specif studi transcript

5589: Etanidazole (1)

acid amino **caus** consequ death disrupt
endotheli excess function growth
interact lead loop prevent
protein result suggest vascular vegf yeast

5591: Amino Acids, Basic (1)

code codon complet domain **famili**
fusion **gene** histori identifi member
nuclear nucleotid partial peptid posit protein replac
result substitut suggest

5586: Nuclear Respiratory Factor 1 (5)

bind **chang** combin compar effect
express famili high
higher level low mice normal organ
promot rat **rate**
respons tissu transcript

5588: NF-E2-Related Factor 1 (4)

activ **caus** **cell** complex earli
express gene **genet** lead
mitochondri neg new **posit**
promot provid rang stage structur
transcript tumour

5590: Glyceryl Ethers (1)

activ adduct analog analogu **approxim**
cell chemic compar
compound deriv effect human
induc inhibit known major minor observ
rel suggest

5592: Aspartate Aminotransferase, Mitochondrial (1)

compar comparison consid defici **differ**
discuss experi light natur observ order **organ**
pattern place possibl process similar special
type wai

5593: Aspartate Aminotransferase, Cytoplasmic (1)

access barley compar comparison cultivar differ
express expression hybrid line maiz
mitochondri observ parent **pattern** plant rice similar
type wheat

5595: Aquaporin 5 (2)

biolog cdna **clone** control develop
express form format gene
growth healthi identifi librari marker
new provid sequenc studi
subject system

5597: Ricin (3)

alter **analysi** approach cell
chang dai data design fusion gener
identifi mutat novel process region reveal
screen sequenc strategi target

5599: Estrogens, Catechol (3)

associ confid **correl** decreas incid
increas interv mechan molecular
ovarian plai produc **product** ratio
relationship **risk role** signific smoke
studi

5594: Flufenamic Acid (1)

action amplitud **cell** demonstr effect
electr increas iron junction measur peptid
potenti puls record **releas** respons rest
stimul threshold wave

5596: PPAR-beta (1)

alpha beta conform conserv damag dna function
growth homolog human injuri mammalian mice
mous nerv **receptor** repair
structur vitro vivo

5598: Methyl Green (1)

algorithm approach base data dystrophi exercis
express fiber method muscl
muscular network perform **predict** problem propos
set skelet smooth train

5600: Cyclohexylamines (1)

altern cancer compound deriv dna drug exon
her-2 her2 intron isoform mice neg neu ovarian
posit splice variant vitro vivo

5601: Expectorants (2)

administr airwai asthma cfr cystic dai design differ
dose extract fibrosi **group** hospit
objective patient receiv respiratori signific studi week

5603: Ketorolac Tromethamine (1)

bilater **case** degener describ diagnos diagnosi
literatur macular man optic present rare report
retin retina reveal syndrom unusu visual woman

5605: Propoxur (1)

addit anim **combin** compar
control differ dynam effect
experiment exposur frequenc higher increas
model potenti releas signific stimul studi
synergist

5607: Arachidonate Lipoxygenases (1)

acid amino carcinoma critic endogen enhanc increas
inhibitor kei mice mix mous **plai** produc
product **role** sourc suggest transgen yield

5602: Misonidazole (3)

assai associ **combin** dai detect evalu
imag magnet mri normal ratio
reson risk scan sensit studi tissu tumor
tumour volum

5604: Carteolol (1)

abil abl **capac** cell
concentr cultur demonstr
dose effect includ irradi microg microm min
potenti **properti** radiat rang
varieti wide

5606: Oxymetazoline (1)

arteri assess clinic comput evalu hypertens **imag**
magnet measur methods mri **patient**
perform reson scan sever symptom techniqu tomographi
volum

5608: Octamer Transcription Factors (2)

abil analys **analysi** **capac** cell data
demonstr **diseas** factor gene genet indic influenc
perform **plai** promot **properti** reveal role studi

5609: Naphthol AS D Esterase (1)

acut cervic **chain** detect fish
fluoresc **hybrid** leukemia
lymphoma **marker** myeloid pcr
polymeras probe quantit
reaction real-tim revers situ
tumor

5611: Fat Emulsions, Intravenous (1)

carcinogen cell chemic diseas effect expos exposur
follow improv induc induct muscul mutagen respond
respons therapi toxic treat
treatment untreat

5613: Therapeutic Uses (1)

administr brca1 carrier dai develop diseas dose drug
factor femal increas male mate metabol
prevent reproduct **risk** sex sexual week

5615: Naphthaleneacetic Acids (1)

adapt anim develop differ experiment express
fit **gene** larg larger model natur
number plant **select** signal size
small smaller studi

5610: Clavulanic Acid (2)

bovin character concentr design differ
gene hospit infect **isol** larg larger
number patient phenotyp pig resist
size small speci **strain**

5612: o-Phthalaldehyde (1)

algorithm analysi blot compar detect express
extract fraction method methyl network
normal predict protein residu reveal set site
tissu western

5614: Hexamethonium (3)

abil adapt compar **control** effect
express field frequenc healthi inhibit mice
movement potenti properti radiat receptor
select space stimul subject

5616: Phosphorylases (1)

arabidopsi chromatographi column contain
determin **extract** fraction gel
leav liquid mass method plant prepar
purifi residu root seed separ site

5617: Cholates (1)

analys **analysisi** blot confirm data
detect determin enzym express **extract** fraction
indic metabol oxid perform prepar protein reveal
studi western

5619: Diphtheria-Tetanus-acellular
Pertussis Vaccines (2)

adult alter area **chang** data
differ **distribut** experi fluid fusion
increas **individu local**
observ **organ** possibl stimul studi
suggest year

5621: Glyceraldehyde 3-Phosphate De-
hydrogenase (NADP+) (1)

analysi chain collect copi detect determin divers
genet isol larg **number** per
popul reaction region remain
sampl sequenc speci strain

5623: Ferrocyanides (1)

agreement **assess** clinic correl evalu express
instrument level mean **measur** methods mrna
patient plasma receptor reliabl scale
SCORE serum valid

5618: Phenothiazines (2)

approach data error estim includ inhibit light
method **multipl** myeloma novel
patient potenti procedur remain singl surgeri
surgic **target** therapeut

5620: Atracurium (3)

clinic compar complex **control** dai differ diseas form
format frequenc higher mean measur methods
patient ratio respect risk signific valu

5622: GABA Agents (1)

affect antibodi **assess** brain decreas dna gene
impact improv **increas** isol level
life methyl physic promot **qualiti**
schizophrenia strain studi

5624: Epichlorohydrin (2)

approxim compar control dai determin differ
dose extract fraction mean measur rang
ratio rel requir respect standard studi
subject **valu**

5625: Anion Exchange Resins (4)

assai cell detect effect evid experi extract
human interact method normal
organ patient process reduc sensit stimul tissu
trial valu

5627: Pepsinogen C (1)

biopsi cancer cervic develop express function
gastric **gene** identifi **interact**
lesion marker microarraai pancreat profil
protein secret specimen stain studi

5629: Kaempferols (1)

activ cancer **cell** colon colorect defici
differenti express gene inhibitor iron
junction kinas line microarraai phosphoryl profil
prolifer signal tyrosin

5631: Trifluoroacetic Acid (1)

aggreg analysi coloni compound defici elev exposur
form format gel higher **level** lower mass
measur plasma promot **protein** serum speci

5626: Sapogenins (1)

activ apoptosi apoptot bax bcl-2 caspas
cell compound deriv differenti
express induc inhibit inhibitor kinas pathwai
phosphoryl **prolifer** protein transfect

5628: Pyridoxal Kinase (1)

biolog cell complet concentr demonstr effect enzym
field forc fusion **human** loss microg
microm min movement partial plasma space system

5630: Serine-Type D-Ala-D-Ala Carboxypeptidase (1)

activ **associ** chain compound conform
crystal enzym infect link pcr polymeras reaction
real-tim relat residu revers site **structur** studi
substrat

5632: Sulfur Compounds (6)

assai assess children compar compound control
detect healthi mean measur mix phenotyp
produc **product** role score
sensit sourc studi subject

5633: Nisoldipine (1)

anim clinic data densiti develop diagnosi
diagnost experiment extract **high** investig
level low malign model random site
studi trial tumour

5635: Nimodipine (2)

adapt avail blood chines data databas differ
effect extract heterogen imag patient **protein**
rat select site **studi** subtyp treat
treatment

5637: Anabasine (1)

chromosom compound conserv effect
experi expos **exposur** follow
inhibitor **initi** intern linkag loci
locu mammalian map **origin**
second seri subsequ

5639: NAD+ Nucleosidase (1)

activ code coli conserv contain defici enzym
escherichia express level locat mrna nucleotid
promot **region sequenc**
strain substrat syndrom toxin

5634: Nitrendipine (2)

adapt analys **analysi** caus channel clinic
diagnosi **effect** extract fraction
inhibit lead prevent protect reduc reduct
report reveal select studi

5636: Nicardipine (1)

adapt data evolut exposur extract factor fit
fraction gene includ investig malign natur potenti risk
select **studi** therapi tumour
vector

5638: Glucosamine 6-Phosphate N-Acetyltransferase (2)

algorithm concentr critic drosophila enzym gene
involv kei method mutant network pathogenesi plai
plant predict random recombin **role** suggest
trial

5640: Ribose-Phosphate Pyrophosphokinase (1)

activ arabidopsi compar decreas enzym express
gene **increas** induc induct level
microarraai mrna plant reduc respond
respons root substrat synthesi

5641: Bone Morphogenetic Protein Receptors (4)

approxim assess **enhanc**
factor **growth** major
measur neg **posit** promot
receptor rel score
signal **specif** state suggest
tgf-beta tgf-beta1 transform

5643: Methylmannosides (1)

addit allow approach better **bind** cell cerevisia develop
gain inform insight **new** promot protein
provid recent residu site understand yeast

5645: Phosphotransferases (Carboxyl Group Acceptor) (1)

activ current defect discuss diverg duplic
enzym evolut evolutionari express metabol
mrna mutant mutat origin
protein recent substrat telomer
wild-typ

5647: Benserazide (3)

affect anim clinic dai delai famili follow
function genet identifi long-term
member model persist screen studi therapi
treatment trial variabl

5642: Cholinergic Agents (4)

assai base **chang control**
detect differ **effect** evid famili
high larg level low receptor sensit
size small studi support tumour

5644: Equilibrative Nucleoside Transport Proteins (1)

arabidopsi behavior broad cognit compound deriv
function impair includ
known learn memori mice plant rang varieti vitro
vivo wide

5646: Diuron (2)

biolog codon concentr earli **effect**
inhibit late neg phase **posit** potenti prevent
protect **reduc** reduct releas stage stimul
substitut system

5648: Pregnanolone (1)

brain central **concentr** determin
effect endogen **enhanc** higher increas low lower
measur **microg microm** micromol min plasma rang
respect suggest

5649: Phosphatidylethanolamine Binding Protein (3)

activ cancer conserv essenti
express function gene identif
identifi includ inhibit mutant pathwai plant
prostat rang **requir** screen signal wide

5651: Isoamylase (1)

bind data defect differ element evid hypothesi
larg larger **mutant** mutat number
plai provid **role** size small
suggest support wild-typ

5653: Triiodobenzoic Acids (1)

alter **cell chang** decreas detect
experi fish fluoresc **hybrid** increas initi
intern label membran origin probe protein
second situ subsequ

5655: Guanosine Diphosphate Mannose (1)

activ addit assembl **combin**
complex compon effect embryo enzym
involv **mechan** molecular plu singl **specif** studi
substrat subunit synergist underli

5650: Mannitol Dehydrogenase (1)

chang condit constant enzym fast indic
intermedi kinet occur plai plant rapid rapidli
role shift slow **state** suggest
switch transit

5652: Triazolam (1)

alcohol clinic compar comparison depend differ effect
isol methods observ oral **patient**
pattern perform signific similar strain studi test type

5654: Allantoin (2)

acid amino complex compon duplic effect encod
evolut evolutionari fusion **gene** kinet modifi
prevent protect reduc reduct state suggest vector

5656: Adenine Phosphoribosyltransferase (2)

analysi approach blot case cell incid length
long mutat **repeat** report requir
reveal short system tandem termin western
women year

5657: Zeatin (1)

caus chromosom cultivar **effect**
enhanc **express** increas lead
linkag loci locu maiz map plant prevent
protect reduct reduct rice wheat

5659: Contraceptive Agents (1)

case caus clinic consequ consid
criteria diagnos **diagnosi** diagnost diseas experi
lead organ patient possibl present rare
report sever symptom

5661: Antigens, Heterophile (5)

approach **ASSOCI** cell compar
control design differ express
frequenc genet health **human** inhibit
peptid plai presenc role strategi **test**
tumor

5663: Gastrointestinal Hormones (2)

assai children continu delai detect follow hospit
level long-term lung marker method network
patient persist predict recoveri
sensit serum tumor

5658: Peroxisome Proliferators (6)

associ cell cluster data
differenti exposur express increas
induc mechan method **model**
process prolifer rat **receptor**
respons select specif test

5660: Uroporphyrins (2)

case clinic data diagnos **diagnosi** diagnost
diseas disord inhibit literatur pain **patient**
present produc **product** rare report sever
skin symptom

5662: Phenylcarbamates (3)

area behavior bind cognit concentr correl
dai diseas express extract growth health
impair learn memori **patient**
perform presenc **time** treatment

5664: Enterobactin (1)

accord analysi base categori classif classifi
cluster data defin differ distinct
group identifi iron junction profil repres set
subgroup yeast

5665: Boric Acids (2)

achiev approach compar complex
control design differ dna frequenc
genotyp healthi isol limit peptid phenotyp
polymorph strain strategi subject success

5667: Pyruvate Synthase (1)

assai care data detect **gene** health
isol literatur mechan molecular mutat
need provid public publish sensit servic specif
strain underli

5669: 1-Methyl-4-phenylpyridinium (2)

allow applic cell effici fusion gene hybrid induc
induct line **method** oxid peptid procedur
protocol **respons** simpl techniqu
transfer vector

5671: Fenclonine (1)

acid administr amino area cell dai
differenti disord dose earli late locat
phase progress prolifer stage studi vitro vivo
week

5666: Nomifensine (1)

concentr detect determin effect
energi fish fluoresc hybrid increas light measur
microg microm min neuron plasma probe rat
respect situ

5668: DNA Topoisomerases, Type II, Bacterial (2)

acid adapt amino approxim assai
detect genet **isol** major mutat
popul protein recombin rel
resist select sensit speci
strain trial

5670: Ganglioside Galactosyltransferase (1)

cell compar complet **control**
differ differenti express extract frequenc
fusion higher lower observ partial prolifer
rate respect signific similar versu

5672: Potassium-Hydrogen Antiporters (1)

accumul **activ** character compar comparison
differ distinct essenti membran
demonstr necessari observ pattern phenotyp requir
resist similar suggest transport type

5673: 1,4-alpha-Glucan Branching Enzyme (2)

allele assess associ bind cancer carrier codon
evalu factor **gene** genotyp measur
month patient polymorph prostat rat **risk**
scale score

5675: Thiostrepton (1)

acid amino compar **control** cultur
data defect differ enzym evid frequenc higher
hypothesi **mutant** mutat primari provid
resist support wild-typ

5677: Dextroamphetamine (2)

analysi area cluster delai depend
effect follow kinet level
long-term neuron oral persist rapid reduc
reduct serum **state** studi system

5679: Amitriptyline (2)

area assess clinic continu delai densiti
develop evalu follow **high**
level long-term **low** measur patient
persist recoveri score studi trial

5674: Teicoplanin (2)

concentr earli event evolut gene
infect initi isol length multipl
mutant origin
phenotyp process
produc **product** repeat
second stage strain

5676: HSP20 Heat-Shock Proteins (2)

complex condit degre discuss environment express
factor genet influenc kinas mass muscl pathwai
peptid **protein** recent residu signal
site structur

5678: Adrenodoxin (1)

abil abl affin **bind** capabl capac cleavag
demonstr displai exhibit indic interact possess
potenti **properti** proteas protein residu
site structur

5680: Melibiose (2)

acid amino bodi compar cultur **differ**
diseas domain enzym fragment **gene**
inhibit marker **pattern** peptid produc
product recombin similar type

5681: Probenecid (2)

agent approxim **develop** drug
femal **function** includ known
major **male** mate model observ oral rang
rel resist sex sexual wide

5683: Inosine Pranobex (1)

cell cultur end fibroblast hbv hcv hepat human
infect **isol** p53 replic revers senesc
strain telomer telomeras viral
viru virus

5685: Iodobenzenes (1)

alter bind **chang** codon core
decreas distribut domain encod fluid increas
local **model** observ open peptid predict
site substitut suggest

5687: Cholic Acid (2)

activ alter cell chang compar
control **develop** differenti dna
extract frequenc higher isol **level**
method plasma prolifer serum signific variabl

5682: Hydroxides (3)

base cell collect data determin distribut
effect evid extract local pair patient prevent
protect provid reduc reduct **sampl**
support time

5684: Rubredoxins (2)

compar condit degre differ dynam higher kinet
lower **model** protein **rate**
respect state structur studi subtyp
transplant trial tumour versu

5686: Cytochromes c2 (1)

adult characterist code codon common
complex decreas distinct elderli featur
increas level nucleotid old older
posit research substitut year young

5688: Protein O-Methyltransferase (1)

absenc accumul **assai** cleavag compound
detect determin factor head indic
neck **presenc** proteas residu **sensit**
site specif studi suggest test

5689: Norpregnadienes (2)

analysi blot cell clinic concentr detect diagnosi
differenti enzym express **human**
microg microm min normal ovarian prolifer
therapi **tissu** western

5691: Boranes (1)

acid analysi CAUS determin differ extract
fraction larg larger lead **normal**
number predict regress relationship **size**
small **tissu** variabl variat

5693: Bumetanide (2)

abil alter caus **chang** decreas demonstr
famili **gene** increas lead marker
mechan member molecular plai properti requir
resist role system

5695: Cefotaxime (1)

articl care current data discuss
distribut environment
factor **genet** health
influenc literatur local
presenc publish review studi trait twin
variati

5690: Megestrol (1)

absenc activ **concentr** dai determin
dose effect enzym head inhibit microg microm
min **normal** plasma presenc
tissu treat **treatment**
week

5692: Aspartate Ammonia-Lyase (2)

activ approach approxim assess defect enzym
evalu gene major measur **mutant**
mutat produc product rel score speci
strategi substrat wild-typ

5694: Rubidium Radioisotopes (1)

addit cell clinic **combin** compound
demonstr **effect** endogen **enhanc** increas inhibitor
plu result simultan singl studi suggest synergist
therapi treatment

5696: Carbohydrate Dehydrogenases (3)

american cell compar cycl dai differ dose gene
higher lesion lower month patient popul
protein rate receptor stain
surviv versu

5697: Distamycins (1)

contain dna domain drosophila electron
genom length long microscopi
morpholog novel potenti protein **repeat**
reveal sequenc short tandem **target**
therapeut

5699: Anti-Dyskinesia Agents (1)

argu arteri bacteri **brain** central coli
consent diseas escherichia ethic issu moral
motor nervou **neuron** paper
practic **research** strain toxin

5701: Isonicotinic Acids (1)

administr anim cours dai develop dose experiment
function inject injuri model
period point question rat receptor remain studi
time week

5703: Diatrizoate Meglumine (1)

case clinic conserv cultur differ experi follow initi
intern larg larger number origin
patient report second size small
surgeri therapi

5698: Receptors, Melanocortin (2)

bodi chain differ effect factor genet includ
influenc larg larger number
protein rang reaction releas
size small stimul weight wide

5700: Cationic Amino Acid Transporter 2 (1)

acid amino assai **base** cell
control **detect** differ express gene
membran modul observ pair regul
regulatori role **sensit** specif synthesi

5702: Muscimol (4)

activ area behavior cognit concentr dai
effect event impair increas **inhibit** inject
learn memori neuron process **rat**
receptor requir stimul

5704: Thiophosphoric Acid Esters (1)

concentr determin drosophila effect exon gene
higher increas low lower measur microg microm
micromol min **mutat** plasma rang
respect test

5705: Metoclopramide (1)

accord clinic compar control differ divid
group higher mean methods random
respect signific statist studi therapi total treatment trial
variant

5707: Tolbutamide (4)

caus compar concentr **control** dai
determin differ express healthi mutat
phenotyp rat resist respect respons risk
signific **studi subject**
subtyp

5709: Polyvinyl Alcohol (3)

analysi analyz assess **complex** content
dai determin differ **distribut** dose
evalu flow fluid **local** measur
observ particl **sampl** score surfac

5711: Sulbactam (2)

arm clinic compar dai design diagnosi differ effect
efficaci **group** hospit improv patient
random receiv signific studi treat **treatment**
trial

5706: RNA, Transfer, Asp (2)

affect alter **chang** complex compon
decreas enzym eukaryot **gene** increas
initi mrna muscl **normal** observ ribosom
rrna subunit **tissu** translat

5708: Vinyl Chloride (3)

affect assai cancer control decreas detect
evolut exposur improv **increas**
level life manag modif **modifi**
presenc qualiti sensit studi suggest

5710: Monoglycerides (2)

cell characterist coli common copi
differ differenti distinct escherichia
featur increas larg morpholog
number pattern plai prolifer
role similar type

5712: Cefuroxime (1)

arm **children** clinic compar dai
design efficaci hospit improv parent produc
product random receiv studi
therapi treatment **trial** week year

5713: Ketoses (1)

blood bodi compar concentr determin differ famili
mean measur member paramet
patient phenotyp predict rang ratio
respect standard test valu

5715: Asbestos, Amphibole (1)

analysi categori classif cluster collect
concentr control data determin differ group
healthi identifi muscl profil report
sampl set studi subject

5717: Desmoglein 2 (3)

analys cell chain complex differenti essenti
express famili genet iron junction
malign member mutat reaction remain
requir specif studi tumour

5719: 17-alpha-Hydroxypregnenolone (1)

children clinic differ femal linkag locu male map
mean measur methods mutat parent
patient ratio reproduct respect sex
sexual valu

5714: Heterogeneous-Nuclear Ribonucleoprotein Group C (2)

activ analysi bind blot cell decreas detect
enzym express increas
interact invas level matrix mrna protein
reveal state translat western

5716: Mannose-6-Phosphate Isomerase (2)

character clinic combin condit
core degre diagnosi effect event gene
heat involv mutat open patient
phenotyp process regul shock
temperatur

5718: Aminomethyltransferase (1)

compar conform control copi crystal determin differ
enzym form group human
increas larg number residu signific singl site
structur total

5720: Receptors, Adenosine A2 (1)

analysi analyz ataxia brain collect data detect determin
diseas disord femal male marker mate motor
neuron reproduct sampl sex sexual

5721: Oncogene Proteins v-mos (1)

analysi categori classif classifi **cluster** conserv
correl **express** fusion identifi
index **mice** mous profil **protein**
relationship set signific subgroup transgen

5723: Scopoletin (1)

addit apoptosi cell demonstr endogen
enhanc form increas induc mix nuclear
potenti produc **product**
protein result sourc stabil suggest yield

5725: Clofibrate (1)

acid alpha amino beta chines differ
express expression **famili**
heterogen histori identifi includ inhibitor ligand
member receptor respect studi subtyp

5727: S-Adenosylhomocysteine (4)

approxim assai associ **bind** clinic complex
detect factor incid methyl **mice** mutat
number rat rel report risk
sensit state studi

5722: RNA, Satellite (1)

aggreg behavior code cognit coloni conserv contain
domain form format locat melanoma memori
motif nucleotid perform **region** rna
sequenc structur

5724: Oxandrolone (1)

adult bodi caus children delai factor
follow growth lead long-term month old
older parent patient persist treat
treatment year young

5726: Glucose Transport Proteins, Facilitative (3)

associ base breast cancer
chromosom differ distribut **gene** local
marker normal pair point promot
region sequenc test
time tissu tumor

5728: 1-Butanol (3)

activ area associ concentr demonstr distribut
extract local mix observ previou **produc**
product ratio report risk sourc
studi suggest yield

5729: Pheromones, Human (1)

behavior care character **characterist**
classic common distinct drosophila
featur health pattern random
repres servic share similar **structur** trial
typic uniqu

5731: Neuromuscular Nondepolarizing Agents (5)

clinic compar concentr **control** dai differ dose
frequenc **GROUP** induc induct observ
patient previou rel report
respons risk studi surgeri

5733: Factor IXa (2)

activ advanc applic biologi compar
complex develop earli factor higher lower
model mutant new **rate** recombin
research risk stage technolog

5735: Lysosomal-Associated Membrane Protein 2 (1)

analys **analysi associ** cardiac
data domin famili heart indic left link median month
patient perform relat reveal studi ventricular year

5730: Veratrine (1)

anim axon composit cord effect heal inject
injuri laser light myelin nerv neuron
neuropathi nuclear peripher **rat** regener
spinal wound

5732: Gout Suppressants (6)

arthriti case clinic compar **control**
differ diseas femal **group** joint
level male organ pain patient
rheumatoid serum sever subject tumour

5734: Receptors, Concanavalin A (1)

bind cell concentr demonstr experi
femal find male organ period plant point
previou report sex sexual site studi suggest

time

5736: Maytansine (1)

agent arm baselin **CANCER** clinic compar drug effect
efficaci **human** improv lung ovarian
pancreat random receiv secret studi treatment trial

5737: CapZ Actin Capping Protein (1)

abil abl **bind** capac cell cultur decreas
demonstr differenti express identif
identifi **increas** level novel
potenti prolifer properti SCREEN site

5739: Senna Extract (1)

anim compar control dai effect exposur factor
healthi increas induc inject methyl **rat**
risk signific studi subject treat
treatment week

5741: Iohexol (5)

case cell compar determin differ group
higher imag lower mean measur method
rate respect subject system test valu
variabl versu

5743: Technetium Tc 99m Dimercapto-
succinic Acid (1)

clinic complic dose effect **function**
imag impair irradii kidnei magnet patient perform
radiat renal segment sever surgeri symptom synthesi
volum

5738: RNA, Transfer, Glu (3)

analysi cell code codon elegan environment
factor gene genet influenc level
mutat popul region sequenc
speci structur substitut tumor variat

5740: Transition Elements (1)

base data dynam experiment fit imag mean measur
model paramet predict propos ratio
region respect sequenc simul theoret theori valu

5742: Metrizamide (1)

cell copi cultur determin element experi
extract follow increas initi insert integr intern larg
method number origin second subsequ techniqu

5744: Technetium Tc 99m Mertiatide
(1)

assess evalu examin follow-up
function imag magnet measur
median month mri patient perform recurr
reson scan techniqu tomographi volum year

5745: Spiperone (1)

analysi assess bind classif
cluster demonstr disord evalu
find measur membran previou
receptor report scale score
set site studi valid

5747: beta-Amylase (2)

approxim base compar control
frequenc major mechan molecular mutant
observ pair plai produc product rel residu
role site state structur

5749: Mebendazole (2)

analysi anim approach blot clinic concentr
develop experiment model organ
produc product strategi studi target test
therapi treatment trial western

5751: CDP-Diacylglycerol-Inositol 3-Phosphatidyltransferase (1)

activ addit blood chang combin effect enzym
induc induct intermedi kinet metabol muscl peripher
respond respons state substrat
switch transit

5746: Quinuclidinyl Benzilate (1)

activ alpha beta caus cell concentr
copi determin express increas isol larg lead microg
microm min number receptor strain
total

5748: Psychosine (2)

approach assess clinic develop earli
event impact improv late life phase
physic process progress qualiti requir
stage strategi target therapi

5750: Antinematodal Agents (6)

associ detect differ enhanc
group identifi individu inhibit
isol mechan method model
mutat new point screen strain
therapi time treatment

5752: Methyl dimethylaminoazobenzene (2)

administr anim cell dai differenti earli
effect genotyp induc inject isol late phase
progress prolifer rat resist stage strain
week

5753: Succinate-Semialdehyde Dehydrogenase (1)

advanc applic approach biologi challeng develop
discoveri ethic field **human** medicin
multipl new research singl technolog tool
understand vitro vivo

5755: Aminacrine (1)

carcinogen chemic densiti effect expos
exposur genotox **high** increas induc
isol level low marker mutagen rat strain
studi **test** toxic

5757: Lynestrenol (1)

bodi cell compar comparison **differ** effect
expos exposur gene growth mice observ pattern
similar toxic type vector vitro vivo weight

5759: Adaptor Protein Complex sigma Subunits (1)

caenorhabd CAUS conserv defect ecolog elegan
function **gene** habitat lead mammalian
modif modifi mutant mutat **protein** sea
season speci wild-typ

5754: Ytterbium (1)

acid **activ** amino broad chromatographi
compound contain extract fraction includ liquid
major prepar promot rang residu site spectrum varieti
wide

5756: Cysteinyldopa (1)

cell damag dna dose effect exposur
fraction immun intracellular ioniz **irradi**
membran protein **radiat**
radiation-induc radiosensit radiotherapi repair
skin transport

5758: Adaptor Protein Complex delta Subunits (1)

character clone complex conserv delta
effect function gene highli homolog
human identifi mammalian mous notch
prevent protect reduc reduct sequenc

5760: Adaptor Protein Complex mu Subunits (1)

character complex conserv data function human
identifi includ investig mammalian mous mutant
mutat phenotyp pool speci **studi**
subunit suggest wild-typ

5761: Dihydrolypoyllysine-Residue
Acetyltransferase (1)

analisi determin discuss event immun
independ involv measur modif modifi predict
process protein recent
regress relationship signific step variabl
variati

5763: Uridine Diphosphate N-
Acetylglucosamine (1)

activ biosynthesi catalyt catalyz complex
compon content cytometri dehydrogenas
determin **enzym** extract flow
fraction load metabol plasmid recombin
substrat subunit

5765: Tetramethylphenylenediamine
(1)

compar decreas examin extent find
increas indic later level mice
mitochondri mous mutant mutat observ reduc
suggest survivin transgen wild-typ

5767: Pyrazolones (1)

activ apoptosi bel-2 **cell** cycl cyclin
differenti express induc inhibit inhibitor
kinas lymphoma melanoma pathwai phosphoryl
prolifer protein rna signal

5762: Fosfomycin (3)

complex concentr correl data enzym error

estim form format **gene** initi isol

method origin recombin resist

respons speci statist

structur

5764: Kv1.5 Potassium Channel (2)

base channel concentr contain core correl

function identifi imag map

mutant observ open pair **region** resist

sequenc signific structur target

5766: Fructokinases (2)

activ alter chang dai decreas diseas
effect express increas inhibit initi level
multipl origin protein reduc reduct renal second
stimul

5768: NADP Transhydrogenase (2)

associ condit defect degre diabet function

insulin mice mitochondri modul mous

mutant mutat pancreat regul

regulatori secret speci temperatur wild-typ

5769: Orotidine-5'-Phosphate Decarboxylase (1)

approach design experi **femal**
follow **initi** intern limit **male**
multipl nuclear origin remain
second sex sexual singl strategi subsequ
success

5771: DNA Topoisomerases, Type I, Archaeal (1)

clone complex demonstr **dna** effect endogen
enhanc enzym experi function increas
interact organ **possibl** potenti
protein releas sequenc stimul suggest

5773: Azocines (1)

assess base data dynam evalu event experiment
fusion involv measur **model**
paramet predict **PROCESS** **propos** scale **SCORE**
simul step valid

5775: Receptors, N-Acetylglucosamine (1)

abil abl bind capac **cell** critic demonstr
exhibit **interact** marker nuclear pathwai
plai potenti properti protein **role**
signal site suggest

5770: Collectins (1)

administr **dai** differ dose effect expos
exposur **gener** indic **larg** larger
lung membran number **size** small
smaller vitro vivo week

5772: Receptor, Bradykinin B1 (1)

acid amino analysi **associ** collect compar complet
divers **dna** genet **genom** haplotyp
imag **polymorph** popul **sampl** sequenc splice
variant variat

5774: Hydromorphone (1)

action alcohol appli applic **dai** depend dose
effect increas **method** oral
potenti protocol puls record **releas** respons
rest **stimul** techniqu

5776: Complement C6 (2)

adapt alter **associ** biolog **chang**
complex distribut gene haplotyp individu
length local observ **polymorph** repeat select
snp studi suggest system

5777: Glycyrrhetic Acid (3)

adapt analysi blot **cell** correl dai detect
differ express **famili** genet member natur
protein reveal **select** signific
studi treatment western

5779: Silicic Acid (2)

analysi blot **classif** cluster codon concentr
content detect determin differ effect element flow
gene isol reveal strain treat treatment
western

5781: Foscarnet (2)

address **assai** **detect** dna
hybrid induc induct isol major mutant mutat
question rais remain resist **respons**
sensit specif strain test

5783: Azinphosmethyl (1)

adapt competit **element** environ evolut exposur fit
gener genom identif **identifi** insert integr natur
novel resist screen **select** sequenc site

5778: Pyrrolnitrin (1)

blood cell control express fluoresc function
mix modul peripher **process** **produc**
product promot protein regul
regulatori role sourc transfect yield

5780: Capreomycin Sulfate (1)

character contain core element encod frame
gene gener **identifi** indic isol
mutant mutat open orf put read
resist strain wild-typ

5782: Firefly Luciferin (1)

anim **compar** comparison complement control
differ distinct effect **express** gene imag
inject muscl observ **pattern** rat similar specif
type vector

5784: Cloxacillin (1)

affect copi determin includ increas infect larg
modifi month **number** patient
possibl resist schizoprenia studi suggest therapi
total treatment year

5785: Toll-Like Receptor 6 (1)

adjust allel **associ** cancer confid
control gene genotyp haplotyp interv
linkag map **mutat** odd polymorph
ratio **risk** smoke snp studi

5787: Cerium (1)

amplif amplifi analysi anim compar complet develop
dna enzym experiment fragment
genom length model pcr primer
provid restrict sequenc studi

5789: Tissue Polypeptide Antigen (1)

activ assai bladder detect determin
diseas evalu gene mobil **mutat** neg
posit primari sensit specif studi test tract urin
urinari

5791: Poly I (1)

amplifi analysi cdna **cell** clone dna
express fluoresc fragment gene infect line
pcr primer promot restrict sequenc transfect
viral viru

5786: Cardenolides (1)

analysi code codon determin differ **gene**
independ measur plai predict receptor
regress relationship **role** signific stabil
substitut suggest variabl variat

5788: HSP110 Heat-Shock Proteins (2)

abil abl apoptosi bind capac cell condit degre
demonstr dna domain fragment **human**
manag medic method potenti properti protein
techniqu

5790: Aphrodisiacs (1)

adapt competit compound defici **drosophila** environ
evolut femal fit host insect **male** mate
melanogast natur promot reproduct **select**
sex sexual

5792: Proline-Directed Protein Kinases (1)

activ **adult** bind cell
differenti dose elderli enzym express irradi
nucleotid old older prolifer radiat
region sequenc site
year young

5793: Thiouridine (2)

abil acid capac complex compon demonstr dna
element **human** initi modif modifi
mrna organ potenti properti ribosom state
subunit translat

5795: Sulfuric Acids (2)

adapt bind concentr direct evid experi gener initi
mix natur origin produc **product**
provid select site sourc structur support yield

5797: Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide (3)

acid amino cell clone demonstr distribut
element follow fusion hybrid individu
inhibit local **peptid** persist
protein receptor sequenc specif
suggest

5799: Stearic Acids (1)

affin **bind** complex delet detect
domain fish fluoresc **genet** hybrid
interact loss molecular probe protein site situ
specif **target** therapeut

5794: Eosinophil-Derived Neurotoxin (1)

associ core critic **develop**
development earli encod gene haplotyp identif
identifi includ known map novel open polymorph
program screen snp

5796: Isosorbide (1)

address african american cmv despit ethnic evid
identifi issu major map **marker**
molecular popul possibl question rais **remain**
studi unknown

5798: Pentachlorophenol (2)

assess compound correl deriv
dna **effect** evalu evid form
format index **measur** provid
reduc reduct scale **score** signific
support valid

5800: Biliverdine (2)

abil approach capac concentr condit data
degre design direct effect evid hypothesi oxid
properti provid rna strategi support treat

treatment

5801: Prokaryotic Initiation Factor-2
(1)

acid amino characterist chines common differ
distinct featur heterogen hybrid identif
identifi **isol** novel phylogenet
screen speci **strain** studi subtyp

5803: Glycine Agents (1)

abil abl alpha antibodi capac condit degre
demonstr disord effect exhibit gene inhibit
potenti properti **receptor**
releas stimul temperatur vector

5805: Intrinsic Factor (1)

affect autosom caus **clinic** delet diagnosi

diagnost domin effect famili gene inherit loss

mutant **mutat** patient remain sever

treat **treatment**

5807: Mannitol Phosphates (1)

analys **analysi** compar content data differ
flow **group** indic interact isol mutant
perform plai reveal **role** signific strain studi
suggest

5802: Deoxyribonuclease HindIII (2)

amplif amplifi **associ** decreas
differ dna essenti fragment
increas isol new pattern pcr primer
provid **requir** restrict sequenc strain type

5804: Strychnine (3)

activ anim bind cell enhanc follow
increas induc induct inhibit method model protein
rat requir **respons** site studi surviv system

5806: Terbium (2)

absenc bind compar domain head higher indic
lower mutat neck observ phenotyp plai
presenc protein rate **role**
stabil studi suggest

5808: Guanylate Cyclase-Activating
Proteins (2)

affect assai autosom bind character characterist
codon common detect domain domin
famili featur inherit member mutat
protein sensit site specif

5809: Dynamin III (1)

affin **bind** bone bound cell complet
complex cultur demonstr fibroblast fusion interact
migrat neuron partial protein replac site specif vitro

5810: Cobra Neurotoxins (1)

administr anim codon compar **control** dai
develop differ dose establish experiment frequenc
hospit human **model** month patient
provid studi week

5811: Azulenes (2)

assai cell **concentr**
detect determin **extract**
factor fraction mean measur method
microg mutant organ prepar respect
risk sensit tumour valu

5812: Glycerophosphates (2)

avail cell data databas decreas dna element evolut
gene includ **INCREAS** infect integr level
patient plasmid rang recomb
regul wide

5813: Pentoxyl (2)

assai damag demonstr detect **dna**
find gener level marker plai previou repair
replic report **role** sensit serum specif
studi suggest

5814: Transcription Factor TFIIB (3)

acid **cell** complex delet domain
experi **express** gene genotyp initi
loss origin polymorph protein residu rna
second **site** stimul transcript

5815: Pristinamycin (1)

assess **associ** character drug evalu isol
link linkag map measur overexpress phenotyp
relat **resist** scale score strain studi suggest valid

5816: Povidone-Iodine (2)

associ bovin compar condit degre
differ experi field hospit movement
observ organ pattern pig possibl space state
studi test type

5817: Receptors, Collagen (2)

alpha beta characterist **combin** common
compar complex decreas delet distinct domain
duplic effect evolut featur **genom**
increas level receptor
sequenc

5819: Galactosidases (1)

achiev approach design embryo
express involv limit matur
mechan method
molecular oocyt optim provid strategi
success techniqu underli understand understood

5821: RNA, Transfer, Gly (2)

chang code **codon** conform initi mrna
nucleotid posit protein remain ribosom rna
singl state **structur** substitut
suggest transit translat trna

5823: Phenylthiourea (3)

behavior complex environment factor
famili genet incid includ influenc
mechan member **molecul** phenotyp popul risk
subject target trait variabl variat

5818: Iothalamic Acid (1)

adapt compar condit degre densiti
differ high induc induct kidney
level low **natur** pattern renal requir
respons select similar type

5820: Erythrosine (1)

acid amino assess bodi care copi cost exposur
impact improv increas larg life manag medic
number physic practic qualiti
weight

5822: Vecuronium Bromide (1)

addit aim clinic conclusions confirm consist demonstr
evalu find indic methods month observ
patient preval previou report studi
suggest year

5824: Nicotinic Antagonists (1)

absenc activ **cell** channel character effect
head hear indic inhibit length long loss
phenotyp presenc repeat
short suggest tandem termin

5825: Tubocurarine (1)

cell channel character conserv consist
demonstr distribut find fluid indic local
loss mammalian observ phenotyp
previou report similar studi suggest

5827: Alanine Dehydrogenase (2)

assess develop enzym evalu gene genet
measur method plant protocol recombin reliabl
requir scale score site standard target techniqu
valid

5829: Adenylate Cyclase Toxin (2)

analysi antibodi antigen area base bodi coli differ
electrophoresi encod gel gene identifi immun
mass pair proteom studi vaccin vector

5831: Berberine Alkaloids (1)

approxim avail base bind
complex data databas element field
inform insert integr major observ pair
rel similar site structur tool

5826: Alanine Racemase (1)

assai coli detect determin encod enzym escherichia
evalu gene genet limit method molecular
monitor sampl sensit specif strain test yeast

5828: Adaptor Protein Complex 1 (1)

affin assai bind compar decreas detect
endogen enhanc increas interact
level metastasi node protein reduc sensit site specif
transcript tumor

5830: Eosinophil Granule Proteins (1)

bowel channel chemotherapi chronic clinic conclusions
diseas dose effect inflammm inflammatori intestin irradi
methods patient radiat radiotherapi
small surgeri surgic

5832: Hydroxycholesterols (5)

cell concentr effect enhanc express
form format gene group
high increas level low
patient produc product rat
reduc suggest test

5833: Nalbuphine (1)

assess clinic conclusions design evalu
hospit main mean **measur**
objective patient perform ratio reliabl scale
score standard studi valid valu

5835: Octanoic Acids (4)

acid assai concentr condit degre detect

differ distribut exposur **famili** local

mean measur member predict ratio respect

sensit **structur** valu

5837: RNA Polymerase Sigma 54 (3)

behavior caus domain evid form format
gene identif identifi interact lead
level novel region regul repeat **screen** sequenc
support transcript

5839: Pronase (2)

adapt cell cluster **differ** distinct
embryo **express** featur matur mechan
molecular oocyt **pattern** point receptor
select similar specif **time** type

5834: Deoxyribonucleases, Type III
Site-Specific (2)

activ chang complex concentr data
element enzym **genom** individu intermedi
kinet residu sequenc **site** state **studi**
substrat switch transit vivo

5836: Streptogramin A (1)

acid amino analysi content cytometri determin
differ drug evalu **flow** gene load observ pathwai

percentag plasmid **recombin** **resist**
signal transport

5838: Pteroylpolyglutamic Acids (1)

circul compar concentr **control** correl determin differ
elev endogen enhanc frequenc **gene** higher increas
level lower measur plasma serum signific

5840: Astringents (1)

clinic **concentr** continu delai

effect follow increas long-term microg microm

min patient persist plasma pregnanc recoveri

respect sever symptom **test**

5841: Penicillin-Binding Proteins (3)

acid amino caus children concentr genet
incid interact isol mortal **popul**
posit preval region resist sequenc strain
structur women year

5843: Sodium-Phosphate Cotransporter Proteins, Type IIb (1)

bind cancer content cytometri determin essenti flow
gene **human** includ load mutat
necessari promot rang requir site suffici varieti wide

5845: Oxytetracycline (3)

bodi data discuss dynam enzym field health
inform level method **model** new
organ provid rat resist serum simul space
target

5847: Drugs, Essential (3)

assess avail care data databas
develop evalu
function health inform
interact measur medic open popul
program resist scale score studi

5842: Fluocinolone Acetonide (1)

achiev approach associ **children**
design dna gene **genet** haplotyp
limit **multipl** optim parent polymorph
provid singl snp strategi success year

5844: Catecholamine Plasma Membrane Transport Proteins (1)

cell control discuss drug experi express function
mechan modul order **organ** possibl
process promot receptor **regul**
regulatori role transcript transfect

5846: Iodocyanopindolol (1)

alpha beta chines compar compound concentr
decreas differ heterogen higher
increas level lower observ **rate**
receptor respect studi subtyp versu

5848: Sulfaphenazole (1)

activ **associ** cell cox-2 effect enzym
examin **express** human inhibit inhibitor
investig link metabol overexpress promot relat studi
suggest transform

5849: Rifamycins (3)

anim clinic concentr diagnosi differ
gener **isol level** model new
pattern plasma provid regul resist select
serum state **strain** type

5851: Luteinizing Hormone, beta Sub-unit (4)

associ cancer case compar complex
control dai effect famili
frequenc **function** gene
human individu member mice
mutat **rat** risk studi

5853: Oxygen Radioisotopes (1)

affect allele alter associ behavior **chang** cognit
genotyp imag impair increas learn memori
patient perform polymorph
schizophrenia studi task volum

5855: Muramic Acids (2)

compound event experi **express**
identif identifi initi involv mutant novel
origin pathwai plai **process** produc
product role screen
second signal

5850: Trimethylsilyl Compounds (2)

acid addit amino **cell combin**
compound effect **express** extract
fraction multipl produc **product** receptor
result singl synergist vector vitro vivo

5852: Lactosylceramides (1)

absenc accumul **cell** compar demonstr deposit differ
extract find **group** head indic **normal**
presenc previou report signific Studi suggest
tissu

5854: Ellipticines (2)

apoptosi cell confer **correl** data divers drug
express gene genet index
interact literatur popul relationship **resist**
sensit signal signific suscept

5856: Trans Fatty Acids (2)

address assess bodi complet data fusion
impact improv **life** major malign
partial physic possibl **qualiti**
question receptor remain studi
tumour

5857: Amino Sugars (1)

base case caus content differ
event experi flow initi involv lead
length long origin pair
process repeat report
second short

5859: Benzamidines (1)

activ anim concentr develop effect
experiment factor growth hormon
human igf-i insulin-lik microg microm min model
plasma residu site studi

5861: Ascorbate Oxidase (1)

abil abl activ capabl capac
demonstr displai enzym exhibit
interact intrins mutant
mutat plant possess potenti
properti retain substrat
wild-typ

5863: Charybdotoxin (2)

activ addit channel concentr core
demonstr effect encod endogen enhanc frame
increas indic open oxid read reduc suggest treat
treatment

5858: Factor XIa (1)

bind chain determin experi extern factor
final follow growth inhibit
initi intern origin pcr polymeras
reaction second seri site subsequ

5860: Clioquinol (1)

anim data develop error estim experiment
express gene method mice model
mous mutant statist studi transgen treat
treatment vector wild-typ

5862: Hydroxocobalamin (2)

acid amino caus clinic diseas divers
factor famili fatti gene genet growth mutat
patient popul retin sever symptom tumor
variat

5864: Nonoxynol (1)

apoptosi bcl-2 bladder cell cultur demonstr effect
endogen enhanc increas induc receptor
reduc studi suggest therapi tract treat
treatment urinari

5865: Spermatocidal Agents (1)

amplif amplifi analysi **apoptosi**
apoptot bax bcl-2 cell death dna
fragment induc length **mice**
mous pcr primer restrict sequenc transgen

5867: Equilin (1)

cancer chang condit effici exposur extract
fraction intermedi kinet liquid mix ovarian
prepar produc **product** sourc
state switch transit yield

5869: Receptor, Serotonin, 5-HT1D (1)

analysi assess behavior collect core densiti
depress disord encod evalu **high** level
low map measur open perform
sampl scale score

5871: Barbiturates (2)

activ **base** case effect evolut
experi **inhibit** inhibitor initi
intern **mechan** molecular
origin pair releas report second
stimul suppress vivo

5866: Amino Acids, Essential (4)

acid amino assai base decreas
detect differ genet **human** increas
isol life pair pattern protein qualiti requir
respons sensit strain

5868: Japanese Encephalitis Vaccines (1)

approach **area** care data design
effect essenti health need prevent
protect provid public reduc reduct **requir**
servic strategi studi therapi

5870: Glyceric Acids (1)

analysi cell collect compar concentr
control detect determin differ
differenti extract fraction frequenc gel higher
mass method prolifer **sampl** techniqu

5872: Zinc Radioisotopes (1)

african american antibodi asian black bodi
concentr diet elev ethnic **level** measur
obes plasma popul serum speci water weight
white

5873: Cadmium Radioisotopes (1)

bodi **concentr** **decreas** **delai** **effect**
endogen **enhanc** **follow** **increas**
level **measur** **microg** **microm** **min** **persist** **plasma**
reduc **respect** **result** **suggest**

5875: 4-Aminobenzoic Acid (2)

allow **analys** **analysi** **appli** **applic** **develop**
differ **enhanc** **genom** **method**
pattern **procedur** **protocol** **rang** **reveal** **simpl**
standard **techniqu** **type** **wide**

5877: Cyclic AMP Response Element-Binding Protein A (1)

cell **critic** **demonstr** **depend** **deplet** **epitheli**
essenti **establish** **express** **function**
indic **maintain** **mainten** **mammari** **necessari** **pancreat**
requir **role** **suffici** **transcript**

5879: Nisin (1)

approach **cell** **coli** **compar** **control**
design **differ** **endogen** **enhanc** **express** **frequenc**
gene **higher** **increas** **limit** **microarra** **profil** **signific**
strategi **test**

5874: Aflatoxin M1 (1)

assess **chromatographi** **determin**
develop **development** **extract**
fraction **impact** **improv** **life** **liquid** **method**
physic **prepar** **procedur** **purifi** **qualiti** **separ** **standard**
techniqu

5876: Calgranulin A (3)

analys **analysi** **base** **control**
differ **express** **gene**
human **life** **pair** **pattern** **presenc**
profil **qualiti** **regul** **reveal** **state** **studi** **subject**
target

5878: Phycoerythrin (3)

absenc **affin** **bind** **brain** **compar**
control **defici** **differ** **field** **form**
format **frequenc** **gene** **movement** **mutat**
presenc **protein** **rat** **site** **space**

5880: Borates (1)

arrest **cell** **compar** **cycl** **cyclin** **decreas** **defect**
densiti **endogen** **enhanc** **high**
increas **level** **low** **mutant**
mutat **reduc** **result** **suggest** **wild-typ**

5881: Nitrogen Radioisotopes (1)

compar content copi decreas determin flow
high increas level low
mean measur month number
patient ratio region respect sequenc valu

5883: Pipobroman (1)

abnorm acut aml chromosom chronic cytogenet
depress disord induc induct leukaemia leukemia
lymphoblast lymphoma mds myeloid patient respond
respons transloc

5885: Apurinic Acid (1)

analysi base classific cluster data differ dna
environment enzym factor
function genet influenc model
organ pair possibl propos set site

5887: Oxycodone (1)

alcohol avail benefit care cost current decis
drug effect factor growth guidelin
manag medic medicin oral
physician practic recommend safeti

5882: Phenformin (1)

activ adjust associ channel confid copi determin
diabet increas interv kinas larg muscul
number odd ratio risk smoke
studi total

5884: Aluminum Hydroxide (1)

anim cytokin develop establish experiment
human ifn-gamma il-6 immun infect mice mitochondri
model mous provid respons studi
transgen vaccin viru

5886: Amrinone (1)

address anim bovin breed
concentr effect extract major
microg microm min mutant pig plasma
possibl question rais remain respect
test

5888: Chlormethiazole (1)

aggreg bodi compar control delai differ divid express
follow form format group long-term
pathwai persist receptor respect signal signific weight

5889: Plague Vaccine (1)

achiev antigen approach design
express gene host immun infect
limit mice mous optim respons strategi success
transfer transgen vaccin vector

5891: Noble Gases (1)

compar dose dynam effect field form format
higher irradi lower **model** patient predict
radiat **rate** respect simul space surviv
versu

5893: Minor Lymphocyte Stimulatory Antigen (1)

activ analys **analysis** block
cell compar confirm data effect indic

inhibit inhibitori invas line **normal** perform

reveal studi suppress **tissu**

5895: DNA, A-Form (2)

allow appli area base data dna dynam fragment
method model new predict
provid rapid region sequenc simpl simul state
techniqu

5890: Isoleucine-tRNA Ligase (1)

algorithm contain ethic inform initi issu
length long method mrna network
predict problem **repeat** research
ribosom set short termin translat

5892: Cefoperazone (1)

blood caus complic dai decreas dose
increas lead level neg oper patient
peripher **posit** postop procedur result surgeri
surgic week

5894: Phenacetin (1)

adapt analysi blot detect enzym **express**
femal male marker **metabol** **metabolit**
natur **normal** protein reveal
select sex sexual **tissu**
western

5896: Ammonium Sulfate (2)

alpha caus dimer distribut domain form
function fusion lead local
mechan molecular mutant protein
receptor solubl specif stabil stabl suggest

5897: 3-Phosphoshikimate 1-Carboxyvinyltransferase (1)

analysis blot construct contain core dynam
encod event fusion gene involv
model open plasmid predict
process read **recombin** reveal
western

5899: Lithocholic Acid (2)

acid addit amino **combin** effect enhanc
express femal **gene** genotyp increas
male metabol modul organ polymorph
region regul sequenc sex

5901: Pregnenes (1)

affect alter approxim **chang** decreas
enhanc femal form format increas major male
methyl observ occur rel sex signific **specif** suggest

5903: Thiopental (3)

behavior caus clinic cognit complic diagnosi
disabl impair lead learn memori mutant oper
patient perform procedur rat
surgeri surgic task

5898: Diphenhydramine (3)

associ bind confid estim extract interv
method odd **patient** popul
process produc product ratio requir resist
risk smoke structur studi

5900: 20-alpha-Hydroxysteroid Dehydrogenase (2)

alter analysi breast cancer **chang**
classif cluster decreas enzym femal increas
level male metabol normal serum
sex **tissu** treat treatment

5902: 3-alpha-Hydroxysteroid Dehydrogenase (B-Specific) (1)

carcinoma demonstr determin effect femal
form format increas male modif
modifi potenti releas sex sexual **specif**

stimul suggest treat

treatment

5904: Follistatin-Related Proteins (1)

allele **associ** effect
function gene genotyp haplotyp
inhibit link polymorph prevent protect **protein**
reduc reduct relat residu signific site studi

5905: Ethionamide (1)

acth adenoma adren adrenocort braf carcinoma

cortisol endocrin follicular gland hormon

hyperplasia hypothyroid neuroendocrin papillari

pheochromocytoma pituitari ptc ret

thyroid

5907: Immunoglobulin alpha-Chains (1)

affect amplif amplifi analysi code codon contain dna fragment nucleotid pcr posit primer

recombin region restrict sequenc singl substitut suggest

5909: Tropicamide (1)

action clinic conclusions determin effect energi extract

fraction increas measur methods patient potenti puls record releas retin solut stimul visual

5911: Receptors, Leukocyte-Adhesion (1)

analysi assess bind content cytometri data

determin evalu flow increas interact investig

load measur observ percentag protein resist

studi

5906: Phenindione (1)

cardiac construct effect environ

environment factor folat gene genet heart herit homolog influenc plasmid platelet recombin studi trait twin variat

5908: Antimony (1)

direct distanc enhanc experi extract field forc increas length long measur motion movement orient repeat short space speed time track

5910: Root Canal Irrigants (1)

analys analysi classific cluster data effect hear identifi indic loss microscopi morpholog perform prevent protect reduc reduct reveal set studi

5912: Zolazepam (1)

anim assess blood continu delai effect evalu follow inhibit inject long-term measur

persist rat recoveri remain scale SCORE spontan valid

5913: Tiletamine (1)

abil analys **analysisi** anim
assess bovin breed evalu indic
measur perform period pig point
properti reveal scale **score time**
valid

5915: Cation Exchange Resins (1)

chang densiti depend electron essenti
high intermedi kinet layer level
low membran microscop microscopi
morpholog observ requir state surfac transit

5917: Allylamine (1)

activ adduct analog analogu chemic chromosom
compar compound deriv differ disord higher
lower mix produc **product rate**
respect versu yield

5919: N-Nitrosopyrrolidine (1)

activ adduct compound conserv cyp2d6
cytochrom degrad deriv drug enzym function
human mammalian **metabol**
metabolit microsom mous p450 protein respect

5914: Glia Maturation Factor (1)

carcinoma cell cohort cultur data
develop development differenti
express incid lesion men mortal popul preval
prolifer rate stain women year

5916: Toyocamycin (1)

apoptosi assai bcl-2 breast cancer cell cytotox effect
express human **induc induct** inhibit line lung
mitochondri protein respond **respons**
transfect

5918: Sclerosing Solutions (1)

abil abl **associ** capac care complic
demonstr gene health oper patient potenti procedur
properti servic **structur** studi surgeri surgic
vector

5920: Oxamic Acid (2)

complet compound **concentr** condit degre
dna element extract fusion hiv-1
infect insert integr isol min partial replic
strain temperatur viru

5921: Taurochenodeoxycholic Acid (1)

acid alter amino analys **analysis**
chang data decreas express **gene**
identifi increas indic microarra perform profil
protein reveal target therapeut

5923: Pargyline (2)

affect cell compar content control
decreas determin differenti flow healthi
increas prolifer rat receptor
schizophrenia signific studi **subject**
suggest target

5925: Nucleoside Diphosphate Sugars (1)

analysi categori classif **cluster** coli differ encod enzym
escherichia **gene** identifi length long profil
region repeat sequenc set short subgroup

5927: Diphenylhexatriene (1)

compound decreas densiti effect elev **high** higher
level low lower measur membran plasma
prevent protect **reduc** reduct retin **serum** transport

5922: Pentanones (1)

compar control decreas determin differ elev
group healthi higher increas level mean
measur methods plasma rat serum signific studi

subject

5924: Bungarotoxins (3)

analys **analysis** bind channel
characterist dai data **diseas** distribut
featur indic local microscopi morpholog
multipl muscl patient perform reveal speci

5926: Glycerylphosphorylcholine (1)

acid amino care concentr elev health higher
level lower measur **mechan** molecular
plasma program provid public **serum** servic underli
understand

5928: Complement C3b Inactivator Proteins (1)

algorithm densiti ethic **high** level
low **mechan** method molecular
mutat network peptid predict receptor
research residu set site underli understand

5929: Amprolium (1)

brain central critic **develop**
development diseas earli effect improv includ lesion
muscl postnat role segment specimen stain therapi treat
treatment

5931: Chymotrypsinogen (1)

anim critic current develop discuss effect
experiment human **model** pancreat
plai recent **role** secret studi suggest
treat **treatment** tumor
understand

5933: Polysorbates (2)

african alter american asian black
chang differ effect ethnic
exposur increas **individu**
normal organ popul preval south
studi **tissu** white

5935: Goosecoid Protein (1)

activ affin bind chondrocyt express factor
gene growth interact promot protein regul rna signal site
specif tgf-beta tgf-beta1 transcript transform

5930: Respiratory Syncytial Virus Vaccines (1)

bladder densiti effect **high** infect level
low lower mobil potenti releas replic stimul
studi suggest tract urin urinari viral viru

5932: Phytochrome B (1)

blue captur color composit differ express
function gene intens **interact** laser
light map modul protein red regul
regulatori shed studi

5934: Methadyl Acetate (1)

alcohol alter **chang** decreas
develop development effect
increas level manag
enhanc **mechan** medic molecular observ oral potenti
reduc releas stimul

5936: Diltiazem (1)

cell compar densiti **differ** effect enzym
high imag level low magnet mri observ
pattern reson similar treat **treatment**
type volum

5937: Carboxin (1)

activ block chain effect enzym
function inhibit inhibitori
mechan mitochondri per polymeras quantit reaction
real-tim residu revers site substrat suppress

5939: Ferrichrome (1)

bladder cdna cerevisia clone encod fungal fungi fungu
gene isol mobil mutat pathogen produc
sequenc speci studi tract urinari yeast

5941: Dibutyl Phthalate (1)

activ carcinogen cell chemic degrad effect
electron enzym expos
exposur genotox line
microscopi morpholog mutagen observ
protein substrat toxic ubiquitin

5943: Receptors, Vasoactive Intestinal Peptide, Type II (2)

alpha beta bladder chines determin differ
domain heterogen includ peptid protein
random **receptor** respect signific
site specif studi subtyp trial

5938: Stigmasterol (1)

allow approach assai clone detect develop dynam
enzym insight isol mass method model
new provid sensit simul specif strain
techniqu

5940: Angiotensin Amide (1)

analys **analysisi** associ blood
characterist common data featur genet haplotyp
includ indic influenc multipl perform polymorph
reveal singl snp studi

5942: Disulfiram (1)

alcohol consumpt depend diverg
drug duplic effect ethanol evolut
evolutionari new **oral** origin research
studi substanc suggest technolog therapi
treatment

5944: Receptors, Vasoactive Intestinal Peptide (3)

alpha beta code codon domain growth includ
initi nucleotid origin peptid posit protein rang
receptor second singl
substitut suggest wide

5945: Receptors, Cyclic AMP (1)

cell defect delet differenti disrupt exhibit
express function impair lack mutagenesi
mutant mutat phenotyp prolifer
reduc rescu suggest wild wild-typ

5946: RNA, Transfer, His (2)

approxim bind case caus cell

children complex gener

growth initi lead major modifi

new origin provid rel report

second test

5947: Mupirocin (2)

acid conclusions dai design dose
follow hospit host incid infect
mortal objective pathogen patient period
preval studi week women year

5948: Benzidines (1)

allel bladder chines compar control
determin differ famili frequenc fusion
genotyp heterogen member metabol observ
polymorph respect signific studi subtyp

5949: Actinium (2)

adapt clinic dai dose evid extract genet mix
natur popul produc product
provid radiat rang select support therapi
treatment wide

5950: gamma-Linolenic Acid (2)

analysi blot bodi compar control differ effect
group hybrid larg plai rat role signific
size small treat treatment weight western

5951: Unithiol (2)

adapt compar control differ enzym event featur
field healthi higher lower movement oxid
process rate respect select space
subject versu

5952: Nortriptyline (1)

agreement assess clinic dai dose evalu
hospit induc induct instrument mean
measur patient reliabl
respons scale score
therapi treatment valid

5953: Pentanols (1)

aggreg behavior cognit coloni convers disabl
famili form format **gene**
histori identifi impair learn **member** memori perform
process regul task

5955: Progesterone Reductase (1)

associ character defici diverg duplic evolut
evolutionari experi gene haplotyp identifi marker
organ origin **phenotyp**
polymorph possibl process snp suggest

5957: Loratadine (1)

chang densiti disord effect follow **high** intermedi
kinet level low malign rapid slow state switch
therapi transit treat **treatment**
tumour

5959: Harringtonines (1)

antibodi apoptosi **cell** data effect
electron error **estim** human induc layer
mass method microscop microscopi
morpholog observ power statist surfac

5954: Steroid Isomerases (2)

activ approxim bone code codon copi enzym
express **gene** increas larg major mutat
number observ **patient**
promot rel substitut suggest

5956: Hexosephosphates (1)

acid **activ** amino anim bind conform
contain CORE develop encod enzym experiment frame
model open put read **structur** studi substrat

5958: Histamine H1 Antagonists, Non-Sedating (1)

bipolar chang densiti depress **disord**
effect high intermedi kinet
level low prevent protect rapid reduc
reduct slow **state** switch transit

5960: Transcription Factor TFIIIB (1)

contain delet domain **element**
genom **insert** insight integr mrna
new protein provid retrotransposon rna
sequenc site termin translat transposit
transposon

5961: Triiodothyronine, Reverse (1)

concentr dai densiti dose effect **high**
higher induc induct inhibit **level** low
lower microg plasma respond **respons**
serum thyroid week

5963: Dystrophin-Associated Protein Complex (2)

adhes alter altern **bind chang**
decreas domain exon increas inhibit interact
level multipl muscl protein serum site
splice structur variant

5965: Transcription Factors, TFIII (1)

case complex function her-2 her2 histon
interact involv lesion loop neg neu
posit protein specimen stain statu suggest
transcript translat

5967: Parasympathomimetics (1)

adapt alpha beta bind competit compound deriv
direct environ evolut evolutionari evolv fit gener natur
plastic pressur receptor **select** trait

5962: Porphobilinogen Synthase (1)

clinic consid diagnosi diagnost discuss
experi mutant mutat order **organ**
patient place possibl present process sever
symptom syndrom wai wild-typ

5964: Methylmethacrylate (2)

abil abl assembl capac **complex** compon
deliveri effici energi form light partiel plai
potenti properti **role** solut stabil
subunit surfac

5966: Tacrine (1)

affin asthma **bind** blood conform crystal cystic
determin **diseas** fibrosi form interact loop **metabol**

peripher promot residu respiratori site

structur

5968: Resins, Plant (2)

approxim children compar content
control dai determin event flow major
observ plant point presenc **process** rel
studi subject **time** tumour

5969: Aurovertins (1)

cell compar content control determin differ express
flow healthi higher human line lower
rate resist respect similar studi subject
versu

5971: Uronic Acids (1)

acid adhes amino cell clinic compound concentr deriv
elev express higher increas level lower measur
molecul mrna patient plasma serum

5973: Bromelains (1)

assai concentr cultur dai decreas
detect dose effect increas
level microg microm min plasma prevent protect
reduc reduct sensit specif

5975: Cucumber Mosaic Virus Satellite
(1)

abil address correl data despit direct
evid exist find hypothesi possibl
properti provid question rais recent remain
signific suggest support

5970: 2,4-Dinitrophenol (4)

approxim case cell dai data differ
dna estim gene growth high level low
method mice pattern primari rel structur
tumour

5972: Exopeptidases (1)

activ adapt biolog diverg domain duplic
enzym evolut evolutionari evolv fit lineag natur
origin residu select site suggest system vertebr

5974: Cofilin 2 (1)

actin biolog cell complet conserv demonstr develop
function fusion human involv
mammalian migrat monkei mous partial regul studi
suggest system

5976: Sermorelin (1)

addit cancer combin effect
follow-up growth human median mice month
patient prostat receptor recurr studi synergist
vitro vivo xenograft year

5977: Receptors, Serotonin, 5-HT3 (1)

adult compar cost dai **differ** dose
interact manag medic older **pattern** period
point receptor similar therapi **time** type
year young

5979: Cytochromes b6 (1)

chang domain enzym includ intermedi
kinet larg major **mitochondri**
question rang remain residu
site slow **state** switch transit
varieti wide

5981: Aequorin (1)

action brain ca2+ calcium channel current
distribut effect fluid gene increas
local muscl **mutat** observ
pattern potenti releas stimul suggest

5983: Gabexate (1)

anim brain continu delai develop experiment
follow includ long-term **model**
pancreat persist rang recoveri residu secret site
studi varieti wide

5978: Alloxan (1)

bodi **concentr** determin effect
enzym higher increas isol measur **mice** microg
microm min mous plasma respect strain vitro
VIVO weight

5980: Enkephalin, D-Penicillamine
(2,5)- (1)

bind chang code codon **effect**
function kinet membran nucleotid posit
prevent protect **reduc** reduct region sequenc
site **state** substitut transit

5982: Phosphotungstic Acid (1)

c-kit cancer case **cell** differenti energi

gastric gastrointestin giant gist hsp90

imatinib kit malign **sarcoma**

soft stem stromal tissu

tumor

5984: p-Aminohippuric Acid (2)

analys **analysi** assai base data
detect distribut genet indic local
membran metabol observ organ pair perform
popul reveal sensit state

5985: Ethylenethiourea (1)

allele alter american associ **chang** core decreas
encod ethnic express frequenc gene genotyp
haplotyp increas open polymorph popul
protein snp

5986: Mexiletine (1)

alcohol atp ca2+ calcium **channel** conform

current depend dimer fold form ion nativ oral

protein sodium solubl stabil stabl

structur

5987: Cytomegalovirus Vaccines (1)

analysi blot clinic compar control
diagnosi diagnost effect healthi improv
individu random remain studi
subject therapi treat
treatment trial western

5988: Cyclodecanes (1)

amplif amplifi analysi **chain** detect
dna fragment **pcr**
polymeras potenti primer quantit
reaction real-tim restrict
revers rt-pcr sequenc **target** therapeut

5989: Sulfoglycosphingolipids (1)

accumul amyloid bone critic cultur deposit diseas
gene injuri involv kei lysosom pathogenesi **plai** renal
role storag suggest transfer vector

5990: Pokeweed Mitogens (2)

cell compar **differ** effect femal
human individu inhibit male
normal pattern potenti produc **product**
releas sex similar stimul **tissu** type

5991: Immunoglobulin delta-Chains (1)

adult chromosom conserv dog elderli
express identifi linkag loci locu
map old older qtl receptor region segment trait
year young

5992: Aporphines (1)

activ arrest cataract cell cycl cyclin effect **express**
human expression len matrix monkei p21 p53 primat suppressor
implant induc invas

5993: Eukaryotic Initiation Factor-5 (1)

addit character chromosom **combin**
complex compon domain effect identifi linkag
loci locu map marker
phenotyp studi subunit
suggest telomer yeast

5995: Cycasin (1)

caus conduct data defect domin drosophila evalu famili
fungal gene includ insect investig mutant mutat
pathogen pool speci **studi** wild-typ

5997: Delta Sleep-Inducing Peptide (1)

code codon **concentr** effect length
long microm min mutat nucleotid peptid posit
question **rat** remain **repeat**
short stress substitut suggest

5999: Chymosin (2)

analysi bind chromosom common
effect featur identifi linkag loci
locu map mass **protein** qtl
reduc reduct splice **structur**
trait variant

5994: 4-Chloro-7-nitrobenzofurazan (1)

anim chain densiti develop dynam electron
experiment **high** interact level low
microscopi **model** morpholog per
polymeras reaction simul studi surfac

5996: Mutant Chimeric Proteins (1)

anim associ bind biolog cell code **codon**
develop experiment **model** nicotin
nucleotid polymorph posit singl stop studi
substitut suggest system

5998: Leghemoglobin (2)

activ bladder cell develop
development **express** extract fraction gene includ
modif modifi mrna plant promot studi transcript
translat vitro vivo

6000: Zinc Phosphate Cement (1)

abil abl approach capac data
demonstr design direct displai **evid**
exhibit hypothesi laser **light** limit
potenti **properti** provid
strategi **support**

6001: Ethers, Cyclic (1)

analisi assai compar content detect
determin differ elev flow higher laser
level light lower measur plasma
rate sensit serum versu

6003: Malathion (1)

compar complex concentr content cytometri
data decreas determin error estim flow
increas level load measur metabol
method microm observ statist

6005: Alkanesulfonates (1)

abil abl **acid** amino capac
character characterist common cultur
demonstr displai distinct exhibit
featur plant potenti properti
similar synthesi unigu

6007: Pyrogens (1)

channel cold **condit** **degre**
differ heat hsp70 increas **mice** mous
observ oral overexpress physiolog preserv shock
temperatur thermal transform transgen

6002: Mollusk Venoms (1)

analisi approach compar **control**
data differ estim frequenc gel gene **genom**
mass method network predict previou report
sequenc set studi

6004: Cyclosteroids (1)

compound concentr copi determin distribut
fluid increas isol larg local microg microm min
mitochondri **number** pattern sperm
strain suggest total

6006: Nitrate Reductase (NADPH) (1)

activ biochem biosynthesi catalyt catalyz class
dehydrogenas **enzym** enzymat fungal
fungi fungu isol metabol pathogen product reaction
reductas speci substrat

6008: Suppressor Factors, Immunologic (1)

activ adduct analog analogu cell cellular chemic
complex compound deriv encod function interact
involv kinas line membran novel **protein**
transport

6009: Transcription Factor RelB (2)

allele alter analysis blot cell **chang**
decreas differenti earli express
genotyp increas late mrna phase polymorph
prolifer protein stage western

6011: Nicorandil (1)

clinic complic diseas event experi follow
initi intern involv occur origin patient
process second sever step
subsequ surgeri surgic symptom

6013: Pharmaceutic Aids (1)

clinic compar comparison control diagnosi diagnost
differ divid greater **group** high higher
implant lower **rate** respect signific similar studi
versu

6015: Equilenin (1)

area differ factor includ locat
mean measur radiat **rang** ratio residu
respect **risk** site stabil stress studi
valu varieti wide

6010: N-Methylscopolamine (1)

anim compar **control** differ duplic
effect evolut frequenc healthi higher imag increas
induc inhibit inject rat signific stress studi subject

6012: Methylhistamines (1)

bladder care cell compar decreas elev health
higher **increas** level plasma
receptor reduc serum servic signific studi test tract
urinari

6014: Oncogene Protein v-akt (1)

agent **cancer** centuri
countri drug
european french
germani institut internat
medic medicin meet
nation research
societi state unite
univers world

6016: Dihydrostreptomycin Sulfate (1)

bacteri defect experi follow host **infect**
initi intern **mutant** mutat novel
origin pathogen potenti **second**
subsequ **target** therapeut
transcript wild-typ

6017: Cytochromes c1 (1)

compar **control** densiti
express frequenc fusion **high** higher
incid level low men mortal mutant mutat
partial preval wild-typ women year

6019: Estradiol Antagonists (1)

compar cours data **differ** end estim evid
express gene hypothesi method microarra pattern
period point provid similar support
time type

6021: Pyruvate Decarboxylase (1)

achiev approach **base** design differ dimer
express fold form gene limit observ pair
plasmid **protein** recombin stabil
stabl strategi structur

6023: Formic Acids (1)

arteri **case** complic consid coronari discuss
drosophila experi hypertens oper **organ**
patient possibl present pressur process rare
report surgeri surgic

6018: gamma-Butyrobetaine Dioxygenase (1)

activ compar control defici differ effect
enzym express **group** level linkag loci
locu map mrna prevent protect reduc reduct signific

6020: Receptors, Adrenergic, alpha (1)

acid adult amino assess
elderli evalu fish hybrid mean **measur**
old older oxid probe scale **score** situ
valid **year** young

6022: 3,3'-Dichlorobenzidine (1)

blue captur **cell** color composit differ dose
effect expos exposur intens irradi laser **light**
membran observ radiat red shed studi

6024: Cefoxitin (1)

antibiot bacteri compound design hospit host
infect main marker medic mix objective
parasit pathogen patient produc
product sourc studi yield

6025: Cefotetan (1)

antibiot **assai** bacteri bacteria
detect determin evalu host infect
limit marker method monitor parasit pathogen
sampl **sensit** specif test virul

6027: Myelin P2 Protein (1)

assai blood **cell** compar
control copi detect determin differ
differenti frequenc higher increas larg
number peptid peripher prolifer
sensit specif

6029: Tear Gases (1)

aberr ablat asthma conclusions cornea
corneal correct evalu examin includ
keratinocyt mean measur methods ocular
perform refract **skin** thick visual

6031: Immunoglobulin Gm Allotypes (1)

area differenti distanc distribut divers genet
geograph includ individu live locat loci microsattelit
popul rang region structur studi variat
wide

6026: Nipecotic Acids (2)

assai children compar control dai
detect event healthi mean measur
presenc process receptor **sensit**
specif studi **subject** system target valu

6028: Quinuclidines (1)

cell clinic continu declin delai follow initi long-term
methods occur pain **patient** persist
primari recoveri remain spontan stress sustain syndrom

6030: Bromine (2)

abil adapt **base** caus content determin
dna evid flow lead level natur pair
produc **product** properti provid
select serum support

6032: Betaxanthins (1)

blood **concentr** determin
distribut endogen
enhanc fluid increas indic
local microg microm min observ oxid
pattern peripher reduc **resist** suggest

6033: Calixarenes (1)

activ alcohol **bind** critic cultur demonstr
depend effect essenti **inhibit** kinas maintain
mainten necessari oral promot **requir**
site suffici suppress

6035: Amino Acid Transport System
y+ (1)

control **develop** development
express function **gene** gener includ involv
mechan membran microarraim modul **mutat** profil
regul regulatori role specif stress

6037: Thromboxane A2 (2)

concentr condit cultur degre determin
effect increas induc induct microg microm min
oxid plasma respond **respons**
structur synthas synthesi temperatur

6039: Dicyclomine (1)

clinic complic cost epilepsi manag medic
oper **patient** perform postop
practic procedur resect seizur sever stress
surgeri surgic symptom underw

6034: Sulfanilamides (2)

alter assess **associ** caus
chang channel decreas discuss evalu
increas lead light **measur**
observ releas research scale **SCORE** stimul
valid

6036: Sucralfate (1)

aim compar **conclusions** control determin differ
factor genet **group** healthi higher
influencc mean measur methods respect signific
studi **subject** volunt

6038: Simethicone (1)

accumul clinic complic cost manag medic
oper **patient** perform postop
practic preoper procedur resect sever stress
surgeri surgic symptom underw

6040: MAP Kinase Kinase Kinase 4 (1)

activ adjust **associ** complex confid effect function
identifi inhibit **interact** interv
involv kinas odd partner protein ratio risk smoke
studi

6041: RNA, Transfer, Tyr (2)

base chain character characterist conserv
differ encod featur **gene human**
observ open pair presenc reaction receptor
region sequenc similar tumour

6043: Coat Protein Complex I (1)

affin assembl **bind** bound complex
compon cytoplasm export hear interact local
loss **nuclear** nuclei nucleu
protein site sperm subunit transloc

6045: Methylergonovine (1)

characterist common condit data degre
direct distinct effect **evid** featur find
heat hypothesi inhibit **provid** releas
stimul suggest **support**
temperatur

6047: Factor VIIIa (1)

addit analys **analysi** brain case
central clinic **combin** compar data effect
indic lesion perform report reveal stain studi
therapi treatment

6042: Kell Blood-Group System (1)

cell compar content control cytometri defici determin
differ earli express flow **group** late
mice mous phase progress signific stabil stage

6044: Adjuvants, Pharmaceutic (1)

adenoma advanc ape breast **cancer**
cervic chemotherapi colon colorect crc hpv
human instabl patient progress prostat regimen
respons surviv toxic

6046: Phosphate Acetyltransferase (1)

acid amino chicken diabet effici gene gener high imag
imprint individu japanes mix plasmid produc
product pure recombin sourc
yield

6048: Receptor, Muscarinic M3 (1)

conserv content cytometri defect determin
distribut effect flow fluid local
mutant mutat observ prevent
protect receptor reduc reduct suggest
wild-typ

6049: Praziquantel (1)

alter area **chang** compar
control decreas differ expos exposur
extract factor frequenc higher increas liver locat
observ risk signific studi

6051: Kininogens (2)

analysi area base complex decreas differ enzym
function gene increas induc
inhibit pair rat receptor regress requir respons
structur variabl

6053: Glyceraldehyde (1)

chain detect **effect** enzym extract
fraction mass mix pcr polymeras prevent
produc **product** protect
quantit reaction reduc reduct site yield

6055: Simazine (1)

african american compar **control** differ discuss
effect ethnic follow frequenc improv month patient
popul recent signific therapi treat
treatment year

6050: RNA, Transfer, Arg (2)

associ cell codon concentr differ experi femal
gene group initi intern male
mutant mutat origin phenotyp second sex
substitut translat

6052: Reptilian Proteins (1)

affect **bodi** content diet effect event
flow increas involv length long measur obes
process releas **repeat**
short step stimul weight

6054: Hemodialysis Solutions (1)

base dai densiti differ dose **group**
high higher induc induct level low
lower observ pair **patient** respond
respons signific week

6056: Sp2 Transcription Factor (1)

activ decreas effect encod express
gene genet **human** level
moleculat monkei mrna potenti prevent primat protect
reduc reduct skin translat

6057: Trifluoperazine (2)

activ alter assai chang compar concentr
decreas degre detect famili
increas level member method mice
observ receptor sensit treat treatment

6059: Ureohydrolases (1)

analysi carcinoma cell clinic critic electrophoresi encod
express gel identifi kei mass **patient**
plai **protein** proteom renal role
spectrometri suggest

6061: HMGN Proteins (1)

chromatin **complex** compon consid
current discuss dna experi histon natur
organ particular possibl process
recent replic speci **structur**
subunit understand

6063: Domperidone (1)

affect alpha anim beta bind control dai effect
function induc inject ligand neuron
rat receptor schizophrenia site studi suggest week

6058: Methysergide (1)

behavior **case** character
characterist cognit common
concentr conserv disord
distinct **featur** kinet microm min
question remain report similar **state**
stress

6060: Enoyl-CoA Hydratase (1)

analysi chain clinic detect electrophoresi gel identifi
mass methods multipl **patient** per
polymeras proteom quantit reaction singl spectrometri
technolog therapi

6062: Dipyrone (1)

behavior cognit cours disabl durat end extract genet
impair learn memori **mice** mous perform period
point rat task **time** transgen

6064: Lysergic Acid Diethylamide (1)

addit affect affin **bind** bound combin
densiti effect **function** high
interact level low protein receptor
schizophrenia site stabil studi suggest

6065: Fenoterol (1)

approach area base bia **data** distribut error
estim genet health method
model popul power probabl random regul set
statist trial

6067: Aminopyridines (1)

activ adduct adenosin analog analogu arrest
cell chemic **compound**
cycl cyclin deriv novel p21 phase potent
synthes synthesi telomer telomeras

6069: Receptors, Tachykinin (1)

administr brain central chines dai densiti differ dose
heterogen **high** **human** level
low muscl receptor respect signific studi subtyp
week

6071: Thenoyltrifluoroacetone (1)

activ assai compar compound critic
depend detect essenti maintain mainten mitochondri
necessari normal p53 requir sensit specif suffici
test **tissu**

6066: Cobra Venoms (1)

CONSERV delta extract function highli
homolog homologu human identifi light
mammalian mous notch novel ortholog
potenti speci strategi **target**
therapeut

6068: Tilorone (1)

abil abl **activ** apoptosi capac caus
CORREL data demonstr error **estim** **gene** lead
method paramet potenti properti relationship
signific statist

6070: Decanoates (1)

acid activ amino approach chines design
differ divers enzym genet heterogen limit
popul residu site strategi studi
substrat subtyp variat

6072: Buspirone (1)

activ altern cyp1a1 cyp2d6 cyp3a4
cytochrom donor drug enzym exon human intron isoform
metabol metabolit microsom p450 splice transplant
variant

6073: Pirenzepine (1)

cancer clinic diseas donor follow-up gastric inhibitor
intestin islet median methods month pancreat
patient recurr secret stress studi
transplant year

6075: Vaccines, Marker (2)

care **cell** differ differenti health infect
length long mean measur prolifer ratio
repeat resist respect short specif test
valu viru

6077: Iodized Oil (1)

associ compar control differ distribut
fluid **group** healthi larg larger local
number respect signific size small studi subject
suggest syndrom

6079: Vanillic Acid (1)

acid activ amino associ block confid cultur
effect induc **inhibit** inhibitori
interv isol mechan odd ratio risk smoke strain
suppress

6074: Clavulanic Acids (1)

analysi chromosom encod enzym epilepsi gel
gene identifi includ linkag loci locu map
mass multipl myeloma seizur singl stress studi

6076: Marek Disease Vaccines (1)

alter **chang** chicken compar
control decreas differ frequenc
higher increas individu infect malign map observ
plasmid recombin signific studi tumour

6078: Iodates (1)

administr assess dai dose effect
evalu inject **measur** methyl
microscopi morpholog potenti **rat**
releas retin scale **score** stimul
valid week

6080: Ant Venoms (1)

agreement **assess** brain conserv
drosophila evalu function highli homolog
human identifi **isol** mammalian
measur mous reliabl scale
score strain valid

6081: Ergotamines (1)

affect analysi approxim **differ**
distribut independ local major observ pattern
plant predict regress rel relationship signific
similar type **variabl** variat

6083: Methylene Chloride (1)

analys base cdna clone complet contain extract
fraction fusion gene genu partial phylogenet
relationship rice rrna sequenc **speci**
tree wheat

6085: Early Growth Response Protein
3 (1)

accompani affect alter caus **chang**
compar decreas express factor growth
increas level mrna observ occur receptor
result signific stress transcript

6087: Receptor, Cannabinoid, CB2 (1)

alpha **associ** beta examin exposur find
independ induc induct investig link observ possibl
receptor relat respond **respons** signific studi suggest

6082: Stainless Steel (2)

blood cancer cleft clone copi effect expos exposur
express **gene** increas larg malign methyl
number peripher rat studi total
tumour

6084: Ferredoxin-Nitrite Reductase (1)

analysi cdna character chromosom clone enzym
express gene identifi **isol** linkag
loci locu map **marker** molecular mrna sequenc
strain type

6086: Receptors, Bradykinin (1)

activ analys characteris compar compound cultur
decreas effect **increas** inhibit
kinas level malign membran **normal** observ
reduc suppress **tissu** tumour

6088: Heparin Lyase (1)

analysi approach approxim data
electrophoresi error estim extract fraction
gel identifi insight major mass method
new observ proteom provid rel

6089: Chlorates (1)

bodi clinic compar control differ
effect healthi multipl patient plant
prevent protect reduc reduct sever signific
singl studi **subject** weight

6091: Ampholyte Mixtures (1)

approach assai data design
detect experi initi intern limit
mean measur origin ratio report respect

second sensit specif strategi **valu**

6093: Receptors, Vasoactive Intestinal Polypeptide, Type I (1)

agonist alpha antagonist beta complet diverg domain
duplic evolut evolutionari evolv fusion ligand
lineag origin partial pathwai **receptor**
signal suggest

6095: Biotinidase (2)

activ adapt behavior clinic defect defici diagnosi
diagnost enzym **function** genet
impair nuclear physiolog plai regul releas role select
stimul

6090: Escherichia coli Vaccines (1)

acid adapt allel amino bind caus cell class
consequ environ evolut fit genotyp lead line natur
neg polymorph posit **select**

6092: Tungsten Compounds (1)

assai avail copi data databas **detect** effect
elegan increas inform inject larg limit
number rat sensit speci
specif stress tool

6094: Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I (1)

acid adult amino conserv core
elderli encod fusion identifi novel older open
read receptor signal **target** therapeut
variant **year** young

6096: Nucleobase Transport Proteins (1)

analysi area blot confirm detect encod examin
express **gene** linkag locat map methyl
protein region resist reveal studi western yeast

6097: Phosphites (1)

carcinoma defect diverg duplic evolut
evolutionari evolv experi gene host infect
mutant mutat **organ** origin
plasmid possibl process recombin wild-typ

6099: alpha-Chlorohydrin (1)

achiev approach chromatographi contain
design determin **extract**
fraction limit liquid **method**
modifi optim prepar procedur purifi separ site
strategi techniqu

6101: Respiratory System Agents (1)

affect area compar **control** data
differ evid frequenc healthi higher incid locat
mortal preval provid studi subject support
women year

6103: Monocyte Chemoattractant Proteins (1)

cell compar content critic determin differ field
flow mean measur morpholog observ phenotyp
plai ratio respect **role** stain suggest valu

6098: Compomers (1)

assess care effect electron evalu inform layer
manag **measur** medic microscopi
morpholog particip practic questionnair scale
score treat **treatment**
valid

6100: Tankyrases (2)

activ analys **analysisi** block cell
data differenti effect enhanc increas
inhibit inhibitor marker prolifer
reveal stimul suggest suppress telomer
telomeras

6102: Octamer Transcription Factor-6 (1)

base cell class cord critic differ domain
essenti extens function injuri necessari nerv
observ pair **protein** requir
spinal suffici wound

6104: Fluorodeoxyuridylate (1)

activ analysi assembli block bone complex
compon **dna** effect electrophoresi gel
identifi **inhibit** inhibitori mass proteom replic
subunit suppress synthesi

6105: Serum Globulins (1)

acut chang clinic current discuss **human**
intermedi kinet leukemia **patient** rapid
recent research slow state switch therapi transit
treatment understand

6107: Ribonucleoprotein, U5 Small Nuclear (1)

complex compon critic crucial domain essenti exon
function **human** interact involv kei
p53 plai protein **role** splice subunit
suggest variant

6109: RNA, Transfer, Ile (1)

analysi cell compar delet **differ** dna
fragment line mitochondri **pattern** pcr predict
regress relationship restrict signific similar type
variabl variat

6111: Anthralin (1)

basal chronic cutan diseas epiderm epidermi
hair inflamm **inflammatori** intestin involv keratin
keratinocyt lesion pigment psoriasi **skin**
topic ultraviolet uvb

6106: Astatine (1)

adjust approach associ confid design dose
effect energi **genet** interv irradi
limit odd **radiat** radiotherapi ratio
risk smoke strategi therapi

6108: Rhamnose (1)

anim bacteri bone bovin breed cell coli construct
defect encod escherichia gene **mutant**
mutat pig plasmid recombin
strain toxin wild-typ

6110: Diazomethane (1)

achiev acid allow amino approach caus design
lead limit method mix optim peptid produc
product sourc strategi success
techniqu yield

6112: Hydroxyprogesterones (1)

analysi **effect** factor fetal find predict
pregnanc prevent previou protect reduc reduct
regress relationship report risk signific studi
variabl variat

6113: LDL-Receptor Related Protein-Associated Protein (1)

cellular cholesterol complement control determin

domain factor function highli involv kei lipid

mechan modul physiolog process regul

regulatori role specif

6115: Cyclofenil (1)

assist cycl fertil follicl fsh germ

hormon infertil ivf ovari ovarian

pregnanc progesteron reproduct

sperm steroid stimul studi

testosteron Women

6117: Carbidopa (1)

analysi core determin encod includ loss open
predict rang read regress relat relationship

signific specif treat

treatment variabl variat
wide

6119: Benzocaine (1)

compar compound control deliveri differ disord divid
effici group involv mechan molecular
particl respect signific surfac transcript underli
understand understood

6114: Benzethonium (1)

blue captur color compar composit control differ essenti
group intens laser light necessari red
requir shed signific stress studi suffici

6116: Catechol 1,2-Dioxygenase (1)

acid amino approach control develop fatti
function insight modul new pathwai provid regul
regulatori research retino role signal technolog
understand

6118: Aristolochic Acids (1)

acid affect alter amino behavior

chang clinic cognit decreas defici
impair increas kidney learn memori observ patient
renal sever symptom

6120: Melitten (1)

complex content cytometri
determin energi flow form kinet load
measur method observ rapid
solut stabil state subunit switch techniqu
transit

6121: Amino Acids, Dicarboxylic (1)

activ anim birth cancer cultur **develop**
development earli effect endotheli enzym fetal includ
inject lung matern pregnanc rat substrat week

6123: Transcription Factor Brn-3C (1)

candid cell cellular control express function
identif **identifi** mechan modul
neuron novel program **regul** regulatori retin
role **screen** transfect visual

6125: Homogentisate 1,2-Dioxygenase (1)

algorithm **concentr** control
enzym healthi higher measur mechan
method microg microm min molecular
network plasma predict respect site studi

subject

6127: Carbimazole (1)

aggreg clinic coloni convers examin **form**
format indic infect involv observ
occur patient present sever suggest symptom
therapi treatment women

6122: Ribulosephosphates (1)

abil abl achiev approach
arabidopsi capac **complex**
compon demonstr design exhibit light
limit optim **plant** potenti
properti strategi subunit success

6124: Iodoquinol (1)

abil abl capac cell code codon
correl demonstr differenti index
infect lesion posit potenti primari prolifer
properti relationship signific substitut

6126: Hematoporphyrins (1)

analysi assess cancer cell **content**
cytometri determin differ evalu
flow increas light load measur
observ ovarian percentag signific vitro vivo

6128: Acetyl-CoA C-Acyltransferase (1)

analysi blot detect electron express
genom layer light microscop
microscopi morpholog nuclear observ plant
protein reveal sequenc structur surfac western

6129: Sodium-Bicarbonate Symporters
(1)

addit **combin** contain core defect
effect embryo encod frame identifi membran
mutant mutat novel
open orf put read transport wild-typ

6131: Peptide PHI (1)

activ alpha beta bladder cdna clone effect
embryo gene inhibit ligand mobil peptid
receptor sequenc studi suppress
tract urin urinari

6133: MafF Transcription Factor (1)

activ data defect **gene** includ
literatur median month multipl **mutant mutat**
oxid **patient** publish report review search singl
wild-typ year

6135: Disaccharidases (1)

american **ASSESS** bodi chines data
differ evalu **evid** form heterogen
measur popul protein provid
scale **SCORE** stabil studi
subtyp **support**

6130: Ganglionic Blockers (1)

chain character characterist chines class common
differ distinct enhanc featur
function heterogen increas per
polymeras reaction receptor speci studi subtyp

6132: Miotics (1)

anterior **cataract** chamber conclusions
disc examin **glaucoma**
implant includ intraocular iol
iop **len** methods ocular par perform
studi surgeri visual

6134: Uridine Kinase (1)

chines data differ **gener** heterogen includ
literatur map **method** mix produc
product report residu site sourc
structur studi subtyp techniqu

6136: Reserpine (1)

belong concentr diverg duplic epitheli evolut
evolutionari **famili** gel histori identifi
includ mass **member** microg microm min origin
protein stabil

6137: Bacitracin (1)

affect belong bind concentr elev **famili**
histori identifi includ level **member** microm min
modifi plasma rel report serum subfamili superfamili